PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SCHECHTER, GP				SCHECHTER, GP			GM-CSF IN HODGKIN DISEASE	ANNALS OF INTERNAL MEDICINE			English	Letter											SCHECHTER, GP (corresponding author), GEORGE WASHINGTON UNIV,DEPT VET AFFAIRS MED CTR,WASHINGTON,DC 20422, USA.							GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				1033	1033		10.7326/0003-4819-116-12-1033	http://dx.doi.org/10.7326/0003-4819-116-12-1033			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586097				2022-12-28	WOS:A1992HY79300020
J	PRAS, E; AKSENTIJEVICH, I; GRUBERG, L; BALOW, JE; PROSEN, L; DEAN, M; STEINBERG, AD; PRAS, M; KASTNER, DL				PRAS, E; AKSENTIJEVICH, I; GRUBERG, L; BALOW, JE; PROSEN, L; DEAN, M; STEINBERG, AD; PRAS, M; KASTNER, DL			MAPPING OF A GENE CAUSING FAMILIAL MEDITERRANEAN FEVER TO THE SHORT ARM OF CHROMOSOME-16	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKAGE ANALYSIS; DNA; AMYLOIDOSIS; IDENTIFICATION; POLYSEROSITIS; C5A-INHIBITOR; LOCALIZATION; ARMENIANS; FREQUENCY; COMMITTEE	Background. Familial Mediterranean fever is an autosomal-recessive disease characterized by acute attacks of fever with sterile peritonitis, pleurisy, or synovitis. The biochemical basis of the disease is unknown, but determining the chromosomal location of the gene for the disorder should be a first step toward defining the biochemical events. Methods and Results. As part of a systematic genome-wide search, we sought evidence of linkage between familial Mediterranean fever and chromosome 16 DNA markers in 27 affected non-Ashkenazi Jewish families from Israel. Two loci from the subtelomeric region of the short arm of chromosome 16 (16p) had lod scores sufficient to establish linkage (a score greater-than-or-equal-to 3). One DNA marker (D16S84) gave a maximal lod score of 9.17 (odds of 10(9.17) to 1 in favor of linkage) at a recombination frequency (theta) of 0.04. A probe associated with the hemoglobin-alpha complex (5'HVR) gave a maximal lod score of 14.47 at a theta of 0.06. Multipoint linkage analysis indicated that the following was the most likely gene order: the centromere, the gene for familial Mediterranean fever, D16S84, hemoglobin-alpha, and the telomere. The maximal multipoint lod score was 19.86. There was a striking degree of homozygosity at chromosome 16p loci in the affected offspring of eight consanguineous couples. Conclusions. The gene that causes familial Mediterranean fever in non-Ashkenazi Jews maps to the short arm of chromosome 16.	NIAMSD,ARTHRITIS & RHEUMATISM BRANCH,BLDG 6,RM 112,BETHESDA,MD 20892; CHAIM SHEBA MED CTR,DEPT MED,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL; NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Aksentijevich, Ivona/AAF-1335-2019	Dean, Michael C/0000-0003-2234-0631; 				AKSENTIJEVICH I, 1991, AM J HUM GENET, V49, P335; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; AYESH SK, 1990, J IMMUNOL, V144, P3066; BARAKAT MH, 1986, Q J MED, V60, P837; Battey, 1986, BASIC METHODS MOL BI; CAVENEE W, 1984, AM J HUM GENET, V36, P10; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; DIAMOND JM, 1987, NATURE, V329, P105, DOI 10.1038/329105a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRADKIN A, 1985, ISRAEL J MED SCI, V21, P757; GERMINO GG, 1990, AM J HUM GENET, V46, P925; GRUBERG L, 1991, CYTOGENET CELL GENET, V58, P2113; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JULIER C, 1990, GENOMICS, V6, P419, DOI 10.1016/0888-7543(90)90471-6; KASTNER DL, 1991, CYTOGENET CELL GENET, V58, P2115; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MEYERHOFF J, 1980, MEDICINE, V59, P66, DOI 10.1097/00005792-198001000-00004; MULLEY JC, 1990, CYTOGENET CELL GENET, V53, P175, DOI 10.1159/000132923; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3122, DOI 10.1093/nar/16.7.3122; OTT J, 1985, ANAL HUMAN GENETIC L, P27; OZDEMIR A I, 1969, American Journal of Gastroenterology, V51, P311; PRAS M, 1982, JOHNS HOPKINS MED J, V150, P22; PRITCHARD MA, 1991, GENOMICS, V10, P801, DOI 10.1016/0888-7543(91)90466-R; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REEDERS S T, 1988, Genomics, V3, P150, DOI 10.1016/0888-7543(88)90146-2; REEDERS ST, 1989, CYTOGENET CELL GENET, V51, P299, DOI 10.1159/000132796; REEDERS ST, 1991, CYTOGENET CELL GENET, V58, P643, DOI 10.1159/000133176; REIMANN HA, 1954, JAMA-J AM MED ASSOC, V154, P1254, DOI 10.1001/jama.1954.02940490018005; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; SCHLESINGER M, 1984, TISSUE ANTIGENS, V24, P65; SCHWABE AD, 1974, MEDICINE, V53, P453, DOI 10.1097/00005792-197411000-00005; SCHWABE AD, 1987, JPN J MED, V26, P370, DOI 10.2169/internalmedicine1962.26.370; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; WILSON D E, 1989, American Journal of Human Genetics, V45, pA168	41	228	236	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1509	1513		10.1056/NEJM199206043262301	http://dx.doi.org/10.1056/NEJM199206043262301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579134				2022-12-28	WOS:A1992HW97200001
J	STIEGMANN, GV; GOFF, JS; MICHALETZONODY, PA; KORULA, J; LIEBERMAN, D; SAEED, ZA; REVEILLE, RM; SUN, JH; LOWENSTEIN, SR				STIEGMANN, GV; GOFF, JS; MICHALETZONODY, PA; KORULA, J; LIEBERMAN, D; SAEED, ZA; REVEILLE, RM; SUN, JH; LOWENSTEIN, SR			ENDOSCOPIC SCLEROTHERAPY AS COMPARED WITH ENDOSCOPIC LIGATION FOR BLEEDING ESOPHAGEAL-VARICES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; CONTROLLED CLINICAL-TRIAL; DISTAL SPLENORENAL SHUNT; LONG-TERM MANAGEMENT; INJECTION SCLEROTHERAPY; COMPLICATIONS; SURVIVAL	Background. Endoscopic sclerotherapy is an accepted treatment for bleeding esophageal varices, but it is associated with substantial local and systemic complications. Endoscopic ligation, a new form of endoscopic treatment for bleeding varices, may be safer. We compared the effectiveness and safety of the two techniques. Methods. In this randomized trial we compared endoscopic sclerotherapy and endoscopic ligation in 129 patients with cirrhosis who had proved bleeding from esophageal varices. Sixty-five patients were treated with sclerotherapy, and 64 with ligation. Initial treatment for acute bleeding was followed by elective retreatment to eradicate varices. The patients were followed for a mean of 10 months, during which we determined the incidence of complications and recurrences of bleeding, the number of treatments needed to eradicate varices, and survival. Results. Active bleeding at the first treatment was controlled by sclerotherapy in 10 of 13 patients (77 percent) and by ligation in 12 of 14 patients (86 percent). Slightly more sclerotherapy-treated patients had recurrent hemorrhage during the study (48 percent vs. 36 percent for the ligation-treated patients, P = 0.072). The eradication of varices required a lower mean (+/- SD) number of treatments with ligation (4 +/- 2 vs. 5 +/- 2, P = 0.056) than with sclerotherapy. The mortality rate was significantly higher in the sclerotherapy group (45 percent vs. 28 percent, P = 0.041), as was the rate of complications (22 percent vs. 2 percent, P < 0.001). The complications of sclerotherapy were predominantly esophageal strictures, pneumonias, and other infections. Conclusions. Patients with cirrhosis who have bleeding esophageal varices have fewer treatment-related complications and better survival rates when they are treated by esophageal ligation than when they are treated by sclerotherapy.	UNIV COLORADO,DEPT MED,DENVER,CO 80202; UNIV COLORADO,EMERGENCY MED RES CTR,DENVER,CO 80202; DENVER VET AFFAIRS HOSP,DENVER,CO; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; HOUSTON VET AFFAIRS HOSP,HOUSTON,TX; UNIV SO CALIF,SCH MED,LIVER UNIT,DOWNEY,CA 90242; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; PORTLAND VET AFFAIRS HOSP,PORTLAND,OR	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; University of Southern California; Oregon Health & Science University	STIEGMANN, GV (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT SURG,C-313,4200 E 9TH AVE,DENVER,CO 80262, USA.							EL-NEWIHI H, 1991, Gastroenterology, V100, pA59; HALPERIN M, 1968, J CHRON DIS, V21, P13, DOI 10.1016/0021-9681(68)90082-9; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; KORULA J, 1985, HEPATOLOGY, V5, P584, DOI 10.1002/hep.1840050410; LARSON AW, 1986, JAMA-J AM MED ASSOC, V255, P497, DOI 10.1001/jama.255.4.497; LORGAT F, 1990, SURG ENDOSC-ULTRAS, V4, P18, DOI 10.1007/BF00591406; LOW DE, 1986, ARCH INTERN MED, V146, P569, DOI 10.1001/archinte.146.3.569; Paquet K J, 1988, Surg Endosc, V2, P18, DOI 10.1007/BF00591393; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; SANDY H, 1983, GASTROINTEST ENDOSC, V31, P243; SARLES HE, 1985, AM J GASTROENTEROL, V80, P595; SCHUMAN BM, 1987, AM J GASTROENTEROL, V82, P823; SPINA GP, 1990, ANN SURG, V211, P178, DOI 10.1097/00000658-199002000-00010; STIEGMANN G, 1990, GASTROINTEST ENDOSC, V36, P188; STIEGMANN GV, 1990, AM J SURG, V159, P21; TERBLANCHE J, 1983, LANCET, V2, P1328; VANSTIEGMANN G, 1986, GASTROINTEST ENDOSC, V32, P230, DOI 10.1016/S0016-5107(86)71815-4; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219; WESTABY D, 1992, GASTROINTEST ENDOSC, V2, P121; 1991, NEW ENGL J MED, V324, P1779; 1984, NEW ENGL J MED, V311, P1594	24	519	525	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1527	1532		10.1056/NEJM199206043262304	http://dx.doi.org/10.1056/NEJM199206043262304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579136				2022-12-28	WOS:A1992HW97200004
J	FRANCIS, CW; PELLEGRINI, VD; MARDER, VJ; TOTTERMAN, S; HARRIS, CM; GABRIEL, KR; AZODO, MV; LEIBERT, KM				FRANCIS, CW; PELLEGRINI, VD; MARDER, VJ; TOTTERMAN, S; HARRIS, CM; GABRIEL, KR; AZODO, MV; LEIBERT, KM			COMPARISON OF WARFARIN AND EXTERNAL PNEUMATIC COMPRESSION IN PREVENTION OF VENOUS THROMBOSIS AFTER TOTAL HIP-REPLACEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; MOLECULAR-WEIGHT HEPARIN; RANDOMIZED TRIAL; SUBCUTANEOUS HEPARIN; CALF COMPRESSION; SURGERY; THROMBOEMBOLISM; SULFINPYRAZONE; BOOTS	Objective. --To compare the effectiveness and safety of warfarin and external pneumatic compression (EPC) in prevention of venous thrombosis after total hip replacement. Design. --Prospective, randomized trial in consecutive patients, with blinded assessment of the primary end point. Setting. --University medical center and large community hospital. Patients. --Patients over age 18 years scheduled for elective primary total hip replacement were eligible. Of 254 patients interviewed, 232 were randomized, 220 patients had surgery and received prophylaxis, and 201 had venography. Interventions. --Patients were randomly assigned to prophylaxis with a device providing bilateral sequential EPC to both the calf and thigh or to receive warfarin in a low-intensity regimen beginning 10 to 14 days preoperatively. Prophylaxis was continued until venography. Main Outcome Measures. --Venous thrombosis was diagnosed by venography between postoperative days 6 and 8. Bleeding was assessed by surgical blood loss, transfusion requirements, changes in hematocrit, and clinically identified bleeding complications. Results. --The total incidence of venous thrombosis was virtually the same in the warfarin and EPC groups (31% vs 27%), but the distribution of thrombi was different. Proximal thrombosis occurred in 12% of patients in the EPC group compared with only 3% in the warfarin group (P = .012, 95% confidence interval for difference, 2% to 18%). In contrast, calf vein thrombosis was more frequent in the warfarin group (21%) than in the EPC group (12%) (P = .021, 95% confidence interval for difference, 0% to 18%). Most proximal thrombi in EPC-treated patients were located within 15 cm of the femoral head and were not continuous with thrombi in deep calf veins. The high incidence of proximal thrombosis in the EPC group resulted in termination of the study by the safety monitoring committee. Blood loss and bleeding complications were similar in the two groups. Conclusion. --Warfarin therapy is significantly more effective than EPC in preventing serious proximal vein thrombosis after total hip replacement. The greater effectiveness of warfarin therapy in preventing proximal vein thrombi and of EPC in preventing thrombosis in the calf suggests that there are differences in the pathogenesis of thrombosis in these two locations.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT ORTHOPAED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT RADIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT STAT,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey J P, 1991, J Arthroplasty, V6 Suppl, pS29, DOI 10.1016/S0883-5403(08)80053-8; BELCH JJF, 1982, THROMB RES, V25, P23, DOI 10.1016/0049-3848(82)90211-0; BERGQVIST D, 1979, ACTA CHIR SCAND, V145, P213; CLARK WB, 1974, LANCET, V2, P5; COE NP, 1978, SURGERY, V83, P230; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COVENTRY MB, 1973, J BONE JOINT SURG AM, VA 55, P1487, DOI 10.2106/00004623-197355070-00016; DEWEESE JA, 1963, SURGERY, V53, P99; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; FRANCIS CW, 1989, J BONE JOINT SURG AM, V71A, P327, DOI 10.2106/00004623-198971030-00003; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; GALLUS A, 1983, BRIT J SURG, V70, P17, DOI 10.1002/bjs.1800700106; HARRIS WH, 1974, J BONE JOINT SURG AM, VA 56, P1552, DOI 10.2106/00004623-197456080-00002; HARRIS WH, 1972, J AMER MED ASSOC, V220, P1319, DOI 10.1001/jama.220.10.1319; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HULL R, 1979, THROMB RES, V16, P37, DOI 10.1016/0049-3848(79)90267-6; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; KAKKAR VV, 1985, AM J SURG, V150, P54; KAKKAR VV, 1969, LANCET, V2, P230; KIM YH, 1988, J BONE JOINT SURG AM, V70A, P878, DOI 10.2106/00004623-198870060-00013; KNIGHT MTN, 1976, LANCET, V2, P1265; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; MUHE E, 1984, AM J SURG, V147, P781, DOI 10.1016/0002-9610(84)90200-9; NICOLAIDES AN, 1980, SURGERY, V87, P69; Paiement G, 1987, J Arthroplasty, V2, P23, DOI 10.1016/S0883-5403(87)80027-X; PAIEMENT GD, 1987, CLIN ORTHOP RELAT R, V223, P188; PATERSON BM, 1989, J BONE JOINT SURG AM, V71, P1130; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; ROBERTS VC, 1974, BRIT MED J, V1, P358, DOI 10.1136/bmj.1.5904.358; ROGERS PH, 1978, J BONE JOINT SURG AM, V60, P758, DOI 10.2106/00004623-197860060-00005; ROTHERMEL JE, 1973, ARCH SURG-CHICAGO, V106, P135; SABRI S, 1971, BMJ, V2, P394; SAUTTER RD, 1983, JAMA-J AM MED ASSOC, V250, P2649, DOI 10.1001/jama.250.19.2649; SKILLMAN JJ, 1978, SURGERY, V83, P354; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; TURPIE AGG, 1979, THROMB RES, V15, P611, DOI 10.1016/0049-3848(79)90171-3; WOOLSON ST, 1991, J BONE JOINT SURG AM, V73A, P507, DOI 10.2106/00004623-199173040-00005	42	139	143	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2911	2915		10.1001/jama.267.21.2911	http://dx.doi.org/10.1001/jama.267.21.2911			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583760				2022-12-28	WOS:A1992HW13300028
J	LEWIS, EJ; HUNSICKER, LG; LAN, SP; ROHDE, RD; LACHIN, JM				LEWIS, EJ; HUNSICKER, LG; LAN, SP; ROHDE, RD; LACHIN, JM			A CONTROLLED TRIAL OF PLASMAPHERESIS THERAPY IN SEVERE LUPUS NEPHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFUSE PROLIFERATIVE GLOMERULONEPHRITIS; CLINICAL-TRIALS; ERYTHEMATOSUS; CLASSIFICATION; ANTIBODIES; PREDNISONE; CRITERIA; DNA; SLE	Background. The prognosis of patients with systemic lupus erythematosus who have glomerulonephritis is poor, despite treatment with immunosuppressive therapy. Plasmapheresis therapy has been used, but there have been few controlled clinical observations of its efficacy. Methods. We carried out a randomized, controlled trial comparing a standard-therapy regimen of prednisone and cyclophosphamide (standard therapy) with a regimen of standard therapy plus plasmapheresis in 86 patients with severe lupus nephritis in 14 medical centers. The patients underwent plasmapheresis three times weekly for four weeks. Drug therapy was standardized, with strict adherence to nine detailed medical-management protocols. Results. Forty-six patients received standard therapy, and 40 patients received standard therapy plus plasmapheresis. The mean follow-up was 136 weeks. Six patients (13 percent) in the standard-therapy group and eight patients (20 percent) in the plasmapheresis group died. Renal failure developed in 8 patients (17 percent) in the standard-therapy group, as compared with 10 (25 percent) in the plasmapheresis group. Thirty patients (35 percent) reached stopping points - 14 (30 percent) in the standard-therapy group and 16 (40 percent) in the plasmapheresis group. A similar number of patients in each group had a decrease in both the serum creatinine concentration and urinary protein excretion to approximately normal values. Patients treated with plasmapheresis had a significantly more rapid reduction of serum concentrations of antibodies against double-stranded DNA and cryoglobulins. Conclusions. Treatment with plasmapheresis plus a standard regimen of prednisone and cyclophosphamide therapy does not improve the clinical outcome in patients with systemic lupus erythematosus and severe nephritis, as compared with the standard regimen alone.	GEORGE WASHINGTON UNIV,CTR BIOSTAT,WASHINGTON,DC 20052; UNIV IOWA,DEPT MED,IOWA CITY,IA 52242	George Washington University; University of Iowa	LEWIS, EJ (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,NEPHROL SECT,1653 W CONGRESS PKWY,CHICAGO,IL 60615, USA.			Lachin, John/0000-0001-9838-2841	NIADDK NIH HHS [R01-AM-27769, R01-AM-27770] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM027770, R01AM027769] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPEL GB, 1987, AM J MED, V83, P877, DOI 10.1016/0002-9343(87)90645-0; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALDWIN DS, 1970, ANN INTERN MED, V73, P929, DOI 10.7326/0003-4819-73-6-929; BALOW JE, 1981, NEPHRON, V27, P171, DOI 10.1159/000182050; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; Churg J, 1982, RENAL DIS CLASSIFICA, P127; CLARK WF, 1981, CAN MED ASSOC J, V125, P171; CLARK WF, 1984, PLASMA THER TRANSFUS, V5, P353; CLOUGH JD, 1990, APHERESIS, P301; Cochran W.G, 1957, STAT METHODS, V6th ed; CORREIA P, 1985, BMJ-BRIT MED J, V290, P126, DOI 10.1136/bmj.290.6462.126; DIXON WJ, 1988, BMDP STATISTICAL SOF; DONADIO JV, 1978, NEW ENGL J MED, V299, P1151, DOI 10.1056/NEJM197811232992102; Fleiss JL, 1981, STAT METHODS RATES P; FRANK MM, 1979, NEW ENGL J MED, V300, P518, DOI 10.1056/NEJM197903083001002; HALPERIN M, 1982, CONTROL CLIN TRIALS, V3, P311, DOI 10.1016/0197-2456(82)90022-8; JONES JV, 1981, J LAB CLIN MED, V97, P589; JONES JV, 1976, LANCET, V1, P709; JONES JV, 1982, CLIN RHEUM DIS, V8, P243; JONES JV, 1979, Q J MED, V48, P555; JONES JV, 1981, ARTHRITIS RHEUM, V24, P1113, DOI 10.1002/art.1780240901; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LACHIN JM, 1992, CONTROL CLIN TRIALS, V13, P62, DOI 10.1016/0197-2456(92)90030-4; LEWIS EJ, 1982, AM J KIDNEY DIS, V2, P182; LEWIS EJ, 1987, AM J KIDNEY DIS, V10, P192, DOI 10.1016/S0272-6386(87)80174-9; MAGIL AB, 1984, MEDICINE, V63, P210, DOI 10.1097/00005792-198407000-00003; Morel-Maroger L, 1976, Adv Nephrol Necker Hosp, V6, P79; POHL MA, 1983, KIDNEY INT, V23, P131; POLLAK VE, 1964, J LAB CLIN MED, V63, P537; Randles R, 1979, INTRO THEORY NONPARA; ROBERTS JL, 1978, AM J MED, V65, P437, DOI 10.1016/0002-9343(78)90770-2; SCHWARTZ MM, 1989, AM J KIDNEY DIS, V13, P273, DOI 10.1016/S0272-6386(89)80033-2; SCHWARTZ MM, 1989, KIDNEY INT, V36, P891, DOI 10.1038/ki.1989.276; Searle S.R., 1971, LINEAR MODELS; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WYSENBECK AJ, 1981, PLASMA THER TRANSF T, V2, P61; 1985, SAS USERS GUIDE STAT	38	354	367	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1373	1379		10.1056/NEJM199205213262101	http://dx.doi.org/10.1056/NEJM199205213262101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1569973	Bronze			2022-12-28	WOS:A1992HU89000001
J	SHOWSTACK, J; FEIN, O; FORD, D; KAUFMAN, A; CROSS, A; MADOFF, M; GOLDBERG, H; ONEIL, E; MOORE, G; SCHROEDER, S; INUI, T				SHOWSTACK, J; FEIN, O; FORD, D; KAUFMAN, A; CROSS, A; MADOFF, M; GOLDBERG, H; ONEIL, E; MOORE, G; SCHROEDER, S; INUI, T			HEALTH OF THE PUBLIC - THE ACADEMIC RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Aging of the population, increasing prevalence of chronic and disabling illnesses with multiple social and behavioral risk factors, concern about quality of care, and escalating costs of medical care require fundamental changes in the way that academic health centers discharge their mission. This article describes a newly developed "Mission Statement" for academic health centers that wish to contribute positively to the health of the populations that they serve. A shift toward addressing the needs of the public may produce increasing institutional strength, long-run stability, and enhanced productivity, as well as higher quality, more cost-effective care for patients. Seventeen centers in the Health of the Public Program are currently conducting activities that implement the described mission elements. The goals and objectives described herein create a foundation for change, with more balanced institutional goals, and could turn an emerging confrontation between academe and its public into an opportunity for both.	HLTH PUBL PROGRAM, 735 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; COLUMBIA UNIV, NEW YORK, NY 10027 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; UNIV NEW MEXICO, ALBUQUERQUE, NM 87131 USA; UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; TUFTS UNIV, BOSTON, MA 02111 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; DUKE UNIV, PEW HLTH PROFESS PROGRAM, DURHAM, NC 27706 USA; HARVARD COMMUNITY HLTH PLAN, BOSTON, MA USA	University of California System; University of California San Francisco; Columbia University; Johns Hopkins University; University of New Mexico; University of North Carolina; University of North Carolina Chapel Hill; Tufts University; University of Washington; University of Washington Seattle; Duke University			Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				GOLDBERG HI, 1991, ACAD MED, V66, P499, DOI 10.1097/00001888-199109000-00001; KAUFMAN A, 1989, ACAD MED, V64, P285, DOI 10.1097/00001888-198906000-00001; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SHELINE B, 1990, TEACH LEARN MED, V2, P170; 1991, DHHS PHS9150213 OFF	5	64	64	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2497	2502		10.1001/jama.267.18.2497	http://dx.doi.org/10.1001/jama.267.18.2497			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1573727				2022-12-28	WOS:A1992HT06800030
J	SETTLEMAN, J; NARASIMHAN, V; FOSTER, LC; WEINBERG, RA				SETTLEMAN, J; NARASIMHAN, V; FOSTER, LC; WEINBERG, RA			MOLECULAR-CLONING OF CDNAS ENCODING THE GAP-ASSOCIATED PROTEIN P190 - IMPLICATIONS FOR A SIGNALING PATHWAY FROM RAS TO THE NUCLEUS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; ALIGNMENT SEARCH TOOL; ONCOGENIC RAS-P21; BINDING DOMAIN; GENE-PRODUCT; P21; RECEPTOR; SEQUENCE; KINASE; BCR	In mitogenically stimulated and tyrosine kinase-transformed cells, a substantial fraction of the ras GTPase-activating protein (GAP) forms a complex with a protein termed p190. We have cloned several cDNAs encoding the p190 protein. Analysis of the predicted protein sequence reveals three distinct domains with homology to previously described sequences. An N-terminal domain of p190 contains sequence motifs that are found in all of the known GTPases. At the C-terminus of the protein is a domain that contains sequences very similar to those found in the break-point cluster region gene product, n-chimerin, and rho GAP, all of which have been shown to possess intrinsic GAP activity on small GTPases. Finally, a 778 aa segment in the middle of p190 is nearly identical in sequence to a recently described transcriptional repressor. This raises the possibility that P190, acting via GAP, can transduce signals from p21ras to the nucleus, perhaps affecting expression of specific cellular genes.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	SETTLEMAN, J (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.				NCI NIH HHS [CA39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECLERC S, 1991, J BIOL CHEM, V266, P17333; LECLERC S, 1991, J BIOL CHEM, V266, P8711; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIVIERE LR, 1990, TECHNIQUES PROTEIN C, V2; SAMBROOK J, 1989, MOL CLONING HDB; SANDERS DA, 1990, CELL GROWTH DIFFER, V1, P251; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	43	322	327	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					539	549		10.1016/0092-8674(92)90454-K	http://dx.doi.org/10.1016/0092-8674(92)90454-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581965				2022-12-28	WOS:A1992HT07800015
J	LI, Y; BOLLAG, G; CLARK, R; STEVENS, J; CONROY, L; FULTS, D; WARD, K; FRIEDMAN, E; SAMOWITZ, W; ROBERTSON, M; BRADLEY, P; MCCORMICK, F; WHITE, R; CAWTHON, R				LI, Y; BOLLAG, G; CLARK, R; STEVENS, J; CONROY, L; FULTS, D; WARD, K; FRIEDMAN, E; SAMOWITZ, W; ROBERTSON, M; BRADLEY, P; MCCORMICK, F; WHITE, R; CAWTHON, R			SOMATIC MUTATIONS IN THE NEUROFIBROMATOSIS-1 GENE IN HUMAN TUMORS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; THYROID CARCINOMA-CELLS; RAS ONCOGENES; TYPE-1 GENE; POINT MUTATIONS; GAP; DIFFERENTIATION; EXPRESSION; TRANSFORMATION; CHILDHOOD	The neurofibromatosis 1 (NF1) gene product, neurofibromin, contains a GTPase-activating protein (GAP)-related domain, or NF1 GRD, that is able to down-regulate p21ras by stimulating its intrinsic GTPase. Since p21ras-GTP is a major regulator of growth and differentiation, mutant neurofibromins resulting from somatic mutations in the NF1 gene might interfere with ras signaling pathways and contribute to the development of tumors. We describe an amino acid substitution in the NF1 GRD, altering Lys-1423, that has occurred in three tumor types: colon adenocarcinoma, myelodysplastic syndrome, and anaplastic astrocytoma, and in one family with neurofibromatosis 1. The GAP activity of the mutant NF1 GRD is 200- to 400-fold lower than that of wild type, whereas binding affinity is unaffected. Thus, germline mutations in NF1 that cause neurofibromatosis 1 can also occur in somatic cells and contribute to the development of sporadic tumors, including tumors not associated with neurofibromatosis 1.	UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT NEUROSURG,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,HUMAN MOLEC BIOL & GENET PROGRAM,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT OBSTET & GYNECOL,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DNA DIAGNOST LAB,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84112; CHIRON CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608; KAROLINSKA INST,DEPT CLIN GENET,S-10401 STOCKHOLM 60,SWEDEN	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Novartis; Karolinska Institutet	LI, Y (corresponding author), UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BLATT J, 1986, CANCER, V57, P1225, DOI 10.1002/1097-0142(19860315)57:6<1225::AID-CNCR2820570627>3.0.CO;2-P; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Cohen B H, 1989, Oncology (Williston Park), V3, P23; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; KIBIRIGE MS, 1989, PEDIATR HEMAT ONCOL, V6, P319, DOI 10.3109/08880018909034303; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LYONS J, 1988, BLOOD, V71, P1707; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLEY JF, 1991, CANCER RES, V51, P1596; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADUA RA, 1988, LEUKEMIA, V2, P503; PETTY EM, 1991, NUCLEIC ACIDS RES, V19, P690, DOI 10.1093/nar/19.3.690; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YOKOTA J, 1988, ONCOGENE, V3, P471	37	310	320	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					275	281		10.1016/0092-8674(92)90408-5	http://dx.doi.org/10.1016/0092-8674(92)90408-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568247				2022-12-28	WOS:A1992HQ18300007
J	TURNER, BM; BIRLEY, AJ; LAVENDER, J				TURNER, BM; BIRLEY, AJ; LAVENDER, J			HISTONE-H4 ISOFORMS ACETYLATED AT SPECIFIC LYSINE RESIDUES DEFINE INDIVIDUAL CHROMOSOMES AND CHROMATIN DOMAINS IN DROSOPHILA POLYTENE NUCLEI	CELL			English	Article							NUCLEOSOME; SITES; DNA; HYPERACETYLATION; TRANSCRIPTION; SEQUENCES; HETEROCHROMATIN; INITIATION; ANTIBODIES; FREQUENCY	Histone H4 isoforms acetylated at lysines 5, 8, 12, or 16 have been shown, by indirect immunofluorescence with site-specific antisera, to have distinct patterns of distribution in interphase, polytene chromosomes from Drosophila larvae. H4 molecules acetylated at lysines 5 or 8 are distributed in overlapping, but nonidentical, islands throughout the euchromatic chromosome arms. Beta-heterochromatin in the chromocenter is depleted in these isoforms, but relatively enriched in H4 acetylated at lysine 12. H4 acetylated at lysine 16 is found at numerous sites along the transcriptionally hyperactive X chromosome in male larvae, but not in male autosomes or any chromosome in female cells. These findings support the hypothesis that H4 molecules acetylated at particular sites mediate unique and specific effects on chromatin function.	UNIV BIRMINGHAM, SCH BIOL SCI, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Birmingham	TURNER, BM (corresponding author), UNIV BIRMINGHAM, SCH MED, DEPT ANAT, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFAGEME CR, 1974, J BIOL CHEM, V249, P3729; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ASHBURNER M, 1989, DROSOPHILA LABORATOR; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; COUPPEZ M, 1987, J BIOL CHEM, V262, P2854; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HILL CS, 1990, EUR J BIOCHEM, V187, P145, DOI 10.1111/j.1432-1033.1990.tb15288.x; IMAI BS, 1986, J BIOL CHEM, V261, P8784; IP YT, 1988, J BIOL CHEM, V263, P14044; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KORGE G, 1987, STRUCTURE FUNCTION E, P27; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MIKLOS GLG, 1988, P NATL ACAD SCI USA, V85, P2051, DOI 10.1073/pnas.85.7.2051; MUNKS RJL, 1991, FEBS LETT, V284, P245, DOI 10.1016/0014-5793(91)80695-Y; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; ROBERGE M, 1991, FEBS LETT, V288, P215, DOI 10.1016/0014-5793(91)81037-9; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; TURNER BM, 1990, J CELL SCI, V96, P335; TURNER BM, 1991, J CELL SCI, V99, P13; WHITLOCK JP, 1977, J BIOL CHEM, V252, P6516; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	40	472	478	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					375	384		10.1016/0092-8674(92)90417-B	http://dx.doi.org/10.1016/0092-8674(92)90417-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568251				2022-12-28	WOS:A1992HQ18300016
J	CREIGHTON, PA; EVANS, AM				CREIGHTON, PA; EVANS, AM			AUDIT OF PRACTICE BASED CERVICAL SMEAR PROGRAM - COMPLETION OF THE CYCLE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine the effectiveness of a practice based cervical screening programme and the changing pattern of abnormal smear results and to improve the quality of care provided for patients. Design-Audit of practice field data on cervical screening from 1980 to 1990. Changes in the programme were made after analysis of first five years' data. Setting-Mixed urban and rural practice of 10 900 patients in Northumberland. Subjects-Women aged 20-65 who had not had a hysterectomy. Results-2356 (85.1%) of the 2767 targeted women had a test during 1980-5 and 2498 (89.5%) of the 2790 women had a test during 1985-90. Inviting women aged 20-25 to attend for a test increased coverage from 45.8% (146/319) in 1980-5 to 82.5% (282/342) in 1985-90. The proportion of women with abnormalities requiring hospital referral rose in the second half of the study, especially among younger women (from 17/39 (44%) to 45/64 (70%) in women aged 25-34). Conclusions-Practice based cervical screening programmes can be highly effective. Cytological abnormalities affect patients psychologically as well as physically and practices should provide support and explanation for patients with abnormal results. Data from individual practices should be aggregated to allow health authorities to plan secondary care effectively.			CREIGHTON, PA (corresponding author), BROOMHILL HLTH CTR, S BROOMHILL NE65 0SR, NORTHD, ENGLAND.							Draper G J, 1982, Health Trends, V14, P37; DUNCAN ID, 1989, UPDATE, V38, P1107; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; JEWELL D, 1988, PRACTITIONER, V232, P484; PATERSON MEL, 1984, BRIT MED J, V289, P896, DOI 10.1136/bmj.289.6449.896; 1989, HLTH NORTHUMBERLAND; 1986, BMJ, V293, P659; 1991, INTEGRATING PRIMARY	8	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					963	966		10.1136/bmj.304.6832.963	http://dx.doi.org/10.1136/bmj.304.6832.963			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581721	Green Published, Bronze			2022-12-28	WOS:A1992HP06400025
J	HILDEBRANDT, M; NELLEN, W				HILDEBRANDT, M; NELLEN, W			DIFFERENTIAL ANTISENSE TRANSCRIPTION FROM THE DICTYOSTELIUM EB4 GENE LOCUS - IMPLICATIONS ON ANTISENSE-MEDIATED REGULATION OF MESSENGER-RNA STABILITY	CELL			English	Article							3' UNTRANSLATED REGION; REVERSE TRANSCRIPTION; GROWTH-FACTOR; CYCLIC-AMP; DISCOIDEUM; EXPRESSION; TRANSFORMATION; CELLS; IDENTIFICATION; POLYMERASE	The 2.2 kb mRNA of the Dictyostelium discoideum prespore gene EB4-PSV is constitutively transcribed during growth and development, but the message is only accumulated when cells form aggregates and establish the prespore-prestalk pattern. Disruption of the pattern by mechanical disaggregation results in a rapid loss of the mRNA, while transcription remains nearly unchanged. In early development and after disaggregation, when the mRNA is unstable, a 1.8 kb antisense transcript originating from the same gene locus is detected. This RNA has apparently no coding capacity and is transcriptionally regulated by a promoter located within the translated region of the gene. Excess transcription of antisense RNA in vegetative cells and after disaggregation suggests its involvement in the control of mRNA stability. In agreement with this assumption, the inhibition of RNA synthesis during disaggregation prevents destabilization of the mRNA. This stability regulation of an endogenous mRNA is reminiscent of the loss of specific mRNAs in cells transformed with antisense constructs.			HILDEBRANDT, M (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.							ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; AMARA JF, 1987, MOL CELL BIOL, V7, P4585, DOI 10.1128/MCB.7.12.4585; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; CANNON M, 1990, PLANT MOL BIOL, V15, P39, DOI 10.1007/BF00017722; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HARLAND R, 1988, DEVELOPMENT, V102, P837; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HILDEBRANDT M, 1991, DEV BIOL, V144, P212, DOI 10.1016/0012-1606(91)90492-L; HILDEBRANDT M, 1991, BIOCHEM BIOPH RES CO, V181, P884, DOI 10.1016/0006-291X(91)91273-F; HILDEBRANDT M, 1991, DEV GENET, V12, P163, DOI 10.1002/dvg.1020120125; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LOOMIS WF, 1991, GENE REGULATION BIOL, P197; MANGIAROTTI G, 1989, BIOCHEM SOC SYMP, V55, P77; MANGIAROTTI G, 1989, DEVELOPMENT, V106, P473; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1982, DEV BIOL, V98, P82; MANIAK M, 1990, NUCLEIC ACIDS RES, V18, P5375, DOI 10.1093/nar/18.18.5375; MANIAK M, 1989, ANAL BIOCHEM, V176, P78, DOI 10.1016/0003-2697(89)90275-3; MANROW RE, 1988, MOL CELL BIOL, V8, P4088, DOI 10.1128/MCB.8.10.4088; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MAY T, 1991, MECH DEVELOP, V33, P147, DOI 10.1016/0925-4773(91)90081-G; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; OKANO H, 1988, EMBO J, V7, P3407, DOI 10.1002/j.1460-2075.1988.tb03214.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TSE WT, 1990, GENE, V88, P293, DOI 10.1016/0378-1119(90)90047-U; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x	48	123	123	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					197	204		10.1016/0092-8674(92)90130-5	http://dx.doi.org/10.1016/0092-8674(92)90130-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555240				2022-12-28	WOS:A1992HM44500018
J	BERGELSON, JM; SHEPLEY, MP; CHAN, BMC; HEMLER, ME; FINBERG, RW				BERGELSON, JM; SHEPLEY, MP; CHAN, BMC; HEMLER, ME; FINBERG, RW			IDENTIFICATION OF THE INTEGRIN VLA-2 AS A RECEPTOR FOR ECHOVIRUS-1	SCIENCE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; RHINOVIRUS RECEPTOR; COLLAGEN RECEPTOR; CELLULAR RECEPTOR; LAMININ RECEPTOR; HELA-CELLS; T-CELLS; POLIOVIRUS; PROTEIN; FIBRONECTIN	Cell surface receptors for echovirus, a common human pathogen, were identified with monoclonal antibodies that protected susceptible cells from infection with echovirus 1. These monoclonal antibodies, which prevented virus attachment to specific receptor sites, recognized the alpha and beta-subunits of the integrin VLA-2 (alpha-2-beta-1), a receptor for collagen and laminin. RD rhabdomyosarcoma cells expressed little VLA-2, did not bind to S-35-labeled virus, and resisted infection until transfected with complementary DNA encoding the alpha-2 subunit of VLA-2. Thus, integrins, adhesion receptors important in interactions between cells and with the extracellular matrix, can mediate virus attachment and infection.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BERGELSON, JM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, INFECT DIS LAB, BOSTON, MA 02115 USA.		Finberg, Robert W/E-3323-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20382] Funding Source: Medline; NIGMS NIH HHS [GM 38903] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BERGELSON JM, UNPUB; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHERRY J, 1983, INFECTIOUS DISEASE F, pCH7; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CROWELL RL, 1983, COMPR VIROL, V18, P1; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MELNICK JL, 1990, VIROLOGY, pCH21; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MODLIN JF, 1988, PEDIATR INFECT DIS J, V7, P311, DOI 10.1097/00006454-198805000-00002; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SHEPLEY MP, 1988, P NATL ACAD SCI USA, V85, P7743, DOI 10.1073/pnas.85.20.7743; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; TYLER KL, 1990, VIROLOGY, pCH10; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	38	250	259	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1992	255	5052					1718	1720		10.1126/science.1553561	http://dx.doi.org/10.1126/science.1553561			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553561				2022-12-28	WOS:A1992HK81200043
J	MUIJEN, M; MARKS, I; CONNOLLY, J; AUDINI, B				MUIJEN, M; MARKS, I; CONNOLLY, J; AUDINI, B			HOME BASED CARE AND STANDARD HOSPITAL-CARE FOR PATIENTS WITH SEVERE MENTAL-ILLNESS - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							PROGRAM	Objective - To compare the efficacy of home based care with standard hospital care in treating serious mental illness. Design - Randomised controlled trial. Setting - South Southwark, London. Patients - 189 patients aged 18-64 living in catchment area. 92 were randomised to home based care (daily living programme) and 97 to standard hospital care. At three months follow up 68 home care and 60 hospital patients were evaluated. Main outcome measures - Use of hospital beds, psychiatric diagnosis, social functioning, patients' and relatives' satisfaction, and activity of daily living programme staff. Results - Home care reduced hospital stay by 80% (median stay six days in home care group, 53 days in hospital group) and did not increase the number of admissions compared with hospital care. On clinical and social outcome there was a non-significant trend in favour of home care, but both groups showed big improvements. On the global adjustment scale home care patients improved by 26.8 points and the hospital group by 21.6 points (difference 5.2; 95% confidence interval -1.5 to 12). Other rating scales showed similar trends. Home care patients required a wide range of support in areas such as housing, finance, and work. Only three patients dropped out from the programme. Conclusions - Home based care may offer some slight advantages over hospital based care for patients with serious mental illness and their relatives. The care is intensive, but the low drop out rate suggests appreciation. Changes to traditional training for mental health workers are required.	MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	South London & Maudsley NHS Trust; University of London; King's College London; University of London; King's College London								BROWN P, 1985, TRANSFER CARE PSYCHI; BRUN P, 1981, AM J PSYCHIAT, V138, P736; DAVIS AE, 1972, AM J ORTHOPSYCHIAT, V42, P375, DOI 10.1111/j.1939-0025.1972.tb02504.x; DEAN C, 1990, BRIT MED J, V301, P1021, DOI 10.1136/bmj.301.6759.1021; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; HOULT J, 1983, AUST NZ J PSYCHIAT, V17, P160, DOI 10.3109/00048678309160000; ING JK, 1974, DESCRIPTION CLASSIFI; KIESLER CA, 1982, AM PSYCHOL, V37, P349, DOI 10.1037/0003-066X.37.4.349; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; MARKS I, 1988, B ROYAL COLLEGE PSYC, V12, P22; MELTZER D, 1991, BRIT MED J, V303, P1023; MUIJEN M, 1989, B ROYAL COLLEGE PSYC, V13, P352; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PEPPER B, 1981, HOSP COMMUNITY PSYCH, V32, P436; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; TEST MA, 1980, ARCH GEN PSYCHIAT, V37, P409; WEISSMAN MM, 1974, ARCH GEN PSYCHIAT, V30, P771; 1986, MAKING REALITY COMMU; 1975, BETTER SERVICES MENT; 1989, CARING PEOPLE	20	135	136	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					749	754		10.1136/bmj.304.6829.749	http://dx.doi.org/10.1136/bmj.304.6829.749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK800	1571681	Bronze, Green Published			2022-12-28	WOS:A1992HK80000021
J	RYAN, M				RYAN, M			RUSSIAN REPORT - PRIORITIES FOR THE NEW HEALTH MINISTER	BRITISH MEDICAL JOURNAL			English	Article											RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							BORODIN V, 1991, MEDITISINSKAYA  1122, P1; DAVIS C, 1980, RISING INFANT MORTAL, P7; GADASINA A, 1991, MEDITSINSKAYA   1220, P1; VEDOMOSTI S, 1991, EZDA DEPUTATOV RSFSR, V48, P1947	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					563	565		10.1136/bmj.304.6826.563	http://dx.doi.org/10.1136/bmj.304.6826.563			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559067	Green Published, Bronze			2022-12-28	WOS:A1992HG59900033
J	BETZ, WJ; BEWICK, GS				BETZ, WJ; BEWICK, GS			OPTICAL ANALYSIS OF SYNAPTIC VESICLE RECYCLING AT THE FROG NEUROMUSCULAR-JUNCTION	SCIENCE			English	Article							SYNAPSIN-I; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; NERVE-TERMINALS; PROTEIN; ACETYLCHOLINE; MEMBRANE; EXOCYTOSIS	The fluorescent dyes FM1-43 and RH414 label motor nerve terminals in an activity-dependent fashion that involves dye uptake by synaptic vesicles that are recycling. This allows optical monitoring of vesicle recycling in living nerve terminals to determine how recycled vesicles reenter the vesicle pool. The results suggest that recycled vesicles mix with the pool morphologically and functionally. One complete cycle of release of transmitter, recycling of a vesicle, and rerelease of transmitter appears to take about 1 minute.			BETZ, WJ (corresponding author), UNIV COLORADO, SCH MED, DEPT PHYSIOL, DENVER, CO 80262 USA.		Bewick, Guy/AAL-8214-2021	Bewick, Guy/0000-0001-8266-7797	NINDS NIH HHS [NS23466, NS10207] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010207, R01NS023466] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARKER LA, 1972, BIOCHEM J, V130, P1063, DOI 10.1042/bj1301063; BETZ W J, 1991, Society for Neuroscience Abstracts, V17, P1157; BETZ W J, 1990, Society for Neuroscience Abstracts, V16, P53; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; CECCARELLI B, 1972, J CELL BIOL, V54, P30, DOI 10.1083/jcb.54.1.30; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; COLLIER B, 1969, CAN J PHYSIOL PHARM, V47, P127, DOI 10.1139/y69-023; HEUSER JE, 1989, Q J EXP PHYSIOL CMS, V74, P1051, DOI 10.1113/expphysiol.1989.sp003333; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; ISRAEL M, 1990, J NEUROCHEM, V55, P1758, DOI 10.1111/j.1471-4159.1990.tb04966.x; ISRAEL M, 1986, P NATL ACAD SCI USA, V83, P9226, DOI 10.1073/pnas.83.23.9226; KOPIN IJ, 1968, J PHARMACOL EXP THER, V161, P271; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; POTTER LT, 1970, J PHYSIOL-LONDON, V206, P145, DOI 10.1113/jphysiol.1970.sp009003; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; TARELLI FT, 1990, PROG BRAIN RES, V84, P83; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VALTORTA F, 1988, NEUROSCIENCE, V24, P593, DOI 10.1016/0306-4522(88)90353-3; WHITTAKER VP, 1990, PROG BRAIN RES, V84, P419; WHITTAKER VP, 1987, ANN NY ACAD SCI, V493, P77, DOI 10.1111/j.1749-6632.1987.tb27185.x; ZIMMERMANN H, 1989, CELL BIOL INT REP, V13, P993, DOI 10.1016/0309-1651(89)90015-5; ZIMMERMANN H, 1979, NEUROSCIENCE, V4, P1773, DOI 10.1016/0306-4522(79)90058-7; ZIMMERMANN H, 1988, HDB EXPT PHARM, V86, P349	27	638	646	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 10	1992	255	5041					200	203		10.1126/science.1553547	http://dx.doi.org/10.1126/science.1553547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553547				2022-12-28	WOS:A1992GY70400037
J	HOLMVANG, G				HOLMVANG, G			USEFULNESS OF MRI IN AORTIC DISSECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	0	0	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1670	1670						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588980				2022-12-28	WOS:A1992HY62800005
J	COTTON, PB				COTTON, PB			THERAPEUTIC GASTROINTESTINAL ENDOSCOPY - PROBLEMS IN PROVING EFFICACY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BILE-DUCT STONES; SPHINCTEROTOMY; SURGERY; TRIAL				COTTON, PB (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC 27710, USA.							COTTON PB, 1989, LANCET, V2, P213; GEENEN JE, 1989, NEW ENGL J MED, V320, P82, DOI 10.1056/NEJM198901123200203; JOHNSON AG, 1987, BRIT J SURG, V74, P555, DOI 10.1002/bjs.1800740703; LAI ECS, 1992, NEW ENGL J MED, V326, P1582, DOI 10.1056/NEJM199206113262401; MORRISSEY JF, 1991, NEW ENGL J MED, V325, P1214, DOI 10.1056/NEJM199110243251705; MORRISSEY JF, 1991, NEW ENGL J MED, V325, P1142, DOI 10.1056/NEJM199110173251606; NEOPTOLEMOS JP, 1987, BRIT MED J, V294, P470, DOI 10.1136/bmj.294.6570.470; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; SMITH AC, 1989, GUT, V30, pA1513; SPEER AG, 1987, LANCET, V2, P57, DOI 10.1016/S0140-6736(87)92733-4; STEIGMANN GV, 1992, NEW ENGL J MED, V326, P1527; WATANAPA P, 1992, BRIT J SURG, V79, P8, DOI 10.1002/bjs.1800790105; WICKHAM JEA, 1987, BRIT MED J, V295, P1581, DOI 10.1136/bmj.295.6613.1581; 1989, JAMA-J AM MED ASSOC, V262, P1369	14	18	18	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1626	1628		10.1056/NEJM199206113262408	http://dx.doi.org/10.1056/NEJM199206113262408			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584265				2022-12-28	WOS:A1992HX63300009
J	ANDERSON, EG				ANDERSON, EG			DYING TO LIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2736	2736						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578586				2022-12-28	WOS:A1992HV26500007
J	BREO, DL				BREO, DL			JFK DEATH .2. DALLAS MDS RECALL THEIR MEMORIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2804	2807		10.1001/jama.267.20.2804	http://dx.doi.org/10.1001/jama.267.20.2804			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578601				2022-12-28	WOS:A1992HV26500032
J	CLINTON, JJ				CLINTON, JJ			ACUTE PAIN MANAGEMENT CAN BE IMPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AGCY HLTH CARE POLICY & RES,OFF FORUM,SUITE 401,2101 E JEFFERSON ST,ROCKVILLE,MD 20852, USA.							1987, PAIN, V30, P69; 1989, ANESTHESIOL CLIN N A, V7, P1	2	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2580	2580		10.1001/jama.267.19.2580	http://dx.doi.org/10.1001/jama.267.19.2580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573734				2022-12-28	WOS:A1992HT82300004
J	IKURA, M; CLORE, GM; GRONENBORN, AM; ZHU, G; KLEE, CB; BAX, A				IKURA, M; CLORE, GM; GRONENBORN, AM; ZHU, G; KLEE, CB; BAX, A			SOLUTION STRUCTURE OF A CALMODULIN-TARGET PEPTIDE COMPLEX BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							LIGHT CHAIN KINASE; NUCLEAR-MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; MEMBRANE CA-2+ PUMP; BINDING DOMAIN; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; HETERONUCLEAR NMR; PROTEIN-KINASE; CENTRAL HELIX	The three-dimensional solution structure of the complex between calcium-bound calmodulin (Ca2+-CaM) and a 26-residue synthetic peptide comprising the CaM binding domain (residues 577 to 602) of skeletal muscle myosin light chain kinase, has been determined using multidimensional heteronuclear filtered and separated nuclear magnetic resonance spectroscopy. The two domains of CaM (residues 6 to 73 and 83 to 146) remain essentially unchanged upon complexation. The long central helix (residues 65 to 93), however, which connects the two domains in the crystal structure of Ca2+-CaM, is disrupted into two helices connected by a long flexible loop (residues 74 to 82), thereby enabling the two domains to clamp residues 3 to 21 of the bound peptide, which adopt a helical conformation. The overall structure of the complex is globular, approximating an ellipsoid of dimensions 47 by 32 by 30 angstroms. The helical peptide is located in a hydrophobic channel that passes through the center of the ellipsoid at an angle of approximately 45-degrees with its long axis. The complex is mainly stabilized by hydrophobic interactions which, from the CaM side, involve an unusually large number of methionines. Key residues of the peptide are Trp4 and Phe17, which serve to anchor the amino- and carboxyl-terminal halves of the peptide to the carboxyl- and amino-terminal domains of CaM, respectively. Sequence comparisons indicate that a number of peptides that bind CaM with high affinity share this common feature containing either aromatic residues or long-chain hydrophobic ones separated by a stretch of 12 residues, suggesting that they interact with CaM in a similar manner.	NIDDKD, CHEM PHYS LAB, BLDG 2, BETHESDA, MD 20892 USA; UNIV MARYLAND, CHEM PHYS PROGRAM, COLLEGE PK, MD 20740 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525; Ikura, Mitsuhiko/0000-0002-9524-1303				ALA A, 1991, BIOCHEMISTRY-US, V30, P5498; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P1; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, IN PRESS BIOCHEMISTR; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BLUMENTHAL DK, 1988, MOL ASPECTS CELLULAR, V5, P341; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; FORSEN HJ, 1966, CALCIUM CELL FUNCTIO, V6, P113; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HUBBAD MJ, 1989, BIOCHEMISTRY-US, V28, P1867; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4569; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P1188, DOI 10.1021/bi00219a004; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; KLEE CB, UNPUB; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MATSUSHIMA N, 1989, J BIOCHEM, V105, P883, DOI 10.1093/oxfordjournals.jbchem.a122773; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ONEIL KT, 1989, PROTEINS, V6, P284, DOI 10.1002/prot.340060311; ONO T, 1989, J BIOL CHEM, V264, P2081; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; PRECHEUR B, 1992, BIOCHEMISTRY-US, V31, P229, DOI 10.1021/bi00116a032; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8; ZUIDERWEG ERP, 1991, J AM CHEM SOC, V113, P370, DOI 10.1021/ja00001a060; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	89	1192	1203	3	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					632	638		10.1126/science.1585175	http://dx.doi.org/10.1126/science.1585175			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585175				2022-12-28	WOS:A1992HR18500024
J	DOLE, VP				DOLE, VP			HAZARDS OF PROCESS REGULATIONS - THE EXAMPLE OF METHADONE-MAINTENANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DOLE, VP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							WEBSTERS 9TH NEW COL	1	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2234	2235		10.1001/jama.267.16.2234	http://dx.doi.org/10.1001/jama.267.16.2234			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556800				2022-12-28	WOS:A1992HN84100036
J	SMITH, J				SMITH, J			THE NEW NHS - 1ST YEARS EXPERIENCE - WEST-SUFFOLK - A CHANGING WORLD	BRITISH MEDICAL JOURNAL			English	Article																		1992, BRIT MED J, V304, P907	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1036	1039		10.1136/bmj.304.6833.1036	http://dx.doi.org/10.1136/bmj.304.6833.1036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586790	Bronze, Green Published			2022-12-28	WOS:A1992HQ14200026
J	BAIN, J				BAIN, J			THE NEW NHS - 1ST YEARS EXPERIENCE - BUDGET HOLDING IN CALVERTON - ONE YEAR ON	BRITISH MEDICAL JOURNAL			English	Article																		BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING	2	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					971	973		10.1136/bmj.304.6832.971	http://dx.doi.org/10.1136/bmj.304.6832.971			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581724	Bronze, Green Published			2022-12-28	WOS:A1992HP06400029
J	GRANT, A; HODDINOTT, C				GRANT, A; HODDINOTT, C			JOINT REPLACEMENT, DENTAL SURGERY, AND ANTIBIOTIC-PROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article									CARDIFF ROYAL INFIRM,DEPT ORTHOPAED SURG,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								JACOBSON JJ, 1987, ORAL SURG ORAL MED O, V63, P122, DOI 10.1016/0030-4220(87)90352-5; LINQVIST C, 1985, ACTA ORTHOP SCAND, V56, P506; NELSON JP, 1990, J BONE JOINT SURG AM, V72A, P1; SULLIVAN PM, 1990, J BONE JOINT SURG AM, V72A, P121, DOI 10.2106/00004623-199072010-00019; THYNE GM, 1991, J BONE JOINT SURG BR, V73, P191, DOI 10.1302/0301-620X.73B2.2005136	5	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					959	959		10.1136/bmj.304.6832.959	http://dx.doi.org/10.1136/bmj.304.6832.959			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581718	Green Published, Bronze			2022-12-28	WOS:A1992HP06400022
J	DONOGHUE, MJ; MORRISVALERO, R; JOHNSON, YR; MERLIE, JP; SANES, JR				DONOGHUE, MJ; MORRISVALERO, R; JOHNSON, YR; MERLIE, JP; SANES, JR			MAMMALIAN MUSCLE-CELLS BEAR A CELL-AUTONOMOUS, HERITABLE MEMORY OF THEIR ROSTROCAUDAL POSITION	CELL			English	Article							MYOSIN HEAVY-CHAIN; DIFFERENT SEGMENTAL LEVELS; SKELETAL-MUSCLES; SELECTIVE REINNERVATION; MONOCLONAL-ANTIBODY; PATTERN-FORMATION; SATELLITE CELLS; MYOGENIC CELLS; RE-INNERVATION; NERVOUS-SYSTEM	We previously documented a > 100-fold rostrocaudal gradient of chloramphenicol acetyltransferase (CAT) expression in the muscles of adult mice that bear a myosin light chain-CAT transgene: successively more caudal muscles express successively higher levels of CAT. Here we studied the development and maintenance of this positional information in vitro. CAT levels reflect the rostrocaudal positions of the muscles from which the cells are derived in cultures established from adult muscles, in clones derived from individual adult myogenic (satellite) cells, in cultures prepared from embryonic myoblasts, and in cell lines derived by retrovirus-mediated transfer of an oncogene to satellite cells. Our results suggest that myoblasts bear a positional memory that is established in embryos, retained in adults, cell autonomous, heritable, stable to transformation, and accessible to study in clonal cell lines.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	DONOGHUE, MJ (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BENNETT MR, 1984, J NEUROSCI, V4, P2204; BIXBY JL, 1979, BRAIN RES, V169, P275, DOI 10.1016/0006-8993(79)91030-8; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; BROWN MC, 1983, NATURE, V304, P741, DOI 10.1038/304741a0; COSSU G, 1983, DEV BIOL, V98, P520, DOI 10.1016/0012-1606(83)90382-2; COSSU G, 1980, CELL DIFFER DEV, V9, P357, DOI 10.1016/0045-6039(80)90035-4; DENNIS MJ, 1981, DEV BIOL, V81, P266, DOI 10.1016/0012-1606(81)90290-6; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DUSTERHOFT S, 1990, DIFFERENTIATION, V45, P185, DOI 10.1111/j.1432-0436.1990.tb00472.x; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; GAMBKE B, 1984, J BIOL CHEM, V259, P2092; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORZA L, 1990, J HISTOCHEM CYTOCHEM, V38, P257, DOI 10.1177/38.2.2137154; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREENE E.C., 1963, AM PHILOS SOC, V2, P227; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; HARTZELL HC, 1973, DEV BIOL, V30, P153, DOI 10.1016/0012-1606(73)90054-7; HAUSCHKA SD, 1974, DEV BIOL, V37, P329, DOI 10.1016/0012-1606(74)90153-5; HOLLIDAY R, 1990, PHILOS T R SOC B, V326, P177; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KONIGSBERG I, 1961, P NATL ACAD SCI USA, V47, P1868, DOI 10.1073/pnas.47.11.1868; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; Langley J N, 1895, J Physiol, V18, P280; LASKOWSKI MB, 1988, J NEUROSCI, V8, P3094; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PURVES D, 1981, J PHYSIOL-LONDON, V313, P49, DOI 10.1113/jphysiol.1981.sp013650; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, HDB MIKROSKOPISCHEN, V11; SENNI MI, 1986, DIFFERENTIATION, V32, P181, DOI 10.1111/j.1432-0436.1986.tb00571.x; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; STREHLER EE, 1985, MOL CELL BIOL, V5, P3168, DOI 10.1128/MCB.5.11.3168; SUZUE T, 1990, NEURON, V5, P421, DOI 10.1016/0896-6273(90)90081-P; SWETT JE, 1970, AM J PHYSIOL, V219, P762, DOI 10.1152/ajplegacy.1970.219.3.762; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; THOMPSON WJ, 1990, J NEUROBIOL, V21, P212, DOI 10.1002/neu.480210114; TRISLER D, 1990, J EXP BIOL, V153, P11; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	58	82	83	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					67	77		10.1016/0092-8674(92)90119-W	http://dx.doi.org/10.1016/0092-8674(92)90119-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555243				2022-12-28	WOS:A1992HM44500007
J	BUSCH, AE; VARNUM, MD; NORTH, RA; ADELMAN, JP				BUSCH, AE; VARNUM, MD; NORTH, RA; ADELMAN, JP			AN AMINO-ACID MUTATION IN A POTASSIUM CHANNEL THAT PREVENTS INHIBITION BY PROTEIN-KINASE-C	SCIENCE			English	Article							K+-CHANNEL; MEMBRANE-PROTEIN; XENOPUS OOCYTES; ION CHANNELS; RAT UTERUS; PHOSPHORYLATION; MODULATION; CLONING; HEART; EXPRESSION	A slowly activating, voltage-dependent potassium channel protein cloned from rat kidney was expressed in Xenopus oocytes. Two activators of protein kinase C, 1-oleoyl-2-acetyl-rac-glycerol and phorbol 12,13-didecanoate, inhibited the current. This inhibition was blocked by the kinase inhibitor staurosporine. Inhibition of the current was not seen in channels in which Ser103 was replaced by Ala, although other properties of the current were unchanged. These results indicate that inhibition of the potassium current results from direct phosphorylation of the channel subunit protein at Ser103.			BUSCH, AE (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		North, Richard/GQA-6156-2022		NIDA NIH HHS [DA03160] Funding Source: Medline; NINDS NIH HHS [NS28504] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003160, R37DA003160] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P2538, DOI 10.1073/pnas.82.8.2538; BUSCH AE, IN PRESS J PHYSL LON; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HURST RS, 1991, MOL PHARMACOL, V40, P572; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; MORAN O, 1991, FEBS LETT, V279, P256, DOI 10.1016/0014-5793(91)80162-V; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PEROZO E, 1990, NEURON, V5, P685, DOI 10.1016/0896-6273(90)90222-2; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; SHEARMAN MS, 1989, PHARMACOL REV, V41, P212; SULLIVAN SK, 1990, P NATL ACAD SCI USA, V87, P4553, DOI 10.1073/pnas.87.12.4553; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TANIYAMA K, 1991, FEBS LETT, V278, P222, DOI 10.1016/0014-5793(91)80121-I; TOHSE N, 1987, AM J PHYSIOL, V253, pH1321, DOI 10.1152/ajpheart.1987.253.5.H1321; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575	26	88	91	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1705	1707		10.1126/science.1553557	http://dx.doi.org/10.1126/science.1553557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553557				2022-12-28	WOS:A1992HK81200038
J	BLOBEL, CP; WOLFSBERG, TG; TURCK, CW; MYLES, DG; PRIMAKOFF, P; WHITE, JM				BLOBEL, CP; WOLFSBERG, TG; TURCK, CW; MYLES, DG; PRIMAKOFF, P; WHITE, JM			A POTENTIAL FUSION PEPTIDE AND AN INTEGRIN LIGAND DOMAIN IN A PROTEIN ACTIVE IN SPERM-EGG FUSION	NATURE			English	Article							MEMBRANE-FUSION; RUBELLA-VIRUS; BINDING-SITE; SEQUENCE; FERTILIZATION; ADHESION; FAMILY; VENOM	THE union of sperm and egg is a special membrane fusion event that gives a signal 1 to begin development. We have hypothesized 2 that proteins mediating cell-cell fusion events resemble viral fusion proteins 3,4 and have shown that PH-30, a sperm surface protein involved in sperm-egg fusion 5, shares biochemical characteristics with viral fusion proteins 6. We report here the complementary DNA and deduced amino-acid sequences of the mature alpha and beta-subunits of PH-30. Both are type-I integral membrane glycoproteins. The alpha-subunit contains a putative fusion peptide typical of viral fusion proteins and the beta-subunit contains a domain related to a family of soluble integrin ligands found in snake venoms. Thus, the PH-30 alpha/beta complex resembles many viral fusion proteins in both its membrane topology and its predicted binding and fusion functions.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CONNECTICUT, CTR HLTH, DEPT PHYSIOL, FARMINGTON, CT 06030 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Connecticut			Wolfsberg, Tyra/D-8296-2017	Wolfsberg, Tyra/0000-0001-5646-9455				ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BOLDT J, 1989, GAMETE RES, V23, P91, DOI 10.1002/mrd.1120230109; BRONSON RA, 1990, BIOL REPROD, V43, P1019, DOI 10.1095/biolreprod43.6.1019; CALARCO PG, 1991, J ELECTRON MICR TECH, V17, P401, DOI 10.1002/jemt.1060170404; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS C G, 1990, New Biologist, V2, P410; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GAN ZR, 1988, J BIOL CHEM, V263, P198; GARSKY VM, 1989, P NATL ACAD SCI USA, V86, P4022, DOI 10.1073/pnas.86.11.4022; HARTER C, 1989, J BIOL CHEM, V264, P6459; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KATOW S, 1988, J GEN VIROL, V69, P2797, DOI 10.1099/0022-1317-69-11-2797; LAM SCT, 1987, J BIOL CHEM, V262, P947; LATHROP WF, 1990, J CELL BIOL, V111, P2939, DOI 10.1083/jcb.111.6.2939; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAZAKI S, 1990, J REPROD FERTIL, P163; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; Snell WJ, 1990, CURR OPIN CELL BIOL, V2, P821, DOI 10.1016/0955-0674(90)90079-T; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; VIDGREN G, 1987, J GEN VIROL, V68, P2347, DOI 10.1099/0022-1317-68-9-2347; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; White JM, 1989, CURR OPIN CELL BIOL, V1, P934, DOI 10.1016/0955-0674(89)90061-6; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; YANAGIMACHI Y, 1988, CURR TOP MEMBR TRANS, V32, P3	40	621	647	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					248	252		10.1038/356248a0	http://dx.doi.org/10.1038/356248a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552944				2022-12-28	WOS:A1992HJ94400061
J	PARKE, TRJ; HADDOCK, G; STEEDMAN, DJ; POLLOK, AJ; LITTLE, K				PARKE, TRJ; HADDOCK, G; STEEDMAN, DJ; POLLOK, AJ; LITTLE, K			RESPONSE TO THE KURDISH REFUGEE CRISIS BY THE EDINBURGH MEDIC-1 TEAM	BRITISH MEDICAL JOURNAL			English	Article							ACCIDENT		ROYAL HOSP SICK CHILDREN,DEPT SURG PAEDIAT,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT ANAESTHET,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	LITTLE, K (corresponding author), ROYAL INFIRM,DEPT ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							DARK PM, 1990, SCOT MED J, V35, P73, DOI 10.1177/003693309003500304; GUILD R, 1991, GUARDIAN        0508, P19; REDMOND AD, 1991, BRIT MED J, V302, P1521, DOI 10.1136/bmj.302.6791.1521; REDMOND AD, 1989, BRIT MED J, V299, P611, DOI 10.1136/bmj.299.6699.611; RUTHERFORD W, 1990, INJURY, V21, P15	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					695	697		10.1136/bmj.304.6828.695	http://dx.doi.org/10.1136/bmj.304.6828.695			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571646	Green Published, Bronze			2022-12-28	WOS:A1992HK76100029
J	WHELTON, PK; APPEL, L; CHARLESTON, J; DALCIN, AT; EWART, C; FRIED, L; KAIDY, D; KLAG, MJ; KUMANYIKA, S; STEFFEN, L; WALKER, WG; OBERMAN, A; COUNTS, K; HATAWAY, H; RACZYNSKI, J; RAPPAPORT, N; WEINSIER, R; BORHANI, NO; BERNAUER, E; BORHANI, P; DELACRUZ, C; ERTL, A; HEUSTIS, D; LEE, M; LOVELACE, W; OCONNOR, E; PEEL, L; SUGARS, C; TAYLOR, JO; CORKERY, BW; EVANS, DA; KEOUGH, ME; MORRIS, MC; PISTORINO, E; SACKS, F; CAMERON, M; CORRIGAN, S; WRIGHT, NK; APPLEGATE, WB; BREWER, A; GOODWIN, L; MILLER, S; MURPHY, J; RANDLE, J; SULLIVAN, J; LASSER, NL; BATEY, DM; DOLAN, L; HAMILL, S; KENNEDY, P; LASSER, VI; KULLER, LH; CAGGIULA, AW; MILAS, NC; YAMAMOTO, ME; VOGT, TM; GREENLICK, MR; HOLLIS, J; STEVENS, V; COHEN, JD; MATTFELDTBEMAN, M; BRINKMANN, C; ROTH, K; SHEPEK, L; HENNEKENS, CH; BURING, J; COOK, N; DANIELSON, E; EBERLEIN, K; GORDON, D; HEBERT, P; MACFADYEN, J; MAYRENT, S; ROSNER, B; SATTERFIELD, S; TOSTESON, H; VANDENBURGH, M; CUTLER, JA; BRITTAIN, E; FARRAND, M; KAUFMANN, P; LAKATOS, E; OBARZANEK, E; BELCHER, J; DOMMEYER, A; MILLS, I; NEIBLING, P; WOODS, M; GOLDMAN, BJK; BLETHEN, E; SACKS, F				WHELTON, PK; APPEL, L; CHARLESTON, J; DALCIN, AT; EWART, C; FRIED, L; KAIDY, D; KLAG, MJ; KUMANYIKA, S; STEFFEN, L; WALKER, WG; OBERMAN, A; COUNTS, K; HATAWAY, H; RACZYNSKI, J; RAPPAPORT, N; WEINSIER, R; BORHANI, NO; BERNAUER, E; BORHANI, P; DELACRUZ, C; ERTL, A; HEUSTIS, D; LEE, M; LOVELACE, W; OCONNOR, E; PEEL, L; SUGARS, C; TAYLOR, JO; CORKERY, BW; EVANS, DA; KEOUGH, ME; MORRIS, MC; PISTORINO, E; SACKS, F; CAMERON, M; CORRIGAN, S; WRIGHT, NK; APPLEGATE, WB; BREWER, A; GOODWIN, L; MILLER, S; MURPHY, J; RANDLE, J; SULLIVAN, J; LASSER, NL; BATEY, DM; DOLAN, L; HAMILL, S; KENNEDY, P; LASSER, VI; KULLER, LH; CAGGIULA, AW; MILAS, NC; YAMAMOTO, ME; VOGT, TM; GREENLICK, MR; HOLLIS, J; STEVENS, V; COHEN, JD; MATTFELDTBEMAN, M; BRINKMANN, C; ROTH, K; SHEPEK, L; HENNEKENS, CH; BURING, J; COOK, N; DANIELSON, E; EBERLEIN, K; GORDON, D; HEBERT, P; MACFADYEN, J; MAYRENT, S; ROSNER, B; SATTERFIELD, S; TOSTESON, H; VANDENBURGH, M; CUTLER, JA; BRITTAIN, E; FARRAND, M; KAUFMANN, P; LAKATOS, E; OBARZANEK, E; BELCHER, J; DOMMEYER, A; MILLS, I; NEIBLING, P; WOODS, M; GOLDMAN, BJK; BLETHEN, E; SACKS, F			THE EFFECTS OF NONPHARMACOLOGIC INTERVENTIONS ON BLOOD-PRESSURE OF PERSONS WITH HIGH NORMAL LEVELS - RESULTS OF THE TRIALS OF HYPERTENSION PREVENTION, PHASE-I	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; FISH-OIL; CALCIUM SUPPLEMENTATION; ORAL CALCIUM; MAGNESIUM; CROSSOVER; MILD	Objective.-To test the short-term feasibility and efficacy of seven nonpharmacologic interventions in persons with high normal diastolic blood pressure. Design.-Randomized control multicenter trials. Setting.-Volunteers recruited from the community, treated and followed up at special clinics. Participants.-Of 16 821 screenees, 2182 men and women, aged 30 through 54 years, with diastolic blood pressure from 80 through 89 mm Hg were selected. Of these, 50 did not return for follow-up blood pressure measurements. Interventions.-Three life-style change groups (weight reduction, sodium reduction, and stress management) were each compared with unmasked nonintervention controls over 18 months. Four nutritional supplement groups (calcium, magnesium, potassium, and fish oil) were each compared singly, in double-blind fashion, with placebo controls over 6 months. Main Outcome Measures.-Primary: change in diastolic blood pressure from baseline to final follow-up, measured by blinded observers. Secondary: changes in systolic blood pressure and intervention compliance measures. Results.-Weight reduction intervention produced weight loss of 3.9 kg (P < .01), diastolic blood pressure change of - 2.3 mm Hg (P < .01), and systolic blood pressure change of -2.9 mmHg (P < .01). Sodium reduction interventions lowered urinary sodium excretion by 44 mmol/24 h (P < .01), diastolic blood pressure by 0.9 mm Hg (P < .05), and systolic blood pressure by 1.7 mm Hg (P < .01). Despite good compliance, neither stress management nor nutritional supplements reduced diastolic blood pressure or systolic blood pressure significantly (P > .05). Conclusions.-Weight reduction is the most effective of the strategies tested for reducing blood pressure in normotensive persons. Sodium reduction is also effective. The long-term effects of weight reduction and sodium reduction, alone and in combination, require further evaluation.	NHLBI, ROOM 604, FED BLDG, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA; UNIV ALABAMA, BIRMINGHAM, AL 35294 USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA; E BOSTON NEIGHBORHOOD HLTH CTR, BOSTON, MA USA; UNIV MISSISSIPPI, JACKSON, MS 39216 USA; UNIV TENNESSEE CTR HLTH SCI, MEMPHIS, TN 38163 USA; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, NEWARK, NJ 07103 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; KAISER PERMANENTE CTR HLTH RES, PORTLAND, OR USA; ST LOUIS UNIV, SCH MED, ST LOUIS, MO 63104 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; TUFTS UNIV, BOSTON, MA 02111 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Davis; University of Mississippi; University of Tennessee System; University of Tennessee Health Science Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kaiser Permanente; Saint Louis University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; Tufts University			Appel, Larry/GLT-2608-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL037852, U01HL037853, U01HL037849] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37853, HL37849, HL37852] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1970, JAMA, V213, P1143; [Anonymous], 1988, BMJ, V297, P319; BONAA KH, 1990, NEW ENGL J MED, V322, P795, DOI 10.1056/NEJM199003223221202; CAPPUCCIO FP, 1985, BRIT MED J, V291, P235, DOI 10.1136/bmj.291.6490.235; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DYCKNER T, 1983, BMJ-BRIT MED J, V286, P1847, DOI 10.1136/bmj.286.6381.1847; FLATEN H, 1990, AM J CLIN NUTR, V52, P300, DOI 10.1093/ajcn/52.2.300; FREDRIKSON M, 1990, Annals of Behavioral Medicine, V12, P30, DOI 10.1207/s15324796abm1201_3; GROBBEE DE, 1986, LANCET, V2, P703; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; Kaufmann Peter G, 1988, Health Psychol, V7 Suppl, P209, DOI 10.1037/0278-6133.7.Suppl.209; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KNAPP HR, 1989, NEW ENGL J MED, V320, P1037, DOI 10.1056/NEJM198904203201603; LANGFORD HG, 1991, HYPERTENSION S1, V17, P155; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MASCIOLI S, 1991, HYPERTENSION S1, V17, P21; MCCARRON DA, 1985, ANN INTERN MED, V103, P825, DOI 10.7326/0003-4819-103-6-825; PATEL C, 1985, BRIT MED J, V290, P1103, DOI 10.1136/bmj.290.6475.1103; PATKI PS, 1990, BRIT MED J, V301, P521, DOI 10.1136/bmj.301.6751.521; Satterfield S, 1991, Ann Epidemiol, V1, P455; Stamler J, 1989, Hypertension, V13, pI2; STAMLER R, 1991, HYPERTENSION S1, V17, P16; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; STRAZZULLO P, 1986, HYPERTENSION, V8, P1084, DOI 10.1161/01.HYP.8.11.1084; WHELTON PK, 1989, AM J CARDIOL, V63, pG26, DOI 10.1016/0002-9149(89)90215-4; WHELTON PK, 1992, IN PRESS ANN EPIDEMI; WHELTON PK, 1989, CIRCULATION S2, V80, P301; WING LMH, 1990, J HYPERTENS, V8, P339, DOI 10.1097/00004872-199004000-00007; WRIGHT BM, 1970, LANCET, V1, P337; [No title captured]; 1985, BMJ, V291, P97; 1985, HYPERTENSION, V7, P457	36	583	588	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1213	1220		10.1001/jama.1992.03480090061028	http://dx.doi.org/10.1001/jama.1992.03480090061028			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1586398				2022-12-28	WOS:A1992HF43900022
J	ACKERS, GK; DOYLE, ML; MYERS, D; DAUGHERTY, MA				ACKERS, GK; DOYLE, ML; MYERS, D; DAUGHERTY, MA			MOLECULAR CODE FOR COOPERATIVITY IN HEMOGLOBIN	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; VALENCY HYBRID HEMOGLOBINS; LIGAND-BINDING; OXYGEN-EQUILIBRIUM; CONCENTRATION-DEPENDENCE; ALLOSTERIC TRANSITIONS; COBALT MYOGLOBINS; GLOBIN STRUCTURE; MECHANISM; PROTEINS	Although tetrameric hemoglobin has been studied extensively as a prototype for understanding mechanisms of allosteric regulation, the functional and structural properties of its eight intermediate ligation forms have remained elusive. Recent experiments on the energetics of cooperativity of these intermediates, along with assignments of their quaternary structures, have revealed that the allosteric mechanism is controlled by a previously unrecognized symmetry feature: quaternary switching from form T to form R occurs whenever heme-site binding creates a tetramer with at least one ligated subunit on each dimeric half-molecule. This "symmetry rule" translates the configurational isomers of heme-site ligation into six observed switchpoints of quaternary transition. Cooperativity arises from both "concerted" quaternary switching and "sequential" modulation of binding within each quaternary form, T and R. Binding affinity is regulated through a hierarchical code of tertiary-quaternary coupling that includes the classical allosteric models as limiting cases.			ACKERS, GK (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110, USA.			Doyle, Michael/0000-0003-4569-6315	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024486] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL40453] Funding Source: Medline; NIGMS NIH HHS [R37-GM24486] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1981, J MOL BIOL, V147, P559, DOI 10.1016/0022-2836(81)90400-9; ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ACKERS GK, 1974, P NATL ACAD SCI USA, V71, P4312, DOI 10.1073/pnas.71.11.4312; ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; ACKERS GK, 1970, ADV PROTEIN CHEM, V24, P323; AMPULSKI RS, 1969, ANAL BIOCHEM, V32, P163, DOI 10.1016/0003-2697(69)90118-3; ANDERSEN ME, 1971, J BIOL CHEM, V246, P2796; ARNONE A, 1986, J MOL BIOL, V188, P693, DOI 10.1016/S0022-2836(86)80015-8; ATHA DH, 1979, J BIOL CHEM, V254, P2390; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BLOUGH NV, 1980, J AM CHEM SOC, V102, P5683, DOI 10.1021/ja00537a050; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; CHIEN JCW, 1976, J BIOL CHEM, V251, P1670; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; DAUGHERTY MA, 1991, P NATL ACAD SCI USA, V88, P1110, DOI 10.1073/pnas.88.4.1110; DAUGHERTY MA, UNPUB; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; DEBRU C, 1990, BIOPHYS CHEM, V37, P15, DOI 10.1016/0301-4622(90)88003-B; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; DOYLE ML, 1991, BIOCHEMISTRY-US, V30, P7263, DOI 10.1021/bi00243a031; DOYLE MP, UNPUB; EDSALL J T, 1972, Journal of the History of Biology, V5, P205, DOI 10.1007/BF00346659; EDSALL JT, 1984, BIOTHERMODYNAMICS, P201; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P13, DOI 10.1021/bi00672a003; FOWLER SA, IN PRESS BIOCHEMISTR; FUNG LWM, 1976, P NATL ACAD SCI USA, V73, P1581, DOI 10.1073/pnas.73.5.1581; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; HERZFELD J, 1974, J MOL BIOL, V82, P231, DOI 10.1016/0022-2836(74)90343-X; HOFFMAN BM, 1970, P NATL ACAD SCI USA, V67, P637, DOI 10.1073/pnas.67.2.637; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6583, DOI 10.1021/bi00240a031; IMAI K, 1980, J MOL BIOL, V138, P635, DOI 10.1016/S0022-2836(80)80021-0; Imai K., 1982, ALLOSTERIC EFFECTS H; JOHNSON ML, 1984, P NATL ACAD SCI-BIOL, V81, P1093, DOI 10.1073/pnas.81.4.1093; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P364; LEE AWM, 1983, P NATL ACAD SCI-BIOL, V80, P7055, DOI 10.1073/pnas.80.23.7055; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LICATA VJ, 1990, BIOCHEMISTRY-US, V29, P9772; LOUIE G, 1988, J MOL BIOL, V201, P765, DOI 10.1016/0022-2836(88)90473-1; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MILLS FC, 1979, P NATL ACAD SCI USA, V76, P273, DOI 10.1073/pnas.76.1.273; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; MINTON A P, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1418, DOI 10.1073/pnas.71.4.1418; MIURA S, 1984, BIOCHEMISTRY-US, V23, P2492, DOI 10.1021/bi00306a027; MIURA S, 1987, BIOCHEMISTRY-US, V26, P2149, DOI 10.1021/bi00382a013; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; MOFFAT K, 1976, J MOL BIOL, V104, P669, DOI 10.1016/0022-2836(76)90128-5; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Monod J., 1972, CHANCE NECESSITY; MYERS DD, UNPUB; NOBLE RW, 1969, J MOL BIOL, V39, P479, DOI 10.1016/0022-2836(69)90139-9; OGAWA S, 1972, J MOL BIOL, V70, P315, DOI 10.1016/0022-2836(72)90542-6; PERRELLA M, 1990, BIOPHYS CHEM, V37, P211, DOI 10.1016/0301-4622(90)88020-S; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; Perrella M, 1981, Methods Enzymol, V76, P133; Perutz M. F., 1970, NATURE, V228, P734; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2174, DOI 10.1021/bi00707a027; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2163, DOI 10.1021/bi00707a026; PETTIGREW DW, 1982, P NATL ACAD SCI-BIOL, V79, P1849, DOI 10.1073/pnas.79.6.1849; SAMAJA M, 1987, J BIOL CHEM, V262, P4528; SHULMAN RG, 1975, Q REV BIOPHYS, V8, P325, DOI 10.1017/S0033583500001840; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SMITH FR, 1991, PROTEINS, V10, P81, DOI 10.1002/prot.340100202; SMITH FR, 1982, P NATL ACAD SCI USA, V84, P7089; SPEROS PC, 1991, BIOCHEMISTRY-US, V30, P7254, DOI 10.1021/bi00243a030; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; VIGGIANO G, 1979, P NATL ACAD SCI USA, V76, P3673, DOI 10.1073/pnas.76.8.3673; WEBER G, 1972, BIOCHEMISTRY-US, V11, P864, DOI 10.1021/bi00755a028; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J., 1990, BINDING LINKAGE; YONETANI T, 1974, J BIOL CHEM, V249, P682	75	299	299	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					54	63		10.1126/science.1553532	http://dx.doi.org/10.1126/science.1553532			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553532				2022-12-28	WOS:A1992GX79100034
J	BAGATELL, CJ; KNOPP, RH; VALE, WW; RIVIER, JE; BREMNER, WJ				BAGATELL, CJ; KNOPP, RH; VALE, WW; RIVIER, JE; BREMNER, WJ			PHYSIOLOGICAL TESTOSTERONE LEVELS IN NORMAL MEN SUPPRESS HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS	ANNALS OF INTERNAL MEDICINE			English	Article						TESTOSTERONE; LIPOPROTEINS, HDL CHOLESTEROL; CORONARY DISEASE; ANDROGENS; SEX FACTORS; CHOLESTEROL	CORONARY HEART-DISEASE; HORMONE-BINDING GLOBULIN; APOLIPOPROTEIN-A-I; SEX-HORMONES; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; PLASMA; LIPIDS; GONADOTROPIN; FRAMINGHAM	Objective: To investigate the role of physiologic levels of testosterone in the control of lipoproteins in healthy men. Design: A double-blind, randomized study. Setting: A university community. Participants: Fifteen healthy men, ages 20 to 36 years. Intervention: We induced acute, reversible hypogonadism in five normal men by administering daily subcutaneous injections of the gonadotropin-releasing-hormone (GnRH) antagonist, Nal-Glu, for 6 weeks. Another group of five normal men received Nal-Glu plus weekly injections of testosterone enanthate, 100 mg/wk, thereby maintaining normal serum testosterone levels. Five additional men received placebo injections. Measurements: Plasma lipids, including high-density lipoprotein (HDL) subfractions HDL2 and HDL3, apoprotein A1, and serum levels of gonadotropins, estradiol, and testosterone were measured before, during, and after treatment. Results: At the end of the treatment period, HDL cholesterol levels in men receiving Nal-Glu increased by 26% (95% Cl, 18% to 34%; P < 0.05). Levels of HDL2, HDL3, and apoprotein A1 increased by 63% (Cl, 16% to 110%), 17% (Cl, 3% to 31%), and 17% (Cl, 5% to 29%), respectively (P < 0.05 for each parameter). Total cholesterol increased by 12% (Cl, 2% to 22%). Low-density lipoprotein (LDL) cholesterol and triglyceride concentrations did not change. No statistically significant changes occurred in any lipid measurement in men receiving Nal-Glu plus androgen replacement or placebo (P > 0.05). Conclusions: Experimental hypogonadism induced by administration of a GnRH antagonist results in a statistically significant increase in HDL cholesterol, including HDL2 and HDL3. These effects are most likely due to decreased androgen levels because they are reversed by administration of antagonist together with testosterone. Our results imply that androgen levels in the normal adult male range have a suppressive effect on HDL cholesterol concentration and may contribute to the increased risk for coronary artery disease in men.	NW LIPID RES CTR, SEATTLE, WA 98104 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA	Salk Institute; University of Washington; University of Washington Seattle	BAGATELL, CJ (corresponding author), DEPT VET AFFAIRS MED CTR, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.				NICHD NIH HHS [P50-HD-12629, HD00890-01] Funding Source: Medline; PHS HHS [K0800890-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD012629] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEN M, 1985, INT J SPORTS MED, V6, P139, DOI 10.1055/s-2008-1025827; Bachorik P S, 1986, Methods Enzymol, V129, P78; BAGATELL CJ, 1989, J CLIN ENDOCR METAB, V69, P43, DOI 10.1210/jcem-69-1-43; BARRETTCONNOR E, 1988, CIRCULATION, V78, P539, DOI 10.1161/01.CIR.78.3.539; BOOKSTEIN L, 1990, ARCH INTERN MED, V150, P1653, DOI 10.1001/archinte.150.8.1653; BREMNER WJ, 1981, J CLIN INVEST, V68, P1044, DOI 10.1172/JCI110327; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; DAI WS, 1984, AM J CARDIOL, V53, P1259, DOI 10.1016/0002-9149(84)90075-4; DENNIS B, 1980, J AM DIET ASSOC, V77, P641; DUELL PB, 1990, ARCH INTERN MED, V150, P2317, DOI 10.1001/archinte.150.11.2317; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDL KE, 1990, METABOLISM, V39, P69, DOI 10.1016/0026-0495(90)90150-B; GODSLAND IF, 1987, AM HEART J, V114, P1467, DOI 10.1016/0002-8703(87)90552-7; GOLDBERG RB, 1985, J CLIN ENDOCR METAB, V60, P203, DOI 10.1210/jcem-60-1-203; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HAFFNER SM, 1983, METABOLISM, V32, P413, DOI 10.1016/0026-0495(83)90052-5; HAMALAINEN E, 1986, METABOLISM, V35, P535, DOI 10.1016/0026-0495(86)90011-9; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HEISS G, 1980, CIRCULATION, V61, P302, DOI 10.1161/01.CIR.61.2.302; HELLER RF, 1983, ACTA ENDOCRINOL-COP, V104, P253, DOI 10.1530/acta.0.1040253; HROMADOVA M, 1989, ENDOCRINOL EXP, V23, P205; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KANTOR MA, 1985, MED SCI SPORT EXER, V17, P462, DOI 10.1249/00005768-198508000-00010; KHAW KT, 1991, ARTERIOSCLER THROMB, V11, P489, DOI 10.1161/01.ATV.11.3.489; KIEL DP, 1989, AM J MED, V87, P35; KIRKLAND RT, 1987, JAMA-J AM MED ASSOC, V257, P502, DOI 10.1001/jama.257.4.502; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; LICHTENSTEIN MJ, 1987, AM J EPIDEMIOL, V126, P647, DOI 10.1093/oxfordjournals.aje.a114704; MASAREI JRL, 1986, ATHEROSCLEROSIS, V60, P79, DOI 10.1016/0021-9150(86)90090-0; MATSUMOTO AM, 1983, J CLIN ENDOCR METAB, V56, P720, DOI 10.1210/jcem-56-4-720; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MILLER NE, 1978, LIPIDS, V13, P914, DOI 10.1007/BF02533850; MOGADAM M, 1990, ARCH INTERN MED, V150, P1645, DOI 10.1001/archinte.150.8.1645; MOORE RD, 1988, AM J MED, V84, P884, DOI 10.1016/0002-9343(88)90067-8; MORRISON JA, 1979, METABOLISM, V28, P641, DOI 10.1016/0026-0495(79)90017-9; PAVLOU SN, 1991, J CLIN ENDOCR METAB, V73, P1360, DOI 10.1210/jcem-73-6-1360; PREMNER WJ, 1991, J CLIN ENDOCR METAB, V73, P465; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SCHWARTZ RS, 1987, METABOLISM, V36, P165, DOI 10.1016/0026-0495(87)90012-6; SCHWARTZ RS, 1988, METABOLISM, V37, P1128, DOI 10.1016/0026-0495(88)90188-6; SEMMENS J, 1983, METABOLISM, V32, P428, DOI 10.1016/0026-0495(83)90002-1; SORVA R, 1988, ATHEROSCLEROSIS, V69, P191, DOI 10.1016/0021-9150(88)90014-7; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TENOVER JS, 1990, J CLIN ENDOCR METAB, V71, P881, DOI 10.1210/jcem-71-4-881; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; TOM L, 1991, CLIN RES, V39, pA91; TRAN ZV, 1983, MED SCI SPORT EXER, V15, P393; Warnick G R, 1986, Methods Enzymol, V129, P101; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WINGARD DL, 1984, ANNU REV PUBL HEALTH, V5, P433, DOI 10.1146/annurev.pu.05.050184.002245	54	113	114	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				967	973		10.7326/0003-4819-116-12-967	http://dx.doi.org/10.7326/0003-4819-116-12-967			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586105				2022-12-28	WOS:A1992HY79300002
J	POTTS, JT				POTTS, JT			RECRUITMENT OF MINORITY PHYSICIANS INTO CAREERS IN INTERNAL-MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Article							SCHOOLS	Despite some initial success in the early 1970s, the important goal of increasing the numbers of under-represented minorities in medical school and on medical faculties has stalled short of proportionate representation. To further the current efforts of the Association of Professors in Medicine (APM) and other national medical groups that are devoted to improving the numbers of minorities in medicine, ideas and program information must be shared among institutions. In this spirit, we review our experience at Massachusetts General Hospital. We found that the first step toward this goal must be an institutional commitment based on increased awareness and on special effort focused on housestaff recruitment. Once the numbers of minorities increase, the department chairperson, training program directors, and other involved faculty can work with younger minority physicians; the cooperative relationship thus created can guide the development of a strong minority recruitment program without requiring an undue time commitment from minority trainees and faculty. The APM has a combined goal: to achieve early practical results in individual departments, to play a catalytic role with the community and other national medical organizations, and to increase the number of minorities entering medical school and careers in medicine generally.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	POTTS, JT (corresponding author), MASSACHUSETTS GEN HOSP, FRUIT ST, BOSTON, MA 02114 USA.							KEITH SN, 1985, NEW ENGL J MED, V313, P1519, DOI 10.1056/NEJM198512123132406; PINNWIGGINS VW, 1985, NEW ENGL J MED, V313, P1540, DOI 10.1056/NEJM198512123132410; SHEA S, 1985, NEW ENGL J MED, V313, P933, DOI 10.1056/NEJM198510103131506; WHITE LJ, 1991, ANN INTERN MED, V114, P63, DOI 10.7326/0003-4819-114-1-63; 1991, ASS AM MED COLLEGES, P1	5	8	8	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1099	1102		10.7326/0003-4819-116-12-1099	http://dx.doi.org/10.7326/0003-4819-116-12-1099			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586126				2022-12-28	WOS:A1992HY79400016
J	SCHUSTER, BL				SCHUSTER, BL			THE MATRIX OF AMBULATORY EDUCATION	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICINE	Ambulatory education has become an essential part of all internal medicine residencies. To develop excellent ambulatory education programs, we must thoroughly understand the opportunities available in such a setting, and the leaders in internal medicine must be willing to experiment with nontraditional locations and rotational formats. An "ambulatory matrix" can be constructed by program directors to help define the educational opportunities available in their institutions and to map the possibilities for educational rotations outside of the hospital wards.	UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14642 USA	University of Rochester								GIRARD DE, 1984, ARCH INTERN MED, V144, P2217, DOI 10.1001/archinte.144.11.2217; MEADOWS JC, 1986, J MED EDUC, V61, P437; Mixter G Jr, 1975, JAMA, V231 Suppl, P98; PETERSDORF RG, 1975, NEW ENGL J MED, V293, P326, DOI 10.1056/NEJM197508142930704; PHILBRICK JT, 1990, AM J MED SCI, V299, P43, DOI 10.1097/00000441-199001000-00010; WOLFE ES, 1982, J MED EDUC, V57, P468; 1991, SPECIAL REQUIREMENTS, P40	7	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1076	1079		10.7326/0003-4819-116-12-1076	http://dx.doi.org/10.7326/0003-4819-116-12-1076			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586120				2022-12-28	WOS:A1992HY79400010
J	MOFENSON, LM; SHEARER, WT; MOYE, J; NUGENT, R; WILLOUGHBY, A				MOFENSON, LM; SHEARER, WT; MOYE, J; NUGENT, R; WILLOUGHBY, A			MANIPULATING THE IMMUNE-SYSTEM WITH IMMUNE GLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											MOFENSON, LM (corresponding author), NIH,BETHESDA,MD 20892, USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				GUPTA A, 1986, AM J DIS CHILD, V140, P143, DOI 10.1001/archpedi.1986.02140160061033; RUBINSTEIN A, 1984, Pediatric Research, V18, p264A, DOI 10.1203/00006450-198404001-01026; 1991, NEW ENGL J MED, V325, P73	3	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1636	1637						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584276				2022-12-28	WOS:A1992HX63300024
J	WINN, JR				WINN, JR			FROM THE FEDERATION-OF-STATE-MEDICAL-BOARDS-OF-THE-UNITED-STATES - FEDERATION SUMMARY OF REPORTED MEDICAL BOARD ACTIONS RELEASED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		SCHNEIDMAN BS, OFFICIAL 1991 SUMMAR	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2857	2859		10.1001/jama.267.21.2857	http://dx.doi.org/10.1001/jama.267.21.2857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583742				2022-12-28	WOS:A1992HW13300004
J	TIESZEN, ME; GRUENBERG, JC				TIESZEN, ME; GRUENBERG, JC			A QUANTITATIVE, QUALITATIVE, AND CRITICAL-ASSESSMENT OF SURGICAL WASTE - SURGEONS VENTURE THROUGH THE TRASH CAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To quantitatively and qualitatively evaluate the surgical waste produced from several common surgical procedures, define categories of waste that might be readily separated for alternative disposal practices or substitution, and determine the change in surgical waste output that elimination or alternative handling methods may effect. Design.-A case series evaluating the surgical waste from five types of surgical procedures including operations of the back, heart, abdomen, hip and knee, and herniorrhaphies, prospectively identified and allocated at the availability of the investigator. Setting.-A single tertiary community teaching hospital. Outcome Measures.-Weight, volume, and percentage of disposable linen, paper, and plastic plus miscellaneous material from surgical waste with a later subset separating plastics from miscellaneous items to completely identify all categories Results.-Surgical waste weighing 610.5 lb (274.7 kg) and occupying 171.6 cu ft (5.1 m3) from 27 cases was examined. Disposable linens accounted for 39% of the weight; paper, 7%; plastic, 26%; and miscellaneous waste, 27%. By volume, disposable linen and paper accounted for 69%; plastic, 23%; and miscellaneous waste, 7%. Disposable linen, paper, and recyclable plastic accounted for 73% +/- 7% (mean +/- SD) by weight and 93% +/- 4% by volume of total surgical waste. Conclusion.-Nationally, annual surgical waste from these five procedures weighs 5.1 X 10(7) lb (2.3 X 10(7) kg) and occupies 1.4 X 10(7) cu ft (4.0 X 10(5) m3). By using reusable linen products and engaging in recycling methods currently available and feasible, we estimate that weight reductions of 73% and volume reductions of 93% in surgical waste are possible.	SAGINAW COOPERAT HOSP INC, DEPT SURG, 1000 HOUGHTON, SAGINAW, MI 48602 USA									Burks J, 1988, Hosp Mater Manage Q, V9, P17; CHADZYNSKI L, 1990, MICH MED, V89, P17; DANCER JW, 1991, MICHIGAN HOSP, V27, P4; Dutlinger B, 1987, J Healthc Mater Manage, V5, P61; Fay M F, 1990, AORN J, V51, P1493, DOI 10.1016/S0001-2092(07)66899-9; GRAVES EJ, 1991, VITAL HLTH STAT 13, V107; GROSSMAN D, 1990, DISCOVER        0411, P36; KUNES E, 1988, OMNI             FEB, P40; KUNES E, 1988, OMNI             FEB, P92; MATHIAS JM, 1990, OR MANAGER, V6, P9; Patterson P, 1990, OR Manager, V6, P8; PATTERSON P, 1990, OR MANAGER, V6, P8; PATTERSON P, 1990, OR MANAGER, V6, P6; RATHJE WL, 1991, NATIONAL GEOGRAP MAY, P117; RUTALA WA, 1989, JAMA-J AM MED ASSOC, V262, P1635, DOI 10.1001/jama.262.12.1635; WAGNER M, 1990, MOD HEALTHCARE, V20, P46; 1985, HOSP PURCHASING NEWS, V9, P14; 1989, JAMA-J AM MED ASSOC, V262, P1669; 1987, MMWR S, V36, pS2; 1985, HOSP PURCHASING NEWS, V9, P26; 1988, INVESTIGATION SOURCE	21	46	47	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2765	2768		10.1001/jama.267.20.2765	http://dx.doi.org/10.1001/jama.267.20.2765			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578596				2022-12-28	WOS:A1992HV26500024
J	BAILEY, CH; CHEN, M; KELLER, F; KANDEL, ER				BAILEY, CH; CHEN, M; KELLER, F; KANDEL, ER			SEROTONIN-MEDIATED ENDOCYTOSIS OF APCAM - AN EARLY STEP OF LEARNING-RELATED SYNAPTIC GROWTH IN APLYSIA	SCIENCE			English	Article							REGULATES NEURITE OUTGROWTH; LONG-TERM SENSITIZATION; SENSORY NEURONS INVITRO; STRUCTURAL-CHANGES; RECEPTOR; SURFACE; FACILITATION; MORPHOLOGY; MEMBRANE; CELLS	The long-term facilitation of synaptic efficacy that is induced by serotonin in dissociated cell cultures of sensory and motor neurons of Aplysia is accompanied by the growth of new synaptic connections. This growth is associated with a down-regulation in the sensory neuron of Aplysia cell adhesion molecules (apCAMs). To examine the mechanisms of this down-regulation, thin-section electron microscopy was combined with immunolabeling by gold-conjugated monoclonal antibodies specific to apCAM. Within 1 hour, serotonin led to a 50% decrease in the density of gold-labeled complexes at the surface membrane of the sensory neuron. This down-regulation was achieved by a heterologous, protein synthesis-dependent activation of the endosomal pathway, which leads to internalization and apparent degradation of apCAM. The internalization is particularly prominent at sites where the processes of the sensory neurons contact one another and may act there to destabilize process-to-process contacts that normally inhibit growth. In turn, the endocytic activation may lead to a redistribution of membrane components to sites where new synapses form.	NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	New York State Psychiatry Institute; Columbia University; Howard Hughes Medical Institute	BAILEY, CH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, 722 W 168 ST, NEW YORK, NY 10032 USA.			Keller, Flavio/0000-0002-6449-6960	NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BAILEY CC, UNPUB; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P9356, DOI 10.1073/pnas.85.23.9356; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CHENG TPO, 1985, J CELL BIOL, V101, P1473, DOI 10.1083/jcb.101.4.1473; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; COVAULT J, 1991, MOL BRAIN RES, V11, P11, DOI 10.1016/0169-328X(91)90015-P; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HELIN K, 1991, J BIOL CHEM, V266, P8363; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Hu Y., UNPUB; Huttner W B, 1991, Curr Opin Neurobiol, V1, P388, DOI 10.1016/0959-4388(91)90058-F; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLER F, 1990, J CELL BIOL, V111, P2637, DOI 10.1083/jcb.111.6.2637; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MAXFIELD FR, 1991, ACIDIFICATION ORGANE, P157; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; PFENNINGER KH, 1982, AXOPLASMIC TRANSPORT, P52; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; WALL DA, 1981, J CELL BIOL, V90, P687, DOI 10.1083/jcb.90.3.687; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633	37	294	298	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					645	649		10.1126/science.1585177	http://dx.doi.org/10.1126/science.1585177			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585177				2022-12-28	WOS:A1992HR18500026
J	SENTENAC, H; BONNEAUD, N; MINET, M; LACROUTE, F; SALMON, JM; GAYMARD, F; GRIGNON, C				SENTENAC, H; BONNEAUD, N; MINET, M; LACROUTE, F; SALMON, JM; GAYMARD, F; GRIGNON, C			CLONING AND EXPRESSION IN YEAST OF A PLANT POTASSIUM-ION TRANSPORT-SYSTEM	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; COMPLEMENTARY-DNA; ESCHERICHIA-COLI; PLASMA-MEMBRANE; GATED CHANNEL; PROTEIN; SEQUENCE; CAMP	A membrane polypeptide involved in K+ transport in a higher plant was cloned by complementation of a yeast mutant defective in K+ uptake with a complementary DNA library from Arabidopsis thaliana. A 2.65-kilobase complementary DNA conferred ability to grow on media with K+ concentration in the micromolar range and to absorb K+ (or Rb-86(+)) at rates similar to those in wild-type yeast. The predicted amino acid sequence (838 amino acids) has three domains: a channel-forming region homologous to animal K+ channels, a cyclic nucleotide-binding site, and an ankyrin-like region.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; INRA,MICROBIOL IPV,F-34060 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE	SENTENAC, H (corresponding author), ECOLE NATL SUPER AGRON MONTPELLIER,INRA,CNRS,URA 573,F-34060 MONTPELLIER,FRANCE.			Sentenac, Herve/0000-0003-3641-4822				AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAN LY, 1990, NATURE, V345, P673; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Luttge U., 1989, Progress in Botany, V50, P51; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MINET M, IN PRESS PLANT J; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; SANDERS D, 1986, J MEMBRANE BIOL, V90, P67, DOI 10.1007/BF01869687; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SPITERI A, 1989, PLANT PHYSIOL, V91, P624, DOI 10.1104/pp.91.2.624; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEVENS CF, 1991, NATURE, V349, P657, DOI 10.1038/349657a0; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	32	566	625	4	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					663	665		10.1126/science.1585180	http://dx.doi.org/10.1126/science.1585180			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585180				2022-12-28	WOS:A1992HR18500031
J	SPOLSKY, CM; PHILLIPS, CA; UZZELL, T				SPOLSKY, CM; PHILLIPS, CA; UZZELL, T			ANTIQUITY OF CLONAL SALAMANDER LINEAGES REVEALED BY MITOCHONDRIAL-DNA	NATURE			English	Article							LIZARDS GENUS CNEMIDOPHORUS; RELATIVE AGE; ORIGIN; EVOLUTION; COMPLEX; FISHES	THE existence of clonally reproducing vertebrates has often served as a foil in attempts to explain the near-ubiquity of sexual reproduction in eukaryotes, but the absence of recombination, with its attendant limitation of new genotypes to those produced through mutations, restricts the adaptive ability of clonal organisms 1-3. It has been argued, therefore, that clonal vertebrate taxa have short lifespans 4-14. Variation in mitochondrial DNA (mtDNA) within clonal populations is interpreted instead as reflecting multiple, although limited, independent hybridization events 8-13,15. On the basis of an analysis of an average of 373 nucleotide pairs, we report here that the mtDNA of clonal, hybrid, gynogenetic mole salamanders (Ambystoma, Ambystomatidae) differs by 5% or more from mtDNA of their closest possible sexual relatives (A. jeffersonianum, A. laterale and A. texanum). Assuming usual rates of mtDNA divergence, these lineages have persisted for about 5 million years, far longer than estimated for other clonal vertebrate populations. The low mtDNA variability in the clonal lineages suggests that they have undergone population reductions during the Pleistocene.			SPOLSKY, CM (corresponding author), UNIV ILLINOIS, DEPT ECOL ETHOL & EVOLUT, URBANA, IL 61801 USA.							AVISE JC, 1987, MOL BIOL EVOL, V4, P514; Bell G., 1982, MASTERPIECE NATURE; Bogart James P., 1989, New York State Museum Bulletin, V466, P170; BROWER AVZ, 1991, EVOLUTION, V45, P1281, DOI 10.1111/j.1558-5646.1991.tb04393.x; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CLANTON WESLEY, 1934, OCC PAPERS MUS ZOOL UNIV MICH, V290, P1; DENSMORE LD, 1989, EVOLUTION, V43, P969, DOI 10.1111/j.1558-5646.1989.tb02543.x; DENSMORE LD, 1989, EVOLUTION, V43, P943, DOI 10.1111/j.1558-5646.1989.tb02541.x; ECHELLE AA, 1989, EVOLUTION, V43, P984, DOI 10.1111/j.1558-5646.1989.tb02544.x; Felsenstein J., 1984, P169; Goddard KA, 1989, EVOLUTION ECOLOGY UN, V466, P268; KRAUS F, 1990, P NATL ACAD SCI USA, V87, P2235, DOI 10.1073/pnas.87.6.2235; Lowcock Leslie Anthony, 1989, New York State Museum Bulletin, V466, P180; MACGREGOR HC, 1964, SCIENCE, V143, P1043, DOI 10.1126/science.143.3610.1043; MAYNARD SMITH J., 1978, EVOLUTION SEX; MINTON SHERMAN A., 1954, HERPETOLOGICA, V10, P173; MORITZ C, IN PRESS GENETICA; MORITZ C, 1989, B NEW YORK STATE MUS, V466, P87; MORITZ CC, 1989, EVOLUTION, V43, P958, DOI 10.1111/j.1558-5646.1989.tb02542.x; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; QUATTRO JM, 1991, GENETICS, V127, P391; SHELDON FH, 1987, MOL BIOL EVOL, V4, P56; SHIELDS GF, 1987, J MOL EVOL, V24, P212, DOI 10.1007/BF02111234; SPOLSKY C, 1986, MOL BIOL EVOL, V3, P44; SPOLSKY CM, IN PRESS EVOLUTION; UZZELL TM, 1967, EVOLUTION, V21, P345, DOI 10.1111/j.1558-5646.1967.tb00163.x; UZZELL TM, 1964, COPEIA, P247; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WRIGHT JW, 1983, HERPETOLOGICA, V39, P410	29	91	97	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1992	356	6371					706	708		10.1038/356706a0	http://dx.doi.org/10.1038/356706a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570013				2022-12-28	WOS:A1992HQ14600058
J	HOFFMAN, M				HOFFMAN, M			NEW CLINICAL-TRIAL PLANNED	SCIENCE			English	Editorial Material																			0	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					305	305		10.1126/science.256.5055.305	http://dx.doi.org/10.1126/science.256.5055.305			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566080				2022-12-28	WOS:A1992HP03200013
J	CHANTLER, C				CHANTLER, C			LEADING FOR HEALTH - RESPONSES - MANAGEMENT AND INFORMATION .6.	BRITISH MEDICAL JOURNAL			English	Article							CARE				CHANTLER, C (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,LONDON SE1 9RT,ENGLAND.							[Anonymous], 1990, SHORT CUT BETTER SER; Black N, 1990, Health Serv Manage Res, V3, P108; BUNKER JP, 1990, BRIT MED J, V301, P531, DOI 10.1136/bmj.301.6751.531; CHANTLER C, 1990, HOW TO DO IT, V3, P30; Chantler C., 1990, MANAGING HLTH RESULT; CRAIG N, 1990, FINANCIAL ACCOUNTABI, V6, P285; Culyer A.J., 1990, HLTH CARE SYSTEMS TR, P29; DISKEN S, 1990, MODELS CLIN MANAGEME; Enthoven A.C., 1985, REFLECTIONS MANAGEME; GRIFFITHS R, 1991, 7 YEARS PROGR GENERA; HAM C, 1990, HLTH CHECK HLTH CARE, P1; PARKER P, 1988, LANCET, V1, P1210; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; ROBERTS J, 1991, BRIT MED J, V302, P34, DOI 10.1136/bmj.302.6767.34; ROBERTS J, 1989, BMJ, V298, P1166; SMITH P, 1990, COMPETITION HLTH CAR, P110; SMITH R, 1989, BRIT MED J, V298, P1166; TOYNBEE P, 1984, LANCET, V1, P1399; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1983, REPORT; 1991, VIRTUE PATIENTS MAKI; 1992, NHS REFORMS 1ST 6 MO; 1984, COMPENDIUM HLTH STAT; 1991, CM1513	24	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					632	635		10.1136/bmj.304.6827.632	http://dx.doi.org/10.1136/bmj.304.6827.632			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559096	Bronze, Green Published			2022-12-28	WOS:A1992HH73300032
J	LANYON, SM				LANYON, SM			INTERSPECIFIC BROOD PARASITISM IN BLACKBIRDS (ICTERINAE) - A PHYLOGENETIC PERSPECTIVE	SCIENCE			English	Article							MITOCHONDRIAL GENOME; DNA; ORGANIZATION; POLYMERASE; SEQUENCE; BIRDS	An 852-base pair region of the cytochrome-b gene was sequenced for the brood parasitic cowbirds and 20 additional taxa of the New World blackbirds (Icterinae). The goal of the study was to determine (i) whether interspecific brood parasitism is multiply derived within the assemblage and (ii) the nature of the evolutionary transformation between various forms of interspecific brood parasitism. Cladistic analysis of the sequence data indicates that brood parasitism evolved a single time within the Icterinae. The primitive form of interspecific brood parasitism in this assemblage is host-specificity, with host-generality representing the derived condition.			LANYON, SM (corresponding author), FIELD MUSEUM NAT HIST,DEPT ZOOL,CHICAGO,IL 60605, USA.			LANYON, SCOTT/0000-0002-6443-3142				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Brooks DR, 1991, PHYLOGENY ECOLOGY BE; DAVIES NB, 1989, J ANIM ECOL, V58, P225, DOI 10.2307/4996; DESJARDINS P, 1990, J MOL BIOL, V212, P599, DOI 10.1016/0022-2836(90)90225-B; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FRAGA RM, 1979, WILSON BULL, V91, P151; Friedmann H., 1929, COWBIRDS; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; GYLLENSTEN UB, 1989, P NATL ACAD SCI USA, V86, P6196; HAMILTON WILLIAM J. III, 1965, THE CONDOR, V67, P361, DOI 10.2307/1365631; HUDSON WH, 1920, BIRDS LA PLATA, P105; LANYON SM, 1985, SYST ZOOL, V34, P397, DOI 10.2307/2413204; Orians GH, 1985, BLACKBIRDS AM, V1st; PAYNE RB, 1977, ANNU REV ECOL SYST, V8, P1, DOI 10.1146/annurev.es.08.110177.000245; Ridley M., 1983, EXPLANATION ORGANIC; ROHWER FC, 1989, CAN J ZOOL, V67, P239, DOI 10.1139/z89-035; ROTHSTEIN SI, 1990, ANNU REV ECOL SYST, V21, P481, DOI 10.1146/annurev.es.21.110190.002405; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SWOFFORD DL, 1985, PAUP PHYLOGENETIC AN	21	98	103	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					77	79		10.1126/science.1553533	http://dx.doi.org/10.1126/science.1553533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553533				2022-12-28	WOS:A1992GX79100040
J	EARLEY, LE				EARLEY, LE			ALTERNATIVE PATHWAYS FOR TRAINING THE GENERAL-INTERNIST AND THE MEDICAL SUBSPECIALIST	ANNALS OF INTERNAL MEDICINE			English	Article							PROSPECTIVE PAYMENT SYSTEM	Considerable attention is being directed from within the discipline of internal medicine to a perceived need for changes in the curriculum for postgraduate training of the internist. Much of this attention has been focused on the training required to properly prepare the general internist for the evolving system of health care. A proposal is presented to change the pattern of training of both the general internist and the medical subspecialist. After 2 years of core training, the general internist would enter 2 additional years of training that would include new material and additional experience in areas such as ambulatory and continuity care. After the core experience, the subspecialist would begin training in the subspecialty. The general internist would be certified as such, and the subspecialist would be certified only in the subspecialty. The proposal is based on the assumptions that 1) more general physicians are needed to meet the nation's health care needs; 2) more time will be required to properly train the general internist; 3) all of the additional and expanded training experiences for the generalist are not essential for training the subspecialist; and 4) the generalists of the future will not come from the ranks of subspecialists. The training needs of the general internist and the subspecialist should be viewed as separate, and curriculum changes should be considered without the restrictions of current patterns of training.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								GRAETTINGER JS, 1988, ANN INTERN MED, V108, P101, DOI 10.7326/0003-4819-108-1-101; GREENBERGER NJ, 1990, ACP OBSERVER     JUL, P2; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; LYTTLE CS, 1991, ANN INTERN MED, V114, P36, DOI 10.7326/0003-4819-114-1-36; PETERSDORF RG, 1975, NEW ENGL J MED, V293, P326, DOI 10.1056/NEJM197508142930704; SCHROEDER SA, 1987, ANN INTERN MED, V106, P768, DOI 10.7326/0003-4819-106-5-768; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; SPIEGEL JS, 1983, NEW ENGL J MED, V308, P1208, DOI 10.1056/NEJM198305193082007; STEIN JH, 1991, ANN INTERN MED, V114, P79, DOI 10.7326/0003-4819-114-1-79	11	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1080	1083		10.7326/0003-4819-116-12-1080	http://dx.doi.org/10.7326/0003-4819-116-12-1080			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586121				2022-12-28	WOS:A1992HY79400011
J	HALLER, DG				HALLER, DG			TREATMENTS FOR ESOPHAGEAL CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SQUAMOUS-CELL CARCINOMA; RADIOTHERAPY; CHEMOTHERAPY				HALLER, DG (corresponding author), HOSP UNIV PENN,PHILADELPHIA,PA 19104, USA.							ANDERSON LL, 1982, CANCER, V50, P1587, DOI 10.1002/1097-0142(19821015)50:8<1587::AID-CNCR2820500820>3.0.CO;2-S; BYFIELD JE, 1990, CANC CHEMOTHERAPY IN, P521; EARLAM R, 1980, BRIT J SURG, V67, P457, DOI 10.1002/bjs.1800670702; EARLAM R, 1980, BRIT J SURG, V67, P381, DOI 10.1002/bjs.1800670602; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; LEICHMAN L, 1984, J CLIN ONCOL, V2, P75, DOI 10.1200/JCO.1984.2.2.75; POPLIN E, 1987, J CLIN ONCOL, V5, P622, DOI 10.1200/JCO.1987.5.4.622; ROGERS EL, 1982, CANCER-AM CANCER SOC, V49, P610, DOI 10.1002/1097-0142(19820201)49:3<610::AID-CNCR2820490335>3.0.CO;2-M; SISCHY B, 1990, P AN M AM SOC CLIN, V9, P105; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911	11	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1629	1631		10.1056/NEJM199206113262410	http://dx.doi.org/10.1056/NEJM199206113262410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584267				2022-12-28	WOS:A1992HX63300011
J	KLEIJMEER, MJ; KELLY, A; GEUZE, HJ; SLOT, JW; TOWNSEND, A; TROWSDALE, J				KLEIJMEER, MJ; KELLY, A; GEUZE, HJ; SLOT, JW; TOWNSEND, A; TROWSDALE, J			LOCATION OF MHC-ENCODED TRANSPORTERS IN THE ENDOPLASMIC-RETICULUM AND CIS-GOLGI	NATURE			English	Article							CLASS-I MOLECULES; HLA-B ANTIGENS; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELLS; INFLUENZA NUCLEOPROTEIN; REGION; BIOSYNTHESIS; RECOGNITION; ASSOCIATION; PEPTIDES	IMMUNE recognition of intracellular proteins is mediated by major histocompatibility complex (MHC) class I molecules that present short peptides to cytotoxic T cells 1-4. Evidence suggests that peptides arise by cleavage of proteins in the cytoplasm and are transported by a signal-independent mechanism into a pre-Golgi region of the cell, where they take part in the assembly of class I heavy chains with beta-2-microglobulin (reviewed in refs 5-7). Analysis of cells that have defects in class I molecule assembly and antigen presentation 8-14 has shown that this phenotype can result from mutations in either of the two ABC transporter genes located in the class II region of the MHC 15-22. This suggested that the protein complex encoded by these two genes 20,22 transports peptides from the cytosol into the endoplasmic reticulum. Here we report additional evidence by showing that the transporter complex is located in the endoplasmic reticulum membrane and is probably oriented with its ATP-binding domains in the cytosol.	IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford	KLEIJMEER, MJ (corresponding author), UNIV UTRECHT,SCH MED,DEPT CELL BIOL,UTRECHT,NETHERLANDS.			Townsend, Alain/0000-0002-3702-0107				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOBBERSTEIN B, 1992, NATURE, V355, P109, DOI 10.1038/355109a0; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	41	197	198	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					342	344		10.1038/357342a0	http://dx.doi.org/10.1038/357342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589036				2022-12-28	WOS:A1992HW13200052
J	MICOZZI, MS				MICOZZI, MS			LINCOLN, KENNEDY, AND THE AUTOPSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MICOZZI, MS (corresponding author), ARMED FORCES INST PATHOL,NATL MUSEUM HLTH & MED,WASHINGTON,DC 20306, USA.							DUNCAN LC, 1911, EVOLUTION AMBULANCE, P4; GILMORE HR, 1954, P ROY SOC MED, V47, P103, DOI 10.1177/003591575404700205; McKusick V A, 1991, Caduceus, V7, P43; MICOZZI MS, 1991, CADUCEUS, V7, P35; RUSH JW, 1992, 44TH ANN M AM AC FOR; TAFT CS, 1865, MED SURG REPORTER, V12, P452	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2791	2791						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578600				2022-12-28	WOS:A1992HV26500030
J	STACEY, GN; BOLTON, BJ; DOYLE, A				STACEY, GN; BOLTON, BJ; DOYLE, A			DNA FINGERPRINTING TRANSFORMS THE ART OF CELL AUTHENTICATION	NATURE			English	Article							QUALITY-CONTROL; MARKERS; LINES	The increasing diversity of new cell cultures is seriously stretching the capabilities of traditional methods of identification. DNA fingerprinting is set to play an important role in increasing confidence in the authenticity of cultures in research and industry.			STACEY, GN (corresponding author), PUBL HLTH LAB SERV APPL MICROBIOL & RES,EUROPEAN COLLECT ANIM CELL CULTURES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND.							HALTON DM, 1983, IN VITRO CELL DEV B, V19, P16, DOI 10.1007/BF02617989; HANLAN CR, 1989, CYTOGENETICS ANIMALS, pR11; HAY RJ, 1988, ANAL BIOCHEM, V171, P225, DOI 10.1016/0003-2697(88)90480-0; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; MOWLES JM, 1990, CYTOTECHNOLOGY, V3, P107, DOI 10.1007/BF00143670; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NELSONRE.WA, 1974, SCIENCE, V184, P1093, DOI 10.1126/science.184.4141.1093; NELSONREES WA, 1976, SCIENCE, V195, P1343; OBRIEN SJ, 1980, IN VITRO CELL DEV B, V16, P119; STACEY GN, 1991, DNA FINGERPRINTING A; STACEY GN, IN PRESS CYTOTECHNOL; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; THACKER J, 1988, SOMAT CELL MOLEC GEN, V14, P519, DOI 10.1007/BF01535307	15	39	40	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					261	262		10.1038/357261a0	http://dx.doi.org/10.1038/357261a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589025				2022-12-28	WOS:A1992HV19500061
J	WHITMAN, M; MELTON, DA				WHITMAN, M; MELTON, DA			INVOLVEMENT OF P21RAS IN XENOPUS MESODERM INDUCTION	NATURE			English	Article							HA-RAS MUTATION; GROWTH-FACTORS; ACTIVIN-A; EMBRYOS; CELLS; DIFFERENTIATION; EMBRYOGENESIS; GASTRULATION; LAEVIS; GENES	DURING early vertebrate embryogenesis, mesoderm is specified by a signal emanating from prospective endoderm. This signal can respecify Xenopus prospective ectoderm as mesoderm, and can be mimicked by members of the fibroblast growth factor and transforming growth factor-beta families 1,2. In other systems, the p21c-ras proto-oncogene product has been implicated in signal transduction for various polypeptide growth factors. We report here that a dominant inhibitory ras mutant blocks the mesoderm-inducing activity of fibroblast growth factor and activin, as well as the endogenous inducing activity of prospective endoderm. A constitutively active ras mutant partially mimics these activities. These results indicate that p21ras may have a central role in the transduction of the mesoderm inductive signal. Basic fibroblast growth factor 3,4 and activin 5-8 have emerged as candidates for endogenous mesoderm-inducing molecules. The character of the mesoderm induced by these two factors is overlapping but distinct when assessed both by histological and molecular criteria 9,10. The signal transduction pathways used during induction by these factors are unknown. We used messenger RNA microinjection of Xenopus eggs to express a dominant inhibitory mutant ras, p21(Asn 17)Ha-ras, in cells competent to respond to inducing factors to examine the role of p21ras in this response. This mutant, which has a reduced affinity for GTP relative to GDP 11, blocks a variety of mitogenic signals in 3T3 fibroblasts 12 as well as the differentiation of pheochromocytoma cells in response to nerve growth factor 13.	DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138				Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Barbacid M., 1987, REV BIOCH, V56, P779; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GODSAVE SF, 1988, DEVELOPMENT, V102, P555; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; JAMRICH M, 1987, GENE DEV, V1, P124, DOI 10.1101/gad.1.2.124; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Ruiz i Altaba A, 1989, Nature, V341, P33; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SYMES K, 1987, DEVELOPMENT, V101, P339; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WHITMAN M, 1989, SCIENCE, V244, P803, DOI 10.1126/science.2658054	29	181	182	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					252	254		10.1038/357252a0	http://dx.doi.org/10.1038/357252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589022				2022-12-28	WOS:A1992HV19500058
J	MARTIN, AP; NAYLOR, GJP; PALUMBI, SR				MARTIN, AP; NAYLOR, GJP; PALUMBI, SR			RATES OF MITOCHONDRIAL-DNA EVOLUTION IN SHARKS ARE SLOW COMPARED WITH MAMMALS	NATURE			English	Article							SEQUENCE EVOLUTION; TEMPO; MODE	THE rate of mitochondrial DNA (mtDNA) evolution has been carefully calibrated only in primates 1. Similarity between the primate calibration and rates estimated for other vertebrates 2-4 has led to widespread assumption of a constant molecular clock in vertebrates even though this has never been rigorously tested 5. We report here the examination of mtDNA sequence variation for 13 species of sharks from two orders that are well represented in the fossil record to test the constancy hypothesis. Nucleotide substitution rates in the cytochrome b and cytochrome oxidase I genes in sharks are seven- to eightfold slower than in primates or ungulates. This difference in substitution rate cannot be explained by nucleotide composition bias, codon-usage bias, selection, or choice of genes sequenced, and was confirmed by comparing species recently separated by the rise of the Isthmus of Panama. Such differences in mtDNA substitution rates among taxa indicate that it is inappropriate to use a calibration for one group to estimate divergence times or demographic parameters for another group. High-resolution studies of molecular evolutionary rates require taxon-specific calibrations.	UNIV HAWAII,KEWALO MARINE LAB,HONOLULU,HI 96822; UNIV HAWAII,DEPT ZOOL,HONOLULU,HI 96822; AMER MUSEUM NAT HIST,DEPT VERTEBRATE PALEONTOL,NEW YORK,NY 10002	University of Hawaii System; University of Hawaii System; American Museum of Natural History (AMNH)								ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; AVISE JC, IN PRESS MOL BIOL EV; BAILEY WJ, 1991, MOL BIOL EVOL, V8, P155; BRITTEN RJ, 1986, SCIENCE, V231, P1393, DOI 10.1126/science.3082006; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; Cappetta H., 1987, HDB PALEOICHTHYOLO B, V3B; COMPAGNO L J V, 1990, NOAA Technical Report NMFS, P357; COMPAGNO LJV, 1989, SHARKS ORDER CARCHAR; DESALLE R, 1987, J MOL EVOL, V26, P157, DOI 10.1007/BF02111289; ESPINOZAARRUBAR.L, 1987, THESIS CALIFORNIA ST; FELSENSTEIN J, 1989, PHYLOGENETIC ANAL PA; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; Hillis David M., 1990, P502; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; JOENJE H, 1989, MUTAT RES, V219, P193, DOI 10.1016/0921-8734(89)90001-5; KEIGWIN LD, 1982, SCIENCE, V6, P350; KENT BW, 1987, FOSSIL SHARKS MARYLA; KESSING BD, 1991, MOL BIOL EVOL; LI WH, 1987, J MOL EVOL, V25, P330, DOI 10.1007/BF02603118; MAISEY JG, 1985, ZOOL J LINN SOC-LOND, V82, P1741; NAYLOR GJP, 1989, THESIS U MARYLAND; Palumbi S, 1991, SIMPLE FOOLS GUIDE P; PARSONS GR, 1990, MAR BIOL, V104, P363, DOI 10.1007/BF01314338; PRATT H L JR, 1990, NOAA Technical Report NMFS, P97; SCHLOTTERER C, 1991, NATURE, V354, P63, DOI 10.1038/354063a0; SHIELDS GF, 1987, J MOL EVOL, V24, P212, DOI 10.1007/BF02111234; THOMAS WK, 1989, J MOL EVOL, V29, P233, DOI 10.1007/BF02100207; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Ward D.J., 1978, Tertiary Research, V2, P23; WILSON AC, 1985, BIOL J LINN SOC, V26, P375, DOI 10.1111/j.1095-8312.1985.tb02048.x	30	428	450	1	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					153	155		10.1038/357153a0	http://dx.doi.org/10.1038/357153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579163				2022-12-28	WOS:A1992HU12200056
J	SELLERS, TA; KUSHI, LH; POTTER, JD; KAYE, SA; NELSON, CL; MCGOVERN, PG; FOLSOM, AR				SELLERS, TA; KUSHI, LH; POTTER, JD; KAYE, SA; NELSON, CL; MCGOVERN, PG; FOLSOM, AR			EFFECT OF FAMILY HISTORY, BODY-FAT DISTRIBUTION, AND REPRODUCTIVE FACTORS ON THE RISK OF POSTMENOPAUSAL BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; GENETIC EPIDEMIOLOGY; BOUND ESTRADIOL; HORMONE LEVELS; WOMEN; ESTROGEN; DISEASE; OBESITY; AGE; RECEPTORS	Background. A family history of breast cancer reflects shared cultural factors, genetic predisposition, or both. There is evidence that the estimated risk associated with a family history of breast cancer increases multiplicatively in combination with other risk factors. We examined the combined effect of family history and anthropometric and reproductive factors on the risk of breast cancer in postmenopausal women. Methods. Using data from a prospective cohort study, we studied 37,105 women 55 to 69 years of age to determine whether known risk factors for breast cancer are modified by a reported family history at the time of entry into the study. Results. During the first four years of follow-up, 493 new breast cancers were diagnosed. The association of the waist-to-hip ratio (the circumference of the waist divided by that of the hips) with the risk of breast cancer was limited predominantly to women with a family history of breast cancer; the age-adjusted relative risk of breast cancer for the women above the fourth quintile for waist-to-hip ratio as compared with those below the first quintile was 3.2 in women with a family history of breast cancer and 1.2 for women without such a family history. An interaction was observed between a family history of breast cancer and the number of live-born children; the protective effect of higher parity was observed primarily among women with a family history of breast cancer. Similarly, the age-adjusted relative risk of breast cancer associated with a late age at first pregnancy (i.e., greater-than-or-equal-to 30 years) was 5.8 for women with a family history of breast cancer and 2.0 for women without such a family history. Conclusions. The increase in the risk of breast cancer associated with a high waist-to-hip ratio, low parity, or greater age at first pregnancy is more pronounced among women with a family history of breast cancer. These findings suggest etiologic differences between familial breast cancer and the sporadic form.	UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	SELLERS, TA (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55455 USA.			Kushi, Lawrence/0000-0001-9136-1175; Potter, John/0000-0001-5439-1500	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742, T32 CA099607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1972, J NATL CANCER I, V48, P1029; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; ANDRIEU N, 1989, INT J CANCER, V44, P415, DOI 10.1002/ijc.2910440306; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BEGG L, 1987, GENET EPIDEMIOL, V4, P233, DOI 10.1002/gepi.1370040402; BOUCHARD C, 1988, INT J OBESITY, V12, P205; Breslow NE, 1987, STATISTICAL METHODS, P1; BRINTON LA, 1982, J NATL CANCER I, V69, P817; BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO;2-H; BULBROOK RD, 1978, EUR J CANCER, V14, P1369, DOI 10.1016/0014-2964(78)90120-2; Byrne C, 1991, Epidemiology, V2, P276, DOI 10.1097/00001648-199107000-00007; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FAREWELL VT, 1977, CANCER, V40, P931, DOI 10.1002/1097-0142(197708)40:2<931::AID-CNCR2820400251>3.0.CO;2-Y; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; FISHMAN J, 1983, CANCER RES, V43, P1884; FISHMAN J, 1979, SCIENCE, V204, P1089, DOI 10.1126/science.451553; FOEKENS JA, 1989, CANCER, V63, P2139, DOI 10.1002/1097-0142(19890601)63:11<2139::AID-CNCR2820631112>3.0.CO;2-D; FOLSOM AR, 1989, CANCER RES, V49, P6828; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; GO RCP, 1983, J NATL CANCER I, V71, P455; GOLDSTEIN AM, 1989, CLIN GENET, V36, P100; GREENLAND S, 1988, SCAND J WORK ENV HEA, V14, P125, DOI 10.5271/sjweh.1945; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENDERSON BE, 1975, NEW ENGL J MED, V293, P790, DOI 10.1056/NEJM197510162931602; HENDERSON BE, 1988, CANCER RES, V48, P246; INGRAM DM, 1990, BRIT J CANCER, V61, P303, DOI 10.1038/bjc.1990.57; KAYE SA, 1991, INT J EPIDEMIOL, V20, P151, DOI 10.1093/ije/20.1.151; KELSEY JL, 1988, CANCER RES, V48, P5615; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1; KING MC, 1980, SCIENCE, V208, P406, DOI 10.1126/science.7367867; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; LUBIN F, 1985, AM J EPIDEMIOL, V122, P579, DOI 10.1093/oxfordjournals.aje.a114137; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; MOORE JW, 1987, BRIT J CANCER, V56, P661, DOI 10.1038/bjc.1987.262; MORGAN RW, 1978, J NATL CANCER I, V60, P965, DOI 10.1093/jnci/60.5.965; MORRIS RD, 1991, AM J PUBLIC HEALTH, V81, P507, DOI 10.2105/AJPH.81.4.507; NAROD SA, 1991, LANCET, V338, P82; OTA DM, 1986, CANCER, V57, P558, DOI 10.1002/1097-0142(19860201)57:3<558::AID-CNCR2820570326>3.0.CO;2-1; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; PEKONEN F, 1988, CANCER RES, V48, P1343; PIKE MC, 1977, J NATL CANCER I, V59, P1351, DOI 10.1093/jnci/59.5.1351; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; REED MJ, 1983, CANCER RES, V43, P3940; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHNEIDER NR, 1983, AM J HUM GENET, V35, P454; SCHWARTZ AG, 1985, JNCI-J NATL CANCER I, V75, P665; SELBY JV, 1989, HUM BIOL, V61, P179; SKOLNICK M H, 1984, Genetic Epidemiology, V1, P363, DOI 10.1002/gepi.1370010408; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; WILSON AF, 1986, GENET EPIDEMIOL, P87; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065; 1985, SAS USERS GUIDE STAT	65	223	224	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1323	1329		10.1056/NEJM199205143262004	http://dx.doi.org/10.1056/NEJM199205143262004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1565145				2022-12-28	WOS:A1992HT80300004
J	IRVING, MH; CATCHPOLE, B				IRVING, MH; CATCHPOLE, B			ABC OF COLORECTAL DISEASES - ANATOMY AND PHYSIOLOGY OF THE COLON, RECTUM, AND ANUS	BRITISH MEDICAL JOURNAL			English	Article									UNIV WESTERN AUSTRALIA,SURG,NEDLANDS,WA 6009,AUSTRALIA	University of Western Australia	IRVING, MH (corresponding author), HOPE HOSP,GEN SURG,SALFORD M6 8HD,LANCS,ENGLAND.								0	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1106	1108		10.1136/bmj.304.6834.1106	http://dx.doi.org/10.1136/bmj.304.6834.1106			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586826	Bronze, Green Published			2022-12-28	WOS:A1992HR13600025
J	COHEN, DI; TANI, Y; TIAN, H; BOONE, E; SAMELSON, LE; LANE, HC				COHEN, DI; TANI, Y; TIAN, H; BOONE, E; SAMELSON, LE; LANE, HC			PARTICIPATION OF TYROSINE PHOSPHORYLATION IN THE CYTOPATHIC EFFECT OF HUMAN-IMMUNODEFICIENCY-VIRUS .1.	SCIENCE			English	Article							T-CELL RECEPTOR; PROTEIN-KINASE; HTLV-III/LAV; SYNCYTIUM FORMATION; ANTIGEN RECEPTOR; HERBIMYCIN-A; ACTIVATION; CD4; INHIBITION; RETROVIRUS	Protein tyrosine phosphorylation is a common mechanism of signaling in pathways that regulate T cell receptor-mediated cell activation, cell proliferation, and the cell cycle. Because human immunodeficiency virus (HIV) is thought to affect normal cell signaling, tyrosine phosphorylation may be associated with HIV cytopathicity. In both HIV-infected cells and transfected cells that stably express HIV envelope glycoproteins undergoing HIVgp41-induced cell fusion, a 30-kilodalton protein was phosphorylated on tyrosine with kinetics similar to those of syncytium formation and cell death. When tyrosine phosphorylation was inhibited by the protein tyrosine kinase inhibitor herbimycin A, envelope-mediated syncytium formation was coordinately reduced. These studies show that specific intracellular signals, which apparently participate in cytopathicity, are generated by HIV and suggest strategies by which the fusion process might be interrupted.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	COHEN, DI (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.							DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOWDA D, 1988, J IMMUNOL, V142, P773; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, J IMMUNOL, V144, P647; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SOMASUNDARAN M, 1988, SCIENCE, V242, P1554, DOI 10.1126/science.3201245; TANI Y, 1987, P NATL ACAD SCI USA, V84, P4831; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WILEY RL, 1988, J VIROL, V62, P139; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	41	105	109	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					542	545		10.1126/science.1570514	http://dx.doi.org/10.1126/science.1570514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1570514				2022-12-28	WOS:A1992HQ18700070
J	SANDERS, SL; WHITFIELD, KM; VOGEL, JP; ROSE, MD; SCHEKMAN, RW				SANDERS, SL; WHITFIELD, KM; VOGEL, JP; ROSE, MD; SCHEKMAN, RW			SEC61P AND BIP DIRECTLY FACILITATE POLYPEPTIDE TRANSLOCATION INTO THE ER	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; YEAST ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE PROTEIN; CHAIN BINDING-PROTEIN; COLI PLASMA-MEMBRANE; PREPRO-ALPHA-FACTOR; CELL-FREE SYSTEM; ESCHERICHIA-COLI; SECRETORY PROTEINS; SACCHAROMYCES-CEREVISIAE	Secretory proteins are segregated from cytosolic proteins by their translocation into the endoplasmic reticulum (ER). A modified secretory protein trapped during translocation across the ER membrane can be cross-linked to two previously identified proteins, Sec61p and BiP (Kar2p). The dependence of this cross-linking upon proteins and small molecules was examined. Mutations in SEC62 and SEC63 decrease the ability of Sec61p to be cross-linked to the secretory polypeptide trapped in translocation. ATP is also required for interaction of Sec61p with the secretory protein. Three kar2 alleles display defective translocation in vitro. Two of these alleles also decrease the ability of Sec61p to be cross-linked to the secretory protein. The third allele, while exhibiting a severe translocation defect, does not affect the interaction of Sec61p with the secretory protein. These results suggest that Sec61p is directly involved in translocation and that BiP acts at two stages of the translocation cycle.	PRINCETON UNIV, DEPT MOLEC BIOL, LEWIS THOMAS LAB, PRINCETON, NJ 08544 USA	Princeton University	SANDERS, SL (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED RES INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Rose, Mark/0000-0003-1112-4765	NIGMS NIH HHS [R01 GM037739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; Sambrook J, 1989, MOL CLONING LABORATO; SANZ P, 1988, EMBO J, V7, P3553, DOI 10.1002/j.1460-2075.1988.tb03232.x; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCHAUER I, 1985, J CELL BIOL, V100, P1664, DOI 10.1083/jcb.100.5.1664; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCOTT JH, 1980, J BACTERIOL, V142, P414, DOI 10.1128/JB.142.2.414-423.1980; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	61	325	326	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					353	365		10.1016/0092-8674(92)90415-9	http://dx.doi.org/10.1016/0092-8674(92)90415-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568250				2022-12-28	WOS:A1992HQ18300014
J	EMANUEL, EJ; EMANUEL, LL				EMANUEL, EJ; EMANUEL, LL			PROXY DECISION-MAKING FOR INCOMPETENT PATIENTS - AN ETHICAL AND EMPIRICAL-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; LIFE; PREFERENCES; CONSENT		HARVARD UNIV, SCH MED, DIV MED ETH, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	EMANUEL, EJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, 44 BINNEY ST, BOSTON, MA 02115 USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; ANNAS GJ, 1991, NEW ENGL J MED, V325, P894; AREEN J, 1987, JAMA-J AM MED ASSOC, V258, P229, DOI 10.1001/jama.258.2.229; ARRAS JD, 1984, HASTINGS CENT REP, V14, P25, DOI 10.2307/3561882; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BUCHANAN AE, 1981, UCLA LAW REV, V29, P386; BUCHANAN AE, 1989, DECIDING OTHERS, pCH2; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DIAMOND EL, 1989, GERONTOLOGIST, V29, P622, DOI 10.1093/geront/29.5.622; EMANUEL EJ, 1991, NEW ENGL J MED, V325, P893; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL EJ, 1987, HASTINGS CENT REP, V17, P15, DOI 10.2307/3562665; EMANUEL EJ, 1988, LANCET, V1, P169; EMANUEL EJ, 1991, ENDS HUMAN LIFE MED, pCH3; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EPSTEIN AM, 1989, MED CARE, V27, pS91, DOI 10.1097/00005650-198903001-00008; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; GUTHEIL TG, 1983, HASTINGS CENT REP, V13, P8, DOI 10.2307/3561610; HIGH DM, 1988, GERONTOLOGIST, V28, P46, DOI 10.1093/geront/28.Suppl.46; HIGH DM, 1991, GERONTOLOGIST, V31, P611, DOI 10.1093/geront/31.5.611; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAPUMA J, 1988, ANN INTERN MED, V108, P121, DOI 10.7326/0003-4819-108-1-121; LEE MA, 1991, J AM GERIATR SOC, V39, P806, DOI 10.1111/j.1532-5415.1991.tb02704.x; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; Lynn J, 1991, Law Med Health Care, V19, P101; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCCUSKER J, 1984, MED CARE, V22, P789, DOI 10.1097/00005650-198409000-00002; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; MINOW, 1985, U MICH JL REF, V18, P972; NEWMAN SA, 1985, NEW YORK LAW SCH HUM, V3, P35; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; RELMAN AS, 1979, NEW ENGL J MED, V300, P1270, DOI 10.1056/NEJM197905313002210; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; STEIBER SR, 1987, HOSPITALS, V61, P72; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; TOMLINSON T, 1990, GERONTOLOGIST, V30, P54, DOI 10.1093/geront/30.1.54; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615; 1983, DECIDING FOREGO LIFE, pCH4; 1987, LIFE SUSTAINING TREA, pCH4	46	172	172	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2067	2071						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552642				2022-12-28	WOS:A1992HM65000033
J	BALEJA, JD; MARMORSTEIN, R; HARRISON, SC; WAGNER, G				BALEJA, JD; MARMORSTEIN, R; HARRISON, SC; WAGNER, G			SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN OF CD2-GAL4 FROM SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							REGULATORY PROTEIN; GAL4 PROTEIN; YEAST; COORDINATION	THE GAL4 protein activates transcription of the genes required for galactose utilization in Saccharomyces cerevisiae 1. The protein, consisting of 881 amino acids, is dimeric when bound to one of the approximately twofold symmetrical DNA sites present in the galactose upstream activating sequence (UAS(G)) 2-5. Here we use two-dimensional NMR spectroscopy to determine the structure of an amino-terminal fragment of GAL4 (residues 1-65). This fragment, a monomer in solution, binds as a dimer specifically to UAS(G)-containing DNA. Residues 9-40 form a well defined, compact globular cluster, whereas residues 1-8 and 41-66 show considerable conformational mobility in the absence of DNA. The compact domain contains a motif in which six cysteines, located on two symmetrically related helix/extended strand units connected by a long loop, coordinate two central zinc ions, forming a bimetal-thiolate cluster 6-11. The zincs were replaced by NMR-active Cd-113 in most of our work and structural parameters are therefore derived from the Cd2-protein. The structure obtained for the GAL4 DNA-binding domain represents a novel DNA-binding motif. Essentially the same conformation is observed for the compact domain in solution using NMR techniques as was seen for the central core of the N-terminal fragment bound to DNA using crystallographic techniques 12. Thus, the core of the DNA-binding domain changes little upon binding DNA.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University								ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GADHAVI PL, 1990, FEBS LETT, V276, P49, DOI 10.1016/0014-5793(90)80504-C; GADHAVI PL, 1991, FEBS LETT, V281, P223, DOI 10.1016/0014-5793(91)80398-M; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HYBERTS SG, IN PRESS PROTEIN SCI; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; MARMORSTEIN R, IN PRESS NATURE; MONTELIONE GT, 1989, J MAGN RESON, V82, P198, DOI 10.1016/0022-2364(89)90183-2; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; POVEY JF, 1990, FEBS LETT, V266, P142, DOI 10.1016/0014-5793(90)81525-S; SERIKAWA Y, 1990, PROTEIN ENG, V3, P267, DOI 10.1093/protein/3.4.267; VASAK M, 1987, J MOL BIOL, V196, P711, DOI 10.1016/0022-2836(87)90042-8; Wuthrich K., 1986, NMR PROTEINS NUCL AC	26	124	126	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					450	453		10.1038/356450a0	http://dx.doi.org/10.1038/356450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557130				2022-12-28	WOS:A1992HL83000070
J	THAKKER, Y; WOODS, S				THAKKER, Y; WOODS, S			STORAGE OF VACCINES IN THE COMMUNITY - WEAK LINK IN THE COLD CHAIN	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess quality of storage of vaccines in the community. Design - Questionnaire survey of general practices and child health clinics, and monitoring of storage temperatures of selected refrigerators. Setting - Central Manchester and Bradford health districts. Subjects - 45 general practices and five child health clinics, of which 40 (80%) responded. Eight practices were selected for refrigeration monitoring. Main outcome measures - Adherence to Department of Health guidelines for vaccine storage, temperature range to which vaccines were exposed over two weeks. Results - Of the 40 respondents, only 16 were aware of the appropriate storage conditions for the vaccines; eight had minimum and maximum thermometers but only one of these was monitored daily. In six of the eight practices selected for monitoring of refrigeration temperatures the vaccines were exposed to either subzero temperatures (three fridges) or temperatures up to 16-degrees-C (three). Two of these were specialised drug storage refrigerators with an incorporated thermostat and external temperature gauges. Conclusion - Vaccines were exposed to temperatures that may reduce their potency. Safe storage of vaccines in the clinics cannot be ensured without adhering to the recommended guidelines. Provision of adequate equipment and training for staff in maintaining the "cold chain" and the use and care of equipment are important components of a successful immunisation programme.	DYNELEY HOUSE,SKIPTON,ENGLAND		THAKKER, Y (corresponding author), PINDERFIELDS HOSP,ROWAN HOUSE,WAKEFIELD WF1 4DG,ENGLAND.							HUNTER S, 1989, BRIT MED J, V299, P661, DOI 10.1136/bmj.299.6700.661; LONGLAND P, 1989, PHARM J, V4, P584; LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MCLEAN AA, 1982, ANN INTERN MED, V97, P451, DOI 10.7326/0003-4819-97-3-451_1; SOKHEY J, 1988, VACCINE, V6, P12, DOI 10.1016/0264-410X(88)90006-0; 1980, WKLY EPIDEMIOL REC, V55, P385; 1990, WKLY EPIDEMIOL REC, V65, P181; 1989, EXPANDED PROGRAMME I; 1990, IMMUNISATION INFECTI; 1980, WKLY EPIDEMIOL REC, V55, P396; 1990, PRACTICAL IMMUNISATI, P6; 1990, MANUFACTURERS RECOMM	12	49	62	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					756	758		10.1136/bmj.304.6829.756	http://dx.doi.org/10.1136/bmj.304.6829.756			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571683	Bronze, Green Published			2022-12-28	WOS:A1992HK80000023
J	RICKWOOD, AMK; CARTY, HM; MCKENDRICK, T; WILLIAMS, MPL; JACKSON, M; PILLING, DW; SPRIGG, A				RICKWOOD, AMK; CARTY, HM; MCKENDRICK, T; WILLIAMS, MPL; JACKSON, M; PILLING, DW; SPRIGG, A			CURRENT IMAGING OF CHILDHOOD URINARY INFECTIONS - PROSPECTIVE SURVEY	BRITISH MEDICAL JOURNAL			English	Article							TRACT INFECTION; CHILDREN; CYSTOGRAPHY	Objectives - To assess whether ultrasonography alone is adequate for routine screening of childhood urinary infection, whether clinical features determine the need for further investigations, and which investigations are most appropriate. Design - Prospective survey of children with proved urinary infection and a preinvestigation record of clinical features. Ultrasonography and intravenous urography were routine, with choice of further studies determined by ultrasonographic findings. Setting - A children's hospital and two district general hospitals in Mersey region. Main outcome measures - Sensitivity and specificity of ultrasonography both generally and in relation to clinical features. Accuracy of intravenous urography compared with radioisotope examinations. Results - Specificity of ultrasonography was good (99% (95% confidence interval 96% to 100%)) but sensitivity modest (43% (32% to 55%)), principally with respect to detecting vesicoureteric reflux and renal scarring. Among older children (aged 2-10 years) with positive ultrasound results and fever or vomiting the sensitivity in detecting reflex (with and without renal scarring) was 78% (62% to 89%) and the specificity 69% (60% to 78%); in detecting renal scarring (with and without reflux) the sensitivity was 100% (80% to 100%) and specificity 65% (56% to 74%). Renal scarring and obstructive uropathies were better assessed by radioisotope examinations than by intravenous urography. Conclusions - Ultrasonography alone is inadequate for routine screening of childhood urinary infection. Though further investigations remain advisable in infants, in older children they can be restricted to a minority who have positive ultrasound examinations or have had fever or vomiting. Radioisotope examinations largely eliminate the need for intravenous urography.	ROYAL LIVERPOOL CHILDRENS HOSP,INST CHILD HLTH,LIVERPOOL L12 2AP,ENGLAND; ROYAL LIVERPOOL CHILDRENS HOSP,DEPT NEPHROL,LIVERPOOL L12 2AP,ENGLAND; ROYAL LIVERPOOL CHILDRENS HOSP,DEPT RADIOL,LIVERPOOL L12 2AP,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	RICKWOOD, AMK (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP,DEPT UROL,ALDER HEY,LIVERPOOL L12 2AP,ENGLAND.							ARMITAGE P, 1982, STATISTICAL METHODS, P371; BERGSTROM T, 1972, ARCH DIS CHILD, V47, P227, DOI 10.1136/adc.47.252.227; DICKINSON JA, 1979, BMJ-BRIT MED J, V1, P1330, DOI 10.1136/bmj.1.6174.1330; Fleiss JL, 1981, STATISTICAL METHODS, P29; HANBURY DC, 1989, BRIT J UROL, V64, P638, DOI 10.1111/j.1464-410X.1989.tb05326.x; MCKERROW W, 1984, BRIT MED J, V289, P299, DOI 10.1136/bmj.289.6440.299; MERRICK MV, 1980, BRIT J RADIOL, V53, P544, DOI 10.1259/0007-1285-53-630-544; MONCRIEFF MW, 1976, ARCH DIS CHILD, V51, P893, DOI 10.1136/adc.51.11.893; OREILLY PH, 1979, J UROLOGY, V121, P153, DOI 10.1016/S0022-5347(17)56703-8; OREILLY PH, 1986, J UROLOGY, V136, P993, DOI 10.1016/S0022-5347(17)45186-X; PETERS AM, 1990, CLIN RADIOL, V41, P44, DOI 10.1016/S0009-9260(05)80932-8; SHERWOOD T, 1984, BRIT MED J, V288, P827, DOI 10.1136/bmj.288.6420.827; SMELLIE JM, 1964, BMJ-BRIT MED J, V2, P1222, DOI 10.1136/bmj.2.5419.1222; SMELLIE JM, 1970, BRIT MED J, V4, P97, DOI 10.1136/bmj.4.5727.97; WHITEAR P, 1990, BRIT J RADIOL, V63, P438, DOI 10.1259/0007-1285-63-750-438; 1981, J UROLOGY, V135, P277	16	42	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					663	665		10.1136/bmj.304.6828.663	http://dx.doi.org/10.1136/bmj.304.6828.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571636	Green Published, Bronze			2022-12-28	WOS:A1992HK76100017
J	STALLKNECHT, K				STALLKNECHT, K			MEDICINE IN EUROPE .12. NURSING IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article											STALLKNECHT, K (corresponding author), DANSK SYGEPLEJERAD,POSTBOKS 1084,DK-1008 COPENHAGEN K,DENMARK.							Seymour J, 1990, Nurs Times, V86, P38; 1988, JUN EUR C NURS VIENN	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					561	562		10.1136/bmj.304.6826.561	http://dx.doi.org/10.1136/bmj.304.6826.561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559066	Green Published, Bronze			2022-12-28	WOS:A1992HG59900032
J	CAMILLERI, M; PRATHER, CM				CAMILLERI, M; PRATHER, CM			THE IRRITABLE-BOWEL-SYNDROME - MECHANISMS AND A PRACTICAL APPROACH TO MANAGEMENT	ANNALS OF INTERNAL MEDICINE			English	Review						COLONIC DISEASES, FUNCTIONAL; ABDOMINAL PAIN; DIARRHEA; CONSTIPATION; GASTROINTESTINAL MOTILITY	SEGMENTAL COLONIC TRANSIT; BILE-ACID MALABSORPTION; GASTROINTESTINAL DISORDERS; CONTROLLED TRIAL; DOUBLE-BLIND; MOTILITY; DISEASE; DIARRHEA; CONSTIPATION; HYPNOTHERAPY	Objective: To develop a practical strategy that facilitates the management of patients with the irritable bowel syndrome (IBS). Study Selection and Data Extraction: Review of the pertinent literature published in major English-language journals for the last 25 years, describing the pathophysiology and treatment of subgroups of patients with IBS. Results: A stepwise approach for practical management of patients with suspected IBS is identified. The first step includes a combination of positive diagnosis of symptoms with limited investigations to exclude underlying structural or biochemical disorders. In the second step, therapeutic trials focus on alleviating the predominant symptoms. For patients with intractable symptoms, the third step combines novel tests to assess altered function and therapeutic trials to correct the dysfunction identified in the individual patient. Conclusions: A practical approach has been developed for management of IBS. It is based on advances in our understanding of the mechanisms resulting in IBS and on targeting therapy to correct the dysfunctions in these patients.			CAMILLERI, M (corresponding author), MAYO CLIN & MAYO FDN, GASTROENTEROL RES UNIT, ROCHESTER, MN 55905 USA.							ALMY TP, 1947, GASTROENTEROLOGY, V8, P616; ALVAREZ WC, 1943, NERVOUSNESS INDIGEST, P83; ARHAN P, 1981, DIS COLON RECTUM, V24, P625, DOI 10.1007/BF02605761; BAYLESS TM, 1966, J AMER MED ASSOC, V197, P968, DOI 10.1001/jama.197.12.968; BAZZOCCHI G, 1990, GASTROENTEROLOGY, V98, P686, DOI 10.1016/0016-5085(90)90289-D; BAZZOCCHI G, 1988, GASTROENTEROLOGY, V94, pA29; BOND JH, 1976, GASTROENTEROLOGY, V70, P1058; BOND JH, 1975, J LAB CLIN MED, V85, P546; CAMILLERI M, 1989, GUT, V30, P468, DOI 10.1136/gut.30.4.468; CAMILLERI M, 1989, DIGEST DIS SCI, V34, P1777, DOI 10.1007/BF01540058; CAMILLERI M, 1989, AM J PHYSIOL, V257, pG284, DOI 10.1152/ajpgi.1989.257.2.G284; CAMILLERI M, 1990, ADV INTERNAL MED, V36, P287; CAMILLERI M, IN PRESS GASTROENTER; CANN PA, 1983, GUT, V24, P405, DOI 10.1136/gut.24.5.405; CANN PA, 1984, DIGEST DIS SCI, V29, P239, DOI 10.1007/BF01296258; CANN PA, 1984, GUT, V25, P168, DOI 10.1136/gut.25.2.168; CHAUDHARY N, 1961, GASTROENTEROLOGY, V40, P1; CONNELL AM, 1962, GUT, V3, P342, DOI 10.1136/gut.3.4.342; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1982, GASTROENTEROLOGY, V83, P529; FORDTRAN JS, 1966, AM J DIG DIS, V11, P503, DOI 10.1007/BF02233563; GREENBAUM DS, 1987, DIGEST DIS SCI, V32, P257, DOI 10.1007/BF01297051; GREYDANUS MP, 1991, GASTROENTEROLOGY, V100, P1311; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HINTON JM, 1969, GUT, V10, P842, DOI 10.1136/gut.10.10.842; HOFMANN AF, 1967, GASTROENTEROLOGY, V52, P752, DOI 10.1016/s0016-5085(67)80140-9; HOROWITZ L, 1962, GASTROENTEROLOGY, V42, P455; HYAMS JS, 1983, GASTROENTEROLOGY, V84, P30; KAMATH KR, 1974, GASTROENTEROLOGY, V66, P16; KAMATH PS, 1987, AM J PHYSIOL, V253, pG427, DOI 10.1152/ajpgi.1987.253.4.G427; KELLOW JE, 1987, GASTROENTEROLOGY, V92, P1885, DOI 10.1016/0016-5085(87)90620-2; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; LENNARDJONES JE, 1983, NEW ENGL J MED, V308, P431, DOI 10.1056/NEJM198302243080805; MAINGUET P, 1977, GUT, V18, P575, DOI 10.1136/gut.18.7.575; Malagelada JRCM, 1986, MANOMETRIC DIAGNOSIS; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MAYER EA, 1990, GASTROENTEROLOGY, V99, P1688, DOI 10.1016/0016-5085(90)90475-G; MCMICHAE.HB, 1965, LANCET, V1, P717; MEARIN F, 1991, GASTROENTEROLOGY, V101, P999, DOI 10.1016/0016-5085(91)90726-2; MERRICK MV, 1985, BRIT MED J, V290, P665, DOI 10.1136/bmj.290.6469.665; Metcalf AM, 1987, GASTROENTEROLOGY, V92, P40, DOI 10.1016/0016-5085(87)90837-7; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; NELIS G F, 1990, Gastroenterology, V98, pA194; NEWCOMER AD, 1983, MAYO CLIN PROC, V58, P339; NYHLIN H, 1983, GASTROENTEROLOGY, V84, P63; ODDSSON E, 1978, SCAND J GASTROENTERO, V13, P409, DOI 10.3109/00365527809181914; OLMOS RV, 1991, EUR J NUCL MED, V18, P346, DOI 10.1007/BF02285463; PAINTER NS, 1972, BRIT MED J, V2, P46, DOI 10.1136/bmj.2.5804.46-b; PEMBERTON J H, 1991, Gastroenterology, V100, pA481; PEMBERTON JH, 1990, SURGICAL TREATMENT D, P39; PRIOR A, 1987, GUT, V28, P1510, DOI 10.1136/gut.28.11.1510; PRIOR A, 1990, GUT, V31, P458, DOI 10.1136/gut.31.4.458; PROANO M, 1990, AM J PHYSIOL, V258, pG856, DOI 10.1152/ajpgi.1990.258.6.G856; RAVICH WJ, 1983, GASTROENTEROLOGY, V84, P26; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; RUMESSEN JJ, 1988, GASTROENTEROLOGY, V95, P694, DOI 10.1016/S0016-5085(88)80016-7; SCIARRETTA G, 1987, GUT, V28, P970, DOI 10.1136/gut.28.8.970; SCOTT RB, 1988, AM J PHYSIOL, V255, pG505, DOI 10.1152/ajpgi.1988.255.4.G505; SPILLER RC, 1986, GASTROENTEROLOGY, V91, P100, DOI 10.1016/0016-5085(86)90445-2; STIVLAND T, 1991, GASTROENTEROLOGY, V101, P107, DOI 10.1016/0016-5085(91)90466-X; SVEDLUND J, 1983, ACTA PSYCHIAT SCAND, V67, P1, DOI 10.1111/j.1600-0447.1983.tb03707.x; SVEDLUND J, 1983, ACTA PSYCHIAT SCAND, V67, P86; SWARBRICK ET, 1980, LANCET, V2, P443; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1989, GASTROENTEROLOGY, V97, P775, DOI 10.1016/0016-5085(89)90653-7; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; THAYSEN EH, 1976, GUT, V17, P965, DOI 10.1136/gut.17.12.965; THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VASSALLO M, 1992, GASTROENTEROLOGY, V102, P102, DOI 10.1016/0016-5085(92)91789-7; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHITEHEAD WE, 1980, DIGEST DIS SCI, V25, P404, DOI 10.1007/BF01395503; WHORWELL PJ, 1987, STRESS MEDICINE, V3, P5, DOI 10.1002/smi.2460030104; WHORWELL PJ, 1984, LANCET, V2, P1232, DOI 10.1016/S0140-6736(84)92793-4	79	108	111	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				1001	1008		10.7326/0003-4819-116-12-1001	http://dx.doi.org/10.7326/0003-4819-116-12-1001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586089				2022-12-28	WOS:A1992HY79300010
J	SUH, I; SHATEN, BJ; CUTLER, JA; KULLER, LH				SUH, I; SHATEN, BJ; CUTLER, JA; KULLER, LH			ALCOHOL-USE AND MORTALITY FROM CORONARY HEART-DISEASE - THE ROLE OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; ALCOHOL DRINKING; LIPOPROTEINS, HDL CHOLESTEROL; MORTALITY; DOSE-RESPONSE RELATIONSHIP, DRUG	CARDIOVASCULAR MORTALITY; CONSUMPTION; MEN; SUBFRACTIONS; FRAMINGHAM; DRINKING	Objective: To study the association between alcohol consumption and death from coronary heart disease and to determine the extent to which the association can be explained by the high-density lipoprotein (HDL) cholesterol level. Design: A cohort study involving men enrolled in the Multiple Risk Factor Intervention Trial (MRFIT). Setting: Community-based study. Participants: Men (n = 11 688) at high risk for developing coronary heart disease but without clinical evidence of it. More than 90% of the men were white, and the average age was 46 years. Five percent of the men abstained from alcohol during the trial, 81% consumed fewer than 21 alcoholic drinks per week, and 14% consumed more than 21 alcoholic drinks per week. Measurements: Average alcohol intake over 7 years was calculated for MRFIT participants who were alive at the end of the trial and who had at least three follow-up records of alcohol consumption. Post-trial mortality during a 3.8-year period was assessed. Results: The adjusted relative risk for death from coronary heart disease for each increase of 7 drinks per week was 0.89 (95% Cl, 0.80 to 1.00), with an apparent dose-response relationship. The average HDL level was associated with the average alcohol intake in a least-squares regression model (beta = -0.0074; P < 0.01). When the average HDL level was included in the proportional hazards model for mortality from coronary heart disease, the absolute value of the coefficient for average drinks per week declined 45%, yielding an adjusted relative risk for each additional 7 drinks per week of 0.94 (Cl, 0.84 to 1.05). Conclusion: In middle-aged men who are light to moderate drinkers, the inverse association between alcohol consumption and death from coronary heart disease can be explained, in large part, by the HDL cholesterol level, which increases with alcohol consumption. However, alcohol consumption cannot be recommended because of the known adverse effects of excess alcohol use.	UNIV MINNESOTA, SCH PUBL HLTH,DIV BIOSTAT, COORDINATING CTR BIOMETR RES,2221 UNIV AVE SE, SUITE 200, MINNEAPOLIS, MN 55414 USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20814 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15261 USA	University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HC22971] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC022971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1987, ACTA MED SCAND, P73; DAVIDSON DM, 1989, WESTERN J MED, V151, P430; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; FERRENCE RG, 1986, J STUD ALCOHOL, V47, P394, DOI 10.15288/jsa.1986.47.394; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; GORDON T, 1981, CIRCULATION, V64, P63; HARTUNG GH, 1990, METABOLISM, V39, P81, DOI 10.1016/0026-0495(90)90152-3; HULLEY SB, 1981, CIRCULATION, V64, P57; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KULLER LH, 1983, AM J EPIDEMIOL, V117, P406, DOI 10.1093/oxfordjournals.aje.a113559; LANGER RD, 1988, AM J EPIDEMIOL, V128, P916; LUPIEN PJ, 1988, CAN J CARDIOL, V4, P102; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MILLER NE, 1988, J EPIDEMIOL COMMUN H, V42, P220, DOI 10.1136/jech.42.3.220; PETERSSON B, 1982, BRIT MED J, V285, P1457, DOI 10.1136/bmj.285.6353.1457; REGAN TJ, 1990, JAMA-J AM MED ASSOC, V264, P377, DOI 10.1001/jama.264.3.377; SHAPER AG, 1988, LANCET, V2, P1267; SHATEN BJ, 1991, PREV MED, V20, P655, DOI 10.1016/0091-7435(91)90061-8; STEINBERG D, 1991, ANN INTERN MED, V114, P967, DOI 10.7326/0003-4819-114-11-967; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; 1974, DHEW2ND REP, P68; 1989, J AM COLL CARDIOL, V13, pA11	29	270	272	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					881	887		10.7326/0003-4819-116-11-881	http://dx.doi.org/10.7326/0003-4819-116-11-881			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580443				2022-12-28	WOS:A1992HW13700001
J	APPENZELLER, O				APPENZELLER, O			EXERCISE-ASSOCIATED TINNITUS AND LIGHT-HEADEDNESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											APPENZELLER, O (corresponding author), LOVELACE FDN MED EDUC & RES,ALBUQUERQUE,NM 87108, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573759				2022-12-28	WOS:A1992HT82300040
J	HARWOOD, AJ; HOPPER, NA; SIMON, MN; DRISCOLL, DM; VERON, M; WILLIAMS, JG				HARWOOD, AJ; HOPPER, NA; SIMON, MN; DRISCOLL, DM; VERON, M; WILLIAMS, JG			CULMINATION IN DICTYOSTELIUM IS REGULATED BY THE CAMP-DEPENDENT PROTEIN-KINASE	CELL			English	Article							DIFFERENTIATION INDUCING FACTOR; PRESTALK GENE-EXPRESSION; CELLULAR SLIME-MOLD; ANTERIOR-LIKE CELLS; STALK CELLS; CYCLIC-AMP; DISCOIDEUM; MORPHOGEN; DIF; TRANSFORMATION	We placed a specific inhibitor of cyclic AMP-dependent protein kinase (PKA) under the control of a prestalk-specific promoter. Cells containing this construct form normally patterned slugs, but under environmental conditions that normally trigger immediate culmination, the slugs undergo prolonged migration. Slugs that eventually enter culmination do so normally but arrest as elongated, hairlike structures that contain neither stalk nor spore cells. Mutant cells do not migrate to the stalk entrance when codeveloped with wild-type cells and show greatly reduced inducibility by DIF, the stalk cell morphogen. These results suggest that the activity of PKA is necessary for the altered pattern of movement of prestalk cells at culmination and their differentiation into stalk cells. We propose a model whereby a protein repressor, under the control of PKA, inhibits precocious induction of stalk cell differentiation by DIF and so regulates the choice between slug migration and culmination.	INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HARWOOD, AJ (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Harwood, Adrian/A-4350-2010	Harwood, Adrian/0000-0003-3124-5169				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; BERKS M, 1990, DEVELOPMENT, V110, P977; BERKS M, 1988, DEV BIOL, V125, P108; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BONNER JT, 1985, J EMBRYOL EXP MORPH, V87, P207; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; DEGUNZBURG J, 1982, EMBO J, V1, P1063, DOI 10.1002/j.1460-2075.1982.tb01297.x; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; FIRTEL RA, 1990, GENE DEV, V4, P18, DOI 10.1101/gad.4.1.18; GEORGE RP, 1972, J GEN MICROBIOL, V70, P477, DOI 10.1099/00221287-70-3-477; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; HARWOOD AJ, 1991, DIFFERENTIATION, V46, P7, DOI 10.1111/j.1432-0436.1991.tb00860.x; HARWOOD AJ, 1991, IN PRESS DEV BIOL; INOUYE K, 1988, DEVELOPMENT, V104, P669; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAKUTANI T, 1986, DEV BIOL, V115, P439, DOI 10.1016/0012-1606(86)90264-2; KAY RR, 1982, P NATL ACAD SCI-BIOL, V79, P3228, DOI 10.1073/pnas.79.10.3228; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KREFFT M, 1983, EXP CELL RES, V147, P235, DOI 10.1016/0014-4827(83)90291-4; KWONG L, 1988, DIFFERENTIATION, V37, P1, DOI 10.1111/j.1432-0436.1988.tb00789.x; KWONG L, 1990, DEVELOPMENT, V110, P303; MAEDA M, 1988, DEV GROWTH DIFFER, V30, P573; MCROBBIE SJ, 1988, DEV BIOL, V125, P59, DOI 10.1016/0012-1606(88)90058-9; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MERKLE RK, 1984, CELL DIFFER DEV, V14, P257, DOI 10.1016/0045-6039(84)90014-9; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NEWELL PC, 1982, J GEN MICROBIOL, V128, P1639; RAPER K, 1940, J E MITCHELL SCI SOC, V59, P241; RAPER KENNETH B., 1952, BULL TORREY BOT CLUB, V79, P25, DOI 10.2307/2482103; RILEY BB, 1990, DEVELOPMENT, V109, P715; SCHAAP P, 1985, DEV BIOL, V111, P51, DOI 10.1016/0012-1606(85)90434-8; SCHINDLER J, 1977, J MOL BIOL, V116, P161, DOI 10.1016/0022-2836(77)90124-3; SIEGERT F, 1991, PHYSICA D, V49, P224, DOI 10.1016/0167-2789(91)90210-Z; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; SUSSMAN M, 1978, EXP CELL RES, V116, P217, DOI 10.1016/0014-4827(78)90078-2; SUSSMAN M, 1977, FRB FIGGRTRNYISYION, P31; TAKEUCHI I, 1977, DEV DIFFERENTIATION, P1; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WANG M, 1989, DEVELOPMENT, V105, P569; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WILLIAMS JG, 1989, DEVELOPMENT, V7, P91	51	129	130	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					615	624		10.1016/0092-8674(92)90225-2	http://dx.doi.org/10.1016/0092-8674(92)90225-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586944				2022-12-28	WOS:A1992HV08900006
J	BARNES, DE; TOMKINSON, AE; LEHMANN, AR; WEBSTER, ADB; LINDAHL, T				BARNES, DE; TOMKINSON, AE; LEHMANN, AR; WEBSTER, ADB; LINDAHL, T			MUTATIONS IN THE DNA LIGASE-I GENE OF AN INDIVIDUAL WITH IMMUNODEFICIENCIES AND CELLULAR-HYPERSENSITIVITY TO DNA-DAMAGING AGENTS	CELL			English	Article							BLOOMS SYNDROME CELLS; SISTER-CHROMATID EXCHANGES; SYNDROME FIBROBLASTS; EXCISION REPAIR; XERODERMA-PIGMENTOSUM; PATIENT 46BR; STRAIN 46BR; RAT-LIVER; SENSITIVITY; DEFECT	Two missense mutations occurring in different alleles of the DNA ligase I gene, encoding the major DNA ligase in proliferating mammalian cells, were detected in a human fibroblast strain (46BR). These cells exhibit retarded joining of Okazaki fragments during DNA replication and hypersensitivity to a variety of DNA-damaging agents. 46BR was derived from a patient who displayed symptoms of immunodeficiency, stunted growth, and sun sensitivity. A strongly reduced ability of DNA ligase I to form a labeled enzyme-adenylate intermediate correlated with the genetic defect in 46BR cells. The data indicate that human DNA ligase I is required for joining of Okazaki fragments during lagging-strand DNA synthesis and the completion of DNA excision repair.	UNIV SUSSEX, MRC, CELL MUTAT UNIT, BRIGHTON BN1 9RR, E SUSSEX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, MRC, CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND	University of Sussex; Imperial College London; Medical Research Council Clinical Trials Unit	BARNES, DE (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LAB, S MIMMS EN6 3LD, HERTS, ENGLAND.							ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BARNES DE, 1992, GENOMICS, V12, P164, DOI 10.1016/0888-7543(92)90422-O; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLOOM D, 1966, J PEDIATR-US, V68, P103, DOI 10.1016/S0022-3476(66)80426-2; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; FRIEDBERG EC, 1985, DNA REPAIR, pCH9; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GERMAN J, 1977, AM J HUM GENET, V29, P248; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; HENDRICKSON EA, 1991, MOL CELL BIOL, V11, P3155, DOI 10.1128/MCB.11.6.3155; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOOK GJ, 1984, MUTAT RES, V131, P223, DOI 10.1016/0167-8817(84)90029-4; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; ISHIZAKI K, 1981, MUTAT RES, V80, P213, DOI 10.1016/0027-5107(81)90189-5; JOHNS MB, 1989, ANAL BIOCHEM, V180, P276, DOI 10.1016/0003-2697(89)90430-2; KAPP LN, 1982, BIOCHIM BIOPHYS ACTA, V696, P226, DOI 10.1016/0167-4781(82)90034-3; KLINEDINST DK, 1991, MUTAT RES, V250, P365, DOI 10.1016/0027-5107(91)90193-R; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; KURIHARA T, 1991, JPN J CANCER RES, V82, P51, DOI 10.1111/j.1349-7006.1991.tb01745.x; LAUER G, 1991, J BACTERIOL, V173, P5047, DOI 10.1128/jb.173.16.5047-5053.1991; LEHMANN AR, 1988, CANCER RES, V48, P6343; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LONN U, 1990, CANCER RES, V50, P3141; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; MARTIN GM, 1973, TISSUE CULTURE METHO, P39; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OCKEY CH, 1986, CARCINOGENESIS, V7, P53, DOI 10.1093/carcin/7.1.53; PETRINI JHJ, 1991, P NATL ACAD SCI USA, V88, P7615, DOI 10.1073/pnas.88.17.7615; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; RUNGER TM, 1989, EMBO J, V8, P1419, DOI 10.1002/j.1460-2075.1989.tb03523.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SODERHALL S, 1976, NATURE, V260, P640, DOI 10.1038/260640a0; SPANOS A, 1986, HUM GENET, V73, P119, DOI 10.1007/BF00291599; SQUIRES S, 1983, CARCINOGENESIS, V4, P565, DOI 10.1093/carcin/4.5.565; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; WEBSTER D, 1982, ATAXIA TELANGIECTASI, P379; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEKSBERG R, 1988, AM J HUM GENET, V42, P816; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016	60	230	234	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					495	503		10.1016/0092-8674(92)90450-Q	http://dx.doi.org/10.1016/0092-8674(92)90450-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581963				2022-12-28	WOS:A1992HT07800011
J	GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE				GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE			LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						TESTICULAR NEOPLASMS; CARDIOVASCULAR DISEASES; CISPLATIN; HYPERCHOLESTEROLEMIA	GERM-CELL TUMORS; COMBINATION CHEMOTHERAPY; DENSITY LIPOPROTEIN; RAYNAUDS-PHENOMENON; SERUM-CHOLESTEROL; RENAL-FUNCTION; CISPLATIN; VINBLASTINE; BLEOMYCIN; TOXICITY	. Objective: To assess cardiovascular risk factors over time in patients who received chemotherapy for disseminated testicular cancer and were apparently cured. . Design: Cohort study. . Setting: Referral center. . Patients: Fifty-seven consecutive patients (median age, 28 years; range, 16 to 43 years) who received cisplatin-containing chemotherapy between 1978 and 1985. . Measurements: Serum cholesterol and high-density lipoprotein (HDL) levels, body mass index (BMI), blood pressure, kidney function, and hormonal status were monitored during follow-up after chemotherapy (median follow-up, 88 months; range, 56 to 143 months). The BMI and cholesterol values obtained 4 to 6 years after chemotherapy were compared with values from a sample of healthy, age-matched Dutch men; the cholesterol level was also compared with that of 31 patients treated with orchidectomy for stage I disease. . Results: The mean cholesterol level in patients at the start of chemotherapy was 3.96 +/- 0.98 mmol/L [153 +/- 38 mg/dL], increasing 4 to 6 years later to 6.12 +/- 1.20 mmol/L [237 +/- 46 mg/dL] (P < 0.001); 49 of 57 patients had an elevated low-density lipoprotein (LDL) cholesterol level (> 3.4 mmol/L [130 mg/dL]), with a mean level of 4.47 +/- 1.05 mmol/L [173 +/- 41 mg/dL]. Compared with a sample of healthy Dutch men, the chemotherapy group had an elevated cholesterol level (P < 0.05). At 4 to 6 years, the mean HDL cholesterol level was 0.76 +/- 0.18 mmol/L [29 +/- 7 mg/dL], which was low compared with that of the healthy Dutch men (P < 0.05). The mean BMI for all patients was 2.8% higher than expected 4 to 6 years after chemotherapy (P < 0.01) but was not higher than expected 7 to 10 years after chemotherapy. . Conclusions: In addition to other known late side effects of chemotherapy in patients with testicular cancer, hypercholesterolemia and overweight might represent risk factors for cardiovascular disease in such patients, especially in those who are younger.	UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV MED ONCOL, OOSTERSINGEL 59, 9713 EZ GRONINGEN, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, BILTHOVEN, NETHERLANDS	University of Groningen; Netherlands National Institute for Public Health & the Environment			Kromhout, Daan/A-8566-2014	Gietema, Jourik/0000-0003-0629-7354; de Vries, Elisabeth/0000-0002-8949-7425				ADOUE D, 1984, ANN INTERN MED, V100, P770, DOI 10.7326/0003-4819-100-5-770_2; ALBERS JJ, 1978, CLIN CHEM, V24, P853; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BOYER M, 1990, J CLIN ONCOL, V8, P21, DOI 10.1200/JCO.1990.8.1.21; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; DOLL DC, 1986, ANN INTERN MED, V105, P48, DOI 10.7326/0003-4819-105-1-48; EDWARDS GS, 1979, CANCER TREAT REP, V63, P551; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; FOSSA SD, 1986, CANCER, V58, P2600, DOI 10.1002/1097-0142(19861215)58:12<2600::AID-CNCR2820581208>3.0.CO;2-D; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG H, 1982, ANN INTERN MED, V96, P311, DOI 10.7326/0003-4819-96-3-311; HANSEN SW, 1990, J CLIN ONCOL, V8, P1695, DOI 10.1200/JCO.1990.8.10.1695; HANSEN SW, 1988, J CLIN ONCOL, V6, P1728, DOI 10.1200/JCO.1988.6.11.1728; HENRIKSSON P, 1990, LANCET, V336, P1178; KROMHOUT D, 1989, 528901002 NAT I PUBL; LEITNER SP, 1986, J CLIN ONCOL, V4, P1500, DOI 10.1200/JCO.1986.4.10.1500; LEJONC JL, 1980, LANCET, V2, P692; MEIJER S, 1983, CANCER, V51, P2035, DOI 10.1002/1097-0142(19830601)51:11<2035::AID-CNCR2820511113>3.0.CO;2-8; MILLER SR, 1981, JNCI-J NATL CANCER I, V67, P297; NYDEGGER UE, 1972, CANCER RES, V32, P1756; OPPENHEIM DS, 1989, ANN INTERN MED, V111, P288, DOI 10.7326/0003-4819-111-4-288; ROOKUS MA, 1987, HUM BIOL, V59, P599; ROTH BJ, 1988, J CLIN ONCOL, V6, P1239, DOI 10.1200/JCO.1988.6.8.1239; SAMUELS BL, 1987, INT J ANDROL, V10, P363, DOI 10.1111/j.1365-2605.1987.tb00204.x; SAMUELS BL, 1987, CANCER CHEMOTH PHARM, V19, P253; SEGAL KR, 1987, J CLIN INVEST, V80, P1050, DOI 10.1172/JCI113159; STOTER G, 1989, J CLIN ONCOL, V7, P1099, DOI 10.1200/JCO.1989.7.8.1099; STUART NSA, 1990, BRIT J CANCER, V61, P479, DOI 10.1038/bjc.1990.106; SUBAR M, 1986, CANCER TREAT REP, V70, P690; VANBARNEVELD PWC, 1984, AM REV RESPIR DIS, V130, P1078; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; VOGELZANG NJ, 1981, ANN INTERN MED, V95, P288, DOI 10.7326/0003-4819-95-3-288; VOGELZANG NJ, 1980, CANCER TREAT REP, V64, P1159; WILLEMSE PHB, 1983, INT J ANDROL, V6, P497, DOI 10.1111/j.1365-2605.1983.tb00341.x; 1988, ACH INTERN MED, V148, P36	36	82	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					709	715		10.7326/0003-4819-116-9-709	http://dx.doi.org/10.7326/0003-4819-116-9-709			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558341				2022-12-28	WOS:A1992HQ62300002
J	REID, RC; SHAPLEY, RM				REID, RC; SHAPLEY, RM			SPATIAL STRUCTURE OF CONE INPUTS TO RECEPTIVE-FIELDS IN PRIMATE LATERAL GENICULATE-NUCLEUS	NATURE			English	Article							RETINAL GANGLION-CELLS; SENSITIVITY; CAT	HUMAN colour vision depends on three classes of cone photoreceptors, those sensitive to short (S), medium (M) or long (L) wavelengths, and on how signals from these cones are combined by neurons in the retina and brain. Macaque monkey colour vision is similar to human, and the receptive fields of macaque visual neurons have been used as an animal model of human colour processing 1. P retinal ganglion cells and parvocellular neurons are colour-selective neurons in macaque retina and lateral geniculate nucleus. Interactions between cone signals feeding into these neurons are still unclear. On the basis of experimental results with chromatic adaptation, excitatory and inhibitory inputs from L and M cones onto P cells (and parvocellular neurons) were thought to be quite specific 2,3 (Fig. 1a). But these experiments with spatially diffuse adaptation did not rule out the 'mixed-surround' hypothesis: that there might be one cone-specific mechanism, the receptive field centre, and a surround mechanism connected to all cone types indiscriminately (Fig. 1e). Recent work has tended to support the mixed-surround hypothesis 4-8. We report here the development of new stimuli to measure spatial maps of the linear L-, M- and S-cone inputs to test the hypothesis definitively. Our measurements contradict the mixed-surround hypothesis and imply cone specificity in both centre and surround.	NYU,CTR NEURAL SCI,NEW YORK,NY 10003	New York University								[Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; CITRON MC, 1981, J NEUROPHYSIOL, V46, P1161, DOI 10.1152/jn.1981.46.6.1161; DEMONASTERIO FM, 1975, J PHYSIOL-LONDON, V251, P167, DOI 10.1113/jphysiol.1975.sp011086; DEVALOIS RL, 1974, VISION RES, V14, P53, DOI 10.1016/0042-6989(74)90116-3; ESTEVEZ O, 1982, VISION RES, V22, P681, DOI 10.1016/0042-6989(82)90104-3; GASKA J P, 1989, Society for Neuroscience Abstracts, V15, P1056; GIELEN CCAM, 1982, BIOL CYBERN, V44, P211, DOI 10.1007/BF00344277; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; HUBEL D, 1991, COLD SPRING HARB SYM, V55, P643; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KAPLAN E, 1986, P NATL ACAD SCI USA, V83, P2755, DOI 10.1073/pnas.83.8.2755; KAPLAN E, 1984, EXP BRAIN RES, V55, P111; LEE BB, 1989, J PHYSIOL-LONDON, V414, P223, DOI 10.1113/jphysiol.1989.sp017685; MILKMAN N, 1980, BEHAV RES METH INSTR, V12, P283, DOI 10.3758/BF03201667; PAULUS W, 1983, VISION RES, V23, P529, DOI 10.1016/0042-6989(83)90128-1; REID C, 1989, SOC NEUR ABSTR, V15, P323; REID C, 1990, INVEST OPHTHALMOL S, V31, P429; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; SUTTER EE, 1992, SIAM J COMPUT, V20, P686; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	25	194	194	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					716	718		10.1038/356716a0	http://dx.doi.org/10.1038/356716a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570016				2022-12-28	WOS:A1992HQ14600062
J	DENMAN, SJ; BURTON, JR				DENMAN, SJ; BURTON, JR			FLUID INTAKE AND URINARY-TRACT INFECTION IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DENMAN, SJ (corresponding author), JOHNS HOPKINS UNIV,FRANCIS SCOTT KEY MED CTR,SCH MED,BALTIMORE,MD 21218, USA.							ANDRIOLE VT, 1968, J LAB CLIN MED, V71, P1; FRIEDMAN SA, 1970, J UROLOGY, V105, P428; Kaye D, 1975, Urol Clin North Am, V2, P407; LONERGAN ET, 1988, GERIATRICS, V43, P23; NUNEZ JFM, 1987, RENAL FUNCTION DISEA, P84; WHELTON A, 1978, JOHNS HOPKINS MED J, V142, P8	6	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2245	&		10.1001/jama.267.16.2245	http://dx.doi.org/10.1001/jama.267.16.2245			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556802				2022-12-28	WOS:A1992HN84100040
J	SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M				SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M			TRANSFERS FROM PRISON FOR URGENT PSYCHIATRIC-TREATMENT - A STUDY OF SECTION-48 ADMISSIONS	BRITISH MEDICAL JOURNAL			English	Article											DONOVAN, M (corresponding author), LANGDON HOSP,BUTLER CLIN,DAWLISH EX7 0NR,DEVON,ENGLAND.							GROUNDS A, 1990, PRINCIPLES PRACTICE; Joseph P L, 1990, Health Trends, V22, P51; MCCLURE GMG, 1987, BRIT J PSYCHIAT, V150, P309, DOI 10.1192/bjp.150.3.309; Smith J, 1991, J FORENSIC PSYCHIATR, V2, P95; 1990, WORKING PARTY REPORT; 1990, 6690 HOM OFF CIRC	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					967	969		10.1136/bmj.304.6832.967	http://dx.doi.org/10.1136/bmj.304.6832.967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP064	1581722	Bronze, Green Published			2022-12-28	WOS:A1992HP06400027
J	GIESE, K; COX, J; GROSSCHEDL, R				GIESE, K; COX, J; GROSSCHEDL, R			THE HMG DOMAIN OF LYMPHOID ENHANCER FACTOR-I BENDS DNA AND FACILITATES ASSEMBLY OF FUNCTIONAL NUCLEOPROTEIN STRUCTURES	CELL			English	Article							INTEGRATION HOST FACTOR; SITE-SPECIFIC RECOMBINATION; SEX-DETERMINING REGION; HISTONE-LIKE PROTEINS; RECEPTOR-ALPHA LOCUS; ECO RI ENDONUCLEASE; COLI IHF PROTEIN; TRANSCRIPTION FACTOR; ATTACHMENT SITE; GENE-REGULATION	The high mobility group (HMG) domain is a DNA-binding motif that is associated with several eukaryotic regulatory proteins, including the lymphoid enhancer-binding factor LEF-1 and the testis-determining factor SRY. Here, we provide evidence that DNA binding by the HMG domain of LEF-1 involves primarily minor groove contacts and induces a bend of approximately 130-degrees in the DNA helix. Bending was also found to accompany sequence-specific DNA binding by the SRY-HMG domain. Examining possible regulatory roles of HMG domain-induced DNA bends, we found that LEF-1 can function in a manner similar to bacterial integration host factor and facilitate communication between widely separated protein-binding sites in a recombination assay. Together with the previous observation that LEF-1 by itself is unable to augment basal promoter activity, these data suggest that HMG domain proteins can serve as "architectural" elements in the assembly of higher-order nucleoprotein structures.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	GIESE, K (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL,SAN FRANCISCO,CA 94143, USA.							DEVARGAS LM, 1989, SCIENCE, V244, P1457; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN S, 1990, STRUCTURE METHODS, V2, P51; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; HO IC, 1990, MOL CELL BIOL, V10, P4720, DOI 10.1128/MCB.10.9.4720; HOCHSCHILD A, 1990, DNA TOPOLOGY ITS BIO; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; LU AL, 1981, J BIOL CHEM, V256, P3200; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Ptashne M., 1986, A GENETIC SWITCH; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANHODLE KE, 1989, CHROMATIN; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x	64	608	617	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					185	195		10.1016/0092-8674(92)90129-Z	http://dx.doi.org/10.1016/0092-8674(92)90129-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555239				2022-12-28	WOS:A1992HM44500017
J	BAKER, D; SOHL, JL; AGARD, DA				BAKER, D; SOHL, JL; AGARD, DA			A PROTEIN-FOLDING REACTION UNDER KINETIC CONTROL	NATURE			English	Article							ALPHA-LYTIC PROTEASE; PRO-REGION; STATE	SYNTHESIS of alpha-lytic protease is as a precursor containing a 166 amino-acid pro region 1 transiently required for the correct folding of the protease domain 2-4. By omitting the pro region in an in vitro refolding reaction we trapped an inactive, but folding competent state (I) having an expanded radius yet native-like secondary structure. The I state is stable for weeks at physiological pH in the absence of denaturant, but rapidly folds to the active, native state on addition of the pro region as a separate polypeptide chain. The mechanism of action of the pro region is distinct from that of the chaperonins 5,6: rather than reducing the rate of off-pathway reactions, the pro region accelerates the rate-limiting step on the folding pathway by more than 10 7. Because both the I and native states are stable under identical conditions with no detectable interconversion, the folding of alpha-lytic protease must be under kinetic and not thermodynamic control.	UNIV CALIF SAN FRANCISCO,BIOPHYS GRAD GRP,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BAKER, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217				BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DILL KA, 1989, BIOCHEMISTRY-US, V29, P133; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FUJINAGA M, 1985, J MOL BIOL, V183, P479; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; KETTNER CA, 1988, BIOCHEMISTRY-US, V27, P7682, DOI 10.1021/bi00420a017; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUNDROT CE, 1988, PROTEINS, V3, P71; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; ROCHE RS, 1984, BIOCHEMISTRY-US, V23, P1888; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9	18	298	303	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					263	265		10.1038/356263a0	http://dx.doi.org/10.1038/356263a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552947				2022-12-28	WOS:A1992HJ94400066
J	WASAN, H; MANSI, JL; BENJAMIN, S; POWLES, R; CUNNINGHAM, D				WASAN, H; MANSI, JL; BENJAMIN, S; POWLES, R; CUNNINGHAM, D			MYELOMA AND BENIGN INTRACRANIAL HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article									ROYAL MARSDEN HOSP,DEPT HAEMATOL,CRC,MED SECT,LONDON,ENGLAND; ROYAL MARSDEN HOSP,LEUKAEMIA UNIT,LONDON,ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust				Wasan, Harpreet/0000-0002-6268-2030; Cunningham, David/0000-0001-5158-1069				BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; COLLIER A, 1987, J NEUROL NEUROSUR PS, V50, P495, DOI 10.1136/jnnp.50.4.495; DIGRE KB, 1988, ARCH NEUROL-CHICAGO, V45, P866, DOI 10.1001/archneur.1988.00520320056015; SHIMPO S, 1968, JAPANESE J CLIN MED, V24, P2444; SUGITA K, 1986, NO TO SHINKEI, V38, P6259	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					685	685		10.1136/bmj.304.6828.685	http://dx.doi.org/10.1136/bmj.304.6828.685			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571640	Green Published, Bronze			2022-12-28	WOS:A1992HK76100023
J	RICHMAN, AD; PRICE, T				RICHMAN, AD; PRICE, T			EVOLUTION OF ECOLOGICAL DIFFERENCES IN THE OLD-WORLD LEAF WARBLERS	NATURE			English	Article							DNA-SEQUENCES; TREES	SYMPATRIC species that belong to the same ecological guild usually differ in their behaviour and morphology, and these differences are often interpreted as adaptations to having to make use of different resources. Evidence supporting this interpretation comes from association between ecology and morphology among species 1, in which an a priori functional relationship is reasonable. But one problem with such comparisons is that members of a guild may be closely related, so the more closely related species can share a greater similarity in their morphology and ecology simply as a result of the lingering legacy of a common ancestor 2-5. In principle, the importance of historical legacy can be evaluated from phylogenetic relationships and times since divergence for all species 2,6, but this is rarely possible because these data are not available. Here we use a phylogeny for eight sympatric species of warbler in the genus Phylloscopus, based on their mitochondrial DNA sequences, to remove the effects of historical legacy. Without these effects, we find strong support for adaptive interpretations of among-species variation in habitat selection, prey-size choice and feeding method. Ecological variation along any of these three niche axes is associated with predictable morphological variation. We also find evidence for historical legacy in that more closely related species are often more similar behaviourally and morphologically. This paradoxical result can be reconciled because the most closely related species tend to differ along only one niche axis, habitat choice. In contrast, the evolution of prey-size choice and feeding method occurred rapidly and early in the diversification of this group. Once a new ecological zone was occupied, subsequent morphological change along these niche axes was limited, accounting for the similarity of closely related species.	UNIV CALIF SAN DIEGO,DEPT BIOL O116,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Brooks DR, 1991, PHYLOGENY ECOLOGY BE; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FRENZEL B, 1968, SCIENCE, V161, P637, DOI 10.1126/science.161.3842.637; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HARVEY PH, 1991, NATURE, V351, P619, DOI 10.1038/351619a0; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; LYNCH M, 1991, EVOLUTION, V45, P1065, DOI [10.2307/2409716, 10.1111/j.1558-5646.1991.tb04375.x]; MARTINS EP, 1991, EVOLUTION, V45, P534, DOI [10.2307/2409910, 10.1111/j.1558-5646.1991.tb04328.x]; MILES DB, 1984, ECOLOGY, V65, P1629, DOI 10.2307/1939141; PRICE T, 1991, J ANIM ECOL, V60, P643, DOI 10.2307/5303; PRICE T, 1990, Journal of the Bombay Natural History Society, V87, P1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sibley C.G., 1990, PHYLOGENY CLASSIFICA; [No title captured]; [No title captured]; [No title captured]; [No title captured]	22	195	198	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					817	821		10.1038/355817a0	http://dx.doi.org/10.1038/355817a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1586399				2022-12-28	WOS:A1992HF63600053
J	FUCHS, VR; REKLIS, DM				FUCHS, VR; REKLIS, DM			AMERICA CHILDREN - ECONOMIC PERSPECTIVES AND POLICY OPTIONS	SCIENCE			English	Article								American children are worse off than those in the previous generation in several important dimensions of mental, physical, and emotional well-being. During the 1960s cultural changes adversely affected children while their material condition improved substantially. By contrast, material conditions deteriorated in the 1980s, especially among children at the lower end of the income distribution. Public policies to improve the material condition of children require a transfer of resources from households that do not have children to those that do. Government programs such as tax credits and child allowances are more efficient and equitable than employer-mandated programs.	NATL BUR ECON RES,STANFORD,CA 94305	National Bureau of Economic Research	FUCHS, VR (corresponding author), STANFORD UNIV,STANFORD,CA 94305, USA.							APPLEBEE AN, 1989, CROSSROADS AM ED, P21; BANE MJ, 1989, SCIENCE, V245, P1047, DOI 10.1126/science.245.4922.1047; BLACKENHORN D, 1990, REBUILDING NEST; DEWITT K, 1991, NY TIMES        0512, P1; FUCHS VR, 1988, WOMENS QUEST EC EQUA, P111; Louv Richard, 1990, CHILDHOODS FUTURE; WALDO DR, 1989, HLTH CARE FINANCING, V10, P114; ZILL N, 1990, US DEP HLTH HUMAN SE, V190; 1991, EC REPORT PRESIDENT, P290; 1991, EC REPORT PRESIDENT, P291; 1991, NY TIMES        0827, P16; 1986, SWEDEN NOW, V6, P27; 1989, STATISTICAL ABSTRACT, P172; 1990, STATISTICAL ABSTRACT, P176; 1991, RHETORIC NEW AM AGEN	15	57	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					41	46		10.1126/science.1553531	http://dx.doi.org/10.1126/science.1553531			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GX791	1553531				2022-12-28	WOS:A1992GX79100032
J	BENNETT, JC				BENNETT, JC			DEVELOPMENT OF A DIDACTIC CURRICULUM IN SCIENCE RELATED TO INTERNAL-MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Article								To best prepare physicians for productive careers in medicine and to instill in them a lifelong commitment to learning, a didactic curriculum for the sciences should be incorporated in training programs. Such a curriculum can be effective only if it can be woven into the fabric of clinical experiences and it is seen by the housestaff as relevant to their needs. A new level of commitment by our clinical teachers and a reassessment of the allocation of time for learning will be required.			BENNETT, JC (corresponding author), UNIV ALABAMA, DEPT MED, DERB-420, BIRMINGHAM, AL 35294 USA.							EISENBERG L, 1988, AM J MED, V84, P483; GOLDMAN L, 1991, COMMUNICATION    SEP; Rosovsky H, 1991, U OWNERS MANUAL; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405	4	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1088	1090		10.7326/0003-4819-116-12-1088	http://dx.doi.org/10.7326/0003-4819-116-12-1088			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586123				2022-12-28	WOS:A1992HY79400013
J	BODENHEIMER, MM				BODENHEIMER, MM			RISK STRATIFICATION IN CORONARY-DISEASE - A CONTRARY VIEWPOINT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						CORONARY DISEASE; EXERCISE TEST; DEATH, SUDDEN; MYOCARDIAL INFARCTION; HEART CATHETERIZATION	ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC-HEART-DISEASE; EXERCISE RADIONUCLIDE ANGIOGRAPHY; LEFT-VENTRICULAR FUNCTION; 10-YEAR FOLLOW-UP; Q-WAVE INFARCTION; ARTERY DISEASE; PROGNOSTIC VALUE; CHEST PAIN; CARDIAC-CATHETERIZATION	Noninvasive stress testing is generally recommended to detect patients who are at increased risk for cardiac death and myocardial infarction. Such tests depend on the presence of a physiologically significant coronary stenosis to detect disease. The low prevalence of events in patients who are able to exercise, however, results in a poor positive predictive value. Also, recent data suggest that a significant number of morbid events result from rapid progression of disease in segments of the coronary artery that initially had only minimal obstruction. Further, from a therapeutic standpoint, only catheterization has been shown in randomized trials to predict which patients are candidates for bypass surgery. Thus, noninvasive testing as an intermediate step to select those patients who require invasive study remains an attractive but unproven hypothesis.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	BODENHEIMER, MM (corresponding author), LONG ISL JEWISH MED CTR, HARRIS CHASANOFF HEART INST, ROOM 2135, NEW HYDE PK, NY 11042 USA.							ABRAHAM RD, 1987, AM J CARDIOL, V60, P225, DOI 10.1016/0002-9149(87)90218-9; AHNVE S, 1988, AM HEART J, V116, P925, DOI 10.1016/0002-8703(88)90142-1; ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; ALLEN WH, 1980, CIRCULATION, V62, P522, DOI 10.1161/01.CIR.62.3.522; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; Bodenheimer M M, 1983, Cardiovasc Clin, V13, P243; BODENHEIMER MM, 1980, AM J CARDIOL, V45, P674, DOI 10.1016/S0002-9149(80)80021-X; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN BG, 1989, ARTERIOSCLEROSIS, V9, pI81; BROWN KA, 1983, J AM COLL CARDIOL, V1, P994, DOI 10.1016/S0735-1097(83)80100-4; BRUCE RA, 1990, T ASSOC LIF, V73, P53; BRUCE RA, 1989, J OCCUP ENVIRON MED, V31, P124; BRUCE RA, 1980, AM J CARDIOL, V46, P371, DOI 10.1016/0002-9149(80)90003-X; BRUSCHKE AVG, 1981, CIRCULATION, V63, P527, DOI 10.1161/01.CIR.63.3.527; CALIFF RM, 1990, AM HEART J, V119, P777, DOI 10.1016/S0002-8703(05)80311-4; CAMPOS CT, 1983, CIRCULATION, V67, P1204, DOI 10.1161/01.CIR.67.6.1204; CHAITMAN BR, 1986, J AM COLL CARDIOL, V8, P1195, DOI 10.1016/S0735-1097(86)80401-6; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CUMMING GR, 1975, CAN MED ASSOC J, V112, P578; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAWBER TR, 1980, FRAMINGHAM STUDY EPI, P74; DEBUSK RF, 1989, ANN INTERN MED, V110, P470, DOI 10.7326/0003-4819-110-6-470; DEBUSK RF, 1983, AM J CARDIOL, V52, P1161, DOI 10.1016/0002-9149(83)90567-2; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; DEFEYTER PJ, 1991, CIRCULATION, V84, P412, DOI 10.1161/01.CIR.84.1.412; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; DETRANO R, 1989, J AM COLL CARDIOL, V14, P1501, DOI 10.1016/0735-1097(89)90388-4; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DITTUS RS, 1987, J AM COLL CARDIOL, V10, P869, DOI 10.1016/S0735-1097(87)80282-6; ELLIS S, 1989, J AM COLL CARDIOL, V13, P1481, DOI 10.1016/0735-1097(89)90336-7; EPSTEIN SE, 1978, AM J CARDIOL, V42, P667, DOI 10.1016/0002-9149(78)90639-2; EPSTEIN SE, 1989, NEW ENGL J MED, V321, P320, DOI 10.1056/NEJM198908033210511; FALK E, 1989, AM J CARDIOL, V63, pE114, DOI 10.1016/0002-9149(89)90242-7; FIORETTI P, 1985, AM J CARDIOL, V55, P1313, DOI 10.1016/0002-9149(85)90495-3; FIORETTI P, 1986, J AM COLL CARDIOL, V8, P40, DOI 10.1016/S0735-1097(86)80089-4; FLEG JL, 1990, CIRCULATION, V81, P428, DOI 10.1161/01.CIR.81.2.428; FREEDMAN SB, 1985, CIRCULATION, V71, P681, DOI 10.1161/01.CIR.71.4.681; Froelicher V F Jr, 1974, Am J Cardiol, V34, P770, DOI 10.1016/0002-9149(74)90694-8; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GIBBONS RJ, 1988, J AM COLL CARDIOL, V11, P28, DOI 10.1016/0735-1097(88)90162-3; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; GIMPLE LW, 1989, AM J CARDIOL, V64, P1243, DOI 10.1016/0002-9149(89)90561-4; GOLDMAN L, 1990, AM HEART J, V119, P733, DOI 10.1016/S0002-8703(05)80054-7; HANSEN JF, 1989, AM HEART J, V117, P290, DOI 10.1016/0002-8703(89)90771-0; HELFANT RH, 1987, J AM COLL CARDIOL, V9, P1194, DOI 10.1016/S0735-1097(87)80327-3; HENDEL RC, 1990, J AM COLL CARDIOL, V15, P109, DOI 10.1016/0735-1097(90)90184-Q; HUNG J, 1984, AM J CARDIOL, V53, P1221, DOI 10.1016/0002-9149(84)90068-7; JOSEPHSON RA, 1990, CIRCULATION, V81, P20, DOI 10.1161/01.CIR.81.1.20; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KAUL S, 1988, CIRCULATION, V77, P745, DOI 10.1161/01.CIR.77.4.745; KAUL S, 1988, J AM COLL CARDIOL, V12, P25, DOI 10.1016/0735-1097(88)90351-8; KEMP HG, 1986, J AM COLL CARDIOL, V7, P479, DOI 10.1016/S0735-1097(86)80456-9; KOSS JH, 1987, AM J CARDIOL, V59, P531, DOI 10.1016/0002-9149(87)91163-5; KOTLER TS, 1990, ANN INTERN MED, V113, P684, DOI 10.7326/0003-4819-113-9-684; KOTLER TS, 1990, ANN INTERN MED, V113, P703; KRONE RJ, 1985, CIRCULATION, V71, P80, DOI 10.1161/01.CIR.71.1.80; LADENHEIM ML, 1986, J AM COLL CARDIOL, V7, P464, DOI 10.1016/S0735-1097(86)80454-5; LAUPACIS A, 1990, CAN J CARDIOL, V6, P157; LEE KL, 1990, CIRCULATION, V82, P1705, DOI 10.1161/01.CIR.82.5.1705; LEPPO JA, 1984, NEW ENGL J MED, V310, P1014, DOI 10.1056/NEJM198404193101603; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MADSEN EB, 1985, AM J CARDIOL, V56, P839, DOI 10.1016/0002-9149(85)90766-0; MARCUS FI, 1988, AM J CARDIOL, V61, P8, DOI 10.1016/0002-9149(88)91295-7; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MARSHALL JC, 1990, AM J CARDIOL, V66, P773, DOI 10.1016/0002-9149(90)90350-A; MCHENRY PL, 1984, CIRCULATION, V70, P547, DOI 10.1161/01.CIR.70.4.547; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MOISE A, 1985, AM J CARDIOL, V56, P30, DOI 10.1016/0002-9149(85)90561-2; MOISE A, 1984, AM J CARDIOL, V54, P1176, DOI 10.1016/S0002-9149(84)80063-6; MORRIS KG, 1985, AM J CARDIOL, V55, P318, DOI 10.1016/0002-9149(85)90368-6; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NGO WL, 1990, CIRCULATION, V82, P359; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PAMELIA FX, 1985, AM J CARDIOL, V55, P920, DOI 10.1016/0002-9149(85)90718-0; PAPANICOLAOU MN, 1986, AM J CARDIOL, V58, P1181, DOI 10.1016/0002-9149(86)90378-4; PEDUZZI P, 1986, PROG CARDIOVASC DIS, V28, P285, DOI 10.1016/0033-0620(86)90006-X; PHILBRICK JT, 1980, AM J CARDIOL, V46, P807, DOI 10.1016/0002-9149(80)90432-4; PROUDFIT WL, 1980, CIRCULATION, V62, P712, DOI 10.1161/01.CIR.62.4.712; QIAO JH, 1991, J AM COLL CARDIOL, V17, P1138, DOI 10.1016/0735-1097(91)90844-Y; RAUTAHARJU PM, 1986, J AM COLL CARDIOL, V8, P1, DOI 10.1016/S0735-1097(86)80084-5; RENTROP KP, 1989, CIRCULATION, V80, P1166, DOI 10.1161/01.CIR.80.5.1166; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; RIVERS JT, 1990, J AM COLL CARDIOL, V16, P340, DOI 10.1016/0735-1097(90)90583-B; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROSCH J, 1976, RADIOLOGY, V119, P513; ROUBIN GS, 1983, CIRCULATION, V67, P743, DOI 10.1161/01.CIR.67.4.743; RYAN TJ, 1985, CIRCULATION, V72, P31; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHRODER R, 1987, J AM COLL CARDIOL, V9, P197, DOI 10.1016/S0735-1097(87)80101-8; SCHULMAN SP, 1988, J AM COLL CARDIOL, V11, P1164, DOI 10.1016/0735-1097(88)90277-X; SCHWARTZ H, 1984, J AM COLL CARDIOL, V4, P1088, DOI 10.1016/S0735-1097(84)80126-6; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SOX HC, 1989, ANN INTERN MED, V110, P456, DOI 10.7326/0003-4819-110-6-456; STADIUS ML, 1985, CIRCULATION, V72, P292, DOI 10.1161/01.CIR.72.2.292; TALIERCIO CP, 1988, MAYO CLIN PROC, V63, P573, DOI 10.1016/S0025-6196(12)64887-3; TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TIBBITS PA, 1987, AM J CARDIOL, V60, P451, DOI 10.1016/0002-9149(87)90284-0; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; WACKERS FJT, 1985, J AM COLL CARDIOL, V6, P27, DOI 10.1016/S0735-1097(85)80247-3; WAHL JM, 1985, ARCH INTERN MED, V145, P253, DOI 10.1001/archinte.145.2.253; WATERS D, 1990, CIRCULATION, V82, P251; WEBSTER M W I, 1990, Journal of the American College of Cardiology, V15, p218A; WEINER DA, 1986, J AM COLL CARDIOL, V8, P741, DOI 10.1016/S0735-1097(86)80412-0; WEINTRAUB WS, 1984, AM J CARDIOL, V54, P43, DOI 10.1016/0002-9149(84)90301-1; WELD FM, 1981, CIRCULATION, V64, P306, DOI 10.1161/01.CIR.64.2.306; WILLIAMS WL, 1984, J AM COLL CARDIOL, V4, P477, DOI 10.1016/S0735-1097(84)80090-X; 1987, LANCET, V1, P871	114	19	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					927	936		10.7326/0003-4819-116-11-927	http://dx.doi.org/10.7326/0003-4819-116-11-927			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580451				2022-12-28	WOS:A1992HW13700009
J	YOST, HJ				YOST, HJ			REGULATION OF VERTEBRATE LEFT RIGHT ASYMMETRIES BY EXTRACELLULAR-MATRIX	NATURE			English	Article							XENOPUS-LAEVIS; PROSPECTIVE AREAS; FIBRONECTIN; GASTRULATION; HANDEDNESS; MOVEMENTS; MIGRATION; NEURULA; EMBRYOS; LAYER	THE vertebrate body is organized along three geometric axes: anterior-posterior, dorsal-ventral and left-right. Left-right axis formation, displayed in heart and gut development, is the least understood, even though it has been studied for many years 1-4. In Xenopus laevis gastrulae, a fibronectin-rich extracellular matrix is deposited on the basal surface of ectoderm cells 5,6 over which cardiac and visceral primordia move during development. Here I report experiments in which localized perturbation of a small patch of extracellular matrix by microsurgery was correlated with localized randomization of left-right asymmetries. Global perturbation of the extracellular matrix by microinjection of Arg-Gly-Asp peptides or heparinase into the blastocoel resulted in global randomization of left-right asymmetries. From these observations, I suggest that left-right axial information is contained in the extracellular matrix early in development and is independently transmitted to cardiac and visceral primordia.			YOST, HJ (corresponding author), UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,4-135 JACKSON HALL,321 CHURCH ST SE,MINNEAPOLIS,MN 55455, USA.							BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BRICKMAN M, 1990, J CELL BIOL, V111, P484; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; BROWN NA, 1990, DEVELOPMENT, V109, P1; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; Clark RAF, 1989, CURR OPIN CELL BIOL, V1, P1000, DOI 10.1016/0955-0674(89)90072-0; FEY J, 1990, DIFFERENTIATION, V42, P144, DOI 10.1111/j.1432-0436.1990.tb00755.x; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; GALLOWAY J, 1990, NATURE, V346, P223, DOI 10.1038/346223a0; GERHART J, 1989, DEVELOPMENT, V107, P37; Keller R., 1990, Seminars in Developmental Biology, V1, P25; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KELLER RE, 1985, J EMBRYOL EXP MORPH, V89, P185; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LINASK KK, 1988, DEV BIOL, V129, P315, DOI 10.1016/0012-1606(88)90378-8; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OPPENHEIMER JM, 1974, AM ZOOL, V15, P867; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHEFLER WC, 1968, STATISTICS BIOL SCI, P1; Spemann Hans., 1906, VERH DEUT ZOOL GES, V16, P195; Takaya H., 1953, Annotationes Zoologicae Japonenses, V26, P38; VONWOELLWARTH C, 1950, ROUX ARCH ENTWICKLUN, V144, P178; WEHRMAKER A, 1969, ROUX ARCH DEV BIOL, V163, P1; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1991, BIOL ASYMMETRY HANDE, P165	28	110	110	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					158	161		10.1038/357158a0	http://dx.doi.org/10.1038/357158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579165				2022-12-28	WOS:A1992HU12200058
J	RUBIN, HR; ROGERS, WH; KAHN, KL; RUBENSTEIN, LV; BROOK, RH				RUBIN, HR; ROGERS, WH; KAHN, KL; RUBENSTEIN, LV; BROOK, RH			WATCHING THE DOCTOR-WATCHERS - HOW WELL DO PEER-REVIEW ORGANIZATION METHODS DETECT HOSPITAL-CARE QUALITY PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine how well one state's peer review organization (PRO) judged the quality of hospital care compared with an independent, credible judgment of quality of care. Design.-Retrospective study comparing a PRO's review, including initial screening, physician review, and final judgments, with an independent "study judgment" based on blinded, structured, implicit reviews of hospital records. Setting.-One state's medical and surgical Medicare hospitalizations during 1985 through 1987 audited randomly by the state's PRO. Sample.-Stratified random sampling of records: 62 records that passed the PRO initial screening process and were not referred for PRO physician review; 50 records that failed the PRO screen and then were confirmed by PRO physicians to be "quality problems." Intervention.-None. Main Outcome Measure.-A study judgment of below standard or standard or above based on the mean of overall ratings by five internists for records in medical diagnosis related groups (DRGs) and by five internists and five surgeons for surgical DRGs. Each step in the PRO review was evaluated for how many records passing or failing that step were judged standard or above or below standard in the study (positive and negative predictive value) and how well that step classified records that the study judged below standard or standard or above (sensitivity and specificity). Results.-An estimated 18% of records reviewed by the PRO were below standard according to the study judgment, compared with 6.3% quality problems according to the PRO's final judgment (difference, 12%; 95% confidence interval, 1 to 23). The PRO's initial screening process failed to detect and refer for PRO physician review two of three records that the study judged below standard. In addition, only one of three of the records that PRO physicians judged to be quality problems were judged below standard by the study judgment. Therefore, the PRO's final quality of care judgment and the study judgment agreed little more than expected by chance, especially about poor quality of care. Although the PRO correctly classified 95% of the records that the study judged standard or above, it detected only 11% of records judged below standard by the study. Conclusions.-Most of all, this PRO review process would be improved by additional preliminary screens to identify the 67% of records that the study judged below standard but that passed its initial screening. The screening process also must be more accurate in order to be cost-effective, as it was only slightly better than random sampling at correctly identifying below standard care. More reproducible physician review is also needed and might be accomplished through improved reviewer selection and training, a structured review method, and more physician reviewers per record.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,PROGRAM MED TECHNOL & PRACTICE ASSESSMENT,BALTIMORE,MD 21218; RAND CORP,SANTA MONICA,CA 90406; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; VET ADM MED CTR,SEPULVEDA,CA 91343	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; RAND Corporation; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA)	RUBIN, HR (corresponding author), JOHNS HOPKINS UNIV HOSP,QUAL CARE RES,1830 E MONUMENT ST,BALTIMORE,MD 21205, USA.		Kahn, Katherine/AAE-2857-2020	Kahn, Katherine/0000-0002-6605-1455				[Anonymous], COMMON SCREENING TES; Barnes C, 1988, Top Health Rec Manage, V9, P72; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BROOK RH, 1973, NEW ENGL J MED, V288, P1323, DOI 10.1056/NEJM197306212882504; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; DANS PE, 1985, NEW ENGL J MED, V313, P1131, DOI 10.1056/NEJM198510313131806; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; KAHN KL, 1989, RAND N3016HCFA; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MCILRATH S, 1991, AM MED NEWS     0513, P2; OLEARY DS, 1991, JAMA-J AM MED ASSOC, V265, P1993, DOI 10.1001/jama.265.15.1993; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBENSTEIN LV, 1991, RAND N3033HCFA; RUBIN HR, 1990, RAND N3066HCFA; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SCHROEDER SA, 1991, JAMA-J AM MED ASSOC, V265, P1995; 1991, UNIFORM CLIN DATA SE; 1990, MED STRATEGY QUALITY, V1, P138; 1988, OAI098800870 OFF INS; 1991, AM MED NEWS     0513, P25	21	126	126	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2349	2354		10.1001/jama.267.17.2349	http://dx.doi.org/10.1001/jama.267.17.2349			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564775				2022-12-28	WOS:A1992HR01500028
J	HARKER, LA; BERNSTEIN, EF; DILLEY, RB; SCALA, TE; SISE, MJ; HYE, RJ; OTIS, SM; ROBERTS, RS; GENT, M				HARKER, LA; BERNSTEIN, EF; DILLEY, RB; SCALA, TE; SISE, MJ; HYE, RJ; OTIS, SM; ROBERTS, RS; GENT, M			FAILURE OF ASPIRIN PLUS DIPYRIDAMOLE TO PREVENT RESTENOSIS AFTER CAROTID ENDARTERECTOMY	ANNALS OF INTERNAL MEDICINE			English	Article						ASPIRIN; DIPYRIDAMOLE; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; CORONARY ARTERIOSCLEROSIS	STENOSIS FOLLOWING ENDARTERECTOMY; MUSCLE CELL-PROLIFERATION; VEIN-GRAFT PATENCY; CORONARY ANGIOPLASTY; RECURRENT STENOSIS; GROWTH-FACTOR; ARTERY; THERAPY; REDUCTION; PATCH	. Objective: To evaluate therapy with aspirin plus dipyridamole in reducing restenosis after carotid endarterectomy. . Patients: A total of 163 patients having 175 surgical carotid endarterectomies. . Intervention: Eighty-three patients (90 endarterectomies) were randomly assigned to receive oral aspirin, 325 mg, plus dipyridamole, 75 mg, beginning 12 hours preoperatively, followed by a second dose administered within 8 hours after the operation, and given three times daily thereafter for 1 year. Eighty patients (85 endarterectomies) received placebo medication that was identical in appearance to the study drugs. . Measurements: After the adequacy of the surgical procedure was confirmed by intraoperative angiography, restenosis at the endarterectomy sites was evaluated using serial duplex ultrasound studies before hospital discharge and at 3-month intervals postoperatively for 1 year. . Results: Based on the time for developing identifiable restenosis and on efficacy analysis, > 50% restenosis developed in 11 operated vessels (16%) in the treated group and in 10 arteries (14%) in the placebo group, yielding an observed risk increase of 14% (95% Cl, -52% to 167%; P > 0.2). By intention-to-treat analysis, > 50% restenosis developed in 16 of 90 operated vessels in treated patients and in 10 of 85 arteries in patients receiving placebo (26% for the treated group and 12% for the placebo group; P = 0.1 8, Mantel-Haenszel statistic), representing an observed risk increase of 11 0% (Cl, -5% to 365%). Similar differences were observed for > 20% restenosis and for the comparison of patients rather than operated vessels by either intention-to-treat or efficacy analyses. . Conclusions: Because therapy not only failed to reduce carotid restenosis but may have actually increased its frequency, treatment with aspirin plus dipyridamole probably has no clinically important benefit on restenosis in patients having carotid endarterectomy.	SCRIPPS CLIN & RES FDN, LA JOLLA, CA 92037 USA; USN HOSP, SAN DIEGO, CA 92134 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA; HAMILTON CIVIC HOSP RES CTR, HAMILTON, ONTARIO, CANADA	Scripps Research Institute; United States Department of Defense; United States Navy; University of California System; University of California San Diego; McMaster University; McMaster University	HARKER, LA (corresponding author), EMORY UNIV, SCH MED, DIV HEMATOL & ONCOL, PO DRAWER AR, ATLANTA, GA 30322 USA.			Hye, Robert/0000-0002-7733-6173				[Anonymous], 1980, CIRCULATION, V62, P449; AWAD IA, 1989, STROKE, V20, P417, DOI 10.1161/01.STR.20.3.417; BERNSTEIN EF, 1983, ANN SURG, V198, P80, DOI 10.1097/00000658-198307000-00016; CALLOW AD, 1982, ARCH SURG-CHICAGO, V117, P1082; CALLOW AD, 1980, AM J SURG, V140, P181, DOI 10.1016/0002-9610(80)90002-1; CANTELMO NL, 1981, ARCH SURG-CHICAGO, V116, P1005; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; Chesebro JH, 1989, CIRCULATION S2, V80, pII; CHESEBRO JH, 1989, CIRCULATION S2, V80, P266; CLAGETT GP, 1989, J VASC SURG, V9, P213, DOI 10.1067/mva.1989.vs0090213; DEHMER GJ, 1988, NEW ENGL J MED, V319, P733, DOI 10.1056/NEJM198809223191201; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; FIELDS WS, 1985, STROKE, V16, P406; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247; FRENCH BN, 1977, STROKE, V8, P597, DOI 10.1161/01.STR.8.5.597; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; GOLDMAN S, 1989, CIRCULATION, V80, P1190, DOI 10.1161/01.CIR.80.5.1190; HANSON SR, 1985, J CLIN INVEST, V75, P1591, DOI 10.1172/JCI111865; HARKER LA, 1991, HEMOSTASIS THROMBOSI; HESS H, 1985, LANCET, V1, P415; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KING SB, 1989, CIRCULATION, V79, P460, DOI 10.1161/01.CIR.79.2.460; LIBBY P, 1987, MOL ASPECTS MED, V9, P499, DOI 10.1016/0098-2997(87)90003-3; LINDNER V, 1991, J CELL BIOCH SC, V15, P118; LYNCH TG, 1983, AM SURGEON, V49, P31; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCCANN RL, 1980, ANN SURG, V191, P238, DOI 10.1097/00000658-198002000-00018; METKE MP, 1979, AM J CARDIOL, V43, P1144, DOI 10.1016/0002-9149(79)90145-0; OKAZAKI H, IN PRESS CIRC RES; ROSS R, 1987, ANNU REV MED, V38, P71, DOI 10.1146/annurev.med.38.1.71; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THOMAS M, 1984, ANN SURG, V200, P74, DOI 10.1097/00000658-198407000-00013; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WILCOX JN, 1991, TRENDS CARDIOVAS MED, V1, P17, DOI 10.1016/1050-1738(91)90054-I; ZIERLER RE, 1982, ARCH SURG-CHICAGO, V117, P1408; IN PRESS BMJ; 1988, BMJ, V296, P320	40	34	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					731	736		10.7326/0003-4819-116-9-731	http://dx.doi.org/10.7326/0003-4819-116-9-731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558344				2022-12-28	WOS:A1992HQ62300005
J	WARREN, HS; DANNER, RL; MUNFORD, RS				WARREN, HS; DANNER, RL; MUNFORD, RS			ANTIENDOTOXIN MONOCLONAL-ANTIBODIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; ESCHERICHIA-COLI		NIH,BETHESDA,MD 20205; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235	National Institutes of Health (NIH) - USA; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WARREN, HS (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.							BAUMGARTNER JD, 1991, NEW ENGL J MED, V325, P281; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; Bermudez LE, 1989, REV INFECT DIS    S7, V11, pS1564; BOGARD WC, 1991, CIRC SHOCK, V34, P119; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; FEELEY TW, 1987, AM REV RESPIR DIS, V135, P665; GAZZANOSANTORO H, 1991, 31ST INT C ANT AG CH, P230; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; SCHUMER W, 1976, ANN SURG, V184, P333, DOI 10.1097/00000658-197609000-00011; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; TENG NNH, 1985, P NATL ACAD SCI USA, V82, P1790, DOI 10.1073/pnas.82.6.1790; TUNE BM, 1989, J UROLOGY, V141, P1463, DOI 10.1016/S0022-5347(17)41347-4; WENZEL R, 1991, 31ST INT C ANT AG CH, P294; WHEELER AP, 1990, AM REV RESPIR DIS, V42, P775; ZANETTI G, 1991, REV INFECT DIS, V13, P985; ZIEGLER EJ, 1987, CLIN RES, V35, pA619; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1991, 1991 OP M VACC REL B, V1; 1991, 1991 OP M VACC REL B, V1, P41; 1991, 1991 OP M VACC REL B, V1, P179; 1991, 1991 OP M VACC REL B, V1, P50; 1991, 1991 OP M VACC REL B, V1, P82; 1987, NEW ENGL J MED, V317, P659; 1991, 1991 OP M VACC REL B, V1, P99	27	176	178	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1153	1157		10.1056/NEJM199204233261711	http://dx.doi.org/10.1056/NEJM199204233261711			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552919				2022-12-28	WOS:A1992HP80000011
J	BAKHEIT, AMO; BEHAN, PO; DINAN, TG; GRAY, CE; OKEANE, V				BAKHEIT, AMO; BEHAN, PO; DINAN, TG; GRAY, CE; OKEANE, V			POSSIBLE UP-REGULATION OF HYPOTHALAMIC 5-HYDROXYTRYPTAMINE RECEPTORS IN PATIENTS WITH POSTVIRAL FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							PROLACTIN; BUSPIRONE; SEROTONIN; MUSCLE	Objective - To study the dynamic function of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Design - Prospective comparison of patients with postviral fatigue syndrome with two control groups. Setting - Department of neurology, University of Glasgow, Southern General Hospital; department of psychiatry, St James's Hospital, Dublin. Subjects - 15 patients with postviral fatigue syndrome, 13 age and sex matched healthy subjects, and 13 patients with primary depression. Main outcome measures - Serum prolactin concentrations before and one, two, and three hours after administration of buspirone. Results - Because of the effects of sex hormones on prolactin secretion data for men and women were analysed separately. There was no significant difference in baseline prolactin concentrations between patients with postviral fatigue syndrome and healthy subjects or those with primary depression. However, the percentage difference between peak and baseline values was significantly higher in patients with postviral fatigue syndrome than the control groups (one way analysis of variance: women, p = 0.003; men, p = 0.004). Conclusions - The results suggest upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome but not in those with primary depression. The buspirone challenge test may therefore be useful in distinguishing these two conditions. Larger studies are required to explore the potential value of drugs acting on central 5-hydroxytryptamine receptors in the treatment of patients with the postviral fatigue syndrome.	GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,SCOTLAND; ST JAMES HOSP,PSYCHIAT,DUBLIN 8,IRELAND; UNIV GLASGOW,NEUROL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; Trinity College Dublin; University of Glasgow			Dinan, Timothy/ABA-8284-2020	Dinan, Timothy/0000-0002-2316-7220; o'keane, veronica/0000-0002-1519-099X				ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BEHAN PO, 1991, BRIT MED BULL, V47, P793, DOI 10.1093/oxfordjournals.bmb.a072511; BROWNSTEIN MJ, 1976, BRAIN RES, V117, P287, DOI 10.1016/0006-8993(76)90736-8; CLUFF E, 1991, REV INFECT DIS S1, V13, P138; FAGAN KG, 1983, J R COLL GEN PRACT, V33, P335; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GOW JW, 1991, BRIT MED BULL, V47, P872, DOI 10.1093/oxfordjournals.bmb.a072517; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GREGORY CA, 1990, PSYCHOPHARMACOLOGY, V100, P283, DOI 10.1007/BF02244420; GROSSER BI, 1987, J CLIN PSYCHIAT, V48, P3; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOLMES GP, 1988, ANN INTERN MED, V18, P378; JAMAL GA, 1989, EUR NEUROL, V29, P272; KATO Y, 1974, J CLIN ENDOCR METAB, V38, P695, DOI 10.1210/jcem-38-4-695; MELTZER HY, 1983, ARCH GEN PSYCHIAT, V40, P1099; NEUHAUSER H, 1988, PSYCHOPHARMACOLOGY S, V96, P393; QUATTRONE A, 1983, BRIT J CLIN PHARMACO, V16, P471, DOI 10.1111/j.1365-2125.1983.tb02202.x; YATHAM LN, 1989, LANCET, V1, P1447; 1987, DIAGNOSTIC STATISTIC	23	153	153	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1010	1012		10.1136/bmj.304.6833.1010	http://dx.doi.org/10.1136/bmj.304.6833.1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586780	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200016
J	BULL, JJ; MOLINEUX, IJ; WERREN, JH				BULL, JJ; MOLINEUX, IJ; WERREN, JH			SELFISH GENES	SCIENCE			English	Editorial Material									UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Texas System; University of Texas Austin; University of Rochester	BULL, JJ (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.			Werren, John/0000-0001-9353-2070				CHAO L, 1981, P NATL ACAD SCI-BIOL, V78, P6324, DOI 10.1073/pnas.78.10.6324; Chesley P, 1936, GENETICS, V21, P525; GERDES K, 1990, NEW BIOL, V2, P1; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Luria S. E., 1987, ESCHERICHIA COLI SAL, P1615; MONGOLD JA, IN PRESS AM NAT; SANDLER L, 1959, GENETICS, V44, P233; Shaw M.W., 1990, Oxford Surveys in Evolutionary Biology, V7, P197; TRIVERS RL, 1974, AM ZOOL, V14, P249; TURNER BC, 1991, AM NAT, V137, P416, DOI 10.1086/285174; WERREN JH, 1988, TRENDS ECOL EVOL, V3, P297, DOI 10.1016/0169-5347(88)90105-X	11	16	16	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					65	65		10.1126/science.1566058	http://dx.doi.org/10.1126/science.1566058			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566058				2022-12-28	WOS:A1992HL82200021
J	DONALDSON, C				DONALDSON, C			AGENDA FOR HEALTH - AN ECONOMIC-VIEW	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY				DONALDSON, C (corresponding author), UNIV ABERDEEN,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND.			Donaldson, Cam/0000-0003-4670-5340				Andersen TF., 1990, CHALLENGES MED PRACT; AUSTER R, 1985, ESSAYS EC HLTH MED C; CARSTAIRS V, 1989, BRIT MED J, V299, P886, DOI 10.1136/bmj.299.6704.886; CORMAN H, 1985, J HEALTH ECON, V4, P213, DOI 10.1016/0167-6296(85)90030-X; DONALDSON C, 1990, J HEALTH ECON, V9, P103, DOI 10.1016/0167-6296(90)90043-3; DONALDSON C, 1988, J HLTH EC, V7, P47; Grossman M., 1975, HOUSEHOLD PRODUCTION, P142; LOOMES G, 1989, SOC SCI MED, V198, P1336; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; 1985, MEASURING HLTH CARE; 1991, LEADING HLTH BMA AGE	11	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					770	771		10.1136/bmj.304.6829.770	http://dx.doi.org/10.1136/bmj.304.6829.770			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK800	1571687	Green Published, Bronze			2022-12-28	WOS:A1992HK80000031
J	BRAAKMAN, I; HELENIUS, J; HELENIUS, A				BRAAKMAN, I; HELENIUS, J; HELENIUS, A			ROLE OF ATP AND DISULFIDE BONDS DURING PROTEIN FOLDING IN THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							CHAIN BINDING-PROTEIN; GLUCOSE-REGULATED PROTEINS; VIRUS-G PROTEIN; HEAT-SHOCK; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; ASSOCIATION; CELLS; GLYCOPROTEINS; DEPLETION	BEING topologically equivalent to the extracellular space, the lumen of the endoplasmic reticulum (ER) provides a unique folding environment for newly synthesized proteins. Unlike other compartments in the cell where folding occurs, the ER is oxidizing and therefore can promote the formation of disulphide bonds 1. The reducing agent dithiothreitol, when added to living cells, inhibits disulphide formation with profound effects on folding 2. Taking advantage of this effect, we demonstrate here that folding of influenza haemagglutinin is energy dependent. Metabolic energy is required to support the correct folding and disulphide bond formation in this well characterized viral glycoprotein, to rescue misfolded proteins from disulphide-linked aggregates, and to maintain the oxidized protein in its folded and oligomerization-competent state.			BRAAKMAN, I (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Braakman, Ineke/0000-0003-1592-4364				BALCH WE, 1986, J BIOL CHEM, V261, P4681; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, IN PRESS EMBO J; CLAIRMONT C A, 1991, Journal of Cell Biology, V115, p255A; CLARKE BL, 1985, J BIOL CHEM, V260, P128; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Gething M J, 1990, Semin Cell Biol, V1, P65; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6	30	256	260	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					260	262		10.1038/356260a0	http://dx.doi.org/10.1038/356260a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552946				2022-12-28	WOS:A1992HJ94400065
J	GRIFFITHS, M; USHERWOOD, MM; REGINALD, PW				GRIFFITHS, M; USHERWOOD, MM; REGINALD, PW			ANTENATAL TEACHING OF THE USE OF SEAT BELTS IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article									WEXHAM PK HOSP,DEPT OBSTET,SLOUGH SL2 4HL,BERKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT OBSTET,AYLESBURY,BUCKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT GYNAECOL,AYLESBURY,BUCKS,ENGLAND; WEXHAM PK HOSP,DEPT GYNAECOL,SLOUGH SL2 4HL,BERKS,ENGLAND				Griffiths, Malcolm/C-5918-2009	Griffiths, Malcolm/0000-0001-6910-2249				GRIFFITHS M, 1991, BRIT J OBSTET GYNAEC, V98, P320, DOI 10.1111/j.1471-0528.1991.tb13402.x; HERBERT DC, 1982, MED J AUSTRALIA, V2, P115; ROTHENBERGER D, 1978, J TRAUMA, V18, P173, DOI 10.1097/00005373-197803000-00004	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					614	614		10.1136/bmj.304.6827.614	http://dx.doi.org/10.1136/bmj.304.6827.614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH733	1559091	Bronze, Green Published			2022-12-28	WOS:A1992HH73300024
J	GRANT, KAM				GRANT, KAM			LEADING FOR HEALTH - RESPONSES .5. WHICH MODEL FOR DELIVERING CARE	BRITISH MEDICAL JOURNAL			English	Article											GRANT, KAM (corresponding author), CITY & HACKNEY HLTH AUTHOR,LONDON EC1A 7BE,ENGLAND.							1991, LEADING HLTH BMA AGE	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					566	568		10.1136/bmj.304.6826.566	http://dx.doi.org/10.1136/bmj.304.6826.566			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559069	Green Published, Bronze			2022-12-28	WOS:A1992HG59900035
J	MILLER, RL; ARMELAGOS, GJ; IKRAM, S; DEJONGE, N; KRIJGER, FW; DEELDER, AM				MILLER, RL; ARMELAGOS, GJ; IKRAM, S; DEJONGE, N; KRIJGER, FW; DEELDER, AM			PALAEOEPIDEMIOLOGY OF SCHISTOSOMA INFECTION IN MUMMIES	BRITISH MEDICAL JOURNAL			English	Article							ANTIGEN		LEIDEN UNIV,PARASITOL LAB,POB 9605,2300 RC LEIDEN,NETHERLANDS; UNIV CAMBRIDGE CHRISTS COLL,CAMBRIDGE,ENGLAND; UNIV FLORIDA,DEPT ANTHROPOL,GAINESVILLE,FL 32611	Leiden University; Leiden University - Excl LUMC; University of Cambridge; State University System of Florida; University of Florida			de Jonge, Niels/A-1786-2012					ADAMS WY, 1977, NUBIA CORRIDOR AFRIC; ARMELAGOS GJ, 1969, SCIENCE, V163, P255, DOI 10.1126/science.163.3864.255; BASSETT EJ, 1980, SCIENCE, V209, P1532, DOI 10.1126/science.7001623; DEELDER AM, 1990, LANCET, V335, P724, DOI 10.1016/0140-6736(90)90838-V; DEELDER AM, 1989, AM J TROP MED HYG, V40, P268, DOI 10.4269/ajtmh.1989.40.268; DEELDER AM, 1976, EXP PARASITOL, V40, P189, DOI 10.1016/0014-4894(76)90081-3; DEJONGE N, 1987, J IMMUNOL METHODS, V99, P195, DOI 10.1016/0022-1759(87)90127-X; DEJONGE N, 1990, THESIS U LEIDEN LEID; GAUTIER A, 1976, EARLIEST MAN ENV LAK; MARTIN DL, 1986, ANAL PREHISTORIC DIE; MARTIN DL, 1984, PALEOPATHOLOGY ORIGI; MILLET NB, 1980, MUMMIES DISEASE ANCI; NASH TE, 1974, J IMMUNOL, V112, P1500	13	43	46	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					555	556		10.1136/bmj.304.6826.555	http://dx.doi.org/10.1136/bmj.304.6826.555			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559065	Green Published, Bronze			2022-12-28	WOS:A1992HG59900029
J	KIM, B; LITTLE, JW				KIM, B; LITTLE, JW			DIMERIZATION OF A SPECIFIC DNA-BINDING PROTEIN ON THE DNA	SCIENCE			English	Article							LEXA REPRESSOR; ESCHERICHIA-COLI; TERMINAL DOMAIN; TRANSCRIPTION; CONTACTS; GCN4; RECA; FOS	Many specific DNA-binding proteins bind to sites with dyad symmetry, and the bound form of the protein is a dimer. For some proteins, dimers form in solution and bind to DNA. LexA repressor of Escherichia coli has been used to test an alternative binding model in which two monomers bind sequentially. This model predicts that a repressor monomer should bind with high specificity to an isolated operator half-site. Monomer binding to a half-site was observed. A second monomer bound to an intact operator far more tightly than the first monomer; this cooperativity arose from protein-protein contacts.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721	University of Arizona	KIM, B (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024178] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24178] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRENT RP, UNPUB; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; Fersht A, 1985, ENZYME STRUCTURE MEC, P56; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GOLEMIS EA, COMMUNICATION; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HURSTEL S, 1986, EMBO J, V5, P793, DOI 10.1002/j.1460-2075.1986.tb04283.x; HURSTEL S, 1988, EMBO J, V7, P269, DOI 10.1002/j.1460-2075.1988.tb02809.x; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1985, P NATL ACAD SCI USA, V82, P2301, DOI 10.1073/pnas.82.8.2301; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LYONS D, UNPUB; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAUER RT, 1990, NATURE, V347, P514, DOI 10.1038/347514b0; SCHNARR M, 1988, FEBS LETT, V234, P56, DOI 10.1016/0014-5793(88)81302-4; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; THLIVERIS AT, 1991, BIOCHIMIE, V73, P449, DOI 10.1016/0300-9084(91)90112-E; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WERTMAN KF, 1985, J BACTERIOL, V163, P376, DOI 10.1128/JB.163.1.376-384.1985; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	35	125	129	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					203	206		10.1126/science.1553548	http://dx.doi.org/10.1126/science.1553548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553548				2022-12-28	WOS:A1992GY70400038
J	RUBIN, SM; CUMMINGS, SR				RUBIN, SM; CUMMINGS, SR			RESULTS OF BONE DENSITOMETRY AFFECT WOMENS DECISIONS ABOUT TAKING MEASURES TO PREVENT FRACTURES	ANNALS OF INTERNAL MEDICINE			English	Article						BONE DENSITY; ESTROGEN REPLACEMENT THERAPY; OSTEOPOROSIS; DENSITOMETRY; HEALTH BEHAVIOR; WOMENS HEALTH	HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; DIETARY CALCIUM; ESTROGEN; RISK; CALCITONIN; DENSITY	Objective: To describe how the results of bone densitometry affect women's decisions about measures to prevent fractures and to determine whether labeling women as having below-normal bone density has adverse effects. Design: Mail survey of a random sample of women. Setting: Four community hospitals in the San Francisco Bay area. Patients: A total of 261 women (response rate, 81.3%) who had undergone bone densitometry. Measurements: Bone densitometry and self-report of changes in attitude and behaviors. Results: Fifty-three percent of the women reported that their first bone density measurements were below normal, and 44% said that they were diagnosed as having osteoporosis on the basis of their test results. Women who reported that their bone density measurements were below normal were much more likely than women with normal results to begin some type of measure to prevent fractures (94% compared with 56%; P < 0.01), to start hormone therapy (38% compared with 8%; P < 0.01), and to take precautions to avoid falling (50% compared with 9%; P < 0.01). Women reporting low bone density, however, also became more fearful of falling (38% compared with 2%; P < 0.01) and limited their activities to avoid falling (24% compared with 2%; P < 0.01). Conclusions: The results of bone densitometry substantially influence women's decisions about beginning estrogen replacement therapy and other preventive measures for osteoporotic fractures. The potential effects of labeling a women as having below-normal bone density need to be considered before densitometry is widely used for unselective screening of women.			RUBIN, SM (corresponding author), UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, BOX 0886, SAN FRANCISCO, CA 94143 USA.							ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; ALOIA JF, 1978, ANN INTERN MED, V89, P356, DOI 10.7326/0003-4819-89-3-356; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CHESTNUT CH, 1988, OSTEOPOROSIS ETIOLOG, P403; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1986, ANN INTERN MED, V104, P817, DOI 10.7326/0003-4819-104-6-817; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; EASTELL R, 1988, OSTEOPOROSIS ETIOLOG, P373; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; ETTINGER B, 1987, AM J OBSTET GYNECOL, V156, P1298, DOI 10.1016/0002-9378(87)90168-2; FATOURECHI V, 1987, ANN INTERN MED, V107, P923, DOI 10.7326/0003-4819-107-6-923; FELDMAN W, 1990, Journal of General Internal Medicine, V5, pS50, DOI 10.1007/BF02600842; Frame P S, 1975, J Fam Pract, V2, P29; GENANT HK, 1989, RADIOLOGY, V170, P817, DOI 10.1148/radiology.170.3.2916037; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOCHERSBERGER G, 1987, ARCH INTERN MED, V147, P1951, DOI 10.1001/archinte.147.11.1951; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LINDSAY R, 1980, LANCET, V2, P1151; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; MACINTYRE I, 1988, LANCET, V1, P900; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P155; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; MICHEL BA, 1989, ARCH INTERN MED, V149, P2325, DOI 10.1001/archinte.149.10.2325; Morrison AS., 1985, SCREENING CHRONIC DI; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PARISIEN M, 1990, ENDOCRIN METAB CLIN, V19, P19, DOI 10.1016/S0889-8529(18)30337-2; REGINSTER JY, 1987, LANCET, V2, P1481; RICHARDSON ML, 1986, SKELETAL RADIOL, V15, P85, DOI 10.1007/BF00350200; RIGGS BL, 1988, ANN INTERN MED, V108, P293, DOI 10.7326/0003-4819-108-2-293; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; THOMAS DB, 1990, MENOPAUSE BIOL CLIN, P101; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WASNICH RD, 1987, OSTEOPOROSIS UPDATE, P123; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITE LJ, 1987, ANN INTERN MED, V107, P932, DOI 10.7326/0003-4819-107-6-932; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1989, GUIDE CLIN PREVENTIV, P239; 1979, CAN MED ASS J, V121, P1193; 1984, JAMA-J AM MED ASSOC, P799	58	146	147	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				990	995		10.7326/0003-4819-116-12-990	http://dx.doi.org/10.7326/0003-4819-116-12-990			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586110				2022-12-28	WOS:A1992HY79300007
J	SELLICK, JA; LONGBINE, D; SCHIFELING, R; MYLOTTE, JM				SELLICK, JA; LONGBINE, D; SCHIFELING, R; MYLOTTE, JM			SCREENING HOSPITAL EMPLOYEES FOR MEASLES IMMUNITY IS MORE COST-EFFECTIVE THAN BLIND IMMUNIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						MEASLES; COST-BENEFIT ANALYSIS; HEALTH PERSONNEL; IMMUNIZATION	TRANSMISSION	Objective: To examine alternative strategies in developing a cost-effective program to assure measles immunity among hospital employees. Design: Observational. Setting: Referral teaching hospital. Participants: Eighteen hundred "established" hospital employees with potential patient contact and 630 newly hired hospital employees. Interventions: Established employees born after 1 January 1957 and all newly hired employees were screened for serologic evidence of measles immunity and immunized if necessary. Measurements: Cost analysis. Results: The cost of screening and directed immunization of established employees was $3.98 per employee compared with a potential cost $10.03 to $42.80 per employee if all employees were "blindly" immunized with monovalent measles vaccine or trivalent mumps-measles-rubella vaccine. The cost of the screening and directed immunization of new employees was $2.42 per employee compared with potential costs $8.30 to $39.34 per employee for blind immunization. These analyses assumed that varying percentages of employees would be able to produce documentation of having received a previous dose of vaccine or of having had measles. Conclusions: In a large referral hospital, screening for measles immunity followed by directed immunization was considerably less expensive than immunizing all potentially susceptible employees.	BUFFALO GEN HOSP, DEPT EMPLOYEE HLTH, BUFFALO, NY 14203 USA; SUNY BUFFALO, BUFFALO, NY 14260 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	SELLICK, JA (corresponding author), BUFFALO GEN HOSP, DEPT MED, 100 HIGH ST, BUFFALO, NY 14203 USA.							ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BRAUNSTEIN H, 1990, AM J DIS CHILD, V144, P296, DOI 10.1001/archpedi.1990.02150270046024; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295; MATHIAS RG, 1989, AM J PUBLIC HEALTH, V79, P475, DOI 10.2105/AJPH.79.4.475; NEUMANN PW, 1985, J CLIN MICROBIOL, V22, P296, DOI 10.1128/JCM.22.2.296-298.1985; SUBBARAO EK, 1991, J INFECT DIS, V163, P876, DOI 10.1093/infdis/163.4.876; WEBER DJ, 1991, J PEDIATR-US, V119, P322, DOI 10.1016/S0022-3476(05)80753-X; WHARTON M, 1990, ARCH INTERN MED, V150, P47, DOI 10.1001/archinte.150.1.47; 1991, MMWR, V40, P369; 1989, MMWR, V38, P1	12	17	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				982	984		10.7326/0003-4819-116-12-982	http://dx.doi.org/10.7326/0003-4819-116-12-982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586108				2022-12-28	WOS:A1992HY79300005
J	LIPSCOMB, GH; MURAM, D; SPECK, PM; MERCER, BM				LIPSCOMB, GH; MURAM, D; SPECK, PM; MERCER, BM			MALE VICTIMS OF SEXUAL ASSAULT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RAPE; MEN	Objective. - To compare the demographics, physical findings, and assault characteristics of incarcerated, sexually assaulted men with those of nonincarcerated, sexually assaulted men. Design. - Case series of 99 adult male victims of sexual assault evaluated over a 3-year period. Setting. - Memphis Sexual Assault Resource Center, a nonhospital-based clinic that serves as the primary resource for sexually assaulted victims in the Memphis and Shelby County, Tennessee, area. Participants. - All adult male victims of sexual assault evaluated at the Memphis Sexual Assault Resource Center during the study period were included in the study. Ninety-nine victims were studied, including 80 incarcerated men and 19 men from the community. Results. - The victims of sexual assault in the community group were older than the victims in the incarcerated group. Apart from the age difference and weapon use, there were no statistically significant differences between the incarcerated and nonincarcerated victims. Conclusions. - The similarities between the two groups suggest that sexual assault of men may not be unique to prisons, and all men are potential victims. Further studies are required to better understand these crimes and to develop education and prevention programs.	MEMPHIS TENN SEXUAL ASSAULT RESOURCE CTR,MEMPHIS,TN		LIPSCOMB, GH (corresponding author), UNIV TENNESSEE,DEPT OBSTET & GYNECOL,853 JEFFERSON AVE,ROOM E102,MEMPHIS,TN 38103, USA.		Speck, Patricia M/AAA-9210-2021	Speck, Patricia M/0000-0001-7172-2762				ANDERSON C L, 1981, Journal of Homosexuality, V7, P145; Brownmiller, 1975, AGAINST OUR WILL; BURGESS AW, 1974, AM J PSYCHIAT, V131, P981; DAVIS AJ, 1968, TRANS-ACT-SOC SCI MO, V6, P8; Geist R F, 1988, Emerg Med Clin North Am, V6, P439; GOTH A, 1979, MAN WHO RAPE; GOTH N, 1980, AM J PSYCHIAT, V137, P806; GOYER PF, 1984, AM J PSYCHIAT, V141, P576; KAUFMAN A, 1980, AM J PSYCHIAT, V137, P221; KEMPE CH, 1978, PEDIATRICS, V62, P382; MASTERS WH, 1986, J SEX MARITAL THER, V12, P35; MEZEY G, 1989, PSYCHOL MED, V19, P205, DOI 10.1017/S0033291700011168; MOSS CS, 1979, PSYCHOL REP, V44, P823, DOI 10.2466/pr0.1979.44.3.823; SAGRIN E, 1976, PSYCHIATRY, V39, P245	14	18	18	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3064	3066		10.1001/jama.267.22.3064	http://dx.doi.org/10.1001/jama.267.22.3064			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588721				2022-12-28	WOS:A1992HW97000028
J	NOVELLO, AC; SHOSKY, J; FROEHLKE, R				NOVELLO, AC; SHOSKY, J; FROEHLKE, R			A MEDICAL RESPONSE TO VIOLENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC; MICHIGAN STATE DEPT PUBL HLTH,DIV EPIDEMIOL,LANSING,MI	United States Public Health Service									0	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3007	3007		10.1001/jama.267.22.3007	http://dx.doi.org/10.1001/jama.267.22.3007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588704				2022-12-28	WOS:A1992HW97000006
J	COHEN, TJ; TUCKER, KJ; LURIE, KG; REDBERG, RF; DUTTON, JP; DWYER, KA; SCHWAB, TM; CHIN, MC; GELB, AM; SCHEINMAN, MM; SCHILLER, NB; CALLAHAM, ML				COHEN, TJ; TUCKER, KJ; LURIE, KG; REDBERG, RF; DUTTON, JP; DWYER, KA; SCHWAB, TM; CHIN, MC; GELB, AM; SCHEINMAN, MM; SCHILLER, NB; CALLAHAM, ML			ACTIVE COMPRESSION-DECOMPRESSION - A NEW METHOD OF CARDIOPULMONARY-RESUSCITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIDAL CARBON-DIOXIDE; OPEN-CHEST CPR; CARDIAC-ARREST; PROGNOSTIC INDICATOR; CORONARY PERFUSION; ABDOMINAL BINDING; HUMAN-BEINGS; VENTILATION; DOGS; SURVIVAL	Objective. --To describe and compare with standard cardiopulmonary resuscitation (CPR) in humans a new form of CPR that involves both active compression and active decompression of the chest. Design. --Patients in cardiac arrest in whom standard advanced cardiac life support failed were randomized to receive 2 minutes of either standard or active compression-decompression (ACD) CPR using a custom, hand-held suction device, followed by 2 minutes of the alternate technique. The ACD device was applied midsternum and used to perform CPR according to the guidelines of the American Heart Association: 80 compressions per minute, compression depth of 3.8 to 5 cm, 50% duty cycle, and constant-volume ventilation. Mechanical Thumper CPR was also compared in five patients. End-tidal carbon dioxide (ETCO2) concentrations and hemodynamic variables were measured. Transesophageal Doppler echocardiography was used to assess contractility, the velocity time integral (an analogue of cardiac output), and diastolic myocardial filling times. Results. --Ten patients were enrolled. The mean +/- SD ETCO2 was 4.3 +/- 3.8 mm Hg with standard CPR and 9.0 +/- 3.9 mm Hg with ACD CPR (P < .0001). Systolic arterial pressure with standard CPR was 52.5 +/- 14.0 mm Hg and with ACD CPR, 88.9 +/- 24.7 mm Hg (P < .003). The velocity time integral increased from 7.3 +/- 2.6 cm with standard CPR to 17.5 +/- 5.6 cm with ACD CPR (P < .0001), and diastolic filling times increased from 0.23 +/- .09 seconds with standard CPR to 0.37 +/- .12 seconds with ACD CPR (P < .004). Mechanical Thumper CPR consistently underperformed both standard and ACD CPR. Minute ventilation obtained in four patients during ACD CPR without endotracheal ventilation was 6.6 +/- 0.9 L/min. After 1 hour of standard CPR failed, three of 10 patients randomized to ACD CPR rapidly converted to a hemodynamically stable rhythm following 2 minutes of ACD CPR. Conclusion. --ACD CPR is a simple manual technique that improved cardiopulmonary circulation in 10 patients during cardiac arrest. Although ACD CPR may have produced a return of spontaneous circulation in three patients refractory to standard measures, its impact on survival when used early in cardiac arrest remains to be determined.	SAN FRANCISCO GEN HOSP,DEPT EMERGENCY,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DIV EMERGENCY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	COHEN, TJ (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DIV CARDIOL,300 COMMUNITY DR,MANHASSET,NY 11030, USA.			Callaham, Michael/0000-0003-2284-256X				BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; BIRCHER N, 1980, CRIT CARE MED, V8, P147, DOI 10.1097/00003246-198003000-00012; BIRCHER N, 1981, CRIT CARE MED, V9, P384, DOI 10.1097/00003246-198105000-00016; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; CALLAHAM M, IN PRESS CRIT CARE M; CHANDRA N, 1981, AM J CARDIOL, V48, P1053, DOI 10.1016/0002-9149(81)90320-9; CHANDRA NC, 1990, CRIT CARE MED, V18, P929, DOI 10.1097/00003246-199009000-00005; CHANDRA NC, 1991, CIRCULATION, V84, P279, DOI 10.1161/01.CIR.84.1.279; COHEN TJ, 1991, CIRCULATION, V84, P9; CRILEY JM, 1976, JAMA-J AM MED ASSOC, V236, P1246, DOI 10.1001/jama.236.11.1246; DELGUERCIO LR, 1963, NEW ENGL J MED, V269, P1398, DOI 10.1056/NEJM196312262692603; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; FISHER DC, 1983, CIRCULATION, V67, P872, DOI 10.1161/01.CIR.67.4.872; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GOETTING MG, 1991, CRIT CARE MED, V19, P1012, DOI 10.1097/00003246-199108000-00007; GUDIPATI CV, 1988, CIRCULATION, V77, P234, DOI 10.1161/01.CIR.77.1.234; HALPERIN HR, 1986, CIRCULATION, V74, P1407, DOI 10.1161/01.CIR.74.6.1407; HOWARD M, 1987, ANN EMERG MED, V16, P253, DOI 10.1016/S0196-0644(87)80169-5; KAPLAN BC, 1973, J TRAUMA, V13, P843, DOI 10.1097/00005373-197313100-00001; KOEHLER RC, 1983, CIRCULATION, V67, P266, DOI 10.1161/01.CIR.67.2.266; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; KRISCHER JP, 1989, CRIT CARE MED, V17, P1263, DOI 10.1097/00003246-198912000-00005; LEWIS JF, 1984, CIRCULATION, V70, P425, DOI 10.1161/01.CIR.70.3.425; LURIE KG, 1990, JAMA-J AM MED ASSOC, V264, P1661, DOI 10.1001/jama.1990.03450130031020; MARTIN GB, 1986, ANN EMERG MED, V15, P125, DOI 10.1016/S0196-0644(86)80005-1; MCDONALD JL, 1982, ANN EMERG MED, V11, P292, DOI 10.1016/S0196-0644(82)80125-X; MEIJBOOM EJ, 1983, CIRCULATION, V68, P437, DOI 10.1161/01.CIR.68.2.437; NIEMANN JT, 1984, AM J CARDIOL, V53, P269, DOI 10.1016/0002-9149(84)90438-7; NIEMANN JT, 1985, AM J CARDIOL, V55, P199, DOI 10.1016/0002-9149(85)90328-5; ORNATO JP, 1989, ANN EMERG MED, V18, P732, DOI 10.1016/S0196-0644(89)80005-8; PEATFIELD RC, 1977, LANCET, V1, P1223; SACK J B, 1991, Journal of the American College of Cardiology, V17, p179A; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; SANDERS AB, 1985, AM J EMERG MED, V3, P147, DOI 10.1016/0735-6757(85)90039-7; SANDERS AB, 1985, ANN EMERG MED, V14, P948, DOI 10.1016/S0196-0644(85)80235-3; SPALDING JMK, 1963, CLIN PRACTICE PHYSL; TREVINO RP, 1985, CRIT CARE MED, V13, P910, DOI 10.1097/00003246-198511000-00012; WALKER JW, 1984, AM J EMERG MED, V2, P391, DOI 10.1016/0735-6757(84)90039-1; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011; 1986, JAMA-J AM MED ASSOC, V255, P2905	44	150	191	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2916	2923		10.1001/jama.267.21.2916	http://dx.doi.org/10.1001/jama.267.21.2916			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583761				2022-12-28	WOS:A1992HW13300029
J	BENDER, B; MILGROM, H				BENDER, B; MILGROM, H			THEOPHYLLINE-INDUCED BEHAVIOR-CHANGE IN CHILDREN - AN OBJECTIVE EVALUATION OF PARENTS PERCEPTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCHOOL PERFORMANCE; CHILDHOOD ASTHMA; RATING-SCALES; DEPRESSION; CAFFEINE; THERAPY; BOYS	Objective. - To evaluate children who take theophylline for the presence of behavioral side effects and to determine whether the beliefs about these side effects held by their parents are supported by their own observations. Design. - A double-blind, placebo-controlled, randomized, crossover protocol. Under both study conditions the children completed tests that measured their attention, impulsivity, memory, activity level, and mood, while the parents rated their behavior. Patients. - The subjects were 8- to 12-year-old children with asthma whose parents had observed adverse behavioral side effects while the children were taking theophylline. Among cited side effects were impulsivity, hyperactivity, altered mood, and impaired attention. Results. - No differences related to treatment could be detected from the parent questionnaires or from six of nine scores of the psychological evaluation of the children. The children, however, made fewer attention errors and showed a mild increase in anxiety and hand tremor of the dominant hand while they were receiving theophylline. All mean changes were small. No significant relationship was found between theophylline concentrations in the serum and degree of change in mood or attention. Eleven of 42 participants were disqualified for noncompliance during the study. Conclusion. - Parental beliefs about the side effects experienced by their children are not supported by their own observations performed through a blinded protocol. These results are in conflict with reports of a high incidence of adverse behavioral side effects attributed to theophylline therapy.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206; PURDUE FREDERICK CO,NORWALK,CT; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PSYCHIAT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; National Jewish Health								ACHENBACH TM, 1981, MONOGR SOC RES CHILD, V46, P188; BECK AT, 1974, PSYCHOL MEASUREMENTS, P151; BENDER B, 1988, AM ACAD CHILD ADOLES, V25, P720; BENDER BG, 1991, PEDIATR PULM, V11, P233, DOI 10.1002/ppul.1950110309; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CHRITIAANSE ME, 1989, J DEV BEHAV PEDIATR, V40, P75; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; CREER TL, 1989, J PEDIATR-US, V115, P850, DOI 10.1016/S0022-3476(89)80122-2; Dunn L.M., 2007, PEABODY PICTURE VOCA; ELKINS RN, 1981, AM J PSYCHIAT, V138, P178; FIRESTONE P, 1979, J ABNORM CHILD PSYCH, V7, P261, DOI 10.1007/BF00916536; FURUKAWA CT, 1988, J ALLERGY CLIN IMMUN, V81, P83, DOI 10.1016/0091-6749(88)90224-2; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; JOAD JP, 1986, J ALLERGY CLIN IMMUN, V78, P1147, DOI 10.1016/0091-6749(86)90264-2; Jones B., 2015, DESIGN ANAL CROSS OV, V3rd; KASENBERG DF, 1987, PEDIATR ASTHMA ALLER, V1, P165; KOVACS M, 1981, ACTA PAEDOPSYCHIATR, V46, P305; MCCARTHY MM, 1981, PEDIATRICS, V68, P749; MCLOUGHLIN J, 1983, ANN ALLERGY, V51, P506; Mrazek D A, 1985, Adv Psychosom Med, V14, P16; MURPHY MB, 1980, BRIT MED J, V281, P1322, DOI 10.1136/bmj.281.6251.1322; NELSON LA, 1987, PEDIATR ASTHMA ALLER, V1, P175; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RAPOPORT JL, 1981, J NERV MENT DIS, V169, P726, DOI 10.1097/00005053-198111000-00007; RAPPAPORT L, 1989, AM J DIS CHILD, V143, P368, DOI 10.1001/archpedi.1989.02150150126032; REYNOLDS CR, 1985, REVISED CHILDRENS; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SCHLIEPER A, 1991, J PEDIATR-US, V118, P449, DOI 10.1016/S0022-3476(05)82167-5; SPRINGER C, 1985, J ALLERGY CLIN IMMUN, V76, P64, DOI 10.1016/0091-6749(85)90806-1; STREISSGUTH AP, 1984, DEV PSYCHOL, V20, P533, DOI 10.1037/0012-1649.20.4.533; TAYLOR JA, 1951, J EXP PSYCHOL, V41, P81, DOI 10.1037/h0059488; WASSER WG, 1981, ANN INTERN MED, V95, P191, DOI 10.7326/0003-4819-95-2-191; WEISBERG P, 1967, PSYCHOL REP, V21, P709, DOI 10.2466/pr0.1967.21.3.709; ZIMET SG, 1986, J AM ACAD CHILD PSY, V25, P76, DOI 10.1016/S0002-7138(09)60601-4; 1991, J ALLERGY CLIN IMMUN, V87, P202; 1989, AM ASTHMA REPORT, P1	37	30	31	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2621	2624						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT823	1573749				2022-12-28	WOS:A1992HT82300028
J	JOHNSON, WG; BRENNAN, TA; NEWHOUSE, JP; LEAPE, LL; LAWTHERS, AG; HIATT, HH; WEILER, PC				JOHNSON, WG; BRENNAN, TA; NEWHOUSE, JP; LEAPE, LL; LAWTHERS, AG; HIATT, HH; WEILER, PC			THE ECONOMIC CONSEQUENCES OF MEDICAL INJURIES - IMPLICATIONS FOR A NO-FAULT INSURANCE PLAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORT	Background. - There has been little research into the actual economic consequences of medical injuries. This inhibits informed discussion of alternatives to malpractice litigation. For example, the cost of no-fault medical accident insurance has been thought to be prohibitive. Method. - As part of a comprehensive analysis of medical injury and litigation, we interviewed a random sample of 794 individuals who had suffered medical adverse events in New York hospitals in 1984 and used their responses to calculate the cost of injuries. We then estimated the costs of a simulated no-fault insurance program that would operate as a second payer to direct insurance sources and would compensate for all financial losses attributed to medical injury. Results. - The estimated costs that would be paid by a simulated no-fault program were $161 million for medical care, $276 million for lost wages, and $441 million in lost household production, or a total of $878 million in 1989 dollars for the cohort of patients who were injured in 1984. Conclusion. - Although our estimate does not include administrative costs, it nonetheless indicates that a no-fault program would not be notably costlier than the more than $1 billion New York physicians now spend annually on malpractice insurance.	BRIGHAM & WOMENS HOSP,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University	JOHNSON, WG (corresponding author), ARIZONA STATE UNIV,COLL BUSINESS,SCH HLTH ADM & POLICY,TEMPE,AZ 85287, USA.		Newhouse, Joseph/AGJ-5632-2022					[Anonymous], 1986, COSTS COMPENSATION P; BERKOWITZ M, 1990, EC CONSEQUENCES TRAU; BOMBAUGH RL, 1971, COLUMBIA LAW REV, V71, P207, DOI 10.2307/1121170; BOVBJERG RR, 1989, NORTHWEST U LAW REV, V83, P908; BRENNAN TA, 1990, CLIN RES, V35, P551; DOUGLASS J, 1990, J FORENSIC EC, V4, P25, DOI DOI 10.5085/0898-5510-4.1.25; FELDSTEIN M, 1978, BROOKINGS PAPERS EC, V1, P1; HENSLER DR, 1991, R3999HHSICJ RAND COR; JOHNSON WG, 1984, IND LABOR RELAT REV, V37, P529, DOI 10.2307/2523670; JOHNSON WG, 1979, RES REPORT US INTERD; JOHNSON WG, 1984, MILBANK Q, V61, P177; Kakalik James S., 1988, COSTS COMPENSATION P; LAMBRINOS J, 1985, J RISK INSUR, V52, P464, DOI 10.2307/252781; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MANNE H, 1985, MED MALPRACTICE POLI; PRIEST GL, 1987, YALE LAW J, V96, P1521, DOI 10.2307/796494; RICE DP, 1990, EC COSTS ALCOHOL DRU; SCHWARTZ A, 1988, YALE LAW J, V97, P353, DOI 10.2307/796411; SCHWARTZ WB, 1978, NEW ENGL J MED, V298, P1282, DOI 10.1056/NEJM197806082982304; Viscusi W. Kip, 1988, INTL REV L EC, V8, P203, DOI DOI 10.1016/0144-8188(88)90006-3; WALKER KE, 1976, TIME USE MEASURE HOU; WEILER PC, 1991, MED MALPRACTICE TRIA; 1987, MED EC          1005; 1985, MED EC          1007; 1965, REPORTING HOSPITALIZ; 1986, WORK LIFE ESTIMATES; 1986, MED EC          1006; 1989, AVERAGE CHARGES HOME; 1980, VITAL STATISTICS US; 1985, EMPLOYEE BENEFITS 19; 1988, MED EC          1003; 1990, PATIENTS DOCTORS LAW; 1982, US BUREAU CENSUS P60, V139	33	72	72	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2487	2492		10.1001/jama.267.18.2487	http://dx.doi.org/10.1001/jama.267.18.2487			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573726				2022-12-28	WOS:A1992HT06800028
J	ROSENBLUM, L; DARROW, W; WITTE, J; COHEN, J; FRENCH, J; GILL, PS; POTTERAT, J; SIKES, K; REICH, R; HADLER, S				ROSENBLUM, L; DARROW, W; WITTE, J; COHEN, J; FRENCH, J; GILL, PS; POTTERAT, J; SIKES, K; REICH, R; HADLER, S			SEXUAL PRACTICES IN THE TRANSMISSION OF HEPATITIS-B VIRUS AND PREVALENCE OF HEPATITIS-DELTA VIRUS-INFECTION IN FEMALE PROSTITUTES IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HOMOSEXUAL MEN; SALIVA; ANTIGEN; SEMEN; NONOXYNOL-9; OUTBREAK; CONTACTS; MARKERS	Objective.- To evaluate heterosexual transmission of hepatitis B virus (HBV) and the prevalence of hepatitis delta virus (HDV) infection in female prostitutes. Design.-Survey. Setting. - Sexually transmitted disease clinics, drug treatment programs, detention centers, and/or outreach efforts in eight areas in the United States. Participants. - A total of 1368 female prostitutes 18 years of age or older. Outcome Measures. - Seropositivity for HBV and HDV infection. Results. - The overall prevalence of past or present HBV infection was 56%: 74% in women who were injecting-drug users (IDUs), 38% in women reporting no history of injecting-drug use (non-IDUs), 51% in whites, 55% in blacks, and 67% in Hispanics. Of 21 HBV carrier IDUs, 21% had HDV infection; of 18 HBV carrier non-IDUs, 6% had HDV infection. In non-IDUs (49%), risk factors for HBV infection were a history of having penile-anal intercourse (odds ratio [OR], 3.1; 95% confidence limits [CL], 1.3, 7.3) and seropositivity for syphilis and human immunodeficiency virus (HIV) infection. In IDUs, factors associated with an increased risk of infection, in addition to behaviors related to injecting-drug use, were the number of lifetime sexual partners, having sexual partners from groups at high risk for HBV infection, and seropositivity for syphilis and HIV infection; spermicide and/or diaphragm use was associated with a markedly decreased risk of HBV infection among blacks (OR, 0.1; 95% CL, 0.03, 0.4) and Hispanics (OR, 0.2; 95% CL, 0.06, 0.9). Conclusion. - This is the first study to suggest that having anal intercourse and failing to use vaginal contraceptives may facilitate transmission of HBV to women. Our data support guidelines that recommend hepatitis B vaccination for prostitutes and persons with a history of sexually transmitted diseases or multiple sexual partners.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; FLORIDA DEPT HLTH & REHAB SERV,TALLAHASSEE,FL; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; NEW JERSEY DEPT HLTH,TRENTON,NJ; UNIV SO CALIF,LOS ANGELES,CA 90089; EL PASO CTY DEPT HLTH & ENVIRONM,COLORADO SPRINGS,CO; GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; CLARK CTY HLTH DIST,LAS VEGAS,NV	Centers for Disease Control & Prevention - USA; Florida Department of Health; University of California System; University of California San Francisco; New Jersey Department of Health & Senior Services; University of Southern California	ROSENBLUM, L (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH,ATLANTA,GA 30333, USA.		Potterat, John J/B-4680-2009					ALTER HJ, 1977, INFECT IMMUN, V16, P928, DOI 10.1128/IAI.16.3.928-933.1977; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ALTER MJ, 1986, JAMA-J AM MED ASSOC, V256, P1307, DOI 10.1001/jama.256.10.1307; BADDOUR LM, 1988, SEX TRANSM DIS, V15, P174, DOI 10.1097/00007435-198807000-00014; COHEN C, 1990, AIDS 2ND DECADE, P253; Darrow William, 1990, AIDS DRUGS PROSTITUT, P18; DAVISON F, 1987, J HEPATOL, V4, P37, DOI 10.1016/S0168-8278(87)80007-7; DECOCK KM, 1988, WESTERN J MED, V148, P307; FIELDS HA, 1986, J CLIN IMMUNOASSAY, V9, P128; GOVINDARAJAN S, 1983, GASTROENTEROLOGY, V85, P160; HEATHCOT.J, 1974, LANCET, V1, P71; HERSH T, 1971, NEW ENGL J MED, V285, P1363, DOI 10.1056/NEJM197112092852408; HICKS DR, 1985, LANCET, V2, P1422; KOFF RS, 1977, GASTROENTEROLOGY, V72, P297; KREISS J, 1989, 5TH P INT C AIDS MON, P36; LETTAU LA, 1987, NEW ENGL J MED, V317, P1256, DOI 10.1056/NEJM198711123172004; LOUV WC, 1988, J INFECT DIS, V158, P518, DOI 10.1093/infdis/158.3.518; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MUSHAWAR IK, 1984, VIRAL HEPATITIS LIVE, P617; NIRUTHISARD S, 1991, 7TH P INT C AIDS FLO, P317; NORTH BB, 1990, HETEROSEXUAL TRANSMI, P273; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PETERSEN NJ, 1982, ANN INTERN MED, V96, P170; PONZETTO A, 1984, HEPATOLOGY, V4, P1111, DOI 10.1002/hep.1840040603; REDEKER AG, 1975, NEW ENGL J MED, V293, P1055; ROSENBERG M, 1987, JAMA-J AM MED ASSOC, V258, P2308; ROSENBLUM LS, 1990, J INFECT DIS, V161, P407, DOI 10.1093/infdis/161.3.407; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SCOTT RM, 1980, J INFECT DIS, V142, P67, DOI 10.1093/infdis/142.1.67; SINGH B, 1976, AM J OBSTET GYNECOL, V126, P422, DOI 10.1016/0002-9378(76)90630-X; SOLOMON RE, 1988, ANN INTERN MED, V108, P51, DOI 10.7326/0003-4819-108-1-51; VOELLER B, 1991, ARCH SEX BEHAV, V20, P233, DOI 10.1007/BF01541846; WEISFUSE IB, 1989, HEPATOLOGY, V9, P872, DOI 10.1002/hep.1840090614; WRIGHT RA, 1975, JAMA-J AM MED ASSOC, V232, P717, DOI 10.1001/jama.232.7.717; 1991, MMWR SRR13, V40, P1; 1985, SAS USERS GUIDE STAT, P171	36	55	57	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2477	2481		10.1001/jama.267.18.2477	http://dx.doi.org/10.1001/jama.267.18.2477			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573724				2022-12-28	WOS:A1992HT06800026
J	HALLMAN, M; BRY, K; HOPPU, K; LAPPI, M; POHJAVUORI, M				HALLMAN, M; BRY, K; HOPPU, K; LAPPI, M; POHJAVUORI, M			INOSITOL SUPPLEMENTATION IN PREMATURE-INFANTS WITH RESPIRATORY-DISTRESS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM CONCENTRATION; PRETERM INFANTS; MYOINOSITOL; PHOSPHOLIPIDS; METABOLISM; SURFACTANT; SORBITOL; LUNG; PHOSPHATIDYLINOSITOL; RETINOPATHY	Background. Inositol influences cellular function and organ maturation. Feeding premature infants inositol-rich breast milk increases their serum inositol concentrations. Whether inositol supplementation benefits infants receiving fluids for parenteral nutrition, which are inositol-free, is not known. Methods. We carried out a placebo-controlled, randomized, double-blind trial to determine the effects of administering inositol (80 mg per kilogram of body weight per day) during the first five days of life to 221 infants with respiratory distress syndrome who were receiving parenteral nutrition (gestational age, 24 to 32 weeks; birth weight, < 2000 g). All the infants were treated with mechanical ventilation and some with surfactant as well. The primary end point was survival at 28 days without bronchopulmonary dysplasia. Results. The 114 patients given inositol had significantly lower mean requirements for inspiratory oxygen (P < 0.01) and mean airway pressure (P < 0.05) from the 12th through the 144th hour of life than did the 107 infants given placebo. Eighty-one infants given inositol and 51 given placebo survived without bronchopulmonary dysplasia (71 percent vs. 55 percent; P = 0.005). In the 65 infants given surfactant, however, inositol had no effect on the degree of respiratory failure. Thirteen infants given inositol and 21 given placebo had retinopathy of prematurity (13 percent vs. 26 percent; P = 0.022); none of the infants given inositol had stage 4 disease, whereas 7 of those given placebo did (0 percent vs. 9 percent; P = 0.012). Among the infants given placebo, those who had poor outcomes (death, bronchopulmonary dysplasia, or stage 4 retinopathy of prematurity) had lower serum inositol concentrations during days 2 through 7 than those who had good outcomes (P < 0.01). Conclusions. The administration of inositol to premature infants with respiratory distress syndrome who are receiving parenteral nutrition during the first week of life is associated with increased survival without bronchopulmonary dysplasia and with a decreased incidence of retinopathy of prematurity.	UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND	University of Helsinki	HALLMAN, M (corresponding author), UNIV CALIF IRVINE,DEPT PEDIAT,COM MED SURG I,RM 109F,IRVINE,CA 92717, USA.		Hoppu, Kalle/A-2811-2009	Hoppu, Kalle/0000-0001-6775-0453				ANCESCHI MM, 1988, PEDIATR RES, V24, P617, DOI 10.1203/00006450-198811000-00016; [Anonymous], 1984, PEDIATRICS, V74, P127; AVERY ME, 1991, NEW ENGL J MED, V324, P910, DOI 10.1056/NEJM199103283241308; BROMBERGER P, 1986, J PEDIATR GASTR NUTR, V5, P455, DOI 10.1097/00005176-198605000-00021; BRY K, 1991, BIOL NEONATE, V60, P249; CLEMENTS RS, 1979, J LAB CLIN MED, V93, P210; ESKO JD, 1980, J BIOL CHEM, V255, P4474; GAIL MH, 1985, CANCER TREAT REP, V69, P1107; GARNER A, 1985, RETINOPATHY PREMATUR, P19; GREENE DA, 1987, NEW ENGL J MED, V316, P599; GUNN TR, 1980, PEDIATRICS, V65, P1096; HALLMAN M, 1986, ARCH DIS CHILD, V61, P1076, DOI 10.1136/adc.61.11.1076; HALLMAN M, 1985, EARLY HUM DEV, V10, P245, DOI 10.1016/0378-3782(85)90055-6; HALLMAN M, 1987, J PEDIATR-US, V110, P604, DOI 10.1016/S0022-3476(87)80561-9; HALLMAN M, 1984, BIOCHIM BIOPHYS ACTA, V795, P67, DOI 10.1016/0005-2760(84)90105-X; HALLMAN M, 1990, LUNG S877, V168, P82; HASHIMOTO M, 1990, DIABETOLOGIA, V33, P597, DOI 10.1007/BF00400203; HAUSMAN RE, 1989, BIOCHIM BIOPHYS ACTA, V1013, P92, DOI 10.1016/0167-4889(89)90133-X; HOLUB BJ, 1986, ANNU REV NUTR, V6, P563, DOI 10.1146/annurev.nu.06.070186.003023; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; KEITH CG, 1989, MED J AUSTRALIA, V150, P293, DOI 10.5694/j.1326-5377.1989.tb136487.x; KRETZER FL, 1988, ARCH DIS CHILD-FETAL, V63, P1151, DOI 10.1136/adc.63.10_Spec_No.1151; LORENZI M, 1986, METABOLISM, V3, P824; MACGREGOR LC, 1986, J BIOL CHEM, V261, P4046; MACGREGOR LC, 1986, METABOLISM, V35, P28, DOI 10.1016/0026-0495(86)90184-8; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MERRITT TA, 1991, J PEDIATR-US, V118, P581, DOI 10.1016/S0022-3476(05)83387-6; MOSES LE, 1986, MED USES STATISTICS, P235; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; OHGA Y, 1990, J BIOL CHEM, V265, P18083; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PEREIRA GR, 1990, AM J CLIN NUTR, V251, P589; PHELPS DL, 1981, PEDIATRICS, V67, P924; QUIRK JG, 1983, OBSTET GYNECOL, V62, P41; REESE AB, 1953, AM J OPHTHALMOL, V6, P1333; TOCE SS, 1984, AM J DIS CHILD, V138, P581, DOI 10.1001/archpedi.1984.02140440065017; WELLS WW, 1978, CYCLITOLS PHOSPHOINO; WILLIAMSON JR, 1986, METABOLISM, V35, P41, DOI 10.1016/0026-0495(86)90186-1	38	118	123	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1233	1239		10.1056/NEJM199205073261901	http://dx.doi.org/10.1056/NEJM199205073261901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560798				2022-12-28	WOS:A1992HR44700001
J	GUNTHEROTH, WG; SPIERS, PS				GUNTHEROTH, WG; SPIERS, PS			SLEEPING PRONE AND THE RISK OF SUDDEN-INFANT-DEATH-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							COT DEATH; OXYGEN-TENSION; POSITION; SUPINE; SIDS	Objective.-To critically analyze reports that show a relationship between sudden infant death syndrome (SIDS) and the prone sleeping position in infants. Data Sources.-Peer-reviewed articles, published letters, book chapters, and local and national health statistics were used, without time or language restrictions. These studies represented three races, four continents, and seven countries; none was published in North America. Study Selection.-No studies were ignored, but only those with case controls were reviewed in detail; we regarded a recent cohort analytic (prospective) study as particularly strong, in addition to six before-and-after (intervention) trials. Data Extraction.-Hill's criteria for decision making were used to assess the quality and validity of the data. Data Synthesis.-Without exception, all studies demonstrated an increased risk for SIDS associated with the prone sleeping position. The published likelihood ratios (relative risk or odds ratio) for SIDS in the prone position compared with SIDS in any other position ranged from 3.5 to 9.3 in seven studies. Publicity against the use of the prone position has been associated with reduction of SIDS by 20% to 67%, paralleling the reduction in use of the prone position, with no increase in deaths from aspiration or in other diagnostic categories. Conclusions.-We recommend avoidance of the prone sleeping position for infants in the first 6 months of life unless there is a specific medical indication for it. Reports from the Netherlands, Great Britain, Australia, and New Zealand indicate that avoiding the prone position for infants in the first 6 months of life could reduce the number of SIDS deaths by as much as 50%. Unfortunately, these findings have received little attention in North America. We offer here an analysis of these reports so that physicians can assess the evidence and advise parents accordingly.			GUNTHEROTH, WG (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98125 USA.							Abramson H, 1944, J PEDIATR-US, V25, P404, DOI 10.1016/S0022-3476(44)80005-1; ADELSON L, 1956, PEDIATRICS, V17, P663; BEAL S, 1988, LANCET, V2, P512; BEAL S, 1988, MED J AUSTRALIA, V149, P562, DOI 10.5694/j.1326-5377.1988.tb120774.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BOWDEN K, 1950, Med J Aust, V1, P65; CAMERON MH, 1986, AUST PAEDIATR J, V22, P37; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; EMERY JL, 1968, BRIT MED J, V3, P209, DOI 10.1136/bmj.3.5612.209; EMERY JL, 1959, BRIT MED J, V2, P925, DOI 10.1136/bmj.2.5157.925; ENGELBERTS AC, 1991, J PAEDIATR CHILD H, V27, P329, DOI 10.1111/j.1440-1754.1991.tb00413.x; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FROGGATT P, 1970, SUDDEN INFANT DEATH, P40; GUNTHEROTH WG, 1990, BRIT MED J, V301, P494, DOI 10.1136/bmj.301.6750.494-a; GUNTHEROTH WG, 1975, J CLIN INVEST, V56, P1371, DOI 10.1172/JCI108217; GUNTHEROTH WG, 1989, CRIB DEATH SUDDEN DE; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOLT KS, 1960, J PEDIATR-US, V57, P571, DOI 10.1016/S0022-3476(60)80086-8; KATTWINKEL J, IN PRESS PEDIATRICS; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MARTIN RJ, 1979, PEDIATRICS, V63, P528; MASTERSON J, 1987, PEDIATRICS, V80, P689; MCGLASHAN ND, 1986, LANCET, V1, P106; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1991, J PAEDIATR CHILD H, V27, P319, DOI 10.1111/j.1440-1754.1991.tb00409.x; NAEYE RL, 1980, SCI AM, V242, P56, DOI 10.1038/scientificamerican0480-56; NELSON EAS, 1989, AUST PAEDIATR J, V25, P202; PEIRANO P, 1986, EARLY HUM DEV, V13, P303, DOI 10.1016/0378-3782(86)90065-4; POSONBY AL, 1992, BMJ-BRIT MED J, V304, P277; ROGNUM TO, 1991, PEDIATRICS, V87, P306; SATERNUS KS, 1985, FESTSCHRIFT LEITHOFF, P67; SENECAL J, 1987, ARCH FR PEDIATR, V44, P131; SOUTHALL DP, 1992, BMJ-BRIT MED J, V304, P265, DOI 10.1136/bmj.304.6822.265; SOUTHALL DP, 1983, PEDIATRICS, V80, P73; TAYLOR BJ, 1991, J PAEDIATR CHILD H, V27, P344, DOI 10.1111/j.1440-1754.1991.tb00416.x; THACH BT, 1986, NEW ENGL J MED, V315, P126, DOI 10.1056/NEJM198607103150210; WAGAMAN MJ, 1979, J PEDIATR-US, V94, P787, DOI 10.1016/S0022-3476(79)80157-2; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; WOOLLEY PV, 1945, J PEDIATR-US, V26, P572, DOI 10.1016/S0022-3476(45)80085-9	44	98	100	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2359	2362		10.1001/jama.267.17.2359	http://dx.doi.org/10.1001/jama.267.17.2359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564777				2022-12-28	WOS:A1992HR01500030
J	BISHOP, DK; PARK, D; XU, LZ; KLECKNER, N				BISHOP, DK; PARK, D; XU, LZ; KLECKNER, N			DMC1 - A MEIOSIS-SPECIFIC YEAST HOMOLOG OF ESCHERICHIA-COLI RECA REQUIRED FOR RECOMBINATION, SYNAPTONEMAL COMPLEX-FORMATION, AND CELL-CYCLE PROGRESSION	CELL			English	Article							DOUBLE-STRAND BREAKS; SINGLE-DIVISION MEIOSIS; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; TOPOISOMERASE-II; MEIOTIC RECOMBINATION; GENETIC-RECOMBINATION; NUCLEOTIDE-SEQUENCE; PACHYTENE ARREST; DNA-SEQUENCES	DMC1 is a new meiosis-specific yeast gene. Dmc1 protein is structurally similar to bacterial RecA proteins. dmc1 mutants are defective in reciprocal recombination, accumulate double-strand break (DSB) recombination intermediates, fail to form normal synaptonemal complex (SC), and arrest late in meiotic prophase. dmc1 phenotypes are consistent with a functional relationship between Dmc1 and RecA, and thus eukaryotic and prokaryotic mechanisms for homology recognition and strand exchange may be related. dmc1 phenotypes provide further evidence that recombination and SC formation are interrelated processes and are consistent with a requirement for DNA-DNA interactions during SC formation. dmc1 mutations confer prophase arrest. Additional evidence suggests that arrest occurs at a meiosis-specific cell cycle "checkpoint" in response to a primary defect in prophase chromosome metabolism. DMC1 is homologous to yeast's RAD51 gene, supporting the view that mitotic DSB repair has been recruited for use in meiotic chromosome metabolism.			BISHOP, DK (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NIGMS NIH HHS [GM-44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BEHAL RH, 1989, BIOCHEM BIOPH RES CO, V164, P941, DOI 10.1016/0006-291X(89)91549-0; BENDER J, 1992, IN PRESS EMBO J; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; BYERS B, 1982, MOL GEN GENET, V187, P47, DOI 10.1007/BF00384382; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CLANCY MJ, 1983, P NATL ACAD SCI-BIOL, V80, P3000, DOI 10.1073/pnas.80.10.3000; CLARK AB, 1991, MOL CELL BIOL, V11, P276; DAVIDOW LS, 1984, GENETICS, V106, P165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FARNET C, 1988, UCLA S MOL CELL BIOL, V83, P201; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; Game J., 1983, YEAST GENETICS FUNDA, P109; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GOTTLINNINFA E, 1986, MOL CELL BIOL, V6, P2185, DOI 10.1128/MCB.6.6.2185; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HENIKOFF S, 1990, NUCLEIC ACIDS RES, V18, P2961, DOI 10.1093/nar/18.10.2961; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; Howard-Flanders P, 1968, Adv Biol Med Phys, V12, P299; HOWARDFL.P, 1968, ANNU REV BIOCHEM, V37, P175, DOI 10.1146/annurev.bi.37.070168.001135; HUISMAN O, 1987, GENETICS, V116, P191; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLAPHOLZ S, 1980, GENETICS, V96, P589; KLAPHOLZ S, 1985, GENETICS, V110, P187; KLECKNER N, 1991, COLD SH Q B, V56, P729; KLEIN HL, 1988, GENETICS, V120, P367; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; LOPES MD, 1990, MOL CELL BIOL, V10, P2966, DOI 10.1128/MCB.10.6.2966; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; MALONE RE, 1983, MOL GEN GENET, V189, P405, DOI 10.1007/BF00325902; Maniatis T., 1982, MOL CLONING; MCCLINTOCK B, 1933, MIKROSK ANAT, V19, P191; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MENEES T, 1992, IN PRESS MOL CELL BI; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; MOENS PB, 1989, CHROMOSOMA, V98, P317, DOI 10.1007/BF00292383; MOENS PB, 1971, J CELL SCI, V9, P665; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEIMAN AM, 1990, CELL REGUL, V1, P391, DOI 10.1091/mbc.1.5.391; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERCIVALSMITH A, 1984, MOL CELL BIOL, V4, P142, DOI 10.1128/MCB.4.1.142; RESNICK MA, 1987, INVESTIGATING GENETI, P157; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P420; SHARON G, 1990, GENETICS, V125, P487; SHERMAN F, 1963, GENETICS, V48, P255; Sherman F., 1983, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SIKORSKI RS, 1989, GENETICS, V122, P19; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER L, 1992, IN PRESS GENETICS; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	89	979	1005	2	65	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					439	456		10.1016/0092-8674(92)90446-J	http://dx.doi.org/10.1016/0092-8674(92)90446-J			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581960				2022-12-28	WOS:A1992HT07800007
J	IEZZONI, LI; FOLEY, SM; DALEY, J; HUGHES, J; FISHER, ES; HEEREN, T				IEZZONI, LI; FOLEY, SM; DALEY, J; HUGHES, J; FISHER, ES; HEEREN, T			COMORBIDITIES, COMPLICATIONS, AND CODING BIAS - DOES THE NUMBER OF DIAGNOSIS CODES MATTER IN PREDICTING IN-HOSPITAL MORTALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE-PAYMENT SYSTEM; HEALTH-CARE; CLAIMS DATA; DRG CREEP; DISEASE; PROSTATECTOMY; REOPERATION; OUTCOMES; ICD-9-CM; DEATH	Objective. - Incomplete coding of secondary diagnoses may bias assessments of patient risks of poor outcomes using administrative health care databases, most of which allow only five diagnoses. The Medicare program is expanding the number of possible diagnoses from five to nine, aiming to improve coding completeness. We examined the impact of having more diagnosis codes available on assessments of risk of death. Design. - We used 1988 computerized hospital discharge abstract data from California, which allow up to 25 diagnoses per discharge, to select a sample of hospitalized patients and assessed the relationship between the presence of 29 specific secondary diagnoses and the risk of in-hospital death. Setting. - Nonfederal acute-care hospitals in California. Study Population. - All patients at least 65 years of age who were hospitalized for stroke, pneumonia, acute myocardial infarction, or congestive heart failure in California in 1988 (N = 162 790). Main Outcome Measures. - Relative risk of death for each specific secondary diagnosis. Results. - Many conditions that on a clinical basis would be expected to increase the risk of death, such as adult-onset diabetes mellitus, previous myocardial infarction, angina, and ventricular premature beats, were associated with a lower risk of in-hospital death. Conclusions. - Bias against coding of chronic or comorbid conditions on the computerized discharge abstracts of patients who die best explains these results. Efforts to improve diagnosis coding completeness solely by increasing the number of available coding spaces may not succeed.	CHARLES A DANA RES INST,BOSTON,MA; HARVARD UNIV,THORNDIKE LAB,CAMBRIDGE,MA 02138; VET AFFAIRS MED CTR,DEPT MED,BOSTON,MA; VET AFFAIRS MED CTR,W HAVEN,CT; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756; BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02215	Harvard University; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Dartmouth College; Boston University	IEZZONI, LI (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT GEN MED & PRIMARY CARE,300 BROOKLINE AVE,ROOM LY 314,BOSTON,MA 02215, USA.			Heeren, Timothy/0000-0001-5643-3559	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006512] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS06512-02] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON G, 1990, JAMA-J AM MED ASSOC, V263, P967, DOI 10.1001/jama.263.7.967; BLUMBERG MS, 1989, RISK ADJUSTED 30 DAY, P8; BROWN F, 1989, ICD9CM AM HOSP PUBLI; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONNELL FA, 1987, ANNU REV PUBL HEALTH, V8, P51, DOI 10.1146/annurev.publhealth.8.1.51; EPSTEIN SE, 1989, NEW ENGL J MED, V321, P320, DOI 10.1056/NEJM198908033210511; Fetter RB, 1980, MED CARE S, V18, P1; Fisher E S, 1991, Epidemiology, V2, P116, DOI 10.1097/00001648-199103000-00005; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; IEZZONI LI, 1991, AM J PUBLIC HEALTH, V81, P74, DOI 10.2105/AJPH.81.1.74; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; LLOYD SS, 1985, JAMA-J AM MED ASSOC, V254, P1330, DOI 10.1001/jama.254.10.1330; MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8; MCMAHON LF, 1986, ANN INTERN MED, V104, P562, DOI 10.7326/0003-4819-104-4-562; MEUX EF, 1990, REPORT RESULTS OSHPD; MULLIN RL, 1985, JAMA-J AM MED ASSOC, V254, P1208, DOI 10.1001/jama.254.9.1208; ROMANO PS, 1992, IN PRESS P MED EFFEC; Roos L L, 1987, Health Care Financ Rev, VSpec No, P5; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS NP, 1988, MED CARE, V26, P221, DOI 10.1097/00005650-198803000-00001; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; STEINWALD B, 1989, HEALTH AFFAIR, V8, P35, DOI 10.1377/hlthaff.8.2.35; SULLIVAN LW, 1991, MEDICARE HOSPITAL MO; VLADECK BC, 1984, ANN INTERN MED, V100, P576, DOI 10.7326/0003-4819-100-4-576; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WENNBERG JW, 1987, SYSTEMATIC STUDY NAT; 1989, INT CLASSIFICATION D; 1990, FED REG         0830, V58, P43213; 1990, MED TREATMENT EFFECT; 1985, OTAH262 OFF TECHN AS, P195; 1990, REPORT RECOMMENDATIO; 1990, DIAGNOSIS RELATED GR	37	347	349	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2197	2203		10.1001/jama.267.16.2197	http://dx.doi.org/10.1001/jama.267.16.2197			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556797				2022-12-28	WOS:A1992HN84100029
J	ALEXANDER, JM; GRANT, AM; CAMPBELL, MJ				ALEXANDER, JM; GRANT, AM; CAMPBELL, MJ			RANDOMIZED CONTROLLED TRIAL OF BREAST SHELLS AND HOFFMAN EXERCISES FOR INVERTED AND NON-PROTRACTILE NIPPLES	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the value of recommending breast shells or Hoffman's exercises, or both, to pregnant women with inverted or non-protractile nipples who intend to breast feed. Design - Randomised controlled trial with a two treatment by two level factorial design. Setting - Antenatal clinics in a district general hospital and the community. Subjects - 96 nulliparous women recruited between 25 and 35 completed weeks in a singleton pregnancy with at least one inverted or non-protractile nipple. Main outcome measures - Anatomical change of nipples, judged blindly before first breast feeding, and success of breast feeding reported by postal questionnaire six weeks postnatally. Results - Sustained improvement in nipple anatomy was more common in the untreated groups but the differences were not significant (52% (25/48) shells v 60% (29/48) no shells; difference -8% (95% confidence interval -28% to 11%) and 54% (26/48) exercises v 58% (28/48) no exercises; -4% (-24% to 16%)). 24 (50%) women not recommended shells and 14 (29%) recommended shells (21%; 40% to 2%) were breast feeding six weeks after delivery (p = 0.05), reflecting more women recommended shells both deciding to bottle feed before delivery and discontinuing breast feeding. The same number of women in exercise and no exercise groups were successfully breast feeding (0%; -20% to 20%). 13% of women approached about the trial (and planning to breast feed) did not attempt breast feeding. Conclusions - Recommending nipple preparation with breast shells may reduce the chances of successful breast feeding. While there is no clear evidence that the treatments offered are effective antenatal nipple examination should be abandoned.	NATL PERINATAL EPIDEMIOL UNIT,PERINATAL TRIALS SERV,OXFORD OX2 6HE,ENGLAND	University of Oxford	ALEXANDER, JM (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT NURSING STUDIES,SOUTHAMPTON S09 4XY,ENGLAND.		Campbell, Michael J/I-4253-2014	Campbell, Michael J/0000-0003-3529-2739				AKRE J, 1990, B WHO S, V67, P47; AKRE J, 1990, B WHO S, V67, P55; AKRE J, 1990, B WHO S, V67, P19; ALEXANDER J, 1991, THESIS U SOUTHAMPTON; BLAIKLEY J, 1953, J OBSTET GYN BRIT EM, V60, P657; CHALMERS I, 1982, EFFECTIVENESS SATISF, P209; COCHRAN WG, 1957, EXPT DESIGNS, P148; DELEE JB, 1947, PRINCIPLES PRACTICE, P99; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GUNTHER M, 1973, INFANT FEEDING, P104; HOFFMAN JB, 1953, AM J OBSTET GYNECOL, V66, P346; HYTTEN FE, 1958, LANCET, V1, P1201; HYTTEN FE, 1954, BMJ-BRIT MED J, V2, P1447, DOI 10.1136/bmj.2.4902.1447; INCH S, 1989, EFFECTIVE CARE PREGN, P335; LARSEN LLV, 1990, INT J CHILDBIRTH FEB, P33; LESPERANCE CM, 1980, BIRTH FAM J, V7, P21, DOI 10.1111/j.1523-536X.1980.tb01361.x; MARTIN J, 1988, INFANT FEEDING 1985; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P138; POOLE K, 1987, NEW GENERATION, V6, P33; RENFREW MJ, 1992, WOMENS HLTH MATTERS, P81; RIORDAN J, 1983, PRACTICAL GUIDE BREA; WALLER H, 1946, ARCH DIS CHILD, V21, P1, DOI 10.1136/adc.21.105.1; [No title captured]; 1944, 91 MIN HLTH PUBL HLT	24	45	45	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1030	1032		10.1136/bmj.304.6833.1030	http://dx.doi.org/10.1136/bmj.304.6833.1030			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586788	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200024
J	AMIRI, P; LOCKSLEY, RM; PARSLOW, TG; SADICK, M; RECTOR, E; RITTER, D; MCKERROW, JH				AMIRI, P; LOCKSLEY, RM; PARSLOW, TG; SADICK, M; RECTOR, E; RITTER, D; MCKERROW, JH			TUMOR-NECROSIS-FACTOR-ALPHA RESTORES GRANULOMAS AND INDUCES PARASITE EGG-LAYING IN SCHISTOSOME-INFECTED SCID MICE	NATURE			English	Article							LYT2+ SPLENIC CELLS; NUDE-MICE; MANSONI EGGS; ATHYMIC MICE; RECONSTITUTION; ANTIGEN; IMMUNOPATHOLOGY; PATHOLOGY; FIBROSIS; ANTIBODY	SCHISTOSOMIASIS (bilharzia) is a parasitic disease caused by several species of schistosome worms (blood flukes). The key pathogenic event in this disease is the formation of granulomas around schistosome eggs trapped in portal venules of the liver 1-9. Granulomas are a distinctive form of chronic inflammation characterized by localized aggregation of activated macrophages around an inciting stimulus 10. Each granuloma evolves to form a fibrous scar; in schistosomiasis, the result is widespread hepatic fibrosis and portal hypertension. To identify the specific immune signal molecules necessary for granuloma formation, we studied schistosome infections in severe combined immunodeficient (SCID) mice, which have normal macrophages but lack functional B or T lymphocytes 11,12. Here we report that the immunoregulatory cytokine tumour necrosis factor-alpha is necessary and sufficient to reconstitute granuloma formation in schistosome-infected SCID mice. Moreover, we find that the parasitic worms require tumour necrosis factor-alpha for egg-laying and for excretion of eggs from the host. The implication of this latter result is that the parasite has adapted so successfully to its host that it uses a host-derived immunoregulatory protein as a signal for replication and transmission.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,ANAT PATHOL SERV 113B,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BYRAM JE, 1977, AM J TROP MED HYG, V26, P944, DOI 10.4269/ajtmh.1977.26.944; BYRAM JE, 1979, AM J TROP MED HYG, V28, P274, DOI 10.4269/ajtmh.1979.28.274; CHEEVER AW, 1985, PARASITE IMMUNOL, V7, P387, DOI 10.1111/j.1365-3024.1985.tb00085.x; CHEEVER AW, 1989, AM J TROP MED HYG, V40, P66, DOI 10.4269/ajtmh.1989.40.66; CHENSUE SW, 1989, J IMMUNOL, V142, P1281; CUSTER RP, 1985, AM J PATHOL, V120, P464; DOENHOFF MJ, 1985, DEV BIOL STAND, V62, P63; DOENHOFF MJ, 1986, T ROY SOC TROP MED H, V80, P503, DOI 10.1016/0035-9203(86)90126-4; DOUGHTY BL, 1982, J IMMUNOL, V128, P37; DUVALL RH, 1967, AM J TROP MED HYG, V16, P483, DOI 10.4269/ajtmh.1967.16.483; GRZYCH JM, 1991, J IMMUNOL, V146, P1322; JAATTELA M, 1991, LAB INVEST, V64, P724; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; MATHEW RC, 1986, INFECT IMMUN, V54, P820, DOI 10.1128/IAI.54.3.820-826.1986; MCGEE HJ, 1984, NATURE, V308, P667, DOI 10.1038/308667a0; OLDS GR, 1989, J INFECT DIS, V159, P798, DOI 10.1093/infdis/159.4.798; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PERRIN PJ, 1988, J IMMUNOL, V141, P1714; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; PRAKASH S, 1990, J IMMUNOL, V144, P317; ROBBINS SL, 1984, PATHOLOGIC BASIS DIS, P64	24	422	441	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					604	607		10.1038/356604a0	http://dx.doi.org/10.1038/356604a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560843				2022-12-28	WOS:A1992HP03100049
J	SCHNOLZER, M; KENT, SBH				SCHNOLZER, M; KENT, SBH			CONSTRUCTING PROTEINS BY DOVETAILING UNPROTECTED SYNTHETIC PEPTIDES - BACKBONE-ENGINEERED HIV PROTEASE	SCIENCE			English	Article							VIRUS TYPE-1 PROTEASE; ASPARTIC PROTEINASES; CRYSTAL-STRUCTURE; MUTAGENESIS; RESOLUTION; INHIBITOR; COMPLEX; HOMOLOGY	Backbone-engineered HIV-1 protease was prepared by a total chemical synthesis approach that combines the act of joining two peptides with the generation of an analog structure. Unprotected synthetic peptide segments corresponding to the two halves of the HIV-1 protease monomer polypeptide chain were joined cleanly and in high yield through unique mutually reactive functional groups, one on each segment. Ligation was performed in 6 molar guanidine hydrochloride, thus circumventing limited solubility of protected peptide segments, the principal problem of the classical approach to the chemical synthesis of proteins. The resulting fully active HIV-1 protease analog contained a thioester replacement for the natural peptide bond between Gly51-Gly52 in each of the two active site flaps, a region known to be highly sensitive to mutational changes of amino acid side chains.	Scripps Res Inst, RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BACA M, 1992, PEPTIDES, P732; BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAYER E, 1991, ANGEW CHEM INT EDIT, V30, P113, DOI 10.1002/anie.199101133; BLAKE J, 1986, INT J PEPT PROT RES, V27, P191; CARTER P, 1986, BIOCHEM J, V237, P1; CHENG HC, 1991, INT J PEPT PROT RES, V38, P70; Epton R., 1990, INNOVATION PERSPECTI, P11; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KENT SBH, 1991, PEPTIDES 1990, P169; KENT SBH, 1989, VIRAL PROTEINASES TH, P223; KENT SBH, IN PRESS INNOVATION; KIYAMA S, 1984, INT J PEPT PROT RES, V23, P174; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KOPPENHOEFER B, 1985, ORG SYNTH, V64, P230; LAPATTO P, 1989, NATURE, V342, P299; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OFFORD R, 1991, PROTEIN ENG, V4, P709, DOI 10.1093/protein/4.7.709; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; SASAKI T, 1991, J ORG CHEM, V56, P3159, DOI 10.1021/jo00009a043; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHNOLZER M, UNPUB; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMASHIRO D, 1988, INT J PEPT PROT RES, V31, P322	36	296	405	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					221	225		10.1126/science.1566069	http://dx.doi.org/10.1126/science.1566069			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566069				2022-12-28	WOS:A1992HM89600029
J	DIETRICH, AJ; OCONNOR, GT; KELLER, A; CARNEY, PA; LEVY, D; WHALEY, FS				DIETRICH, AJ; OCONNOR, GT; KELLER, A; CARNEY, PA; LEVY, D; WHALEY, FS			CANCER - IMPROVING EARLY DETECTION AND PREVENTION - A COMMUNITY PRACTICE RANDOMIZED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY CARE; PHYSICIANS	Objective - To test the impact of physician education and facilitator assisted office system interventions on cancer early detection and preventive services. Design - A randomised trial of two interventions alone and in combination. Setting and subjects - Physicians in 98 ambulatory care practices in the United States. Interventions - The education intervention consisted of a day long physician meeting directed at improving knowledge, attitudes, and skills relevant to cancer prevention and early detection. The office system intervention consisted of assistance from a project facilitator in establishing routines for providing needed services. These routines included division of responsibilities for providing services among physicians and their staff and the use of medical record flow sheets. Main outcome measures - The proportions of patients provided the cancer prevention and early detection services indicated annually according to the US National Cancer Institute. Results - Based on cross sectional patient surveys, the office system intervention was associated with an increase in mammography, the recommendation to do breast self examination, clinical breast examination, faecal occult blood testing, advice to quit smoking, and the recommendation to decrease dietary fat. Education was associated only with an increase in mammography. Record review for a patient cohort confirmed cross sectional survey findings regarding the office system for mammography and faecal occult blood testing. Conclusion - Community practices assisted by a facilitator in the development and implementation of an office system can substantially improve provision of cancer early detection and preventive services.	DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT MED,HANOVER,NH 03756	Dartmouth College	DIETRICH, AJ (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756, USA.				NATIONAL CANCER INSTITUTE [P30CA023108, R01CA046075] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA46075, CA23108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; BUTRUM RR, 1988, AM J CLIN NUTR, V48, P888, DOI 10.1093/ajcn/48.3.888; CHOMET J, 1990, BRIT MED J, V300, P1504, DOI 10.1136/bmj.300.6738.1504; COULTER A, 1991, BRIT J GEN PRACT, V41, P140; DAVIDSON RA, 1984, ARCH INTERN MED, V144, P2167, DOI 10.1001/archinte.144.11.2167; DICKEY LL, 1990, J FAM PRACTICE, V31, P431; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; DRAPER NR, 1981, APPLIED REGRESSION A; DUNN EV, 1988, J MED EDUC, V63, P775; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; FULLARD E, 1984, BRIT MED J, V289, P1585, DOI 10.1136/bmj.289.6458.1585; GLYNN TJ, 1989, 892064 NAT I HLTH PU; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P351; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; NETER J, 1985, APPLIED LINEAR STATI; PATTERSON J, 1989, AM J PREV MED, V5, P44, DOI 10.1016/S0749-3797(18)31128-0; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; WEINGARTEN MA, 1989, FAM PRACT, V6, P120, DOI 10.1093/fampra/6.2.120; WINICKOFF RN, 1984, MED CARE, V22, P527, DOI 10.1097/00005650-198406000-00003; 1990, JAMA-J AM MED ASSOC, V264, P54; 1987, STOP SMOKING KIT; 1987, WORKING GUIDELINES E; 1991, BMJ, V302, P1057; 1988, CANCER LETT, V14, P4	25	222	223	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					687	691		10.1136/bmj.304.6828.687	http://dx.doi.org/10.1136/bmj.304.6828.687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571644	Green Published, Bronze			2022-12-28	WOS:A1992HK76100027
J	BURKE, W; INUI, TS				BURKE, W; INUI, TS			DO WE STILL NEED PRIMARY CARE TRACKS	ANNALS OF INTERNAL MEDICINE			English	Article							INTERNAL-MEDICINE; TRAINING-PROGRAMS; GENERAL MEDICINE; RESIDENTS; EDUCATION; CURRICULUM; TIME	Primary care tracks in internal medicine residency programs were initiated in the late 1970s in response to the need for more primary care physicians. These programs have shown that internists can be trained effectively in ambulatory settings. Graduates of primary care tracks are more likely to choose careers in general internal medicine than are other internal medicine graduates. Primary care internist training has been accompanied by the growth of academic general internal medicine divisions and by the enhancement of the scientific base for ambulatory care practice and medical education. Expanded ambulatory training opportunities, modeled after current primary care tracks, should be offered to all residents in internal medicine. At the same time, primary care tracks should be revised to address deficiencies in current ambulatory training. These tracks should be designed to commit most resident time to ambulatory care settings, to involve residents in community-based and interdisciplinary health care, and to expose residents to conditions outside of the medical sector that affect health. Revised primary care tracks can serve as pathfinder programs for ongoing reform in internal medicine residency training. Three models for organizing and funding such reform are presented.	UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	BURKE, W (corresponding author), UNIV WASHINGTON, MED CTR, DEPT MED, RG-20, SEATTLE, WA 98195 USA.				PHS HHS [67-0046] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN RM, 1990, ANN INTERN MED, V113, P243, DOI 10.7326/0003-4819-113-3-243; BARKER LR, 1990, J GEN INTERN MED, V5, pS3, DOI 10.1007/BF02600433; BRANCH WT, 1990, J GEN INTERN MED, V5, pS15, DOI 10.1007/BF02600434; Crandall L A, 1990, J Rural Health, V6, P19, DOI 10.1111/j.1748-0361.1990.tb00188.x; Delbanco T L, 1988, J Gen Intern Med, V3, pS34, DOI 10.1007/BF02600250; EISENBERG JM, 1989, NEW ENGL J MED, V320, P1525, DOI 10.1056/NEJM198906083202305; EISENBERG JM, 1990, J GEN INTERN MED, V5, pS70, DOI 10.1007/BF02600440; FOURNIER AM, 1990, J GEN INTERN MED, V5, P166, DOI 10.1007/BF02600519; HALPERIN AK, 1990, J GEN INTERN MED, V5, pS35, DOI 10.1007/BF02600436; INUI TS, 1992, MED SCH MISSION POPU; JENSEN NM, 1989, CIRRICULUM INTERNAL; KERN DE, 1990, J GEN INTERN MED, V5, P218, DOI 10.1007/BF02600538; KERN DE, 1989, J GEN INTERN MED, V4, P421, DOI 10.1007/BF02599696; KOSECOFF J, 1985, ANN INTERN MED, V102, P250, DOI 10.7326/0003-4819-102-2-250; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; LURIE N, 1989, NEW ENGL J MED, V320, P1673, DOI 10.1056/NEJM198906223202507; MARTIN GJ, 1989, J GEN INTERN MED, V4, P304, DOI 10.1007/BF02597402; MCPHEE SJ, 1987, JAMA-J AM MED ASSOC, V258, P1491, DOI 10.1001/jama.258.11.1491; NELSON RL, 1990, MAYO CLIN PROC, V65, P809, DOI 10.1016/S0025-6196(12)62571-3; NOBLE J, ASSESSMENT DEV SUPPO; PHILBRICK JT, 1990, AM J MED SCI, V299, P43, DOI 10.1097/00000441-199001000-00010; ROSEVEAR GC, 1989, ACAD MED, V64, P253, DOI 10.1097/00001888-198905000-00011; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SKEFF K M, 1988, Journal of General Internal Medicine, V3, pS26, DOI 10.1007/BF02600249; STRELNICK AH, 1988, ANN INTERN MED, V109, P324, DOI 10.7326/0003-4819-109-4-324; WILKERSON L, 1990, J GEN INTERN MED S1, V1, pS44; WITZBURG RA, 1988, J GEN INTERN MED, V3, P48, DOI 10.1007/BF02595756; WOLFE ES, 1982, J MED EDUC, V57, P468	28	10	10	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1065	1070		10.7326/0003-4819-116-12-1065	http://dx.doi.org/10.7326/0003-4819-116-12-1065			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586118				2022-12-28	WOS:A1992HY79400008
J	CALLAHAN, CM; RIVARA, FP				CALLAHAN, CM; RIVARA, FP			URBAN HIGH-SCHOOL YOUTH AND HANDGUNS - A SCHOOL-BASED SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ADOLESCENTS; FIREARMS; SUICIDE; REGULATIONS; OWNERSHIP	Objective. - To determine the prevalence of handgun ownership among urban high school youth and investigate associations with socioeconomic status, ethnicity, and deviant behaviors. Design. - Survey of half of the Seattle, Wash, public high schools, which enroll 50% of the school district's 11th-grade students (N = 970). Main Outcome Measures. - Self-reports of handgun ownership, perceived access to handguns, racial/ethnic identity, social status (Hollingshead's Two Factor Index of Social Position), and social deviance (Seattle Self-Report Instrument) were determined. Results. - Thirty-four percent of the students reported easy access to handguns (47% of males, 22% of females) and 6.4% reported owning a handgun (11.4% of males, 1.5% of females). Reported firearm experiences indicated a high rate of handgun utilization: 33% of handgun owners had fired at someone, 9.7% of female students reported a firearm homicide or suicide in family members or close friends, and 6% of male students reported carrying a handgun to school sometime in the past. Handgun ownership was more common among students who reported deviant behaviors. Adjusting for age, gender, and racial/ethnic group and controlling for covariation among the problem behaviors, gang membership (odds ratio [OR], 8.8; 95% confidence interval [CI], 3.7 to 20.8), sentencing by a judge (OR, 4.6; 95% CI, 1.3 to 15.5), selling drugs (OR, 3.7; 95% CI, 1.8 to 7.8), suspension or expulsion from school (OR, 3.5; 95% CI, 1.7 to 7.0), and assault and battery (OR, 2.5; 95% CI, 1.1 to 5.9) were associated with handgun ownership. However, 22% of male handgun owners did not report any of the above behaviors. Conclusion. - The availability of handguns to the urban high school students surveyed is pervasive, and it is not limited to high-risk groups.	UNIV WASHINGTON,DEPT MICROBIOL IMMUNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					PHS HHS [R49/CCR 002570] Funding Source: Medline; BHP HRSA HHS [5T32 PE1002] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); BHP HRSA HHS		Affair a AMACoS, 1989, PUBLIC HLTH REP, V104, P111; ANDERSON C, 1989, DATA PROFILE DISTRIC; [Anonymous], J ADOLESC HLTH CARE; BOYD JH, 1986, AM J PUBLIC HEALTH, V76, P1240, DOI 10.2105/AJPH.76.10.1240; Christoffel K K, 1986, Pediatr Emerg Care, V2, P75, DOI 10.1097/00006565-198606000-00003; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; DEAN AG, 1990, EPIINFO VERSION 5; Dryfoos JG., 1990, ADOLESCENTS RISK PRE; FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V263, P3290; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; FORD AB, 1979, AM J PUBLIC HEALTH, V69, P459, DOI 10.2105/AJPH.69.5.459; GAUSCHE M, 1989, Pediatric Emergency Care, V5, P64, DOI 10.1097/00006565-198903000-00018; GRAHAM PM, 1989, J ADOLESCENT HEALTH, V10, P534, DOI 10.1016/0197-0070(89)90017-X; HINDELANG MJ, 1981, MEASURING DELINQUENC, P123; HOLLINGSHEAD AB, 1958, SOCIAL CLASS MENTAL, P387; HULLEY SB, 1988, DESIGNING CLIN RES E, P206; JESSOR R, 1980, AM J PUBLIC HEALTH, V70, P604, DOI 10.2105/AJPH.70.6.604; KELLERMANN AL, 1990, AM J EPIDEMIOL, V131, P1080, DOI 10.1093/oxfordjournals.aje.a115600; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; KROHN B, 1990, WASHINGTON ED DIRECT; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARKUSH RE, 1984, AM J PUBLIC HEALTH, V74, P123, DOI 10.2105/AJPH.74.2.123; SADOWSKI LS, 1989, AM J DIS CHILD, V143, P1410, DOI 10.1001/archpedi.1989.02150240032012; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; TONKIN RS, 1987, J ADOLESCENT HEALTH, V8, P213, DOI 10.1016/0197-0070(87)90269-5; WINTEMUTE GJ, 1988, AM J PUBLIC HEALTH, V78, P824, DOI 10.2105/AJPH.78.7.824; WINTEMUTE GJ, 1987, J TRAUMA, V27, P532, DOI 10.1097/00005373-198705000-00013; 1989, NATIONAL ADOLESCENT; 1991, MMWR, V40, P681	30	138	140	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3038	3042		10.1001/jama.267.22.3038	http://dx.doi.org/10.1001/jama.267.22.3038			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588717				2022-12-28	WOS:A1992HW97000023
J	ABRAMSON, SV; BURKE, JF; KELLY, JJ; KITCHEN, JG; DOUGHERTY, MJ; YIH, DF; MCGEEHIN, FC; SHUCK, JW; PHIAMBOLIS, TP				ABRAMSON, SV; BURKE, JF; KELLY, JJ; KITCHEN, JG; DOUGHERTY, MJ; YIH, DF; MCGEEHIN, FC; SHUCK, JW; PHIAMBOLIS, TP			PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION; TRICUSPID VALVE INSUFFICIENCY; CARDIOMYOPATHY, CONGESTIVE; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE	CONGESTIVE HEART-FAILURE; TRICUSPID REGURGITATION; NONINVASIVE ESTIMATION; DOPPLER ULTRASOUND; SYSTOLIC PRESSURE; PULSED DOPPLER; PROGNOSIS; ECHOCARDIOGRAPHY; SURVIVAL; DETERMINANTS	Objective: To ascertain whether pulmonary hypertension, as assessed noninvasively by continuous-wave Doppler of tricuspid regurgitation, can be an important independent factor in the prognosis of patients with ischemic or idiopathic dilated cardiomyopathy. Design: Cohort study of consecutive patients with dilated cardiomyopathy in whom follow-up was obtained on all survivors for 28 months. Setting: Outpatient cardiology private practice office in a tertiary care center. Patients: Consecutive sample of 108 patients who presented for a scheduled office visit during a 15-month period. Measurements: M-mode, two-dimensional, and Doppler echocardiographic examinations were done on all patients at entry into the study and on survivors 1 year later. All examinations included extensive pulsed- and continuous-wave Doppler evaluation for tricuspid regurgitation. Main Outcome Measures: Overall mortality, mortality due to myocardial failure, and hospitalization for congestive heart failure. Results: Twenty-eight patients had a high velocity of tricuspid regurgitation (> 2.5 m/s), and 80 patients had a low velocity (less-than-or-equal-to 2.5 m/s). After 28 months of follow-up, the mortality rate was 57% in patients with a high velocity compared with 17% in patients with a low velocity (difference of 40%, 95% Cl, 20% to 60%). Hospitalization for congestive heart failure occurred in 75% and 26% of patients, respectively (difference of 49%, Cl, 30% to 68%). Eighty-nine percent of patients with a high velocity either died or were hospitalized compared with only 32% of patients with a low velocity (difference of 57%, Cl, 42% to 72%). The peak velocity of tricuspid regurgitation was the only prognostic variable selected using stepwise logistic regression models for the three outcome events. Conclusion: Noninvasive assessment of pulmonary hypertension using continuous-wave Doppler of tricuspid regurgitation can predict morbidity and mortality in patients with ischemic or idiopathic dilated cardiomyopathy.	LANKENAU HOSP, ECHOCARDIOG LAB, SUITE 356 LANKENAU MED BLDG E, 100 LANCASTER AVE W CITY LINE, WYNNEWOOD, PA 19096 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA	Lankenau Medical Center; Jefferson University								ABBASI AS, 1980, CIRCULATION, V61, P143, DOI 10.1161/01.CIR.61.1.143; BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; CLELAND JGF, 1987, BRIT HEART J, V58, P572; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DIAZ RA, 1987, BRIT HEART J, V58, P393; DOUGLAS PS, 1989, J AM COLL CARDIOL, V13, P311, DOI 10.1016/0735-1097(89)90504-4; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; HATLE L, 1981, BRIT HEART J, V45, P157; IKRAM H, 1987, BRIT HEART J, V57, P521; Kannel W B, 1989, Cardiol Clin, V7, P1; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KELLY TL, 1990, AM HEART J, V119, P1111, DOI 10.1016/S0002-8703(05)80242-X; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; MASSIE BM, 1987, CIRCULATION, V75, P11; MIKAMI T, 1984, AM J CARDIOL, V53, P160, DOI 10.1016/0002-9149(84)90702-1; Newman T J, 1988, Am J Med, V84, P140, DOI 10.1016/0002-9343(88)90221-5; PACKER M, 1987, CIRCULATION, V75, P55; POLAK JF, 1983, J AM COLL CARDIOL, V2, P217, DOI 10.1016/S0735-1097(83)80156-9; ROMEO F, 1989, CLIN CARDIOL, V12, P387, DOI 10.1002/clc.4960120708; SIMONSON JS, 1988, J AM COLL CARDIOL, V11, P557, DOI 10.1016/0735-1097(88)91531-8; STEWART RAH, 1990, Q J MED, V74, P309; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; WILSON JR, 1987, CIRCULATION, V75, P64; WYATT HL, 1980, CIRCULATION, V61, P1119, DOI 10.1161/01.CIR.61.6.1119; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657; YOSHIDA K, 1988, CIRCULATION, V78, P840, DOI 10.1161/01.CIR.78.4.840	32	248	256	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					888	895		10.7326/0003-4819-116-11-888	http://dx.doi.org/10.7326/0003-4819-116-11-888			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580444				2022-12-28	WOS:A1992HW13700002
J	ONORATO, IM; WASSILAK, SG; MEADE, B				ONORATO, IM; WASSILAK, SG; MEADE, B			EFFICACY OF WHOLE-CELL PERTUSSIS-VACCINE IN PRESCHOOL-CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTECTIVE EFFICACY; HOUSEHOLD EXPOSURE; DIPHTHERIA; ANTIBODY; DTP	Objective.-To evaluate the efficacy of currently used whole-cell pertussis vaccines. Design.-Active surveillance to detect pertussis cases in Baltimore, Md, Denver, Colo, and Milwaukee, Wis, and investigation of secondary attack rates in 347 household contacts, aged 1 through 4 years, to estimate vaccine efficacy. Outcome Measure.-Vaccine efficacy was estimated using different case definitions for pertussis. Results.-Vaccine efficacy was 64%, 81%, and 95% for case definitions of mild cough, paroxysmal cough, and severe clinical illness, respectively. Requiring laboratory confirmation increased efficacy to 95% to 98% for culture-positive children and to 77% to 95% for culture- or serology-confirmed cases, depending on disease severity. Vaccine efficacy for typical paroxysmal cough increased from 44% for one diphtheria, tetanus, and pertussis vaccine dose to 80% for four or more doses. Conclusions.-The trend toward increasing vaccine efficacy with different case definitions may be due to improved efficacy in preventing severe illness and to case definitions that are more specific for pertussis. Whole-cell pertussis vaccine was highly effective in preventing pertussis in preschool children exposed to infection within their households. Direct side-by-side efficacy studies of whole-cell vaccine and the recently licensed acellular vaccine will be necessary to assure that comparable protection is afforded by the new vaccines if they are to be used for immunization of infants.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014	US Food & Drug Administration (FDA)	ONORATO, IM (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,TECH INFORMAT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333, USA.							[Anonymous], 1988, LANCET, Vi, P955; BEGG RC, 1984, NEW ZEAL MED J, V97, P408; BLACKWELDER WC, 1991, AM J DIS CHILD, V145, P1285, DOI 10.1001/archpedi.1991.02160110077024; BLENNOW M, 1988, BRIT MED J, V296, P1570, DOI 10.1136/bmj.296.6636.1570; BLUMBERG DA, 1990, J PEDIATR-US, V117, P46, DOI 10.1016/S0022-3476(05)82442-4; CODY CL, 1981, PEDIATRICS, V68, P650; COUTLER HL, 1985, SHOT DARK; FINE PEM, 1987, REV INFECT DIS, V9, P866; FINE PEM, 1988, INT J EPIDEMIOL, V17, P635, DOI 10.1093/ije/17.3.635; HINMAN AR, 1984, PUBLIC HEALTH REP, V99, P255; HOLLANDER HO, 1991, J INFECT DIS, V163, P1046; Howson CP, 1991, ADVERSE EFFECTS PERT; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MEADE BD, 1990, DHHS PUBLICATION, P322; MORTIMER EA, 1990, AM J DIS CHILD, V144, P899, DOI 10.1001/archpedi.1990.02150320063029; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; REGAN J, 1977, J CLIN MICROBIOL, V6, P303; STORSAETER J, 1990, VACCINE, V8, P457, DOI 10.1016/0264-410X(90)90246-I; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1992, MMWR, V41, P1; 1984, WEEKLY EPIDEMIOL REC, V59, P26; 1984, MMWR, V33, P573; 1991, MMWR, V40, P1; 1991, ANN NEUROL, V29, P458	26	79	83	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2745	2749		10.1001/jama.267.20.2745	http://dx.doi.org/10.1001/jama.267.20.2745			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578592				2022-12-28	WOS:A1992HV26500020
J	LOHMAN, PHM; SANKARANARAYANAN, K; ASHBY, J				LOHMAN, PHM; SANKARANARAYANAN, K; ASHBY, J			CHOOSING THE LIMITS TO LIFE	NATURE			English	Editorial Material							COMPRESSION; MORBIDITY		ICI PLC,PLC CENT TOXICOL LAB,MACCLESFIELD SK10 4TJ,ENGLAND		LOHMAN, PHM (corresponding author), LEIDEN UNIV,MGC DEPT RADIAT GENET & CHEM MUTAGENESIS,2333 AL LEIDEN,NETHERLANDS.							AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ASHBY J, 1991, NATURE, V352, P185, DOI 10.1038/352185a0; BOTHIG S, 1989, INT J EPIDEMIOL, V18, pS29; FRIES JF, 1988, PERSPECT BIOL MED, V31, P407; FRIES JF, 1989, LANCET, V1, P481; HARMAN D, 1991, P NATL ACAD SCI USA, V88, P5360, DOI 10.1073/pnas.88.12.5360; PETO R, 1985, ASSESSMENT RISK LOW, P3; POIRIER S, 1987, INT J CANCER, V39, P293, DOI 10.1002/ijc.2910390305; 1979, IARC MONOGRAPHS EVAL, V19, P377	10	19	19	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					185	186		10.1038/357185a0	http://dx.doi.org/10.1038/357185a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589010				2022-12-28	WOS:A1992HV19500016
J	SACKETT, DL				SACKETT, DL			A PRIMER ON THE PRECISION AND ACCURACY OF THE CLINICAL EXAMINATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAGE QUESTIONNAIRE; ALCOHOL		MCMASTER UNIV,FAC MED,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,FAC MED,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA; HAMILTON CIVIC HOSP,HAMILTON,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University								BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; KNIPSCHILD P, 1988, BRIT MED J, V297, P1578, DOI 10.1136/bmj.297.6663.1578; LUNDBERG GD, 1984, JAMA-J AM MED ASSOC, V252, P1911, DOI 10.1001/jama.252.14.1911; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SIMEL DL, 1988, J GEN INTERN MED, V3, P423, DOI 10.1007/BF02595917; SPITERI MA, 1988, LANCET, V1, P873; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; THEODOSSI A, 1981, Liver, V1, P21	9	253	259	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2638	2644		10.1001/jama.267.19.2638	http://dx.doi.org/10.1001/jama.267.19.2638			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573753				2022-12-28	WOS:A1992HT82300033
J	CORMACK, BP; STRUHL, K				CORMACK, BP; STRUHL, K			THE TATA-BINDING PROTEIN IS REQUIRED FOR TRANSCRIPTION BY ALL 3 NUCLEAR-RNA POLYMERASES IN YEAST-CELLS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; PROMOTER ELEMENT; MOLECULAR MECHANISMS; ACTIVATOR PROTEIN; ESCHERICHIA-COLI; DNA-SEQUENCES; GENE; INVITRO; INITIATION	Using temperature- and proteolytically sensitive derivatives to inactivate the function of the yeast TATA-binding protein (TBP) in vivo, we investigated the requirement of TBP for transcription by the three nuclear RNA polymerases in yeast cells. TBP is required for RNA polymerase II (pol II) transcription from promoters containing conventional TATA elements as well as functionally distinct promoters that lack TATA-like sequences. TBP is also required for transcription of the U6 snRNA and two different tRNA genes mediated by RNA pol III as well as transcription of ribosomal RNA mediated by RNA pol I. For all promoters tested, transcription decreases rapidly and specifically upon inactivation of TBP, strongly suggesting that TBP is directly involved in the transcription process. These observations suggest that TBP is required for transcription of all nuclearly encoded genes in yeast, although distinct molecular mechanisms are probably involved for the three RNA polymerase transcription machineries.			CORMACK, BP (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BUTT TR, 1988, J BIOL CHEM, V263, P16364; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FIRE A, 1984, J BIOL CHEM, V259, P2509; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEMET S, 1988, J BIOL CHEM, V263, P10048; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	74	325	328	1	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					685	696		10.1016/0092-8674(92)90232-2	http://dx.doi.org/10.1016/0092-8674(92)90232-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586947				2022-12-28	WOS:A1992HV08900013
J	OLIVER, SG; VANDERAART, QJM; AGOSTONI-CARBONE, ML; AIGLE, M; ALBERGHINA, L; ALEXANDRAKI, D; ANTOINE, G; ANWAR, R; BALLESTA, JPG; BENIT, P; BERBEN, G; BERGANTINO, E; BITEAU, N; BOLLE, PA; BOLOTINFUKUHARA, M; BROWN, A; BROWN, AJP; BUHLER, JM; CARCANO, C; CARIGNANI, G; CEDERBERG, H; CHANET, R; CONTRERAS, R; CROUZET, M; DAIGNANFORNIER, B; DEFOOR, E; DELGADO, M; DEMOLDER, J; DOIRA, C; DUBOIS, E; DUJON, B; DUSTERHOFT, A; ERDMANN, D; ESTEBAN, M; FABRE, F; FAIRHEAD, C; FAYE, G; FELDMANN, H; FIERS, W; FRANCINGUESGAILLARD, MC; FRANCO, L; FRONTALI, L; FUKUHARA, H; FULLER, LJ; GALLAND, P; GENT, ME; GIGOT, D; GILLIQUET, V; GLANSDORFF, N; GOFFEAU, A; GRENSON, M; GRISANTI, P; GRIVELL, LA; DEHAAN, M; HAASEMANN, M; HATAT, D; HOENICKA, J; HEGEMANN, J; HERBERT, CJ; HILGER, F; HOHMANN, S; HOLLENBERG, CP; HUSE, K; IBORRA, F; INDGE, KJ; ISONO, K; JACQ, C; JACQUET, M; JAMES, CM; JAUNIAUX, JC; JIA, Y; JIMENEZ, A; KELLY, A; KLEINHANS, U; KREISL, P; LANFRANCHI, G; LEWIS, C; VANDERLINDEN, CG; LUCCHINI, G; LUTZENKIRCHEN, K; MAAT, MJ; MALLET, L; MANNHAUPT, G; MARTEGANI, E; MATHIEU, A; MAURER, CTC; MCCONNELL, D; MCKEE, RA; MESSENGUY, F; MEWES, HW; MOLEMANS, F; MONTAGUE, MA; FALCONI, MM; NAVAS, L; NEWLON, CS; NOONE, D; PALLIER, C; PANZERI, L; PEARSON, BM; PEREA, J; PHILIPPSEN, P; PIERARD, A; PLANTA, RJ; PLEVANI, P; POETSCH, B; POHL, F; PURNELLE, B; RAD, MR; RASMUSSEN, SW; RAYNAL, A; REMACHA, M; RICHTERICH, P; ROBERTS, AB; RODRIGUEZ, F; SANZ, E; SCHAAFFGERSTENSCHLAGER, I; SCHERENS, B; SCHWEITZER, B; SHU, Y; SKALA, J; SLONIMSKI, PP; SOR, F; SOUSTELLE, C; SPIEGELBERG, R; STATEVA, LI; STEENSMA, HY; STEINER, S; THIERRY, A; THIREOS, G; TZERMIA, M; URRESTARAZU, LA; VALLE, G; VETTER, I; VANVLIETREEDIJK, JC; VOET, M; VOLCKAERT, G; VREKEN, P; WANG, H; WARMINGTON, JR; VON WETTSTEIN, D; WICKSTEED, BL; WILSON, C; WURST, H; XU, G; YOSHIKAWA, A; ZIMMERMANN, FK; SGOUROS, JG				OLIVER, SG; VANDERAART, QJM; AGOSTONI-CARBONE, ML; AIGLE, M; ALBERGHINA, L; ALEXANDRAKI, D; ANTOINE, G; ANWAR, R; BALLESTA, JPG; BENIT, P; BERBEN, G; BERGANTINO, E; BITEAU, N; BOLLE, PA; BOLOTINFUKUHARA, M; BROWN, A; BROWN, AJP; BUHLER, JM; CARCANO, C; CARIGNANI, G; CEDERBERG, H; CHANET, R; CONTRERAS, R; CROUZET, M; DAIGNANFORNIER, B; DEFOOR, E; DELGADO, M; DEMOLDER, J; DOIRA, C; DUBOIS, E; DUJON, B; DUSTERHOFT, A; ERDMANN, D; ESTEBAN, M; FABRE, F; FAIRHEAD, C; FAYE, G; FELDMANN, H; FIERS, W; FRANCINGUESGAILLARD, MC; FRANCO, L; FRONTALI, L; FUKUHARA, H; FULLER, LJ; GALLAND, P; GENT, ME; GIGOT, D; GILLIQUET, V; GLANSDORFF, N; GOFFEAU, A; GRENSON, M; GRISANTI, P; GRIVELL, LA; DEHAAN, M; HAASEMANN, M; HATAT, D; HOENICKA, J; HEGEMANN, J; HERBERT, CJ; HILGER, F; HOHMANN, S; HOLLENBERG, CP; HUSE, K; IBORRA, F; INDGE, KJ; ISONO, K; JACQ, C; JACQUET, M; JAMES, CM; JAUNIAUX, JC; JIA, Y; JIMENEZ, A; KELLY, A; KLEINHANS, U; KREISL, P; LANFRANCHI, G; LEWIS, C; VANDERLINDEN, CG; LUCCHINI, G; LUTZENKIRCHEN, K; MAAT, MJ; MALLET, L; MANNHAUPT, G; MARTEGANI, E; MATHIEU, A; MAURER, CTC; MCCONNELL, D; MCKEE, RA; MESSENGUY, F; MEWES, HW; MOLEMANS, F; MONTAGUE, MA; FALCONI, MM; NAVAS, L; NEWLON, CS; NOONE, D; PALLIER, C; PANZERI, L; PEARSON, BM; PEREA, J; PHILIPPSEN, P; PIERARD, A; PLANTA, RJ; PLEVANI, P; POETSCH, B; POHL, F; PURNELLE, B; RAD, MR; RASMUSSEN, SW; RAYNAL, A; REMACHA, M; RICHTERICH, P; ROBERTS, AB; RODRIGUEZ, F; SANZ, E; SCHAAFFGERSTENSCHLAGER, I; SCHERENS, B; SCHWEITZER, B; SHU, Y; SKALA, J; SLONIMSKI, PP; SOR, F; SOUSTELLE, C; SPIEGELBERG, R; STATEVA, LI; STEENSMA, HY; STEINER, S; THIERRY, A; THIREOS, G; TZERMIA, M; URRESTARAZU, LA; VALLE, G; VETTER, I; VANVLIETREEDIJK, JC; VOET, M; VOLCKAERT, G; VREKEN, P; WANG, H; WARMINGTON, JR; VON WETTSTEIN, D; WICKSTEED, BL; WILSON, C; WURST, H; XU, G; YOSHIKAWA, A; ZIMMERMANN, FK; SGOUROS, JG			THE COMPLETE DNA-SEQUENCE OF YEAST CHROMOSOME-III	NATURE			English	Article							ALTERNATION GEL-ELECTROPHORESIS; TRANSFER-RNA GENES; SACCHAROMYCES-CEREVISIAE; TRANSPOSABLE ELEMENT; NUCLEOTIDE-SEQUENCE; RECOMBINATION; EXPRESSION; FRAGMENT; CLONING; VECTORS	The entire DNA sequence of chromosome III of the yeast Saccharomyces cerevisiae has been determined. This is the first complete sequence analysis of an entire chromosome from any organism. The 315-kilobase sequence reveals 182 open reading frames for proteins longer than 100 amino acids, of which 37 correspond to known genes and 29 more show some similarity to sequences in databases. Of 55 new open reading frames analysed by gene disruption, three are essential genes; of 42 non-essential genes that were tested, 14 show some discernible effect on phenotype and the remaining 28 have no overt function.	LEIDEN UNIV, DEPT CELL BIOL GENET, NL-2300 RA LEIDEN, NETHERLANDS; UNIV MILAN, DIPARTIMENTO GENET & BIOL MICROORGANISMI, I-20122 MILAN, ITALY; LBMS, F-33000 BORDEAUX, FRANCE; UNIV MILAN, DIPARTIMENTO FISIOL & BIOCHIM, I-20122 MILAN, ITALY; INST MOLEC BIOL & BIOTECHNOL, GR-71110 IRAKLION, GREECE; CTR UNIV ORSAY, INST CURIE, F-91405 ORSAY, FRANCE; CTR BIOL MOLEC, E-28049 MADRID, SPAIN; FAC SCI AGRON ETAT GEMBLOUX, B-5030 GEMBLOUX, BELGIUM; DIPARTIMENTO CHIM BIOL, I-35100 PADUA, ITALY; UNIV PARIS 11, INST GENET & MICROBIOL, F-91405 ORSAY, FRANCE; UNIV ABERDEEN, DEPT MOLEC & CELL BIOL, ABERDEEN AB9 1FX, SCOTLAND; CENS, SERV BIOCHIM, F-91191 GIF SUR YVETTE, FRANCE; INST MICROBIOL, W-6100 DARMSTADT, GERMANY; LAB MOLEC BIOL, B-9000 GHENT, BELGIUM; KATHOLIEKE UNIV LEUVEN, GENTECHNOL LAB, B-3001 LOUVAIN, BELGIUM; LA CRUZ DEL CAMPO SA, E-41080 SEVILLE, SPAIN; CTR ENSEIGNEMENT & RECH IND ALIMENTAIRES & CHIM, COOVI, RES INST, B-1070 BRUSSELS, BELGIUM; INST PASTEUR, F-75724 PARIS 15, FRANCE; UNIV GIESSEN, INST MIKROBIOL & MOLEK BIOL, W-6300 GIESSEN, GERMANY; UNIV MUNICH, INST PHYSIOL CHEM, W-8000 MUNICH 2, GERMANY; UNIV ROME, DEPT CELL & DEV BIOL, I-00185 ROME, ITALY; INST FOOD RES, NORWICH NR4 7UA, NORFOLK, ENGLAND; CATHOLIC UNIV LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV LIBRE BRUXELLES, CELL PHYSIOL & YEAST GENET LAB, B-1050 BRUSSELS, BELGIUM; UNIV AMSTERDAM, MOLEC BIOL SECT, 1098 SM AMSTERDAM, NETHERLANDS; MARTINSRIED INST PROT SEQUENCES, W-8033 MARTINSRIED, GERMANY; ECOLE NORM SUPER, F-75231 PARIS 05, FRANCE; CNRS, CTR GENET MOLEC, F-91190 GIF SUR YVETTE, FRANCE; UNIV DUSSELDORF, INST MIKROBIOL, W-4000 DUSSELDORF 1, GERMANY; KOBE UNIV, DEPT BIOL, KOBE 657, JAPAN; UNIV DUBLIN TRINITY COLL, DEPT GENET, DUBLIN 2, IRELAND; FREE UNIV AMSTERDAM, DEPT BIOCHEM & MOLEC BIOL, 1081 HV AMSTERDAM, NETHERLANDS; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA; UNIV CONSTANCE, FAK BIOL, W-7750 CONSTANCE, GERMANY; CARLSBERG LAB, DK-2500 COPENHAGEN, DENMARK; COMMISS EUROPEAN COMMUNITIES, B-1049 BRUSSELS, BELGIUM	Leiden University; Leiden University - Excl LUMC; University of Milan; University of Milan; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Liege; UDICE-French Research Universities; Universite Paris Saclay; University of Aberdeen; CEA; KU Leuven; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Justus Liebig University Giessen; University of Munich; Sapienza University Rome; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Universite Catholique Louvain; Universite Libre de Bruxelles; University of Amsterdam; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Heinrich Heine University Dusseldorf; Kobe University; Trinity College Dublin; Vrije Universiteit Amsterdam; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Konstanz	OLIVER, SG (corresponding author), UNIV MANCHESTER, INST SCI & TECHNOL, MANCHESTER BIOTECHNOL CTR, MANCHESTER M60 1QD, LANCS, ENGLAND.		Hoenicka, Janet/B-2908-2014; Brown, Alistair J.P./B-6627-2014; Hohmann, Stefan/K-9895-2013; Muzi-Falconi, Marco/A-6035-2012; Dujon, Bernard A/F-4971-2010; Navas, Luigi/ABI-6516-2020; Berben, Gilbert/AAS-8739-2020; Oliver, Stephen/AAQ-5992-2021; Remacha, Miguel/G-1250-2016; Berben, Gilbert/ABF-4648-2021; Dujon, Bernard/AAL-8410-2021; Fairhead, Cecile/D-9011-2014; Mewes, Hans-Werner/A-8204-2019	Hoenicka, Janet/0000-0002-6790-6988; Hohmann, Stefan/0000-0002-0809-1985; Muzi-Falconi, Marco/0000-0001-7046-6090; Berben, Gilbert/0000-0002-6167-1970; Oliver, Stephen/0000-0003-3410-6439; Dujon, Bernard/0000-0003-4661-3534; VALLE, GIORGIO/0000-0003-4377-5685; Fairhead, Cecile/0000-0002-0456-0377; Wilson, Cathal/0000-0002-0637-8608; Alberghina, Lilia/0000-0003-1694-931X; Sgouros, John G./0000-0002-9141-5257; Mewes, Hans-Werner/0000-0002-9713-6398; PLEVANI, PAOLO/0000-0003-1869-2626; Martegani, Enzo/0000-0001-9196-4224				ARNOLD W, 1988, J MOL BIOL, V203, P715, DOI 10.1016/0022-2836(88)90205-7; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BOEKE JD, 1989, MOBILE DNA, P335; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUTTON LL, 1986, MOL CELL BIOL, V6, P1352, DOI 10.1128/MCB.6.4.1352; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; Cook A. H., 1958, CHEM BIOL YEASTS; DEJONGE P, 1986, YEAST, V2, P193, DOI 10.1002/yea.320020307; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EIGEL A, 1982, EMBO J, V1, P1245, DOI 10.1002/j.1460-2075.1982.tb00020.x; FELDMAN H, 1976, NUCLEIC ACIDS RES, V3, P2379, DOI 10.1093/nar/3.9.2379; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GRANDBASTIEN MA, 1989, NATURE, V337, P376, DOI 10.1038/337376a0; JIA Y, 1991, YEAST, V7, P413, DOI 10.1002/yea.320070411; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; KONIECZNY A, 1991, GENETICS, V127, P801; LARKIN JC, 1987, MOL CELL BIOL, V7, P1764, DOI 10.1128/MCB.7.5.1764; LINK AJ, 1991, GENETICS, V127, P681; MARTIN WJ, 1989, GENOME, V31, P1073, DOI 10.1139/g89-184; Maxam A M, 1980, Methods Enzymol, V65, P499; MORTIMER RK, 1986, GENETICS, V113, P35; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MOUNT SM, 1985, MOL CELL BIOL, V5, P1630, DOI 10.1128/MCB.5.7.1630; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; NEWLON CS, 1991, GENETICS, V129, P343; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PETES TD, 1973, COLD SPRING HARB SYM, V38, P9, DOI 10.1101/SQB.1974.038.01.004; RODRIGUEZ F, 1991, YEAST, V7, P631, DOI 10.1002/yea.320070612; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; STRATHERN JN, 1979, CELL, V18, P309, DOI 10.1016/0092-8674(79)90050-3; Strathern JN., 1982, MOL BIOL YEAST SACCH; STUCKA R, 1989, NUCLEIC ACIDS RES, V17, P4993, DOI 10.1093/nar/17.13.4993; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Toh-e A, 1985, Yeast, V1, P159, DOI 10.1002/yea.320010204; WARMINGTON JR, 1987, NUCLEIC ACIDS RES, V15, P8963, DOI 10.1093/nar/15.21.8963; WARMINGTON JR, 1985, NUCLEIC ACIDS RES, V13, P6679, DOI 10.1093/nar/13.18.6679; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	51	750	952	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1992	357	6373					38	46		10.1038/357038a0	http://dx.doi.org/10.1038/357038a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1574125				2022-12-28	WOS:A1992HT22900051
J	SAID, G; GOULONGOEAU, C; SLAMA, G; TCHOBROUTSKY, G				SAID, G; GOULONGOEAU, C; SLAMA, G; TCHOBROUTSKY, G			SEVERE EARLY-ONSET POLYNEUROPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS - A CLINICAL AND PATHOLOGICAL-STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROPATHY; DEGENERATION; PATHOGENESIS; PAINFUL	Background and Methods. The pathophysiologic features of diabetic neuropathy, a common and disabling long-term complication of diabetes mellitus, are poorly understood. We studied five patients, 22 to 34 years old, in whom an uncommonly severe symmetric polyneuropathy developed soon after the onset of insulin-dependent diabetes. Their autonomic function and nerve conduction were studied, and sural-nerve biopsy specimens were examined by light and electron microscopy. Other causes of neuropathy were carefully excluded. Results. Four patients had autonomic dysfunction with postural hypotension, fainting, diarrhea, and Argyll Robertson pupils and peripheral neuropathy with loss of sensation of pain and changes in temperature that followed a pattern suggestive of a length-dependent degeneration of nerve fibers. In contrast, the fifth patient had muscle weakness and atrophy of limb extremities, with "glove and stocking" sensory loss, but little autonomic dysfunction. In the biopsy specimens of sural nerves, the mean (+/- SD) density of myelinated fibers was reduced to 20 +/- 14 percent of that measured in five control patients, and the density of unmyelinated fibers was reduced to 6 +/- 4 percent of that in the controls. Regenerating fibers accounted for 38 +/- 11 percent of the myelinated axons. Abnormalities of the myelin sheath affected 33 +/- 21 percent of the isolated fibers, and axonal degeneration 11 +/- 8 percent. Dying-back fibers, a characteristic of the centripetal degeneration of peripheral axons, were also identified. The dying-back process progressed at the rate of a few hundred micrometers per day. Conclusions. Early-onset symptomatic polyneuropathy in patients with diabetes mellitus is characterized by the loss of both myelinated and unmyelinated nerve fibers. Spontaneous axonal regeneration is remarkably frequent, even when neuropathy is severe.	UNIV PARIS 11,HOP BICETRE,SERV NEUROL,PARIS,FRANCE; HOP HOTEL DIEU,SERV DIABETOL,F-75181 PARIS 04,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite								ALI Z, 1989, J NEUROL NEUROSUR PS, V52, P94, DOI 10.1136/jnnp.52.1.94; AZERAD E, 1961, PRESSE MED, V69, P1419; BEHSE F, 1990, ACTA NEUROL SCAND  S, V82, P3; BRITLAND ST, 1990, DIABETES, V39, P898, DOI 10.2337/diabetes.39.8.898; BROWN MJ, 1976, ARCH NEUROL-CHICAGO, V33, P164, DOI 10.1001/archneur.1976.00500030020004; CORNIL V, 1907, MANUEL HISTOLOGIE PA, V3, P527; Dieulafoy G., 1906, CLIN MED HOTEL DIEU, P130; DYCK P J, 1987, P223; DYCK PJ, 1986, ANN NEUROL, V19, P425, DOI 10.1002/ana.410190503; EWING D J, 1987, P66; FAGERBERG SE, 1963, ACTA MED SCAND, V174, P711; FUJIMURA H, 1991, BRAIN, V114, P1929, DOI 10.1093/brain/114.4.1929; GREENE DA, 1987, NEW ENGL J MED, V316, P599; JAMAL GA, 1987, MUSCLE NERVE, V10, P537, DOI 10.1002/mus.880100608; JOHNSON PC, 1986, ANN NEUROL, V19, P450, DOI 10.1002/ana.410190505; KING RHM, 1989, NEUROPATH APPL NEURO, V15, P339, DOI 10.1111/j.1365-2990.1989.tb01234.x; LLEWELYN JG, 1991, BRAIN, V114, P867, DOI 10.1093/brain/114.2.867; MCINTYRE AK, 1980, PHYSL PERIPHERAL NER, P41; MELTON LJ, 1987, DIABETIC NEUROPATHY, P27; PARKHOUSE N, 1988, NEW ENGL J MED, V318, P1306, DOI 10.1056/NEJM198805193182005; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; Sabin T.D., 1978, PHYSL PATHOBIOLOGY A, P431; SAID G, 1984, NEUROLOGY, V34, P1025, DOI 10.1212/WNL.34.8.1025; SAID G, 1983, BRAIN, V106, P791, DOI 10.1093/brain/106.4.791; SIDENIUS P, 1987, P260; THOMAS PK, 1984, PERIPHERAL NEUROPATH, P1773; VERGELY P, 1893, GAZ HEBD MED CHIR, V32, P376	28	111	111	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1257	1263		10.1056/NEJM199205073261905	http://dx.doi.org/10.1056/NEJM199205073261905			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560802				2022-12-28	WOS:A1992HR44700005
J	HIGGINS, TL; ESTAFANOUS, FG; LOOP, FD; BECK, GJ; BLUM, JM; PARANANDI, L				HIGGINS, TL; ESTAFANOUS, FG; LOOP, FD; BECK, GJ; BLUM, JM; PARANANDI, L			STRATIFICATION OF MORBIDITY AND MORTALITY OUTCOME BY PREOPERATIVE RISK-FACTORS IN CORONARY-ARTERY BYPASS PATIENTS - A CLINICAL SEVERITY SCORE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPEN-HEART-SURGERY; DISEASE CLASSIFICATION-SYSTEM; OBJECTIVELY DERIVED WEIGHTS; CARDIAC SURGICAL PROCEDURES; HOSPITAL MORTALITY; MYOCARDIAL-INFARCTION; MULTIFACTORIAL INDEX; OPERATIVE MORTALITY; PREDICTING SURVIVAL; APACHE-II	Objective.-To relate morbidity and mortality risk to preoperative severity of illness in patients undergoing coronary artery bypass grafting. Design.-Retrospective analysis of 5051 patients using univariate and logistic regression to identify risk factors associated with perioperative morbidity and mortality. Prospective application of models to a subsequent 2-year validation cohort (n = 4069). Setting.-Cleveland Clinic Foundation. Patients.-All adult patients undergoing coronary artery bypass graft surgery between July 1, 1986, and June 30,1988 (reference group), and July 1, 1988, and June 30, 1990 (validation group). Main Outcome Measures.-Mortality and morbidity (myocardial infarction and use of intra-aortic balloon pump, mechanical ventilation for 3 or more days, neurological deficit, oliguric or anuric renal failure, or serious infection). Main Results.-Emergency procedure, preoperative serum creatinine levels of greater than 168-mu-mol/L, severe left ventricular dysfunction, preoperative hematocrit of 0.34, increasing age, chronic pulmonary disease, prior vascular surgery, reoperation, and mitral valve insufficiency were found to be predictive of mortality. In addition to these factors, diabetes mellitus, body weight of 65 kg or more, aortic stenosis, and cerebrovascular disease were predictive of morbidity. Logistic regression equations were developed, and a simple additive score for clinical use was designed by allocating each of these risk-factor values of 1 to 6 points. Both methods predict mortality. Increased morbidity was demonstrated with increases in score. Conclusions.-The logistic or clinical models developed are superior to the currently available methods for comparing mortality outcome and provide previously unavailable information on morbidity based on preoperative status. The clinical scoring system is useful for preoperative estimates of morbidity and mortality risks.	CLEVELAND CLIN EDUC FDN,DEPT THORAC & CARDIOVASC SURG,CLEVELAND,OH 44106; CLEVELAND CLIN EDUC FDN,DEPT BIOSTAT & EPIDEMIOL,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Cleveland Clinic Foundation	HIGGINS, TL (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOTHORAC ANESTHESIOL,CARDIOTHORAC INTENS CARE UNIT,GS-160,CLEVELAND,OH 44195, USA.		Higgins, Thomas L/A-8385-2009; Higgins, Thomas L/I-9438-2019	Higgins, Thomas L/0000-0002-9958-0767				COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2, P941; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; FOSTER ED, 1984, ANN THORAC SURG, V38, P563, DOI 10.1016/S0003-4975(10)62312-0; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HIGGINS TL, 1990, MAY ANN M SOC CARD A; HIGGINS TL, 1991, SEMIN THORAC CARDIOV, V13, P111; HIGGINS TL, 1991, SEMIN THORAC CARDIOV, V3, P111; HIGGINS TL, 1991, ANESTHESIOLOGY, P75; HOOD AB, 1984, MED CARE, V22, P98; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOUCHOUKOS NT, 1980, CIRCULATION, V62, P84; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; LOOP FD, 1988, CLEV CLIN J MED, V55, P23, DOI 10.3949/ccjm.55.1.23; LOOP FD, 1975, J THORAC CARDIOV SUR, V69, P40; LYTLE BW, 1987, J THORAC CARDIOV SUR, V93, P847; LYTLE BW, 1988, CLEV CLIN J MED, V55, P79, DOI 10.3949/ccjm.55.1.79; MATSUDA H, 1986, J CARDIOVASC SURG, V27, P595; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Metz CE, 1984, INFORMATION PROCESSI; PAIEMENT B, 1983, CAN ANAESTH SOC J, V30, P61, DOI 10.1007/BF03007718; PARSONNET V, 1989, CIRCULATION, V79, P3; PARSONNET V, 1988, J THORAC CARDIOV SUR, V96, P198; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; PEPER WA, 1988, CLEV CLIN J MED, V55, P63, DOI 10.3949/ccjm.55.1.63; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; SLOGOFF S, 1985, ANESTHESIOLOGY, V62, P107, DOI 10.1097/00000542-198502000-00002	36	652	687	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2344	2348		10.1001/jama.267.17.2344	http://dx.doi.org/10.1001/jama.267.17.2344			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564774				2022-12-28	WOS:A1992HR01500027
J	OTTO, DH				OTTO, DH			CALL ME MISTER, PLEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2307	2307						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564762				2022-12-28	WOS:A1992HR01500008
J	SHINOHARA, A; OGAWA, H; OGAWA, T				SHINOHARA, A; OGAWA, H; OGAWA, T			RAD51 PROTEIN INVOLVED IN REPAIR AND RECOMBINATION IN SACCHAROMYCES-CEREVISIAE IS A RECA-LIKE PROTEIN	CELL			English	Article							DNA STRAND TRANSFER; YEAST SACCHAROMYCES-CEREVISIAE; SENSITIVE METHOD; GENE DISRUPTION; MEIOTIC CELLS; BINDING; BETA; BACTERIOPHAGE-T4; PURIFICATION; SELECTION	The RAD51 gene of S. cerevisiae is involved in mitotic recombination and repair of DNA damage and also in meiosis. We show that the rad51 null mutant accumulates meiosis-specific double-strand breaks (DSBs) at a recombination hotspot and reduces the formation of physical recombinants. Rad51 protein shows structural similarity to RecA protein, the bacterial strand exchange protein. Furthermore, we have found that Rad51 protein is similar to RecA in its DNA binding properties and binds directly to Rad52 protein, which also plays a crucial role in recombination. These results suggest that the Rad51 protein, probably together with Rad52 protein, is involved in a step to convert DSBs to the next intermediate in recombination. Rad51 protein is also homologous to a meiosis-specific Dmc1 protein of S. cerevisiae.			SHINOHARA, A (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,1-1 MACHIKANEYAMA,TOYONAKA,OSAKA 560,JAPAN.							ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDERON IL, 1983, CURR GENET, V7, P93, DOI 10.1007/BF00365632; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COLE GM, 1989, MOL CELL BIOL, V9, P3314, DOI 10.1128/MCB.9.8.3314; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; Game J., 1983, YEAST GENETICS FUNDA, P109; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZ WS, 1988, MOL CELL BIOL, V8, P2730, DOI 10.1128/MCB.8.7.2730; KIPLING D, 1991, NATURE, V353, P509, DOI 10.1038/353509a0; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD NJ, 1984, CRC CR REV BIOCH MOL, V15, P125, DOI 10.3109/10409238409102299; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MORRISON DP, 1979, MOL GEN GENET, V175, P57, DOI 10.1007/BF00267856; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; OGAWA T, 1992, IN PRESS J MOL BIOL; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; RESNICK MA, 1987, INVESTIGATING GENETI, P157; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAEKI T, 1980, MUTAT RES, V73, P251, DOI 10.1016/0027-5107(80)90192-X; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBASTIAN J, 1990, MOL CELL BIOL, V10, P4630, DOI 10.1128/MCB.10.9.4630; SHERMAN F, 1963, GENETICS, V48, P255; Sherman F., 1983, METHODS YEAST GENETI; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; SMOLARSKY M, 1970, BIOCHIM BIOPHYS ACTA, V199, P447, DOI 10.1016/0005-2787(70)90087-0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; TATEISHI S, 1991, MOL CELL BIOL, V11, P2593; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WITKIN EM, 1969, ANNU REV MICROBIOL, V23, P487, DOI 10.1146/annurev.mi.23.100169.002415; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	72	1063	1093	0	69	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					457	470		10.1016/0092-8674(92)90447-K	http://dx.doi.org/10.1016/0092-8674(92)90447-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581961				2022-12-28	WOS:A1992HT07800008
J	VIONNET, N; STOFFEL, M; TAKEDA, J; YASUDA, K; BELL, GI; ZOUALI, H; LESAGE, S; VELHO, G; IRIS, F; PASSA, P; FROGUEL, P; COHEN, D				VIONNET, N; STOFFEL, M; TAKEDA, J; YASUDA, K; BELL, GI; ZOUALI, H; LESAGE, S; VELHO, G; IRIS, F; PASSA, P; FROGUEL, P; COHEN, D			NONSENSE MUTATION IN THE GLUCOKINASE GENE CAUSES EARLY-ONSET NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							DNA; POLYMORPHISMS; POLYMERASE	MATURITY-ONSET diabetes of the young (MODY) is a form of non-insulin-dependent (type 2) diabetes mellitus (NIDDM) which is characterized by an early age at onset and an autosomal dominant mode of inheritance 1. Except for these features, the clinical characteristics of patients with MODY are similar to those with the more common late-onset form(s) of NIDDM. Previously 2 we observed tight linkage between DNA polymorphisms in the glucokinase gene on the short arm of chromosome 7 and NIDDM in a cohort of sixteen French families having MODY. Glucokinase is an enzyme that catalyses the formation of glucose-6-phosphate from glucose and may be involved in the regulation of insulin secretion and integration of hepatic intermediary metabolism 3. Because the glucokinase gene was a candidate for the site of the genetic lesion in these families, we scanned this gene for mutations. Here we report the identification of a nonsense mutation in the gene encoding glucokinase and its linkage with early-onset diabetes in one family. To our knowledge, this result is the first evidence implicating a mutation in a gene involved in glucose metabolism in the pathogenesis of NIDDM.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM,5841 S MARYLAND AVE,MC1028,CHICAGO,IL 60637; HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-91000 EVRY,FRANCE; UNIV CHICAGO,DEPT MOLEC BIOL & MED,CHICAGO,IL 60637; GENETHON,F-91000 EVRY,FRANCE	Howard Hughes Medical Institute; University of Chicago; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Chicago			Velho, Gilberto/Q-6724-2017; FROGUEL, Philippe/O-6799-2017; Vionnet, Nathalie/N-6302-2017	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784; Stoffel, Markus/0000-0003-1304-5817				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875	12	569	594	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					721	722		10.1038/356721a0	http://dx.doi.org/10.1038/356721a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570017				2022-12-28	WOS:A1992HQ14600064
J	MUSCH, A; WIEDMANN, M; RAPOPORT, TA				MUSCH, A; WIEDMANN, M; RAPOPORT, TA			YEAST SEC PROTEINS INTERACT WITH POLYPEPTIDES TRAVERSING THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							PREPRO-ALPHA-FACTOR; POST-TRANSLATIONAL TRANSLOCATION; CELL-FREE SYSTEM; SIGNAL SEQUENCE; NASCENT POLYPEPTIDES; SECRETORY PROTEINS; FACTOR INVITRO; IMPORT; COMPONENT; INSERTION	We show by photocross-linking that nascent secretory proteins, during their passage through the endoplasmic reticulum membrane of S. cerevisiae, are in physical contact with Sec61p and Sec62p, two genetically identified membrane proteins that are essential for in vivo translocation. Sec61p seems to be in continuous contact, whereas Sec62p is involved only transiently. Translocation comprises both ATP-dependent and -independent phases of interaction with the Sec proteins. The results suggest a direct role of the Sec proteins in translocation.			MUSCH, A (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,O-1115 BERLIN,GERMANY.							ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, IN PRESS CELL, V69; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STIRLING CJ, 1992, IN PRESS MOL BIOL CE; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WIEDMANN M, 1988, EMBO J, V7, P1763, DOI 10.1002/j.1460-2075.1988.tb03006.x	41	111	112	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					343	352		10.1016/0092-8674(92)90414-8	http://dx.doi.org/10.1016/0092-8674(92)90414-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568249				2022-12-28	WOS:A1992HQ18300013
J	BEEMAN, RW; FRIESEN, KS; DENELL, RE				BEEMAN, RW; FRIESEN, KS; DENELL, RE			MATERNAL-EFFECT SELFISH GENES IN FLOUR BEETLES	SCIENCE			English	Article							YELLOW MONKEY FLOWER; DROSOPHILA-MELANOGASTER; FEMALE STERILITY; HYBRIDS; POPULATIONS; CHROMOSOME; GENETICS; GENOME	A previously unknown class of dominant, maternal-effect lethal M factors was found to be widespread in natural populations of the flour beetle, Tribolium castaneum, collected on several continents. Such factors are integrated into the host chromosomes at variable locations and show the remarkable property of self-selection by maternal-effect lethality to all hatchlings that do not inherit a copy of the factor itself. Offspring are rescued by either paternally or maternally inherited copies. The M-bearing chromosome is thereby perpetuated at the expense of its non-M homolog. M factors that map to different regions of the genome do not rescue one another's maternal-effect lethality. Factors expressing these properties are predicted to spread in a population, even in the absence of any additional selective advantage. Similar factors also occur in the related species T. confusum.	KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,MANHATTAN,KS 66506	Kansas State University	BEEMAN, RW (corresponding author), USDA ARS,N CENT REG,US GRAIN MKT RES LAB,1515 COLL AVE,MANHATTAN,KS 66502, USA.			Friesen, Kenlee/0000-0003-1211-3953				BEEMAN RW, 1986, J HERED, V77, P451, DOI 10.1093/oxfordjournals.jhered.a110279; BEEMAN RW, 1990, J ECON ENTOMOL, V83, P1745, DOI 10.1093/jee/83.5.1745; BEEMAN RW, UNPUB; CHRISTIE P, 1987, EVOLUTION, V41, P571, DOI 10.1111/j.1558-5646.1987.tb05827.x; CHRISTIE P, 1984, J HERED, V75, P510, DOI 10.1093/oxfordjournals.jhered.a110004; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; HUTTER P, 1990, GENETICS, V124, P909; KIDWELL MG, 1977, GENETICS, V86, P813; NUR U, 1988, SCIENCE, V240, P512, DOI 10.1126/science.3358129; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; ORR HA, 1989, EVOLUTION, V43, P180, DOI 10.1111/j.1558-5646.1989.tb04216.x; ORR HA, 1987, GENETICS, V116, P555; PICARD G, 1978, BIOL CELLULAIRE, V31, P235; WADE MR, COMMUNICATION	14	135	141	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					89	92		10.1126/science.1566060	http://dx.doi.org/10.1126/science.1566060			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566060				2022-12-28	WOS:A1992HL82200032
J	MILLER, JB				MILLER, JB			MYOBLAST DIVERSITY IN SKELETAL MYOGENESIS - HOW MUCH AND TO WHAT END	CELL			English	Review							FIBER TYPES; EXPRESSION; CELLS; GENE; DIFFERENTIATION; MUSCLES; LINEAGE; EMBRYO		HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Harvard University; Harvard Medical School	MILLER, JB (corresponding author), MASSACHUSETTS GEN HOSP,NEUROMUSCULAR LAB,BOSTON,MA 02129, USA.			Miller, Jeffrey/0000-0001-5273-2201				BUTLER J, 1982, J EXP ZOOL, V224, P65, DOI 10.1002/jez.1402240108; CONDON K, 1990, DEV BIOL, V138, P275, DOI 10.1016/0012-1606(90)90197-Q; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; GRIESHAMMER U, 1992, CELL, V69; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; HOH JFY, 1991, MUSCLE NERVE, V14, P316; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1987, TRENDS NEUROSCI, V10, P325, DOI 10.1016/0166-2236(87)90089-0; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SCHAFER DA, 1987, CELL, V48, P659, DOI 10.1016/0092-8674(87)90244-3; TOLIAS PP, 1990, EMBO J, V9, P1457, DOI 10.1002/j.1460-2075.1990.tb08262.x; WHITE NK, 1975, DEV BIOL, V44, P346, DOI 10.1016/0012-1606(75)90405-4	20	74	74	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					1	3		10.1016/0092-8674(92)90111-O	http://dx.doi.org/10.1016/0092-8674(92)90111-O			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555234				2022-12-28	WOS:A1992HM44500001
J	ROBINSON, MS; KREIS, TE				ROBINSON, MS; KREIS, TE			RECRUITMENT OF COAT PROTEINS ONTO GOLGI MEMBRANES IN INTACT AND PERMEABILIZED CELLS - EFFECTS OF BREFELDIN-A AND G-PROTEIN ACTIVATORS	CELL			English	Article							MONOCLONAL-ANTIBODIES; UNCOATING ATPASE; CLATHRIN; TRANSPORT; STACK; PITS; PURIFICATION; ADAPTORS; VESICLES; BINDING	Brefeldin A (BFA) causes a rapid redistribution of coat proteins (e.g., gamma-adaptin) associated with the clathrin-coated vesicles that bud from the trans-Golgi network (TGN), while the clathrin-coated vesicles that bud from the plasma membrane are unaffected. Gamma-Adaptin redistributes with the same kinetics as beta-COP, a coat protein associated with the non-clathrin-coated vesicles that bud from the Golgi complex. Upon removal of BFA, however, gamma-adaptin recovers its perinuclear distribution more rapidly. Redistribution of both proteins can be prevented by pretreating cells with AIF4-. Recruitment of adaptors from the cytosol onto the TGN membrane has been reconstituted in a permeabilized cell system and is increased by addition of GTP-gamma-S and blocked by addition of BFA. These results suggest a role for G proteins in the control of the clathrin-coated vesicle cycle at the TGN and further extend the similarities between clathrin-coated vesicles and non-clathrin-coated vesicles.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	ROBINSON, MS (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; DAVOUST J, 1991, P AM I PHYSICS, V226, P385; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, IN PRESS SCIENCE; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KIRCHHAUSEN T, 1991, IN PRESS J BIOL CHEM; KREIS TE, 1979, P NATL ACAD SCI USA, V76, P3414; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SERAFINI T, 1991, NATURE, V349, P215; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	40	333	335	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					129	138		10.1016/0092-8674(92)90124-U	http://dx.doi.org/10.1016/0092-8674(92)90124-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555237				2022-12-28	WOS:A1992HM44500012
J	WADE, DT; COLLEN, FM; ROBB, GF; WARLOW, CP				WADE, DT; COLLEN, FM; ROBB, GF; WARLOW, CP			PHYSIOTHERAPY INTERVENTION LATE AFTER STROKE AND MOBILITY	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; GAIT ASSESSMENT; SCALE	Objective - To determine whether the intervention of a physiotherapist improved mobility in patients seen more than one year after stroke. Design - Randomised crossover trial comparing two groups offered intervention by a physiotherapist, one immediately after entry into the trial and the other after a delay of three months. The intervention consisted of identifying problems and offering advice and help to solve the problems. Setting - Patients' homes in Oxfordshire. Subjects - Patients who had reduced mobility due to a stroke more than one year before entry; 60 were recruited from a community stroke register and 34 in other ways. Main outcome measures - Standard measures of mobility including gait speed, functional ambulation categories, the Nottingham extended activities of daily living index, and individual items from the Barthel activities of daily living index and the Frenchay activities index. Measures of manual dexterity, depression, and anxiety were used as controls. Results - 94 patients entered the trial and 49 were randomised to immediate and 45 to delayed physiotherapy; 89 were compared at the crossover point. At randomisation the two groups were comparable. At three months the group given early therapy showed an improvement in gait speed whereas the untreated group had declined (differences of -3.9 v 6.4 s to walk 10 m; p < 0.01); between three and six months the group given delayed therapy showed improvement and the previously treated group declined (differences of 6.5 v -3.9 s to walk 10 m; p < 0.01). A 9% (95% confidence interval 0% to 18%) decrease in time taken to walk 10 m was associated with treatment and a 12% (2% to 19%) increase when patients were untreated. Other measures did not change significantly. Conclusion - Intervention of an experienced physiotherapist late after stroke specifically improves mobility, albeit by a small amount, but the effects do not seem to be maintained, perhaps because there is an underlying decline in mobility in these patients. Gait speed offers a simple and sensitive measure of outcome.	WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	WADE, DT (corresponding author), RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442				ARMITAGE P, 1987, STATISTICAL METHODS; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BRADSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; BURNSIDE IG, 1982, ARCH PHYS MED REHAB, V63, P217; Chin P., 1982, ADV STROKE THERAPY, P197; Collen F M, 1991, Int Disabil Stud, V13, P50; Collen F M, 1991, Int Disabil Stud, V13, P12; Collen F M, 1990, Int Disabil Stud, V12, P6; Collin C, 1988, Int Disabil Stud, V10, P61; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P567; Corcoran P J, 1970, Arch Phys Med Rehabil, V51, P69; HELLER A, 1987, J NEUROL NEUROSUR PS, V50, P714, DOI 10.1136/jnnp.50.6.714; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; LEHMANN JF, 1975, ARCH PHYS MED REHAB, V56, P375; Lincoln N, 1979, Physiotherapy, V65, P48; May D, 1985, Int Rehabil Med, V7, P182; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P110; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; Stewart D., 1990, CLIN REHABIL, V4, P273, DOI 10.1177/026921559000400404; WADE D, 1987, SCANDINAVIAN J REHAB, V9, P25; Wade D T, 1985, Int Rehabil Med, V7, P176; Wade D.T., 1992, MEASUREMENT NEUROLOG, P78; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WOLFSON L, 1990, J GERONTOL, V45, pM12, DOI 10.1093/geronj/45.1.M12; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	26	174	181	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					609	613		10.1136/bmj.304.6827.609	http://dx.doi.org/10.1136/bmj.304.6827.609			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559090	Green Published, Bronze			2022-12-28	WOS:A1992HH73300023
J	SELVIN, PR; COOK, DN; PON, NG; BAUER, WR; KLEIN, MP; HEARST, JE				SELVIN, PR; COOK, DN; PON, NG; BAUER, WR; KLEIN, MP; HEARST, JE			TORSIONAL RIGIDITY OF POSITIVELY AND NEGATIVELY SUPERCOILED DNA	SCIENCE			English	Article							FLUORESCENCE DEPOLARIZATION; ESCHERICHIA-COLI; DEPENDENCE; PROTEIN; MACROMOLECULES; REQUIREMENT; DYNAMICS; REPEAT	Time-correlated single-photon counting of intercalated ethidium bromide was used to measure the torsion constants of positively supercoiled, relaxed, ana negatively supercoiled pBR322 DNA, which range in superhelix density from +0.042 to -0.123. DNA behaves as coupled, nonlinear torsional pendulums under superhelical stress, and the anharmonic term in the Hamiltonian is approximately 15 percent for root-mean-square fluctuations in twist at room temperature. At the level of secondary structure, positively supercoiled DNA is significantly more flexible than negatively supercoiled DNA. These results exclude certain models that account for differential binding affinity of proteins to positively and negatively supercoiled DNA.	UNIV CALIF BERKELEY,DEPT PHYS,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794	University of California System; University of California Berkeley; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	SELVIN, PR (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CHEM BIODYNAM LAB,BERKELEY,CA 94720, USA.				FDA HHS [FD 8R1 GM 41911A-03-NF-03/92] Funding Source: Medline	FDA HHS		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ALLISON SA, 1979, CHEM PHYS, V41, P35, DOI 10.1016/0301-0104(79)80131-7; ANDERSON P, 1978, BIOCHEMISTRY-US, V17, P594, DOI 10.1021/bi00597a006; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BAUER W, 1970, Journal of Molecular Biology, V47, P419, DOI 10.1016/0022-2836(70)90312-8; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FUJIMOTO BS, 1990, NATURE, V344, P175, DOI 10.1038/344175a0; HAHN S, 1986, J MOL BIOL, V188, P355, DOI 10.1016/0022-2836(86)90160-9; HOGAN M, 1979, BIOCHEMISTRY-US, V18, P280, DOI 10.1021/bi00569a007; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; HUNT NG, IN PRESS J CHEM PHYS; HURST JE, IN PRESS J CHEM PHYS; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; LIDE DR, 1990, CRC HDB CHEM PHYSICS; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILLAR DP, 1982, J CHEM PHYS, V76, P2080, DOI 10.1063/1.443182; SELVIN PR, 1990, THESIS U CALIFORNIA; SHIBATA JH, 1984, BIOCHEMISTRY-US, V23, P1188, DOI 10.1021/bi00301a025; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SONG L, 1990, J MOL BIOL, V214, P307, DOI 10.1016/0022-2836(90)90163-G; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; THOMAS JC, 1983, BIOCHEMISTRY-US, V22, P6194, DOI 10.1021/bi00295a024; WU PG, 1988, BIOCHEMISTRY-US, V27, P8128, DOI 10.1021/bi00421a023	30	59	59	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					82	85		10.1126/science.1553534	http://dx.doi.org/10.1126/science.1553534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553534				2022-12-28	WOS:A1992GX79100042
J	KATTWINKEL, N; VILLANUEVA, AG; LABIB, SB; ARETZ, HT; WALEK, JW; BURNS, DL; KLENZ, JT				KATTWINKEL, N; VILLANUEVA, AG; LABIB, SB; ARETZ, HT; WALEK, JW; BURNS, DL; KLENZ, JT			MYOCARDIAL-INFARCTION CAUSED BY CARDIAC MICROVASCULOPATHY IN A PATIENT WITH THE PRIMARY ANTIPHOSPHOLIPID SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; ANTIPHOSPHOLIPID SYNDROME; VASCULAR-DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMAPHERESIS	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIBODIES	Antiphospholipid antibodies occur in various clinical states, including the primary antiphospholipid syndrome. Clinical features in these conditions appear to be caused by vasculopathy associated with the presence of these antibodies. We report the case of a patient with primary antiphospholipid syndrome who experienced cardiac necrosis secondary to myocardial microvasculopathy in the absence of vasculitis. This case demonstrates unequivocally that noninflammatory myocardial microvasculopathy occurs in the primary antiphospholipid syndrome per se without any clinical or immunologic signs of systemic lupus erythematosus or other disease process. The histopathologic findings in the skin and myocardial biopsies showed a noninflammatory vasculopathy characterized by bland thrombi and lack of infiltration of the vessel wall by inflammatory cells. Ultrastructural examination of the myocardial biopsy confirmed the vascular thrombosis and endothelial activation and showed no deposits in basement membranes. The patient survived after appropriate treatment. Evidence presented here supports the concept that the vasculopathy in the antiphospholipid syndrome is distinct from other types of vascular occlusions seen in systemic lupus erythematosus. We suggest that myocardial biopsy can be crucial in showing an underlying myocardial ischemic process despite "normal" findings on coronary angiography. Results of the biopsy hastened the decision to use potentially lifesaving plasmapheresis and anticoagulation therapy in this patient.	NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA		KATTWINKEL, N (corresponding author), LAHEY CLIN MED CTR, RHEUMATOL SECT, 41 MALL RD, BURLINGTON, MA 01805 USA.							ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; ASHERSON RA, 1986, BRIT HEART J, V56, P190; ASHERSON RA, 1989, Q J MED, V73, P1103; BROWN JH, 1988, BRIT MED J, V296, P1505, DOI 10.1136/bmj.296.6635.1505; GREISMAN SG, 1991, ARCH INTERN MED, V151, P389, DOI 10.1001/archinte.151.2.389; KOCHENOUR NK, 1987, OBSTET GYNECOL, V69, P460; MAARAVI Y, 1989, ANN RHEUM DIS, V48, P853, DOI 10.1136/ard.48.10.853; MATTILA K, 1989, CLIN IMMUNOL IMMUNOP, V51, P414, DOI 10.1016/0090-1229(89)90039-1; MURPHY JJ, 1989, BRIT HEART J, V62, P61	9	57	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				974	976		10.7326/0003-4819-116-12-974	http://dx.doi.org/10.7326/0003-4819-116-12-974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586106				2022-12-28	WOS:A1992HY79300003
J	NUCKOLLS, JG				NUCKOLLS, JG			INTERNAL-MEDICINE PRACTICE IN TRANSITION - IMPLICATIONS FOR CURRICULUM CHANGES	ANNALS OF INTERNAL MEDICINE			English	Article							PRACTICE GUIDELINES	The curriculum for internal medicine needs to be changed to eliminate the dichotomy between training and practice. At the same time, changing medical needs and the actual conditions of medical practice must be taken into account. The new curriculum, at the very least, needs to emphasize the central position of general internists in health care delivery. To accomplish this, several subjects must be added to the curriculum, including additional training in ambulatory care, management of chronic disease, medical procedures, and the doctor-patient relationship. Learning to direct a coordinated health care team should also be included. A more definitive restructuring would require reorganizing medical centers around three major departments: primary care, subspecialty medicine, and surgery.			NUCKOLLS, JG (corresponding author), BLUE RIDGE HLTH ASSOCIATES INC, 199 HOSP DR, SUITE 5, GALAX, VA 24333 USA.							BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; 1988, INTERNAL MED NE 0601, V21; 1990, POLICY MANUAL 1990; 1989, FUTURE GENERAL INTER; 1988, PHYSICIAN CHARACTERI	6	16	16	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1051	1054		10.7326/0003-4819-116-12-1051	http://dx.doi.org/10.7326/0003-4819-116-12-1051			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586114				2022-12-28	WOS:A1992HY79400004
J	SIMON, TL; STEHLING, L				SIMON, TL; STEHLING, L			INDICATIONS FOR AUTOLOGOUS TRANSFUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SIMON, TL (corresponding author), UNITED BLOOD SERV,SCOTTSDALE,AZ, USA.							AuBuchon J P, 1989, Transfus Med Rev, V3, P290, DOI 10.1016/S0887-7963(89)70089-4; CREGAN P, 1991, TRANSFUSION, V31, P172, DOI 10.1046/j.1537-2995.1991.31291142950.x; 1988, JAMA-J AM MED ASSOC, V260, P2700	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573760				2022-12-28	WOS:A1992HT82300039
J	CIESIELSKI, C; MARIANOS, D; OU, CY; DUMBAUGH, R; WITTE, J; BERKELMAN, R; GOOCH, B; MYERS, G; LUO, CC; SCHOCHETMAN, G; HOWELL, J; LASCH, A; BELL, K; ECONOMOU, N; SCOTT, B; FURMAN, L; CURRAN, J; JAFFE, H				CIESIELSKI, C; MARIANOS, D; OU, CY; DUMBAUGH, R; WITTE, J; BERKELMAN, R; GOOCH, B; MYERS, G; LUO, CC; SCHOCHETMAN, G; HOWELL, J; LASCH, A; BELL, K; ECONOMOU, N; SCOTT, B; FURMAN, L; CURRAN, J; JAFFE, H			TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS IN A DENTAL PRACTICE	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HEALTH PERSONNEL; INFECTION CONTROL; DENTISTS; ACQUIRED IMMUNODEFICIENCY SYNDROME	HEPATITIS-B TRANSMISSION; ORAL SURGEON; OUTBREAK; TYPE-1; AIDS; PROFESSIONALS; INFECTION; BLOOD; RISK	Objective: To determine if patients of a dentist with the acquired immunodeficiency syndrome (AIDS) became infected with human immunodeficiency virus (HIV) during their dental care and, if so, to identify possible mechanisms of transmission. Design: Retrospective epidemiologic follow-up of the dentist, his office practice, and his former patients. Setting: The practice of a dentist with AIDS in Florida. Participants: A dentist with AIDS, his health care providers and employees, and former patients of the dentist, including eight HIV-infected patients. Measurements: Identification of risks for HIV transmission (if present), degree of genetic relatedness of the viruses, and identification of infection control and other office practices. Results: Five of the eight HIV-infected patients had no confirmed exposures to HIV other than the dental practice and were infected with HIV strains that were closely related to those of the dentist. Each of the five had invasive dental procedures, done by the dentist after he was diagnosed with AIDS. Four of these five patients shared visit days (P > 0.2). Breaches in infection control and other dental office practices to explain these transmissions could not be identified. Conclusion: Although the specific incident that resulted in HIV transmission to these patients remains uncertain, the epidemiologic evidence supports direct dentist-to-patient transmission rather than a patient-to-patient route.	CTR DIS CONTROL, NATL CTR PREVENT SERV, DIV ORAL HLTH, ATLANTA, GA 30333 USA; FLORIDA DEPT HLTH & REHAB SERV, W PALM BEACH, FL 33401 USA; FLORIDA DEPT HLTH & REHAB SERV, TALLAHASSEE, FL 32301 USA; UNIV CALIF LOS ALAMOS SCI LAB, LOS ALAMOS, NM 87545 USA	Centers for Disease Control & Prevention - USA; Florida Department of Health; Florida Department of Health; United States Department of Energy (DOE); Los Alamos National Laboratory	CIESIELSKI, C (corresponding author), CTR DIS CONTROL, DIV HIV AIDS, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							AHTONE J, 1983, J AM DENT ASSOC, V106, P219, DOI 10.14219/jada.archive.1983.0416; ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BURGER H, 1990, VACCINES 90, P255; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; CARL M, 1982, LANCET, V1, P731; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; Comer R W, 1991, J Dent Educ, V55, P187; COUTINHO RA, 1982, LANCET, V1, P345; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; FLOWER AJE, 1990, 1990 INT S VIR HEP L, P94; FLYNN NM, 1987, WESTERN J MED, V146, P439; GOODMAN RA, 1982, ANN INTERN MED, V96, P119, DOI 10.7326/0003-4819-96-1-119_1; GROB PJ, 1981, LANCET, V2, P1218; HADLER SC, 1981, ANN INTERN MED, V95, P133, DOI 10.7326/0003-4819-95-2-133; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LEVIN ML, 1974, JAMA-J AM MED ASSOC, V228, P1139, DOI 10.1001/jama.228.9.1139; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MATHE AA, 1980, LANCET, V1, P16; MILLER RG, 1988, AIDS NERVOUS SYSTEM, P65; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; MYERS G, 1990, HUMAN RETROVIRUSES A; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; OU CY, 1992, IN PRESS SCIENCE, P255; POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; REINGOLD AL, 1982, J INFECT DIS, V145, P262, DOI 10.1093/infdis/145.2.262; RIMLAND D, 1977, NEW ENGL J MED, V296, P953, DOI 10.1056/NEJM197704282961701; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SNYDMAN DR, 1976, ANN INTERN MED, V85, P573, DOI 10.7326/0003-4819-85-5-573; SO YT, 1988, ARCH NEUROL-CHICAGO, V45, P945, DOI 10.1001/archneur.1988.00520330023005; WELCH J, 1989, LANCET, V1, P205; 1987, J HOSP INFECT, V9, P34; 1988, REPORT PRESIDENTIAL, P33; 1987, MMWR, V36, P132; 1987, MMWR, V36, P1; 1986, MMWR, V35, P221; 1990, MMWR, V39, P489; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	49	183	187	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					798	805		10.7326/0003-4819-116-10-798	http://dx.doi.org/10.7326/0003-4819-116-10-798			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567094				2022-12-28	WOS:A1992HT80200003
J	HILL, TE				HILL, TE			THE ER INCIDENT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						EMERGENCY SERVICE HOSPITAL; PHYSICIAN-PATIENT RELATIONS; RACE RELATIONS; SOCIAL RESPONSIBILITY; HOSPITALS, URBAN		Several staff members of an inner city public hospital dressed up a homeless alcoholic and took him to a party. Because the patient was black and the staff members were white, the incident exploded in the news and prompted intense debate among housestaff. The working conditions and doctor-patient differences found in inner city training programs can induce cynicism in housestaff, as well as a sense of superiority that can be only partially explained by racism. The example of a British country practitioner struggling to achieve a intimacy with his patients illustrates the even greater challenge for physicians in troubled U.S. cities.	STANFORD UNIV, STANFORD, CA 94305 USA	Stanford University			Hill, Terry/W-1222-2019	Hill, Terry/0000-0002-6771-8813				Berger John, 1967, 7 UOMO; SUDNOW D, 1967, PASSING SOCIAL ORG D, P28	2	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					867	868		10.7326/0003-4819-116-10-867	http://dx.doi.org/10.7326/0003-4819-116-10-867			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567101				2022-12-28	WOS:A1992HT80200014
J	MAX, MB; LYNCH, SA; MUIR, J; SHOAF, SE; SMOLLER, B; DUBNER, R				MAX, MB; LYNCH, SA; MUIR, J; SHOAF, SE; SMOLLER, B; DUBNER, R			EFFECTS OF DESIPRAMINE, AMITRIPTYLINE, AND FLUOXETINE ON PAIN IN DIABETIC NEUROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELIEVES POSTHERPETIC NEURALGIA; DOUBLE-BLIND CROSSOVER; TOOTH-PULP SENSATIONS; RATIO SCALES; ANTIDEPRESSANTS; PHARMACOKINETICS; DESCRIPTORS; MECHANISMS; RECEPTORS; ANALGESIA	Background. Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions. Selective agents might be safer and more effective. Methods. We carried out two randomized, double-blind, crossover studies in patients with painful diabetic neuropathy, comparing amitriptyline with the relatively selective blocker of norepinephrine reuptake desipramine in 38 patients, and comparing the selective blocker of serotonin reuptake fluoxetine with placebo in 46 patients. Fifty-seven patients were randomly assigned to a study as well as to the order of treatment, permitting comparison among all three drugs and placebo as the first treatment. The patients rated the degree of pain present each day using verbal descriptors, and they also assessed the extent of pain relief globally at the end of each treatment period. Results. After individual dose titration, the mean daily doses of the drugs were as follows: amitriptyline, 105 mg; desipramine, 111 mg; and fluoxetine, 40 mg. There was moderate or greater relief of pain in 28 of the 38 patients (74 percent) who received amitriptyline, 23 of the 38 patients (61 percent) who received desipramine, 22 of the 46 patients (48 percent) who received fluoxetine, and 19 of the 46 patients (41 percent) who received placebo. The differences in responses between amitriptyline and desipramine and between fluoxetine and placebo were not statistically significant, but both amitriptyline and desipramine were superior to placebo. Amitriptyline and desipramine were as effective in patients who were not depressed as in depressed patients, but fluoxetine was effective only in depressed patients. Conclusions. Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter. Blockade of norepinephrine reuptake is likely to mediate the analgesic effect of these antidepressant drugs in diabetic neuropathy. Fluoxetine, which blocks serotonin uptake, is no more effective than placebo for the relief of pain.	NIAAA, CTR CLIN, DEPT NURSING, BETHESDA, MD USA; NIAAA, CLIN STUDIES LAB, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	MAX, MB (corresponding author), NIDR, NEUROBIOL & ANESTHESIOL BRANCH, PAIN RES CLIN, BLDG 10, RM 3C-405, BETHESDA, MD 20892 USA.							BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; BERGSTROM RF, 1988, BRIT J PSYCHIAT, V153, P47, DOI 10.1192/S0007125000297286; BESSON JM, 1990, SEP P INT S SER PAIN; BLACKWELL B, 1987, PSYCHIATRY UPDATE AM, V6, P724; DUBNER R, 1983, ANNU REV NEUROSCI, V6, P381, DOI 10.1146/annurev.ne.06.030183.002121; ESLER MD, 1991, AM J PHYSIOL, V260, pR817, DOI 10.1152/ajpregu.1991.260.4.R817; FIELDS HL, 1990, PAIN SYNDROMES NEURO; FULLER RW, 1991, MED RES REV, V11, P17, DOI 10.1002/med.2610110103; GHOSTINE SY, 1984, J NEUROSURG, V60, P1263, DOI 10.3171/jns.1984.60.6.1263; GOMEZPEREZ FJ, 1985, PAIN, V23, P395, DOI 10.1016/0304-3959(85)90010-7; GRACELY RH, 1978, PAIN, V5, P19, DOI 10.1016/0304-3959(78)90021-0; GRACELY RH, 1978, PAIN, V5, P5, DOI 10.1016/0304-3959(78)90020-9; GRACELY RH, 1979, SCIENCE, V203, P1261, DOI 10.1126/science.424753; GRACELY RH, 1982, ANESTH ANALG, V61, P751; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HEFT MW, 1980, PAIN, V9, P363, DOI 10.1016/0304-3959(80)90050-0; HEFT MW, 1984, J DENT RES, V63, P129, DOI 10.1177/00220345840630020601; KENNEY JT, 1989, CLIN CHEM, V35, P2134; KISHOREKUMAR R, 1990, CLIN PHARMACOL THER, V47, P305, DOI 10.1038/clpt.1990.33; KISHOREKUMAR R, 1989, PAIN, V37, P223, DOI 10.1016/0304-3959(89)90134-6; KVINESDAL B, 1984, JAMA-J AM MED ASSOC, V251, P1727, DOI 10.1001/jama.251.13.1727; LANGOHR HD, 1982, EUR NEUROL, V21, P309, DOI 10.1159/000115497; MAX MB, 1991, PAIN, V45, P3, DOI 10.1016/0304-3959(91)90157-S; MAX MB, 1988, NEUROLOGY, V38, P1427, DOI 10.1212/WNL.38.9.1427; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; MAX MB, 1991, ADV PAIN RES THER, V18, P55; MODELL W, 1958, JAMA-J AM MED ASSOC, V167, P2190, DOI 10.1001/jama.1958.72990350005006; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P116; POTTER WZ, 1984, ADV BIOCHEM PSYCHOPH, V39, P373; RICHELSON E, 1984, J PHARMACOL EXP THER, V230, P94; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; RICHELSON E, 1989, AM PSYCHIATRIC ASS T, V3, P1773; RUDORFER MV, 1987, PSYCHOPHARMACOLOGY 3, P1353; RUMORE MM, 1986, PAIN, V25, P7, DOI 10.1016/0304-3959(86)90004-7; SAGEN J, 1985, BRAIN RES, V331, P285, DOI 10.1016/0006-8993(85)91554-9; SHADER RI, 1989, COMPREHENSIVE TXB PS, P2037; SINDRUP SH, 1990, PAIN, V42, P135, DOI 10.1016/0304-3959(90)91157-E; WARD NG, 1990, MANAGEMENT PAIN, P310; WATSON CP, 1982, NEUROLOGY, V32, P671, DOI 10.1212/WNL.32.6.671; WATSON CPN, 1985, PAIN, V23, P387, DOI 10.1016/0304-3959(85)90009-0; WATSON CPN, 1992, PAIN, V48, P29, DOI 10.1016/0304-3959(92)90128-X; 1987, DIAGNOSTIC STATISTIC, V213, P33	42	808	832	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1250	1256		10.1056/NEJM199205073261904	http://dx.doi.org/10.1056/NEJM199205073261904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560801				2022-12-28	WOS:A1992HR44700004
J	ROTH, J; KEMPF, A; REUTER, G; SCHAUER, R; GEHRING, WJ				ROTH, J; KEMPF, A; REUTER, G; SCHAUER, R; GEHRING, WJ			OCCURRENCE OF SIALIC ACIDS IN DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; LIMAX-FLAVUS; WILMS TUMOR; GLYCOPROTEINS; LOCALIZATION; ANTIGENS; LECTIN	Sialylated oligosaccharides, which are cell type-specific and developmentally regulated, have been implicated in a variety of complex biological events. Their broad functional importance is reflected by their presence in a wide variety of phyla extending from Echinodermata through higher vertebrates. Here, sialic acids are detected throughout development in an insect, Drosophila. Homopolymers of alpha-2,8-linked sialic acid, polysialic acid, are developmentally regulated and only expressed during early Drosophila development.	UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; UNIV KIEL,INST BIOCHEM,W-2300 KIEL 1,GERMANY	University of Basel; University of Kiel								ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BERG EL, 1991, J BIOL CHEM, V266, P14869; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; DENNIS RD, 1988, J NEUROCHEM, V51, P1490, DOI 10.1111/j.1471-4159.1988.tb01116.x; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FINNE J, 1985, J BIOL CHEM, V260, P1265; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HALL AK, 1985, DEV BIOL, V110, P39, DOI 10.1016/0012-1606(85)90061-2; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFF SD, 1989, CANCER RES, V49, P6883; HUSMANN M, 1990, J HISTOCHEM CYTOCHEM, V38, P209, DOI 10.1177/38.2.1688896; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; KRAUSS JH, 1988, ARCH MICROBIOL, V150, P584, DOI 10.1007/BF00408254; LACKIE PM, 1990, DEVELOPMENT, V110, P933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; MCKRAKEN GH, 1974, LANCET, V2, P246; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MOMOI T, 1986, J BIOL CHEM, V261, P6270; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NORJIRI H, 1986, P NATL ACAD SCI USA, V83, P782; NUDELMAN ED, 1989, J BIOL CHEM, V264, P18719; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; REUTER G, 1986, ANAL BIOCHEM, V157, P39, DOI 10.1016/0003-2697(86)90193-4; ROGERS GN, 1985, J BIOL CHEM, V260, P7362; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; ROTH J, 1984, J HISTOCHEM CYTOCHEM, V32, P1167, DOI 10.1177/32.11.6208237; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SHUKLA AK, 1982, J CHROMATOGR, V244, P81, DOI 10.1016/S0021-9673(00)80124-7; SILVER RP, 1981, NATURE, V289, P696, DOI 10.1038/289696b0; TAATJES DJ, 1987, HISTOCHEM J, V19, P235, DOI 10.1007/BF01680634; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357	50	146	147	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					673	675		10.1126/science.1585182	http://dx.doi.org/10.1126/science.1585182			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585182				2022-12-28	WOS:A1992HR18500035
J	STOLLEY, PD; LASKY, T				STOLLEY, PD; LASKY, T			FIBIGER,JOHANNES AND HIS NOBEL-PRIZE FOR THE HYPOTHESIS THAT A WORM CAUSES STOMACH-CANCER	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						HISTORY OF MEDICINE; STOMACH NEOPLASMS; NEMATODE INFECTIONS; NOBEL PRIZE; RESEARCH DESIGN		The 1926 Nobel Prize was awarded to Johannes Fibiger for his research linking a nematode to stomach cancer. His research was contested as early as 1918 but was finally refuted in 1937. Fibiger was a competent and well-regarded scientist; nonetheless, undeveloped research methods and an inadequate knowledge base permitted the scientific community to mistake the importance of his findings.			STOLLEY, PD (corresponding author), UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, 660 W REDWOOD ST, BALTIMORE, MD 21201 USA.		Lasky, Tamar/AAR-3410-2021					BULLOCK FD, 1918, J CANC RES, V3, P227; CLEMMESEN J, 1978, ACTA PATHOL MICROB S, V270, P1; CRAMER W., 1937, American Journal of Cancer, V31, P537; DAINTITH J, 1981, BIOGRAPHICAL ENCY SC, P261; Fibiger J., 1919, J CANCER RES CLIN, V4, P367; FIBIGER J, 1965, PHYSL MED, P122; Goldblatt H, 1927, J EXP MED, V46, P699, DOI 10.1084/jem.46.5.699; HITCHCOCK CR, 1952, JNCI-J NATL CANCER I, V12, P1345; Pappenheimer AM, 1924, J EXP MED, V40, P719, DOI 10.1084/jem.40.6.719; Passey RD, 1936, J PATHOL BACTERIOL, V42, P425, DOI 10.1002/path.1700420209; Ruffer MA, 1911, J PATHOL BACTERIOL, V15, P1, DOI 10.1002/path.1700150102; SECHER K, 1947, DANISH CANCER RES J; Sjoquist J, 1965, PHYSL MED, P47; WERNSTEDT W, 1965, PHYSL MED, P119; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	15	22	23	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					765	769		10.7326/0003-4819-116-9-765	http://dx.doi.org/10.7326/0003-4819-116-9-765			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558350				2022-12-28	WOS:A1992HQ62300012
J	HANCOCK, BD				HANCOCK, BD			ABC OF COLORECTAL DISEASES - HEMORRHOIDS	BRITISH MEDICAL JOURNAL			English	Article											HANCOCK, BD (corresponding author), WYTHENSHAWE HOSP,MANCHESTER,ENGLAND.								0	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1042	1044		10.1136/bmj.304.6833.1042	http://dx.doi.org/10.1136/bmj.304.6833.1042			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586792	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200028
J	HYNES, RO				HYNES, RO			INTEGRINS - VERSATILITY, MODULATION, AND SIGNALING IN CELL-ADHESION	CELL			English	Review							PLATELET GLYCOPROTEIN-IIB; FIBRONECTIN RECEPTOR COMPLEX; CHICKEN-EMBRYO FIBROBLASTS; SITE-DIRECTED MUTAGENESIS; CULTURED HUMAN-MONOCYTES; AMINO-ACID-SEQUENCE; LEUKOCYTE ADHESION; CYTOPLASMIC DOMAIN; BETA-SUBUNIT; MONOCLONAL-ANTIBODY		MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	HYNES, RO (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.							ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BODARY S C, 1991, Journal of Cell Biology, V115, p289A; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BRAY PF, 1990, J BIOL CHEM, V265, P9587; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; BURKLY LC, 1991, EUR J IMMUNOL, V21, P2871, DOI 10.1002/eji.1830211132; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUSK M, 1992, IN PRESS J BIOL CHEM; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BUYON JP, 1990, J IMMUNOL, V144, P191; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1991, J IMMUNOL, V147, P398; CHAN BMC, 1992, IN PRESS J BIOL CHEM; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DAVIS LS, 1990, J IMMUNOL, V145, P785; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FERREIRA OC, 1991, EXP CELL RES, V193, P20, DOI 10.1016/0014-4827(91)90533-Z; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRELINGER AL, 1990, J BIOL CHEM, V104, P1655; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GULINO D, 1990, J BIOL CHEM, V265, P9575; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HORVATH AR, 1990, ONCOGENE, V5, P1349; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KELLY T, 1987, J BIOL CHEM, V262, P17189; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LASKY LA, 1992, IN PRESS INFLAMMATIO; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MANNING DR, 1991, THROMB HAEMOSTASIS, V66, P393; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; ROBERTS K, 1991, J EXP MED, V173, P231, DOI 10.1084/jem.173.1.231; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUEGG C, 1992, IN PRESS J CELL BIOL; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SADOUL JL, 1985, BIOCHEM J, V227, P887, DOI 10.1042/bj2270887; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; SCHWARTZ MA, 1990, ONCOGENE, V5, P55; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SONG WK, 1992, IN PRESS J CELL BIOL; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SPORN SA, 1990, J IMMUNOL, V144, P4434; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SUZUKI S, 1990, P NATL ACAD SCI USA, V87, P5354, DOI 10.1073/pnas.87.14.5354; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TAPLEY P, 1989, ONCOGENE, V4, P325; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VALMU L, 1991, EUR J IMMUNOL, V21, P2857, DOI 10.1002/eji.1830211130; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; WOODS A, 1988, EXP CELL RES, V177, P272, DOI 10.1016/0014-4827(88)90461-2; WRIGHT SD, 1984, J CELL BIOL, V99, P336, DOI 10.1083/jcb.99.1.336; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YAMADA A, 1991, J IMMUNOL, V146, P53; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1991, BIOCHEM BIOPH RES CO, V176, P1443, DOI 10.1016/0006-291X(91)90448-G	179	9354	9679	10	644	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					11	25		10.1016/0092-8674(92)90115-S	http://dx.doi.org/10.1016/0092-8674(92)90115-S			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555235				2022-12-28	WOS:A1992HM44500003
J	WINDERICKX, J; LINDSEY, DT; SANOCKI, E; TELLER, DY; MOTULSKY, AG; DEEB, SS				WINDERICKX, J; LINDSEY, DT; SANOCKI, E; TELLER, DY; MOTULSKY, AG; DEEB, SS			POLYMORPHISM IN RED PHOTOPIGMENT UNDERLIES VARIATION IN COLOR MATCHING	NATURE			English	Article							MOLECULAR-GENETICS; VISION; PIGMENTS; CONE	GENETIC variation of human senses within the normal range probably exists but usually cannot be investigated in detail for lack of appropriate methods. The study of subtle perceptual differences in red-green colour vision is feasible since both photopigment genotypes and psychophysical phenotypes can be assessed by sophisticated techniques. Red-green colour vision in humans is mediated by two different visual pigments: red (long-wavelength sensitive) and green (middle-wavelength sensitive). The apoproteins of these highly homologous photopigments are encoded by genes on the X chromosome 1. Colour matches of males with normal colour vision fall into two main groups that appear to be transmitted by X-linked inheritance 2-6. This difference in colour matching is likely to reflect small variations in the absorption maxima of visual pigments 7-11, suggesting the presence of two common variants of the red and/or green visual pigments that differ in spectral positioning 5,6. We report that a common single amino-acid polymorphism (62% Ser, 38% Ala) at residue 180 of the X-linked red visual pigment explains the finding of two major groups in the distribution of colour matching among males with normal colour vision.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHYSIOL BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ALPERN M, 1979, J PHYSIOL-LONDON, V288, P85; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P647, DOI 10.1113/jphysiol.1977.sp011786; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; EISNER A, 1981, J OPT SOC AM, V71, P705, DOI 10.1364/JOSA.71.000705; EISNER AE, 1987, J OPT SOC AM, V4, pP123; LUTZE M, 1990, VISION RES, V30, P149, DOI 10.1016/0042-6989(90)90134-7; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POKORNY J, 1989, DOC OPHTHALMOL, V52, P512; SMITH VC, 1976, VISION RES, V16, P1087, DOI 10.1016/0042-6989(76)90247-9; Stiles W. S., 1959, OPT ACTA, V6, P1, DOI [10.1080/713826267, DOI 10.1080/713826267]; WAALER GHM, 1967, NATURE, V215, P406, DOI 10.1038/215406a0	20	159	161	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					431	433		10.1038/356431a0	http://dx.doi.org/10.1038/356431a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557123				2022-12-28	WOS:A1992HL83000062
J	GARDINI, A				GARDINI, A			DEVELOPMENT OF QUALITY ASSURANCE IN ITALY	BRITISH MEDICAL JOURNAL			English	Article																		ALBERTI V, 1990, QA, V5, P51; DIANA L, 1990, QA, V1, P33; LIVA C, 1985, EUROPEAN NEWSLETTER, V2, P5; MARCHI AG, 1988, QA, V1, P36; PERRARO F, 1988, QA, V2, P96; SELLE V, 1990, QA, V3, P11; SIRCHIA G, 1989, QA, V1, P49; 1988, QUALITY ASSURANCE HL, V1, P97	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					703	705		10.1136/bmj.304.6828.703	http://dx.doi.org/10.1136/bmj.304.6828.703			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571649	Green Published, Bronze			2022-12-28	WOS:A1992HK76100032
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - PRIVATE INSURANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		BARER ML, 1992, HEALTH AFFAIR, V11, P44, DOI 10.1377/hlthaff.11.1.44; DANZON PM, 1992, HEALTH AFFAIR, V11, P21, DOI 10.1377/hlthaff.11.1.21; ETHEREDGE L, 1991, HEALTH AFFAIR, V10, P93, DOI 10.1377/hlthaff.10.4.93; FREUDENHEIM M, 1990, NY TIMES        0205, pPA1; GABEL J, 1991, HEALTH AFFAIR, V10, P48, DOI 10.1377/hlthaff.10.4.48; HALL MA, 1992, NEW ENGL J MED, V326, P565, DOI 10.1056/NEJM199202203260812; HELMS WD, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.2.7; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; Law Sylvia, 1974, BLUE CROSS WHAT WENT; Levit K R, 1991, Health Care Financ Rev, V13, P83; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; MCLAUGHLIN CG, 1992, HEALTH AFFAIR, V11, P28, DOI 10.1377/hlthaff.11.2.28; MEYER JA, 1991, UNPUB NATIONAL PLAN; PEAR R, 1991, NY TIMES        1127, pPA1; SHEILS JF, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.1.7; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; THORPE KE, 1992, JAMA-J AM MED ASSOC, V267, P945, DOI 10.1001/jama.267.7.945; WINSLOW R, 1992, WALL STREET J   0406, pPR14; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; WOOLSEY C, 1992, BUSINESS INSURA 0127, pP3; ZELLERS WK, 1992, HEALTH AFFAIR, V11, P174, DOI 10.1377/hlthaff.11.1.174; 1988, GPO85568 LIB C C RES; 1992, HMO FACT SHEET; 1992, PHYSICIAN PAYMENT RE; 1990, CRITICAL DISTINCTION; 1992, S PS LIFE HLTH INSUR; 1992, GAOGGD9244 GEN ACC O; 1991, GAOHRD9190 GEN ACC O	30	22	22	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1715	1720		10.1056/NEJM199206183262526	http://dx.doi.org/10.1056/NEJM199206183262526			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588998				2022-12-28	WOS:A1992HY62800033
J	THOMPSON, JS; HAIST, SA; DESIMONE, PA; ENGELBERG, J; RICH, EC				THOMPSON, JS; HAIST, SA; DESIMONE, PA; ENGELBERG, J; RICH, EC			THE ACCELERATED INTERNAL-MEDICINE PROGRAM AT THE UNIVERSITY-OF-KENTUCKY	ANNALS OF INTERNAL MEDICINE			English	Article							RESIDENCY	Concern is growing about the ability of categorical medicine residency programs, structured within academic health centers, to provide balanced, progressive, postgraduate internal medicine education. Detrimental factors, including over-representation of critically ill patients, shortened length of hospitalization, stress, discontinuity between undergraduate and graduate training, rotational assignments driven by hospital service imperatives, and total costs, may all negatively affect internal medicine residency education. Therefore, an experimental accelerated internal medicine (AIM) curriculum combining 3 years of undergraduate with 3 years of graduate internal medicine education has been initiated by the Department of Medicine and the College of Medicine at the University of Kentucky. After completion of the third year and during the first 13 months of the AIM curriculum, selected students are rotated through an integrated series of educational experiences that incorporate all of the requirements for graduation from medical school and progressively advance the students' skills, knowledge, and responsibilities to that of a second-year resident. Thereafter, the curriculum is similar to that of the categorical residents, except that more ambulatory care and off-site rotations are interspersed to better provide the educational experiences representative of the practice of internal medicine. Evaluations of the first groups of AIM residents indicate that their performance has equaled that of the control residents who graduated after 4 years from the College of Medicine. Furthermore, the AIM residents report general acceptance by their fellow residents and attending physicians and report no undue stress in making the transition.	VET ADM MED CTR, LEXINGTON, KY 40511 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	THOMPSON, JS (corresponding author), UNIV KENTUCKY, COLL MED, 800 ROSE ST, LEXINGTON, KY 40506 USA.							BUTTERFIELD PS, 1988, ARCH INTERN MED, V148, P1428, DOI 10.1001/archinte.148.6.1428; EBERT RH, 1988, HEALTH AFFAIR, V7, P5, DOI 10.1377/hlthaff.7.2.5; JOHNSON JE, 1986, ARCH INTERN MED, V146, P937, DOI 10.1001/archinte.146.5.937; MANDEL JH, 1988, ARCH INTERN MED, V148, P853, DOI 10.1001/archinte.148.4.853; REUBEN DB, 1988, ARCH INTERN MED, V148, P914, DOI 10.1001/archinte.148.4.914; SCHROEDER S A, 1988, Journal of General Internal Medicine, V3, pS5, DOI 10.1007/BF02600247; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; 1988, ANN INTERN MED, V108, P139	9	10	10	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1084	1087		10.7326/0003-4819-116-12-1084	http://dx.doi.org/10.7326/0003-4819-116-12-1084			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586122				2022-12-28	WOS:A1992HY79400012
J	DOOLEY, SW; VILLARINO, ME; LAWRENCE, M; SALINAS, L; AMIL, S; RULLAN, JV; JARVIS, WR; BLOCH, AB; CAUTHEN, GM				DOOLEY, SW; VILLARINO, ME; LAWRENCE, M; SALINAS, L; AMIL, S; RULLAN, JV; JARVIS, WR; BLOCH, AB; CAUTHEN, GM			NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS IN A HOSPITAL UNIT FOR HIV-INFECTED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							EPIDEMIC	Objective. - To assess nosocomial transmission of tuberculosis (TB). Design. - A historical cohort study of hospitalized patients with the human immunodeficiency virus (HIV) and a purified protein derivative (PPD) tuberculin skin test survey of health care workers (HCWs). Setting. - A large public teaching hospital in San Juan, Puerto Rico. Patients. - For the cohort study, a case patient was defined as any patient in the HIV unit at the hospital who developed culture-positive TB from 31 days or more after admission through December 31, 1989. For the PPD survey, of 1420 HCWs from the hospital, 908 agreed to participate and had sufficient data for analysis. Main Outcome Measures. - For the cohort study, to compare the risk of developing active TB among patients who were exposed to hospital roommates with infectious TB and the risk among nonexposed patients. For the HCW PPD survey, to determine the prevalence of and risk factors for tuberculous infection. Results. - Eight of 48 (9.7/10 000 person-days) exposed case patients vs four of 192 (0.8/10 000 person-days) nonexposed case patients developed active TB (relative risk [RR] = 11; 95% confidence interval [Cl], 2.3, 50.3). Positive PPDs (greater-than-or-equal-to 10 mm of induration) in HCWs were associated with older age (P = .0001) and with history of community TB exposure (P = .0002). In a multivariable logistic model that adjusted for these variables, HIV unit nurses (nine of 19) and nurses in the internal medicine ward (45 of 90) had a higher proportion of positive PPDs than the reference group (clerical personnel on other floors: 35 of 188, P = .0005). Conclusions. - These data suggest that patient-to-patient transmission of TB in HIV units can occur and that HCWs are at risk of acquiring TB infection.	HOSPITAL MUNICIPAL,SAN JUAN,PR; CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	DOOLEY, SW (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,MAILSTOP E-10,ATLANTA,GA 30333, USA.							CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; Kent PT, 1985, GUIDE LEVEL 3 LAB; 1985, SAS USERS GUIDE STAT; 1991, MMWR, V40, P585; 1990, MMWR, V39, P1	10	197	203	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2632	2634		10.1001/jama.267.19.2632	http://dx.doi.org/10.1001/jama.267.19.2632			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573751				2022-12-28	WOS:A1992HT82300031
J	POOLEWILSON, PA; LINDSAY, D				POOLEWILSON, PA; LINDSAY, D			ADVANCES IN THE TREATMENT OF CHRONIC HEART-FAILURE	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							THERAPY; DIGOXIN				POOLEWILSON, PA (corresponding author), ROYAL BROMPTON HOSP, NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND.							COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; KLEBER FX, 1992, BRIT HEART J, V67, P289; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PARAMESHWAR J, IN PRESS BR J GEN PR; PARAMESHWAR J, IN PRESS J R COLL PH; Poole-Wilson PA, 1989, DIS HEART, P24; POOLEWILSON PA, 1989, CARDIOVASC DRUG THER, V2, P733, DOI 10.1007/BF00133201; RICHARDSON A, 1987, LANCET, V2, P709; SMITH WM, 1985, AM J CARDIOL, V55, pA3, DOI 10.1016/0002-9149(85)90789-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1990, AM J CARDIOL, V66, P313	14	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1992	304	6834					1069	1070		10.1136/bmj.304.6834.1069	http://dx.doi.org/10.1136/bmj.304.6834.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586817	Bronze, Green Published			2022-12-28	WOS:A1992HR13600006
J	WETZLER, M; TALPAZ, M; KELLAGHER, MJ; GUTTERMAN, JY; KURZROCK, R				WETZLER, M; TALPAZ, M; KELLAGHER, MJ; GUTTERMAN, JY; KURZROCK, R			MYELOKATHEXIS - NORMALIZATION OF NEUTROPHIL COUNTS AND MORPHOLOGY BY GM-CSF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COLONY-STIMULATING FACTOR; MONOCYTES; ADHESION		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,BOX 41,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Kurzrock, Razelle/AAU-9782-2020	Talpaz, Moshe/0000-0003-3361-3981				BISHOP CR, 1968, J CLIN INVEST, V47, P249, DOI 10.1172/JCI105721; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; ELLIOTT MJ, 1990, J IMMUNOL, V145, P167; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; KRILL CE, 1964, NEW ENGL J MED, V270, P973, DOI 10.1056/NEJM196405072701902; SISSON SD, 1988, BLOOD, V72, P1368; WETZLER M, 1990, AM J MED, V89, P663, DOI 10.1016/0002-9343(90)90187-I; ZUELZER WW, 1964, NEW ENGL J MED, V270, P699, DOI 10.1056/NEJM196404022701402	9	29	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2179	2180		10.1001/jama.267.16.2179	http://dx.doi.org/10.1001/jama.267.16.2179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556785				2022-12-28	WOS:A1992HN84100010
J	MACKIE, RM; HOLE, D				MACKIE, RM; HOLE, D			AUDIT OF PUBLIC-EDUCATION CAMPAIGN TO ENCOURAGE EARLIER DETECTION OF MALIGNANT-MELANOMA	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To evaluate a public campaign to encourage earlier referral and treatment of primary cutaneous malignant melanoma and thus reduce mortality related to melanoma. Design - Production and distribution of educational material aimed at adults. Update information sent to general practitioners before campaign. Analysis of data on melanoma before and after campaign in June 1985. Setting - West of Scotland, population 2.7 million. Main outcome measures - Total numbers of referrals per month to melanoma clinic, numbers of melanomas diagnosed, change in distribution of thickness, and mortality before and after introducing the campaign. Results - Referrals to the pigmented lesion clinic increased by 278%, from five a week in June-July 1984 to 19 a week in June-July 1985. Twice as many women as men were referred to the clinic (49% of referrals were of women aged under 65). The numbers of newly diagnosed primary cutaneous melanoma were 63 (12/month) in January-May 1985 and 146 (21/month) in June-December 1985, an increase of 131%. The percentage of tumours detected that were less than 1.5 mm thick rose significantly by 16% (95% confidence interval 11% to 19%), from 38% (328) in 1979-84 to 54% (592) in 1985-9. Mortality began to fall in women from 1988. Conclusions - The public education campaign succeeded in reducing the absolute number of thick tumours and melanoma related mortality in women.	GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW,SCOTLAND		MACKIE, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND.							Cox DR., 1970, ANAL BINARY DATA; DOHERTY VR, 1986, BRIT MED J, V292, P987, DOI 10.1136/bmj.292.6526.987; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; FIELD SI, 1987, J AM ACAD DERMATOL, V16, P578, DOI 10.1016/S0190-9622(87)70077-2; MACKIE RM, IN PRESS LANCET; MCLEOD GR, 1988, PIGMENT CELL, V9, P131; SMITH T, 1979, BRIT MED J, V1, P253, DOI 10.1136/bmj.1.6158.253	7	166	167	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1012	1015		10.1136/bmj.304.6833.1012	http://dx.doi.org/10.1136/bmj.304.6833.1012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586781	Green Published			2022-12-28	WOS:A1992HQ14200017
J	DECLUE, JE; PAPAGEORGE, AG; FLETCHER, JA; DIEHL, SR; RATNER, N; VASS, WC; LOWY, DR				DECLUE, JE; PAPAGEORGE, AG; FLETCHER, JA; DIEHL, SR; RATNER, N; VASS, WC; LOWY, DR			ABNORMAL REGULATION OF MAMMALIAN P21(RAS) CONTRIBUTES TO MALIGNANT-TUMOR GROWTH IN VONRECKLINGHAUSEN (TYPE-1) NEUROFIBROMATOSIS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; RAS P21; SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDE; SCHWANN-CELLS; GENE-PRODUCT; GAP; DOMAIN; MUTATIONS; BINDING	Tumor cell lines derived from malignant schwannomas removed from patients with neurofibromatosis type 1 (NF1) have been examined for the level of expression of NF1 protein. All three NF1 lines examined expressed lower levels of NF1 protein than control cells, and the level in one line was barely detectable. The tumor lines expressed normal levels of p120GAP and p21ras. Although the p21ras proteins isolated from the tumor cells had normal (nonmutant) biochemical properties in vitro, they displayed elevated levels of bound GTP in vivo. The level of total cellular GAP-like activity was reduced in extracts from the tumor line that expresses very little NF1 protein. Introduction of the catalytic region of GAP into this line resulted in morphological reversion and lower in vivo GTP binding by endogenous p21ras. These data implicate NF1 protein as a tumor suppressor gene product that negatively regulates p21ras and define a "positive" growth role for ras activity in NF1 malignancies.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PSYCHIAT, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT HUMAN GENET, RICHMOND, VA 23298 USA; UNIV CINCINNATI, COLL MED, DEPT ANAT & CELL BIOL, CINCINNATI, OH 45267 USA	Harvard University; Brigham & Women's Hospital; Virginia Commonwealth University; Virginia Commonwealth University; University System of Ohio; University of Cincinnati	DECLUE, JE (corresponding author), NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA.			RATNER, NANCY/0000-0001-5030-9354	NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, CANCER RES, V51, P712; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DER CJ, 1988, ONCOGENE, V3, P105; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	58	508	518	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					265	273		10.1016/0092-8674(92)90407-4	http://dx.doi.org/10.1016/0092-8674(92)90407-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568246				2022-12-28	WOS:A1992HQ18300006
J	LECHLEITER, JD; CLAPHAM, DE				LECHLEITER, JD; CLAPHAM, DE			MOLECULAR MECHANISMS OF INTRACELLULAR CALCIUM EXCITABILITY IN X-LAEVIS OOCYTES	CELL			English	Article							INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; XENOPUS-OOCYTES; MUSCLE-CELLS; RELEASE; CA-2+; WAVE; PROPAGATION; ACTIVATION; EGGS	Following receptor activation in Xenopus ooctyes, spiral waves of intracellular Ca2+ release were observed. We have identified key molecular elements in the pathway that give rise to Ca2+ excitability. The patterns of Ca2+ release produced by GTP-gamma-S and by inositol 1,4,5-trisphosphate (IP3) are indistinguishable from receptor-induced Ca2+ patterns. The regenerative Ca2+ activity is critically dependent on the presence of IP3 and on the concentration of intracellular Ca2+, but is independent of extracellular Ca2+. Broad regions of the intracellular milieu can be synchronously excited to initiate Ca2+ waves and produce pulsating foci of Ca2+ release. By testing the temperature dependence of wavefront propagation, we provide evidence for an underlying process limited by diffusion, consistent with the elementary theory of excitable media. We propose a model for intracellular Ca2+ signaling in which wave propagation is controlled by IP3-mediated Ca2+ release from internal stores, but is modulated by the cytoplasmic concentration and diffusion of Ca2+.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BERRIDGE M J, 1991, Current Biology, V1, P296, DOI 10.1016/0960-9822(91)90089-F; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLITON C, 1992, IN PRESS J MICROSC; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P97, DOI 10.1016/0143-4160(91)90012-4; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; DOCKERY JD, 1988, PHYSICA D, V30, P177, DOI 10.1016/0167-2789(88)90105-4; DUPONT G, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P461; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOERSTER P, 1989, P NATL ACAD SCI USA, V86, P6831, DOI 10.1073/pnas.86.18.6831; GIRARD S, 1992, IN PRESS BIOPHYS J; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; GURNEY AM, 1987, P NATL ACAD SCI USA, V84, P3496, DOI 10.1073/pnas.84.10.3496; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; KEENER JP, 1986, SIAM J APPL MATH, V46, P1039, DOI 10.1137/0146062; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MILLER RN, 1981, BIOPHYS J, V34, P227, DOI 10.1016/S0006-3495(81)84847-3; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; Segel IH, 1976, BIOCH CALCULATIONS; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1991, NEW BIOL, V3, P3; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Winfree A.T., 1987, TIME BREAKS 3 DIMENS; Winfree A. T., 1990, APPL MECH REV, V43, P297; WINFREE AT, 1980, GEOMETRY BIOL TIME, P246; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0; Zykov V. S., 1980, Biophysics, V25, P906	49	335	341	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					283	294		10.1016/0092-8674(92)90409-6	http://dx.doi.org/10.1016/0092-8674(92)90409-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568248				2022-12-28	WOS:A1992HQ18300008
J	MARMORSTEIN, R; CAREY, M; PTASHNE, M; HARRISON, SC				MARMORSTEIN, R; CAREY, M; PTASHNE, M; HARRISON, SC			DNA RECOGNITION BY GAL4 - STRUCTURE OF A PROTEIN DNA COMPLEX	NATURE			English	Article							REQUIRES SEQUENCES ADJACENT; ZINC FINGER; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; BINDING DOMAIN; KLUYVEROMYCES-LACTIS; AMINO-ACIDS; MACROMOLECULAR STRUCTURES; ASPERGILLUS-NIDULANS; NUCLEOTIDE-SEQUENCE	A specific DNA complex of the 65-residue, N-terminal fragment of the yeast transcriptional activator, GAL4, has been analysed at 2.7 angstrom resolution by X-ray crystallography. The protein binds as a dimer to a symmetrical 17-base-pair sequence. A small, Zn2+-containing domain recognizes a conserved CCG triplet at each end of the site through direct contacts with the major groove. A short coiled-coil dimerization element imposes 2-fold symmetry. A segment of extended polypeptide chain links the metal-binding module to the dimerization element and specifies the length of the site. The relatively open structure of the complex would allow another protein to bind coordinately with GAL4.	HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Howard Hughes Medical Institute	MARMORSTEIN, R (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.			Carey, Michael/0000-0003-3899-6280				ANDRIANOPOULOS A, 1990, MOL CELL BIOL, V10, P3194, DOI 10.1128/MCB.10.6.3194; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BALZI E, 1987, J BIOL CHEM, V262, P16871; BAUM JA, 1987, MOL CELL BIOL, V7, P1256, DOI 10.1128/MCB.7.3.1256; BERI RK, 1987, NUCLEIC ACIDS RES, V15, P7991, DOI 10.1093/nar/15.19.7991; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR MANUAL; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; DICKERSON R E, 1990, P1; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOPPER JE, 1978, P NATL ACAD SCI USA, V75, P2878, DOI 10.1073/pnas.75.6.2878; JOHNSTON M, 1988, GENETICS, V120, P63; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KIM J, 1988, CURR GENET, V14, P319, DOI 10.1007/BF00419988; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARCZAK JE, 1991, MOL CELL BIOL, V11, P2609, DOI 10.1128/MCB.11.5.2609; MESSENGUY F, 1986, EUR J BIOCHEM, V157, P77, DOI 10.1111/j.1432-1033.1986.tb09640.x; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PAN T, 1990, J BIOL CHEM, V265, P21427; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; SALMERON JM, 1990, GENETICS, V125, P21; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VASAK M, 1987, J MOL BIOL, V196, P711, DOI 10.1016/0022-2836(87)90042-8; WITTE MM, 1990, MOL CELL BIOL, V10, P5128, DOI 10.1128/MCB.10.10.5128; WITTE MM, 1988, MOL CELL BIOL, V8, P3726, DOI 10.1128/MCB.8.9.3726; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WRAY LV, 1987, MOL GEN GENET, V125, P139; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261	63	567	595	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					408	414		10.1038/356408a0	http://dx.doi.org/10.1038/356408a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557122				2022-12-28	WOS:A1992HL83000054
J	SCHOPPA, NE; MCCORMACK, K; TANOUYE, MA; SIGWORTH, FJ				SCHOPPA, NE; MCCORMACK, K; TANOUYE, MA; SIGWORTH, FJ			THE SIZE OF GATING CHARGE IN WILD-TYPE AND MUTANT SHAKER POTASSIUM CHANNELS	SCIENCE			English	Article							SQUID GIANT-AXON; SODIUM-CHANNEL; K+ CHANNELS; CURRENTS; DROSOPHILA; INACTIVATION; ACTIVATION; CDNA; LOCUS; GENE	The high sensitivity of voltage-gated ion channels to changes in membrane potential implies that the process of channel opening is accompanied by large charge movements. Previous estimates of the total charge displacement, q, have been deduced from the voltage dependence of channel activation and have ranged from 4 to 8 elementary charges (e0). A more direct measurement of q in Drosophila melanogaster Shaker 29-4 potassium channels yields a q value of 12.3 e0. A similar q value is obtained from mutated Shaker channels having reduced voltage sensitivity. These results can be explained by a model for channel activation in which the equilibria of voltage-dependent steps are altered in the mutant channels.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; UNIV CALIF BERKELEY,DEPT ENTOMOL,BERKELEY,CA 94720	Yale University; University of California System; University of California Berkeley								Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BEZANILLA F, 1982, NATURE, V296, P657, DOI 10.1038/296657a0; CONTI F, 1984, EUR BIOPHYS J BIOPHY, V11, P137, DOI 10.1007/BF00276629; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IVERSON LE, 1990, J NEUROSCI, V10, P2903; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KEYNES RD, 1974, J PHYSIOL-LONDON, V239, P393, DOI 10.1113/jphysiol.1974.sp010575; KOREN G, 1990, NEURON, V2, P39; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MEVES H, 1974, J PHYSIOL-LONDON, V243, P847, DOI 10.1113/jphysiol.1974.sp010780; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NONNER W, 1975, PFLUEGERS ARCH, V375, P75; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; SCHAUF CL, 1986, ION CHANNELS NEURAL, P3; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SPIRES S, 1989, J GEN PHYSIOL, V93, P263, DOI 10.1085/jgp.93.2.263; STRUHMER W, 1991, PFLUEGERS ARCH, V418, P423; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; WHITE MM, 1985, J GEN PHYSIOL, V85, P539, DOI 10.1085/jgp.85.4.539; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	29	371	377	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1712	1715		10.1126/science.1553560	http://dx.doi.org/10.1126/science.1553560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553560				2022-12-28	WOS:A1992HK81200041
J	GORDON, CR; SPITZER, O; SHUPAK, A; DOWECK, I				GORDON, CR; SPITZER, O; SHUPAK, A; DOWECK, I			SURVEY OF MAL DE DEBARQUEMENT	BRITISH MEDICAL JOURNAL			English	Article											GORDON, CR (corresponding author), ISRAEL NAVAL HYPERBAR INST,MOT SICKNESS & HUMAN PERFORMANCE LAB,POB 8040,IL-31080 HAIFA,ISRAEL.			Gordon, Carlos/0000-0003-1576-214X; Doweck, Ilana/0000-0002-1065-0299				BROWN JJ, 1987, AM J OTOLARYNG, V8, P219, DOI 10.1016/S0196-0709(87)80007-8; Irwin J., 1881, LANCET, V118, P907, DOI DOI 10.1016/S0140-6736(02)38129-7; Reason JT., 1975, MOTION SICKNESS; WIKER SF, 1979, AVIAT SPACE ENVIR MD, V50, P1046; WIKER SF, 1979, CGD2979 US DEP TRANS	5	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					544	544		10.1136/bmj.304.6826.544	http://dx.doi.org/10.1136/bmj.304.6826.544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559057	Green Published, Bronze			2022-12-28	WOS:A1992HG59900020
J	MASON, J; PROCTOR, R				MASON, J; PROCTOR, R			REDUCING YOUTH VIOLENCE - THE PHYSICIANS ROLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, J (corresponding author), US PHS,OFF COMMUN,ROOM 719-H,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201, USA.								0	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3003	3003						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588703				2022-12-28	WOS:A1992HW97000005
J	HEALY, B				HEALY, B			FROM FORM TO FUNCTION - BETTER IMAGING TECHNIQUES EXTEND STUDY OF LIVING SYSTEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2863	2863						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583743				2022-12-28	WOS:A1992HW13300005
J	TOKARS, JI; BELL, DM; CULVER, DH; MARCUS, R; MENDELSON, MH; SLOAN, EP; FARBER, BF; FLIGNER, D; CHAMBERLAND, ME; MCKIBBEN, PS; MARTONE, WJ				TOKARS, JI; BELL, DM; CULVER, DH; MARCUS, R; MENDELSON, MH; SLOAN, EP; FARBER, BF; FLIGNER, D; CHAMBERLAND, ME; MCKIBBEN, PS; MARTONE, WJ			PERCUTANEOUS INJURIES DURING SURGICAL-PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-B; RISK; TRANSMISSION; OPERATIONS; INFECTION; SURGEONS	Objective. --To study the numbers and circumstances of percutaneous injuries (eg, needle sticks, cuts) that occur during surgical procedures. Surgical personnel risk infection with blood-borne pathogens from percutaneous injuries; some injuries might also place patients at risk by exposing them to a health care worker's blood. Design. --Observers present at 1382 surgical procedures recorded information about the procedure, the personnel present, and percutaneous injuries that occurred. Setting. --Four US teaching hospitals during 1990. Participants. --Operating room personnel in five surgical specialties. Main Outcome Measures. --Numbers and circumstances of percutaneous injuries among surgical personnel and instances in which surgical instruments that had injured a worker recontacted the patient's surgical wound. Results. --Ninety-nine injuries occurred during 95 (6.9%) of the 1382 procedures. Seventy-six injuries (77%) were caused by suture needles and affected the nondominant hand (62 injuries [63%]), especially the distal forefinger. The risk of injury adjusted for confounding variables by logistic regression was higher during vaginal hysterectomy (odds ratio [OR], 3.5; 95% confidence interval [Cl], 1.6 to 7.5) and lower during certain orthopedic procedures (OR, 0.2; Cl, 0.1 to 0.7) than during 11 other types of procedures (reference group; OR, 1.0). Use of fingers rather than an instrument to hold the tissue being sutured was associated with 35 injuries (35%). Eighty-eight injuries (89%) were sustained by resident or attending surgeons; in 28 (32%) of the 88 injuries in surgeons, the sharp object that caused the injury recontacted the patient. Conclusion. --Percutaneous injuries occur regularly during surgery, placing surgical personnel and, to a lesser extent, patients at risk for infection with blood-borne pathogens. Many such injuries may be preventable with changes in devices, techniques, or protective equipment; all such measures require careful evaluation to determine their efficacy in reducing injury and their effect on patient care.	N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DIV INFECT DIS,MANHASSET,NY 11030; CHRIST HOSP,DEPT EMERGENCY MED,OAK LAWN,IL; CUNY MT SINAI SCH MED,DEPT MED,DIV INFECT DIS,NEW YORK,NY 10029; COOK CTY HOSP,DEPT EMERGENCY MED,CHICAGO,IL 60612	Cornell University; Northwell Health; North Shore University Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; John H Stroger Junior Hospital Cook County	TOKARS, JI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP A-07,ATLANTA,GA 30333, USA.			Marcus, Ruthanne/0000-0002-9094-0674				Bell DM, 1991, AM J MED S3B, V91, P294; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; BICKEL JT, 1990, J FORENSIC SCI, V35, P12; DIAZBUXO JA, 1991, SURG GYNECOL OBSTET, V172, P312; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; QUEBBEMAN EJ, 1991, ANN SURG, V214, P614, DOI 10.1097/00000658-199111000-00012; SERRANO CW, 1991, OBSTET GYNECOL, V77, P525; TELFORD GL, 1987, SURG ROUNDS, V10, P30; WELCH J, 1989, LANCET, V1, P205; WRIGHT JG, 1991, JAMA-J AM MED ASSOC, V266, P1668, DOI 10.1001/jama.266.12.1668; 1991, MMWR, V40, P309; 1991, MMWR, V40, P1; 1987, MMWR S2S, V36, pS3	19	196	199	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2899	2904		10.1001/jama.267.21.2899	http://dx.doi.org/10.1001/jama.267.21.2899			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583758				2022-12-28	WOS:A1992HW13300026
J	GODINOT, M; MAHBOUBI, M				GODINOT, M; MAHBOUBI, M			EARLIEST KNOWN SIMIAN PRIMATE FOUND IN ALGERIA	NATURE			English	Article							EGYPT; OLIGOCENE; POSITION; FAYUM	THE record of early fossil Simiiformes (Anthropoidea 1) from the Late Eocene and Early Oligocene of Africa and the Arabian Peninsula has increased dramatically in recent years 2-6. We report here the discovery of a new, diminutive and much older (Early or Middle Eocene) simian from an Algerian locality, Glib Zegdou. This species is smaller than any other living or fossil African simiiform. Derived similarities shared with Aegyptopithecus suggest that the new genus is more closely related to propliopithecines than to oligopithecines, implying that these two subfamilies differentiated during the Early Eocene. The new discovery confirms predictions about the great antiquity of Simiiformes 7-9 and emphasizes a long and endemic African history for higher primates.	UNIV ORAN,INST SCI TERRE,ORAN,ALGERIA	Universite d'Oran	GODINOT, M (corresponding author), UNIV MONTPELLIER 2,INST SCI EVOLUT,CNRS,URA 327,CASE COURRIER 64,PL EUGENE BATAILLON,F-34095 MONTPELLIER 05,FRANCE.		Godinot, Marc/F-6964-2010; Klein, Richard G/B-5910-2009					BEARD KC, 1991, NATURE, V349, P64, DOI 10.1038/349064a0; BONIS L, 1988, Z C R HEBD ACAD SC 2, V306, P929; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; Fleagle JG, 1988, PRIMATE ADAPTATION E; Gevin P., 1974, B SOC HIST NAT AFR N, V60, P371; Gingerich P.D., 1980, P123; Gingerich P. D., 1977, Geobios Lyon Memoire Special, VNo. 1, P165; GINGERICH PD, 1982, AM J PHYS ANTHROPOL, V58, P81, DOI 10.1002/ajpa.1330580110; Godinot M., 1988, Courier Forschungsinstitut Senckenberg, V107, P383; GODINOT M, 1988, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V205, P113; Godinot M., 1981, Palaeovertebrata (Montpellier), V10, P43; HOFFSTETTER R, 1977, B MEM SOC ANTHRO PAR, V4, P327, DOI 10.3406/bmsap.1977.1886; HOFFSTETTER R, 1982, ANN PALEONTOL, V68, P241; Kay R.F., 1984, P467; Martin R.D., 1990, PRIMATE ORIGINS EVOL; RASMUSSEN DT, 1990, INT J PRIMATOL, V11, P439, DOI 10.1007/BF02196131; RASMUSSEN DT, 1988, FOLIA PRIMATOL, V51, P182; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; SIMONS EL, 1990, SCIENCE, V247, P1567, DOI 10.1126/science.2108499; SIMONS EL, 1988, AM J PRIMATOL, V15, P337, DOI 10.1002/ajp.1350150407; SIMONS EL, 1989, P NATL ACAD SCI USA, V86, P9956, DOI 10.1073/pnas.86.24.9956; SIMONS EL, 1983, NATURE, V304, P624, DOI 10.1038/304624a0; SUDRE J, 1975, CR ACAD SCI D NAT, V280, P1539; Sudre J., 1979, Palaeovertebrata (Montpellier), V9, P83; Szalay F.S., 1979, EVOLUTIONARY HIST PR; THOMAS H, 1988, Z C R HEBD ACAD SC 2, V306, P823	26	78	82	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					324	326		10.1038/357324a0	http://dx.doi.org/10.1038/357324a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589034				2022-12-28	WOS:A1992HW13200046
J	KRUMHOLZ, HM; DOUGLAS, PS; LAUER, MS; PASTERNAK, RC				KRUMHOLZ, HM; DOUGLAS, PS; LAUER, MS; PASTERNAK, RC			SELECTION OF PATIENTS FOR CORONARY ANGIOGRAPHY AND CORONARY REVASCULARIZATION EARLY AFTER MYOCARDIAL-INFARCTION - IS THERE EVIDENCE FOR A GENDER BIAS	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; SEX FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; WOMENS HEALTH; SELECTION BIAS	ARTERY BYPASS-SURGERY; WOMEN; MORTALITY; SEX; DISEASE; MEN	Objective: To determine whether a gender bias exists in the selection of patients for diagnostic and therapeutic cardiovascular procedures early after myocardial infarction. Design: A retrospective cohort study. Setting: A community-based tertiary care teaching hospital. Patients: A total of 2473 consecutive patients with a principal discharge diagnosis of acute myocardial infarction and a peak creatine kinase MB fraction of at least 4%. Measurements: Comparison of men and women regarding the frequency with which they underwent various cardiac procedures. Results: Women had coronary angiography during hospitalization for myocardial infarction much less frequently than men (odds ratio, 0.55; 95% Cl, 0.46 to 0.65), but the age-adjusted rates were similar in women and men (odds ratio, 0.91; Cl, 0.75 to 1.12). An abnormal ejection fraction (< 50%) was equally frequent in women and men who underwent left ventriculography (odds ratio, 0.85; Cl, 0.56 to 1.30). Among patients who had coronary angiography, women had a significantly lower rate of severe coronary artery disease, defined as either a left main stenosis of more than 50%, three-vessel disease, or two-vessel disease with a proximal left anterior descending stenosis of more than 70% (odds ratio, 0.67; Cl, 0.48 to 0.93). When adjustments were made for age, women had percutaneous transluminal coronary angioplasty as often as men (odds ratio, 1.16; Cl, 0.83 to 1.62) but had coronary artery bypass graft surgery significantly less frequently (odds ratio, 0.58; Cl, 0.37 to 0.91). When adjustments were made for age and the severity of coronary artery disease, the difference in rates was of borderline significance (odds ratio, 0.65; Cl, 0.41 to 1.01). Conclusions: No evidence of a difference in the rate of coronary angiography early after myocardial infarction between women and men was found after age adjustment. Among patients who have cardiac catheterization early after myocardial infarction, women and men are equally likely to have angioplasty, but women are less likely than men to have coronary artery bypass surgery.	MASSACHUSETTS GEN HOSP, CELL BIOL UNIT, 32 FRUIT ST, BOSTON, MA 02114 USA; BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; LAHEY CLIN FDN, MED CTR, CARDIOL SECT, BURLINGTON, MA 01805 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Lahey Hospital & Medical Center			Lauer, Michael S/L-9656-2013; , Harlan/AAI-2875-2020	Lauer, Michael S/0000-0002-9217-8177; Douglas, Pamela/0000-0001-9876-4049	NHLBI NIH HHS [HL-07374] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JOHANSSON S, 1984, EUR HEART J, V5, P374, DOI 10.1093/oxfordjournals.eurheartj.a061671; KENNEDY RH, 1982, NEW ENGL J MED, V307, P986, DOI 10.1056/NEJM198210143071605; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SAFRAN C, 1989, ANN INTERN MED, V111, P751, DOI 10.7326/0003-4819-111-9-751; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; ZIR LM, 1976, CIRCULATION, V53, P627, DOI 10.1161/01.CIR.53.4.627	22	252	256	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					785	790		10.7326/0003-4819-116-10-785	http://dx.doi.org/10.7326/0003-4819-116-10-785			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567092				2022-12-28	WOS:A1992HT80200001
J	MEHLIN, H; DANEHOLT, B; SKOGLUND, U				MEHLIN, H; DANEHOLT, B; SKOGLUND, U			TRANSLOCATION OF A SPECIFIC PREMESSENGER RIBONUCLEOPROTEIN PARTICLE THROUGH THE NUCLEAR-PORE STUDIED WITH ELECTRON-MICROSCOPE TOMOGRAPHY	CELL			English	Article							CHIRONOMUS-TENTANS; BALBIANI RINGS; PROTEIN IMPORT; RNA TRANSPORT; COMPLEX; ENVELOPE; OOCYTES; BINDING; GENES; CELL	A specific premessenger ribonucleoprotein (RNP) particle in the salivary glands of the dipteran Chironomus tentans was studied with electron microscope tomography during translocation from the cell nucleus to the cytoplasm. The RNP particle consists of a thin RNP fiber tightly folded into a ribbon, which is bent into a ring-like structure. Upon translocation through the pore, the particle is first orientated in a specific manner at the pore entrance, and subsequently the bent ribbon is gradually straightened and transported through the pore with the 5' end of the RNA in the lead. Concomitantly, the elementary RNP fiber constituting the ribbon is gradually unpacked and will appear more or less extended on the cytoplasmic side of the pore complex. The ordered nature of the process suggests a specific recognition of the RNP particle at the nuclear pore.			MEHLIN, H (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT MOLEC GENET,S-10401 STOCKHOLM 60,SWEDEN.		Skoglund, Ulf/B-5829-2015	Skoglund, Ulf/0000-0002-3407-0053				AGUTTE PS, 1976, NATURE, V263, P165, DOI 10.1038/263165a0; Agutter P S, 1984, Subcell Biochem, V10, P281; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; ANDERSSON K, 1980, EXP CELL RES, V130, P313, DOI 10.1016/0014-4827(80)90008-7; BEERMANN W, 1962, MAI C GES SCHAFT PHY, P64; CASE ST, 1983, J BIOL CHEM, V258, P7793; CLAWSON GA, 1985, MOL CELL BIOCHEM, V67, P87, DOI 10.1007/BF02370167; Daneholt B, 1976, Prog Nucleic Acid Res Mol Biol, V19, P319; DANEHOLT B, 1977, J CELL BIOL, V3, P149; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FETHERSTONE C, 1988, J CELL BIOL, V107, P1289; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P317, DOI 10.1016/S0022-5320(70)80065-X; FRANKE WW, 1981, J CELL BIOL, V91, P39; GALLER R, 1985, EMBO J, V4, P2977, DOI 10.1002/j.1460-2075.1985.tb04032.x; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; JONES RE, 1980, J CELL BIOL, V86, P235, DOI 10.1083/jcb.86.1.235; LAMB MM, 1979, CELL, V17, P835, DOI 10.1016/0092-8674(79)90324-6; LONN U, 1977, NATURE, V270, P630, DOI 10.1038/270630a0; MAUL GR, 1977, INT REV CYTOL      S, V6, P75; MCDONALD JR, 1980, FEBS LETT, V116, P145, DOI 10.1016/0014-5793(80)80629-6; MEHLIN H, 1991, EXP CELL RES, V193, P72, DOI 10.1016/0014-4827(91)90539-7; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; OLINS AL, 1980, EUR J CELL BIOL, V22, P714; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; PETERS R, 1984, EMBO J, V3, P1831, DOI 10.1002/j.1460-2075.1984.tb02055.x; Preobrazhensky A A, 1978, Prog Nucleic Acid Res Mol Biol, V21, P1, DOI 10.1016/S0079-6603(08)60265-2; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIS H, 1989, Journal of Cell Biology, V109, p134A; ROWLAND SW, 1979, TOP APPL PHYS, V32, P9; SCHEER U, 1988, CELL BIOL INT REP, V12, P669, DOI 10.1016/0309-1651(88)90083-5; SCHRODER HC, 1987, PROG NUCLEIC ACID RE, V34, P89, DOI 10.1016/S0079-6603(08)60494-8; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SKOGLUND U, 1986, TRENDS BIOCHEM SCI, V11, P499, DOI 10.1016/0968-0004(86)90077-0; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; WIESLANDER L, 1984, J MOL EVOL, V20, P304, DOI 10.1007/BF02104736; WURTZ T, 1990, P NATL ACAD SCI USA, V87, P831, DOI 10.1073/pnas.87.2.831; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; [No title captured]	52	224	227	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					605	613		10.1016/0092-8674(92)90224-Z	http://dx.doi.org/10.1016/0092-8674(92)90224-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586943				2022-12-28	WOS:A1992HV08900005
J	HIRAI, Y; TAKEBE, K; TAKASHINA, M; KOBAYASHI, S; TAKEICHI, M				HIRAI, Y; TAKEBE, K; TAKASHINA, M; KOBAYASHI, S; TAKEICHI, M			EPIMORPHIN - A MESENCHYMAL PROTEIN ESSENTIAL FOR EPITHELIAL MORPHOGENESIS	CELL			English	Article							CADHERIN ADHESION MOLECULES; CELL-SURFACE; EMBRYONIC HISTOGENESIS; GENE-EXPRESSION; MESSENGER-RNAS; INDUCTION; PHOSPHATIDYLINOSITOL; ORGANOGENESIS; KIDNEY; GLAND	A novel 150 kd protein expressed on the surface of mesenchymal cells of mouse embryonic tissues was identified. A monoclonal antibody to this molecule inhibited various processes of epithelial morphogenesis, such as hair follicle growth and lung epithelial tubular formation, in organ cultures of these tissues. Sequence analysis of cDNA encoding this protein revealed that it had 289 amino acids with a hydrophobic stretch at the C-terminus. NIH 3T3 cells transfected with the cDNA of this protein expressed the exogenous 150 kd protein on their surface. When lung epithelial cells were cocultured with these transfected cells, they showed normal tubular morphogenesis, but not with untransfected NIH 3T3 cells. These results indicate that this protein, termed epimorphin, plays a central role in epithelial-mesenchymal interactions.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	HIRAI, Y (corresponding author), BIOMAT RES INST,1 TAYA CHO,SAKAE KU,YOKOHAMA 244,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER J, 1988, J BIOL CHEM, V263, P10016; BERGER J, 1989, P NATL ACAD SCI USA, V86, P1457, DOI 10.1073/pnas.86.5.1457; Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BLAKESLEE D, 1976, J IMMUNOL METHODS, V13, P305, DOI 10.1016/0022-1759(76)90078-8; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CUTLER LS, 1973, DEV BIOL, V33, P229, DOI 10.1016/0012-1606(73)90133-4; DEMARCHEZ M, 1981, ARCH ANAT MICROSC MO, V70, P205; DEUCHAR E.M., 1975, CELLULAR INTERACTION; DHOUAILLY D, 1978, DEV BIOL, V65, P58, DOI 10.1016/0012-1606(78)90179-3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARDY MH, 1983, J INVEST DERMATOL, V80, P27, DOI 10.1111/1523-1747.ep12530968; HARDY MH, 1954, ANN NY ACAD SCI, V53, P546; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HIRAI Y, 1989, DEVELOPMENT, V105, P263; HIRAI Y, 1991, CYTOTECHNOLOGY, V6, P209, DOI 10.1007/BF00624759; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEHTONEN E, 1975, J EMBRYOL EXP MORPH, V33, P187; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASUI T, 1981, J EMBRYOL EXP MORPH, V62, P277; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MIZUNO T, 1990, CELL DIFFER DEV, V31, P151, DOI 10.1016/0922-3371(90)90117-F; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NOGAWA H, 1981, J EMBRYOL EXP MORPH, V66, P209; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SAWYER RH, 1983, EPITHELIAL MESENCHYM; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SLAVKIN HC, 1976, DEV BIOL, V50, P428, DOI 10.1016/0012-1606(76)90163-9; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; TAKIGUCHI K, 1988, DEV GROWTH DIFFER, V30, P241; TANABE Y, 1988, MOL CELL BIOL, V8, P466; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WARTIOVAARA J, 1974, J EMBRYOL EXP MORPH, V31, P667; WESSELS NK, 1977, TISSUE INTERACTION D; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X	52	214	227	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					471	481		10.1016/0092-8674(92)90448-L	http://dx.doi.org/10.1016/0092-8674(92)90448-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581962				2022-12-28	WOS:A1992HT07800009
J	RIVIER, DH; RINE, J				RIVIER, DH; RINE, J			AN ORIGIN OF DNA-REPLICATION AND A TRANSCRIPTION SILENCER REQUIRE A COMMON ELEMENT	SCIENCE			English	Article							MATING-TYPE GENES; SACCHAROMYCES-CEREVISIAE; YEAST SILENCER; S-CEREVISIAE; REPRESSION; LOCI; SEGREGATION; HISTONE-H4; PURIFICATION; COMPONENTS	A eukaryotic chromosomal origin of replication was identified in the yeast Saccharomyces cerevisiae. By several criteria, including map position, deletion analysis, and a synthetic form of saturation mutagenesis, the origin co-localized with the HMR-E silencer, which is a DNA element that represses transcription of the adjacent genes. A specific site within the silencer was required for both initiation of chromosomal replication and for repression of transcription. This analysis directly demonstrates that initiation of eukaryotic chromosomal replication is dependent on specific sequence elements and that a particular element can act in both initiation of chromosomal replication and regulation of transcription.			RIVIER, DH (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV GENET,401 BARKER HALL,BERKELEY,CA 94720, USA.				NIEHS NIH HHS [ES07075] Funding Source: Medline; NIGMS NIH HHS [GM 31105] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXROD A, 1991, MOL CELL BIOL, V11, P1080; APARICIO OM, 1991, CELL, V66, P1; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER B, UNPUB; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; GIESMAN D, 1991, MOL CELL BIOL, V11, P1069, DOI 10.1128/MCB.11.2.1069; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KLAR AJS, 1981, CELL, V25, P517, DOI 10.1016/0092-8674(81)90070-2; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MILLS AD, 1989, J CELL SCI, V94, P471; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RINE J, 1987, GENETICS, V116, P9; RIVIER D, UNPUB; RIVIER DH, IN PRESS CURR OPIN C; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SPRADLING AC, 1990, GENETICS, V126, P779; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; TERLETH C, 1990, EMBO J, V9, P2899, DOI 10.1002/j.1460-2075.1990.tb07480.x; THOMAS GP, 1980, CELL, V22, P523; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L	48	130	132	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					659	663		10.1126/science.1585179	http://dx.doi.org/10.1126/science.1585179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585179				2022-12-28	WOS:A1992HR18500030
J	SHUSTER, AM; GOLOLOBOV, GV; KVASHUK, OA; BOGOMOLOVA, AE; SMIRNOV, IV; GABIBOV, AG				SHUSTER, AM; GOLOLOBOV, GV; KVASHUK, OA; BOGOMOLOVA, AE; SMIRNOV, IV; GABIBOV, AG			DNA HYDROLYZING AUTOANTIBODIES	SCIENCE			English	Article								A DNA-nicking activity was detected in the sera of patients with various autoimmune pathologies and was shown to be a property of autoantibodies. The DNA hydrolyzing activity, which was purified by affinity and high-performance liquid chromatography, corresponded in size to immunoglobulin M (IgM) and IgG and had a positive response to antibodies to human IgG. The DNA hydrolyzing autoantibodies were stable to acid shock and yielded a DNA degradation pattern that was different from that of deoxyribonuclease (DNase) I and blood DNase.	VA ENGELHARDT MOLEC BIOL INST,VAVILOV STR 32,MOSCOW 117984,USSR	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS								BRONSHTEIN IV, 1990, B EXP BIOL MED  P, V12, P598; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Harlow E., 1988, ANTIBODIES LAB MANUA, P630; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; REIMER G, 1987, VIRCHOWS ARCH B, V54, P131, DOI 10.1007/BF02899205	5	343	375	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					665	667		10.1126/science.1585181	http://dx.doi.org/10.1126/science.1585181			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585181				2022-12-28	WOS:A1992HR18500032
J	COATS, AJS				COATS, AJS			TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											COATS, AJS (corresponding author), NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND.							BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; HRICIK DE, 1983, J CARDIOVASC MED, V8, P397; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	4	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1220	1220						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1557097				2022-12-28	WOS:A1992HR00800012
J	WISEMAN, MR; VIZARD, E; BENTOVIM, A; LEVENTHAL, J				WISEMAN, MR; VIZARD, E; BENTOVIM, A; LEVENTHAL, J			RELIABILITY OF VIDEO TAPED INTERVIEWS WITH CHILDREN SUSPECTED OF BEING SEXUALLY ABUSED	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the reliability of judgments about the likelihood of child sexual abuse based only on video recorded interviews. Design - Blinded rating of likelihood of abuse by seven professional groups and comparison with consensus rating. Setting - Child and adolescent psychiatry centre. Subjects - Four people from each of seven professional disciplines: specialist psychiatrists, general psychiatrists, experimental psychologists, trainee social workers, trainee clinical psychologists, lawyers, and police. Main outcome measure - Rating of 12 recorded interviews. Results - Agreement between the consensus panel and professional groups was 83% (151/183) for high likelihood cases (seven cases) and 89% (118/132) for low likelihood cases (five). Specialist psychiatrists and the police were better able to identify high likelihood cases than were other groups with less experience of interviewing sexually abused children (91% (48/53) v 79% (102/129); p = 0.05). Conclusions - Raters could accurately distinguish children with low likelihood of abuse on interview evidence alone, but those with more experience of dealing with sexual abuse were better at identifying high likelihood cases.	TAVISTOCK CLIN,LONDON NW3,ENGLAND; HOSP SICK CHILDREN,LONDON WC1N 3JH,ENGLAND; YALE UNIV,DEPT PEDIAT,NEW HAVEN,CT 06520	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Yale University	WISEMAN, MR (corresponding author), GUYS HOSP,DEPT CHILD & ADOLESCENT PSYCHIAT,LONDON SE1 9RT,ENGLAND.							Butler-Sloss E., 1988, REPORT INQUIRY CHILD; DAVIES G, 1991, CLIN APPROACHES SEX; VIZARD E, 1988, CHILD SEXUAL ABUSE F, P105; VIZARD E, 1991, CLIN APPROACHES SEX; Westcott H., 1989, ADOPTION FOSTERING, V13, P6; 1991, GUIDE ARRANGEMENTS I	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1089	1091		10.1136/bmj.304.6834.1089	http://dx.doi.org/10.1136/bmj.304.6834.1089			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586822	Green Published, Bronze			2022-12-28	WOS:A1992HR13600017
J	YOUNG, JB; FORSTER, A				YOUNG, JB; FORSTER, A			THE BRADFORD COMMUNITY STROKE TRIAL - RESULTS AT 6 MONTHS	BRITISH MEDICAL JOURNAL			English	Article								Objective - Comparison of day hospital attendance and home physiotherapy for stroke patients leaving hospital to determine which service produces greater functional and social improvement for the patient, reduces emotional stress for the care giver, and lessens the need for community support. Design - Stratified, randomised trial of stroke patients attending day hospital two days a week or receiving home treatment from a community physiotherapist. The six month assessment results are reported in this paper. Subjects - Patients over 60 years old resident within the Bradford metropolitan district discharged home after a new stroke with residual disability. Setting - Four day hospitals in two health authorities and domiciliary work undertaken by experienced community physiotherapists. Main outcome measures - Barthel index, functional ambulatory categories, Motor Club assessment, Frenchay activities index, and Nottingham health profile were used. Carers' stress was indicated by the general health questionnaire. Treatment given and community care provided were recorded. Results - Of 124 patients recruited, 108 were available for reassessment at six months. Both treatment groups had significantly improved in functional abilities between discharge and six months. The improvements were significantly greater for patients treated at home (Mann-Whitney test; Barthel index, median difference 2 (95% confidence interval 0 to 3) p = 0.01; Motor Club assessment, median difference 2 (1 to 5), p = 0.01). The home treated patients received less treatment (median difference 16 (11 to 21) treatments, p < 0.001). More than a third of patients in both groups showed depressed mood, and a quarter of care givers were emotionally distressed. Conclusions - Home physiotherapy seems to be slightly more effective and more resource efficient than day hospital attendance and should be the preferred rehabilitation method for aftercare of stroke patients. New strategies are needed to address psychosocial function for both patients and care givers.			YOUNG, JB (corresponding author), ST LUKES HOSP,DEPT HLTH CARE ELDERLY,BRADFORD BD5 0NA,ENGLAND.			Forster, Anne/0000-0001-7466-4414; young, john/0000-0003-4085-9306				AHLSIO B, 1984, STROKE, V15, P886, DOI 10.1161/01.STR.15.5.886; Altman DG., 1982, STATISTICS PRACTICE, P6; Ashburn A, 1982, Physiotherapy, V68, P109; BROCKLEHURST JC, 1981, SOC SCI MED-MED SOC, V15, P35, DOI 10.1016/0271-7123(81)90043-2; BURNARD S, 1988, PHYSIOTHERAPY, V74, P4; CAMPBELL MJ, 1989, STATISTICS CONFIDENC, P71; EAGLE DJ, 1991, CAN MED ASSOC J, V144, P699; EBRAHIM S, 1986, J EPIDEMIOL COMMUN H, V40, P166, DOI 10.1136/jech.40.2.166; Forster A, 1989, Int Disabil Stud, V11, P181; FORSTER A, 1990, PHYSIOTHERAPY, V76, P495; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; GLOSSOP ES, 1981, PHYSIOTHERAPY, V67, P79; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDBERG DP, 1988, USERSS GUIDE GENERAL; GORE SM, 1982, STATISTICS PRACTICE, P44; Hildick-Smith M, 1985, Int Rehabil Med, V7, P120; HOLBROOK M, 1982, J ROY COLL PHYS LOND, V16, P100; Hunt SM, 1986, MEASURING HLTH STATU; KETTLE M, 1989, CLIN REHABIL, V3, P131; MAHONEY F I, 1965, Md State Med J, V14, P61; SCHMIDT SM, 1986, ARCH PHYS MED REHAB, V67, P99, DOI 10.1016/0003-9993(86)90110-3; STOKOE D, 1985, AGE AGEING, V14, P308, DOI 10.1093/ageing/14.5.308; TUCKER MA, 1984, BRIT MED J, V289, P1209, DOI 10.1136/bmj.289.6453.1209; Wade D T, 1985, Int Rehabil Med, V7, P176; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; YOUNG J, 1991, CLIN REHABILITATION, V5, P127; Young J, 1991, CLIN REHABIL, V5, P283	28	126	126	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1085	1089		10.1136/bmj.304.6834.1085	http://dx.doi.org/10.1136/bmj.304.6834.1085			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586821	Green Published, Bronze			2022-12-28	WOS:A1992HR13600016
J	WHITTY, P; JONES, I				WHITTY, P; JONES, I			FOR DEBATE - PUBLIC-HEALTH HERESY - A CHALLENGE TO THE PURCHASING ORTHODOXY	BRITISH MEDICAL JOURNAL			English	Article							INEQUALITIES		QUEEN MARY & WESTFIELD COLL,DEPT GEOG,HLTH SERV RES UNIT,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London	WHITTY, P (corresponding author), LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1 7HT,ENGLAND.			Jones, Ian/0000-0002-1682-9134				[Anonymous], 1988, CM289; [Anonymous], 1989, CM555; Ashton J., 1986, Health Promotion, V1, P319, DOI 10.1093/heapro/1.3.319; ASHTON J, 1991, BRIT MED J, V302, P1413, DOI 10.1136/bmj.302.6790.1413; Black D., 1980, INEQUALITIES HLTH; Blaxter M., 1990, HLTH LIFESTYLES; BULL AR, 1990, J PUBLIC HEALTH MED, V12, P205, DOI 10.1093/oxfordjournals.pubmed.a042547; FRANCOME C, 1991, NHS REFORMS 1ST 6 MO; GATHERER A, 1991, PUBLIC HLTH PHYSICIA, V2, P2; GODBER GE, 1986, COMMUNITY MED, V8, P1; HAM C, 1991, HLTH SERVICE J, V101, P20; Hunter D, 1991, Health Serv J, V101, P22; MARMOT MG, 1986, LANCET, V2, P274; MAY A, 1991, HLTH SERVICE J, V101, P14; MCKEOWN T, 1989, ROLE MED; ROLAND M, 1991, BRIT MED J, V303, P171, DOI 10.1136/bmj.303.6795.171; Scheuer M A, 1991, Health Serv J, V101, P18; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; Tomlin Z, 1991, Health Serv J, V101, P12; WEBSTER C, 1986, RADICAL COMMUNITY ME, V3, P10; WEBSTER D, 1991, BRIT MED J, V302, P1450, DOI 10.1136/bmj.302.6790.1450; WHITEHEAD M, 1988, INQUALITIES HLTH; 1989, SHAPING NATIONS HLTH; 1991, BMJ, V303, P299; 1991, LANCET, V337, P1381; 1991, GENERAL HOUSEHOLD SU; 1985, TARGETS SUPPORT HLTH; 1991, CM1523	28	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1039	1041		10.1136/bmj.304.6833.1039	http://dx.doi.org/10.1136/bmj.304.6833.1039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586791	Bronze, Green Published			2022-12-28	WOS:A1992HQ14200027
J	FRIEDMAN, JM; LEIBEL, RL				FRIEDMAN, JM; LEIBEL, RL			TACKLING A WEIGHTY PROBLEM	CELL			English	Review							BODY-WEIGHT; MICE; OBESITY; MOUSE; GENE		ROCKEFELLER UNIV, HUMAN BEHAV & METAB LAB, NEW YORK, NY 10021 USA	Rockefeller University	FRIEDMAN, JM (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.		Friedman, Jeffrey M/E-5784-2011					BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BRAY GA, 1989, AM J CLIN NUTR, V50, P891, DOI 10.1093/ajcn/50.5.891; BRAY GA, 1989, VITAM HORM, V45, P1; BULTMAN SJ, 1991, P NATL ACAD SCI USA, V88, P8062, DOI 10.1073/pnas.88.18.8062; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DURSO M, 1990, GENOMICS, V7, P531, DOI 10.1016/0888-7543(90)90196-2; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1991, MAMM GENOME, V1, P130, DOI 10.1007/BF00351059; HARRIS MI, 1991, DIABETES CARE, V14, P639, DOI 10.2337/diacare.14.7.639; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KEESEY R. E, 1980, OBESITY, P144; KEESEY RE, 1986, ANNU REV PSYCHOL, V37, P109; LANDER ES, 1989, GENETICS, V121, P185; LEITER EH, 1989, FASEB J, V3, P2231, DOI 10.1096/fasebj.3.11.2673897; MOLL PP, 1991, AM J HUM GENET, V49, P1243; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NORIO R, 1984, CLIN GENET, V25, P1; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; ROHNERJEANRENAUD F, 1989, ENDOCRINOLOGY, V124, P733, DOI 10.1210/endo-124-2-733; SIRACUSA LD, 1987, GENETICS, V117, P93; SMITH GP, 1991, PROG OBES R, P25; STRAUSS WM, 1992, EMBO J, V11, P417, DOI 10.1002/j.1460-2075.1992.tb05070.x; STRAUSS WM, 1991, MOUSE MOL GENETICS, P68; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; WOODS SC, 1989, ANN NY ACAD SCI, V575, P236	32	119	149	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					217	220		10.1016/0092-8674(92)90402-X	http://dx.doi.org/10.1016/0092-8674(92)90402-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568242				2022-12-28	WOS:A1992HQ18300001
J	KIPREOS, ET; WANG, JYJ				KIPREOS, ET; WANG, JYJ			CELL-CYCLE REGULATED BINDING OF C-ABL TYROSINE KINASE TO DNA	SCIENCE			English	Article							PROTEIN	The proto-oncogene c-abl encodes a protein tyrosine kinase that is localized in the cytoplasm and the nucleus. The large carboxyl-terminal segment of c-Abl was found to contain a DNA-binding domain that was necessary for the association of c-Abl with chromatin. The DNA-binding activity of c-Abl was lost during mitosis when the carboxyl-terminal segment became phosphorylated. In vitro phosphorylation of the DNA-binding domain by cdc2 kinase abolished DNA binding. Homozygous mutant mice expressing a c-Abl tyrosine kinase without the DNA-binding domain have been reported to die of multiple defects at birth. Thus, binding of the c-Abl tyrosine kinase to DNA may be essential to its biological function.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [R01 CA043054, CA 43054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hancock R, 1977, Methods Cell Biol, V15, P127, DOI 10.1016/S0091-679X(08)60213-7; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1984, CELL, V36, P349; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233	12	195	202	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					382	385		10.1126/science.256.5055.382	http://dx.doi.org/10.1126/science.256.5055.382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566087				2022-12-28	WOS:A1992HP03200038
J	NARAYANAN, R; KLEMENT, JF; RUBEN, SM; HIGGINS, KA; ROSEN, CA				NARAYANAN, R; KLEMENT, JF; RUBEN, SM; HIGGINS, KA; ROSEN, CA			IDENTIFICATION OF A NATURALLY-OCCURRING TRANSFORMING VARIANT OF THE P65 SUBUNIT OF NF-KAPPA-B	SCIENCE			English	Article							ENHANCER-BINDING-PROTEIN; REL ONCOGENE ENCODES; THYMIDINE KINASE; CELL-LINES; GENE; EXPRESSION; NUCLEAR; TRANSACTIVATION; LYMPHOPOIESIS; HOMOLOGY	Transcription factor NF-kappa-B comprises two proteins, p50 and p65, that have sequence similarity to the v-rel oncogene. In primary hematopoietic cell populations an alternatively spliced form of NF-kappa-B p65 mRNA was observed that encoded a protein designated p65-DELTA. Expression of the p65-DELTA cDNA in Rat-1 fibroblasts resulted in focus formation, anchorage-independent growth in soft agar, and tumor formation in athymic nude mice, effects not obtained with expression of p65 or a p65-DELTA mutant that contains a disruption within the transcriptional activation domain. Thus, p65-DELTA, which associated weakly and interfered with DNA binding by p65, may sequester an essential limiting regulatory factor or factors required for NF-kappa-B function.	ROCHE INST MOLEC BIOL, DEPT GENE REGULAT, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA	Roche Holding				Narayanan, Ramaswamy/0000-0001-9346-9083				BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COLLINS LS, 1987, J IMMUNOL, V138, P1082; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HENDERSON AJ, 1990, J IMMUNOL, V145, P423; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ITO E, 1990, ONCOGENE, V5, P1755; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMENT J, UNPUB; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; NARAYANAN R, 1989, EXP HEMATOL, V17, P832; NARAYANAN RB, UNPUB; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUBEN SM, 1992, MOL CELL BIOL, V12, P144; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; THEILEN GH, 1966, J NATL CANCER I, V37, P731; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	30	83	85	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					367	370		10.1126/science.256.5055.367	http://dx.doi.org/10.1126/science.256.5055.367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566083				2022-12-28	WOS:A1992HP03200033
J	PALAZZO, RE; VAISBERG, E; COLE, RW; RIEDER, CL				PALAZZO, RE; VAISBERG, E; COLE, RW; RIEDER, CL			CENTRIOLE DUPLICATION IN LYSATES OF SPISULA-SOLIDISSIMA OOCYTES	SCIENCE			English	Article							SURF CLAM; CELL-CYCLE; EGGS; CENTROSOMES; REPRODUCTION	A cell-free system has been developed that executes centriole duplication. Surf clam (Spisula solidissima) oocytes, arrested at late prophase of meiosis I, do not contain centrioles, centrosomes, or asters. Serial section high-voltage electron microscopy (HVEM) of asters and spindles isolated from potassium chloride-activated oocytes indicates that within 4 minutes oocytes assemble a single centriole that is duplicated by 15 minutes when assembly of the first meiotic spindle is complete. A mixture of lysates from unactivated oocytes and potassium chloride-activated oocytes induces centriole formation and duplication. Astral microtubule content in these lysate mixtures increases with time.	ACAD SCI USSR,PROT RES INST,MOSCOW V-71,USSR; WADSWORTH CTR LABS & RES,ALBANY,NY 12201; SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12222	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	PALAZZO, RE (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01219] Funding Source: Medline; PHS HHS [R01-40198, R01-43264] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN RD, 1953, BIOL BULL, V105, P213, DOI 10.2307/1538639; Bornens M., 1984, MEMBRANE STRUCTURE F, P99; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; DIRKSEN ER, 1991, BIOL CELL, V72, P31, DOI 10.1016/0248-4900(91)90075-X; Fulton C, 1971, ORIGIN CONTINUITY CE, P170; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; KLOTZ C, 1990, J CELL BIOL, V110, P405, DOI 10.1083/jcb.110.2.405; KURIYAMA R, 1986, DEV BIOL, V114, P151, DOI 10.1016/0012-1606(86)90391-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGO F J, 1970, Journal of Ultrastructure Research, V33, P495, DOI 10.1016/S0022-5320(70)90177-2; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; PALAZZO RE, 1988, ZOOL SCI, V5, P603; REBHUN LI, 1959, BIOL BULL, V117, P518, DOI 10.2307/1538865; RIEDER CL, 1985, J ELECTRON MICR TECH, V2, P11, DOI 10.1002/jemt.1060020103; SACHS MI, 1971, J ULTRA MOL STRUCT R, V36, P806, DOI 10.1016/S0022-5320(71)90032-3; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405; SLUDER G, 1990, ADV CELL BIOL, V3, P221; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; WEISENBERG RC, 1975, J CELL BIOL, V64, P146, DOI 10.1083/jcb.64.1.146; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN	22	89	89	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					219	221		10.1126/science.1566068	http://dx.doi.org/10.1126/science.1566068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566068				2022-12-28	WOS:A1992HM89600028
J	SIDRANSKY, D; TOKINO, T; HAMILTON, SR; KINZLER, KW; LEVIN, B; FROST, P; VOGELSTEIN, B				SIDRANSKY, D; TOKINO, T; HAMILTON, SR; KINZLER, KW; LEVIN, B; FROST, P; VOGELSTEIN, B			IDENTIFICATION OF RAS ONCOGENE MUTATIONS IN THE STOOL OF PATIENTS WITH CURABLE COLORECTAL TUMORS	SCIENCE			English	Article							FLOW-CYTOMETRIC DNA; RECTAL ADENOCARCINOMAS; NATURAL-HISTORY; GENE-MUTATIONS; CANCER; COLON; TUMORIGENESIS; PROLIFERATION; PREVENTION; EVOLUTION	Colorectal (CR) tumors are usually curable if detected before metastasis. Because genetic alterations are associated with the development of these tumors, mutant genes may be found in the stool of individuals with CR neoplasms. The stools of nine patients whose tumors contained mutations of K-ras were analyzed. In eight of the nine cases, the ras mutations were detectable in DNA purified from the stool. These patients included those with benign and malignant neoplasms from proximal and distal colonic epithelium. Thus, colorectal tumors can be detected by a noninvasive method based on the molecular pathogenesis of the disease.	JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21231; MD ANDERSON HOSP,DEPT CELL BIOL,HOUSTON,TX 77054; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,GASTROINTESTINAL ONCOL SECT,HOUSTON,TX 77030; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Tokino, Takashi/AAI-9887-2021		NCI NIH HHS [CA35494, CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, P30CA006973, R37CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; BEART RW, 1991, TXB CLIN ONCOLOGY, P213; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; COOPER JN, 1991, NEW ENGL J MED, V326, P136; COPELAND EM, 1968, AM J SURG, V116, P875, DOI 10.1016/0002-9610(68)90458-3; DECOSSE JJ, 1991, NEW ENGL J MED, V326, P134; DELATTRE P, 1989, LANCET, V335, P353; DUKES CE, 1958, BRIT J CANCER, V12, P309, DOI 10.1038/bjc.1958.37; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EISENBERG B, 1982, CANCER, V49, P1131, DOI 10.1002/1097-0142(19820315)49:6<1131::AID-CNCR2820490611>3.0.CO;2-T; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRINNELL RS, 1950, ANN SURG, V2, P494; HAMMARBERG C, 1986, ACTA ONCOL, V25, P45, DOI 10.3109/02841868609136377; KNOERNSCHILD H E, 1963, Surg Forum, V14, P137; LIPKIN M, 1988, CANCER RES, V48, P235; LIPKIN M, 1963, J CLIN INVEST, V42, P767, DOI 10.1172/JCI104769; MACDONALD WC, 1964, GASTROENTEROLOGY, V46, P405; MEHL LE, 1991, J SURG ONCOL, V47, P243, DOI 10.1002/jso.2930470409; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MORSON BC, 1974, CANCER, V34, P845, DOI 10.1002/1097-0142(197409)34:3+<845::AID-CNCR2820340710>3.0.CO;2-H; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; QUIRKE P, 1987, J PATHOL, V151, P285, DOI 10.1002/path.1711510408; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICH T, 1983, CANCER-AM CANCER SOC, V52, P1317, DOI 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6; Rosenberg SA., CANC PRINCIPLES PRAC, Ved, P895; SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TRIBUKAIT B, 1983, ACTA PATH MICRO IM A, V91, P89; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELIN S, 1963, AMER J ROENTGENOL RA, V90, P673; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	46	668	749	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					102	105		10.1126/science.1566048	http://dx.doi.org/10.1126/science.1566048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566048				2022-12-28	WOS:A1992HL82200037
J	CURTIN, JJ; SAMPSON, MA				CURTIN, JJ; SAMPSON, MA			NEED FOR OPEN ACCESS NON-SCREENING MAMMOGRAPHY IN A HOSPITAL WITH A SPECIALIST BREAST CLINIC SERVICE	BRITISH MEDICAL JOURNAL			English	Article							ASPIRATION CYTOLOGY; FALSE ALARMS; CANCER; DIAGNOSIS; ACCURACY; WOMEN	Objective - Assessment of open access non-screening mammography in a hospital with a breast clinic. Design - Retrospective analysis of patients sent for first mammogram to our open access service by general practitioners and breast clinic in the year April 1989 to March 1990. Setting - District general hospital serving 200 000 people before the introduction of breast screening. Subjects - 361 symptomatic women referred directly by general practitioners and 226 women referred by the breast clinic for first, non-screening mammograms. Main outcome measures - Radiographic reports on all patients. Final diagnosis in patients reported as having possible or probable neoplasm. Results - Of the women referred directly by general practitioners one (0.2%) was reported as showing probable malignancy (later histologically confirmed) and 15 (4%) as showing possible malignancy (on follow up none had proved malignancy). Of the women referred by the breast clinic 38 (17%) were reported as showing probable malignancy (all had confirmed carcinomas) and 35 (15%) as showing possible malignancy (19 (54%) had proved malignancy). 18 of the proved malignancies were in women under 50 years old, 26 were in women over 64 years, and 14 were in women of screening age. 54 (93%) of the 58 patients with proved breast cancer and an abnormal mammogram had a discrete breast lump. Conclusions - General practitioners accurately divided women into low and high risk groups, resulting in few abnormalities being detected in patients referred directly for mammography. This suggests that an open access non-screening mammography service for general practitioners is unnecessary in an area with a specialist breast clinic. The large proportion of cancers in women outside of screening age emphasises the need for such clinics.			CURTIN, JJ (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,DEPT RADIOL,HARROW HA1 3UJ,MIDDX,ENGLAND.			Sampson, Madeleine/0000-0003-1265-5103				ASHLEY S, 1989, BRIT J SURG, V76, P835, DOI 10.1002/bjs.1800760825; BAINES CJ, 1986, RADIOLOGY, V160, P295, DOI 10.1148/radiology.160.2.3523590; BANERJEE AK, 1988, LANCET, V2, P336; CAHILL CJ, 1981, BRIT J SURG, V68, P882, DOI 10.1002/bjs.1800681215; DEVITT JE, 1989, LANCET, V2, P1257; DIXON JM, 1983, LANCET, V2, P564; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; EDEIKEN S, 1988, CANCER, V61, P263, DOI 10.1002/1097-0142(19880115)61:2<263::AID-CNCR2820610211>3.0.CO;2-Z; EGELI RA, 1979, CANCER-AM CANCER SOC, V43, P878, DOI 10.1002/1097-0142(197903)43:3<878::AID-CNCR2820430315>3.0.CO;2-K; GARSTIN WIH, 1990, LANCET, V335, P299, DOI 10.1016/0140-6736(90)90125-O; HANSELL DM, 1988, CLIN RADIOL, V39, P150; MANN BD, 1983, ARCH SURG-CHICAGO, V118, P23; MARTIN JE, 1979, AM J ROENTGENOL, V132, P737, DOI 10.2214/ajr.132.5.737; SMALLWOOD J, 1985, BRIT J SURG, V72, P841, DOI 10.1002/bjs.1800721022; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; WALLIS MG, 1991, CLIN RADIOL, V44, P13, DOI 10.1016/S0009-9260(05)80218-1; YELLAND A, 1991, BRIT MED J, V302, P618, DOI 10.1136/bmj.302.6777.618; 1988, LANCET, V2, P411	18	10	10	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					549	551		10.1136/bmj.304.6826.549	http://dx.doi.org/10.1136/bmj.304.6826.549			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559063	Green Published, Bronze			2022-12-28	WOS:A1992HG59900027
J	ELLMAN, JA; MENDEL, D; SCHULTZ, PG				ELLMAN, JA; MENDEL, D; SCHULTZ, PG			SITE-SPECIFIC INCORPORATION OF NOVEL BACKBONE STRUCTURES INTO PROTEINS	SCIENCE			English	Article							ENGINEERED DISULFIDE; TRANSFER-RNA; ACID; LYSOZYME; ELONGATION; STABILITY; ALPHA; BONDS	A number of unnatural amino acids and amino acid analogs with modified backbone structures were substituted for alanine-82 in T4 lysozyme. Replacements included alpha,alpha-disubstituted amino acids, N-alkyl amino acids, and lactic acid, an isoelectronic analog of alanine. The effects of these electronic and structural perturbations on the stability of T4 lysozyme were determined. The relatively broad substrate specificity of the Escherichia coli protein biosynthetic machinery suggests that a wide range of backbone and side-chain substitutions can be introduced, allowing a more precise definition of the factors affecting protein stability.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CTR ADV MAT,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Ellman, Jonathan A/C-7732-2013					ALBER T, 1987, METHOD ENZYMOL, V154, P511; BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P619, DOI 10.1002/bip.360260505; BENEDETTI E, 1989, BIOPOLYMERS, V28, P175, DOI 10.1002/bip.360280119; BHUTA A, 1981, BIOCHEMISTRY-US, V20, P8, DOI 10.1021/bi00504a002; BHUTA P, 1982, BIOCHEMISTRY-US, V21, P899, DOI 10.1021/bi00534a014; CONNELLY P, 1991, BIOCHEMISTRY-US, V30, P1887, DOI 10.1021/bi00221a022; ELLMAN J, IN PRESS METHODS ENZ; FAHNESTOCK S, 1971, SCIENCE, V173, P340, DOI 10.1126/science.173.3994.340; FAHNESTOCK S, 1972, BIOCHIM BIOPHYS ACTA, V269, P62, DOI 10.1016/0005-2787(72)90074-3; JOESTEN MD, 1974, HYDROGEN BONDING, P309; KAMLET MJ, 1983, J ORG CHEM, V48, P2877, DOI 10.1021/jo00165a018; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; NELSON MA, 1982, MOL GEN GENET, V188, P69, DOI 10.1007/BF00332997; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PATERSON Y, 1981, J AM CHEM SOC, V103, P2947, DOI 10.1021/ja00401a007; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; PERRY LJ, 1987, PROTEIN ENG, V1, P101, DOI 10.1093/protein/1.2.101; RAE ID, 1979, INT J PEPT PROT RES, V133, P304; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; WELLS JA, 1986, J BIOL CHEM, V261, P6564; WIBERG KB, 1987, J AM CHEM SOC, V109, P5935, DOI 10.1021/ja00254a006; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001	28	191	247	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					197	200		10.1126/science.1553546	http://dx.doi.org/10.1126/science.1553546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553546				2022-12-28	WOS:A1992GY70400036
J	SALTZMAN, LE; MERCY, JA; OCARROLL, PW; ROSENBERG, ML; RHODES, PH				SALTZMAN, LE; MERCY, JA; OCARROLL, PW; ROSENBERG, ML; RHODES, PH			WEAPON INVOLVEMENT AND INJURY OUTCOMES IN FAMILY AND INTIMATE ASSAULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOMESTIC VIOLENCE; HOMICIDE; WOMEN; GUNS	Objective. - To compare the risk of death and the risk of nonfatal injury during firearm-associated family and intimate assaults (FIAs) with the risks during non-firearm-associated FiAs. Design. - Records review of police incident reports of FIAs that occurred in 1984. Victim outcomes (death, nonfatal injury, no injury) and weapon involvement were examined for incidents involving only one perpetrator. Setting. - City of Atlanta, Ga, within Fulton County. Participants. - Stratified sample (n = 142) of victims of nonfatal FIAs, drawn from seven nonfatal crime categories, plus all fatal victims (n = 23) of FIAs. Main Outcome Measures.-Risk of death (vs nonfatal injury or no injury) during FIAs involving firearms, relative to other types of weapons; risk of nonfatal injury (vs all other outcomes, including death) during FIAs involving firearms, relative to other types of weapons. Results. - Firearm-associated FIAs were 3.O times (95% confidence interval, 0.9 to 10.0) more likely to result in death than FIAs involving knives or other cutting instruments and 23.4 times (95% confidence interval, 7.0 to 78.6) more likely to result in death than FIAs involving other weapons or bodily force. Overall, firearm-associated FIAs were 12.0 times (95% confidence interval, 4.6 to 31.5) more likely to result in death than non-firearm-associated FIAs. Conclusions. - Strategies for limiting the number of deaths and injuries resulting from FIAs include reducing the access of potential FIA assailants to firearms, modifying firearm lethality through redesign, and establishing programs for primary prevention of violence among intimates.			SALTZMAN, LE (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH & INJURY CONTROL,DIV INJURY CONTROL,ATLANTA,GA 30333, USA.				PHS HHS [U50/CCU400931-01-1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS D, 1982, ABUSIVE PARTNER ANAL, P170; [Anonymous], 1968, U CHICAGO LAW REV; BAKER SP, 1985, AM J PUBLIC HEALTH, V75, P587, DOI 10.2105/AJPH.75.6.587; BILLINGHAM RE, 1987, FAM RELAT, V36, P283, DOI 10.2307/583541; Campbell J, 1981, ANS Adv Nurs Sci, V3, P67; Conklin JE, 1972, ROBBERY CRIMINAL JUS; Cook P., 1991, CRIME JUSTICE REV RE, P1; COOK PJ, 1981, ANN AM ACAD POLIT SS, V455, P63, DOI 10.1177/000271628145500107; COOK PJ, 1987, J CRIM LAW CRIM, V78, P357, DOI 10.2307/1143453; Cox DR, 1974, THEORETICAL STATISTI; FOLLINGSTAD DR, 1988, CLIN PSYCHOL REV, V8, P373, DOI 10.1016/0272-7358(88)90065-7; Gelles R., 1990, INTIMATE VIOLENCE FA, V2nd ed.; Goetting A., 1989, J FAM VIOLENCE, V4, P285, DOI [10.1007/bf00980429Goetting, DOI 10.1007/BF00980429GOETTING]; HABER JD, 1985, AM J NURS, V85, P1010, DOI 10.2307/3425176; HEDEBOE J, 1985, AM J PUBLIC HEALTH, V75, P651, DOI 10.2105/AJPH.75.6.651; Hotaling G T, 1986, Violence Vict, V1, P101; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; Levy B., 1984, SKILLS VIOLENCE FREE; MCLEER SV, 1987, ANN EMERG MED, V16, P1155, DOI 10.1016/S0196-0644(87)80476-6; Mercy J A, 1988, Violence Vict, V3, P285; PARROT A, 1986, ACQUAINTANCE RAPE SE; Rand M., 1986, USE WEAPONS COMMITTI; RAND MR, 1990, HANDGUN CRIME VICTIM; SALTZMAN L, 1977, IN PRESS AM J PUBLIC; Saltzman L E, 1990, Violence Vict, V5, P3; SAUNDERS DG, 1991, EMERG CARE Q, V7, P51; Schulman Mark, 1979, SURVEY SPOUSAL VIOLE; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; SPROULE CF, 1989, CAN J CRIMINOL, V31, P245; STARK E, 1981, OFFICE DOMESTIC VIOL, V7; Stets J.E., 1989, PHYSICAL VIOLENCE AM, P151; STRAUS MA, 1986, B NEW YORK ACAD MED, V62, P446; SWEETMAN S, 1987, REPORT ATTORNEY GENE; TESKE R, 1983, SPOUSE ABUSE TEXAS S; WEBSTER DE, 1991, ISSUES SCI TECHN SPR, P73; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO; 1958, VITAL STATISTICS MOR; 1989, INJURY PREVENTION M; 1991, HLTH PEOPLE 2000 NAT; 1991, NATIONAL CRIME SURVE; 1989, MMWR, V38, P17; 1984, PREVENTING FAMILY VI; 1990, CRIMINAL VICTIMIZATI	45	88	88	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3043	3047		10.1001/jama.267.22.3043	http://dx.doi.org/10.1001/jama.267.22.3043			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588718				2022-12-28	WOS:A1992HW97000024
J	WEIL, DS; HEMENWAY, D				WEIL, DS; HEMENWAY, D			LOADED GUNS IN THE HOME - ANALYSIS OF A NATIONAL RANDOM SURVEY OF GUN OWNERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIREARMS; SUICIDE; DEATHS	Objective. - To identify factors associated with keeping guns loaded. Four hypotheses were tested: that people are more likely to keep their firearms loaded if (1) the primary reason for owning a gun is protection, (2) the gun is a handgun, (3) there are no children in the household, or (4) the gun owner has not received training in the proper use of firearms. Design and Setting. - A random national telephone survey of gun owners conducted in December 1989. A screening question was used to identify individuals as gun owners. Participants were called at home. Participants. - 605 individuals (approximately two thirds of the population contacted) participated in the survey. All were 18 years and older, most were men (64%), and a few were nonwhite (12%). The majority owned more than one gun (77%). Results. - Three of the four hypotheses were substantiated by the data. Handgun owners (odds ratio [OR], 2.17; 95% confidence interval [CI], 1.67 to 2.82), individuals who owned a firearm principally for protection (OR, 1.65; 95% CI, 1.30 to 2.11), and people who lived in households without children (OR, 1.42; 95% CI, 1.13 to 1.82) were all more likely to keep a gun loaded than other individuals. Instruction in the proper use of firearms did not seem to affect the, probability of keeping guns loaded (OR, 0.86; 95% CI, 0.69 to 1.07). Conclusions. - The spontaneous nature of many firearm deaths has led to speculation that a substantial proportion of firearm-related morbidity and mortality could be prevented if easy access to loaded weapons were reduced through appropriate storage practices. Our findings show that a significant proportion of gun owners disregard basic safety procedures. However, without information on the specific content of safety instruction, we cannot say that education about safe storage practices is ineffective.			WEIL, DS (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,4TH FLOOR,KRESGE,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							[Anonymous], 1968, U CHICAGO LAW REV; BARLOW B, 1982, J PEDIATR SURG, V17, P927, DOI 10.1016/S0022-3468(82)80469-7; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; COOK PJ, IN PRESS TECHNOLOGY; Gastil R., 1989, ENCY SO CULTURE, P1469; HEINS M, 1974, AM J PUBLIC HEALTH, V64, P326, DOI 10.2105/AJPH.64.4.326; HEMENWAY D, 1990, J POLICY ANAL MANAG, V9, P94, DOI 10.2307/3325116; HEMENWAY D, 1988, PRICES CHOICES, P249; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KECK NJ, 1988, AM J DIS CHILD, V142, P623, DOI 10.1001/archpedi.1988.02150060057029; KELLERMANN AL, 1990, AM J EPIDEMIOL, V131, P1080, DOI 10.1093/oxfordjournals.aje.a115600; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; MOORE M, 1990, GPO198820204580044 U; ORDOG GJ, 1988, AM J DIS CHILD, V142, P618, DOI 10.1001/archpedi.1988.02150060052028; PATTERSON PJ, 1987, AM J DIS CHILD, V141, P221, DOI 10.1001/archpedi.1987.04460020111042; RIVARA FP, 1982, J DEV BEHAV PEDIATR, V3, P35; ROSENBERG ML, 1991, VIOLENCE AM PUBLIC H, P3; RUSHFORTH NB, 1975, AM J EPIDEMIOL, V100, P499; SEIDEN RH, 1977, OMEGA-J DEATH DYING, V8, P267, DOI 10.2190/KXY8-J7QB-7BR7-J8YW; THORNBERRY OT, 1988, TELEPHONE SURVEY MET, P25; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WINTEMUTE GJ, 1987, W J MED, V46, P374; WRIGHT JD, 1983, GUN WEAPONS CRIME VI; ZIMRING FE, 1983, CITIZENS GUIDE GUN C; 1986, NATIONAL DATA PROGRA; 1987, FIREARMS SAFETY DEPE; 1991, LOS ANGELES TIM 0529; 1990, TIME            0129, P16; 1990, US DHHS PHS9150212 P, P236; 1991, GAOPEMD919 US GEN AC; 1986, 1985 FED BUR INV REP; 1983, 197078 CTR DIS CONTR	32	91	91	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3033	3037		10.1001/jama.267.22.3033	http://dx.doi.org/10.1001/jama.267.22.3033			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588716				2022-12-28	WOS:A1992HW97000022
J	STEAD, WW				STEAD, WW			GENETICS AND RESISTANCE TO TUBERCULOSIS - COULD RESISTANCE BE ENHANCED BY GENETIC-ENGINEERING	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						GENETIC ENGINEERING; TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; IMMUNITY, NATURAL; BCG VACCINE	ULTRAVIOLET AIR DISINFECTION; INFECTION	Recent observations strongly suggest a significant role for genetic factors in innate resistance to infection by Mycobacterium tuberculosis. This relation was discovered in a study of tuberculosis in Arkansas nursing homes and was supported by data from three outbreaks of tuberculosis in two prisons. A person's resistance level was found to correlate with the region of his or her ancestry. Ancestors of person's in the more resistant group tended to derive from densely populated areas and cities rife with tuberculosis, whereas the ancestors of person's in the more susceptible group tended to derive from areas once free of tuberculosis. In accordance with current genetic theory, those persons who are less resistant to tuberculosis would be expected to be more resistant to infections endemic to the region once inhabited by their ancestors. Isolation of the gene previously shown to confer specific innate (nonimmune) resistance to tuberculosis should result in the creation of a more rational approach to increasing the capacity of human macrophages to kill tubercle bacilli without producing a positive tuberculin skin test.			STEAD, WW (corresponding author), ARKANSAS DEPT HLTH, TB PROGRAM, 4815 MARKHAM ST, LITTLE ROCK, AR 72205 USA.							[Anonymous], 1882, BERLINER KLIN WOCHEN, V19, P221; BORREL A, 1920, Ann. Inst. Pasteur, V34, P105; BROTHWELL D, 1967, DISEASES ANTIQUITY S, P115; BUDD W, 1867, LANCET, V2, P451; BUSHNELL G, 1920, STUDY EPIDEMIOLOGY T; CAVALLISFORZA LL, 1991, IN PRESS SCI AM, V265, P104; COCKBURN A, 1963, EVOLUTION ERADICATIO, P219; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; CROSBY AW, 1986, ECOLOGICAL IMPERIALI, P139; CROWLE AJ, 1990, INFECT IMMUN, V58, P632, DOI 10.1128/IAI.58.3.632-638.1990; Cummins SL, 1929, BRIT MED J, V1929, P39, DOI 10.1136/bmj.2.3575.39; CUMMINS SL, 1939, PRIMITIVE TUBERCULOS, P14; CUMMINS SL, 1908, BR J TUBERC, V2, P35; CURTIN PD, 1968, POLIT SCI QUART, V83, P190, DOI 10.2307/2147089; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; FLINT A, 1866, PRACTICAL TREATISE P, P465; GOWEN JW, 1948, ANNU REV MICROBIOL, V2, P215, DOI 10.1146/annurev.mi.02.100148.001243; GOWEN JW, 1951, GENETICS 20TH CENTUR; GRMEK MD, 1989, DISEASES ANCIENT GRE, P177; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HORWITZ O, 1973, INT J EPIDEMIOL, V2, P145, DOI 10.1093/ije/2.2.145; HUTT FB, 1958, GENETIC RESISTANCE D; Kiple K., 1984, CARIBBEAN SLAVE BIOL; Kiple K. F, 2003, ANOTHER DIMENSION BL; LICHTENSTEIN H, 1928, TRAVELS AFRICA 1803; Livingstone DA, 1857, MISSIONARY TRAVELS R; LURIE MB, 1964, RESISTANCE TUBERCULO; MALO D, 1991, GENOMICS, V10, P356, DOI 10.1016/0888-7543(91)90320-E; MAYS EE, 1975, TXB BLACK RELATED DI, P418; MCCAULAY D, 1867, LANCET, V2, P451; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; MCPEEK M, 1992, CLIN EXP IMMUNOL, V87, P163; MCVICAR H, 1908, S AFRICAN MED RECORD, V6, P161; MCVICAR H, 1908, S AFRICAN MED RECORD, V6, P181; MCVICAR H, 1908, S AFRICAN MED RECORD, V6, P197; MCVICAR H, 1908, S AFRICAN MED RECORD, V6, P229; MCVICAR H, 1908, S AFRICAN MED RECORD, V6, P213; MILLAR JG, 1908, BRIT MED J, V1, P380; MOTULSKY ARNO G., 1960, HUMAN BIOL, V32, P28; NARDELL EA, 1990, AM REV RESPIR DIS, V142, P501, DOI 10.1164/ajrccm/142.3.501; NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302; NUTELS N, 1968, PAN AM HLTH ORG SCI, V165, P68; O'BRIEN S J, 1991, Current Biology, V1, P209, DOI 10.1016/0960-9822(91)90058-5; OSLER W, 1892, PRINCIPLES PRACTICE, P198; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; Ranke K, 1910, ARCH KINDERHEILKD, V54, P279; RENNIE J, 1992, SCI AM, V266, P122, DOI 10.1038/scientificamerican0192-122; RICH A, 1951, PATHOGENESIS TUBERCU, P134; RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286; SCHURR E, 1990, J INFECT DIS, V161, P634, DOI 10.1093/infdis/161.4.634; SCHURR E, 1991, IMMUNOL TODAY, V12, P42; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9; STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STEAD WW, 1991, NEW ENGL J MED, V325, P1882, DOI 10.1056/NEJM199112263252612; TURNER GA, 1907, REPORT PRINCIPAL DIS; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Villemin J.A., 1868, ETUDES TUBERCULOSE P; WILLIAMS RA, 1975, TXB BLACK RELATED DI, P88; Wolfe A.J., 2002, ANDROMEDA STRAIN, V93, P183; Yandell Lunsford P., 1831, TRANSYLVANIA J MED A, V4, P83; 1991, MMWR, V40, P649; 1991, ARKANSAS DEMOCR 1116, pA4; 1991, MMWR, V40, P585	67	125	126	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					937	941		10.7326/0003-4819-116-11-937	http://dx.doi.org/10.7326/0003-4819-116-11-937			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580452				2022-12-28	WOS:A1992HW13700010
J	MYERBURG, RJ; KESSLER, KM; MALLON, SM; COX, MM; DEMARCHENA, E; INTERIAN, A; CASTELLANOS, A				MYERBURG, RJ; KESSLER, KM; MALLON, SM; COX, MM; DEMARCHENA, E; INTERIAN, A; CASTELLANOS, A			LIFE-THREATENING VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH SILENT-MYOCARDIAL-ISCHEMIA DUE TO CORONARY-ARTERY SPASM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; AMBULATORY ELECTROCARDIOGRAMS; PROGRAMMED STIMULATION; SEGMENT DEPRESSION; VARIANT ANGINA; STABLE ANGINA; SURVIVORS; MECHANISMS; DISEASE; ARREST	Background. Silent myocardial ischemia in patients with coronary atherosclerosis is associated with an increased risk of adverse cardiac events, including sudden death. The relation between silent ischemia and the initiation of potentially fatal ventricular arrhythmias has not been defined, however. Methods. As part of a long-term study of sudden cardiac death, data on arrhythmias, coronary anatomy, and responses to ergonovine testing to provoke coronary artery spasm were collected prospectively among survivors of out-of-hospital cardiac arrest who had no flow-limiting coronary artery lesions, prior myocardial infarctions, or other structural causes of cardiac arrest and no angina pectoris. Associations between silent myocardial ischemia due to coronary artery spasm and the occurrence and characteristics of life-threatening ventricular arrhythmias were studied by both invasive and noninvasive techniques. Results. Silent ischemic events were associated with the initiation of life-threatening ventricular arrhythmias in five patients with induced or spontaneous focal coronary artery spasm (or both). These patients were identified among a group of 356 survivors of out-of-hospital cardiac arrest who were evaluated between 1980 and 1991. In two of the five patients reperfusion, rather than ischemia itself, correlated with the onset of the ventricular arrhythmia. Only one of the five had an inducible arrhythmia during electrophysiologic testing. Titration of the dose of a calcium-entry-blocking agent (verapamil, diltiazem, or nifedipine) against the ability of ergonovine to provoke spasm was successful in preventing both the provocation of spasm and arrhythmias in all four patients who were tested. Conclusions. Silent myocardial ischemia due to coronary artery spasm can initiate potentially fatal arrhythmias in patients without flow-limiting structural coronary artery lesions. The role of silent ischemia, reperfusion, or both in the initiation of fatal arrhythmias in larger groups of patients with advanced coronary artery lesions remains to be defined.	MIAMI VET AFFAIRS MED CTR,MIAMI,FL		MYERBURG, RJ (corresponding author), UNIV MIAMI,SCH MED,DEPT MED,DIV CARDIOL D39,POB 016960,MIAMI,FL 33101, USA.				NHLBI NIH HHS [HL-28130] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028130] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMSTERDAM EA, 1988, AM J CARDIOL, V62, P24; CECCHI AC, 1983, J AM COLL CARDIOL, V1, P934, DOI 10.1016/S0735-1097(83)80213-7; CHIERCHIA S, 1983, J AM COLL CARDIOL, V1, P924, DOI 10.1016/S0735-1097(83)80211-3; CLUSIN WT, 1983, LANCET, V1, P272, DOI 10.1016/S0140-6736(83)91688-4; COHN PF, 1987, AM J CARDIOL, V59, P746, DOI 10.1016/0002-9149(87)91085-X; COHN PF, 1986, AM J MED, V81, P2, DOI 10.1016/0002-9343(86)90971-X; DEANFIELD JE, 1984, AM J CARDIOL, V54, P1195, DOI 10.1016/S0002-9149(84)80066-1; DEANFIELD JE, 1983, LANCET, V2, P753; DEANFIELD JE, 1984, AM J CARDIOL, V54, P1321, DOI 10.1016/S0002-9149(84)80090-9; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; DELEBARRE P, 1980, ARCH MAL COEUR VAISS, V73, P1145; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; FURUKAWA T, 1991, CIRCULATION, V84, P368, DOI 10.1161/01.CIR.84.1.368; GOMES JA, 1989, J AM COLL CARDIOL, V14, P1618; GOTTLIEB SO, 1988, JAMA-J AM MED ASSOC, V259, P1030, DOI 10.1001/jama.259.7.1030; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KERIN NZ, 1979, CIRCULATION, V60, P1343; KIMURA S, 1986, J AM COLL CARDIOL, V7, P833, DOI 10.1016/S0735-1097(86)80345-X; LEARY T, 1934, AM HEART J, V10, P338; MANNING AS, 1984, J MOL CELL CARDIOL, V16, P497, DOI 10.1016/S0022-2828(84)80638-0; MASERI A, 1982, ANN NY ACAD SCI, V382, P204, DOI 10.1111/j.1749-6632.1982.tb55218.x; MASERI A, 1978, AM J CARDIOL, V42, P1019, DOI 10.1016/0002-9149(78)90691-4; MORADY F, 1984, J AM COLL CARDIOL, V4, P39, DOI 10.1016/S0735-1097(84)80316-2; MORADY F, 1987, J AM COLL CARDIOL, V9, P1004, DOI 10.1016/S0735-1097(87)80300-5; MYERBURG RJ, 1991, PACE, V14, P935, DOI 10.1111/j.1540-8159.1991.tb04138.x; MYERBURG RJ, 1992, HEART DIS, V1, P756; NADEMANEE K, 1987, J AM COLL CARDIOL, V1, P1; PINA IL, 1988, CHEST, V94, P1287, DOI 10.1378/chest.94.6.1287; PRATT CM, 1983, J AM COLL CARDIOL, V2, P789, DOI 10.1016/S0735-1097(83)80224-1; PRCHKOV VK, 1974, ANN INTERN MED, V81, P858, DOI 10.7326/0003-4819-81-6-858; RITCHIE JL, 1985, AM J CARDIOL, V55, P645, DOI 10.1016/0002-9149(85)90129-8; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; SAVAGE HR, 1987, CLIN CARDIOL, V10, P621, DOI 10.1002/clc.4960101107; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; SELLERS TD, 1987, AM J CARDIOL, V59, P828; SHARMA B, 1987, AM J CARDIOL, V59, P740, DOI 10.1016/0002-9149(87)91084-8; SHEPS DS, 1989, AM HEART J, V117, P177, DOI 10.1016/0002-8703(89)90673-X; STERN S, 1974, BRIT HEART J, V36, P481; SUNG RJ, 1981, MIAMI MED, V51, P26; WATERS DD, 1979, CIRCULATION, V59, P580, DOI 10.1161/01.CIR.59.3.580; WHITAKER MP, 1989, AM J CARDIOL, V64, P591, DOI 10.1016/0002-9149(89)90484-0	42	284	289	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1451	1455		10.1056/NEJM199205283262202	http://dx.doi.org/10.1056/NEJM199205283262202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1574091				2022-12-28	WOS:A1992HV46900002
J	JOHNSON, RE; JAFFE, JH; FUDALA, PJ				JOHNSON, RE; JAFFE, JH; FUDALA, PJ			A CONTROLLED TRIAL OF BUPRENORPHINE TREATMENT FOR OPIOID DEPENDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEROIN-ADDICTS; METHADONE; MAINTENANCE; OPIATE; ABUSE; DETOXIFICATION	Objective.-To assess the efficacy of buprenorphine for short-term maintenance/detoxification. Design.-A randomized, double-blind, parallel group study comparing buprenorphine, 8 mg/d, methadone, 60 mg/d, and methadone, 20 mg/d, in a 17-week maintenance phase followed by an 8-week detoxification phase. Setting.-Outpatient facilities at the Addiction Research Center, Baltimore, Md. Patients.-One hundred sixty-two volunteers seeking treatment for opioid dependence. Intervention.-In addition to the medication, counseling using a relapse prevention model was offered but not required. Primary Outcome Measures.-Retention time in treatment, urine samples negative for opioids, and failure to maintain abstinence. Results.-Throughout the maintenance phase, retention rates were significantly greater for buprenorphine (42%) than for methadone, 20 mg/d (20%, P < .04); the percentage of urine samples negative for opioids was significantly greater for buprenorphine (53%, P < .001) and methadone, 60 mg/d (44%, P < .04), than for methadone, 20 mg/d (29%). Failure to maintain abstinence during the maintenance phase was significantly greater for methadone, 20 mg/d, than for buprenorphine (P < .03). During the detoxification phase, no differences were observed between groups with respect to urine samples negative for opioids. For the entire 25 weeks, retention rates for buprenorphine (30%, P < .01) and methadone, 60 mg/d (20%, P < .05), were significantly greater than for methadone, 20 mg/d (6%). All treatments were well tolerated, with similar profiles of self-reported adverse effects. The percentages of patients who received counseling did not differ between groups. Conclusions.-Buprenorphine was as effective as methadone, 60 mg/d, and both were superior to methadone, 20 mg/d, in reducing illicit opioid use and maintaining patients in treatment for 25 weeks.	NIDA,ADDICT RES CTR,BALTIMORE,MD	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)								BABST DV, 1971, BRIT J ADDICT, V66, P195; Ball JC, 1991, EFFECTIVENESS METHAD, P212; BERRY GJ, 1972, 4TH P NAT C METH TRE, P409; BICKEL WK, 1988, CLIN PHARMACOL THER, V43, P72, DOI 10.1038/clpt.1988.13; BICKEL WK, 1988, J PHARMACOL EXP THER, V247, P47; BROWN BS, 1972, COMPR PSYCHIAT, V13, P391, DOI 10.1016/0010-440X(72)90010-7; BROWN BS, 1973, INT J ADDICT, V8, P49, DOI 10.3109/10826087309048763; BUDD K, 1981, ANAESTHESIA, V36, P900, DOI 10.1111/j.1365-2044.1981.tb08867.x; CHILDRESS AR, 1991, DRUG ABUSE MENTAL HL, V106, P167; COX DR, 1972, J R STAT SOC B, V34, P187; DBLUMBERG H, 1967, TOXICOL APPL PHARM, V10, P406; DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304; DOLE VP, 1965, JAMA-J AM MED ASSOC, V193, P80; FUDALA PJ, 1990, CLIN PHARMACOL THER, V47, P525, DOI 10.1038/clpt.1990.67; GARBUTT GD, 1972, 4TH P NAT C METH TRE, P411; GOLDSTEIN A, 1972, CLIN PHARMACOL THER, V13, P59; GOLDSTEIN A, 1972, ARCH GEN PSYCHIAT, V26, P291; GOLDSTEIN A, 1970, 3RD P NAT C METH TRE, P31; HARGREAVES WA, 1983, US DHHS ADM831281 PU, P19; HIGGINS ST, 1986, DRUG ALCOHOL DEPEN, V17, P311, DOI 10.1016/0376-8716(86)90080-3; HSER Y-I, 1990, International Journal of the Addictions, V25, P1295; JAFFE JH, 1970, INT J ADDICT, V5, P375, DOI 10.3109/10826087009057006; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; JOHNSON RE, 1989, CLIN PHARMACOL THER, V46, P335, DOI 10.1038/clpt.1989.147; KLEBER H D, 1985, Journal of Substance Abuse Treatment, V2, P117, DOI 10.1016/0740-5472(85)90036-4; KOSTEN TR, 1989, LIFE SCI, V44, P887, DOI 10.1016/0024-3205(89)90589-4; KOSTEN TR, 1988, LIFE SCI, V42, P635, DOI 10.1016/0024-3205(88)90454-7; LING W, 1976, ARCH GEN PSYCHIAT, V33, P709; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MARTIN WR, 1973, ARCH GEN PSYCHIAT, V28, P784; Martin WR, 1984, PHARMACOL REV, V35, P283; MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620; MELLO NK, 1980, SCIENCE, V207, P657, DOI 10.1126/science.7352279; MELLO NK, 1982, J PHARMACOL EXP THER, V223, P30; MELLO NK, 1989, SCIENCE, V245, P859, DOI 10.1126/science.2772637; MILBY JB, 1988, J NERV MENT DIS, V176, P409, DOI 10.1097/00005053-198807000-00003; PEACHEY JE, 1988, BRIT J ADDICT, V83, P193; REISINGER M, 1985, DRUG ALCOHOL DEPEN, V16, P257, DOI 10.1016/0376-8716(85)90050-X; RICHMAN A, 1966, CAN PSYCHIAT ASSOC J, V11, P107, DOI 10.1177/070674376601100207; SANSONE J, 1980, INT J ADDICT, V15, P711, DOI 10.3109/10826088009040050; SEOW SSW, 1986, MED J AUSTRALIA, V144, P407, DOI 10.5694/j.1326-5377.1986.tb128412.x; SZAPOCZNIK J, 1977, INT J ADDICT, V12, P1067, DOI 10.3109/10826087709027271; 1984, NATIONAL SUMMARY NAR	45	438	445	1	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2750	2755		10.1001/jama.267.20.2750	http://dx.doi.org/10.1001/jama.267.20.2750			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV265	1578593				2022-12-28	WOS:A1992HV26500021
J	CAMPION, EW				CAMPION, EW			DESPERATE DISEASES AND PLASMAPHERESIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Abel JJ, 1914, J PHARMACOL EXP THER, V5, P625; ANGELL M, 1989, NEW ENGL J MED, V321, P464, DOI 10.1056/NEJM198908173210708; BERKMAN E, 1982, NEW ENGL J MED, V306, P1418, DOI 10.1056/NEJM198206103062310; DAU PC, 1981, ARCH NEUROL-CHICAGO, V38, P544, DOI 10.1001/archneur.1981.00510090038003; DWOSH IL, 1983, NEW ENGL J MED, V308, P1124, DOI 10.1056/NEJM198305123081903; JONES JV, 1981, J LAB CLIN MED, V97, P589; Klein HG, 1986, J CLIN APHERESIS, V3, P1; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; REIMANN PM, 1990, INTENS CARE MED, V16, P3, DOI 10.1007/BF01706318; Shakespeare William, HAMLET; SHUMAK KH, 1984, NEW ENGL J MED, V310, P762, DOI 10.1056/NEJM198403223101206; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; 1985, JAMA-J AM MED ASSOC, V253, P819	14	33	33	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1425	1427		10.1056/NEJM199205213262109	http://dx.doi.org/10.1056/NEJM199205213262109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1569977				2022-12-28	WOS:A1992HU89000009
J	CHOE, S; BENNETT, MJ; FUJII, G; CURMI, PMG; KANTARDJIEFF, KA; COLLIER, RJ; EISENBERG, D				CHOE, S; BENNETT, MJ; FUJII, G; CURMI, PMG; KANTARDJIEFF, KA; COLLIER, RJ; EISENBERG, D			THE CRYSTAL-STRUCTURE OF DIPHTHERIA-TOXIN	NATURE			English	Article							AERUGINOSA EXOTOXIN-A; TUMOR NECROSIS FACTOR; AMINO-ACID-SEQUENCE; PSEUDOMONAS-AERUGINOSA; RECEPTOR-BINDING; CRYSTALLOGRAPHIC REFINEMENT; NUCLEOTIDE-BINDING; ACTIVE-SITE; FRAGMENT; RESOLUTION	The crystal structure of the diphtheria toxin dimer at 2.5 angstrom resolution reveals a Y-shaped molecule of three domains. The catalytic domain, called fragment A, is of the alpha + beta-type. Fragment B actually consists of two domains. The transmembrane domain consists of nine alpha-helices, two pairs of which are unusually apolar and may participate in pH-triggered membrane insertion and translocation. The receptor-binding domain is a flattened beta-barrel with a jelly-roll-like topology. Three distinct functions of the toxin, each carried out by a separate structural domain, can be useful in designing chimaeric proteins, such as immunotoxins, in which the receptor-binding domain is substituted with antibodies to target other cell types.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; HARVARD UNIV, SCH MED, SHIPLEY INST MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	University of California System; University of California Los Angeles; Harvard University; Harvard Medical School	CHOE, S (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Curmi, Paul/G-7185-2011; Ibrahim, Essam Hassan/G-1960-2018	Curmi, Paul/0000-0001-5762-7638; Ibrahim, Essam Hassan/0000-0003-0130-2257; Collier, R John/0000-0002-2427-4239				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; BRUNGER AT, 1991, ACTA CRYSTALLOGR A, V47, P195, DOI 10.1107/S0108767390011795; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1986, BIOCHEMISTRY-US, V25, P2425, DOI 10.1021/bi00357a019; CARROLL SF, 1988, MOL MICROBIOL, V2, P293, DOI 10.1111/j.1365-2958.1988.tb00031.x; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P9491, DOI 10.1073/pnas.87.23.9491; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; COLLIER RJ, 1982, J BIOL CHEM, V257, P5283; COLLINS CM, 1985, BIOCHIM BIOPHYS ACTA, V828, P138, DOI 10.1016/0167-4838(85)90049-4; COLOMBATTI M, 1989, METHOD ENZYMOL, V178, P404; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FUJII G, 1991, J MOL BIOL, V222, P861, DOI 10.1016/0022-2836(91)90577-S; GIANNINI G, 1984, NUCLEIC ACIDS RES, V12, P4063, DOI 10.1093/nar/12.10.4063; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KIYOKAWA T, 1991, PROTEIN ENG, V4, P463, DOI 10.1093/protein/4.4.463; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LORY S, 1980, P NATL ACAD SCI-BIOL, V77, P267, DOI 10.1073/pnas.77.1.267; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; PAPINI E, 1991, J BIOL CHEM, V266, P2494; PAPINI E, 1989, J BIOL CHEM, V264, P12385; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PROIA RL, 1980, J BIOL CHEM, V255, P2025; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1979, THESIS U CALIFORNIA; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHAO JM, 1988, BIOCHEMISTRY-US, V27, P3398, DOI 10.1021/bi00409a041	50	579	610	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1992	357	6375					216	222		10.1038/357216a0	http://dx.doi.org/10.1038/357216a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589020				2022-12-28	WOS:A1992HV19500046
J	LINDNER, K				LINDNER, K			ENCOURAGE INFORMATION THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		[Anonymous], 1982, PRESIDENTS COMMISSIO	1	7	7	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2592	2592						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573737				2022-12-28	WOS:A1992HT82300008
J	BOYSEN, G; PETERSEN, P				BOYSEN, G; PETERSEN, P			ASPIRIN FOR CEREBRAL TRANSIENT ISCHEMIC ATTACKS OR MINOR ISCHEMIC STROKES	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											BOYSEN, G (corresponding author), RIGSHOSP,DK-2100 COPENHAGEN,DENMARK.							BOYSEN G, 1988, STROKE, V19, P1211, DOI 10.1161/01.STR.19.10.1211; UK-TIA Study Group, 1988, BMJ, V296, P316; 1991, NEW ENGL J MED, V325, P1261; 1991, LANCET, V338, P1345	4	1	1	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1288	1288						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560807				2022-12-28	WOS:A1992HR44700011
J	WEILER, PC; NEWHOUSE, JP; HIATT, HH				WEILER, PC; NEWHOUSE, JP; HIATT, HH			PROPOSAL FOR MEDICAL LIABILITY REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALPRACTICE; TORT		BRIGHAM & WOMENS HOSP,DIV GEN MED,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health			Newhouse, Joseph/AGJ-5632-2022					BOVBJERG RR, 1989, NORTHWEST U LAW REV, V83, P908; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BURSTIN H R, 1991, Clinical Research, V39, p189A; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; JOHNSON KB, 1989, VANDERBILT LAW REV, V42, P1365; JOHNSON WG, IN PRESS JAMA; LAWTHERS AG, IN PRESS HLTH POLITI; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MANUEL BM, 1990, NEW ENGL J MED, V322, P627, DOI 10.1056/NEJM199003013220912; Mills DH, 1977, REPORT MED INSURANCE; MOORE MJ, 1990, COMPENSATION MECHANI; PRIEST GL, 1987, YALE LAW J, V96, P1521, DOI 10.2307/796494; US Congress Office of Technology Assessment, 1985, PREVENTING ILLNESS I; WEILER PA, IN PRESS PATIENTS DO; WEILER PC, 1991, MED MALPRACTICE TRIA; 1990, PATIENTS DOCTORS LAW	19	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2355	2358		10.1001/jama.267.17.2355	http://dx.doi.org/10.1001/jama.267.17.2355			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HR015	1564776				2022-12-28	WOS:A1992HR01500029
J	VARKI, A				VARKI, A			OF PRIDE, PREJUDICE, AND DISCRIMINATION - WHY GENERALIZATIONS CAN BE UNFAIR TO THE INDIVIDUAL	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						FOREIGN MEDICAL GRADUATES; EDUCATION, MEDICAL; DISCRIMINATION; PREJUDICE		. The categorization of individuals into groups can serve some useful purposes. If the individuals being grouped are heterogeneous, however, the categories used are likely to be flawed. Thus, any resulting generalizations are also flawed, especially when applied to a given individual in a group. The most serious attendant dangers can be misplaced pride, misguided prejudice, and unfair discrimination. The categorization of physicians according to their original medical training and the generalizations that result are examined here. The principles advanced could also be applied to many other forms of categorization.			VARKI, A (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, 9-JCI, LA JOLLA, CA 92093 USA.							BOGDONOFF MD, 1991, ANN INTERN MED, V114, P426, DOI 10.7326/0003-4819-114-5-426; BOGDONOFF MD, 1991, ANN INTERN MED, V114, P1063; CONN HL, 1989, ACAD MED, V64, P448, DOI 10.1097/00001888-198908000-00007; KARNAD A, 1991, ANN INTERN MED, V114, P1062; KELLIS DS, 1991, ANN INTERN MED, V114, P1062; MICK SS, 1991, MED CARE, V29, P229, DOI 10.1097/00005650-199103000-00005; NAGELBERG S, 1980, AM J PSYCHIAT, V137, P690; NORCINI JJ, 1991, ANN INTERN MED, V114, P33, DOI 10.7326/0003-4819-114-1-33; ROBINSON GH, 1989, ACAD MED, V64, P357, DOI 10.1097/00001888-198907000-00001; VERGHESE A, 1991, ANN INTERN MED, V114, P1062, DOI 10.7326/0003-4819-114-12-1062	10	17	17	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					762	764		10.7326/0003-4819-116-9-762	http://dx.doi.org/10.7326/0003-4819-116-9-762			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558349				2022-12-28	WOS:A1992HQ62300011
J	SHAPIRO, DS; KENNEY, SC; JOHNSON, M; DAVIS, CH; KNIGHT, ST; WYRICK, PB				SHAPIRO, DS; KENNEY, SC; JOHNSON, M; DAVIS, CH; KNIGHT, ST; WYRICK, PB			BRIEF REPORT - CHLAMYDIA-PSITTACI ENDOCARDITIS DIAGNOSED BY BLOOD CULTURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CAMPUS BOX 7290,816 FLOB,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIAID NIH HHS [U01-AI31496] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031496] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRKHEAD JS, 1974, BRIT HEART J, V36, P728; BROMAGE D, 1980, J INFECTION, V2, P151, DOI 10.1016/S0163-4453(80)91209-8; COLL R, 1967, BRIT MED J, V4, P35, DOI 10.1136/bmj.4.5570.35; DICK DC, 1977, BRIT HEART J, V39, P914; Dymock I W, 1971, Br J Clin Pract, V25, P240; GRIST NR, 1964, BRIT MED J, V2, P21, DOI 10.1136/bmj.2.5400.21; HARRIS AA, 1984, ANN INTERN MED, V101, P502, DOI 10.7326/0003-4819-101-4-502; JANNACH JR, 1958, AMA J DIS CHILD, V96, P734, DOI 10.1001/archpedi.1958.02060060736016; JARIWALLA AG, 1980, BRIT MED J, V280, P155, DOI 10.1136/bmj.280.6208.155; JONES RB, 1982, JAMA-J AM MED ASSOC, V247, P655, DOI 10.1001/jama.247.5.655; KNIGHT ST, 1989, J MICROBIOL METH, V10, P255, DOI 10.1016/0167-7012(89)90013-4; LEVISON DA, 1971, LANCET, V2, P844; REGAN RJ, 1979, BRIT HEART J, V42, P349, DOI 10.1136/hrt.42.3.349; REID JM, 1982, BRIT MED J, V284, P237, DOI 10.1136/bmj.284.6311.237-a; SCHELD WM, 1990, PRINCIPLES PRACTICE, P691; SCHOLTE AJ, 1930, NED TIJDSCHR GENEES, V74, P2741; SUTTON GC, 1967, CIRCULATION, V36, P830, DOI 10.1161/01.CIR.36.6.830; THOMAS DJB, 1977, PRACTITIONER, V218, P394; VOSTI GJ, 1961, ANN INTERN MED, V54, P764, DOI 10.7326/0003-4819-54-4-764; WALKER LJE, 1987, BRIT HEART J, V57, P58; WARD C, 1975, BRIT MED J, V4, P734, DOI 10.1136/bmj.4.5999.734; WARD C, 1974, LANCET, V2, P734	22	41	43	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1192	1195		10.1056/NEJM199204303261805	http://dx.doi.org/10.1056/NEJM199204303261805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1557094				2022-12-28	WOS:A1992HR00800005
J	KUZNETSOV, SA; LANGFORD, GM; WEISS, DG				KUZNETSOV, SA; LANGFORD, GM; WEISS, DG			ACTIN-DEPENDENT ORGANELLE MOVEMENT IN SQUID AXOPLASM	NATURE			English	Article							FAST AXONAL-TRANSPORT; INHIBITION; MECHANISM; MICROFILAMENTS; MICROTUBULES; FILAMENTS; MOTILITY; VANADATE; PROTEIN; KINESIN	STUDIES of organelle movement in axoplasm extruded from the squid giant axon have led to the basic discoveries of microtubule-dependent organelle motility 1-3 and the characterization of the microtubule-based motor proteins kinesin and cytoplasmic dynein 4,5. Rapid organelle movement in higher animal cells, especially in neurons, is considered to be microtubule-based. The role of actin filaments, which are also abundant in axonal cytoplasm 6,7, has remained unclear. The inhibition of organelle movement in axoplasm by actin-binding proteins 8-11 such as DNase I, gelsolin and synapsin I has been attributed to their ability to disorganize the microtubule domains where most of the actin-filaments are located 7. Here we provide evidence of a new type of organelle movement in squid axoplasm which is independent of both microtubules and microtubule-based motors. This movement is ATP-dependent, unidirectional, actin-dependent, and probably generated by a myosin-like motor. These results demonstrate that an actomyosin-like mechanism can be directly involved in the generation of rapid organelle transport in nerve cells.	TECH UNIV MUNICH,INST ZOOL,W-8046 GARCHING,GERMANY; DARTMOUTH COLL,DEPT BIOL SCI,HANOVER,NH 03755; MV LOMONOSOV STATE UNIV,FAC BIOL,DEPT MOLEC BIOL,MOSCOW 119899,USSR	Technical University of Munich; Dartmouth College; Lomonosov Moscow State University	KUZNETSOV, SA (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.			Langford, George/0000-0001-9737-2182; Weiss, Dieter G./0000-0002-1789-2995				ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; BRADY ST, 1984, NATURE, V310, P56, DOI 10.1038/310056a0; CALDWELL PC, 1960, J PHYSIOL-LONDON, V152, P561, DOI 10.1113/jphysiol.1960.sp006509; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; GIBBONS IR, 1978, P NATL ACAD SCI USA, V75, P2220, DOI 10.1073/pnas.75.5.2220; GILBERT SP, 1989, J CELL BIOL, V109, P2379, DOI 10.1083/jcb.109.5.2379; GOLDBERG DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7448, DOI 10.1073/pnas.77.12.7448; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; ISENBERG G, 1980, BRAIN RES, V194, P588, DOI 10.1016/0006-8993(80)91247-0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MCGUINNESS TL, 1989, J NEUROSCI, V9, P4138; MORRIS JR, 1984, J CELL BIOL, V98, P2064, DOI 10.1083/jcb.98.6.2064; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SMITH SJ, 1990, EUR J BIOCHEM, V193, P69, DOI 10.1111/j.1432-1033.1990.tb19305.x; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WEISS D G, 1989, P221; WEISS DG, 1988, CELL MOTIL CYTOSKEL, V10, P285, DOI 10.1002/cm.970100133; WEISS DG, 1986, J CELL SCI S, V5, P1; WEST JJ, 1967, J BIOL CHEM, V242, P1140; WEST JJ, 1967, BIOCHEM BIOPH RES CO, V29, P611, DOI 10.1016/0006-291X(67)90530-X; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	29	324	325	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					722	725		10.1038/356722a0	http://dx.doi.org/10.1038/356722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570018				2022-12-28	WOS:A1992HQ14600065
J	VANDERMECHE, FGA; SCHMITZ, PIM				VANDERMECHE, FGA; SCHMITZ, PIM			A RANDOMIZED TRIAL COMPARING INTRAVENOUS IMMUNE GLOBULIN AND PLASMA-EXCHANGE IN GUILLAIN-BARRE-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE INFLAMMATORY POLYRADICULONEUROPATHY; GAMMA-GLOBULIN; DEMYELINATING POLYNEUROPATHY; MYASTHENIA-GRAVIS; IMMUNOGLOBULIN; THERAPY; ANTIBODIES; INHIBITION; SAFETY; CELLS	Background. The subacute demyelinating polyneuropathy known as Guillain-Barre syndrome improves more rapidly with plasma exchange than with supportive care alone. We conducted a multicenter trial to determine whether intravenous immune globulin is as effective as the more complicated treatment with plasma exchange. Methods. To enter the study, patients had to have had Guillain-Barre syndrome for less than two weeks and had to be unable to walk independently. They were randomly assigned to receive either five plasma exchanges (each of 200 to 250 ml per kilogram of body weight) or five doses of a preparation of intravenous immune globulin (0.4 g per kilogram per day). The predefined outcome measure was improvement at four weeks by at least one grade on a seven-point scale of motor function. Results. After 150 patients had been treated, strength had improved by one grade or more in 34 percent of those treated with plasma exchange, as compared with 53 percent of those treated with immune globulin (difference, 19 percent; 95 percent confidence interval, 3 percent to 34 Percent; P = 0.024). The median time to improvement by one grade was 41 days with plasma exchange and 27 days with immune globulin therapy (P = 0.05). The immune globulin group had significantly fewer complications and less need for artificial ventilation. Conclusions. In the acute Guillain-Barre syndrome, treatment with intravenous immune globulin is at least as effective as plasma exchange and may be superior.	DANIEL DENHOED CANC CTR,DEPT TRIALS & STAT,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	VANDERMECHE, FGA (corresponding author), ACAD HOSP ROTTERDAM,DEPT NEUROL EE2222,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							ARNASON BGW, 1984, PERIPHERAL NEUROPATH, P2050; ARSURA EL, 1986, ARCH INTERN MED, V146, P1365, DOI 10.1001/archinte.146.7.1365; ASBURY AK, 1981, ANN NEUROL, V9, P1, DOI 10.1002/ana.410090703; AUDET AM, 1989, MED DECIS MAKING, V9, P324; BANFFER JRJ, 1987, A VAN LEEUW J MICROB, V53, P183, DOI 10.1007/BF00393846; BORDET JC, 1987, THROMB RES, V47, P165, DOI 10.1016/0049-3848(87)90373-2; BURLESON DG, 1988, ARCH SURG-CHICAGO, V123, P1379; COOK L, 1988, J CLIN IMMUNOL, V8, P23, DOI 10.1007/BF00915153; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GREENWOOD RJ, 1984, LANCET, V1, P877; IMBACH P, 1981, LANCET, V1, P1128; KLEYWEG RP, 1988, NEUROLOGY, V38, P1639, DOI 10.1212/WNL.38.10.1639; KLEYWEG RP, 1991, MUSCLE NERVE, V14, P1103, DOI 10.1002/mus.880141111; KLEYWEG RP, 1991, J NEUROL NEUROSUR PS, V54, P957, DOI 10.1136/jnnp.54.11.957; LEE ML, 1987, CLIN THER, V9, P300; LEE ML, 1988, VIRAL HEPATITIS LIVE, P596; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MCKHANN GM, 1988, ANN NEUROL, V23, P347, DOI 10.1002/ana.410230406; OOMES P G, 1990, Journal of Neurology, V237, pS10; OOMES PG, 1990, ANTIBODIES GANGLIOSI; OSTERMAN PO, 1986, LANCET, V2, P1161; OSTERMAN PO, 1984, LANCET, V2, P1296; ROPPER AH, 1988, ARCH NEUROL-CHICAGO, V45, P314, DOI 10.1001/archneur.1988.00520270096026; SALAMA A, 1983, LANCET, V2, P193; SCHWARTZ RS, 1987, AM J MED, V83, P46, DOI 10.1016/0002-9343(87)90550-X; SULTAN Y, 1984, LANCET, V2, P765; TOYKA KV, 1987, MUSCLE NERVE, V10, P222, DOI 10.1002/mus.880100305; Uhr J W, 1968, Adv Immunol, V8, P81, DOI 10.1016/S0065-2776(08)60465-4; VANDERMECHE FGA, 1989, BRAIN, V112, P1563, DOI 10.1093/brain/112.6.1563; VANDOORN PA, 1988, NEUROLOGY, V38, P1592, DOI 10.1212/WNL.38.10.1592; VERMEULEN M, 1985, J NEUROL SCI, V70, P317, DOI 10.1016/0022-510X(85)90173-X; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P605, DOI 10.1136/jnnp.51.5.605; 1987, ANN NEUROL, V22, P753; 1985, NEUROLOGY, V35, P1096; 1986, JAMA-J AM MED ASSOC, V256, P1333	35	950	964	3	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1123	1129		10.1056/NEJM199204233261705	http://dx.doi.org/10.1056/NEJM199204233261705			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552913				2022-12-28	WOS:A1992HP80000005
J	BHOPAL, RS; DIGGLE, P; ROWLINGSON, B				BHOPAL, RS; DIGGLE, P; ROWLINGSON, B			PINPOINTING CLUSTERS OF APPARENTLY SPORADIC CASES OF LEGIONNAIRES-DISEASE	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To test the hypothesis that many non-outbreak cases of legionnaires' disease are not sporadic and to attempt to pinpoint cases clustering in space and time. Design - Descriptive study of a case series, 1978-86. Setting - 15 health boards in Scotland. Patients - 203 probable cases of non-outbreak, non-travel, community acquired legionnaires' disease in patients resident in Scotland. Main measures - Date of onset of disease and postcode and health board of residence of cases. Results - Space-time clustering was present and numerous groups of cases were identified, all but two being newly recognised. Nine cases occurred during three months within two postcodes in Edinburgh, and an outbreak was probably missed. In several places cases occurred in one area over a prolonged period-for example, nine cases in postcode districts G11.5 and G12.8 in Glasgow during five years (estimated mean annual incidence of community acquired, non-outbreak, non-travel legionnaires' disease of 146 per million residents v 4.8 per million for Scotland). Statistical analysis showed that the space time clustering of cases in the Glasgow and Edinburgh areas was unusual (p = 0.036, p = 0.068 respectively). Conclusion - Future surveillance requires greater awareness that clusters can be overlooked; case searching whenever a case is identified; collection of complete information particularly of date of onset of the disease and address or postcode; ongoing analysis for space-time clustering; and an accurate yet workable definition of sporadic cases. Other researchers should re-examine their data on apparently sporadic infection.	UNIV LANCASTER,SCH ENGN COMP & MATH SCI,DEPT MATH,LANCASTER LA1 4YF,ENGLAND	Lancaster University	BHOPAL, RS (corresponding author), SCH HLTH CARE SCI,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Diggle, Peter J/A-3025-2009	Rowlingson, Barry/0000-0002-8586-6625; Diggle, Peter/0000-0003-3521-5020				ADDISS DG, 1989, J INFECT DIS, V159, P572, DOI 10.1093/infdis/159.3.572; BARTLETT CLR, 1986, LEGIONELLA INFECTION; BHOPAL R S, 1990, Health Bulletin (Edinburgh), V48, P288; BHOPAL RS, 1991, J INFECTION, V22, P153, DOI 10.1016/0163-4453(91)91569-J; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P281; BHOPAL RS, 1991, EPIDEMIOL INFECT, V106, P45, DOI 10.1017/S0950268800056430; BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; BHOPAL RS, 1991, J INFECTION, V22, P97, DOI 10.1016/0163-4453(91)91178-Z; DIGGLE P., 1985, APPL STAT-J ROY ST C, V34, P138, DOI DOI 10.2307/2347366; DIGGLE PJ, 1983, STATISTICAL ANAL SPA; DIGGLE PJ, 1991, 2ND ORDER ANAL SPACE; ENGLAND AC, 1981, ANN INTERN MED, V94, P164, DOI 10.7326/0003-4819-94-2-164; FALLON RJ, 1982, J HYG-CAMBRIDGE, V89, P439, DOI 10.1017/S002217240007100X; GATRELL AC, 1991, ENVIRON PLANN A, V23, P1447, DOI 10.1068/a231447; HELMS CM, 1984, AM J MED SCI, V288, P2, DOI 10.1097/00000441-198407000-00001; KNOX G, 1963, BRIT J PREV SOC MED, V17, P121; MCFARLANE JT, 1990, RESPIRATORY MED, P906; Nimmo A W, 1984, Health Bull (Edinb), V42, P199; RASHED K, 1986, LANCET, V1, P197; Ripley BD, 1981, SPAT STAT-NETH; ROTHMAN KJ, 1990, AM J EPIDEMIOL, V132, pS6, DOI 10.1093/oxfordjournals.aje.a115790; STOUT JE, 1987, JAMA-J AM MED ASSOC, V257, P1215, DOI 10.1001/jama.257.9.1215; TIMBURY MC, 1986, J HYG-CAMBRIDGE, V97, P393, DOI 10.1017/S0022172400063580; 1986, LANCET, V2, P380; 1987, 2ND COMM INQ REP	25	32	32	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1022	1027		10.1136/bmj.304.6833.1022	http://dx.doi.org/10.1136/bmj.304.6833.1022			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586784	Bronze, Green Published			2022-12-28	WOS:A1992HQ14200020
J	SADLER, DW; POUNDER, DJ; URQUHART, GED; PORTERBOVERI, M				SADLER, DW; POUNDER, DJ; URQUHART, GED; PORTERBOVERI, M			PREVALENCE OF HIV ANTIBODY IN FORENSIC CASES	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,ROYAL INFIRM,DEPT FORENS MED,DUNDEE DD1 9ND,SCOTLAND; TAYSIDE HLTH BOARD,DEPT PUBL HLTH MED,DUNDEE,SCOTLAND; UNIV DUNDEE,ROYAL INFIRM,DEPT MED MICROBIOL,DUNDEE DD1 9ND,SCOTLAND	Royal Infirmary of Edinburgh; University of Dundee; Royal Infirmary of Edinburgh; University of Dundee								EVANS BG, 1991, BRIT MED J, V302, P1351, DOI 10.1136/bmj.302.6789.1351; MCCORMICK A, 1991, BRIT MED J, V302, P1365, DOI 10.1136/bmj.302.6789.1365; MOSS AR, 1973, AIDS, V3, P5589; SMITH R, 1990, BRIT MED J, V301, P518, DOI 10.1136/bmj.301.6751.518; 1991, LANCET, V337, P950	5	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1027	1028		10.1136/bmj.304.6833.1027	http://dx.doi.org/10.1136/bmj.304.6833.1027			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586785	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200021
J	BARRY, CE; HAYES, SF; HACKSTADT, T				BARRY, CE; HAYES, SF; HACKSTADT, T			NUCLEOID CONDENSATION IN ESCHERICHIA-COLI THAT EXPRESS A CHLAMYDIAL HISTONE HOMOLOG	SCIENCE			English	Article							GENE-EXPRESSION; PSEUDOMONAS-AERUGINOSA; DNA; PROTEIN; TRACHOMATIS; VIRULENCE; BACTERIA; CYCLE; H1	Chlamydial cell types are adapted for either extracellular survival or intracellular growth. In the transcriptionally inert elementary bodies, the chromosome is densely compacted; in metabolically active reticulate bodies, the chromatin is loosely organized. Condensation of the chlamydial nucleoid occurs concomitant with expression of proteins homologous to eukaryotic histone H1. When the Chlamydia trachomatis 18-kilodalton histone homolog Hcl is expressed in Escherichia coli, a condensed nucleoid structure similar to that of chlamydiae is observed with both light and electron microscopy. These results support a role for Hc1 in condensation of the chlamydial nucleoid.	NIAID, ROCKY MT LABS, INTRACELLULAR PARASITES LAB, HAMILTON, MT 59840 USA; NIAID, ROCKY MT LABS, VECTORS & PATHOGENS LAB, STRUCT PATHOBIOL SECT, HAMILTON, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Barry, III, Clifton/H-3839-2012; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X; Hackstadt, Ted/0000-0003-1367-5528				ARNDTJOVIN DJ, 1989, METHOD CELL BIOL, V30, P417; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; COSTERTON JW, 1976, CAN J MICROBIOL, V22, P16, DOI 10.1139/m76-003; DERETIC V, 1990, J BACTERIOL, V172, P5544, DOI 10.1128/jb.172.10.5544-5554.1990; DERETIC V, 1991, MOL MICROBIOL, V5, P1577, DOI 10.1111/j.1365-2958.1991.tb01903.x; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HACKSTADT T, 1991, J BACTERIOL, V173, P7046, DOI 10.1128/jb.173.21.7046-7049.1991; HACKSTADT T, 1991, P NATL ACAD SCI USA, V88, P3937, DOI 10.1073/pnas.88.9.3937; HATCH TP, 1986, J BACTERIOL, V165, P379, DOI 10.1128/jb.165.2.379-385.1986; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; KATO J, 1990, P NATL ACAD SCI USA, V87, P2887, DOI 10.1073/pnas.87.8.2887; Larsson L.-I., 1988, IMMUNOCYTOCHEMISTRY; MANAFI M, 1991, MICROBIOL REV, V55, P335, DOI 10.1128/MMBR.55.3.335-348.1991; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NEWHALL WJ, 1987, INFECT IMMUN, V55, P162, DOI 10.1128/IAI.55.1.162-168.1987; PERARA E, 1990, CHLAMYDIAL INFECTION, P44; PETTIJOHN DE, 1982, CELL, V30, P667, DOI 10.1016/0092-8674(82)90269-0; PINCUS SH, 1990, J EXP MED, V172, P745, DOI 10.1084/jem.172.3.745; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; ROBINSON EN, 1984, INFECT IMMUN, V46, P361, DOI 10.1128/IAI.46.2.361-366.1984; SCHACHTER J, 1988, CURR TOP MICROBIOL, V138, P109; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SJASTAD K, 1982, J GEN MICROBIOL, V128, P3037; SOLBRIG MV, 1990, MOL MICROBIOL, V4, P1535, DOI 10.1111/j.1365-2958.1990.tb02064.x; STONINGT.OG, 1971, P NATL ACAD SCI USA, V68, P6, DOI 10.1073/pnas.68.1.6; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAO S, 1991, J BACTERIOL, V173, P2818, DOI 10.1128/JB.173.9.2818-2822.1991; WAGAR EA, 1988, INFECT IMMUN, V56, P1678, DOI 10.1128/IAI.56.7.1678-1684.1988	35	96	99	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					377	379		10.1126/science.256.5055.377	http://dx.doi.org/10.1126/science.256.5055.377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566085				2022-12-28	WOS:A1992HP03200036
J	NORMAND, C				NORMAND, C			LEADING FOR HEALTH - RESPONSES .8. FUNDING HEALTH-CARE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article											NORMAND, C (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.			Normand, Charles/0000-0002-0885-5754				BOSANQUET N, 1989, WILL YOU STILL LOVE; CICHON M, 1991, INT LABOUR REV, V130, P3; FIGUERAS J, 1991, HLTH CARE INFRASTRUC; McGuire A, 1988, EC HLTH CARE; NORMAND C, 1991, BRIT MED J, V303, P1572, DOI 10.1136/bmj.303.6817.1572; PHELPS C, 1974, COINSURANCE DEMAND H; PROPER C, 1990, COMPETITION HLTH CAR; ROBINSON R, 1991, PUBLIC MONEY MANAGEM, V11, P19; SHEIBER G, 1991, HLTH AFFAIRS, V10, P22; 1991, LEADING HLTH BMA AGE	10	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					768	771		10.1136/bmj.304.6829.768	http://dx.doi.org/10.1136/bmj.304.6829.768			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK800	1571686	Green Published, Bronze			2022-12-28	WOS:A1992HK80000030
J	HUGHES, C				HUGHES, C			MEDICINE IN EUROPE - EUROPEAN LAW, MEDICINE, AND THE SOCIAL CHARTER .14.	BRITISH MEDICAL JOURNAL			English	Article											HUGHES, C (corresponding author), BRITISH MED ASSOC,DEPT LEGAL,LONDON WC1H 9JP,ENGLAND.							de Smith S., 1973, CONSTITUTIONAL ADM L; 1992, 1ST EUR COMM REP	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					700	703		10.1136/bmj.304.6828.700	http://dx.doi.org/10.1136/bmj.304.6828.700			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK761	1571648	Green Published, Bronze			2022-12-28	WOS:A1992HK76100031
J	OKEEFFE, ST; TSAPATSARIS, NP; BEETHAM, WP				OKEEFFE, ST; TSAPATSARIS, NP; BEETHAM, WP			INCREASED PREVALENCE OF MIGRAINE AND CHEST PAIN IN PATIENTS WITH PRIMARY RAYNAUD DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						RAYNAUDS DISEASE; MIGRAINE; CHEST PAIN; VASOCONSTRICTION; HEADACHE	VARIANT ANGINA; FIBROMYALGIA; POPULATION; HEADACHES; DISORDER; SPASM	Objective: To investigate the prevalence of headaches and recurrent chest pain in patients with primary Raynaud disease. Design: Postal survey. Setting: Raynaud disease clinic at the Lahey Clinic Medical Center, a tertiary care hospital. Participants: A consecutive series of 120 patients with primary Raynaud disease who had been observed for at least 2 years, 97 of whom received and 93 of whom completed the questionnaire, and a control group of 93 age- and sex-matched hospital employees with Raynaud phenomenon. Results: Migraine was diagnosed in 57 (61%) patients with primary Raynaud disease and in 21 (23%) of the control group (odds ratio, 5.4; 95% Cl, 2.8 to 10.3). Migraine with aura and migraine without aura were more common in patients with Raynaud disease than in the control subjects (27% compared with 5%; P < 0.001 and 34% compared with 17%; P = 0.008, respectively). Nonmigrainous headaches were more common in the control group (51% compared with 25%; P = 0.003). Chest pains were reported by 44 (47%) of the patients with Raynaud disease and by 15 (16%) of the control group (odds ratio, 4.4; Cl, 2.4 to 9.3). Chest pains were more frequently reported by patients with Raynaud disease who had migraine (34 of 57, 60%) than by patients without migraine (10 of 36, 28%; P = 0.003). Conclusions: An increased prevalence of migraine was found in patients with primary Raynaud disease. Chest pain, often diagnosed as musculoskeletal or nonspecific, was common in patients with primary Raynaud phenomenon, especially in patients who had coexisting migraine.	LAHEY CLIN MED CTR, VASC MED & HYPERTENS SECT, 41 MALL RD, BURLINGTON, MA 01805 USA	Lahey Hospital & Medical Center				O'Keeffe, Shaun/0000-0002-7682-5004				APPENZELLER O, 1963, J NEUROL NEUROSUR PS, V26, P447, DOI 10.1136/jnnp.26.5.447; COFFMAN JD, 1975, PROG CARDIOVASC DIS, V18, P123, DOI 10.1016/0033-0620(75)90002-X; COFFMAN JD, 1989, RAYNAUDS PHENOMENON, P3; DALESSANDRO R, 1988, J NEUROL NEUROSUR PS, V51, P21, DOI 10.1136/jnnp.51.1.21; FAM AG, 1985, CAN MED ASSOC J, V133, P379; HEUPLER FA, 1980, AM J CARDIOL, V45, P873, DOI 10.1016/0002-9149(80)90134-4; ISENBERG DA, 1982, ANN RHEUM DIS, V41, P30, DOI 10.1136/ard.41.1.30; LEPPERT J, 1987, ANGIOLOGY, V38, P871, DOI 10.1177/000331978703801201; LEVINE PR, 1989, SOUTHERN MED J, V82, P580, DOI 10.1097/00007611-198905000-00010; MARICQ HR, 1986, J CHRON DIS, V39, P423, DOI 10.1016/0021-9681(86)90109-8; MARKUS HS, 1992, J NEUROL, V239, P39, DOI 10.1007/BF00839210; MASERI A, 1987, J AM COLL CARDIOL, V9, P249, DOI 10.1016/S0735-1097(87)80372-8; MILLER D, 1981, NEW ENGL J MED, V304, P763, DOI 10.1056/NEJM198103263041306; OLESEN J, 1987, ARCH NEUROL-CHICAGO, V44, P321, DOI 10.1001/archneur.1987.00520150061023; PAL B, 1989, ANN RHEUM DIS, V48, P312, DOI 10.1136/ard.48.4.312; PELLEGRINO MJ, 1990, ARCH PHYS MED REHAB, V71, P526; PRIOLLET P, 1987, AM J MED, V83, P494, DOI 10.1016/0002-9343(87)90760-1; RASKIN NH, 1988, HEADACHE, P99; ROBERTSON D, 1978, LANCET, V1, P452; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; SILMAN A, 1990, BMJ-BRIT MED J, V301, P590, DOI 10.1136/bmj.301.6752.590; TAYLOR PJ, 1970, BRIT J IND MED, V27, P364; WATERS WE, 1975, J NEUROL NEUROSUR PS, V38, P613, DOI 10.1136/jnnp.38.6.613; WELCH KMA, 1987, ARCH NEUROL-CHICAGO, V44, P323, DOI 10.1001/archneur.1987.00520150063024; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; ZAHAVI I, 1984, ARCH INTERN MED, V144, P742, DOI 10.1001/archinte.144.4.742	27	53	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				985	989		10.7326/0003-4819-116-12-985	http://dx.doi.org/10.7326/0003-4819-116-12-985			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586109				2022-12-28	WOS:A1992HY79300006
J	WARTMAN, SA; OSULLIVAN, PS; CYR, MG				WARTMAN, SA; OSULLIVAN, PS; CYR, MG			AMBULATORY-BASED RESIDENCY EDUCATION - IMPROVING THE CONGRUENCE OF TEACHING, LEARNING, AND PATIENT-CARE	ANNALS OF INTERNAL MEDICINE			English	Article							INTERNAL MEDICINE; MODEL	Residency education in internal medicine should be based in the ambulatory setting. The challenge in ambulatory education lies not only in the unique opportunities afforded by the setting but also in the careful implementation of a program based on sound educational principles. We have designed a new ambulatorybased model of internal medicine residency that adheres to the principles of adult learning theory. Four aspects of the proposed residency model are discussed: the setting, the teaching-learning model, the curriculum, and the schedule. Potential barriers to implementation of the model are reviewed, and solutions are suggested. Residency programs in internal medicine are at an important crossroad. Either we can substantially change the programs'content and focus, or we can risk the continued unpopularity and "second-class" status of the programs among medical students. Internal medicine needs to be recognized and accepted as a fundamental primary care discipline to justify continued public support in an era of overspecialization.	BAYSTATE MED CTR, SPRINGFIELD, MA 01107 USA; UNIV MIAMI, MIAMI, FL 33152 USA; TUFTS UNIV, BEDFORD, MA USA; RHODE ISL HOSP, PROVIDENCE, RI 02902 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Baystate Medical Center; University of Miami; Tufts University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	WARTMAN, SA (corresponding author), MT SINAI MED CTR, DEPT MED, 4300 ALTON RD, MIAMI BEACH, FL 33140 USA.			O'Sullivan, Patricia/0000-0002-8706-4095				ALLAN DM, 1984, CONTINUING ED HLTH P, P218; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BARKER LR, 1990, J GEN INTERN MED, V5, pS3, DOI 10.1007/BF02600433; BERMAN J, 1990, TEACH LEARN MED, V2, P98; Blumberg P., 1990, TEACH LEARN MED, V2, P149; Bucher R., 1977, BECOMING PROFESSIONA; DAY SC, 1990, J GEN INTERN MED, V5, P421, DOI 10.1007/BF02599432; EISENBERG JM, 1990, J GEN INTERN MED, V5, pS70, DOI 10.1007/BF02600440; ELLSBURY KE, 1987, J FAM PRACTICE, V25, P273; FLEMING LA, 1991, MAY NAT M SOC GEN IN; GREER DS, 1990, J GEN INTERN MED, V5, pS53, DOI 10.1007/BF02600438; HALPERIN AK, 1990, J GEN INTERN MED, V5, pS35, DOI 10.1007/BF02600436; Justice D., 1988, KNOWING DOING LEARNI, V1st, P49; KIHM JT, 1991, J GEN INTERN MED, V6, P233, DOI 10.1007/BF02598966; LEVINSON W, 1990, EVAL HEALTH PROF, V13, P445, DOI 10.1177/016327879001300406; LOWDERMILK D, 1991, QUALITATIVE HLTH RES, V1, P100; OSULLIVAN PS, 1991, CLIN RES, V39, pA620; OSULLIVAN PS, 1991, TEACH LEARN MED, V3, P101; PACCIONE GA, 1989, ARCH INTERN MED, V149, P2407, DOI 10.1001/archinte.149.11.2407; REICHGOTT MJ, 1983, J MED EDUC, V58, P703; REUBEN DB, 1988, ARCH INTERN MED, V148, P914, DOI 10.1001/archinte.148.4.914; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SHINE KI, 1986, NEW ENGL J MED, V314, P52, DOI 10.1056/NEJM198601023140110; SKEFF KM, 1986, J GEN INTERN MED, V1, P315, DOI 10.1007/BF02596211; TOSTESON DC, 1991, JAMA-J AM MED ASSOC, V265, P1022, DOI 10.1001/jama.265.8.1022; WARTMAN SA, 1990, JAMA-J AM MED ASSOC, V263, P2649; WARTMAN SA, 1990, J GEN INTERN MED, V5, pS59, DOI 10.1007/BF02600439; WARTMAN SA, 1987, ADAPTING CLIN ED NEW; WEINHOLTZ D, 1983, MED EDUC, V17, P364, DOI 10.1111/j.1365-2923.1983.tb01121.x; WIGTON RS, 1980, J MED EDUC, V55, P423	30	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1071	1075		10.7326/0003-4819-116-12-1071	http://dx.doi.org/10.7326/0003-4819-116-12-1071			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586119				2022-12-28	WOS:A1992HY79400009
J	ROSENBERG, ML; OCARROLL, PW; POWELL, KE				ROSENBERG, ML; OCARROLL, PW; POWELL, KE			LETS BE CLEAR - VIOLENCE IS A PUBLIC-HEALTH PROBLEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ROSENBERG, ML (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH & INJURY CONTROL,DIV INJURY CONTROL,ATLANTA,GA 30333, USA.								0	112	113	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3071	3072						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588723				2022-12-28	WOS:A1992HW97000030
J	LALIKOS, JF				LALIKOS, JF			THE GREAT WAIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2971	2971						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583768				2022-12-28	WOS:A1992HW13300038
J	SULMASY, DP				SULMASY, DP			PHYSICIANS, COST CONTROL, AND ETHICS	ANNALS OF INTERNAL MEDICINE			English	Article						ETHICS, MEDICAL; COST CONTROL; HEALTH CARE RATIONING; HEALTH RESOURCES	HEALTH-CARE	Rising health care expenditures have led to numerous cost-control proposals. An examination of the ethical questions surrounding the role that physicians play in the control of health care costs suggests that unilateral rationing decisions by individual physicians at the bedside are morally unacceptable. Such decisions are arbitrary, ineffective in redistributing health care resources, and formally unjust. Restrictive gatekeeping (the creation of financial incentives for physicians to limit care given to individual patients) also seems unacceptable because of its morally significant effects. First, it disguises the role of those actually responsible for cost-control decisions; second, it routinely creates a "moral stress test" by forcing physicians to act in ways that are contrary to their own interests in order to serve the needs of patients; third, it undermines the trust between doctor and patient; and fourth, it rations by class of persons rather than class of technology. In contrast, a morally sound system would attempt to control costs by honestly informing patients and assigning responsibility justly, would encourage physicians to act in the interests of patients, would foster trust, and would recognize the great importance of equal treatment for all patients. Such a system would depend on input from an informed public and would apply equally to all members of society.			SULMASY, DP (corresponding author), GEORGETOWN UNIV, MED CTR, CTR CLIN BIOETH, 311 KOBER COGAN HALL, WASHINGTON, DC 20007 USA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; BELLAH RN, 1985, HABITS OF HEART; CALLAHAN D, 1990, NEW ENGL J MED, V322, P1810, DOI 10.1056/NEJM199006213222511; ENGELHARDT HT, 1988, NEW ENGL J MED, V319, P1086, DOI 10.1056/NEJM198810203191610; ENGELHARDT HT, 1986, F BIOETHICS, P342; Flexner A, 1915, SCHOOL SOC, V1, P901; Illich I., 1976, MED NEMESIS; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; MACKIE DL, 1981, GROUP IPA HMOS, P155; MENZEL PT, 1990, STRONG MED ETHICAL R; PELLEGRINO ED, 1988, PATIENTS GOOD RESTOR, P54; PELLEGRINO ED, 1988, PATIENTS GOOD RESTOR, P172; Pelligrino E D, 1986, J Contemp Health Law Policy, V2, P23; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; RICH S, 1991, WASHINGTON POST 0824, pA2; SHAW GB, 1962, COMPLETE PLAYS PREFA, V1, P1; WELCH HG, 1991, ANN INTERN MED, V115, P223, DOI 10.7326/0003-4819-115-3-223; WELCH WP, 1990, MILBANK Q, V68, P221, DOI 10.2307/3350097; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; 1990, HLTH CARE FINANCING, V11, P1; 1985, NICHOMACHEAN ETHICS, P123	21	119	119	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					920	926		10.7326/0003-4819-116-11-920	http://dx.doi.org/10.7326/0003-4819-116-11-920			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580450				2022-12-28	WOS:A1992HW13700008
J	GEIST, V				GEIST, V			ENDANGERED SPECIES AND THE LAW	NATURE			English	Editorial Material											GEIST, V (corresponding author), UNIV CALGARY,FAC ENVIRONM DESIGN,CALGARY T2N 1N4,ALBERTA,CANADA.							BARTOS L, 1981, ZOOL ANZ, V207, P260; BARTOS L, 1981, ZOOL ANZEIGER JENA, V208, P30; BARTOS L, 1981, ZOOL ANZEIGER JENA, V207, P217; GEIST V, 1991, CAN J ZOOL, V69, P706, DOI 10.1139/z91-103; GEIST V, 1991, ARCTIC, V44, P287; GITTLEMAN JL, 1991, NATURE, V351, P524, DOI 10.1038/351524a0; HALTENORTH T, 1963, HDB ZOOLOGIE, V1, P1; HARRINGTON S, 1982, I FOREST, V30, P64; HIRSCH J, 1976, SAG RAC REL ABSTR, V6, P1; LEHMAN N, 1991, EVOLUTION, V45, P104, DOI 10.1111/j.1558-5646.1991.tb05270.x; NADLER C F, 1973, Zeitschrift fuer Saeugetierkunde, V38, P109; OBRIEN SJ, 1991, SCIENCE, V251, P1187, DOI 10.1126/science.251.4998.1187; RENNIE J, 1991, SCI AM, V256, P18; SMITH MH, 1986, J MAMMAL, V67, P103, DOI 10.2307/1381006; SMITH MH, 1985, WHITE TAILED DEER, P119; WAYNE RK, 1991, NATURE, V351, P565, DOI 10.1038/351565a0	16	32	40	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					274	276		10.1038/357274a0	http://dx.doi.org/10.1038/357274a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589032				2022-12-28	WOS:A1992HW13200018
J	LEE, SH; EWERT, DP; FREDERICK, PD; MASCOLA, L				LEE, SH; EWERT, DP; FREDERICK, PD; MASCOLA, L			RESURGENCE OF CONGENITAL-RUBELLA SYNDROME IN THE 1990S - REPORT ON MISSED OPPORTUNITIES AND FAILED PREVENTION POLICIES AMONG WOMEN OF CHILDBEARING AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; IMMUNIZATION; PROGRAM; VACCINATION	Objective. - To assess previous missed opportunities for rubella screening and vaccination of women delivering infants with congenital rubella syndrome and to discuss prevention strategies. Design. - Descriptive analysis of data collected through interviews and review of medical records. Population Studied. - Twenty-one women who delivered infants with congenital rubella syndrome in four Southern California counties from January 1, 1990, through January 8, 1991. Results. - Twelve (57%) of the women had a total of 22 known missed opportunities for rubella screening or vaccination. Of the 22 missed opportunities, three (14%) were missed screenings at the time of marriage, two (9%) were missed screenings during previous pregnancies, five (23%) were missed screenings during induced abortions, and 12 (55%) were missed opportunities for vaccination postpartum or after induced abortions. Nine (43%) of the women had no known missed opportunities for rubella screening or vaccination. Of 12 women educated in California, only four (33%) were subject to the 1982 California school rubella immunization requirement. Conclusions. - Congenital rubella syndrome could have been prevented in more than half of the infants born to these women if missed opportunities for rubella testing and/or vaccination had not occurred. Because premarital rubella testing and school immunization requirements do not ensure that all women of childbearing age are immune to rubella, physicians and hospitals should establish procedures for postpartum rubella vaccination of susceptible women. Family planning and abortion clinics should implement routine rubella testing and follow-up vaccination of susceptible women.	LOS ANGELES CTY DEPT HLTH SERV,ACUTE COMMUNICABLE DIS CONTROL UNIT,ROOM 231,313 N FIGUEROA ST,LOS ANGELES,CA 90012; CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,LOS ANGELES,CA					Frederick, Paul/0000-0002-7936-5488				ANTHONY N, 1977, AM J PUBLIC HEALTH, V67, P763, DOI 10.2105/AJPH.67.8.763; COCHI SL, 1989, AM J EPIDEMIOL, V129, P349, DOI 10.1093/oxfordjournals.aje.a115138; DALES LG, 1981, WESTERN J MED, V135, P266; GRILLNER L, 1973, SCAND J INFECT DIS, V5, P237, DOI 10.3109/inf.1973.5.issue-4.01; KAPLAN KM, 1990, AM J DIS CHILD, V144, P118, DOI 10.1001/archpedi.1990.02150250130050; KLEIN EB, 1980, J PEDIATR-US, V97, P774, DOI 10.1016/S0022-3476(80)80264-2; LANDES RD, 1980, J PEDIATR-US, V97, P465, DOI 10.1016/S0022-3476(80)80207-1; LOSONSKY GA, 1982, J INFECT DIS, V145, P661, DOI 10.1093/infdis/145.2.661; NELSON DB, 1982, AM J PUBLIC HEALTH, V72, P710, DOI 10.2105/AJPH.72.7.710; ORENSTEIN WA, 1984, JAMA-J AM MED ASSOC, V251, P1988, DOI 10.1001/jama.251.15.1988; POLK BF, 1982, AM J EPIDEMIOL, V115, P19, DOI 10.1093/oxfordjournals.aje.a113276; PREBLUD SR, 1986, J INFECT DIS, V154, P367, DOI 10.1093/infdis/154.2.367; ROBERTSON SE, 1987, AM J PUBLIC HEALTH, V77, P1347, DOI 10.2105/AJPH.77.10.1347; SERDULA MK, 1986, PUBLIC HEALTH REP, V101, P329; SEWELL CM, 1986, AM J PUBLIC HEALTH, V76, P1250, DOI 10.2105/AJPH.76.10.1250; SHLIAN DM, 1978, JAMA-J AM MED ASSOC, V240, P662, DOI 10.1001/jama.240.7.662; TINGLE AJ, 1985, J INFECT DIS, V152, P606, DOI 10.1093/infdis/152.3.606; TINGLE AJ, 1986, J INFECT DIS, V154, P368, DOI 10.1093/infdis/154.2.368; VOGT RL, 1985, AM J PUBLIC HEALTH, V75, P1088, DOI 10.2105/AJPH.75.9.1088; 1985, MMWR, V34, P228; 1985, MMWR, V34, P65; 1986, MMWR, V35, P779; 1986, MMWR, V35, P770; 1990, MMWR, V39, P32; 1990, MMWR, V39, P1; 1991, MMWR, V40, P93	26	41	41	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2616	2620		10.1001/jama.267.19.2616	http://dx.doi.org/10.1001/jama.267.19.2616			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT823	1573748				2022-12-28	WOS:A1992HT82300027
J	PROSSER, RL				PROSSER, RL			ALTERATION OF MEDICAL RECORDS SUBMITTED FOR MEDICOLEGAL REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											PROSSER, RL (corresponding author), UNIV KANSAS,LAWRENCE,KS 66045, USA.							ANGELL M, 1988, NEW ENGL J MED, V318, P1462, DOI 10.1056/NEJM198806023182210; BAKER R, 1991, JAMA-J AM MED ASSOC, V262, P2233; LOCK S, 1988, BRIT MED J, V297, P1531, DOI 10.1136/bmj.297.6662.1531; NOVAK DH, 1991, JAMA-J AM MED ASSOC, V261, P2980	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2630	2631						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573750				2022-12-28	WOS:A1992HT82300030
J	NAKAMURA, Y; YANAGAWA, H; KAWASAKI, T				NAKAMURA, Y; YANAGAWA, H; KAWASAKI, T			MORTALITY AMONG CHILDREN WITH KAWASAKI-DISEASE IN JAPAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPH-NODE SYNDROME; TERM FOLLOW-UP; CORONARY ANEURYSMS; ABNORMALITIES; ANGIOGRAPHY; POPULATION	Background and Methods. It is not certain whether patients with Kawasaki disease have a higher death rate than the age-matched healthy population. We therefore undertook a study to investigate this question. Between July 1982 and December 1988, 53 collaborating treatment centers collected data on all patients who had an unequivocal new diagnosis of Kawasaki disease; patients who had recurrent disease or whose first visit to the treatment center occurred more than 14 days after the onset of symptoms were excluded. Patients were followed from the time of the first visit to the treatment center until December 31, 1989, or until death, whichever occurred first. The expected number of deaths was calculated from Japanese vital-statistics data and compared with the number observed. Results. Of 4676 patients who met the eligibility criteria, 4608 (98.5 percent) were followed through either the end of the study or the date of death. Thirteen patients (10 boys and 3 girls) died during the study period. The number of deaths expected was 7.61 (ratio of observed to expected deaths, 1.71; 95 percent confidence interval, 0.91 to 2.92). The ratio was 2.04 (95 percent confidence interval, 0.98 to 3.76) for boys and 1.11 (95 percent confidence interval, 0.23 to 3.23) for girls. During the acute phase of the disease (the first two months after onset), the ratios of observed to expected deaths were higher: 9.86 overall (95 percent confidence interval, 3.95 to 20.31), 13.33 for boys (95 percent confidence interval, 4.89 to 29.07), and 3.85 for girls (95 percent confidence interval, 0.10 to 21.42). After the acute phase, however, both sexes had ratios of observed to expected deaths that were lower than 1, and the difference from the control population was not statistically significant. Conclusions. The mortality rate among boys with Kawasaki disease in Japan is twice that among healthy boys of the same age, and most deaths occur within two months of diagnosis. The mortality rate among girls with the disease appears similar to that among healthy girls, although the numbers are very small.	KAWASAKI DIS RES INFORMAT CTR,TOKYO,JAPAN		NAKAMURA, Y (corresponding author), JICHI MED SCH,DEPT PUBL HLTH,YAKUSHIJI 3311-1,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							AKAGI T, 1990, AM HEART J, V120, P366, DOI 10.1016/0002-8703(90)90081-8; ANDERSON TM, 1985, AM HEART J, V110, P107, DOI 10.1016/0002-8703(85)90523-X; BECKER A E, 1986, Pediatric Pathology, V6, P1; FUJIWARA T, 1988, CIRCULATION, V78, P345, DOI 10.1161/01.CIR.78.2.345; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; KOHR RM, 1986, J PEDIATR-US, V108, P256, DOI 10.1016/S0022-3476(86)80997-0; KURIBAYASHI S, 1989, RADIOLOGY, V172, P629, DOI 10.1148/radiology.172.3.2772168; NAKAMURA Y, 1991, PEDIATRICS, V88, P1144; PAHL E, 1989, J AM COLL CARDIOL, V14, P1318, DOI 10.1016/0735-1097(89)90435-X; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; SHULMAN ST, 1987, AM J DIS CHILD, V141, P420, DOI 10.1001/archpedi.1987.04460040078020; SUZUKI A, 1987, Heart and Vessels, V3, P159, DOI 10.1007/BF02058793; SUZUKI A, 1988, PEDIATR CARDIOL, V9, P1, DOI 10.1007/BF02279876; SUZUKI A, 1984, ACTA PAEDIATR JPN, V26, P121; TATARA K, 1987, J PEDIATR-US, V111, P705, DOI 10.1016/S0022-3476(87)80246-9; TATARA K, 1989, Heart and Vessels, V5, P47, DOI 10.1007/BF02058358; TURNERGOMES S, 1986, J PEDIATR-US, V108, P928, DOI 10.1016/S0022-3476(86)80929-5; YANAGAWA H, 1987, PEDIATRICS, V80, P58; YANAGAWA H, 1988, J INFECT DIS, V158, P1296, DOI 10.1093/infdis/158.6.1296; YANAGISAWA M, 1985, PEDIATR CARDIOL, V6, P11, DOI 10.1007/BF02265402	21	38	38	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1246	1249		10.1056/NEJM199205073261903	http://dx.doi.org/10.1056/NEJM199205073261903			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560800				2022-12-28	WOS:A1992HR44700003
J	MAKELA, TP; KOSKINEN, PJ; VASTRIK, I; ALITALO, K				MAKELA, TP; KOSKINEN, PJ; VASTRIK, I; ALITALO, K			ALTERNATIVE FORMS OF MAX AS ENHANCERS OR SUPPRESSORS OF MYC-RAS COTRANSFORMATION	SCIENCE			English	Article							DNA-BINDING; EMBRYO FIBROBLASTS; PROTEINS; TRANSCRIPTION; EXPRESSION; ONCOGENES; PROBES; CELLS; MOTIF; DIMER	Max is a basic-helix-loop-helix-leucine zipper protein capable of forming sequence-specific DNA binding complexes with Myc proteins. An alternatively spliced messenger RNA has been identified that encodes a form of Max truncated at the COOH-terminus. This DELTA-Max protein retained the ability to bind to the CACGTG motif in a complex with c-Myc but lacks the nuclear localization signal and the putative regulatory domain of Max. When tested in a myc-ras cotransformation assay in rat embryo fibroblasts, Max suppressed, whereas DELTA-Max enhanced, transformation. Thus, the maxgene may encode both a negative and a positive regulator of c-Myc function.	UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, DEPT PATHOL, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; University of Helsinki			Koskinen, Päivi J/G-8939-2014; Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009; Vastrik, Imre/C-2690-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; 				ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; EVAN GI, 1988, CURR TOP MICROBIOL, V141, P189; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TE, UNPUB; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLAN JL, 1987, P NATL ACAD SCI USA, V84, P5311, DOI 10.1073/pnas.84.15.5311; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAKSELA K, 1990, J CELL BIOCHEM, V42, P153, DOI 10.1002/jcb.240420306; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WINQVIST R, 1984, EMBO J, V3, P2947, DOI 10.1002/j.1460-2075.1984.tb02237.x; ZIFF EB, COMMUNICATION	29	137	142	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					373	377		10.1126/science.256.5055.373	http://dx.doi.org/10.1126/science.256.5055.373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566084				2022-12-28	WOS:A1992HP03200035
J	ZYSKIND, JW; SMITH, DW				ZYSKIND, JW; SMITH, DW			DNA-REPLICATION, THE BACTERIAL-CELL CYCLE, AND CELL-GROWTH	CELL			English	Review							ESCHERICHIA-COLI CHROMOSOME; GUANOSINE TETRAPHOSPHATE; DAM METHYLTRANSFERASE; ORIGIN; INITIATION; PROTEIN; METHYLATION; INVITRO		UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	ZYSKIND, JW (corresponding author), SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182, USA.							BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BERNANDER R, 1990, CELL, V60, P365, DOI 10.1016/0092-8674(90)90588-6; BLAKELY G, 1991, NEW BIOL, V3, P789; BOYE E, 1991, J BACTERIOL, V173, P4537, DOI 10.1128/JB.173.14.4537-4539.1991; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAATEN BA, 1991, J BACTERIOL, V173, P1789, DOI 10.1128/jb.173.5.1789-1800.1991; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CHIARAMELLO AE, 1990, J BACTERIOL, V172, P2013, DOI 10.1128/jb.172.4.2013-2019.1990; CLERGET M, 1991, NEW BIOL, V3, P780; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; Helmstetter CE., 1987, ESCHERICHIA COLI SAL, P1594; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KIMURA T, 1989, MOL GEN GENET, V219, P69, DOI 10.1007/BF00261159; KUEMPEL PL, 1989, CELL, V59, P581, DOI 10.1016/0092-8674(89)90001-9; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; LOUARN JM, 1991, J BACTERIOL, V173, P5097, DOI 10.1128/jb.173.16.5097-5104.1991; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; OGAWA T, 1991, MOL GEN GENET, V230, P193, DOI 10.1007/BF00290668; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; POLACZEK P, 1990, New Biologist, V2, P574; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHAUS N, 1981, J BACTERIOL, V145, P904, DOI 10.1128/JB.145.2.904-913.1981; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1992, IN PRESS J BACTERIOL; XIAO H, 1991, J BIOL CHEM, V266, P5980; YUNG BYM, 1990, J BIOL CHEM, V265, P1282	37	84	85	2	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					5	8		10.1016/0092-8674(92)90112-P	http://dx.doi.org/10.1016/0092-8674(92)90112-P			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555241				2022-12-28	WOS:A1992HM44500002
J	VU, ET; KRASNE, FB				VU, ET; KRASNE, FB			EVIDENCE FOR A COMPUTATIONAL DISTINCTION BETWEEN PROXIMAL AND DISTAL NEURONAL INHIBITION	SCIENCE			English	Article							ESCAPE BEHAVIOR; DENDRITES; CRAYFISH; CELLS	Most neurons have inhibitory synapses both "proximally" near the spike-initiating zone and "distally" on dendrites. Although distal inhibition is thought to be an adaptation for selective inhibition of particular dendritic branches, another important distinction exists between proximal and distal inhibition. Proximal inhibition can attenuate excitatory input absolutely so that no amount of excitation causes firing. Distal inhibition, however, inhibits relatively; any amount of it can be overcome by sufficient excitation. These properties are used as predicted in the circuit-mediating crayfish escape behavior. Many neuronal computations require relative inhibition. This could partly account for the ubiquity of distal inhibition.	UNIV CALIF LOS ANGELES,DEPT PSYCHOL,NEUROSCI PROGRAM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								EDEWAYEDWARDS DH, 1991, J NEUROSCI, V11, P2117; FUJITA Y, 1979, BRAIN RES, V175, P59, DOI 10.1016/0006-8993(79)90514-6; JACK JJB, 1975, ELECTRIC CURRENT FLO, P197; KOCH C, 1986, TRENDS NEUROSCI, V9, P204, DOI 10.1016/0166-2236(86)90060-3; KRASNE FB, 1969, J EXP BIOL, V50, P29; KRASNE FB, 1988, J NEUROSCI, V8, P3703; KRASNE FB, 1975, J EXP BIOL, V63, P433; LLINAS R, 1971, J NEUROPHYSIOL, V34, P532, DOI 10.1152/jn.1971.34.4.532; LLINAS R, 1975, ADV NEUROL, V12, P1; McClelland J. L., 1986, PARALLEL DISTRIBUTED, V2; MORI K, 1984, J NEUROSCI, V4, P2291; Rall W, 1964, NEURAL THEORY MODELI, P73; ROBERTS A, 1968, J EXP BIOL, V48, P545; Shepherd GM, 1990, SYNAPTIC ORG BRAIN, P439; TERZUOLO CA, 1968, STRUCTURE FUNCTION I, P261; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; WINE JJ, 1972, J EXP BIOL, V56, P1	17	82	88	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1710	1712		10.1126/science.1553559	http://dx.doi.org/10.1126/science.1553559			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553559				2022-12-28	WOS:A1992HK81200040
J	FORSTER, P				FORSTER, P			MEDICINE IN EUROPE - EQUAL OPPORTUNITIES - PROGRESS SO FAR .13.	BRITISH MEDICAL JOURNAL			English	Article											FORSTER, P (corresponding author), BMA NW REG OFF,MANCHESTER M20 8RX,ENGLAND.							ALLEN I, 1989, DISCUSSING DOCTORS C; DOCKSEY C, 1991, INDIANA LAW J, V4, P258; 1991, WOMEN MEN BRITAIN; 1989, 1ST ANN REPORT EMPLO; 1991, EQUAL OPPORTUNITIES; 1991, WOMEN DOCTORS THEIR	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					630	632		10.1136/bmj.304.6827.630	http://dx.doi.org/10.1136/bmj.304.6827.630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559095	Bronze, Green Published			2022-12-28	WOS:A1992HH73300031
J	NATHADWARAWALA, KM; RICHARDS, CAL; LAWRIE, B; THOMAS, GO; WILES, CM				NATHADWARAWALA, KM; RICHARDS, CAL; LAWRIE, B; THOMAS, GO; WILES, CM			LESSON OF THE WEEK - RECURRENT ASPIRATION DUE TO ARNOLD-CHIARI TYPE-I MALFORMATION	BRITISH MEDICAL JOURNAL			English	Article							DYSPHAGIA		NEVILL HALL HOSP,ABERGAVENNY,GWENT,WALES; UNIV HOSP WALES,NEUROL,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University								ACHIRON A, 1990, NEUROLOGY, V40, P186, DOI 10.1212/WNL.40.1.186-a; ADAMS RD, 1986, PRINCIPLES NEUROLOGY, P912; BERCIANO J, 1990, NEUROLOGY, V40, P1637, DOI 10.1212/WNL.40.10.1637-c; DYSTE GN, 1989, J NEUROSURG, V71, P159, DOI 10.3171/jns.1989.71.2.0159; LINDEN P, 1983, ARCH PHYS MED REHAB, V64, P281; MOHR PD, 1977, Q J MED, V46, P85; Nicklin J, 1990, CLIN REHABIL, V4, P335, DOI 10.1177/026921559000400414	7	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					565	566		10.1136/bmj.304.6826.565	http://dx.doi.org/10.1136/bmj.304.6826.565			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559068	Green Published, Bronze			2022-12-28	WOS:A1992HG59900034
J	GILMAN, S				GILMAN, S			MEDICAL PROGRESS .2. ADVANCES IN NEUROLOGY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANSCRANIAL DOPPLER ULTRASOUND; HUMAN TEMPORAL-LOBE; CEREBROVASCULAR-DISEASE; SURGICAL-TREATMENT; CAROTID ARTERIES; PATHO-PHYSIOLOGY; STROKE; SEIZURES; BRAIN; INFARCTION				GILMAN, S (corresponding author), UNIV MICHIGAN,MED CTR,DEPT NEUROL,1500 E MED CTR DR,1914 TAUBMAN CTR,ANN ARBOR,MI 48109, USA.							AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; ANDERSON VE, 1991, EPILEPSY RES S, V4, P920; [Anonymous], 1989, EPILEPSIA, V30, P389; BALDYMOULINIER M, 1990, CURRENT PROBLEMS EPI, V7; BERKOVIC SF, 1991, ANN NEUROL, V29, P175, DOI 10.1002/ana.410290210; BROOKS DJ, 1992, CLIN BRAIN IMAGING P, P217; BROTT T, 1990, STROKE, V21, P181; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; CAPLAN LR, 1990, NEUROLOGY, V40, P696, DOI 10.1212/WNL.40.4.696; CASCINO GD, 1991, ANN NEUROL, V30, P31, DOI 10.1002/ana.410300107; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CAWTHON RM, 1990, CELL, V62, P608; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408; CHUGANI HT, 1988, NEUROLOGY, V38, P1178, DOI 10.1212/WNL.38.8.1178; DEWITT LD, 1984, ANN NEUROL, V16, P535, DOI 10.1002/ana.410160503; EBERSOLE JS, 1989, AMBULATORY EEG MONIT; ELWES RDC, 1985, LANCET, V2, P752; ENGEL J, 1990, ELECTROEN CLIN NEURO, V76, P296, DOI 10.1016/0013-4694(90)90031-E; ENGEL J, 1990, NEUROLOGY, V40, P1670, DOI 10.1212/WNL.40.11.1670; ENGEL J, 1991, GUIDELINES LONG TERM, P35; ENGEL J, 1989, CONT NEUROLOGY SERIE, V31; ENGEL J, 1991, COMPREHENSIVE EPILEP, P385; ENGEL J, 1987, SURGICAL TREATMENT E; ENGEL J, 1991, PRINCIPLES NEUROSURG, P319; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; FISHER M, 1989, MED THERAPY ACUTE ST; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; GOTMAN J, 1985, ELECTROENCEPHALOGR S, V37; GROTTA JC, 1987, NEW ENGL J MED, V317, P1505, DOI 10.1056/NEJM198712103172405; GUMNIT RJ, 1987, ADV NEUROLOGY, V46; HACHINSKI V, 1991, J NEUROL SCI, V103, P1, DOI 10.1016/0022-510X(91)90274-B; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1986, ARCH NEUROL-CHICAGO, V43, P1287, DOI 10.1001/archneur.1986.00520120063017; HENRY TR, 1990, J CEREBR BLOOD F MET, V10, P748, DOI 10.1038/jcbfm.1990.128; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; KAWANO H, 1990, STROKE S1, V21, P98; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LEE RJ, 1991, STROKE, V22, P734, DOI 10.1161/01.STR.22.6.734; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEPPIK IE, 1988, EPILEPSIA, V29, pS79, DOI 10.1111/j.1528-1157.1988.tb05801.x; LEPPIK IE, 1991, NEUROLOGY, V41, P1785, DOI 10.1212/WNL.41.11.1785; LEPPIK IE, 1990, NEUROLOGY, V40, P4; LEVY R, 1989, ANTIEPILEPTIC DRUGS; LUDERS HO, 1992, EPILEPSY SURGERY; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MCDONALD JW, 1991, ANN NEUROL, V29, P529, DOI 10.1002/ana.410290513; McKusick V, 1966, MENDELIAN INHERITANC; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MORI E, 1991, Neurology, V41, P347; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PAXTON R, 1974, BRIT J RADIOL, V47, P530, DOI 10.1259/0007-1285-47-561-530; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; ROSS JS, 1989, NEUROLOGY, V39, P1369, DOI 10.1212/WNL.39.10.1369; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROWAN AJ, 1992, NONEPILEPTIC PSEUDOE; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SALGADO ED, 1986, ANN NEUROL, V20, P502, DOI 10.1002/ana.410200410; Sato S., 1990, ADV NEUROLOGY, V54; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SPENCER SS, 1987, SURGICAL TREATMENT E, P425; STEINBERG GK, 1989, STROKE, V20, P1247, DOI 10.1161/01.STR.20.9.1247; SUTHERLING WW, 1990, NEUROLOGY, V40, P87, DOI 10.1212/WNL.40.1.87; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; 1991, NEW ENGL J MED, V325, P1261; 1985, NEW ENGL J MED, V313, P1191; 1982, JAMA-J AM MED ASSOC, V247, P633; 1991, STROKE, V22, P153; 1986, ARCH NEUROL-CHICAGO, V43, P71; 1988, BMJ, V296, P320; 1991, NEW ENGL J MED, V324, P1225; 1991, NEW ENGL J MED, V325, P445	80	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1671	1676		10.1056/NEJM199206183262506	http://dx.doi.org/10.1056/NEJM199206183262506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588981				2022-12-28	WOS:A1992HY62800006
J	GELBER, RD; LENDERKING, WR; COTTON, DJ; COLE, BF; FISCHL, MA; GOLDHIRSCH, A; TESTA, MA				GELBER, RD; LENDERKING, WR; COTTON, DJ; COLE, BF; FISCHL, MA; GOLDHIRSCH, A; TESTA, MA			QUALITY-OF-LIFE EVALUATION IN A CLINICAL-TRIAL OF ZIDOVUDINE THERAPY IN PATIENTS WITH MILDLY SYMPTOMATIC HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF LIFE; ZIDOVUDINE; ACQUIRED IMMUNODEFICIENCY SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN IMMUNODEFICIENCY VIRUS	PLACEBO-CONTROLLED TRIAL; ADJUSTED SURVIVAL ANALYSIS; AIDS-RELATED COMPLEX; ADJUVANT THERAPY; BREAST-CANCER; DOUBLE-BLIND; AZT	Objective: To evaluate the effects of zidovudine therapy in patients with mildly symptomatic HIV infection using Q-TWiST (quality-adjusted: Time Without Symptoms and Toxicity). Design: Analysis of a previously reported multi-center, randomized, placebo-controlled clinical trial. Setting: Thirty-two AIDS Clinical Trial units. Patients: A total of 351 patients with mildly symptomatic HIV infection were assigned to placebo, and 360 patients were assigned to zidovudine, 1200 mg/d. Measurements: A modified Q-TWiST method for comparing treatments based on time spent without severe symptomatic adverse events and without disease progression. Zidovudine and placebo were compared in a threshold utility analysis considering reduction in quality of life associated with adverse events and disease progression. Adverse events defined by laboratory findings were distinguished from findings representing symptomatic events. Results: The incidence of severe symptomatic adverse events was 22.8% for the zidovudine group and 15.1% for the placebo group (P = 0.01), but, as previously reported, zidovudine improved progression-free survival relative to placebo (at 18 months, 91% compared with 81%; P = 0.001). In an 18 month period, patients receiving zidovudine went an average of 14.5 months without disease progression or a severe symptomatic adverse event compared with 14.7 months for placebo. The zidovudine group gained 0.9 months without disease progression but lost 1.1 months due to adverse events. Within the 18-month observation period, treatment provided more Q-TWiST than placebo if the quality of life after HIV disease progression was assumed to be 10% to 20% worse than the quality of life after a severe symptomatic adverse event. Conclusions: The Q-TWiST analysis projects that quality-of-life reductions due to severe symptomatic adverse events might be balanced by the quality-of-life benefits of delayed HIV disease progression for patients who receive zidovudine for mildly symptomatic HIV infection. At currently recommended doses (500 to 600 mg/d half the dose used in this study) zidovudine therapy is likely to yield a more favorable results.	HARVARD UNIV, SCH PUBL HLTH, CTR STAT & DATA ANAL, BOSTON, MA 02115 USA; OSPED CIV, DEPT ONCOL, LUGANO, SWITZERLAND; UNIV MIAMI, JACKSON MEM HOSP, SCH MED, DEPT MED, MIAMI, FL 33101 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Miami	GELBER, RD (corresponding author), HARVARD UNIV, SCH MED,DANA FARBER CANC INST, DIV BIOSTAT & EPIDEMIOL,MAYER 432, 44 BINNEY ST, BOSTON, MA 02115 USA.		Testa, Marianna/L-9768-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095030] Funding Source: NIH RePORTER; NIAID NIH HHS [N0-AI-95030] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULKER JP, 1991, 7 INT C AIDS FLOR, P211; BOZZETTE SA, 1991, MAR AIDS CLIN TRIALS; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GELBER RD, 1986, J CLIN ONCOL, V4, P1772, DOI 10.1200/JCO.1986.4.12.1772; GLASZIOU PP, 1990, STAT MED, V9, P1259, DOI 10.1002/sim.4780091106; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WU AW, 1990, J ACQ IMMUN DEF SYND, V3, P683; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011	13	77	77	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				961	966		10.7326/0003-4819-116-12-961	http://dx.doi.org/10.7326/0003-4819-116-12-961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586104				2022-12-28	WOS:A1992HY79300001
J	OWEN, RS; CARPENTER, JP; BAUM, RA; PERLOFF, LJ; COPE, C				OWEN, RS; CARPENTER, JP; BAUM, RA; PERLOFF, LJ; COPE, C			MAGNETIC-RESONANCE-IMAGING OF ANGIOGRAPHICALLY OCCULT RUNOFF VESSELS IN PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MR ANGIOGRAPHY; PULSE SEQUENCE; FLOW; ARTERIOGRAPHY; BYPASS	Background. Bypass grafting to arteries of the lower leg has become standard surgical management of advanced peripheral vascular disease. Its success depends on identifying suitable distal vessels. Preoperative preparation includes imaging of the arteries of the lower leg, usually by conventional contrast arteriography. An alternative procedure, magnetic resonance (MR) angiography, has been successfully employed in patients with various cardiovascular diseases, but its possible value in patients with peripheral vascular disease has received little attention. Methods. We used both conventional and MR angiography in preoperative studies of the lower-leg vessels of 23 patients (25 legs) with peripheral arteriosclerosis and arterial insufficiency, and developed independent therapeutic plans based on the information provided by each technique. When the plans differed, the interventional procedure judged more likely to save the limb was performed. The findings of conventional and MR angiography were verified by intraoperative arteriography, postinterventional arteriography, or direct operative exploration. Results. MR angiography detected all vessels identified by conventional angiography, whereas conventional arteriography failed to detect 22 percent of the runoff vessels identified by MR angiography. The detection by MR angiography of vessels not identified by conventional angiography altered the surgical management of the disorders of four patients (17 percent) and guided successful bypass procedures. Conclusions. MR angiography is a noninvasive technique with greater sensitivity than conventional contrast arteriography for detecting distal runoff vessels in patients with peripheral arterial occlusive disease.	UNIV PENN,SCH MED,DEPT RADIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT VASC SURG,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								AXEL L, 1987, J COMPUT ASSIST TOMO, V11, P31, DOI 10.1097/00004728-198701000-00006; DOUSSET V, 1991, RADIOLOGY, V179, P437, DOI 10.1148/radiology.179.2.2014288; DUMOULIN CL, 1989, MAGN RESON MED, V9, P139, DOI 10.1002/mrm.1910090117; EDELMAN RR, 1990, AM J ROENTGENOL, V154, P937, DOI 10.2214/ajr.154.5.2108568; FLANIGAN DP, 1982, SURGERY, V92, P627; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KELLER PJ, 1989, RADIOLOGY, V173, P527, DOI 10.1148/radiology.173.2.2798885; KERR TM, 1991, J VASC SURG, V14, P649; LENZ GW, 1988, RADIOLOGY, V166, P875, DOI 10.1148/radiology.166.3.3340788; PATEL KR, 1988, J VASC SURG, V7, P531, DOI 10.1067/mva.1988.avs0070531; RICCO JB, 1983, ANN SURG, V198, P646, DOI 10.1097/00000658-198311000-00015; SCARPATO R, 1981, ARCH SURG-CHICAGO, V116, P1053; SPRITZER CE, 1990, RADIOLOGY, V176, P255, DOI 10.1148/radiology.176.1.2353099; WAUGH JR, 1992, RADIOLOGY, V182, P243, DOI 10.1148/radiology.182.1.1727290; WEHRLI FW, 1990, MAGNET RESON MED, V14, P187, DOI 10.1002/mrm.1910140205	15	286	291	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1577	1581		10.1056/NEJM199206113262428	http://dx.doi.org/10.1056/NEJM199206113262428			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584257				2022-12-28	WOS:A1992HX63300001
J	MANKIN, HJ				MANKIN, HJ			CURRENT CONCEPTS - NONTRAUMATIC NECROSIS OF BONE (OSTEONECROSIS)	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SYSTEMIC LUPUS-ERYTHEMATOSUS; TOTAL HIP-REPLACEMENT; FEMORAL-HEAD; AVASCULAR NECROSIS; RENAL-TRANSPLANTATION; STEROID-THERAPY; FOLLOW-UP; DISEASE; SCINTIGRAPHY; DIAGNOSIS		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	MANKIN, HJ (corresponding author), MASSACHUSETTS GEN HOSP, ORTHOPAED SERV, FRUIT ST, BOSTON, MA 02114 USA.							ALROWAIH A, 1991, ACTA ORTHOP SCAND, V62, P19, DOI 10.3109/17453679108993085; ANTONINUS MA, 1906, GOLDEN BOOK M AURELI, P29; BAYNE O, 1985, ORTHOP CLIN N AM, V16, P727; BOETTCHER WG, 1970, J BONE JOINT SURG AM, VA 52, P322, DOI 10.2106/00004623-197052020-00013; BOETTCHER WG, 1970, J BONE JOINT SURG AM, VA 52, P312, DOI 10.2106/00004623-197052020-00012; BULLOUGH PG, 1990, ANN RHEUM DIS, V49, P412, DOI 10.1136/ard.49.6.412; CATTO M, 1976, ASEPTIC NECROSIS BON, P3; CHANDLER F A, 1948, J Int Coll Surg, V11, P34; CHRYSSANTHOU CP, 1978, CLIN ORTHOP RELAT R, V130, P94; CORNELL CN, 1985, ORTHOP CLIN N AM, V16, P757; CRUESS RL, 1986, CLIN ORTHOP RELAT R, V208, P30; DAVIDSON JK, 1985, CLIN RADIOL, V36, P27, DOI 10.1016/S0009-9260(85)80012-X; Davidson JK, 1976, ASEPTIC NECROSIS BON, P147; DUMONT M, 1984, CLIN NUCL MED, V9, P44, DOI 10.1097/00003072-198401000-00015; FERLIC DC, 1989, J HAND SURG-AM, V14A, P13, DOI 10.1016/0363-5023(89)90053-1; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301-620X.67B1.3155745; FISHEL B, 1987, J RHEUMATOL, V14, P601; GENEZ BM, 1988, RADIOLOGY, V168, P521, DOI 10.1148/radiology.168.2.3393675; GIACOMELLO A, 1989, ADV EXP MED BIOL, V253, P211; Glimcher M. J., 1979, CLIN ORTHOP RELAT R, V138, P284; GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P273; GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P283; GOODMAN AH, 1963, J BONE JOINT SURG AM, V45, P723, DOI 10.2106/00004623-196345040-00004; GOTTSCHALK F, 1989, CLIN ORTHOP RELAT R, V249, P219; HALLER J, 1988, AM J ROENTGENOL, V151, P355, DOI 10.2214/ajr.151.2.355; HERMANN G, 1986, AM J ROENTGENOL, V147, P943, DOI 10.2214/ajr.147.5.943; HUNGERFORD DS, 1985, ORTHOP CLIN N AM, V16, P635; HUNGERFORD DS, 1978, CLIN ORTHOP RELAT R, V130, P144; Jaffe HL, 1934, ARCH SURG-CHICAGO, V29, P566, DOI 10.1001/archsurg.1934.01180040042005; JOHANSON NA, 1990, ORTHOP CLIN N AM, V21, P191; JONES JP, 1985, ORTHOP CLIN N AM, V16, P595; KAHLSTROM SC, 1939, SURG GYNECOL OBSTET, V68, P129; KENZORA JE, 1978, CLIN ORTHOP RELAT R, V130, P8; KRISTENSEN KD, 1991, ACTA ORTHOP SCAND, V62, P113, DOI 10.3109/17453679108999235; LANGEVITZ P, 1990, J RHEUMATOL, V17, P402; LAROCHE M, 1990, J RHEUMATOL, V17, P549; LAUSTEN GS, 1990, ACTA ORTHOP SCAND, V61, P507, DOI 10.3109/17453679008993572; LEARMONTH ID, 1990, J BONE JOINT SURG BR, V72, P387, DOI 10.1302/0301-620X.72B3.2341433; LOTKE PA, 1988, J BONE JOINT SURG AM, V70A, P470, DOI 10.2106/00004623-198870030-00027; MANKIN H J, 1962, Bull Hosp Joint Dis, V23, P42; MANKIN HJ, 1990, METABOLIC BONE DISEA, P730; MARCUS ND, 1973, J BONE JOINT SURG AM, VA 55, P1351, DOI 10.2106/00004623-197355070-00002; METSELAAR HJ, 1985, ACTA ORTHOP SCAND, V56, P413, DOI 10.3109/17453678508994360; MEYERS MH, 1988, CLIN ORTHOP RELAT R, P51; MIDDLEMISS H, 1976, ASPETIC NECROSIS BON, P271; MILGRAM JW, 1990, RADIOLOGIC HISTOLOGI, P958; MOTOHASHI M, 1991, CLIN ORTHOP RELAT R, V266, P156; ORLIC D, 1990, INT ORTHOP, V14, P383, DOI 10.1007/BF00182650; Orwin J F, 1991, J Arthroplasty, V6, P1, DOI 10.1016/S0883-5403(06)80151-8; PELLICCI PM, 1984, CLIN ORTHOP RELAT R, V185, P59; POLLACK MS, 1987, SKELETAL RADIOL, V16, P121, DOI 10.1007/BF00367759; RADFORD PJ, 1989, J BONE JOINT SURG BR, V71, P456, DOI 10.1302/0301-620X.71B3.2656719; ROSENTHAL DI, 1989, RADIOLOGY, V170, P143, DOI 10.1148/radiology.170.1.2909087; SEILER JG, 1989, J BONE JOINT SURG AM, V71A, P28, DOI 10.2106/00004623-198971010-00006; SHUPAK R, 1983, J RHEUMATOL, V10, P261; Simmons D J, 1989, J Arthroplasty, V4, P7, DOI 10.1016/S0883-5403(89)80047-6; Steinberg ME, 1989, CLIN ORTHOP RELAT R, V249, P199; STEINBERG ME, 1990, CLIN ORTHOP RELAT R, V261, P11; STULBERG BN, 1991, CLIN ORTHOP RELAT R, P140; Sugioka Y, 1978, CLIN ORTHOP RELAT R, V130, P191; TAWN DJ, 1989, BRIT J RADIOL, V62, P790, DOI 10.1259/0007-1285-62-741-790; TAYLOR LJ, 1984, J BONE JOINT SURG BR, V66, P431, DOI 10.1302/0301-620X.66B3.6725356; TRANCIK T, 1990, CLIN ORTHOP RELAT R, V256, P120; TRUMBLE TE, 1990, J HAND SURG-AM, V15A, P557, DOI 10.1016/S0363-5023(09)90015-6; URBANIAK JR, 1991, JUL BON S PORTL; VAKIL N, 1989, GASTROENTEROLOGY, V96, P62, DOI 10.1016/0016-5085(89)90764-6; VANBLARCOM ST, 1990, AM J ROENTGENOL, V155, P95, DOI 10.2214/ajr.155.1.2112875; WANG TY, 1988, AM J MED, V84, P1085, DOI 10.1016/0002-9343(88)90319-1; WARNER JJP, 1987, CLIN ORTHOP RELAT R, V225, P104; WATANABE Y, 1989, RHEUMATOL INT, V9, P25, DOI 10.1007/BF00270286; WEINER ES, 1989, J RHEUMATOL, V16, P604; ZIZIC TM, 1985, AM J MED, V79, P596, DOI 10.1016/0002-9343(85)90057-9; 1939, SURG GYNECOL OBSTET, V68, P631	73	630	667	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1473	1479						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1574093				2022-12-28	WOS:A1992HV46900006
J	WHITCOMB, ME; DESGROSEILLIERS, JP				WHITCOMB, ME; DESGROSEILLIERS, JP			PRIMARY CARE MEDICINE IN CANADA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									ROYAL COLL PHYSICIANS & SURGEONS CANADA,OTTAWA,ONTARIO,CANADA; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; BABBOTT D, 1991, ANN INTERN MED, V114, P16, DOI 10.7326/0003-4819-114-1-16; CANTOR JC, 1991, JAMA-J AM MED ASSOC, V265, P1002, DOI 10.1001/jama.265.8.1002; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; HAYWARD RA, 1991, ANN INTERN MED, V115, P308, DOI 10.7326/0003-4819-115-4-308; HUGHES RG, 1991, NEW ENGL J MED, V325, P404, DOI 10.1056/NEJM199108083250606; IGLEHART JK, 1990, NEW ENGL J MED, V322, P562, DOI 10.1056/NEJM199002223220827; LIPKIN M, 1990, ANN INTERN MED, V112, P371, DOI 10.7326/0003-4819-112-5-371; LOMAS J, 1989, HEALTH AFFAIR, V8, P80, DOI 10.1377/hlthaff.8.1.80; MCLAUGHLIN MA, 1991, ACAD MED, V66, pS43, DOI 10.1097/00001888-199109000-00036; PETERSDORF RG, 1992, NEW ENGL J MED, V326, P408, DOI 10.1056/NEJM199202063260610; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; Schmittling G, 1991, Fam Med, V23, P297; SCHMITTLING G, 1991, FAM MED, V23, P392; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; STEIN JH, 1991, ANN INTERN MED, V114, P79, DOI 10.7326/0003-4819-114-1-79; WHITCOMB ME, 1986, NEW ENGL J MED, V314, P710, DOI 10.1056/NEJM198603133141111; WHITCOMB ME, IN PRESS JAMA; 1990, SUPPLYING PHYSICIANS; 1990, REPORT MANPOWER; 1986, NATIONAL RESIDENT MA; 1991, NATIONAL RESIDENT MA; 1988, 1ST REPORT COUNCIL, V1	23	19	19	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1469	1472		10.1056/NEJM199205283262205	http://dx.doi.org/10.1056/NEJM199205283262205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1574092	Bronze			2022-12-28	WOS:A1992HV46900005
J	GIOVANNUCCI, E; TOSTESON, TD; SPEIZER, FE; VESSEY, MP; COLDITZ, GA				GIOVANNUCCI, E; TOSTESON, TD; SPEIZER, FE; VESSEY, MP; COLDITZ, GA			A LONG-TERM STUDY OF MORTALITY IN MEN WHO HAVE UNDERGONE VASECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSTATE-CANCER; MYOCARDIAL-INFARCTION; TESTICULAR CANCER; SPERM ANTIGENS; RISK-FACTORS; ATHEROSCLEROSIS; DISEASE; MOUSE; ASSOCIATION; EMBRYOS	Background. Vasectomy is a reliable and widely accepted method of contraception, but there is some uncertainty and few data about a possible long-term adverse effect on health. Methods. We examined the relation between vasectomy and mortality rates from cardiovascular disease, cancer, and all causes in a retrospective cohort of husbands of members of the Nurses' Health Study. In 1989 we obtained data by questionnaire on 14,607 men who had undergone vasectomy as of 1976 and 14,607 men who had not. Results. Among the men who were free of cancer at the start of the study, 1052 died: 446 of cardiovascular disease, 341 of cancer, and 265 of other causes. Vasectomy was associated with reductions in mortality from all causes (age-adjusted relative risk, 0.85; 95 percent confidence interval, 0.76 to 0.96) and mortality from cardiovascular disease (relative risk, 0.76; 95 percent confidence interval, 0.63 to 0.92). Vasectomy was unrelated to mortality from all forms of cancer (relative risk, 1.01; 95 percent confidence interval, 0.82 to 1.25). Among men who had a vasectomy at least 20 years earlier, the procedure had no relation to mortality from all causes (relative risk, 1.11; 95 percent confidence interval, 0.92 to 1.33) or that from cardiovascular disease (relative risk, 0.85; 95 percent confidence interval, 0.63 to 1.16). However, mortality from cancer was increased in men who had a vasectomy at least 20 years earlier (relative risk, 1.44; 95 percent confidence interval, 1.07 to 1.92). The excess risk of cancer in these men was due primarily to lung cancer. None of the observed associations were confounded by smoking habits, body-mass index, alcohol consumption, or educational level. Conclusions. Vasectomy is not associated with an increase in overall mortality or mortality from cardiovascular disease. Our study also found no increase in overall mortality from cancer after vasectomy, but there was an apparent increase in the risk of cancer 20 or more years after vasectomy that requires further study.	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	Harvard University; Brigham & Women's Hospital; University of Oxford	GIOVANNUCCI, E (corresponding author), HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092913] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40935] Funding Source: Medline; NICHD NIH HHS [N01-HD-09-2913] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEXANDER NJ, 1981, INT J EPIDEMIOL, V10, P217, DOI 10.1093/ije/10.3.217; ALEXANDER NJ, 1978, SCIENCE, V201, P538, DOI 10.1126/science.96532; ANDERSON DJ, 1982, J NATL CANCER I, V69, P551; ANDERSON DJ, 1983, AM J PATHOL, V111, P129; ANSBACHE.R, 1972, FERTIL STERIL, V23, P640; ANSBACHER R, 1981, FERTIL STERIL, V36, P222; CALE ARJ, 1990, BRIT MED J, V300, P370, DOI 10.1136/bmj.300.6721.370; CAMPBELL WB, 1983, BRIT J UROL, V55, P430, DOI 10.1111/j.1464-410X.1983.tb03338.x; CASTRO JE, 1974, CANCER RES, V34, P2055; CHI IC, 1990, INT J EPIDEMIOL, V19, P1113, DOI 10.1093/ije/19.4.1113; CHISM SE, 1976, J IMMUNOL, V117, P1870; CLARKSON TB, 1980, J CLIN INVEST, V65, P15, DOI 10.1172/JCI109645; Coggin J H Jr, 1974, Adv Cancer Res, V19, P105, DOI 10.1016/S0065-230X(08)60053-6; Cox D. R., 1984, ANAL SURVIVAL DATA; GABH Rose, 1982, WHO MONOGRAPH SERIES; GACHELIN G, 1977, DEV BIOL, V57, P199, DOI 10.1016/0012-1606(77)90365-7; GOLDACRE MJ, 1983, NEW ENGL J MED, V308, P805, DOI 10.1056/NEJM198304073081403; GOLDBERG EH, 1977, TRANSPLANT P, V9, P1363; GUANGHUA T, 1988, INT J EPIDEMIOL, V17, P608; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; LAUSCH RN, 1974, PROG EXP TUMOR RES, V19, P48; LEWIS RB, 1976, ARTHRITIS RHEUM, V19, P1256, DOI 10.1002/art.1780190605; LINNET L, 1978, CLIN EXPT IMMUNOLOGY, V30, P413; MASSEY FJ, 1984, JAMA-J AM MED ASSOC, V252, P1023, DOI 10.1001/jama.252.8.1023; MENGE AC, 1978, DEV BIOL, V63, P111, DOI 10.1016/0012-1606(78)90117-3; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; MILLER DG, 1967, ANN INTERN MED, V66, P507, DOI 10.7326/0003-4819-66-3-507; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; PARMIANI G, 1974, INT J CANCER, V14, P555, DOI 10.1002/ijc.2910140416; PERLMAN JA, 1991, AM J EPIDEMIOL, V134, P107, DOI 10.1093/oxfordjournals.aje.a115985; PERRIN EB, 1984, AM J PUBLIC HEALTH, V74, P128, DOI 10.2105/AJPH.74.2.128; PETITTI DB, 1982, AM J PUBLIC HEALTH, V72, P476, DOI 10.2105/AJPH.72.5.476; RITCHEY ML, 1985, J UROLOGY, V133, P42, DOI 10.1016/S0022-5347(17)48775-1; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSENBERG L, 1986, AM J EPIDEMIOL, V123, P1049, DOI 10.1093/oxfordjournals.aje.a114333; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; SAMUEL T, 1975, CLIN EXP IMMUNOL, V21, P65; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SIDNEY S, 1987, J UROLOGY, V138, P795, DOI 10.1016/S0022-5347(17)43377-5; SOLTER D, 1976, DEV BIOL, V52, P98, DOI 10.1016/0012-1606(76)90010-5; SPITZ MR, 1991, AM J EPIDEMIOL, V134, P108, DOI 10.1093/oxfordjournals.aje.a115986; STRADER CH, 1988, AM J EPIDEMIOL, V128, P56, DOI 10.1093/oxfordjournals.aje.a114958; TALAL N, 1967, AM J MED, V43, P50, DOI 10.1016/0002-9343(67)90148-9; WALKER AM, 1981, LANCET, V1, P13	44	54	55	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1392	1398		10.1056/NEJM199205213262104	http://dx.doi.org/10.1056/NEJM199205213262104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1569975				2022-12-28	WOS:A1992HU89000004
J	TAYLOR, CR				TAYLOR, CR			GREAT EXPECTATIONS - THE READING HABITS OF YEAR-2 MEDICAL-STUDENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TAYLOR, CR (corresponding author), UNIV SO CALIF,SCH MED,DEPT PATHOL,HMR 204,2011 ZONAL AVE,LOS ANGELES,CA 90033, USA.							BILLINGS JS, 1887, T ASSOC AM PHYSICIAN, V2, P57; BORDAGE G, 1987, MED EDUC, V21, P183, DOI 10.1111/j.1365-2923.1987.tb00689.x; DURACK DT, 1978, NEW ENGL J MED, V298, P773, DOI 10.1056/NEJM197804062981405; MAYO WJ, 1933, COLLECTED PAPERS MAY, V25, P1105; OKELL CC, 1938, LANCET, V1, P107; 1991, ENV LEARNING INTERIM; 1984, GPEP REPORT REPORT P; 1991, USC CLASS 1994 SURVI; 1986, MED EDUC, V20, P378	9	26	27	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1436	1440		10.1056/NEJM199205213262118	http://dx.doi.org/10.1056/NEJM199205213262118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1569996				2022-12-28	WOS:A1992HU89000035
J	BLENDON, RJ; SZALAY, US; KNOX, RA				BLENDON, RJ; SZALAY, US; KNOX, RA			SHOULD PHYSICIANS AID THEIR PATIENTS IN DYING - THE PUBLIC PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BOSTON GLOBE,BOSTON,MA		BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115, USA.							KENT C, 1991, MED HLTH        1202, V45, pA2; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WOOD F, 1990, AM PROFILE OPINIONS, P627; 1991, AM VIEW ANGING RESUL; 1989, PHYSICIAN PUBLIC ATT; 1991, NY TIMES        1107, pB14; 1990, GENERAL SOCIAL SURVE	9	181	182	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2658	2662		10.1001/jama.267.19.2658	http://dx.doi.org/10.1001/jama.267.19.2658			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573758				2022-12-28	WOS:A1992HT82300038
J	STRUHL, G; JOHNSTON, P; LAWRENCE, PA				STRUHL, G; JOHNSTON, P; LAWRENCE, PA			CONTROL OF DROSOPHILA BODY PATTERN BY THE HUNCHBACK MORPHOGEN GRADIENT	CELL			English	Article							KRUPPEL GENE-EXPRESSION; FUSHI-TARAZU; SEGMENTATION GENE; GAP GENE; ABDOMINAL SEGMENTATION; SPATIAL EXPRESSION; HEAD DEVELOPMENT; BICOID PROTEIN; MATERNAL GENE; EMBRYO	Most of the thoracic and abdominal segments of Drosophila are specified early in embryogenesis by the overlapping activities of the hunchback (hb), Kruppel, knirps, and giant gap genes. The orderly expression of these genes depends on two maternal determinants: bicoid, which activates hb transcription anteriorly, and nanos, which blocks translation of hb transcripts posteriorly. Here we provide evidence that the resulting gradient of hb protein dictates where the Kruppel, knirps, and giant genes are expressed by providing a series of concentration thresholds that regulate each gene independently. Thus, hb protein functions as a classical morphogen, triggering several distinct responses as a function of its graded distribution.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology	STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT GENET & DEV, NEW YORK, NY 10032 USA.			Lawrence, Peter/0000-0002-9554-8268				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; Dalcq A, 1938, FORM CAUSALITY EARLY; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1968, 12TH P INT C GEN, V2, P96; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY D, 1988, DROS INF SERV, V68; LINDSLEY DL, 1985, DROS INF SERV, V62; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; Sander K, 1975, Ciba Found Symp, V0, P241; Sander Klaus, 1959, Wilhelm Roux Arch Entwickl Mech Org, V151, P430, DOI 10.1007/BF00573355; Sander Klaus, 1960, Wilhelm Roux Arch Entwickl Mech Org, V151, P660, DOI 10.1007/BF00577816; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1989, CIBA F SYMP, V144, P65; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; von Ubisch L, 1953, ENTWICKLUNGSPROBLEME; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8	63	229	232	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					237	249		10.1016/0092-8674(92)90405-2	http://dx.doi.org/10.1016/0092-8674(92)90405-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568245	hybrid			2022-12-28	WOS:A1992HQ18300004
J	MOREL, A; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ				MOREL, A; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ			MOLECULAR-CLONING AND EXPRESSION OF A RAT VIA ARGININE VASOPRESSIN RECEPTOR	NATURE			English	Article							EUKARYOTIC MESSENGER-RNAS; TRANSLATIONAL START SITE; MUSCLE CELL-LINE; SEQUENCES UPSTREAM; ADENYLATE-CYCLASE; MAMMALIAN-CELLS; BINDING-SITES; CDNA; HEPATOCYTES; COMPILATION	THE neurohypophyseal hormone arginine vasopressin has diverse actions 1-7, including the inhibition of diuresis, contraction of smooth muscle, stimulation of liver glycogenolysis and modulation of adrenocorticotropic hormone release from the pituitary. Arginine vasopressin receptors are G protein-coupled and have been divided into at least three types 8; the V1a (vascular/hepatic) 1-9-11 and V1b (anterior pituitary) 12 receptors which act through phosphatidylinositol hydrolysis to mobilize intracellular Ca2+, and the V2 (kidney) receptor 1,13,14 which is coupled to adenylate cyclase. We report here the cloning of a complementary DNA encoding the hepatic V1a arginine vasopressin receptor. The liver cDNA encodes a protein with seven putative transmembrane domains, which binds arginine vasopressin and related compounds with affinities similar to the native rat V1a receptor. The messenger RNA corresponding to the cDNA is distributed in rat tissues known to contain V1a receptors.	NIMH,CELL BIOL LAB,BLDG 36,ROOM 3A-17,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Brownstein, Michael/B-8609-2009; Lolait, Stephen/AAG-4483-2020; Morel, Alain/AAU-7496-2021	morel, alain/0000-0003-0125-1883				AIYAR N, 1986, LIFE SCI, V39, P37, DOI 10.1016/0024-3205(86)90435-2; ANTONI FA, 1984, NEUROPEPTIDES, V4, P413, DOI 10.1016/0143-4179(84)90116-1; ANTONI FA, 1984, NEUROENDOCRINOLOGY, V39, P186, DOI 10.1159/000123976; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BALLA T, 1985, ENDOCRINOLOGY, V117, P421, DOI 10.1210/endo-117-1-421; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; BUTLEN D, 1978, MOL PHARMACOL, V14, P1006; CHASE LR, 1968, SCIENCE, V159, P545, DOI 10.1126/science.159.3814.545; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEMENTS JA, 1986, ENDOCR REV, V116, P416; DEWIED D, 1977, LIFE SCI, V20, P192; GILLIES GE, 1982, NATURE, V299, P355, DOI 10.1038/299355a0; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HOLMES MC, 1984, NEUROENDOCRINOLOGY, V39, P162, DOI 10.1159/000123973; JARD S, 1985, FRONTIERS HORMONE RE, V13, P89; KASTING NW, 1980, CAN J PHYSIOL PHARM, V58, P316, DOI 10.1139/y80-054; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KIRK CJ, 1977, FEBS LETT, V83, P267, DOI 10.1016/0014-5793(77)81020-X; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MATSUGUCHI H, 1980, PHYSIOLOGIST, V23, P29; MEIDAN R, 1985, ENDOCRINOLOGY, V116, P416, DOI 10.1210/endo-116-1-416; Michell R H, 1979, Biochem Soc Trans, V7, P861; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PHILLIPS PA, 1990, ENDOCRINOLOGY, V126, P1478, DOI 10.1210/endo-126-3-1478; THIBONNIER M, 1986, AM J PHYSIOL, V251, P115; VANREE JM, 1978, BIOCHEM PHARMACOL, V27, P1793, DOI 10.1016/0006-2952(78)90021-7; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	31	469	475	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					523	526		10.1038/356523a0	http://dx.doi.org/10.1038/356523a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560825				2022-12-28	WOS:A1992HN23100059
J	PRENTICE, MB; FLOWER, AJE; MORGAN, GM; NICHOLSON, KG; RANA, B; FIRMIN, RK; MITCHELL, CJ				PRENTICE, MB; FLOWER, AJE; MORGAN, GM; NICHOLSON, KG; RANA, B; FIRMIN, RK; MITCHELL, CJ			INFECTION WITH HEPATITIS-B VIRUS AFTER OPEN-HEART-SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HOST DEFENSE FUNCTIONS; CARDIOPULMONARY BYPASS; HUMAN-BEINGS; TRANSMISSION; STAFF; FEATURES; ANTIGEN; HBSAG; SERUM		LEICESTER ROYAL INFIRM,LEICESTER PUBL HLTH LAB,LEICESTER LE1 5WW,ENGLAND; LEICESTERSHIRE AREA HLTH AUTHOR,PUBL HLTH MED,LEICESTER LE1 6TY,ENGLAND; GROBY RD HOSP,INFECT DIS,LEICESTER LE3 9QE,ENGLAND; GROBY RD HOSP,CARDIOTHORAC SURG,LEICESTER LE3 9QE,ENGLAND	University of Leicester			Prentice, Michael/AAE-7246-2019	Prentice, Michael/0000-0003-1117-2388				ALEXANDER GJM, 1987, LANCET, V2, P66; BARKER LF, 1971, J AMER MED ASSOC, V216, P1970, DOI 10.1001/jama.216.12.1970; BERRIDGE DC, 1990, BRIT J SURG, V77, P585, DOI 10.1002/bjs.1800770540; CLEE WB, 1987, BMJ-BRIT MED J, V295, P530, DOI 10.1136/bmj.295.6597.530; COBB J, 1987, BRIT MED J, V294, P1667, DOI 10.1136/bmj.294.6588.1667; COUTINHO RA, 1982, LANCET, V1, P345; FRATER RWM, 1990, AIDS SURGERY, P121; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HARRISON TJ, 1985, BRIT MED J, V290, P663, DOI 10.1136/bmj.290.6469.663; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HOFMANN H, 1988, INFECTION, V16, P171, DOI 10.1007/BF01644095; HOSIE KB, 1988, LANCET, V2, P1500; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; POLAKOFF S, 1986, BRIT MED J, V293, P33, DOI 10.1136/bmj.293.6538.33; SIM AJW, 1988, BRIT MED J, V296, P80, DOI 10.1136/bmj.296.6615.80; SMEDIRA N, 1989, ADV TRAUMA, V4, P67; SNYDMAN DR, 1976, ANN INTERN MED, V85, P573, DOI 10.7326/0003-4819-85-5-573; VANVELZENBLAD H, 1985, ANN THORAC SURG, V39, P212, DOI 10.1016/S0003-4975(10)62581-7; VANVELZENBLAD H, 1985, ANN THORAC SURG, V39, P207, DOI 10.1016/S0003-4975(10)62578-7; WELCH J, 1989, LANCET, V1, P205; YELLOWLESS H, 1981, GUIDANCE HEPATITIS B; 1985, MMWR, V34, P73; 1991, BMJ, V303, P184; 1990, IMMUNISATION INFECTI; 1983, HOSPITAL INPATIENT E	26	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					761	764		10.1136/bmj.304.6829.761	http://dx.doi.org/10.1136/bmj.304.6829.761			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571684	Green Published, Bronze			2022-12-28	WOS:A1992HK80000025
J	WANG, YC; FROST, BJ				WANG, YC; FROST, BJ			TIME TO COLLISION IS SIGNALED BY NEURONS IN THE NUCLEUS ROTUNDUS OF PIGEONS	NATURE			English	Article							MOTION; FLIES	THROUGHOUT the animal kingdom, the sight of a rapidly approaching object usually signals danger and elicits an escape response 1-6. Gibson 7 suggested that the symmetrical expansion of an object's image (looming) is the critical variable determining that the object is on a collision course with the observer. Similarly, large expanding flow-fields like those produced by locomotion may precipitate manoeuvres such as turning or landing 8,9. From such observations it has been shown that the optic flow parameter, tau, which specifies time to contact with the approaching object best fits the behavioural data 10,11. We describe a subpopulation of neurons in the nucleus rotundus of the pigeon brain that respond selectively to objects moving on a collision course towards the bird. These neurons give their maximum response at a constant time before contact occurs, even when the size of the stimulus or its velocity is varied widely. We propose that these neurons are signalling the time to collision of approaching objects.	QUEENS UNIV,DEPT PHYSIOL,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT PSYCHOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada								BORST A, 1988, NATURWISSENSCHAFTEN, V75, P265, DOI 10.1007/BF00378023; COGGSHALL JC, 1972, J EXP BIOL, V57, P401; DEAN P, 1989, TRENDS NEUROSCI, V12, P137, DOI 10.1016/0166-2236(89)90052-0; FROST BJ, 1990, VISION RES, V30, P1677, DOI 10.1016/0042-6989(90)90152-B; FROST BJ, 1983, SCIENCE, V220, P744, DOI 10.1126/science.6836313; Gibson J.J., 1986, ECOLOGICAL APPROACH; HAYES WN, 1967, ANIM BEHAV, V15, P102, DOI 10.1016/S0003-3472(67)80018-6; HILTON SH, 1982, J EXP BIOL, V100, P158; LEE DN, 1981, NATURE, V293, P293, DOI 10.1038/293293a0; Loeb G. E., 1986, ELECTROMYOGRAPHY EXP; MARTINOYA C, 1990, BIOL CYBERN, V63, P127, DOI 10.1007/BF00203035; REVZIN AM, 1970, BRAIN BEHAV EVOLUT, V3, P195; SCHIFF W, 1962, SCIENCE, V136, P982, DOI 10.1126/science.136.3520.982; SCHIFF W, 1965, PSYCHOL MONOGR, V79; SWANSTON MT, 1986, PERCEPT PSYCHOPHYS, V39, P309, DOI 10.3758/BF03202998; WAGNER H, 1982, NATURE, V297, P147, DOI 10.1038/297147a0	16	217	221	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					236	238		10.1038/356236a0	http://dx.doi.org/10.1038/356236a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552942				2022-12-28	WOS:A1992HJ94400056
J	BLACK, N				BLACK, N			LEADING FOR HEALTH - RESPONSES .7. RESEARCH, AUDIT, AND EDUCATION	BRITISH MEDICAL JOURNAL			English	Article											BLACK, N (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.							RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; 1991, RES HLTH RES DEV STR; 1991, LEADING HLTH BMA AGE	4	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					698	700		10.1136/bmj.304.6828.698	http://dx.doi.org/10.1136/bmj.304.6828.698			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571647	Green Published, Bronze			2022-12-28	WOS:A1992HK76100030
J	TULLOCH, DE				TULLOCH, DE			HOSPICES AND THE NHS	BRITISH MEDICAL JOURNAL			English	Letter											TULLOCH, DE (corresponding author), MARIA SKLODOWSKA CURIE MEM INST ONCOL,EDINBURGH EH1 2AH,SCOTLAND.							DOUGLAS C, 1992, BRIT MED J, V304, P579	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					717	718		10.1136/bmj.304.6828.717-c	http://dx.doi.org/10.1136/bmj.304.6828.717-c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571668	Green Published, Bronze			2022-12-28	WOS:A1992HK76100064
J	COHEN, JJ				COHEN, JJ			ROLES OF VARIOUS ORGANIZATIONS IN INTERNAL-MEDICINE CURRICULUM REFORM	ANNALS OF INTERNAL MEDICINE			English	Article								The curriculum in internal medicine for medical students and residents is being driven increasingly by the service demands of our teaching hospitals and is badly in need of fundamental reform. In reasserting the primacy of education as the driving force for the curriculum, numerous tasks must be done to achieve successful reform. These tasks are well within the scope of the several organizations that command leadership positions in the discipline of internal medicine and that represent the spectrum of activities required to discharge the specialty's public responsibility. These organizations include the Association of Professors of Medicine (APM), the Association of Program Directors in Internal Medicine (APDIM), the Society of General Internal Medicine (SGIM), The Residency Review Committee for Internal Medicine (RRC-IM), the American Board of Internal Medicine (ABIM), the American College of Physicians (ACP), the American Society of Internal Medicine (ASIM), and the Federated Council of Internal Medicine (FCIM). The challenge posed by the need for curriculum reform is to rouse these organizations to concerted action. Each of the seven organizations must assume a specific role and a unique set of responsibilities in the epic reforms envisioned.			COHEN, JJ (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, STONY BROOK, NY 11733 USA.								0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1111	1115		10.7326/0003-4819-116-12-1111	http://dx.doi.org/10.7326/0003-4819-116-12-1111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586129				2022-12-28	WOS:A1992HY79400019
J	FEDERMAN, DD				FEDERMAN, DD			RELATION OF THE INTERNAL-MEDICINE RESIDENCY AND THE MEDICAL-SCHOOL CURRICULUM	ANNALS OF INTERNAL MEDICINE			English	Article							STUDENTS	Students should have contact with faculty members in internal medicine throughout their medical education. Faculty internists should play a role in admission of students, in the basic science courses of the first year of medical school, and in the introductory course to clinical medicine and pathophysiology of the second year of medical school. The core medical clerkship is not an academic advertisement and should not be designed specifically to attract students to internal medicine. The core clerkship is designed for all students, regardless of their intended specialty and should include inpatient and outpatient care in a context and at a pace that allow time for reflection, reading, and problem solving. The advanced medicine experience should give students at least a glimpse of the mastery of the discipline of internal medicine. For students entering internal medicine, the fourth year of medical school and first year of residency could be combined to improve the content and quality of both.			FEDERMAN, DD (corresponding author), HARVARD UNIV, SCH MED, 25 SHATTUCK ST, BOSTON, MA 02115 USA.							FELTOVICH J, 1989, ACAD MED, V64, P36, DOI 10.1097/00001888-198901000-00015; HALPERIN AK, 1990, J GEN INTERN MED, V5, pS35, DOI 10.1007/BF02600436; LIPKIN M, 1990, ANN INTERN MED, V112, P371, DOI 10.7326/0003-4819-112-5-371; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; SCHWARTZ RW, 1990, ACAD MED, V65, P207, DOI 10.1097/00001888-199003000-00016	5	11	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1061	1064		10.7326/0003-4819-116-12-1061	http://dx.doi.org/10.7326/0003-4819-116-12-1061			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586117				2022-12-28	WOS:A1992HY79400007
J	WIGTON, RS				WIGTON, RS			TRAINING INTERNISTS IN PROCEDURAL SKILLS	ANNALS OF INTERNAL MEDICINE			English	Article							COLLEGE-OF-PHYSICIANS; NATIONAL SURVEY; 700 MEMBERS	The procedural skills of internists have been scrutinized recently because of concern for quality of care and because of economic and liability issues. The findings of recent surveys of program directors and practicing internists about procedural skills are reviewed. The results of these surveys in relation to the American Board of Internal Medicine's (ABIM) new training requirements and New York State's new policy requiring credentialing of residents in training are also discussed. Surveys show that internists do a large number and variety of procedures, that the number of procedures varies with the nature and location of practice, and that internists who more recently completed training do more procedures. Many graduates do not master the procedures their program directors think they should, and many learn procedures, often without supervision, after they have entered practice. The ABIM has recently ruled that residents must have documented experience and competence in specific core procedures to become eligible for certification. Also, New York State, in the wake of the Libby Zion case, now requires that all residents be credentialed in the procedures they do during training. Programs in internal medicine need to decide which procedures their residents will master and assure that their residents receive the training and testing necessary for competency and for formal certification of mastery in each procedure. Programs may restructure rotations to assure adequate experience. In the new era of accountability, certification of training and of competence in procedural skills will be an important function of training programs.			WIGTON, RS (corresponding author), UNIV NEBRASKA, COLL MED, MED CTR, GEN INTERNAL MED SECT, 600 S 42ND ST, OMAHA, NE 68198 USA.							GABRYEL TF, 1991, ACAD MED, V66, P613, DOI 10.1097/00001888-199110000-00016; HILDRETH EA, 1987, ANN INTERN MED, V107, P585, DOI 10.7326/0003-4819-107-4-585; TAPE TG, 1990, ANN INTERN MED, V113, P392, DOI 10.7326/0003-4819-113-5-392; WIGTON RS, 1989, ANN INTERN MED, V111, P1023, DOI 10.7326/0003-4819-111-12-1023; WIGTON RS, 1989, ANN INTERN MED, V111, P932, DOI 10.7326/0003-4819-111-11-932; WIGTON RS, 1990, ANN INTERN MED, V113, P540, DOI 10.7326/0003-4819-113-7-540; IN PRESS GUIDE EVALU; 1988, HOSPITAL CLIN PRIVIL	8	30	30	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1091	1093		10.7326/0003-4819-116-12-1091	http://dx.doi.org/10.7326/0003-4819-116-12-1091			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586124				2022-12-28	WOS:A1992HY79400014
J	WILLIAMS, JW; SIMEL, DL				WILLIAMS, JW; SIMEL, DL			DOES THIS PATIENT HAVE ASCITES - HOW TO DIVINE FLUID IN THE ABDOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTPUT CARDIAC-FAILURE; NEPHROTIC SYNDROME; WATER-RETENTION; PATHOGENESIS; CIRRHOSIS; PREGNANCY; DIAGNOSIS; SODIUM		VET ADM MED CTR,AMBULATORY CARE SERV,DURHAM,NC 27705; DUKE UNIV,MED CTR,DIV GEN INTERNAL MED,DURHAM,NC 27710; VET ADM MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC 27705	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Williams, John/AAM-4572-2020; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558				BENDER MD, 1988, CECIL TXB MED, P790; BENDER MD, 1989, GASTROINTESTINAL DIS, P1943; CATTAU EL, 1982, JAMA-J AM MED ASSOC, V247, P1164, DOI 10.1001/jama.247.8.1164; CUMMINGS S, 1985, WESTERN J MED, V142, P633; DEGOWIN EL, 1982, BEDSIDE DIAGNOSTIC E; ESPINOZA P, 1987, DIGEST DIS SCI, V32, P244, DOI 10.1007/BF01297048; GOLDBERG BB, 1973, ARCH INTERN MED, V131, P217, DOI 10.1001/archinte.131.2.217; GOLDBERG BB, 1970, RADIOLOGY, V96, P15, DOI 10.1148/96.1.15; GUARINO JR, 1986, NEW ENGL J MED, V315, P1555; GUYTON AC, 1983, TXB MED PHYSL, P836; LAWSON JD, 1959, NEW ENGL J MED, V260, P652, DOI 10.1056/NEJM195903262601307; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1065, DOI 10.1056/NEJM198810203191606; SIMEL DL, 1988, J GEN INTERN MED, V3, P423, DOI 10.1007/BF02595917	14	61	62	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2645	2648		10.1001/jama.267.19.2645	http://dx.doi.org/10.1001/jama.267.19.2645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573754				2022-12-28	WOS:A1992HT82300034
J	BICKELL, NA; PIEPER, KS; LEE, KL; MARK, DB; GLOWER, DD; PRYOR, DB; CALIFF, RM				BICKELL, NA; PIEPER, KS; LEE, KL; MARK, DB; GLOWER, DD; PRYOR, DB; CALIFF, RM			REFERRAL PATTERNS FOR CORONARY-ARTERY DISEASE TREATMENT - GENDER BIAS OR GOOD CLINICAL JUDGMENT	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; SELECTION BIAS; SEX FACTORS; CORONARY ARTERY BYPASS; REFERRAL AND CONSULTATION; WOMENS HEALTH	ACUTE MYOCARDIAL-INFARCTION; SEX-DIFFERENCES; BYPASS-SURGERY; PROGNOSTIC PREDICTION; MEDICAL COMPLAINTS; REGRESSION-MODELS; FEMALE PATIENTS; WOMEN; MORTALITY; SURVIVAL	Objective: To determine whether a gender bias exists in referral for coronary bypass graft surgery among patients with catheterization-documented coronary artery disease. Design: Historical cohort study (1969 to 1984). Setting: A referral medical center. Patients: A total of 5795 patients with catheterization-documented coronary artery disease. Measurements: Surgical referral patterns of men and women grouped by risk for cardiac death and by treatment effectiveness. Time trends were evaluated for three periods: 1969 to 1974, 1975 to 1979, and 1980 to 1984. Results: Overall, when no adjustment was made for baseline risk for cardiac death, no statistical difference was found between men and women regarding referral for surgery (46% compared with 44%, respectively). When an adjustment was made for such risk, the male-to-female odds ratio for surgical referral was 1.28 (95% Cl, 1.05 to 1.58) among patients with a low risk for cardiac death. This effect was most evident in the 1980 to 1984 period (odds ratio, 1.73; Cl, 1.29 to 2.31). In the high-risk group, the odds ratio was 0.84 (Cl, 0.68 to 1.04), with little change occurring during the study. Men were more likely to be referred for surgery when surgery offered the least survival benefit relative to medical therapy (odds ratio, 1.29; Cl, 1.08 to 1.54). This effect was most pronounced in the 1980 to 1984 period (odds ratio, 1.63; Cl, 1.27 to 2.10). Conclusions: Women are less likely than men to be referred for coronary bypass graft surgery among patients with a low risk for cardiac death, in whom surgery offers little or no survival benefit over medical treatment. Women are at least as likely as men to be referred for bypass surgery among more symptomatic and more severely diseased patients, in whom surgery offers the greatest survival benefits. These trends were most prominent in the recent years of the study. Based on surgical survival benefits, these referral patterns may represent more appropriate treatment referral for women than men.	UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University				Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER; AHRQ HHS [HS-06503, HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271; CALIFF RM, 1988, CIRCULATION, V78, P185; CALIFF RM, 1972, JR STAT SOC B, V34, P187; COLAMECO S, 1983, J FAM PRACTICE, V16, P1117; COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; DEVLIN TF, 1986, 11TH P ANN SAS US GR, P646; DOLISZNY KM, 1989, CIRCULATION, V80, P410; EAKER ED, 1987, CORONARY HEART DISEA, P122; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GREER S, 1986, J FAM PRACTICE, V23, P49; HARLAN WR, 1987, CORONARY HEART DISEA, P131; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HIBARD JH, 1984, INT Q COMMUNITY HLTH, V4, P95; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; JONES RH, 1981, CIRCULATION, V64, P586, DOI 10.1161/01.CIR.64.3.586; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; KOSKENVUO M, 1986, SOC SCI MED, V23, P605, DOI 10.1016/0277-9536(86)90154-1; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MCCRANIE EW, 1978, SOC SCI MED-MED SOC, V12, P111, DOI 10.1016/0160-7979(78)90032-2; NATHANSON CA, 1977, SOC SCI MED, V11, P13, DOI 10.1016/0037-7856(77)90141-X; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PRYOR DB, 1984, J CHRON DIS, V37, P521, DOI 10.1016/0021-9681(84)90003-1; PRYOR DB, 1987, CIRCULATION, V76, P13; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; PRYOR DB, 1989, CIRCULATION S2, V80, P409; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; STACK RS, 1988, J AM COLL CARDIOL, V11, P1141, DOI 10.1016/0735-1097(88)90274-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stone CJ, 1985, P STAT COMP SECT AM, P45; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VERBRUGGE LM, 1981, MED CARE, V19, P609, DOI 10.1097/00005650-198106000-00005; VERBRUGGE LM, 1987, WOMEN HEALTH, V12, P103, DOI 10.1300/J013v12n02_07; WAGNER PJ, 1988, BEHAVIORAL MED, V6, P9; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; Wallen J, 1979, Women Health, V4, P135, DOI 10.1300/J013v04n02_03; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Wingard DL, 1987, CORONARY HEART DISEA, P99	49	174	174	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					791	797		10.7326/0003-4819-116-10-791	http://dx.doi.org/10.7326/0003-4819-116-10-791			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567093				2022-12-28	WOS:A1992HT80200002
J	ANDRULIS, DP; WESLOWSKI, VB; HINTZ, E; SPOLARICH, AW				ANDRULIS, DP; WESLOWSKI, VB; HINTZ, E; SPOLARICH, AW			COMPARISONS OF HOSPITAL-CARE FOR PATIENTS WITH AIDS AND OTHER HIV-RELATED CONDITIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; INFECTION	Objective. - To compare utilization and financing of inpatient care for persons with the acquired immunodeficiency syndrome (AIDS) (as defined by the Center's for Disease Control) and those with "other HIV [human immunodeficiency virus]-related illness." Design. - A mailed survey of the members of five national organizations representing public, teaching, children's, community, and Catholic hospitals. The survey requested information on demographics, service utilization, costs, and financing of care for AIDS and other HIV patients. Statistical analysis using paired t tests was conducted to evaluate differences between group means for AIDS and other HIV patients. Differences among categorical variables were evaluated by calculation of proportions and compared using chi-2 tests. Participants. - Five hundred eighteen of 1158 hospitals surveyed responded to the AIDS and other HIV portions of the survey. Results. - Three hundred twenty-five hospitals reported treating at least one other HIV patient. These 325 hospitals treated 30% of all AIDS patients (16213) estimated to have been alive during 1988, and provided care to over 11 000 other HIV patients. Service utilization by other HIV patients was found to comprise a substantial portion of the total HIV burden and related costs, representing 35% of all HIV-related admissions, 29% of all inpatient costs, and 35% of all inpatient losses. Demographic and mode of exposure analysis indicated that other HIV patients were more likely than AIDS patients to be intravenous drug users, female, nonwhite, and to have no source of public or private coverage for their health care. Conclusions. - Our results demonstrate that accounting for only the utilization of services by persons with AIDS as defined by the Centers for Disease Control will understate significantly the total burden of the HIV epidemic on hospitals. The results suggest that the expanded definition proposed by the Centers for Disease Control would incorporate a large hospitalized HIV population.			ANDRULIS, DP (corresponding author), NATL PUBL HLTH & HOSP INST,1212 NEW YORK AVE NW,SUITE 800,WASHINGTON,DC 20005, USA.							ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FOX DM, 1990, J HEALTH POLIT POLIC, V15, P341, DOI 10.1215/03616878-15-2-341; HELLINGER F, 1990, PUBLIC HLTH REP, V5, P1; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; SCITOVSKY A, 1990, MILBANK Q, V67, P318; SEAGE GR, 1990, AM J PUBLIC HEALTH, V80, P835, DOI 10.2105/AJPH.80.7.835; SOLOMON DJ, 1989, PUBLIC HEALTH REP, V104, P416; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; ZUCCONI SI, 1990, HLTH CARE UTILIZATIO; 1990, MMWR, V39, P117; 1991, HIV AIDS SURVEILLANC, P1; 1990, DISABILITY SOCIAL SE, P1; 1990, MMWR, V39, P110; 1987, MMWR S7S, V36, P1; 1990, HIV AIDS SURVEILLANC, P1; 1987, MMWR S1S, V36, P1	19	54	55	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2482	2486		10.1001/jama.267.18.2482	http://dx.doi.org/10.1001/jama.267.18.2482			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573725				2022-12-28	WOS:A1992HT06800027
J	KOSIK, KS				KOSIK, KS			ALZHEIMERS-DISEASE - A CELL BIOLOGICAL PERSPECTIVE	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; AMYLOID PRECURSOR PROTEIN; HEREDITARY CEREBRAL-HEMORRHAGE; MICROTUBULE-ASSOCIATED PROTEINS; X-RAY-DIFFRACTION; BETA-PROTEIN; MESSENGER-RNA; NEUROFIBRILLARY TANGLES; CYTOPLASMIC DOMAIN; SENILE PLAQUES	An almost bewildering number of findings concerning Alzheimer's disease mask the significant recent progress in understanding the molecular basis of some inherited forms of this disease and the proteolytic processing of proteins related to the disease. Alzheimer's disease is an amyloidosis, a condition in which certain proteins or protein fragments precipitate in various tissues as amyloid, fibrillar aggregates with a beta-pleated sheet conformation. Alzheimer's is also characterized by neuritic lesions and cell death. Some rare forms of the disease are now known to arise from a mutation in an amyloidogenic protein. Another recent insight is the discovery of an endosomal-lysosomal processing pathway capable of generating protein fragments that can deposit extracellularly as amyloid fibrils. Key future directions for cellular-based research in Alzheimer's disease include the study of membrane trafficking and the passage of intracellular material to the extracellular milieu, molecular signaling among intracellular compartments, the interaction between organelles and the neuronal cytoskeleton, and the nature of cytoskeletal reorganization after neuronal injury.	BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, DEPT MED, DIV NEUROL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	KOSIK, KS (corresponding author), HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.				NIA NIH HHS [AG06601] Funding Source: Medline; NINDS NIH HHS [NS29031] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006601] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREADIS A, UNPUB; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; BARCIKOWSKA M, 1989, ACTA NEUROPATHOL, V78, P225, DOI 10.1007/BF00687751; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BENSON MD, 1989, TRENDS NEUROSCI, V12, P88, DOI 10.1016/0166-2236(89)90162-8; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BRION JP, 1988, NEUROSCIENCE, V25, P139, DOI 10.1016/0306-4522(88)90013-9; BRION JP, 1985, ARCH BIOL, V96, P229; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; COLE GM, 1990, INT CONGR SER, V884, P113; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DICKSON DW, 1988, AM J PATHOL, V132, P86; ELLISMAN M, 1987, ADV BEHAV BIOL, V34, P61; EPSTEIN CJ, IN PRESS MOL GENETIC; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GIRONES N, 1991, J BIOL CHEM, V266, P22159; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GOREVIC PD, 1991, NEW ENGL J MED, V325, P1780, DOI 10.1056/NEJM199112193252505; GOREVIC PD, 1986, J NEUROPATH EXP NEUR, V45, P647, DOI 10.1097/00005072-198611000-00004; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, IN PRESS NATURE; HALL GF, 1991, P NATL ACAD SCI USA, V88, P5016, DOI 10.1073/pnas.88.11.5016; HARDY J, 1991, LANCET, V337, P1342; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOLTZMAN DM, 1992, EMBO J, V11, P619, DOI 10.1002/j.1460-2075.1992.tb05094.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P575, DOI 10.1016/0197-4580(91)90089-3; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JONES CY, UNPUB; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOSIK KS, 1989, ANN NEUROL, V26, P352, DOI 10.1002/ana.410260308; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KSIEZAKREDING J, 1991, NEURON, V6, P1; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEIFER D, 1992, J NEUROPATH EXP NEUR, V51, P133, DOI 10.1097/00005072-199203000-00003; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MANN DMA, 1990, ACTA NEUROPATHOL, V80, P318, DOI 10.1007/BF00294651; MANN DMA, 1992, NEUROSCI LETT, V137, P225, DOI 10.1016/0304-3940(92)90409-Z; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MILLER DL, 1990, J NEUROPATH EXP NEUR, V49, P267, DOI 10.1097/00005072-199005000-00024; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NIETO A, 1988, BIOCHEM BIOPH RES CO, V154, P660, DOI 10.1016/0006-291X(88)90190-8; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PENG I, 1986, J CELL BIOL, V102, P252, DOI 10.1083/jcb.102.1.252; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRELLI F, 1990, BIOCHEM BIOPH RES CO, V170, P301, DOI 10.1016/0006-291X(90)91274-V; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; REFOLO LM, 1991, J NEUROSCI, V11, P3888; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SCHMIDT ML, 1991, LAB INVEST, V64, P352; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1982, SCIENCE, V215, P1243, DOI 10.1126/science.6120571; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TANZI RE, IN PRESS AM J HUM GE; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANNOSTRAND WE, 1989, NATURE, V341, P546; VULLIET PR, UNPUB; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YEN SH, 1987, AM J PATHOL, V126, P81	121	264	288	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					780	783		10.1126/science.1589757	http://dx.doi.org/10.1126/science.1589757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589757				2022-12-28	WOS:A1992HT23500029
J	STARNES, CO				STARNES, CO			COLEY TOXINS IN PERSPECTIVE	NATURE			English	Editorial Material							TUMOR NECROSIS FACTOR; INTERFERON				STARNES, CO (corresponding author), AMGEN INC,1840 DEHAVILLARD DR,THOUSAND OAKS,CA 91320, USA.							AXELROD RS, 1988, CANCER, V61, P2219, DOI 10.1002/1097-0142(19880601)61:11<2219::AID-CNCR2820611116>3.0.CO;2-D; BERENDT MJ, 1978, J EXP MED, V148, P1560, DOI 10.1084/jem.148.6.1560; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COLEY WB, 1909, PRACTITIONER, V83, P589; DEMETRI GD, 1989, J CLIN ONCOL, V7, P1545, DOI 10.1200/JCO.1989.7.10.1545; Harmer TW, 1914, BOSTON MED SURG J, V171, P253, DOI 10.1056/NEJM191408131710701; JOHNSTON BARBARA J., 1962, CANCER CHEMOTHER REPTS, V21, P43; MCINTOSH JK, 1989, CANCER RES, V49, P1408; NAUTS HC, 1946, CANCER RES, V6, P205; SPRIGGS DR, 1992, TUMOR NECROSIS FACTO, P394; TICHATSCHEK E, 1988, CANCER IMMUNOL IMMUN, V27, P278	11	169	177	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					11	12		10.1038/357011a0	http://dx.doi.org/10.1038/357011a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1574121				2022-12-28	WOS:A1992HT22900022
J	KNOLL, AH				KNOLL, AH			THE EARLY EVOLUTION OF EUKARYOTES - A GEOLOGICAL PERSPECTIVE	SCIENCE			English	Article							RIBOSOMAL-RNA; PROTEROZOIC PLANKTON; ORIGIN; CHLOROPLASTS; AUSTRALIA; CANADA; BASIN	Molecular phylogenies of eukaryotic organisms imply patterns of biological and environmental history that can be tested against the geological record. As predicted by sequence comparisons, Precambrian rocks show evidence of episodic increases in biological diversity and atmospheric oxygen concentrations. Nonetheless, complete integration of the two records remains elusive and may require that the earliest macroscopic organisms be recognized as extinct experiments in eukaryotic multicellularity.			KNOLL, AH (corresponding author), HARVARD UNIV, BOT MUSEUM, CAMBRIDGE, MA 02138 USA.							ALLISON CW, 1986, J PALEONTOL, V60, P973, DOI 10.1017/S0022336000022538; [Anonymous], EARTHS EARLIEST BIOS; [Anonymous], 1985, PALEOALGOLOGY; BARGHOORN ES, 1965, SCIENCE, V147, P563, DOI 10.1126/science.147.3658.563; BHATTACHARYA D, 1990, J PHYCOL, V26, P181, DOI 10.1111/j.0022-3646.1990.00181.x; BUTTERFIELD NJ, 1990, SCIENCE, V250, P104, DOI 10.1126/science.11538072; BUTTERFIELD NJ, 1988, NATURE, V334, P424, DOI 10.1038/334424a0; BUTTERFIELD NJ, 1992, THESIS HARVARD U CAM; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; CLOUD P, 1976, Paleobiology, V2, P351; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DERRY LA, IN PRESS GEOCHIM COS; DOOLITTLE RF, 1989, INT CONGR SER, V824, P73; DOUGLAS SE, 1991, NATURE, V350, P148, DOI 10.1038/350148a0; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P3584, DOI 10.1128/jb.170.8.3584-3592.1988; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRANT SWF, 1991, J PALEONTOL, V65, P1; GREY K, 1990, PRECAMBRIAN RES, V46, P307, DOI 10.1016/0301-9268(90)90018-L; Hermann T. N., 1990, ORGANIC WORLD BILLIO; HOFMANN HJ, 1981, CAN J EARTH SCI, V18, P443, DOI 10.1139/e81-038; HOLLAND HD, 1990, AM J SCI, V290A, P1; HORODYSKI RJ, 1980, J PALEONTOL, V54, P649; HORODYSKI RJ, 1990, AM J SCI, V290A, P149; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JANKAUSKAS T, 1989, MIKROFOSSILLI DOKEMB; KASTING JF, 1987, PRECAMBRIAN RES, V34, P205, DOI 10.1016/0301-9268(87)90001-5; KAUFMAN AJ, 1992, GEOLOGY, V20, P181, DOI 10.1130/0091-7613(1992)020<0181:BACCON>2.3.CO;2; KNOLL AH, 1991, J PALEONTOL, V65, P531, DOI 10.1017/S0022336000030663; KNOLL AH, 1989, NATURE, V337, P602, DOI 10.1038/337602a0; KNOLL AH, 1991, SCI AM, V265, P64, DOI 10.1038/scientificamerican1091-64; KNOLL AH, IN PRESS PALYNOLOGY; KNOLL AH, 1978, J PALEONTOL, V52, P576; KNOLL AH, IN PRESS BIOTIC RESP; KNOLL AH, IN PRESS PALAEONTOLO; LAKE JA, 1989, CAN J MICROBIOL, V35, P109, DOI 10.1139/m89-017; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Margulis L., 1982, 5 KINGDOMS ILLUSTRAT; Margulis L., 1993, SYMBIOSIS CELL EVOLU; Margulis L., 1989, HDB PROTOCTISTA; Moczydlowska M., 1991, FOSSILS STRATA, V29, P1; NURSALL JR, 1959, NATURE, V183, P1170, DOI 10.1038/1831170b0; OURISSON G, 1987, ANNU REV MICROBIOL, V41, P301, DOI 10.1146/annurev.mi.41.100187.001505; PEAT C J, 1978, BMR (Bureau of Mineral Resources) Journal of Australian Geology and Geophysics, V3, P1; PERASSO R, 1989, NATURE, V339, P142, DOI 10.1038/339142a0; Postgate J. R., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P31; RAFF RA, 1989, INT CONGR SER, V824, P247; RUNNEGAR B, 1982, J GEOL SOC AUST, V29, P395, DOI 10.1080/00167618208729222; Schopf JW, 1983, EARTHS EARLIEST BIOS; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SOKOLOV BS, 1990, VENDIAN SYSTEM, V1; SUMMONS RE, 1990, AM J SCI, V290A, P212; Tappan H, 1980, PALEOBIOLOGY PLANT P; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TOWE KM, 1990, NATURE, V348, P54, DOI 10.1038/348054a0; VIDAL G, 1983, GEOL SOC AM MEM, V161, P265; VOSSBRINCK CR, 1987, NATURE, V326, P411, DOI 10.1038/326411a0; WALTER MR, 1990, AM J SCI, V290A, P133; WHATLEY JM, 1981, ANN NY ACAD SCI, V361, P154, DOI 10.1111/j.1749-6632.1981.tb46517.x; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; Yin L., 1985, PALAEONTOLOGIA CATHA, V2, P229; ZANG WL, 1989, NATURE, V337, P642, DOI 10.1038/337642a0; ZECHMAN FW, 1990, J PHYCOL, V26, P700, DOI 10.1111/j.0022-3646.1990.00700.x; Zhang Zhongying, 1986, Journal of Micropalaeontology, V5, P9; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	68	517	545	3	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					622	627		10.1126/science.1585174	http://dx.doi.org/10.1126/science.1585174			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585174				2022-12-28	WOS:A1992HR18500022
J	WONG, T; DETSKY, AS				WONG, T; DETSKY, AS			PREOPERATIVE CARDIAC RISK ASSESSMENT FOR PATIENTS HAVING PERIPHERAL VASCULAR-SURGERY	ANNALS OF INTERNAL MEDICINE			English	Review						VASCULAR SURGERY; PERIPHERAL VASCULAR DISEASES; CORONARY DISEASE; RISK FACTORS; RADIONUCLIDE IMAGING	PERIOPERATIVE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; ABDOMINAL AORTIC-ANEURYSM; DIPYRIDAMOLE-THALLIUM SCINTIGRAPHY; RADIONUCLIDE VENTRICULOGRAPHY; EJECTION FRACTION; ISCHEMIA; RECONSTRUCTION; REVASCULARIZATION; COMPLICATIONS	. Purpose: To review the methods used for preoperative cardiac risk stratification of patients having peripheral vascular surgery. . Data Sources: Relevant studies published before August 1991 were identified using a MEDLINE search of the English-language literature, followed by a manual search of the references of all identified articles. . Study Selection: All clinical studies evaluating methods used for preoperative cardiac risk stratification of patients having peripheral vascular surgery. . Data Extraction: The key data extracted from each article included the inclusion and exclusion criteria of the study patients, the techniques used for testing and the corresponding definitions of positive test results, and the clinical outcomes of the tested patients. Data were analyzed using a Bayesian conceptual framework, and pretest probabilities were converted to post-test probabilities using calculation of likelihood ratios. . Results: Patients with high scores on clinical cardiac risk indexes (Goldman index > 12 or Detsky index > 15), or more than three of the criteria identified by Eagle (age > 70 years, diabetes, angina, Q waves on electrocardiogram, or ventricular arrhythmias) are likely to be at higher risk for cardiac death and myocardial infarction after vascular surgery. Those with both low scores and none of Eagle's criteria may be at lower risk, but this result has not been reproduced by independent studies. Neither group of patients would benefit from further investigation for cardiac risk stratification. Patients with one or two of these criteria may be at intermediate risk and would benefit most from further testing for the purposes of risk stratification. Most of the published evidence shows that the absence of redistribution on dipyridamole-thallium scanning identifies a low risk for postoperative cardiac complications, whereas the presence of redistribution predicts a high risk. Preliminary reports suggest that preoperative monitoring for silent myocardial ischemia may also be useful in identifying a high-risk subset of patients. . Conclusions: Patients identified clinically to be at either very low or high risk for cardiac complications after peripheral vascular surgery are unlikely to benefit from further risk stratification. Dipyridamole-thallium scanning is the test of choice for further evaluation of patients at intermediate clinical risk because studies have shown that it is sensitive enough to rule out a high-risk status for patients who do not have redistribution.	UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV MANITOBA, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Toronto; University of Manitoba	WONG, T (corresponding author), ST BONIFACE GEN HOSP, DEPT MED, 409 TACHE AVE, WINNIPEG R2H 2A6, MANITOBA, CANADA.							BERTRAND M, 1990, Anesthesiology (Hagerstown), V73, pA86; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BREWSTER DC, 1985, J VASC SURG, V2, P504, DOI 10.1067/mva.1985.avs0020504; CHARLSON ME, 1989, J CLIN EPIDEMIOL, V42, P25, DOI 10.1016/0895-4356(89)90022-X; CHUNG F, 1988, ANESTHESIOLOGY, V69, P343, DOI 10.1097/00000542-198809000-00010; CUTLER BS, 1987, J VASC SURG, V5, P91, DOI 10.1067/mva.1987.avs0050091; CUTLER BS, 1979, AM J SURG, V137, P484, DOI 10.1016/0002-9610(79)90119-3; CUTLER BS, 1981, AM J SURG, V141, P501, DOI 10.1016/0002-9610(81)90148-3; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; FLEISHER L A, 1990, Anesthesiology (Hagerstown), V73, pA75; FLETCHER JP, 1988, J CARDIOVASC SURG, V29, P666; FRANCO CD, 1989, J VASC SURG, V10, P656, DOI 10.1067/mva.1989.16173; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HERTZER NR, 1979, ARCH SURG-CHICAGO, V114, P1336; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; JEFFREY CC, 1983, ANESTHESIOLOGY, V58, P462, DOI 10.1097/00000542-198305000-00013; JOSEPHSON MA, 1982, AM HEART J, V103, P1008, DOI 10.1016/0002-8703(82)90564-6; KAPLAN JA, 1979, CARDIAC ANESTHESIA; KAZMERS A, 1988, J VASC SURG, V8, P128, DOI 10.1067/mva.1988.avs0080128; KAZMERS A, 1990, SURG GYNECOL OBSTET, V171, P481; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KNIGHT AA, 1988, ANESTHESIOLOGY, V68, P681, DOI 10.1097/00000542-198805000-00005; LANE SE, 1989, AM J CARDIOL, V64, P1275, DOI 10.1016/0002-9149(89)90567-5; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LETTE J, 1991, J VASC SURG, V14, P160; LEVINSON JR, 1990, AM J CARDIOL, V66, P406, DOI 10.1016/0002-9149(90)90694-V; MAKAROUN MS, 1990, ARCH SURG-CHICAGO, V125, P1610; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; MARWICK TH, 1990, CLIN CARDIOL, V13, P14, DOI 10.1002/clc.4960130105; MCCANN RL, 1989, J VASC SURG, V9, P583, DOI 10.1067/mva.1989.vs0090583; MCCANN RL, 1989, J VASC SURG, V10, P240; MCPHAIL N, 1988, J VASC SURG, V7, P60, DOI 10.1067/mva.1988.avs0070060; MCPHAIL NV, 1989, J VASC SURG, V10, P51, DOI 10.1067/mva.1989.vs0100051; MCPHAIL NV, 1990, CAN J SURG, V33, P224; MOSLEY JG, 1985, BRIT J SURG, V72, P886, DOI 10.1002/bjs.1800721113; OUYANG P, 1989, AM J CARDIOL, V64, P1113, DOI 10.1016/0002-9149(89)90862-X; PASTERNACK PF, 1989, AM J SURG, V158, P113, DOI 10.1016/0002-9610(89)90357-7; PASTERNACK PF, 1984, J VASC SURG, V1, P320, DOI 10.1067/mva.1984.avs0010320; PASTERNACK PF, 1989, J VASC SURG, V10, P617, DOI 10.1067/mva.1989.15572; PASTERNACK PF, 1985, CIRCULATION, V72, P13; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROZANSKI A, 1983, NEW ENGL J MED, V309, P518, DOI 10.1056/NEJM198309013090902; RUDDY T, 1989, Journal of the American College of Cardiology, V13, p149A; SACHS RN, 1988, SURGERY, V103, P584; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SAUVE MD, 1989, CLIN RES, V37, pA325; SLOGOFF S, 1985, ANESTHESIOLOGY, V62, P107, DOI 10.1097/00000542-198502000-00002; TOAL KW, 1984, AM J SURG, V148, P825, DOI 10.1016/0002-9610(84)90447-1; YOUNIS LT, 1990, AM HEART J, V119, P1287, DOI 10.1016/S0002-8703(05)80177-2; ZELDIN RA, 1984, CAN J SURG, V27, P402	56	94	96	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					743	753		10.7326/0003-4819-116-9-743	http://dx.doi.org/10.7326/0003-4819-116-9-743			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558348				2022-12-28	WOS:A1992HQ62300009
J	WARNOCK, M				WARNOCK, M			GREEN-COLLEGE LECTURE - ETHICAL CHALLENGES IN EMBRYO MANIPULATION	BRITISH MEDICAL JOURNAL			English	Article											WARNOCK, M (corresponding author), GIRTON COLL,CAMBRIDGE CB3 0JG,ENGLAND.							1982, SPLICING LIFE	1	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1045	1049		10.1136/bmj.304.6833.1045	http://dx.doi.org/10.1136/bmj.304.6833.1045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586793	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200029
J	JACOBSEN, JR; PRUDENT, JR; KOCHERSPERGER, L; YONKOVICH, S; SCHULTZ, PG				JACOBSEN, JR; PRUDENT, JR; KOCHERSPERGER, L; YONKOVICH, S; SCHULTZ, PG			AN EFFICIENT ANTIBODY-CATALYZED AMINOACYLATION REACTION	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; BINDING-ENERGY	An antibody generated against a neutral phosphonate diester transition-state analog was found to catalyze the aminoacylation of the 3'-hydroxyl group of thymidine with an alanyl ester. A comparison of the apparent second-order rate constant of the antibody-catalyzed reaction [5.4 x 10(4) molar-1 minute-1 (M-1 min-1)] with that of the uncatalyzed reaction (2.6 x 10(-4) M-1 min-1) revealed this to be a remarkably efficient catalyst. Moreover, although the concentration of water (55 M) greatly exceeds that of the secondary alcohol, the antibody selectively catalyzes acyl transfer to thymidine. The antibody exhibits sequential binding, with Michaelis constants of 770-mu-M and 260-mu-M for acyl acceptor and donor, respectively, and a dissociation constant of 240 pM for hapten. This antibody-catalyzed reaction provides increased insight into the requirements for efficient aminoacylation catalysts and may represent a first step toward the generation of "aminoacyl transfer RNA synthetases" with novel specificities.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,DEPT BIOORGAN CHEM,PALO ALTO,CA 94304	University of California System; University of California Berkeley				Prudent, James/0000-0002-8948-1781	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024695] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24695] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1986, TRENDS BIOCHEM SCI, V11, P321, DOI 10.1016/0968-0004(86)90289-6; HALDANE JBS, 1930, ENZYMES, P182; JACKSON DY, IN PRESS ANGEW CHEM; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PECHT I, 1972, J MOL BIOL, V68, P241, DOI 10.1016/0022-2836(72)90211-2; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; STORM DR, 1972, J AM CHEM SOC, V94, P5805, DOI 10.1021/ja00771a045; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120	24	60	61	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					365	367		10.1126/science.256.5055.365	http://dx.doi.org/10.1126/science.256.5055.365			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566082				2022-12-28	WOS:A1992HP03200032
J	MARTINEZ, C; DEGEUS, P; LAUWEREYS, M; MATTHYSSENS, G; CAMBILLAU, C				MARTINEZ, C; DEGEUS, P; LAUWEREYS, M; MATTHYSSENS, G; CAMBILLAU, C			FUSARIUM-SOLANI CUTINASE IS A LIPOLYTIC ENZYME WITH A CATALYTIC SERINE ACCESSIBLE TO SOLVENT	NATURE			English	Article							X-RAY; LIPASE	LIPASES belong to a class of esterases whose activity on triglycerides is greatly enhanced at lipid-water interfaces 1. This phenomenon, called interfacial activation 2, has a structural explanation: a hydrophobic lid, which at rest covers the catalytic site, is displaced on substrate or inhibitor binding, and probably interacts with the lipid matrix 3-6. Fusarium solani pisi cutinase belongs to a group of homologous enzymes of relative molecular mass 22-25K (ref. 7) capable of degrading cutin, the insoluble lipid-polyester matrix covering the surface of plants 7, and hydrolysing triglycerides 7,8. Cutinases differ from classical lipases in that they do not exhibit interfacial activation; they are active on soluble as well as on emulsified triglycerides. Cutinases therefore establish a bridge between esterases and lipases. We report here the three-dimensional structure of a recombinant cutinase from F. solani pisi, expressed in Escherichia coli 9,10. Cutinase is an alpha-beta protein; the active site is composed of the triad Ser 120, His 188 and Asp 175. Unlike other lipases, the catalytic serine is not buried under surface loops, but is accessible to solvent. This could explain why cutinase does not display interfacial activation.	FAC MED NORD,CNRS,LCCMB,F-13326 MARSEILLE 15,FRANCE; CORVAS INT NV,B-9000 GHENT,BELGIUM	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite								ABERGEL C, 1990, J MOL BIOL, V215, P215, DOI 10.1016/S0022-2836(05)80339-0; BLOW D, 1991, NATURE, V351, P444, DOI 10.1038/351444a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; COLLOCH N, 1987, J MOL GRAPHICS, V5, P170; CONNOLLY ML, 1983, SCIENCE, V306, P287; DEGEUS P, Patent No. 894004621; DEREWENDA ZS, IN PRESS BIOCH CELL; ETTINGER WF, 1987, BIOCHEMISTRY-US, V26, P7883, DOI 10.1021/bi00398a052; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kolattukudy PE., 1981, METHODS ENZYMOLOGY, P652; LAUWEREYS M, 1991, LIPASES STRUCTURE ME, V16, P243; LIAO DI, 1990, J BIOL CHEM, V265, P6528; PULLMAN B, 1970, THEOR CHIM ACTA, V18, P344; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	26	350	378	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					615	618		10.1038/356615a0	http://dx.doi.org/10.1038/356615a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560844				2022-12-28	WOS:A1992HP03100053
J	CLARKE, S				CLARKE, S			USE OF THERMOMETERS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							TEMPERATURE; CHILDREN; FEVER	Objective-To identify the attitudes of general practitioners towards the use of thermometers in general practice. Design-Postal questionnaire survey. Setting-All general practitioners in the catchment area of Frimley Park Hospital, Surrey. Subjects-145 general practitioners. Main outcome measures-Answers to questions covering a variety of aspects concerning the use of thermometers in general practice. Results-116 (80%) doctors replied. Seven doctors did not have any method of taking a patient's temperature; up to 12 more doctors did not use their thermometers and 56 doctors used them infrequently, less than once a fortnight. Mercury glass thermometers were most commonly used (80 doctors; 69%), but only 8% of doctors used them correctly. Six doctors failed to clean their thermometers between patients. The study failed to identify the roles of axillary and rectal temperature readings. Conclusion-There is a wide variation in attitudes towards the use of thermometers in general practice.	THE SURGERY,CAMBERLEY,SURREY,ENGLAND									BANCO L, 1984, AM J DIS CHILD, V138, P976, DOI 10.1001/archpedi.1984.02140480078024; BARRUS D, 1983, PAEDIATR NURSE, V9, P1010; BERGESON PS, 1974, CLIN PEDIATR, V13, P350, DOI 10.1177/000992287401300416; COGGON DNM, 1976, BRIT MED J, V1, P692, DOI 10.1136/bmj.1.6011.692; DAVID CB, 1983, AM J DIS CHILD, V137, P87, DOI 10.1001/archpedi.1983.02140270077025; Ferguson G T, 1971, Hospitals, V45, P62; KNAPP HA, 1966, AM J SURG, V112, P139, DOI 10.1016/S0002-9610(66)91522-4; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; LEWIT EM, 1982, JAMA-J AM MED ASSOC, V247, P321, DOI 10.1001/jama.247.3.321; Martyn K K, 1988, Nurse Pract, V13, P31; NORRIS J, 1985, CONT PAEDIATR, V2, P22; OGREN JM, 1990, AM J DIS CHILD, V144, P101; REISINGER KS, 1979, PEDIATRICS, V64, P4; SCHOLEFIELD JH, 1982, AM J DIS CHILD, V136, P198, DOI 10.1001/archpedi.1982.03970390012002; SHANN F, 1981, LANCET, V1, P310; SHARP GB, 1988, NURSE PRACT      JUL, P9; 1971, NURS TIMES, V67, P1139; 1986, IRISH MED J, V79, P15; 1977, NURSING CARE, V10, P14	19	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					961	963		10.1136/bmj.304.6832.961	http://dx.doi.org/10.1136/bmj.304.6832.961			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581720	Bronze, Green Published			2022-12-28	WOS:A1992HP06400024
J	WALKER, C; GOLDSWORTHY, TL; WOLF, DC; EVERITT, J				WALKER, C; GOLDSWORTHY, TL; WOLF, DC; EVERITT, J			PREDISPOSITION TO RENAL-CELL CARCINOMA DUE TO ALTERATION OF A CANCER SUSCEPTIBILITY GENE	SCIENCE			English	Article							VONHIPPEL-LINDAU DISEASE; TUMORS; RATS; ADENOCARCINOMAS; IDENTIFICATION; NEOPLASMS; ADENOMAS; LOCUS	A single germ line gene mutation at a tumor susceptibility locus in a rodent model of hereditary human renal cancer caused a 70-fold increase in susceptibility to chemical carcinogenesis. A carcinogen that targeted both renal epithelial and mesenchymal cells caused an increase in tumors of epithelial origin in susceptible animals; the number of carcinogen-induced mesenchymal tumors was unaffected by the presence of the mutation at the susceptibility locus. Thus, this mutation defines a genetic locus for susceptibility to carcinogen-induced tumors and modulation of carcinogen susceptibility by this locus exhibits cell-type specificity.			WALKER, C (corresponding author), CHEM IND INST TOXICOL, POB 12137, RES TRIANGLE PK, NC 27709 USA.			Everitt, Jeffrey/0000-0003-0273-6284				CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DIETRICH DR, 1991, MUTAT RES, V248, P239, DOI 10.1016/0027-5107(91)90060-2; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; EVERITT J, UNPUB; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FUNAKI K, 1991, CANCER RES, V51, P4415; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HARD G C, 1986, Toxicologic Pathology, V14, P112; HARD GC, 1984, CARCINOGENESIS, V5, P1047, DOI 10.1093/carcin/5.8.1047; JOHANNESSEN JV, 1980, J SUBMICR CYTOL PATH, V12, P463; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1990, GENETIC BASIS FOR CARCINOGENESIS, P15; LAMIELL JM, 1989, MEDICINE, V68, P1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MEADOWS AT, 1988, B CANCER, V75, P125; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OUTZEN HC, 1983, SEMIN ONCOL, V10, P378; RECIO L, 1991, MOL CARCINOGEN, V4, P350, DOI 10.1002/mc.2940040504; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SOLLEVELD H A, 1986, Toxicologic Pathology, V14, P168, DOI 10.1177/019262338601400204; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALKER C, 1991, CANCER RES, V51, P2973; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALTER TA, 1989, CANCER GENET CYTOGEN, V43, P15, DOI 10.1016/0165-4608(89)90123-4; WEINBERG RA, 1989, CIBA F SYMP, V142, P99; ZBAR B, 1989, IMPORTANT ADV ONCOL, V41	33	82	82	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1992	255	5052					1693	1695		10.1126/science.1553556	http://dx.doi.org/10.1126/science.1553556			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553556				2022-12-28	WOS:A1992HK81200033
J	MCHENRY, PM; HOLE, DJ; MACKIE, RM				MCHENRY, PM; HOLE, DJ; MACKIE, RM			MELANOMA IN PEOPLE AGED 65 AND OVER IN SCOTLAND, 1979-89	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA	Objective - Detailed analysis of primary cutaneous melanoma first diagnosed in Scotland in patients aged 65 and over. Design - Comparison of changing incidence, sex distribution, site, histogenetic type, tumour thickness, and prognosis of all primary cutaneous melanomas in patients aged 65 and over diagnosed in Scotland in the 11 years 1979-89 with similar data for patients aged under 65. Setting - Data were obtained from the Scottish Melanoma Group's database, established in 1979, which aims to record detailed clinical, pathological, and surgical follow up details of all primary cutaneous melanomas registered in Scotland. Patients - 1430 patients (954 women, 476 men) aged 65 and over; comprising over a third of the 3903 patients with primary melanoma recorded for all age groups in Scotland during this period. Results - The overall incidence of melanoma in patients aged 65 and over increased from 12.2/100000 in 1979 to 20.7/100000 in 1989, with the greatest increase seen in older men, from 7.8/100000 in 1979 to 18.0/100000 in 1989. The site most commonly affected was the face in both men and women (33% of all tumours). The most common histogenetic type was superficial spreading melanoma. 526 patients (37%) had melanomas with a tumour thickness of 3.5 mm or greater in the older age group, compared with 453 patients (18%) in those aged under 65. The highest proportion of thick tumours was seen in older men. Five year survival figures for 616 patients diagnosed between 1979 and 1984 were 88%, 66%, and 47% for thin, intermediate, and thick tumours respectively. Overall five year survival for the older age group was 64% compared with 78% for the younger age group. Conclusion - The increase in melanoma in the elderly and the high proportion of thick tumours, especially in men, require a specific educational programme for both primary and secondary prevention directed towards the older population.	RUCHILL HOSP,CANCER SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND		MCHENRY, PM (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,DEPT DERMATOL,GLASGOW G11 6NT,SCOTLAND.							BALCH CM, 1985, CUTANEOUS MELANOMA; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; COHEN HJ, 1987, J CLIN ONCOL, V5, P100, DOI 10.1200/JCO.1987.5.1.100; Cox DR., 1970, ANAL BINARY DATA; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; RIVERS JK, 1989, J AM ACAD DERMATOL, V21, P717, DOI 10.1016/S0190-9622(89)70243-7; SHAW HM, 1980, CANCER, V46, P2731, DOI 10.1002/1097-0142(19801215)46:12<2731::AID-CNCR2820461232>3.0.CO;2-2	8	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					746	749		10.1136/bmj.304.6829.746	http://dx.doi.org/10.1136/bmj.304.6829.746			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571680	Green Published, Bronze			2022-12-28	WOS:A1992HK80000020
J	GADD, EM; FLETCHER, MF				GADD, EM; FLETCHER, MF			DO SENIOR REGISTRARS HAVE ADEQUATE MANAGEMENT-TRAINING	BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP,DEPT GERIATR MED,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND		GADD, EM (corresponding author), QUEEN ELIZABETH PSYCHIAT HOSP,DEPT PSYCHIAT,BIRMINGHAM B15 2QZ,ENGLAND.							BOODHOO JA, 1991, PSYCHIATRIC B, V15, P480; HINDLE J, 1990, BRIT J HOSP MED, V43, P363; SMITH GJ, 1986, BRIT MED J, V292, P150, DOI 10.1136/bmj.292.6513.150; 1990, PSYCHIATRIC B, V14, P373; 1989, DOCTORS MANAGEMENT D	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					546	547		10.1136/bmj.304.6826.546	http://dx.doi.org/10.1136/bmj.304.6826.546			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559059	Green Published, Bronze			2022-12-28	WOS:A1992HG59900023
J	KEHOE, RF; MANDER, AJ				KEHOE, RF; MANDER, AJ			LITHIUM TREATMENT - PRESCRIBING AND MONITORING HABITS IN HOSPITAL AND GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To define current clinical practice of lithium prescribing and monitoring and to compare hospital based practice with general practice. Design - Prospective study of doctors' practice. Setting - Psychiatric hospital day and outpatient facilities and general practices in Edinburgh and Midlothian district (population 600 000). Subjects - 458 patients taking lithium who had been stabilised and who remained as outpatients during the year of study. 219 were treated by their general practitioner and 190 by the hospital; 49 had shared care or care transferred during the study. Main outcome measures - Daily dose, duration of treatment, psychiatric diagnosis, mean annual serum lithium concentration, frequency of occurrence of and response to raised serum concentrations. Results - Compared with hospital doctors general practitioners were more likely to prescribe lithium three or more times daily (43/219 (general practice) v 10/190 (hospital); chi-2 = 18.6, p = 0.001) and to estimate serum concentrations less frequently (4.5 v 5.3 measurements/year; t = 3.04, p = 0.003), and their patients were more likely to experience raised lithium concentrations (39/219 v 17/190; chi-2 = 6.8, p = 0.01). One third of doctors made no response to raised lithium concentrations in the next six weeks. Conclusions - General practitioners and hospital doctors care for similar types of patients and the stringency of lithium surveillance varies greatly among doctors. Certain aspects of practice give cause for concern and could be improved by following more uniform guidelines.			KEHOE, RF (corresponding author), ROYAL EDINBURGH & ASSOC HOSP,EDINBURGH EH10 5HF,SCOTLAND.							ABOUSALEH M, 1990, PRACTICAL REV PSYC 2, V10, P10; [Anonymous], 1978, INT CLASSIFICATION D; CRAMMER J, 1982, USE DRUGS PSYCHIATRY; DASGUPTA K, 1990, GEN HOSP PSYCHIAT, V12, P83, DOI 10.1016/0163-8343(90)90019-9; GELDER M, 1989, OXFORD TXB PSYCHIATR; GELENBERG AJ, 1989, NEW ENGL J MED, V321, P1489, DOI 10.1056/NEJM198911303212201; GITLIN MJ, 1984, HOSP COMMUNITY PSYCH, V35, P363; KEHOE RF, 1989, PSYCHIATR B R COLL P, V13, P611; King J. R., 1991, PSYCHIAT B, V15, P138, DOI [10.1192/pb.15.3.138, DOI 10.1192/PB.15.3.138]; LOUDON JB, 1988, COMPANION PSYCHIATRI; MCREADIE RG, 1985, BRIT J PSYCHIAT, V146, P70; VESTERGAARD P, 1989, PHARMACOPSYCHIATRY, V22, P99, DOI 10.1055/s-2007-1014587; WALKER RG, 1982, KIDNEY INT, V21, P513; 1991, BRIT NATIONAL FORMUL; 1989, MED NEWS, V1, P2	15	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					552	554		10.1136/bmj.304.6826.552	http://dx.doi.org/10.1136/bmj.304.6826.552			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG599	1559064	Green Published, Bronze			2022-12-28	WOS:A1992HG59900028
J	SINGH, V; SEHGAL, A; LUHRA, UK				SINGH, V; SEHGAL, A; LUHRA, UK			SCREENING FOR CERVICAL-CANCER BY DIRECT INSPECTION	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the efficacy of visual screening for cervical cancer in the maternal and child health setting. Design - Clinical and cytological screening. Setting - Maternal and child health centres, Delhi. Subjects - 44970 women attending the centres from May 1988 to March 1991. Results - 238 cancers in early stages (0-IIa) were detected cytologically and proved through biopsy. Prevalence of cancer in women defined as high risk through examination by speculum was 29/1000 as compared to 1.53/1000 among women with a normal looking cervix. Though only 11.4% women belonged to the high risk category, 63% had early stage cancer. If all women with bleeding symptoms were included in the high risk category, the yield of cancer would be 71.4% (170/238) by referring only 15.6% of women attending maternal and child health centres for further evaluation through cytology or colposcopy. Conclusion - Though visual screening is a suboptimal strategy in comparison to the cytological screening, it may be useful where there is a heavy load of prevalent cancer and where cytological screening may not be available for years to come.			SINGH, V (corresponding author), MAULANA AZAD MED COLL,INST CYTOL & PREVENT ONCOL ICMR,BAHADUR SHAH ZAFAR MARG,NEW DELHI 110002,INDIA.							SEHGAL A, 1991, LANCET, V338, P282, DOI 10.1016/0140-6736(91)90420-T; Snedecor GW, 1967, STATISTICAL METHODS, P199; STJERNSWARD J, 1987, WORLD HEALTH FORUM, V8, P2	3	58	58	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					534	535		10.1136/bmj.304.6826.534	http://dx.doi.org/10.1136/bmj.304.6826.534			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559055	Green Published, Bronze			2022-12-28	WOS:A1992HG59900017
J	KULIG, K				KULIG, K			CURRENT CONCEPTS - INITIAL MANAGEMENT OF INGESTIONS OF TOXIC-SUBSTANCES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WHOLE BOWEL IRRIGATION; ACTIVATED-CHARCOAL; DRUG OVERDOSE; POISONED PATIENT; GASTRIC LAVAGE; IPECAC; ABSORPTION; SYRUP; PREVENTION		COLORADO EMERGENCY MED RES CTR,DENVER,CO		KULIG, K (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT SURG,DIV EMERGENCY MED & TRAUMA,CAMPUS BOX B215,4200 E 9TH AVE,DENVER,CO 80262, USA.							ALBERTSON TE, 1989, ANN EMERG MED, V18, P56, DOI 10.1016/S0196-0644(89)80314-2; BRETT AS, 1988, ARCH INTERN MED, V148, P437; BROWN CR, 1987, VET HUM TOXICOL, V29, P492; BROWNING RG, 1990, ANN EMERG MED, V19, P683, DOI 10.1016/S0196-0644(05)82479-5; CALLAHAM M, 1985, ANN EMERG MED, V14, P1, DOI 10.1016/S0196-0644(85)80725-3; CARAVATI EM, 1991, ANN EMERG MED, V20, P147, DOI 10.1016/S0196-0644(05)81213-2; CURTIS RA, 1984, ARCH INTERN MED, V144, P48, DOI 10.1001/archinte.144.1.48; FISER DH, 1990, NEW ENGL J MED, V322, P1579; FORD M, 1990, Emergency Medicine Clinics of North America, V8, P495; HOFFMAN R S, 1990, Emergency Medicine Clinics of North America, V8, P467; HOFFMAN RS, 1990, AM J EMERG MED, V8, P523, DOI 10.1016/0735-6757(90)90155-S; HOFFMAN RS, 1990, VET HUM TOXICOL, V32, P164; KELLERMANN AL, 1987, ANN EMERG MED, V16, P1206, DOI 10.1016/S0196-0644(87)80225-1; KULIG K, 1985, ANN EMERG MED, V14, P562, DOI 10.1016/S0196-0644(85)80780-0; KULIG K, 1985, AM J EMERG MED, V6, P573; LINAKIS J G, 1990, Veterinary and Human Toxicology, V32, P351; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; MCNAMARA RM, 1987, AM J EMERG MED, V5, P97; MERIGIAN KS, 1990, AM J EMERG MED, V8, P479, DOI 10.1016/0735-6757(90)90146-Q; NEUVONEN PJ, 1988, MED TOXICOL ADV DRUG, V3, P33, DOI 10.1007/BF03259930; NEUVONEN PJ, 1983, EUR J CLIN PHARMACOL, V24, P557, DOI 10.1007/BF00609903; OLSON KR, 1987, MED TOXICOL ADV DRUG, V2, P52, DOI 10.1007/BF03259860; ORLOWSKI JP, 1990, AM J DIS CHILD, V144, P112, DOI 10.1001/archpedi.1990.02150250124049; OSTERLOH J D, 1990, Emergency Medicine Clinics of North America, V8, P693; ROBERTS JR, 1978, JACEP-J AM COLL EMER, V7, P260, DOI 10.1016/S0361-1124(78)80335-9; ROBERTSON WO, 1979, VET HUM TOXICOL, V21, P87; ROSENBERG PJ, 1988, ANN EMERG MED, V17, P681, DOI 10.1016/S0196-0644(88)80610-3; RUSLI M, 1987, ANN EMERG MED, V16, P314, DOI 10.1016/S0196-0644(87)80178-6; TANDBERG D, 1981, ANN EMERG MED, V10, P521, DOI 10.1016/S0196-0644(81)80007-8; TENENBEIN M, 1987, ARCH INTERN MED, V147, P905, DOI 10.1001/archinte.147.5.905; TENENBEIN M, 1987, J PEDIATR-US, V111, P142, DOI 10.1016/S0022-3476(87)80365-7; THOMPSON AM, 1987, HUM TOXICOL, V6, P215, DOI 10.1177/096032718700600307; TOMASZEWSKI C, 1990, Veterinary and Human Toxicology, V32, P351; WALD P, 1986, ANN EMERG MED, V15, P80, DOI 10.1016/S0196-0644(86)80493-0; Ward J T Jr, 1983, Am J Emerg Med, V1, P71, DOI 10.1016/0735-6757(83)90039-6; WATSON W A, 1989, Journal of Emergency Medicine, V7, P373, DOI 10.1016/0736-4679(89)90309-0; WOLOWODIUK OJ, 1984, ANN EMERG MED, V13, P1148, DOI 10.1016/S0196-0644(84)80341-8	37	40	40	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1677	1681						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588982				2022-12-28	WOS:A1992HY62800007
J	COLEMAN, RA; WINTER, HS; WOLF, B; GILCHRIST, JM; CHEN, YT				COLEMAN, RA; WINTER, HS; WOLF, B; GILCHRIST, JM; CHEN, YT			GLYCOGEN-STORAGE-DISEASE TYPE-III (GLYCOGEN DEBRANCHING ENZYME DEFICIENCY) - CORRELATION OF BIOCHEMICAL DEFECTS WITH MYOPATHY AND CARDIOMYOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						GLYCOGEN STORAGE DISEASE TYPE-III; GLYCOGEN DEBRANCHING ENZYME SYSTEM; MUSCULAR DISEASES; MYOCARDIAL DISEASES; LIVER DISEASES; GROWTH DISORDERS	IMMUNOBLOT ANALYSES; INVOLVEMENT; ADULTS	Objective: To determine whether a specific subtype of glycogen storage disease type III is associated with myopathy and cardiomyopathy. Design: Case series. Setting: Three referral medical centers. Patients: All patients with glycogen storage disease type III who were followed in 1990 and for whom both immunoblot analysis and clinical data were available. Main Outcome Measures: Evaluation for myopathy and cardiomyopathy included determinations of serum creatine kinase activity; muscle strength testing; ischemic exercise testing; nerve conduction studies; and electromyographic, electrocardiographic, and echocardiographic studies. Results: Three patients with deficient debranching enzyme activity and deficient immunoreactive material in liver but normal debranching enzyme activity in muscle (glycogen storage disease IIIb) had no clinical evidence of myopathy or cardiomyopathy. Serum creatine kinase activity, muscle strength, ischemic exercise testing, electrocardiograms, and echocardiograms were normal in these patients. These studies and electromyograms were abnormal in seven patients with total debranching enzyme deficiency and an absence of immunoreactive material in both liver and muscle (glycogen storage disease IIIa) and in three patients who had debranching enzyme transferase deficiency but normal glucosidase activity in both liver and muscle (glycogen storage disease IIId). All 10 of these patients had progressive myopathy, and 6 had progressive cardiomyopathy. Conclusion: Clinical features of glycogen storage disease type III correlate with the particular biochemical defect seen with the disorder. Assessments of debranching enzyme or debranching enzyme transferase activity in muscle can be used to predict whether patients with glycogen storage disease type III will develop myopathy and cardiomyopathy.	DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT HUMAN GENET, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PEDIAT, RICHMOND, VA 23298 USA; RHODE ISL HOSP, DEPT NEUROL, PROVIDENCE, RI 02902 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; Virginia Commonwealth University; Virginia Commonwealth University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039078] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR30] Funding Source: Medline; NIDDK NIH HHS [DK 39078] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES EJ, 1975, FEBS LETT, V58, P181, DOI 10.1016/0014-5793(75)80254-7; BROWN BI, 1968, CARBOHYD METABOL, P123; Brown D.H., 1966, METHOD ENZYMOL, P515, DOI 10.1016/0076-6879(66)08093-5; BRUNBERG JA, 1971, ARCH NEUROL-CHICAGO, V25, P171, DOI 10.1001/archneur.1971.00490020089011; CHEN YT, 1987, AM J HUM GENET, V41, P1002; COLEMAN RA, 1986, MUSCLE NERVE, V9, P216, DOI 10.1002/mus.880090305; CORNELIO F, 1984, ARCH NEUROL-CHICAGO, V41, P1027, DOI 10.1001/archneur.1984.04050210025008; DAESCHEL IE, 1983, J AM DIET ASSOC, V83, P135; DIMAURO S, 1979, ANN NEUROL, V5, P422, DOI 10.1002/ana.410050504; DING JH, 1990, J PEDIATR-US, V116, P95, DOI 10.1016/S0022-3476(05)81652-X; FORBES GB, 1953, J PEDIATR-US, V42, P645, DOI 10.1016/S0022-3476(53)80420-8; HERS HG, 1967, EUR J BIOCHEM, V2, P257, DOI 10.1111/j.1432-1033.1967.tb00133.x; Hers HG, 1989, METABOLIC BASIS INHE, P425; ILLINGWORTH B, 1956, J BIOL CHEM, V218, P123; MOSES SW, 1986, ACTA PAEDIATR SCAND, V75, P289, DOI 10.1111/j.1651-2227.1986.tb10201.x; MURASE T, 1973, J NEUROL SCI, V20, P287, DOI 10.1016/0022-510X(73)90190-1; NELSON TE, 1970, ANAL BIOCHEM, V33, P87, DOI 10.1016/0003-2697(70)90442-2; PERNOT C, 1978, ARCH MAL COEUR VAISS, V71, P428; POWELL HC, 1985, MUSCLE NERVE, V8, P667, DOI 10.1002/mus.880080808; SLONIM AE, 1983, METABOLISM, V32, P70, DOI 10.1016/0026-0495(83)90159-2; SLONIM AE, 1982, ANN NEUROL, V11, P420, DOI 10.1002/ana.410110417; VANHOOF F, 1967, EUR J BIOCHEM, V2, P265; YANG BZ, 1990, AM J HUM GENET, V47, P735	23	64	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					896	900		10.7326/0003-4819-116-11-896	http://dx.doi.org/10.7326/0003-4819-116-11-896			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580445				2022-12-28	WOS:A1992HW13700003
J	THERIOT, JA; MITCHISON, TJ; TILNEY, LG; PORTNOY, DA				THERIOT, JA; MITCHISON, TJ; TILNEY, LG; PORTNOY, DA			THE RATE OF ACTIN-BASED MOTILITY OF INTRACELLULAR LISTERIA-MONOCYTOGENES EQUALS THE RATE OF ACTIN POLYMERIZATION	NATURE			English	Article							FILAMENTS	THE Gram-positive bacterium Listeria monocytogenes is a facultative intracellular pathogen capable of rapid movement through the host cell cytoplasm 1. The biophysical basis of the motility of L. monocytogenes is an interesting question in its own right, the answer to which may shed light on the general processes of actin-based motility in cells. Moving intracellular bacteria display phase-dense 'comet tails' made of actin filaments, the formation of which is required for bacterial Motility 2,3. We have investigated the dynamics of the actin filaments in the comet tails using the technique of photoactivation of fluorescence, which allows monitoring of the movement and turnover of labelled actin filaments after activation by illumination with ultraviolet light. We find that the actin filaments remain stationary in the cytoplasm as the bacterium moves forward, and that length of the comet tails is linearly proportional to the rate of movement. Our results imply that the motile mechanism involves continuous polymerization and release of actin filaments at the bacterial surface and that the rate of filament generation is related to the rate of movement. We suggest that actin polymerization provides the driving force for bacterial propulsion.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA	University of California System; University of California San Francisco; University of Pennsylvania; University of Pennsylvania	THERIOT, JA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Theriot, Julie/HHN-2034-2022	Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P490, DOI 10.1073/pnas.79.2.490; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; OSTER GF, 1987, J CELL SCI, P35; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; SANDERS MC, 1990, J CELL BIOL, V110, P359, DOI 10.1083/jcb.110.2.359; SANGER J M, 1990, Journal of Cell Biology, V111, p415A; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TILNEY LG, IN PRESS J CELL BIOL	13	431	437	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1992	357	6375					257	260		10.1038/357257a0	http://dx.doi.org/10.1038/357257a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589024				2022-12-28	WOS:A1992HV19500060
J	WANG, L; HELMANN, JD; WINANS, SC				WANG, L; HELMANN, JD; WINANS, SC			THE A-TUMEFACIENS TRANSCRIPTIONAL ACTIVATOR OCCR CAUSES A BEND AT A TARGET PROMOTER, WHICH IS PARTIALLY RELAXED BY A PLANT TUMOR METABOLITE	CELL			English	Article							AGROBACTERIUM TI-PLASMID; ESCHERICHIA-COLI; RNA-POLYMERASE; REGULATORY PROTEINS; BINDING-SPECIFICITY; INDUCIBLE GENES; DNA; SEQUENCE; ORGANIZATION; FAMILY	Octopine is released from crown gall tumors as a nutrient source and a signal molecule for the plant pathogen Agrobacterium tumefaciens. Some or all octopine-inducible genes are regulated by a protein called OccR. Primer extension analysis showed that OccR protein represses the occR gene and both represses and activates the occQ operon, which is divergently transcribed from occR. These promoters initiate transcription 46 bp apart. This regulatory system was reconstituted in vitro using purified OccR protein and Escherichia coli RNA polymerase. OccR binds with high affinity to a single site overlapping these promoters. Octopine shortens the DNAase I footprint of OccR and increases the gel mobility of OccR-DNA complexes by relaxing an OccR-incited DNA bend.			WANG, L (corresponding author), CORNELL UNIV,MICROBIOL SECT,ITHACA,NY 14853, USA.			Helmann, John/0000-0002-3832-3249	NIGMS NIH HHS [1 R29 GM2893-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P575, DOI 10.1146/annurev.mi.42.100188.003043; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1989, J BIOL CHEM, V264, P903; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHANG M, 1991, J BACTERIOL, V173, P1590, DOI 10.1128/jb.173.5.1590-1597.1991; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CHUNG YT, 1990, MOL CELL BIOL, V10, P206, DOI 10.1128/MCB.10.1.206; DEGREVE H, 1981, PLASMID, V6, P235, DOI 10.1016/0147-619X(81)90069-X; DESSAUX Y, 1987, MOL GEN GENET, V208, P301, DOI 10.1007/BF00330457; DEVOS G, 1981, PLASMID, V6, P249, DOI 10.1016/0147-619X(81)90070-6; ECKERT RL, 1987, CURRENT PROTOCOLS MO; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; HABEEB LF, 1991, MOL PLANT MICROBE IN, V4, P379, DOI 10.1094/MPMI-4-379; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HELMANN JD, 1989, J BACTERIOL, V171, P222, DOI 10.1128/jb.171.1.222-229.1989; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; HRYNIEWICZ MM, 1991, J BACTERIOL, V173, P5876, DOI 10.1128/jb.173.18.5876-5886.1991; HUANG MW, 1990, J BACTERIOL, V172, P1814, DOI 10.1128/jb.172.4.1814-1822.1990; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JIN SG, 1990, J BACTERIOL, V172, P531, DOI 10.1128/jb.172.2.531-537.1990; KADO CI, 1991, CRIT REV PLANT SCI, V10, P1, DOI 10.1080/07352680490273310; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KERPPOLA TK, 1991, NATURE, V254, P1210; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLAPWIJK PM, 1979, J BACTERIOL, V141, P424; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; REAM W, 1989, ANNU REV PHYTOPATHOL, V27, P583, DOI 10.1146/annurev.py.27.090189.003055; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; ROTHMEL RK, 1991, J BACTERIOL, V173, P4717, DOI 10.1128/jb.173.15.4717-4724.1991; SCHELL MA, 1989, J BACTERIOL, V171, P1952, DOI 10.1128/jb.171.4.1952-1959.1989; SCHINDLER U, 1989, J BACTERIOL, V171, P847, DOI 10.1128/jb.171.2.847-854.1989; SCHRODER J, 1990, 5TH INT S MOL GEN PL, P52; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STACHEL SE, 1986, EMBO J, V5, P1445, DOI 10.1002/j.1460-2075.1986.tb04381.x; STACHEL SE, 1985, EMBO J, V4, P891, DOI 10.1002/j.1460-2075.1985.tb03715.x; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; SUMMERS WC, 1970, ANAL BIOCHEM, V33, P459; TABATA S, 1989, J BACTERIOL, V171, P1665, DOI 10.1128/jb.171.3.1665-1672.1989; TEMPE J, 1982, MOL BIOL PLANT TUMOR, P00451, DOI DOI 10.1016/B978-0-12-394380-4.50022-0; Tempe J, 1982, MOL BIOL PLANT TUMOR, P427, DOI [10.1016/B978-0-12-394380-4.50021-9, DOI 10.1016/B978-0-12-394380-4.50021-9]; THOMASHOW MF, 1980, CELL, V19, P729, DOI 10.1016/S0092-8674(80)80049-3; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VALDIVIA RH, 1991, J BACTERIOL, V173, P6398, DOI 10.1128/jb.173.20.6398-6405.1991; VONBODMAN SB, 1992, P NATL ACAD SCI USA, V89, P643, DOI 10.1073/pnas.89.2.643; VONLINTIG J, 1991, MOL PLANT MICROBE IN, V4, P370, DOI 10.1094/MPMI-4-370; WINANS SC, 1986, P NATL ACAD SCI USA, V83, P8278, DOI 10.1073/pnas.83.21.8278; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAMBRYSKI P, 1989, CELL, V56, P193, DOI 10.1016/0092-8674(89)90892-1; ZAMBRYSKI P, 1988, ANNU REV GENET, V22, P1, DOI 10.1146/annurev.ge.22.120188.000245; ZAMBRYSKI P, 1989, MOBILE DNA, P309; ZWEIB C, 1989, GENE DEV, V3, P606; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	69	118	122	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					659	667		10.1016/0092-8674(92)90229-6	http://dx.doi.org/10.1016/0092-8674(92)90229-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586946				2022-12-28	WOS:A1992HV08900010
J	IRVING, M; LOMBARDI, V; PIAZZESI, G; FERENCZI, MA				IRVING, M; LOMBARDI, V; PIAZZESI, G; FERENCZI, MA			MYOSIN HEAD MOVEMENTS ARE SYNCHRONOUS WITH THE ELEMENTARY FORCE-GENERATING PROCESS IN MUSCLE	NATURE			English	Article							STRIATED-MUSCLE; MECHANISM; FIBERS; HYDROLYSIS; ACTOMYOSIN; LENGTH; ACTIN	MOTOR proteins such as myosin, dynein and kinesin use the free energy of ATP hydrolysis to produce force or motion, but despite recent progress 1-4 their molecular mechanism is unknown. The best characterized system is the myosin motor which moves actin filaments in muscle 5-12. When an active muscle fibre is rapidly shortened the force first decreases, then partially recovers over the next few milliseconds 5. This elementary force-generating process is thought to be due to a structural 'working stroke' in the myosin head domain 5-9, although structural studies have not provided definitive support for this 10-12. X-ray diffraction has shown that shortening steps produce a large decrease in the intensity of the 14.5 nm reflection arising from the axial repeat of the myosin heads along the filaments 13,14 . This was interpreted as a structural change at the end of the working stroke, but the techniques then available did not allow temporal resolution of the elementary force-generating process itself. Using improved measurement techniques, we show here that myosin heads move by about 10 nm with the same time course as the elementary force-generating process.	UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,I-50134 FLORENCE,ITALY; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	University of Florence; MRC National Institute for Medical Research	IRVING, M (corresponding author), UNIV LONDON KINGS COLL,DEPT BIOPHYS CELL & MOLEC BIOL,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.		Ferenczi, Michael/F-9510-2015	Ferenczi, Michael/0000-0002-0349-331X				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1980, J PHYSIOL-LONDON, V305, pP15; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1991, NATURE, V352, P284, DOI 10.1038/352284a0; IRVING M, 1987, FIBROUS PROTEIN STRU, P495; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MATSUBARA I, 1985, J PHYSIOL-LONDON, V361, P151, DOI 10.1113/jphysiol.1985.sp015638; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	30	184	187	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					156	158		10.1038/357156a0	http://dx.doi.org/10.1038/357156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579164				2022-12-28	WOS:A1992HU12200057
J	WATKINS, H; ROSENZWEIG, A; HWANG, DS; LEVI, T; MCKENNA, W; SEIDMAN, CE; SEIDMAN, JG				WATKINS, H; ROSENZWEIG, A; HWANG, DS; LEVI, T; MCKENNA, W; SEIDMAN, CE; SEIDMAN, JG			CHARACTERISTICS AND PROGNOSTIC IMPLICATIONS OF MYOSIN MISSENSE MUTATIONS IN FAMILIAL HYPERTROPHIC CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEAVY-CHAIN GENE; SUDDEN-DEATH; CLINICAL MANIFESTATIONS; PATHO-PHYSIOLOGY; MOLECULAR-BASIS; INTERRELATIONS; SEQUENCE; THERAPY; DNA	Background. Familial hypertrophic cardiomyopathy is characterized by a variable degree of myocardial hypertrophy and a wide range of symptoms. Different mutations in the beta-cardiac myosin heavy-chain gene have been identified in three affected families. However, neither the proportion of cases attributable to myosin mutations nor the effects of different mutations on clinical outcome are known. Methods. Using a ribonuclease protection assay, we screened the beta-cardiac myosin heavy-chain genes of probands from 25 unrelated families with familial hypertrophic cardiomyopathy; this assay is a sensitive method for detecting the presence and location of mutations. We further defined the mutations by analyzing their nucleotide sequences. The clinical features of the disease were compared in families with various myosin mutations. Results. Seven mutations in the beta-cardiac myosin heavy-chain gene were identified in 12 of the 25 families. All were missense mutations (i.e., causing the substitution of a single amino acid) clustered in the head and head-rod junction regions of the molecule. Six mutations resulted in a change in the charge of the amino acid. Patients with mutations that changed the charge of the altered amino acid (such as that from arginine to glutamine at nucleotide 403 or from arginine to cysteine at nucleotide 453) had a significantly shorter life expectancy (mean age at death, 33 years), whereas patients with the one mutation that did not produce a change in charge (Val606Met) had nearly normal survival. However, patients with different mutations did not differ appreciably in their clinical manifestations of familial hypertrophic cardiomyopathy. Conclusions. Different missense mutations in the beta-cardiac myosin heavy-chain gene can be identified in approximately 50 percent of families with hypertrophic cardiomyopathy. In those families, a definite genetic diagnosis can be made in all members. Since the location of a mutation or its DNA-sequence alteration (or both) appears to influence survival, we suggest that the precise definition of the disease-causing mutation can provide important prognostic information about affected members.	ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND; TAICHUNG VET GEN HOSP,DIV CARDIOL,TAICHUNG,TAIWAN; HOWARD HUGHES MED INST,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV CARDIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114	St Georges University London; Taichung Veterans General Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	WATKINS, H (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.		McKenna, William J/C-3243-2008; Rosenzweig, Anthony/AAD-7893-2019	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046320, R29HL041474] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02228, HL-46320, HL-41474] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; Cox D. R., 1984, ANAL SURVIVAL DATA; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P4051, DOI 10.1093/nar/18.13.4051; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P3227, DOI 10.1093/nar/18.11.3227; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KAUFMAN DL, 1990, GENOMICS, V8, P656, DOI 10.1016/0888-7543(90)90252-P; KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE ET, 1980, STATISTICAL METHODS; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1978, AM J CARDIOL, V41, P1133, DOI 10.1016/0002-9149(78)90870-6; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1989, CIRCULATION, V80, P1489, DOI 10.1161/01.CIR.80.5.1489; MCKENNA WJ, 1989, DISEASES HEART, P9233; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NEWMAN H, 1985, J AM COLL CARDIOL, V5, P1064, DOI 10.1016/S0735-1097(85)80006-1; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; SOLOMON SD, 1990, AM J HUM GENET, V47, P389; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; YOUSSOUFIAN H, 1988, AM J HUM GENET, V42, P718	36	586	614	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1108	1114		10.1056/NEJM199204233261703	http://dx.doi.org/10.1056/NEJM199204233261703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552912				2022-12-28	WOS:A1992HP80000003
J	TIAN, M; MANIATIS, T				TIAN, M; MANIATIS, T			POSITIVE CONTROL OF PRE-MESSENGER-RNA SPLICING INVITRO	SCIENCE			English	Article							DROSOPHILA DOUBLESEX GENE; SEXUAL-DIFFERENTIATION; U2 SNRNP; BINDING PROTEINS; REGULATORY GENE; MELANOGASTER; IDENTIFICATION; SEQUENCES; TRANSFORMER-2; PURIFICATION	Positive control of the sex-specific alternative splicing of doublesex (dsx) precursor messenger RNA (pre-mRNA) in Drosophila melanogaster involves the activation of a female-specific 3' splice site by the products of the transformer (tra) and transformer-2 (tra-2) genes. The mechanisms of this process were investigated in an in vitro system in which the female-specific 3' splice site could be activated by recombinant Tra or Tra-2 (or both). An exon sequence essential for regulation in vivo was shown to be both necessary and sufficient for activation in vitro. Nuclear proteins in addition to Tra and Tra-2 were found to bind specifically to this exon sequence. Therefore, Tra and Tra-2 may act by promoting the assembly of a multiprotein complex on the exon sequence. This complex may facilitate recognition of the adjacent 3' splice site by the splicing machinery.			TIAN, M (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM42231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERIN M, UNPUB; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RIAN M, UNPUB; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; SUMMERS MD, 1987, TEXAS AGR EXP STN B, V1555; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	178	183	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					237	240		10.1126/science.1566072	http://dx.doi.org/10.1126/science.1566072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566072				2022-12-28	WOS:A1992HM89600034
J	WEI, ML; CRESSWELL, P				WEI, ML; CRESSWELL, P			HLA-A2 MOLECULES IN AN ANTIGEN-PROCESSING MUTANT-CELL CONTAIN SIGNAL SEQUENCE-DERIVED PEPTIDES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; MONOCLONAL-ANTIBODIES; EXPRESSION; PROTEIN; ASSOCIATION; TRANSPORT; REGION; GENE	THE mutant human cell line T2 is defective in antigen presentation in the context of class I major histocompatibility complex (MHC) molecules 1,2, and also in that transfected T2 cells show poor surface expression of exogenous human class I (HLA) alleles 3. Both defects are thought to lie in the transport of antigenic peptides derived from cytosolic proteins into the endoplasmic reticulum (ER) 1,2, as peptide-deficient class I molecules might be expected to be either unstable or retained in the ER 4. The products of several mouse class I (H-2) genes, and the endogenous gene HLA-A2 do, however, reach the surface of T2 cells at reasonable levels although they are non-functional 3,5,6. We report here that, as expected, poorly surface-expressed HLA molecules do not significantly bind endogenous peptides. Surprisingly, H-2 molecules expressed in T2 also lack associated peptides, arguing that 'empty' complexes of mouse class I glycoproteins with human beta-2-microglobulin are neither retained in the ER nor unstable. HLA-A2 molecules, however, do bind high levels of a limited set of endogenous peptides. We have sequenced three of these peptides and find that two, a 9-mer and an 11-mer, are derived from a putative signal sequence (of IP-30, an interferon-gamma-inducible protein 7), whereas a third, a 13-mer, is of unknown origin. The unusual length of two of the peptides argues that the 9-mers normally associated with HLA-A2 molecules may be generated before their transport from the cytosol rather than in a pre-Golgi compartment. To our knowledge, this is the first report of the isolation of a fragment of a eukaryotic signal peptide generated in vivo.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06510; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Howard Hughes Medical Institute; Yale University; Duke University				Wei, Maria/0000-0002-3568-1921				ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HARMON RC, 1983, IMMUNOGENETICS, V18, P541, DOI 10.1007/BF00364395; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; OZATO K, 1981, J IMMUNOL, V126, P317; PARHAM P, 1979, J IMMUNOL, V123, P342; ROCHE PA, 1990, J IMMUNOL, V144, P1849; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213	29	499	508	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					443	446		10.1038/356443a0	http://dx.doi.org/10.1038/356443a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557127				2022-12-28	WOS:A1992HL83000067
J	STRINGER, MD; PLEDGER, G; DRAKE, DP				STRINGER, MD; PLEDGER, G; DRAKE, DP			CHILDHOOD DEATHS FROM INTUSSUSCEPTION IN ENGLAND AND WALES, 1984-9	BRITISH MEDICAL JOURNAL			English	Article							CURRENT MANAGEMENT; DIAGNOSIS; CHILDREN; INFANCY; REFLUX	Objective - To assess the incidence of potentially avoidable factors contributing to death of children with intussusception. Design - Review of children who died with intussusception in England and Wales between 1984 and 1989 from data of the Office of Population Censuses and Surveys, case notes, coroners' records, and necropsy reports. Main outcome measures - Unambiguous objective criteria such as failure to diagnose intussusception within 24 hours of admission. Results - 33 children died of acute intussusception in England and Wales between 1984 and 1989 compared with 67 in the previous six years. Their median age was 7 months (range 2 months to 12 years), and two thirds were boys. Half of the deaths occurred at home or soon after arrival at hospital but 15 patients had surgery. Potentially avoidable factors contributing to death were identified in 20 (61%) children, all but three of whom had ileocolic intussusception. These factors were excessive delay in diagnosis, inadequate intravenous fluid and antibiotic therapy, delay in recognising recurrent or residual intussusception after hydrostatic reduction, and surgical complications. Of the 13 patients in whom no avoidable factors were identified, there were nine of 11 children with isolated small bowel intussusception, who tended to have atypical presentations. Conclusion - Although the mortality from intussusception has declined, there remains ample opportunity for improved management.	NEWCASTLE AREA HLTH AUTHOR,NEWCASTLE TYNE,ENGLAND; HOSP SICK CHILDREN,PEDIAT SURG,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BEASLEY SW, 1988, PEDIATR SURG INT, V3, P135; BEASLEY SW, 1987, AUST NZ J SURG, V57, P11, DOI 10.1111/j.1445-2197.1987.tb01231.x; BRUCE J, 1987, J PEDIATR GASTR NUTR, V6, P663, DOI 10.1097/00005176-198709000-00003; CAMPLING EA, 1990, REPORT NATIONAL CONF; DENNISON WM, 1970, BRIT J SURG, V57, P679, DOI 10.1002/bjs.1800570912; EIN SH, 1971, J PEDIATR SURG, V6, P16, DOI 10.1016/0022-3468(71)90663-4; EIN SH, 1976, J PEDIATR SURG, V11, P563, DOI 10.1016/S0022-3468(76)80013-9; EKLOF O, 1980, PEDIATR RADIOL, V9, P199, DOI 10.1007/BF01092945; FITCH SJ, 1985, GASTROINTEST RADIOL, V10, P181, DOI 10.1007/BF01893098; Goodman R.M., 1983, MALFORMED INFANT CHI; HEDLUND GL, 1990, RADIOLOGY, V174, P187, DOI 10.1148/radiology.174.1.2294546; HICKEY RW, 1990, ANN EMERG MED, V19, P390, DOI 10.1016/S0196-0644(05)82343-1; HUTCHISON IF, 1980, BRIT J SURG, V67, P209, DOI 10.1002/bjs.1800670314; MORRISON B, 1948, BRIT MED J, V1, P776, DOI 10.1136/bmj.1.4555.776; NIXON JR, 1974, J IRISH MED ASSOC, V67, P134; PALDER SB, 1991, J PEDIATR SURG, V26, P271, DOI 10.1016/0022-3468(91)90501-J; PLEDGER HG, 1969, BMJ-BRIT MED J, V4, P466, DOI 10.1136/bmj.4.5681.466; PLEDGER HG, 1987, BMJ-BRIT MED J, V295, P1233, DOI 10.1136/bmj.295.6608.1233; PRACROS JP, 1985, LANCET, V2, P733; RAVITCH MM, 1986, PEDIATR SURG, P868; SPARNON AL, 1984, AUST NZ J SURG, V54, P353; STEYN J, 1961, BMJ-BRIT MED J, V1, P1730, DOI 10.1136/bmj.1.5241.1730; WEST KW, 1987, SURGERY, V102, P704; 1978, HOSPITAL INPATIENT E; 1978, MORTALITY STATISTICS; 1982, HOSPITAL ACTIVITY AN; 1987, HOSPITAL ACTIVITY AN	27	44	44	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					737	739		10.1136/bmj.304.6829.737	http://dx.doi.org/10.1136/bmj.304.6829.737			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571677	Green Published, Bronze			2022-12-28	WOS:A1992HK80000016
J	LOOKER, D; ABBOTTBROWN, D; COZART, P; DURFEE, S; HOFFMAN, S; MATHEWS, AJ; MILLERROEHRICH, J; SHOEMAKER, S; TRIMBLE, S; FERMI, G; KOMIYAMA, NH; NAGAI, K; STETLER, GL				LOOKER, D; ABBOTTBROWN, D; COZART, P; DURFEE, S; HOFFMAN, S; MATHEWS, AJ; MILLERROEHRICH, J; SHOEMAKER, S; TRIMBLE, S; FERMI, G; KOMIYAMA, NH; NAGAI, K; STETLER, GL			A HUMAN RECOMBINANT HEMOGLOBIN DESIGNED FOR USE AS A BLOOD SUBSTITUTE	NATURE			English	Article							HUMAN-HEMOGLOBIN; ESCHERICHIA-COLI; RESOLUTION; FRAGMENT	THE need to develop a blood substitute is now urgent because of the increasing concern over blood-transmitted viral and bacterial pathogens 1. Cell-free haemoglobin solutions 2,3 and human haemoglobin synthesized in Escherichia coli 4 and Saccharomyces cerevisiae 5 have been investigated as potential oxygen-carrying substitutes for red blood cells. But these haemoglobins cannot be used as a blood substitute because (1) the oxygen affinity in the absence of 2,3-bisphosphoglycerate is too high to allow unloading of enough oxygen in the tissues 6, and (2) they dissociate into alpha-beta dimer 7 that are cleared rapidly by renal filtration 8-10, which can result in long-term kidney damage 7-9. We have produced a human haemoglobin using an expression vector containing one gene encoding a mutant beta-globin with decreased oxygen affinity and one duplicated, tandemly fused alpha-globin gene. Fusion of the two alpha-globin subunits increases the half-life of this haemoglobin molecule in vivo by preventing its dissociation into alpha-beta dimers and therefore also eliminates renal toxicity.	SOMATOGEN INC,5797 CENT AVE,BOULDER,CO 80301; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology								ACKERS GK, 1974, P NATL ACAD SCI USA, V71, P4312, DOI 10.1073/pnas.71.11.4312; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRO G P, 1991, Biomaterials Artificial Cells and Immobilization Biotechnology, V19, P357; BUCCI E, 1989, J BIOL CHEM, V264, P6191; BUNN HF, 1969, J EXP MED, V129, P925, DOI 10.1084/jem.129.5.925; BUNN HF, 1969, J EXP MED, V129, P909, DOI 10.1084/jem.129.5.909; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; LEE R, 1989, J SURG RES, V47, P407, DOI 10.1016/0022-4804(89)90092-9; LOEB WF, 1989, CLIN CHEM LABORATORY, P460; MANNING LR, 1991, P NATL ACAD SCI USA, V88, P3329, DOI 10.1073/pnas.88.8.3329; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; MOSS GS, 1984, SURGERY, V95, P249; Mulder AG, 1934, J CELL COMPAR PHYSL, V5, P383, DOI 10.1002/jcp.1030050310; NAGAI K, 1982, J BIOL CHEM, V257, P1622; POOL R, 1990, SCIENCE, V250, P1654; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SNYDER SR, 1987, P NATL ACAD SCI USA, V84, P7280, DOI 10.1073/pnas.84.20.7280; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57	22	265	296	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					258	260		10.1038/356258a0	http://dx.doi.org/10.1038/356258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552945				2022-12-28	WOS:A1992HJ94400064
J	SUTER, U; WELCHER, AA; OZCELIK, T; SNIPES, GJ; KOSARAS, B; FRANCKE, U; BILLINGSGAGLIARDI, S; SIDMAN, RL; SHOOTER, EM				SUTER, U; WELCHER, AA; OZCELIK, T; SNIPES, GJ; KOSARAS, B; FRANCKE, U; BILLINGSGAGLIARDI, S; SIDMAN, RL; SHOOTER, EM			TREMBLER MOUSE CARRIES A POINT MUTATION IN A MYELIN GENE	NATURE			English	Article							HYPOMYELINATION; CHROMOSOME-11; NEUROPATHY; LOCUS; MICE; MAP	THE autosomal dominant trembler mutation 1 (Tr), maps to mouse chromosome 11 (ref. 2) and manifests as a Schwann-cell defect 3 characterized by severe hypomyelination 4 and continuing Schwann-cell proliferation throughout life 5,6. Affected animals move clumsily and develop tremor and transient seizures at a young age. We have recently described a potentially growth-regulating myelin protein, peripheral myelin protein-22 (PMP-22; refs 7,8), which is expressed by Schwann cells and found in peripheral myelin. We now report the assignment of the gene for PMP-22 to mouse chromosome 11. Cloning and sequencing of PMP-22 complementary DNAs from inbred Tr mice reveals a point mutation that substitutes an aspartic acid residue for a glycine in a putative membrane-associated domain of the PMP-22 protein. Our results identify the PMP-22 gene as a likely candidate for the mouse trembler locus and will encourage the search for mutations in the corresponding human gene in pedigrees with hypertrophic neuropathies such as Charcot-Marie-Tooth 9 and Dejerine-Sottas 10 diseases (hereditary motor and sensory neuropathies I and III).	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET & PEDIAT,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,DIV NEUROGENET,SOUTHBOROUGH,MA 01772; UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01605	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Harvard University; University of Massachusetts System; University of Massachusetts Worcester			Suter, Ueli/A-1624-2010					AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; DAVISSON MT, 1978, CYTOGENET CELL GENET, V22, P552, DOI 10.1159/000131022; DELEON M, 1991, J NEUROSCI RES, V29, P437; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYCK PJ, 1971, MAYO CLIN PROC, V46, P432; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; HENRY EW, 1983, J NEUROPATH EXP NEUR, V42, P688, DOI 10.1097/00005072-198311000-00008; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MCALPINE PJ, 1990, GENOMICS, V7, P408, DOI 10.1016/0888-7543(90)90175-T; MUNKE M, 1986, CYTOGENET CELL GENET, V42, P236, DOI 10.1159/000132284; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; PERKINS CS, 1981, NEUROPATH APPL NEURO, V7, P115, DOI 10.1111/j.1365-2990.1981.tb00081.x; PHAMDINH D, 1991, P NATL ACAD SCI USA, V88, P7562, DOI 10.1073/pnas.88.17.7562; SNIPES GJ, IN PRESS J CELL BIOL; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195	17	380	392	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					241	244		10.1038/356241a0	http://dx.doi.org/10.1038/356241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552943				2022-12-28	WOS:A1992HJ94400058
J	CABANES, L; COSTES, F; WEBER, S; REGNARD, J; BENVENUTI, C; CASTAIGNE, A; GUERIN, F; LOCKHART, A				CABANES, L; COSTES, F; WEBER, S; REGNARD, J; BENVENUTI, C; CASTAIGNE, A; GUERIN, F; LOCKHART, A			IMPROVEMENT IN EXERCISE PERFORMANCE BY INHALATION OF METHOXAMINE IN PATIENTS WITH IMPAIRED LEFT-VENTRICULAR FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE HEART-FAILURE; BRONCHIAL HYPERRESPONSIVENESS; CAPACITY; METHACHOLINE; DYSFUNCTION; AIRWAYS; DOGS	Background. Bronchial hyperresponsiveness to cholinergic stimuli such as the inhalation of methacholine is common in patients with impaired left ventricular function. Such hyperresponsiveness is best explained by cholinergic vasodilation of blood vessels in the small air-ways, with extravasation of plasma due to high left ventricular filling pressure. Because this vasodilation may be prevented by the inhalation of the vasoconstrictor agent methoxamine, we studied the effect of methoxamine on exercise performance in patients with chronic left ventricular dysfunction. Methods. We studied 19 patients with a mean left ventricular ejection fraction of 22+/-4 percent and moderate exertional dyspnea. In the first part of the study, we performed treadmill exercise tests in 10 patients (group 1) at a constant maximal workload to assess the effects of 10 mg of inhaled methoxamine on the duration of exercise (a measure of endurance). In the second part of the study, we used a graded exercise protocol in nine additional patients (group 2) to assess the effects of inhaled methoxamine on maximal exercise capacity and oxygen consumption. Both studies were carried out after the patients inhaled methoxamine or placebo given according to a randomized, double-blind, crossover design. Results. In group 1, the mean (+/-SD) duration of exercise increased from 293+/-136 seconds after the inhalation of placebo to 612+/-257 seconds after the inhalation of methoxamine (P = 0.001). In group 2, exercise time (a measure of maximal exercise capacity) increased from 526+/-236 seconds after placebo administration to 578+/-255 seconds after methoxamine (P = 0.006), and peak oxygen consumption increased from 18.5+/-6.0 to 20.0+/-6.0 ml per minute per kilogram of body weight (P = 0.03). Conclusions. The inhalation of methoxamine enhanced exercise performance in patients with chronic left ventricular dysfunction. However, the improvement in the duration of exercise at a constant workload (endurance) was much more than the improvement in maximal exercise capacity assessed with a progressive workload. These data suggest that exercise-induced vasodilation of airway vessels may contribute to exertional dyspnea in such patients. Whether or not inhaled methoxamine can provide long-term benefit in patients with heart failure will require further study.	UNIV PARIS 05,HOP COCHIN,DEPT PHYSIOL,PARIS,FRANCE; VAL DE MARNE UNIV,HOP HENRI MONDOR,DEPT CARDIOL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	CABANES, L (corresponding author), UNIV PARIS 05,HOP COCHIN,DEPT CARDIOL,SERV CARDIOL,27 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.							Altman D. G., 1991, PRACTICAL STAT MED R, P325; ARAMENDIA P, 1962, CIRC RES, V10, P3, DOI 10.1161/01.RES.10.1.3; AROWOLO ROA, 1980, BRIT J PHARMACOL, V68, P283, DOI 10.1111/j.1476-5381.1980.tb10417.x; BENGE W, 1980, CIRCULATION, V61, P955, DOI 10.1161/01.CIR.61.5.955; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BOSCHETTO P, 1989, AM REV RESPIR DIS, V139, P416, DOI 10.1164/ajrccm/139.2.416; CABANES LR, 1989, NEW ENGL J MED, V320, P1317, DOI 10.1056/NEJM198905183202005; DEFFEBACH ME, 1987, AM REV RESPIR DIS, V135, P463; FRANCIOSA JA, 1979, AM J MED, V67, P460, DOI 10.1016/0002-9343(79)90794-0; FRANCIOSA JA, 1981, AM J CARDIOL, V47, P33, DOI 10.1016/0002-9149(81)90286-1; FREEDMAN BJ, 1972, B PHYSIO-PATHOL RESP, V8, P545; GIBBS JSR, 1990, J AM COLL CARDIOL, V15, P52, DOI 10.1016/0735-1097(90)90174-N; HIGGINBOTHAM MB, 1983, AM J CARDIOL, V51, P52, DOI 10.1016/S0002-9149(83)80010-1; HOGG JC, 1987, AM REV RESPIR DIS, V135, pS54; KIKUCHI R, 1984, J APPL PHYSIOL, V57, P1640, DOI 10.1152/jappl.1984.57.6.1640; LIPKIN DP, 1986, BRIT HEART J, V55, P439; LLOYD TC, 1980, J APPL PHYSIOL, V49, P620, DOI 10.1152/jappl.1980.49.4.620; LUNG MAKY, 1976, LIFE SCI, V19, P577, DOI 10.1016/0024-3205(76)90239-3; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; PATTERSON JA, 1972, AM J CARDIOL, V30, P757, DOI 10.1016/0002-9149(72)90151-8; PISON C, 1989, CHEST, V96, P230, DOI 10.1378/chest.96.2.230; RENAULT P, 1949, J FR MED CHIR THORAC, V3, P141; ROLLA G, 1990, EUR RESPIR J, V3, P127; RUSHMER RF, 1961, CARDIOVASCULAR DYNAM, P470; SASAKI F, 1990, CHEST, V97, P534, DOI 10.1378/chest.97.3.534; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; Wasserman K, 1990, CIRCULATION S2, V81, P1114; WEBER KT, 1982, CIRCULATION, V65, P1213, DOI 10.1161/01.CIR.65.6.1213; WILSON JR, 1983, AM J CARDIOL, V51, P1358, DOI 10.1016/0002-9149(83)90312-0	29	48	50	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1661	1665		10.1056/NEJM199206183262503	http://dx.doi.org/10.1056/NEJM199206183262503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588979				2022-12-28	WOS:A1992HY62800003
J	FISHER, JC				FISHER, JC			THE SILICONE CONTROVERSY - WHEN WILL SCIENCE PREVAIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONNECTIVE-TISSUE DISEASE; BREAST IMPLANTS; AUGMENTATION; MAMMOPLASTY; CANCER				FISHER, JC (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.							ANDERSON N, 1988, 1988 M FDA ADV PAN G; BALCH CM, 1991, 1991 FDA ADV PAN GEN; BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501; CALNAN KC, 1992, SILICONE GELE BREAST; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; GAYOU RM, 1979, PLAST RECONSTR SURG, V63, P700, DOI 10.1097/00006534-197905000-00015; HAUSNER RJ, 1978, PLAST RECONSTR SURG, V62, P381, DOI 10.1097/00006534-197809000-00007; HEGGERS JP, 1992, FEB TOX FOR  WASH; IVERSON R, 1990, PATIENT SURVEY COMMI; JENNINGS DA, 1991, ANN PLAS SURG, V27, P553, DOI 10.1097/00000637-199112000-00007; OPPENHEIMER BS, 1955, CANCER RES, V15, P333; RUDOLPH R, 1978, PLAST RECONSTR SURG, V62, P185, DOI 10.1097/00006534-197808000-00006; SERGENT JS, 1992, SILICONE GEL BREAST; SILVERSTEIN MJ, 1988, ARCH SURG-CHICAGO, V123, P681; STAHL DL, 1992, 1992 FDA ADV PAN GEN; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; 1991, REPORT BREAST IMPLAN	18	67	67	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1696	1698		10.1056/NEJM199206183262511	http://dx.doi.org/10.1056/NEJM199206183262511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588986				2022-12-28	WOS:A1992HY62800011
J	BENSON, JA				BENSON, JA			INTEGRATING EMERGING DISCIPLINES	ANNALS OF INTERNAL MEDICINE			English	Article								The dynamics of medicine force us to continually update the content of residency curricula. Before selecting the material to be added or withdrawn from the curricula, goals for the desired product must be established. Further, the potential effects of emerging disciplines on the structure and composition of departments and residencies must be carefully considered. The Residency Review Committee for Internal Medicine (RRC-IM) is the principal instrument for forcing the integration of emerging disciplines into clinical education. Several questions must be considered when deciding how best to integrate these new disciplines. Should selected internists be designated to teach them? What are the most appropriate training sites? Which disciplines should be linked for pedagogic efficiency and relevance? How do we separate the educational pathways for generalists and subspecialists? The strategy of requiring additional training for a second certificate from the American Board of Internal Medicine (ABIM) has served internal medicine well for 50 years. Innovations in science and technology, however, are occurring at an accelerated pace. One solution may be to separate standardized residency training into multiple 4-year tracks that produce variously skilled graduates.	OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA	Oregon Health & Science University	BENSON, JA (corresponding author), AMER BOARD INTERNAL MED, 200 SW MARKET ST, SUITE 1950, PORTLAND, OR 97201 USA.							Beeson P B, 1991, Pharos Alpha Omega Alpha Honor Med Soc, V54, P2; CROWN V, 1991, ACAD MED, V66, P226, DOI 10.1097/00001888-199104000-00012; EARLEY LE, 1987, 1987 ABIM SUMM C POR, P51; SELDIN DW, 1981, T ASSOC AM PHYSICIAN, V94, pR75; STEIN JH, 1991, ANN INTERN MED, V114, P79, DOI 10.7326/0003-4819-114-1-79; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; WALDMAN RH, 1991, J GEN INTERN MED, V6, P265, DOI 10.1007/BF02598977	7	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1106	1110		10.7326/0003-4819-116-12-1106	http://dx.doi.org/10.7326/0003-4819-116-12-1106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586128				2022-12-28	WOS:A1992HY79400018
J	LEVINE, RL; PEPE, PE; FROMM, RE; CURKA, PA; CLARK, PA				LEVINE, RL; PEPE, PE; FROMM, RE; CURKA, PA; CLARK, PA			PROSPECTIVE EVIDENCE OF A CIRCADIAN-RHYTHM FOR OUT-OF-HOSPITAL CARDIAC ARRESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; FREQUENCY; DEATH	Objectives. --Published studies have indicated a circadian rhythm in the occurrence of sudden cardiac death. However, these studies have involved either retrospective analyses of death certificates or analyses of data collected during studies of pharmacologic agents in selected populations. Purpose. --To determine whether a circadian pattern could be clearly demonstrated in a prospective study of out-of-hospital sudden cardiac death in a large, unselected population. Design. --All adult cases of sudden death of presumed primary cardiac cause from a large urban population were prospectively evaluated over a 12-month period. The incidence of sudden cardiac death was analyzed using harmonic regression of the data tabulated by hour of the day. Results. --During the year of study, 1019 consecutive primary cardiac arrests were analyzed. A significant circadian pattern was found (P < .0001) with the frequency of cardiac arrests increasing dramatically from 6 AM until noon. Conclusions. --This prospective study of out-of-hospital cardiac arrest confirms the existence of a circadian rhythm. These data have important implications for future investigations concerning the pathophysiology of sudden cardiac deaths.	CITY HOUSTON CTR RESUSCITAT & EMERGENCY MED SERV,410 BAGBY,SUITE 300,HOUSTON,TX 77002; BAYLOR COLL MED,PULM & CRIT CARE SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,CARDIOL SECT,HOUSTON,TX 77030; METHODIST HOSP,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston								ARGENTINO C, 1990, STROKE, V21, P387, DOI 10.1161/01.STR.21.3.387; COUCH RD, 1990, AM J FOREN MED PATH, V11, P106, DOI 10.1097/00000433-199006000-00003; LAMBERT CR, 1989, AM J CARDIOL, V64, P835, DOI 10.1016/0002-9149(89)90827-8; LUCENTE M, 1988, AM J CARDIOL, V62, P670, DOI 10.1016/0002-9149(88)91200-3; MANCIA G, 1988, J CARDIOVASC PHARM, V12, pS11, DOI 10.1097/00005344-198812007-00003; MILLARCRAIG MW, 1978, LANCET, V1, P795; MULCAHY D, 1988, LANCET, V2, P755; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Nademanee K, 1988, CIRCULATION S2, V78, P610; NESTO RW, 1991, AM J CARDIOL, V67, P128, DOI 10.1016/0002-9149(91)90433-L; PEPINE CJ, 1991, JAMA-J AM MED ASSOC, V265, P386, DOI 10.1001/jama.265.3.386; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; 1987, TXB ADV CARDIAC LIFE, P1	13	109	110	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2935	2937		10.1001/jama.267.21.2935	http://dx.doi.org/10.1001/jama.267.21.2935			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583765				2022-12-28	WOS:A1992HW13300033
J	BRETT, AS				BRETT, AS			THE CASE AGAINST PERSUASIVE ADVERTISING BY HEALTH MAINTENANCE ORGANIZATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COST-CONTAINMENT; COMPETITION; OPHTHALMOLOGY; PHYSICIANS; AUTONOMY				BRETT, AS (corresponding author), NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215, USA.							ALTMAN SH, 1988, J HEALTH POLIT POLIC, V13, P323, DOI 10.1215/03616878-13-2-323; ARRINGTON RL, 1982, J BUS ETHICS, V1, P3, DOI 10.1007/BF00382800; AVELLONE JC, 1978, NEW ENGL J MED, V299, P478, DOI 10.1056/NEJM197808312990913; BEAUCHAMP TL, 1988, ETHICAL THEORY BUSIN, P421; CARSON TL, 1985, J BUS ETHICS, V4, P93, DOI 10.1007/BF00383562; CRISP R, 1987, J BUS ETHICS, V6, P413, DOI 10.1007/BF00382898; EISENBERG JM, 1985, ANN INTERN MED, V102, P537, DOI 10.7326/0003-4819-102-4-537; EVANS RG, 1990, J HEALTH POLIT POLIC, V15, P101, DOI 10.1215/03616878-15-1-101; FREIDSON E, 1973, MILBANK FUND Q, V51, P473, DOI 10.2307/3349630; GALBRAITH JOHN KENNETH, 1958, AFFLUENT SOC, P155; GEIST RW, 1978, NEW ENGL J MED, V299, P483, DOI 10.1056/NEJM197808312990914; GINZBERG E, 1987, NEW ENGL J MED, V316, P1151, DOI 10.1056/NEJM198704303161811; Lippke RL., 1989, BUS PROF ETHICS J, V8, P35, DOI [10.5840/bpej19898417, DOI 10.5840/BPEJ19898417]; MARGO CE, 1988, SURV OPHTHALMOL, V33, P211, DOI 10.1016/0039-6257(88)90089-6; MERRILL J, 1986, J HEALTH POLIT POLIC, V10, P613, DOI 10.1215/03616878-10-4-613; NELSON P, 1978, ETHICS FREE ENTERPRI, P187; READE JM, 1987, NEW ENGL J MED, V316, P1315, DOI 10.1056/NEJM198705213162106; RELMAN AS, 1978, NEW ENGL J MED, V299, P476, DOI 10.1056/NEJM197808312990912; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V259, P696, DOI 10.1001/jama.259.5.696; RODNING CB, 1987, AM J MED, V82, P1209, DOI 10.1016/0002-9343(87)90227-0; SCHROEDER JL, 1985, JAMA-J AM MED ASSOC, V254, P3080, DOI 10.1001/jama.254.21.3080; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; TROBE JD, 1988, SURV OPHTHALMOL, V33, P214, DOI 10.1016/0039-6257(88)90090-2; WAIDE J, 1987, J BUS ETHICS, V6, P73, DOI 10.1007/BF00382020; Wilkie J. R., 1990, WALL STREET J, pB1; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805	27	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1353	1357		10.1056/NEJM199205143262010	http://dx.doi.org/10.1056/NEJM199205143262010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT803	1565149				2022-12-28	WOS:A1992HT80300010
J	CARSON, JL; KELLEY, MA; DUFF, A; WEG, JG; FULKERSON, WJ; PALEVSKY, HI; SCHWARTZ, JS; THOMPSON, BT; POPOVICH, J; HOBBINS, TE; SPERA, MA; ALAVI, A; TERRIN, ML				CARSON, JL; KELLEY, MA; DUFF, A; WEG, JG; FULKERSON, WJ; PALEVSKY, HI; SCHWARTZ, JS; THOMPSON, BT; POPOVICH, J; HOBBINS, TE; SPERA, MA; ALAVI, A; TERRIN, ML			THE CLINICAL COURSE OF PULMONARY-EMBOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENOUS THROMBOSIS; LATE PROGNOSIS; FILTER	Background. Pulmonary embolism is a potentially fatal disorder. Information about the outcome of clinically recognized pulmonary embolism is sparse, particularly given that new treatments for more seriously ill patients are now available. Methods. We prospectively followed 399 patients with pulmonary embolism diagnosed by lung scanning and pulmonary angiography, who were enrolled in a multicenter diagnostic trial. We reviewed all hospitalizations, all new investigations of pulmonary embolism, and all deaths among the patients within one year of diagnosis. Results. Of the 399 patients, 375 (94 percent) received treatment for pulmonary embolism, usually conventional anticoagulation. Only 10 patients (2.5 percent) died of pulmonary embolism; 9 of them had clinically suspected recurrent pulmonary embolism. Clinically apparent pulmonary embolism recurred in 33 patients (8.3 percent), of whom 45 percent died during follow-up. Ninety-five patients with pulmonary embolism (23.8 percent) died within one year. The conditions associated with these deaths were cancer (relative risk, 3.8; 95 percent confidence interval, 2.3 to 6.4), left-sided congestive heart failure (relative risk, 2.7; 95 percent confidence interval, 1.5 to 4.6), and chronic lung disease (relative risk, 2.2; 95 percent confidence interval, 1.2 to 4.0). The most frequent causes of death in patients with pulmonary embolism were cancer (in 34.7 percent), infection (22.1 percent), and cardiac disease (16.8 percent). Conclusions. When properly diagnosed and treated, clinically apparent pulmonary embolism was an uncommon cause of death, and it recurred in only a small minority of patients. Most deaths were due to underlying diseases. Patients with pulmonary embolism who had cancer, congestive heart failure, or chronic lung disease had a higher risk of dying within one year than did other patients with pulmonary embolism.	UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT RADIOL, PHILADELPHIA, PA 19104 USA; LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA USA; UNIV MICHIGAN, SCH MED, DEPT MED, ANN ARBOR, MI 48104 USA; DUKE UNIV, SCH MED, DEPT MED, DURHAM, NC 27706 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA; MARYLAND MED RES INST, BALTIMORE, MD USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Duke University; Harvard University; Massachusetts General Hospital; Henry Ford Health System; Henry Ford Hospital	CARSON, JL (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, DIV GEN INTERNAL MED, NEW BRUNSWICK, NJ 08903 USA.							ALPERT JS, 1976, JAMA-J AM MED ASSOC, V236, P1477, DOI 10.1001/jama.236.13.1477; [Anonymous], 1970, J AMER MED ASSOC, V214, P2163; [Anonymous], 1974, JAMA, V229, P1606; BARRITT DW, 1960, LANCET, V1, P1309; COON WW, 1969, ANN SURG, V170, P559, DOI 10.1097/00000658-196910000-00007; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; GREENFIELD LJ, 1981, ARCH SURG-CHICAGO, V116, P1451; HALL RJC, 1977, BRIT HEART J, V39, P1128; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HAYS WL, 1973, STATISTICS SOCIAL SC, P404; HERMANN RE, 1961, AM J SURG, V102, P19, DOI 10.1016/0002-9610(61)90680-8; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1989, ARCH INTERN MED, V149, P2549, DOI 10.1001/archinte.149.11.2549; HYERS TM, 1989, CHEST, V95, pS37, DOI 10.1378/chest.95.2.37S; KANTER B, 1988, CHEST, V93, P170, DOI 10.1378/chest.93.1.170; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LEE ET, 1980, STATISTICAL METHODS; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; MACINTYRE D, 1982, POSTGRAD MED J, V58, P222, DOI 10.1136/pgmj.58.678.222; MONREAL M, 1989, CHEST, V95, P976, DOI 10.1378/chest.95.5.976; MORRELL MT, 1963, BRIT MED J, P830, DOI 10.1136/bmj.2.5361.830; MOSER KM, 1987, ANN INTERN MED, V107, P560, DOI 10.7326/0003-4819-107-4-560; MURPHY ML, 1968, CIRCULATION, V38, P1116, DOI 10.1161/01.CIR.38.6.1116; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; PARASKOS JA, 1973, NEW ENGL J MED, V289, P55, DOI 10.1056/NEJM197307122890201; PHEAR D, 1960, LANCET, V2, P832; SECKERWALKER RH, 1970, BRIT MED J, V4, P135; Siegel S., 1956, NONPARAMETRIC STAT, P96; SUTTON GC, 1977, BRIT HEART J, V39, P1135; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHEELER AP, 1988, ARCH INTERN MED, V148, P1321, DOI 10.1001/archinte.148.6.1321; 1988, SAS PROCEDURES GUIDE, P441	35	834	869	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1240	1245		10.1056/NEJM199205073261902	http://dx.doi.org/10.1056/NEJM199205073261902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560799				2022-12-28	WOS:A1992HR44700002
J	KIEL, DP; BARON, JA; ANDERSON, JJ; HANNAN, MT; FELSON, DT				KIEL, DP; BARON, JA; ANDERSON, JJ; HANNAN, MT; FELSON, DT			SMOKING ELIMINATES THE PROTECTIVE EFFECT OF ORAL ESTROGENS ON THE RISK FOR HIP FRACTURE AMONG WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING; HIP FRACTURES; OSTEOPOROSIS; ESTROGEN REPLACEMENT THERAPY; BONE DENSITY	HORMONE-REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; BONE-MINERAL CONTENT; LIFE-STYLE FACTORS; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; DIETARY CALCIUM; ENDOMETRIAL CARCINOMA; FOREARM FRACTURES; SLENDER SMOKER	. Objective: To determine if the association between smoking and osteoporotic fractures is related to the quantity of cigarettes smoked and to determine if smoking modifies the protection by estrogens. . Design: Cohort study. . Setting: A population-based cohort study, the Framingham Study. . Participants: A total of 2873 women in the Framingham Study followed through examination 19 (1985-1987). . Measurements: All fractures of the proximal femur sustained by women in the Framingham Study from 1948 to 1987 were ascertained. At almost all examinations, available information on cigarette smoking was used to classify women as "ever smokers" compared with "never smokers," and, among "ever smokers," "current" compared with "former smokers." A similar classification for estrogen use was created. Information on potentially confounding variables was taken from each examination, including age, adiposity (weight/height 2), alcohol consumption (ounces per week), and caffeine intake (coffee and tea). . Results: Overall, 207 hip fractures occurred among 34 700 woman-examinations of observation. In the entire cohort, current smoking did not appear to increase hip fracture risk (adjusted odds ratio [AOR], 1.22; 95% Cl, 0.76 to 1.95; P > 0.2). Also overall, current estrogen use appeared to be protective (AOR, 0.38; Cl, 0.12 to 1.21, P = 0.10). Among current smokers, however, estrogen use did not protect against fracture (AOR for current use, 1.26; Cl, 0.29 to 5.45), whereas estrogen was protective in nonsmokers (AOR for current or past use, 0.37; Cl, 0. 1 9 to 0. 75; P = 0.005). . Conclusions: Overall, smoking does not appear to increase the risk for hip fracture in women. Although estrogen replacement protects nonsmokers from fracture, smoking may negate the protective skeletal effects of estrogen replacement therapy.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT MED, HANOVER, NH 03756 USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, BOSTON, MA 02118 USA	Brown University; Dartmouth College; Boston Medical Center	KIEL, DP (corresponding author), RHODE ISL HOSP, 593 EDDY ST, PROVIDENCE, RI 02903 USA.			Kiel, Douglas/0000-0001-8474-0310; Felson, David/0000-0002-2668-2447	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DANIELL HW, 1972, J AMER MED ASSOC, V221, P509, DOI 10.1001/jama.1972.03200180051022; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; Hollo I, 1979, Aktuelle Gerontol, V9, P365; JENSEN GF, 1986, EUR J CLIN INVEST, V16, P239, DOI 10.1111/j.1365-2362.1986.tb01335.x; JENSEN J, 1988, AM J OBSTET GYNECOL, V159, P820, DOI 10.1016/S0002-9378(88)80144-3; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P351; KRALL EA, 1991, J BONE MINER RES, V6, P331; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; KREIGER N, 1986, AM J EPIDEMIOL, V123, P291, DOI 10.1093/oxfordjournals.aje.a114237; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAVECCHIA C, 1991, INT J EPIDEMIOL, V20, P671, DOI 10.1093/ije/20.3.671; LINDSAY R, 1981, OSTEOPOROSIS RECENT, P481; LU AYH, 1972, J BIOL CHEM, V247, P1727; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCULLOCH RG, 1990, CAN MED ASSOC J, V142, P221; MCNAIR P, 1980, MINER ELECTROL METAB, V3, P94; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; ROTHMAN KJ, 1986, EPIDEMIOLOGY, P226; RUNDGREN A, 1984, MECH AGEING DEV, V28, P273, DOI 10.1016/0047-6374(84)90027-7; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SOWERS MR, 1985, AM J CLIN NUTR, V41, P1045, DOI 10.1093/ajcn/41.5.1045; SPARROW D, 1982, ARCH ENVIRON HEALTH, V37, P246, DOI 10.1080/00039896.1982.10667572; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; SUOMINEN H, 1984, AGE AGEING, V13, P273, DOI 10.1093/ageing/13.5.273; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	46	111	116	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					716	721		10.7326/0003-4819-116-9-716	http://dx.doi.org/10.7326/0003-4819-116-9-716			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558342				2022-12-28	WOS:A1992HQ62300003
J	THORNLEYBROWN, D; GALLA, JH; WILLIAMS, PD; KANT, KS; RASHKIN, M				THORNLEYBROWN, D; GALLA, JH; WILLIAMS, PD; KANT, KS; RASHKIN, M			LITHIUM TOXICITY ASSOCIATED WITH A TRICHOBEZOAR	ANNALS OF INTERNAL MEDICINE			English	Note						LITHIUM; HEMODIALYSIS; BEZOARS; DRUG TOXICITY	INTOXICATION; HEMODIALYSIS	Severe lithium intoxication is an indication for emergency dialysis. We present the case of a 47-year-old woman who was brought to the emergency department comatose with a lithium level of 3.94 meg L. Despite normal renal function, good urine output, and three hemodialyses, her lithium level was 4.22 meg L 84 hours after admission. Esophagogastroduodenoscopy showed a trichobezoar with associated pill fragments that were subsequently identified as lithium. Although a bezoar is an unusual cause of persistent drug toxicity, it must be included in the differential diagnosis of drug toxicity that does not respond to standard therapy. especially when associated with an unexpected rise in drug level. Recognition of this entity may be life-saving.			THORNLEYBROWN, D (corresponding author), UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,DIV NEPHROL & HYPERTENS,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.							AMDISEN A, 1975, DAN MED BULL, V22, P277; BOGACZ K, 1987, AM J MED, V83, P783, DOI 10.1016/0002-9343(87)90915-6; DeBakey M, 1938, SURGERY, V4, P934; DEBAKEY M, 1939, SURGERY, V5, P132; GOODNICK PJ, 1981, CLIN PHARMACOL THER, V29, P47, DOI 10.1038/clpt.1981.8; GROTH U, 1974, CLIN PHARMACOL THER, V16, P490; HANSEN HE, 1978, Q J MED, V47, P123; JACOBSEN D, 1987, J TOXICOL-CLIN TOXIC, V25, P81, DOI 10.3109/15563658708992615; JAEGER A, 1985, J TOXICOL-CLIN TOXIC, V23, P501; RAY MJ, 1988, DIGEST DIS SCI, V33, P106, DOI 10.1007/BF01536638; SINGER I, 1981, KIDNEY INT, V19, P374, DOI 10.1038/ki.1981.28	11	4	4	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					739	740		10.7326/0003-4819-116-9-739	http://dx.doi.org/10.7326/0003-4819-116-9-739			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558346				2022-12-28	WOS:A1992HQ62300007
J	PETO, R				PETO, R			STATISTICS OF CHRONIC DISEASE-CONTROL	NATURE			English	Editorial Material							RANDOMIZED TRIALS				PETO, R (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD OX2 6HE, ENGLAND.							ABE O, 1992, LANCET, V339, P71; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V1, P397; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COLLINS R, 1991, BRIT HEART J, V66, P250; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1985, CIRCULATION, V72, P451; SILVERBERG E, 1988, CA A J CLIN, V38, P9; SUN ZT, 1991, CANCER DETECT PREV, V15, P313; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1991, TOBACCO ATTRIBUTABLE; 1991, POPULATION STUDIES, V120	18	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1992	356	6370					557	558		10.1038/356557a0	http://dx.doi.org/10.1038/356557a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560838				2022-12-28	WOS:A1992HP03100021
J	MONTAN, S; INGEMARSSON, I; MARSAL, K; SJOBERG, NO				MONTAN, S; INGEMARSSON, I; MARSAL, K; SJOBERG, NO			RANDOMIZED CONTROLLED TRIAL OF ATENOLOL AND PINDOLOL IN HUMAN-PREGNANCY - EFFECTS ON FETAL HEMODYNAMICS	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-FLOW; HYPERTENSION	Objective-To compare the effects of uteroplacental circulation of two beta-adrenoceptor blockers, atenolol (cardioselective) and pindolol (non-selective with intrinsic sympathomimetic activity). Design-Controlled double blind double dummy study. Setting-Departments of obstetrics and gynaecology in two Swedish university hospitals. Subjects-29 women with pregnancy induced hypertension in the third trimester, 13 randomised to atenolol and 16 to pindolol. Main outcome measures-Pulsatility index in fetal aorta, umbilical artery, and maternal arcuate artery. Volumetric blood flow in fetal aorta and umbilical vein. Results-Mean arterial blood pressure decreased by 9.0 (95% confidence interval -13.0 to -5.0) mm Hg in the atenolol group and by 7.8 (-11.4 to -4.2) mm Hg in the pindolol group. During atenolol treatment the pulsatility index increased significantly from 1.82 (SD 0.20) to 2.07 (0.32) in the fetal thoracic descending aorta, from 1.44 (0.28) to 1.79 (0.27) in the abdominal aorta, and from 0.93 (0.17) to 1.05 (0.19) in the umbilical artery; the volumetric blood flow in the umbilical vein decreased from 106 (28.8) to 84 (22.6) ml/min/kg. No such changes were seen after treatment with pindolol. Birth weight was similar in the two groups but placental weight was significantly different (529 (122) g in atenolol group v 653 (136) g in pindolol group; p = 0.03). Conclusion-The hypotensive effect was similar with both drugs, but only the beta-1-blocker atenolol had significant effects on fetal haemodynamics, although within normal ranges. The implications of these findings can be only speculative, but negative fetal consequences of beta-1-adrenoceptor blockade cannot be excluded.	UNIV LUND,MALMO GEN HOSP,DEPT OBSTET & GYNAECOL,S-21401 MALMO,SWEDEN	Lund University	MONTAN, S (corresponding author), UNIV LUND HOSP,DEPT OBSTET & GYNAECOL,S-22185 LUND,SWEDEN.							BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587; CLARK BJ, 1984, TRIANGLE, V23, P33; DUCKLES SP, 1984, ANNU REV PHARMACOL, V24, P65; EIKNES SH, 1982, ACTA OBSTET GYN SCAN, V61, P307; EIKNES SH, 1984, ULTRASOUND MED BIOL, V10, P329, DOI 10.1016/0301-5629(84)90167-4; GUDMUNDSSON S, 1988, ACTA OBSTET GYN SCAN, V67, P347, DOI 10.3109/00016348809004234; KARLSSON K, 1984, ACTA OBSTET GYNAEC S, V118, pS81; KJELLMER I, 1984, ACTA OBSTET GYNAEC S, V118, pS75; LINGMAN G, 1986, EARLY HUM DEV, V13, P151, DOI 10.1016/0378-3782(86)90003-4; LUNDGREN Y, 1984, ACTA OBSTET GYNECO S, V118, pS85; LUNELL NO, 1984, GYNECOL OBSTET INVES, V18, P269, DOI 10.1159/000299092; LUNELL NO, 1981, ROYAL COLLEGE PHYSIC, V591, P34; MANINTVELD AJ, 1982, BR J CLIN PHARM S, V3, pS245; MONTAN S, 1987, BRIT J OBSTET GYNAEC, V94, P312, DOI 10.1111/j.1471-0528.1987.tb03097.x; REYNOLDS B, 1984, ARCH DIS CHILD, V59, P1061, DOI 10.1136/adc.59.11.1061; RUBIN PC, 1984, AM J OBSTET GYNECOL, V150, P389, DOI 10.1016/S0002-9378(84)80145-3; RUBIN PC, 1983, LANCET, V1, P431; THULESIUS O, 1982, BRIT J CLIN PHARMACO, V13, pS229, DOI 10.1111/j.1365-2125.1982.tb01917.x	18	68	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					946	949		10.1136/bmj.304.6832.946	http://dx.doi.org/10.1136/bmj.304.6832.946			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581716	Bronze, Green Published			2022-12-28	WOS:A1992HP06400019
J	SERRANO, L; NEIRA, JL; SANCHO, J; FERSHT, AR				SERRANO, L; NEIRA, JL; SANCHO, J; FERSHT, AR			EFFECT OF ALANINE VERSUS GLYCINE IN ALPHA-HELICES ON PROTEIN STABILITY	NATURE			English	Article							OCCURRING AMINO-ACIDS; CAVITY SURFACE-AREA; SIDE-CHAIN PACKING; RANDOM POLY(HYDROXYBUTYLGLUTAMINE-CO-L-PROLINE); PROLINE PARAMETERS; FORMING TENDENCIES; HYDROPHOBIC CORE; WATER; CONSTANTS; ENERGETICS	THE rational design of proteins requires knowledge of the helix-forming propensities (s-values) of the different amino acids. There is, however, considerable controversy about the relative values for alanine and glycine 1-12. We find from experiments on mutants of barnase that the relative effect of Ala versus Gly on helix stability depends crucially on the position in the helix (whether they are at the ends (caps) or are internal) and the context (the influence of their neighbours). Glycine is greatly preferred at the N and C caps. At internal positions, Ala stabilizes the helix relative to Gly by 0.4 to 2 kcal mol-1. The variation results from a combination of burial of hydrophobic surface on folding and interference with hydrogen bonding of the protein with solvent. There is a good empirical correlation between the relative stabilizing effects of Ala and Gly with the total change in solvent-accessible hydrophobic surface area of the folded protein on mutation of Gly to Ala. It is not valid to assign to each amino acid a unique s-value that is generally applicable to all positions in all helices in all proteins.			SERRANO, L (corresponding author), MRC,CAMBRIDGE RC PROT ENGN,PROT FUNCT & DESIGN UNIT,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Sancho, javier/AAA-1225-2019; Neira, Jose/ABF-4210-2021; Serrano, Luis/B-3355-2013; Fersht, Alan R/B-2189-2008	Sancho, javier/0000-0002-2879-9200; Serrano, Luis/0000-0002-5276-1392; Neira, Jose Luis/0000-0002-4933-0428				ALTMANN KH, 1990, BIOPOLYMERS, V30, P107, DOI 10.1002/bip.360300112; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; HARRIS MJ, 1972, J PHYS CHEM-US, V77, P2694; HERMANN RB, 1972, J PHYS CHEM-US, V76, P2754, DOI 10.1021/j100663a023; HOROVITZ A, 1991, J MOL BIOL, V219, P5, DOI 10.1016/0022-2836(91)90852-W; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KEMP DS, 1991, NATURE, V352, P451, DOI 10.1038/352451a0; LESK AM, NATURE, V352, P379; LIFSON S, 1961, J CHEM PHYS, V34, P1963, DOI 10.1063/1.1731802; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRESTA LG, 1988, SCIENCE, V240, P2632; REYNOLDS JA, 1974, P NATL ACAD SCI USA, V71, P2925, DOI 10.1073/pnas.71.8.2925; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SALI D, 1988, NATURE, V335, P563; SCHERAGA HA, 1985, P NATL ACAD SCI USA, V82, P5585, DOI 10.1073/pnas.82.17.5585; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; SERRANO L, IN PRESS J MOL BIOL; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; STREHLOW KG, 1989, BIOCHEMISTRY-US, V28, P2130, DOI 10.1021/bi00431a025; SUEKI M, 1984, MACROMOLECULES, V17, P148, DOI 10.1021/ma00132a006; [No title captured]	32	195	196	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					453	455		10.1038/356453a0	http://dx.doi.org/10.1038/356453a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557131				2022-12-28	WOS:A1992HL83000071
J	WARREN, WS; MAYR, S; GOSWAMI, D; WEST, AP				WARREN, WS; MAYR, S; GOSWAMI, D; WEST, AP			LASER-ENHANCED NMR-SPECTROSCOPY	SCIENCE			English	Article								Experimental studies show that optical irradiation far from any absorption bands can shift the resonances in a nuclear magnetic resonance (NMR) spectrum without significant heating. This effect may lead to increased dispersion in NMR studies of complex molecules.			WARREN, WS (corresponding author), PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544, USA.		Goswami, Debabrata/A-9347-2009	Goswami, Debabrata/0000-0002-2052-0594				ATKINS PW, 1983, MOL QUANTUM MECHANIC; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; Evans M, COMMUNICATION; EVANS MW, 1991, J PHYS CHEM-US, V95, P2256, DOI 10.1021/j100159a030; FORSTER MO, 1908, J CHEM SOC, V95, P942; VANDERZIEL JP, 1965, PHYS REV LETT, V15, P190, DOI 10.1103/PhysRevLett.15.190	6	48	48	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1683	1685		10.1126/science.1553555	http://dx.doi.org/10.1126/science.1553555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553555				2022-12-28	WOS:A1992HK81200029
J	RICHARDSON, A; CHARNY, M; HANMERLLOYD, S				RICHARDSON, A; CHARNY, M; HANMERLLOYD, S			PUBLIC-OPINION AND PURCHASING	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To explore the use of a questionnaire to obtain representative public opinions on health services. To examine residents' priorities, knowledge, and views on the public's role in decision making. Design - Self administered postal questionnaire. Population - Random sample of 1500 residents in Bath District Health Authority, drawn from electoral registers. Main outcome measures - Levels of agreement or disagreement with statements provided and degree of importance given to services and aspects of services. Results - 70 questionnaires were returned unopened. Completed questionnaires were returned by 704 (49.2%) of the 1430 remaining residents. Kidney dialysis was thought very important by 559 (87%) respondents and family planning by only 58 (9%). Public priorities did not seem to reflect value for money. Clear information about treatment was rated as very important by 530 (76%) and comfortable waiting areas by 70 (10%). 372 (53%) of respondents said that they would definitely travel to a hospital outside the district to reduce their wait for surgery. Knowledge of the services provided by the authority and the money available to it was poor. 446 (65%) respondents wanted greater public involvement in decision making. Conclusions - A postal questionnaire can provide useful information about public priorities and perceptions about the services provided. More information about health services and their costs and benefits should be given to the public to assist greater public participation in decision making.	BRISTOL POLYTECH,BRISTOL BUSINESS SCH,BRISTOL BS16 1QY,ENGLAND	University of West England	RICHARDSON, A (corresponding author), BATH HLTH AUTHORI,PUBL HLTH DIRECTORATE,BATH BA1 3QE,ENGLAND.							DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; HICKS NR, 1991, BRIT MED J, V302, P991, DOI 10.1136/bmj.302.6783.991; MORTAGY AK, 1985, J EPIDEMIOL COMMUN H, V39, P183, DOI 10.1136/jech.39.2.183; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; YU J, 1983, J MARKETING RES, V20, P36, DOI 10.2307/3151410; 1990, NHS INFORMS YOU; 1988, STATISTICAL PACKAGE	9	33	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					680	682		10.1136/bmj.304.6828.680	http://dx.doi.org/10.1136/bmj.304.6828.680			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571639	Green Published, Bronze			2022-12-28	WOS:A1992HK76100021
J	MASCARI, MJ; GOTTLIEB, W; ROGAN, PK; BUTLER, MG; WALLER, DA; ARMOUR, JAL; JEFFREYS, AJ; LADDA, RL; NICHOLIS, RD				MASCARI, MJ; GOTTLIEB, W; ROGAN, PK; BUTLER, MG; WALLER, DA; ARMOUR, JAL; JEFFREYS, AJ; LADDA, RL; NICHOLIS, RD			THE FREQUENCY OF UNIPARENTAL DISOMY IN PRADER-WILLI SYNDROME - IMPLICATIONS FOR MOLECULAR DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARENTAL ORIGIN; ANGELMAN SYNDROME; CHROMOSOME-ABNORMALITIES; 15Q DELETIONS; X-CHROMOSOME; HUMAN DNA; LOCUS; POLYMORPHISMS; TRISOMY; PROBES	Background. Prader-Willi syndrome is a genetic disorder characterized by infantile hypotonia, obesity, hypogonadism, and mental retardation, but it is difficult to diagnose clinically in infants and young children. In about two thirds of patients, a cytogenetically visible deletion can be detected in the paternally derived chromosome 15(15q11q13). Recently, patients with Prader-Willi syndrome have been described who do not have the cytogenetic deletion but instead have two copies of the 15q11q13 region that are inherited from the mother (with none inherited from the father). This unusual form of inheritance is known as maternal uniparental disomy. Using molecular genetic techniques, we sought to determine the frequency of uniparental disomy in Prader-Willi syndrome. Methods. We performed molecular analyses using DNA markers within 15q11ql3 and elsewhere on chromosome 15 in 30 patients with Prader-Willi syndrome who had no cytogenetically visible deletion. We also studied their parents. Three patients with Prader-Willi syndrome who had a cytogenetic deletion served as controls. Results. In 18 of the 30 patients without a cytogenetic deletion (60 percent), we demonstrated the presence of maternal uniparental disomy for chromosome 15 and its association with advanced maternal age. In another eight patients (27 percent), we identified large molecular deletions. The remaining four patients (13 percent) had evidence of normal biparental inheritance for chromosome 15; three of these patients were the only ones in the study who had some atypical clinical features. Conclusions. In about 20 percent of all cases, Prader-Willi syndrome results from the inheritance of both copies of chromosome 15 from the mother (maternal uniparental disomy). With the combined use of cytogenetic and molecular techniques, the genetic basis of Prader-Willi syndrome can be identified in up to 95 percent of patients.	UNIV FLORIDA, INST BRAIN, DEPT NEUROSCI, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, COLL MED, CTR MAMMALIAN GENET, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, COLL MED, DEPT PEDIAT, DIV GENET, GAINESVILLE, FL 32611 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT PEDIAT, DIV GENET, NASHVILLE, TN 37232 USA; UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, DIV CHILD & ADOLESCENT PSYCHIAT, DALLAS, TX 75230 USA; UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Leicester	MASCARI, MJ (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT PEDIAT, DIV GENET, 500 UNIV DR, HERSHEY, PA 17033 USA.		Rogan, Peter/B-9845-2017	Rogan, Peter/0000-0003-2070-5254; Armour, John/0000-0002-8558-8506	NICHD NIH HHS [P01 HD030329] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALDRIDGE J, 1984, AM J HUM GENET, V36, P546; ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; ANTONARAKIS SE, 1991, NEW ENGL J MED, V324, P872, DOI 10.1056/NEJM199103283241302; ARMOUR JAL, 1990, GENOMICS, V8, P501, DOI 10.1016/0888-7543(90)90037-U; AUGHTON DJ, 1990, AM J DIS CHILD, V144, P1251, DOI 10.1001/archpedi.1990.02150350083032; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BRISSENDEN JE, 1986, GENET EPIDEMIOL, V3, P231, DOI 10.1002/gepi.1370030404; BUTLER MG, 1983, LANCET, V1, P1285; BUTLER MG, 1986, AM J MED GENET, V23, P793, DOI 10.1002/ajmg.1320230307; BUTLER MG, 1989, AM J HUM GENET, V45, P140; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; Cassidy S B, 1984, Curr Probl Pediatr, V14, P1; CASSIDY SB, IN PRESS AM J HUM GE; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P6964; DONLON TA, 1988, HUM GENET, V80, P322, DOI 10.1007/BF00273644; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P4408, DOI 10.1073/pnas.83.12.4408; DRISCOLL DJ, IN PRESS GENOMICS; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GREENBERG F, 1987, AM J MED GENET, V28, P845, DOI 10.1002/ajmg.1320280409; HALL JG, 1990, AM J HUM GENET, V46, P857; HALL JG, 1992, NEW ENGL J MED, V326, P827, DOI 10.1056/NEJM199203193261210; HAMABE J, 1990, NUCLEIC ACIDS RES, V18, P5579, DOI 10.1093/nar/18.18.5579; HASSOLD T, 1985, HUM GENET, V70, P11, DOI 10.1007/BF00389450; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; HAWKEY CJ, 1976, J MED GENET, V13, P152, DOI 10.1136/jmg.13.2.152; HIGGS DR, 1986, P NATL ACAD SCI USA, V83, P5165, DOI 10.1073/pnas.83.14.5165; Holm V. A., 1981, PRADERWILLI SYNDROME, P27; KAPLAN LC, 1987, AM J MED GENET, V28, P45, DOI 10.1002/ajmg.1320280107; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KUPKE KG, 1989, AM J HUM GENET, V45, P599; LEDBETTER DH, 1987, AM J MED GENET, V28, P779, DOI 10.1002/ajmg.1320280402; LEDBETTER DH, 1981, NEW ENGL J MED, V304, P325, DOI 10.1056/NEJM198102053040604; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MASCARI MJW, 1991, THESIS PENNSYLVANIA; MAY KM, 1990, AM J HUM GENET, V46, P754; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NICHOLLS RD, 1991, AM J HUM GENET, V49, P334; NICHOLLS RD, IN PRESS SEMINARS DE; NICHOLLS RD, IN PRESS ANN NEUROL; NICHOLLS RD, IN PRESS AM J MED GE; RICH DC, 1988, NUCLEIC ACIDS RES, V16, P8740, DOI 10.1093/nar/16.17.8740; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SEABRIGH.M, 1971, LANCET, V2, P971; SMEETS DFCM, 1992, NEW ENGL J MED, V326, P807, DOI 10.1056/NEJM199203193261206; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPENCE JE, 1988, AM J HUM GENET, V42, P217; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; WARBURTON D, 1988, AM J HUM GENET, V42, P215; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WILLIAMS CA, 1989, AM J MED GENET, V32, P339, DOI 10.1002/ajmg.1320320313; YU RL, 1981, CYTOGENET CELL GENET, V31, P111, DOI 10.1159/000131634; ZACKOWSKI JL, IN PRESS AM J MED GE	60	227	229	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1599	1607		10.1056/NEJM199206113262404	http://dx.doi.org/10.1056/NEJM199206113262404			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584261	Green Accepted			2022-12-28	WOS:A1992HX63300005
J	PURDY, LJ				PURDY, LJ			KNIFE AND GUN CLUBS OF AMERICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3086	3086						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW970	1588726				2022-12-28	WOS:A1992HW97000034
J	TERET, SP; WINTEMUTE, GJ; BEILENSON, PL				TERET, SP; WINTEMUTE, GJ; BEILENSON, PL			THE FIREARM FATALITY REPORTING SYSTEM - A PROPOSAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILD RESTRAINT LAWS; COVERAGE; DEATHS; STATES; GAPS		UNIV CALIF DAVIS,SACRAMENTO MED CTR,SCH MED,SACRAMENTO,CA 95817	University of California System; University of California Davis	TERET, SP (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,JOHNS HOPKINS INJURY PREVENT CTR,624 N BROADWAY,BALTIMORE,MD 21205, USA.				PHS HHS [R49CCR302484-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER S, 1991, INJURY FACT BOOK; BAUM HM, 1990, J SAFETY RES, V21, P1, DOI 10.1016/0022-4375(90)90042-A; BOYD JH, 1986, AM J PUBLIC HEALTH, V76, P1240, DOI 10.2105/AJPH.76.10.1240; FELL JC, 860038 SOC AUT ENG I; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Rice DP, 1989, COST INJURY US REPOR; ROBERTSON LS, 1989, AM J PUBLIC HEALTH, V79, P300, DOI 10.2105/AJPH.79.3.300; ROBERTSON LS, 1981, AM J PUBLIC HEALTH, V71, P818, DOI 10.2105/AJPH.71.8.818; ROKAW WM, 1990, PUBLIC HEALTH REP, V105, P447; TERET SP, 1986, AM J PUBLIC HEALTH, V76, P31, DOI 10.2105/AJPH.76.1.31; WAGENAAR AC, 1987, J TRAUMA, V27, P726, DOI 10.1097/00005373-198707000-00006; WELLS JK, 1989, AM J PUBLIC HEALTH, V79, P332, DOI 10.2105/AJPH.79.3.332; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WRIGHT J, 1989, INJURY PREVENTION M; 1977, INT STATISTICAL CLAS; 1988, CRIME US 1987	18	45	45	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3073	3074		10.1001/jama.267.22.3073	http://dx.doi.org/10.1001/jama.267.22.3073			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588724				2022-12-28	WOS:A1992HW97000031
J	SCHOENDORF, KC; HOGUE, CJR; KLEINMAN, JC; ROWLEY, D				SCHOENDORF, KC; HOGUE, CJR; KLEINMAN, JC; ROWLEY, D			MORTALITY AMONG INFANTS OF BLACK AS COMPARED WITH WHITE COLLEGE-EDUCATED PARENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; POSTNEONATAL MORTALITY; UNITED-STATES; PRETERM LABOR	Background. In the United States, black infants are twice as likely to die as white infants; this difference reflects both black infants' higher rates of low birth weight and the higher mortality among black infants of normal birth weight. We studied mortality in infants born to college-educated parents in order to investigate this gap while controlling for sociodemographic variables. Methods. We used the National Linked Birth and Infant Death Files for 1983 through 1985 to calculate infant mortality rates for children born to college-educated parents. The study population consisted of 865,128 white infants and 42,230 black infants. A separate effect of birth weight was assessed by examining mortality rates before and after the exclusion of infants weighing less than 2500 g at birth (low-birth-weight infants). Results. In this population, the infant mortality rate was 10.2 per 1000 live births for black infants and 5.4 per 1000 live births for white infants; the adjusted odds ratio for death among black infants was 1.82 (95 percent confidence interval, 1.64 to 2.01). The rate of low birth weight was more than twice as high among blacks (7 percent) as among whites (3 percent), although the mortality rate in this group was not higher among blacks than among whites. Black infants were three times as likely as white infants die of causes attributable to perinatal events, including prematurity. They were no more likely to die of the sudden infant death syndrome. After the exclusion of low-birth-weight infants, the mortality rates for black and white infants were equal. Conclusions. In contrast to black infants in the general population, black infants born to college-educated parents have higher mortality rates than similar white infants only because of their higher rates of low birth weight. Black and white infants of normal birth weight have equivalent mortality rates.	CTR DIS CONTROL, CTR CHRON DIS PREVENT & HLTH PROMOT, DIV REPROD HLTH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	SCHOENDORF, KC (corresponding author), CTR DIS CONTROL, NATL CTR HLTH STAT, DIV ANAL, RM 1080, 6525 BELCREST RD, HYATTSVILLE, MD 20782 USA.							ALEXANDER GR, 1987, AM J PREV MED, V3, P243; BINKIN NJ, 1985, JAMA-J AM MED ASSOC, V253, P372; DESANJOSE S, 1991, J EPIDEMIOL COMMUN H, V45, P207, DOI 10.1136/jech.45.3.207; DIXON WJ, 1988, BMDP STATISTICAL SOF; EMANUEL I, 1986, ANN NY ACAD SCI, V477, P27, DOI 10.1111/j.1749-6632.1986.tb40318.x; EMANUEL I, 1989, Journal of Public Health Policy, V10, P299, DOI 10.2307/3342793; HOGUE CJR, 1987, PUBLIC HEALTH REP, V102, P126; KESSEL SS, 1988, CLIN PERINATOL, V15, P745, DOI 10.1016/S0095-5108(18)30671-7; KESSEL SS, 1984, JAMA-J AM MED ASSOC, V251, P1978, DOI 10.1001/jama.251.15.1978; Kleinman J C, 1990, MMWR CDC Surveill Summ, V39, P31; KLEINMAN JC, 1991, AM J DIS CHILD, V145, P194, DOI 10.1001/archpedi.1991.02160020086023; KLEINMAN JC, 1988, AM J EPIDEMIOL, V127, P274, DOI 10.1093/oxfordjournals.aje.a114803; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; KLEINMAN JC, 1990, PEDIATRICS, V86, P1091; KRIEGER N, 1991, J EPIDEMIOL COMMUN H, V45, P35, DOI 10.1136/jech.45.1.35; ROMERO R, 1988, SEMIN PERINATOL, V12, P262; ROMERO R, 1989, OBSTET GYNECOL, V73, P576; SAPPENFIELD WM, 1987, PUBLIC HEALTH REP, V102, P182; SKOLL MA, 1989, AM J OBSTET GYNECOL, V161, P813; 1988, HLTH INTERVIEW SURVE; 1991, DDHS PHS911232 PUBL, P68; 1990, LINKED BIRTH INFANT	22	279	282	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1522	1526		10.1056/NEJM199206043262303	http://dx.doi.org/10.1056/NEJM199206043262303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579135				2022-12-28	WOS:A1992HW97200003
J	WONGBERINGER, A; JACOBS, RA; GUGLIELMO, BJ				WONGBERINGER, A; JACOBS, RA; GUGLIELMO, BJ			TREATMENT OF FUNGURIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTIONS; GENITOURINARY FUNGAL-INFECTIONS; RENAL-ALLOGRAFT; AMPHOTERICIN-B; MANAGEMENT; CANDIDIASIS; FLUCYTOSINE; CANDIDURIA; DIAGNOSIS; IRRIGANT	We evaluated the use of antifungal agents in the treatment of uncomplicated funguria by reviewing all case reports and studies regarding the treatment of funguria published in the English language from 1960 to 1991 (MEDLINE). Adult patients treated for uncomplicated funguria were included. Patients with fungal pyelonephritis and/or other systemic fungal manifestations were excluded from our analysis. All investigations were assessed for study design, sample size, definition of significant funguria, treatment regimen, inclusion of predisposing risk factors in outcome analysis, end points of therapy, and patient follow-up. Direct comparison of the studies on the use of antifungals in the treatment of uncomplicated funguria was not possible given the differing definitions of significant funguria, inconsistent reporting of risk factors, varying treatment regimens, end points of therapy, and duration of follow-up. Case reports and studies involving antifungals such as amphotericin B bladder irrigation, miconazole nitrate bladder irrigation, ketoconazole, and flucytosine were reviewed. Amphotericin B bladder irrigation appeared to be most effective and ketoconazole the least effective treatment of uncomplicated funguria. Predisposing risk factors, such as the presence of an indwelling urinary catheter, appear to play an important role in the persistence of positive cultures and failure of pharmacologic interventions. Until prospective, well-controlled studies are performed, no recommendation can be made for the treatment of uncomplicated funguria. In symptomatic patients therapy is indicated; however, the best regimen is unknown.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DIV CLIN PHARM, 521 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DIV INFECT DIS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								Ahearn D G, 1966, Sabouraudia, V5, P110; BEILKE MA, 1988, BRIT J UROL, V62, P7, DOI 10.1111/j.1464-410X.1988.tb04255.x; CUETARA M M, 1972, British Journal of Urology, V44, P475, DOI 10.1111/j.1464-410X.1972.tb10109.x; DRUTZ DJ, 1988, DISEASES KIDNEY, V1, P1015; FISHER J, 1979, SOUTHERN MED J, V72, P1281, DOI 10.1097/00007611-197910000-00019; FISHER JF, 1982, REV INFECT DIS, V4, P1107; FRYE KR, 1988, J UROLOGY, V139, P1245, DOI 10.1016/S0022-5347(17)42880-1; GOLDMAN HJ, 1960, JAMA-J AM MED ASSOC, V174, P359, DOI 10.1001/jama.1960.03030040013004; GRAYBILL JR, 1983, J UROLOGY, V129, P68, DOI 10.1016/S0022-5347(17)51922-9; GUZIEL LP, 1975, AM J MED SCI, V269, P123, DOI 10.1097/00000441-197501000-00013; HAMORY BH, 1978, J UROLOGY, V120, P444, DOI 10.1016/S0022-5347(17)57223-7; HARDER EJ, 1975, ARCH INTERN MED, V135, P231, DOI 10.1001/archinte.135.2.231; HEEL RC, 1981, KETOCONAZOLE MANAGEM, P115; HSU CCS, 1990, INFECTION, V18, P280, DOI 10.1007/BF01647004; IRBY PB, 1990, J UROLOGY, V143, P447, DOI 10.1016/S0022-5347(17)39987-1; IRETON RC, 1985, TRANSPLANTATION, V39, P453, DOI 10.1097/00007890-198504000-00025; KAUFFMAN CA, 1974, AM J MED, V57, P217, DOI 10.1016/0002-9343(74)90446-X; KNEPSHIELD JH, 1968, ARCH INTERN MED, V122, P441, DOI 10.1001/archinte.122.5.441; LIPSKY BA, 1989, ANN INTERN MED, V110, P138, DOI 10.7326/0003-4819-110-2-138; MICHIGAN S, 1976, J UROLOGY, V116, P390, DOI 10.1016/S0022-5347(17)58830-8; PALMER BF, 1989, TRANSPLANT P, V21, P3598; RIVETT AG, 1986, UROL RES, V14, P183, DOI 10.1007/BF00441110; ROHNER TJ, 1980, J UROLOGY, V124, P142, DOI 10.1016/S0022-5347(17)55334-3; SALES JL, 1973, CAN J SURG, V16, P139; SCHONEBECK J, 1972, SCAND J UROL NEPHROL, V6, P37, DOI 10.3109/00365597209132078; SCHONEBECK J, 1972, SCAND J UROL NEPHROL, V6, P136, DOI 10.3109/00365597209133626; SCHONEBECK J, 1972, SCAND J UROL NEPHROL, V6, P123, DOI 10.3109/00365597209133624; SCHONEBECK J, 1971, Scandinavian Journal of Urology and Nephrology, V5, P281, DOI 10.3109/00365597109133614; SCHONEBECK J, 1970, J UROL NEPHROL, V4, P171; SENECA H, 1968, J UROLOGY, V100, P266, DOI 10.1016/S0022-5347(17)62518-7; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STARK RP, 1984, NEW ENGL J MED, V311, P560, DOI 10.1056/NEJM198408303110903; TENNANT FS, 1968, ARCH INTERN MED, V122, P435, DOI 10.1001/archinte.122.5.435; WISE GJ, 1973, JAMA-J AM MED ASSOC, V224, P1636, DOI 10.1001/jama.224.12.1636; WISE GJ, 1980, J UROLOGY, V124, P70, DOI 10.1016/S0022-5347(17)55301-X; WISE GJ, 1987, J UROLOGY, V138, P1413, DOI 10.1016/S0022-5347(17)43657-3; WISE GJ, 1985, J UROLOGY, V133, P61, DOI 10.1016/S0022-5347(17)48784-2; WISE GJ, 1976, J UROLOGY, V116, P778, DOI 10.1016/S0022-5347(17)59009-6; WISE GJ, 1982, J UROLOGY, V128, P82, DOI 10.1016/S0022-5347(17)52765-2; ZINCKE H, 1973, J UROLOGY, V109, P612, DOI 10.1016/S0022-5347(17)60494-4	40	39	39	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2780	2785		10.1001/jama.267.20.2780	http://dx.doi.org/10.1001/jama.267.20.2780			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578598				2022-12-28	WOS:A1992HV26500027
J	MARZUK, PM; TARDIFF, K; SMYTH, D; STAJIC, M; LEON, AC				MARZUK, PM; TARDIFF, K; SMYTH, D; STAJIC, M; LEON, AC			COCAINE USE, RISK-TAKING, AND FATAL RUSSIAN ROULETTE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BEHAVIOR	Objective. - To examine the association between recent cocaine use and risk taking, particularly in the form of playing Russian roulette, a paradigm for extreme risk-taking behavior. Design. - A case-control study. Cases and Controls. - The prevalence of cocaine use among all Russian roulette fatalities (N = l4) was compared with a demographically similar, randomly selected sample (N = 54) of all suicides by handgun during a contemporaneous 4-year period in New York City, NY. Results. - Recent use of cocaine, the most common drug found at autopsy, was detected in 64% of Russian roulette fatalities and in 35% of the control group (P < .05). All Russian roulette fatalities were male and usually young and unemployed. Blacks and Hispanics accounted for 80% of all cases and were overrepresented compared with their numbers in the general population. Conclusion. - In some populations cocaine may be associated with life-threatening risk-taking behaviors.	CORNELL UNIV,MED CTR,COLL MED,DEPT AFRC,NEW YORK,NY 10021; NYU,SCH MED,DEPT FORENS MED,NEW YORK,NY 10003; NEW YORK OFF CHIEF MED EXAMINER,NEW YORK,NY	Cornell University; New York University	MARZUK, PM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PSYCHIAT,1300 YORK AVE,NEW YORK,NY 10021, USA.							ADLAF EM, 1983, DRUG ALCOHOL DEPEN, V11, P287, DOI 10.1016/0376-8716(83)90020-0; AMBRE J, 1988, J ANAL TOXICOL, V34, P53; Brown G L, 1986, Ann N Y Acad Sci, V487, P175, DOI 10.1111/j.1749-6632.1986.tb27897.x; COHEN PA, 1977, PERS SOC PSYCHOL B, V11, P119; COLE P, 1980, STATISTICAL METHODS; DACKIS CA, 1985, NEUROSCI BIOBEHAV RE, V9, P447; FISHBAIN DA, 1987, AM J PSYCHIAT, V144, P563; KOGAN N, 1967, NEW DIR PSYCH, V3, P111; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; TEGER AI, 1969, J PERS SOC PSYCHOL, V11, P170, DOI 10.1037/h0027054; WEISS JMA, 1957, PSYCHIATR, V20, P17	12	10	11	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2635	2637						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT823	1573752				2022-12-28	WOS:A1992HT82300032
J	BRANSTETTER, T				BRANSTETTER, T			BLUE MOON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2453	2453						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1573718				2022-12-28	WOS:A1992HT06800011
J	MANDELBLATT, JS; WHEAT, ME; MONANE, M; MOSHIEF, RD; HOLLENBERG, JP; TANG, J				MANDELBLATT, JS; WHEAT, ME; MONANE, M; MOSHIEF, RD; HOLLENBERG, JP; TANG, J			BREAST-CANCER SCREENING FOR ELDERLY WOMEN WITH AND WITHOUT COMORBID CONDITIONS - A DECISION-ANALYSIS MODEL	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; MAMMOGRAPHY; GERIATRICS; HEALTH SERVICES FOR THE AGED	PRIMARY-CARE; MORTALITY; MAMMOGRAPHY; AGE; SURVIVAL; PATTERNS; PREVENTION; REDUCTION; DIAGNOSIS; PROJECT	. Objective: To determine whether breast cancer screening extends life for women aged 65 years or more with and without comorbid medical conditions. . Setting: A provider-patient encounter. . Design: A decision analysis of the utility of screening for breast cancer. . Measurements: Clinical examination and mammography among four groups of women aged 65 to 85 or more years: average health, mild hypertension, congestive heart failure, and average-health black women. The effects of screening were estimated using the best quality data available. . Results: Screening saved life at all ages among patients studied. Savings were highest for black women and decreased with increasing age and comorbidity. Screening all average-health women aged 65 or more saved 67 912 years of life. For women who had cancer, screening extended life by 617 days for average-health women between 65 and 69 years of age and 178 days for those aged 85 years or more. Perioperative mortality and test characteristics had little effect on the results. The risks equaled the benefits of screening only when operative mortality was between 27% and 62%. The marginal costs of screening during a routine office visit were $138 and increased with advancing age and decreasing test specificity. Benefits persisted after adjustment for changes in long-term quality of life; however, for women aged 85 years and older (with and without comorbidities), the short-term morbidity of anxiety or discomfort associated with screening may have outweighed the benefits. . Conclusion: No inherent reason exists to impose an upper-age limit for breast cancer screening; however, more data are needed on women's preferences for screening strategies.	MONTEFIORE MED CTR, BRONX, NY 10467 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CABRINI MED CTR, MALVERN, VIC 3140, AUSTRALIA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cabrini Health	MANDELBLATT, JS (corresponding author), MEM SLOAN KETTERING CANC CTR, DIV CANC CONTROL, 1275 YORK AVE, BOX 60, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE ON AGING [K08AG000471] Funding Source: NIH RePORTER; NIA NIH HHS [KO8 AG00471] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON NK, 1991, CANCER, V67, P844, DOI 10.1002/1097-0142(19910201)67:3+<844::AID-CNCR2820671416>3.0.CO;2-B; AARONSON NK, 1991, CANCER, V67, P839, DOI 10.1002/1097-0142(19910201)67:3+<839::AID-CNCR2820671415>3.0.CO;2-0; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ALLEN C, 1986, J AM GERIATR SOC, V34, P637, DOI 10.1111/j.1532-5415.1986.tb04904.x; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAINES CJ, 1988, J CAN ASSOC RADIOL, V39, P273; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK JS, 1990, J AM GERIATR SOC, V38, P168, DOI 10.1111/j.1532-5415.1990.tb03480.x; BLOOM JR, 1991, CANCER, V67, P855, DOI 10.1002/1097-0142(19910201)67:3+<855::AID-CNCR2820671418>3.0.CO;2-1; BURACK RC, 1987, PREV MED, V16, P739, DOI 10.1016/0091-7435(87)90014-4; CARBONE PP, 1983, PERSPECTIVES PREVENT, P63; CELENTANO DD, 1982, PREV MED, V11, P454, DOI 10.1016/0091-7435(82)90048-2; CHAO A, 1987, PREV MED, V16, P710, DOI 10.1016/0091-7435(87)90053-3; DEVITT JE, 1970, CAN MED ASSOC J, V103, P923; EDDY D, 1987, US C OFFICE TECHNOLO; EDDY D, 1990, COSTS EFFECTIVENESS; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GREENWALD P, 1986, NATL CANCER I MONOGR, V2, P27; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; HERBSMAN H, 1981, CANCER-AM CANCER SOC, V47, P2358, DOI 10.1002/1097-0142(19810515)47:10<2358::AID-CNCR2820471006>3.0.CO;2-K; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; KASSIRER JP, 1976, YALE J BIOL MED, V49, P149; KLEINFELD G, 1963, ANN SURG, V157, P600, DOI 10.1097/00000658-196304000-00016; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MULLER CM, 1990, OTAS SERIES PREVENTI; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; PAUKER SG, 1976, ANN INTERN MED, V85, P8, DOI 10.7326/0003-4819-85-1-8; PLANTE DA, 1986, AM J MED, V80, P1169, DOI 10.1016/0002-9343(86)90680-7; POLEDNAK AP, 1986, CANCER, V58, P807, DOI 10.1002/1097-0142(19860801)58:3<807::AID-CNCR2820580333>3.0.CO;2-X; ROSEN PP, 1985, J SURG ONCOL, V28, P90, DOI 10.1002/jso.2930280204; SHAPIRO S, 1982, AM J PUBLIC HEALTH, V72, P1142, DOI 10.2105/AJPH.72.10.1142; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SINGER RB, 1976, MED RISKS; SONDIK E, 1989, ANN CANCER STATISTIC; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TEMIANKA D, 1989, JAMA-J AM MED ASSOC, V262, P1950, DOI 10.1001/jama.1989.03430140064016; TURNBULL AD, 1978, CLIN BULL, V8, P139; VERBEEK ALM, 1984, LANCET, V1, P1222; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; Weinstein MC, 1980, CLIN DECISION ANAL; WHITE LJ, 1985, ANN INTERN MED, V103, P143, DOI 10.7326/0003-4819-103-1-143; 1981, VITAL STATISTICS US, V2; 1986, SURVEY PUBLIC AWAREN, P1; 1983, CA-CANCER J CLIN, V33, P255; 1989, GUIDE CLIN PREVENTIV, P26; 1990, JAMA-J AM MED ASSOC, V264, P54; 1988, MMWR, V37, P3357; 1973, NIH902789 NCI PHS US; 1987, STUDY WOMENS AWARENE; 1989, JAMA-J AM MED ASSOC, V261, P2535	65	139	138	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					722	730		10.7326/0003-4819-116-9-722	http://dx.doi.org/10.7326/0003-4819-116-9-722			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558343				2022-12-28	WOS:A1992HQ62300004
J	MORIKAWA, K; MATSUMOTO, O; TSUJIMOTO, M; KATAYANAGI, K; ARIYOSHI, M; DOI, T; IKEHARA, M; INAOKA, T; OHTSUKA, E				MORIKAWA, K; MATSUMOTO, O; TSUJIMOTO, M; KATAYANAGI, K; ARIYOSHI, M; DOI, T; IKEHARA, M; INAOKA, T; OHTSUKA, E			X-RAY STRUCTURE OF T4 ENDONUCLEASE-V - AN EXCISION REPAIR ENZYME SPECIFIC FOR A PYRIMIDINE DIMER	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; DNA GLYCOSYLASE; NACL CONCENTRATION; BACTERIOPHAGE-T4; GENE; PURIFICATION; CLEAVAGE; PROTEINS	The x-ray structure of T4 endonuclease V, an enzyme responsible for the first step of a pyrimidine-dimer-specific excision-repair pathway, was determined at a 1.6-angstrom resolution. The enzyme consists of a single compact domain classified into an all-alpha-structure. This single domain has two distinct catalytic activities: it functions as a pyrimidine dimer glycosylase and as an apurinic-apyrimidinic endonuclease. The amino-terminal segment penetrates between two major helices and prevents their direct contact. The refined structure suggests the residues involved in the substrate binding and the catalysis of the glycosylation reaction.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	MORIKAWA, K (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.			Ariyoshi, Mariko/0000-0002-1361-2642				DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; Doi T., UNPUB; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LLOYD RS, 1989, PROTEINS, V6, P128, DOI 10.1002/prot.340060204; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MCMILLAN S, 1981, J VIROL, V40, P211, DOI 10.1128/JVI.40.1.211-223.1981; MONOHARAN M, 1988, J AM CHEM SOC, V110, P2690; MORIKAWA K, 1988, J MOL BIOL, V202, P683, DOI 10.1016/0022-2836(88)90298-7; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; WARNER HR, 1981, J VIROL, V40, P204, DOI 10.1128/JVI.40.1.204-210.1981; YASUDA S, 1970, P NATL ACAD SCI USA, V67, P1839, DOI 10.1073/pnas.67.4.1839	31	117	118	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					523	526		10.1126/science.1575827	http://dx.doi.org/10.1126/science.1575827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1575827				2022-12-28	WOS:A1992HQ18700064
J	NATTINGER, AB; GOTTLIEB, MS; VEUM, J; YAHNKE, D; GOODWIN, JS				NATTINGER, AB; GOTTLIEB, MS; VEUM, J; YAHNKE, D; GOODWIN, JS			GEOGRAPHIC-VARIATION IN THE USE OF BREAST-CONSERVING TREATMENT FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MASTECTOMY; RADIOTHERAPY; CONSENSUS; SERVICES; SURGERY	Background. In the past decade there has been an increase in the use of treatment designed to conserve the breast for women with breast cancer. The extent to which such treatment has been adopted in various regions of the country and whether characteristics of hospitals and patients predict its use are not known, however. Methods. We used national data on Medicare claims for inpatient care provided in 1986 to study 36,982 women 65 to 79 years of age, who had local or regional breast cancer and underwent either mastectomy or breast-conserving treatment (local excision, quadrantectomy, or subtotal mastectomy). Information about the hospitals at which these women were treated was obtained from an American Hospital Association survey. Results. Of the 36,982 women, 12.1 percent had breast-conserving surgery and 87.9 percent had a mastectomy. The frequency of breast-conserving surgery ranged from 3.5 percent to 21.2 percent in various states. The highest rate of use was in the Middle Atlantic states (20.0 percent) and New England (17.2 percent), and the lowest was in the East South Central states (5.9 percent) and the West South Central states (7.3 percent). Breast-conserving treatment was used more often in urban than in rural areas, in teaching hospitals than in nonteaching hospitals, in large hospitals than in small hospitals, and in hospitals with on-site radiation therapy or geriatric services than in others. Most of the geographic variation persisted after adjustment for the characteristics of hospitals and patients for which data were available. Conclusions. There is substantial geographic variation in the use of breast-conserving surgery, which cannot be explained by differences in hospital characteristics. Hospital characteristics that were independently predictive of greater use of breast-conserving surgery were the size of the metropolitan area, the status of the institution as a teaching hospital, and the availability of radiation therapy and geriatric services.	MED COLL WISCONSIN,DEPT BIOSTAT & CLIN EPIDEMIOL,MILWAUKEE,WI 53226; UNIV WISCONSIN,SCH MED,DEPT MED,MILWAUKEE,WI 53201	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Milwaukee	NATTINGER, AB (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV GEN INTERNAL MED,8700 W WISCONSIN AVE,BOX 135,MILWAUKEE,WI 53226, USA.			Nattinger, Ann/0000-0002-8189-3300	NCI NIH HHS [1-R01-CA54676-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEBER RB, 1987, ARCH INTERN MED, V147, P1543, DOI 10.1001/archinte.147.9.1543; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; Harris J. R., 1985, CANCER PRINCIPLES PR, P1119; HARRIS JR, 1985, NEW ENGL J MED, V313, P1365, DOI 10.1056/NEJM198511213132128; HOSMER DW, 1989, APPLIED LOGICAL REGR; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LAU J, 1991, CLIN RES, V39, pA252; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LIBERATI A, 1991, AM J PUBLIC HEALTH, V81, P38, DOI 10.2105/AJPH.81.1.38; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; ROSS LL, 1982, MED CARE, V20, P266; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; 1990, 1990 NIH CONS DEV C, V8; 1990, HCFA0330 HLTH CAR FI; 1987, HOSPITAL STATISTICS	22	468	468	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1102	1107		10.1056/NEJM199204233261702	http://dx.doi.org/10.1056/NEJM199204233261702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552911	Bronze			2022-12-28	WOS:A1992HP80000002
J	JOHANSSON, JE; ADAMI, HO; ANDERSSON, SO; BERGSTROM, R; HOLMBERG, L; KRUSEMO, UB				JOHANSSON, JE; ADAMI, HO; ANDERSSON, SO; BERGSTROM, R; HOLMBERG, L; KRUSEMO, UB			HIGH 10-YEAR SURVIVAL RATE IN PATIENTS WITH EARLY, UNTREATED PROSTATIC-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; CARCINOMA; PROSTATECTOMY	Objective. - To learn about the natural history of untreated, early-stage prostatic cancer. Design. - Cohort study with a mean follow-up of 123 months (range, 81 to 165 months). Setting. - Population-based, regionally well defined. Patients. - A consecutive sample of 223 patients (98% of all eligible) with early-stage (TO-2, NX, MO), initially untreated prostatic cancer. Main Outcome Measures. - Progression-free, disease-specific, and overall survival. Need for palliative and terminal care. Intervention. - Patients with tumor progression were hormonally treated (orchiectomy or estrogens) if they had symptoms. Results. - After complete follow-up, only 19 (8.5%) of the 223 patients had died of prostate cancer and 105 (85%) of a total of 124 deaths were from other causes. The 10-year, disease-specific survival rate was 86.8% (95% confidence interval, 80.7% to 92.9%) and was equally high (87.9%) in a subgroup of 58 patients who met current indications for radical prostatectomy. The progression-free, 10-year survival rate was 53.1% (95% confidence interval, 44.2% to 62.0%). In 50 of 76 patients, local growth provided the only evidence of progression, and endocrine treatment was generally successful in these cases. Following an initial increase, the rate of disease progression and death from prostate cancer decreased during the last years of follow-up. Conclusion. - The low disease-specific mortality rate especially in patients with highly and moderately differentiated tumors, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.	UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, UPPSALA, SWEDEN; UNIV UPPSALA, DEPT STAT, S-75105 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT SURG, UPPSALA, SWEDEN; UNIV UPPSALA, CTR DATA, S-75105 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University; Uppsala University Hospital; Uppsala University	JOHANSSON, JE (corresponding author), OREBRO MED CTR HOSP, DEPT UROL, S-70185 OREBRO, SWEDEN.							ADOLFSSON J, 1990, J UROLOGY, V144, P1404, DOI 10.1016/S0022-5347(17)39754-9; BAGSHAW MA, 1985, CANCER, V55, P2079, DOI 10.1002/1097-0142(19850501)55:9+<2079::AID-CNCR2820551408>3.0.CO;2-X; BAKKE A, 1985, 1985 P FINN UR CLUB, P58; CORRIERE JN, 1970, CANCER, V25, P911, DOI 10.1002/1097-0142(197004)25:4<911::AID-CNCR2820250426>3.0.CO;2-Y; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; GEORGE NJR, 1988, LANCET, V1, P494; GERVASI LA, 1989, J UROLOGY, V142, P332, DOI 10.1016/S0022-5347(17)38748-7; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; HANASH KA, 1972, J UROLOGY, V107, P450, DOI 10.1016/S0022-5347(17)61053-X; HANDLEY R, 1988, BRIT J UROL, V62, P249, DOI 10.1111/j.1464-410X.1988.tb04328.x; HOSTETTER AL, 1990, AM J CLIN PATHOL, V94, P693, DOI 10.1093/ajcp/94.6.693; JOHANSSON JE, 1989, LANCET, V1, P799; KARNOFSKY DA, 1946, EVALUATION CHEMOTHER; LARSON A, 1985, SCAND J UROL NEPHROL, P30; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; MIDDLETON RG, 1990, UROL CLIN N AM, V17, P779; MOSKOVITZ B, 1987, UROL INT, V42, P49, DOI 10.1159/000281849; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHMIDT J D, 1976, Urology, V7, P602, DOI 10.1016/0090-4295(76)90085-6; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; WHITMORE WF, 1988, NATL CANCER I MONOGR, V7, P7; 1978, TNM CLASSIFICATION M; 1980, INT HISTOLOGICAL CLA, V22	27	446	451	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2191	2196		10.1001/jama.267.16.2191	http://dx.doi.org/10.1001/jama.267.16.2191			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556796				2022-12-28	WOS:A1992HN84100028
J	REED, A; RAMSDEN, S; MARSHALL, J; BALL, J; OBRIEN, J; FLYNN, A; ELTON, N; ELKABIR, D; JOSEPH, P				REED, A; RAMSDEN, S; MARSHALL, J; BALL, J; OBRIEN, J; FLYNN, A; ELTON, N; ELKABIR, D; JOSEPH, P			PSYCHIATRIC MORBIDITY AND SUBSTANCE-ABUSE AMONG RESIDENTS OF A COLD WEATHER SHELTER	BRITISH MEDICAL JOURNAL			English	Article							LONDON		GREAT CHAPEL ST MED CTR,LONDON W1V 7AL,ENGLAND; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London				O'Brien, John/0000-0002-0837-5080				KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1011; LODGEPATCH IC, 1971, BRIT J PSYCHIAT, V118, P313; PRIEST RG, 1971, AM J PSYCHOTHER, V25, P194, DOI 10.1176/appi.psychotherapy.1971.25.2.194; RAMSDEN SS, 1989, BRIT MED J, V298, P372, DOI 10.1136/bmj.298.6670.372; WELLER BGA, 1907, LANCET, V1, P553	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1028	1029		10.1136/bmj.304.6833.1028	http://dx.doi.org/10.1136/bmj.304.6833.1028			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586786	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200022
J	ORENTLICHER, D				ORENTLICHER, D			THE ILLUSION OF PATIENT CHOICE IN END-OF-LIFE DECISIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CRITICALLY ILL; RESUSCITATION; INFORMATION; PREFERENCES; PHYSICIANS; DOCTORS				ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUNSEL,CHICAGO,IL 60610, USA.							BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; CALLAHAN D, 1983, HASTINGS CENT REP, V20, P22; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; KATZ J, 1984, SILENT WORLD DOCTOR, P48; KODISH E, 1991, NEW ENGL J MED, V325, P1349, DOI 10.1056/NEJM199111073251905; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LEVY DR, 1985, PEDIATRICS, V75, P639; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOUISELL DW, 1989, MED MALPRACTICE; MALLOY TR, 1991, AM GERIATRIC SOC AM; MARTEAU TM, 1989, BRIT J SOC PSYCHOL, V28, P89, DOI 10.1111/j.2044-8309.1989.tb00849.x; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WALLACE LM, 1986, SOC SCI MED, V22, P29, DOI 10.1016/0277-9536(86)90305-9; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YOUNGNER SJ, 1983, ANN INTERN MED, V99, P252, DOI 10.7326/0003-4819-99-2-252; 1987, GUIDELINES TERMINATI, P26; 1982, MAKING HLTH CARE DEC, P1; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1983, DECIDING FOREGO LIFE, P43; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1992, CURRENT OPINIONS 199	35	81	81	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2101	2104		10.1001/jama.267.15.2101	http://dx.doi.org/10.1001/jama.267.15.2101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552646				2022-12-28	WOS:A1992HM65000038
J	MCADAMS, AL				MCADAMS, AL			A RIGHT-TO-DIE	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					765	766		10.1136/bmj.304.6829.765	http://dx.doi.org/10.1136/bmj.304.6829.765			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571685	Bronze, Green Published			2022-12-28	WOS:A1992HK80000027
J	FLETCHER, RH; FLETCHER, SW				FLETCHER, RH; FLETCHER, SW			TEACHING PREVENTIVE MEDICINE AND HEALTH MAINTENANCE	ANNALS OF INTERNAL MEDICINE			English	Article							RESIDENT PHYSICIANS; INTERNAL MEDICINE; PROGRAM; SMOKING; CARE; PERFORMANCE; REMINDERS; CANCER	Preventive health care is an important part of the practice of internal medicine but is poorly taught and practiced in most residencies. A successful curriculum would impart knowledge of the preventive health care guidelines recommended by expert groups; provide opportunities for residents to understand the conceptual basis of preventive care; expose residents to clinical faculty with positive attitudes toward prevention; help residents to learn skills in physical examination, screening tests, and counseling in behavioral modification relevant to prevention; and provide a practice environment in which high-quality preventive health care is possible. All of the skills can be learned as other aspects of medicine are now learned-under the guidance of capable and respected faculty teaching at the bedside, in the clinics, and during ward rounds and conferences.			FLETCHER, RH (corresponding author), AMER COLL PHYSICIANS, INDEPENDENCE MALL W, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA.							AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BARKER WH, 1983, TEACHING PREVENTIVE; BARTMAN BA, 1991, CLIN RES, V39, pA595; CAMPBELL HS, 1991, AM J PREV MED, V7, P1; FEDSON DS, 1987, AM J MED, V82, P42, DOI 10.1016/0002-9343(87)90560-2; FLETCHER RH, 1985, ANN INTERN MED, V102, P859, DOI 10.7326/0003-4819-102-6-859; FLETCHER RH, 1986, J GEN INTERN MED, V1, P340, DOI 10.1007/BF02596216; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; FLETCHER SW, 1985, JAMA-J AM MED ASSOC, V253, P2224, DOI 10.1001/jama.253.15.2224; HARRIS RP, 1990, AM J PREV MED, V6, P145, DOI 10.1016/S0749-3797(18)31019-5; HAWES R, 1986, AM J MED, V80, P465, DOI 10.1016/0002-9343(86)90721-7; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; JENSEN NM, 1989, CURRICULUM INTERNAL; KAATZ S, 1991, CLIN RES, V39, pA602; KAHN KL, 1984, CLIN RES, V32, pA649; KENNEY RD, 1988, ARCH INTERN MED, V148, P2469, DOI 10.1001/archinte.148.11.2469; KNIGHT BP, 1987, AM J PREV MED, V3, P19; KOSECOFF J, 1985, ANN INTERN MED, V102, P250, DOI 10.7326/0003-4819-102-2-250; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; OCKENE JK, 1988, ARCH INTERN MED, V148, P1039, DOI 10.1001/archinte.148.5.1039; ROMM FJ, 1981, SOUTHERN MED J, V74, P265, DOI 10.1097/00007611-198103000-00004; STRECHER VJ, 1989, J GEN INTERN MED, V4, P160, DOI 10.1007/BF02602359; 1979, CAN MED ASS J, V121, P1193; 1978, 1 RW JOHNS F SPEC RE	27	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1094	1098		10.7326/0003-4819-116-12-1094	http://dx.doi.org/10.7326/0003-4819-116-12-1094			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586125				2022-12-28	WOS:A1992HY79400015
J	NOBLE, J				NOBLE, J			GENERAL INTERNAL-MEDICINE IN INTERNAL-MEDICINE - AT THE CORE OR ON THE PERIPHERY	ANNALS OF INTERNAL MEDICINE			English	Article							RESIDENCY	In the past decade, faculty in sections of general internal medicine have assumed responsibility for training residents, for staffing clinical practices, and for developing new domains of health services and effectiveness research. These activities form the core of internal medicine: They are integral to the role of internal medicine as an academic and patient care discipline, and they complement the activities of the internal medicine subspecialties. The effect of general internal medicine on internal medicine, therefore, has been to shift the focus away from the subspecialty services-which compartmentalize a patient's medical problems-and back to the concept of the patient as a "whole" person. The role and territory of the general internist are changing as a result of this shift in focus, and general internal medicine is emerging as the new core discipline in internal medicine. These changes have allowed for an expanded capacity of internal medicine to provide new services, modified curricula, and innovative research.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston University	NOBLE, J (corresponding author), BOSTON CITY HOSP, 818 HARRISON AVE, ACC-3 PRIMARY CARE, BOSTON, MA 02118 USA.							BARKER LR, 1990, J GEN INTERN MED, V5, pS3, DOI 10.1007/BF02600433; Colwill J M, 1988, Fam Med, V20, P250; DUBOS RJ, 1977, MAN ADAPTING, P447; ENGEL GL, 1988, TASK MED, P117; FRIEDMAN RH, 1985, ANN INTERN MED, V103, P439, DOI 10.7326/0003-4819-103-3-439; FRIEDMAN RH, 1990, 1990 DIRECTORY PRIMA; JENSEN NM, 1989, CIRRICULUM INTERNAL; NOBLE J, 1992, ANN INTERN MED, V116, P482, DOI 10.7326/0003-4819-116-6-482; NOBLE J, 1989, SGIM NEWS        AUG, P2; OSLER W, 1915, COMING AGE INTERNAL, P1; REITEMEIER RJ, 1991, ANN INTERN MED, V114, P69, DOI 10.7326/0003-4819-114-1-69; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; STEIN JH, 1991, ANN INTERN MED, V114, P79, DOI 10.7326/0003-4819-114-1-79; THANE M, 1988, CIRRICULUM BOSTON U	15	16	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1058	1060		10.7326/0003-4819-116-12-1058	http://dx.doi.org/10.7326/0003-4819-116-12-1058			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586116				2022-12-28	WOS:A1992HY79400006
J	ANNAS, GJ				ANNAS, GJ			SETTING STANDARDS FOR THE USE OF DNA-TYPING RESULTS IN THE COURTROOM - THE STATE-OF-THE-ART	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1990, HASTINGS CENT REP, V20, P35; [Anonymous], 1992, DNA TECHNOLOGY FOREN; CHAKRABORTY R, 1991, SCIENCE, V254, P1735, DOI 10.1126/science.1763323; LANDER ES, 1991, AM J HUM GENET, V48, P819; LEWONTIN RC, 1991, SCIENCE, V254, P1745, DOI 10.1126/science.1845040; 1990, GENETIC WITNESS FORE	6	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1641	1644		10.1056/NEJM199206113262418	http://dx.doi.org/10.1056/NEJM199206113262418			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584280	Green Published			2022-12-28	WOS:A1992HX63300031
J	HANNAH, ME; HANNAH, WJ; HELLMANN, J; HEWSON, S; MILNER, R; WILLAN, A				HANNAH, ME; HANNAH, WJ; HELLMANN, J; HEWSON, S; MILNER, R; WILLAN, A			INDUCTION OF LABOR AS COMPARED WITH SERIAL ANTENATAL MONITORING IN POSTTERM PREGNANCY - A RANDOMIZED CONTROLLED TRIAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROLONGED PREGNANCY; MANAGEMENT	Background. The rates of perinatal mortality and neonatal morbidity are higher for post-term pregnancies than for term pregnancies. It is not known, however, whether the induction of labor results in better outcomes than does serial fetal monitoring while awaiting spontaneous labor. Methods. We studied 3407 women with uncomplicated pregnancies of 41 or more weeks' duration. The women were randomly assigned to undergo induction of labor or to have serial antenatal monitoring and spontaneous labor unless there was evidence of fetal or maternal compromise, in which case labor was induced or cesarean section was performed. In the induction group, labor was induced by the intracervical application of prostaglandin E2. Serial antenatal monitoring consisted of counts of fetal kicks, nonstress tests, and assessments of amniotic-fluid volume. The outcomes we measured were the rates of perinatal mortality, neonatal morbidity, and delivery by cesarean section. Results. Among the 1701 women in the induction group, 360 (21.2 percent) underwent cesarean section, as compared with 418 (24.5 percent) of the 1706 women in the monitoring group (P = 0.03). This difference resulted from a lower rate of cesarean section performed because of fetal distress among the women in the induction group (5.7 percent vs. 8.3 percent, P = 0.003). When two infants with lethal congenital anomalies were excluded, there were no perinatal deaths in the induction group and two stillbirths in the monitoring group (P not significant). The frequency of neonatal morbidity was similar in the two groups. Conclusions. In post-term pregnancy, the induction of labor results in a lower rate of cesarean section than serial antenatal monitoring; the rates of perinatal mortality and neonatal morbidity are similar with the two approaches to management.	UNIV TORONTO, HOSP SICK CHILDREN, DEPT PEDIAT, TORONTO M5G 1X8, ONTARIO, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University	HANNAH, ME (corresponding author), UNIV TORONTO, WOMENS COLL HOSP, DEPT OBSTET & GYNECOL, 76 GRENVILLE ST, TORONTO M5S 1B2, ONTARIO, CANADA.							AUGENSEN K, 1987, BRIT MED J, V294, P1192, DOI 10.1136/bmj.294.6581.1192; BAKKETEIG L, 1989, EFFECTIVE CARE PREGN, P765; BEISCHER NA, 1969, AM J OBSTET GYNECOL, V103, P476, DOI 10.1016/S0002-9378(15)31849-4; BERGSJO P, 1989, ACTA OBSTET GYN SCAN, V68, P683, DOI 10.3109/00016348909006139; BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; CARDOZO L, 1986, BMJ-BRIT MED J, V293, P1059, DOI 10.1136/bmj.293.6554.1059; CROWLEY P, 1984, BRIT J OBSTET GYNAEC, V91, P444, DOI 10.1111/j.1471-0528.1984.tb04781.x; Crowley P., 1989, EFFECTIVE CARE PREGN, P776; CROWLEY P, 1991, OXFORD DATABASE PERI; DYSON DC, 1987, AM J OBSTET GYNECOL, V156, P928, DOI 10.1016/0002-9378(87)90359-0; HENRY G R, 1969, Journal of Obstetrics and Gynaecology of the British Commonwealth, V76, P795; JOHNSON JM, 1986, AM J OBSTET GYNECOL, V154, P269, DOI 10.1016/0002-9378(86)90653-8; KATZ Z, 1983, EUR J OBSTET GYN R B, V15, P71, DOI 10.1016/0028-2243(83)90175-2; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, P988; Martin J N Jr, 1989, J Miss State Med Assoc, V30, P105; MCCLUREBROWNE JC, 1963, AM J OBSTET GYNECOL, V85, P573, DOI 10.1016/0002-9378(63)90304-1; Medearis AL, 1990, 10TH P ANN M SOC PER, P17; RACKER D, 1953, LANCET, V265, P953; SHIME J, 1984, AM J OBSTET GYNECOL, V148, P547, DOI 10.1016/0002-9378(84)90745-2; SUIKKARI AM, 1983, ACTA OBSTET GYNECO S, V116, P58; WITTER FR, 1987, AM J PERINAT, V4, P206, DOI 10.1055/s-2007-999774; 1989, MED FODELSEREGISTRER, P22	22	331	338	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1587	1592		10.1056/NEJM199206113262402	http://dx.doi.org/10.1056/NEJM199206113262402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584259	Bronze			2022-12-28	WOS:A1992HX63300003
J	GURWITZ, JH; AVORN, J; ROSSDEGNAN, D; CHOODNOVSKIY, I; ANSELL, J				GURWITZ, JH; AVORN, J; ROSSDEGNAN, D; CHOODNOVSKIY, I; ANSELL, J			AGING AND THE ANTICOAGULANT RESPONSE TO WARFARIN THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						AGING; ANTICOAGULANTS; WARFARIN; PROTHROMBIN TIME; DRUG MONITORING	PROTHROMBIN TIME; DRUG-THERAPY; VITAMIN-K; AGE; REQUIREMENTS; DETERMINANTS; WEIGHT	Objective: To assess the effect of aging on the anticoagulant response to warfarin. Design: Retrospective cohort study. Setting: A university hospital outpatient anticoagulation clinic. Patients: All patients (n = 530) monitored in the anticoagulation clinic over a 10-year period (1980 to 1990). The 530 study patients had a mean age of 61.5 (+/- 14.7) years (age range, 12 to 90 years). The patients were stratified into four age groups: younger than 50 years (n = 97); 50 to 59 years (n = 107); 60 to 69 years (n = 149); and 70 years or older (n = 177). Measurements: For each patient, a dose-adjusted mean prothrombin time ratio was calculated by dividing the mean prothrombin time ratio by the mean daily warfarin dose. Results: Older patients were more likely to be female (P < 0.001), to have more medical problems (P < 0.001), to be taking more medications (P < 0.001), and to weigh less than younger patients (P < 0.001). Across age groups, there were no significant differences in the use of medications that potentiated or inhibited the anticoagulant effects of warfarin. The prothrombin time ratio, when adjusted for dose, was significantly increased in older patients (P < 0.001). The increased anticoagulant response to warfarin seen with increasing patient age persisted even after simultaneously controlling for relevant demographic and clinical variables in a multivariate model. Other factors significantly associated with an increased sensitivity to warfarin included use of a medication with a potentiating interactive effect with warfarin, female gender, and overall medication use. Increased body weight and duration of warfarin use exceeding 6 months were found to be inversely related to anticoagulant response. Conclusion: The anticoagulant response to warfarin is exaggerated with advancing age. This finding emphasizes the need for close monitoring of older patients treated with warfarin therapy.	BETH ISRAEL HOSP, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, WORCESTER, MA 01655 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester					NIA NIH HHS [K08 AG00510-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAMPION EW, 1988, J GERONTOL, V43, pM18, DOI 10.1093/geronj/43.1.M18; COON WW, 1977, ANN SURG, V186, P149, DOI 10.1097/00000658-197708000-00006; DOBRZANSKI S, 1983, J CLIN HOSP PHARM, V8, P75, DOI 10.1111/j.1365-2710.1983.tb00899.x; ECCLES J T, 1975, Age and Ageing, V4, P161, DOI 10.1093/ageing/4.3.161; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1317; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; GREENBLATT DJ, 1985, PHARMACOKINETICS CLI, P84; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HALLAK HO, 1991, DRUG METAB DISPOS, V19, P278; HAYES MJ, 1975, BRIT J CLIN PHARMACO, V2, P69, DOI 10.1111/j.1365-2125.1975.tb00474.x; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1986, CHEST, V89, pS11, DOI 10.1378/chest.89.2_Supplement.11S; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HOTRAPHINYO K, 1978, CLIN EXP PHARMACOL P, V5, P143, DOI 10.1111/j.1440-1681.1978.tb00664.x; HUSTED S, 1977, BRIT J CLIN PHARMACO, V4, P559, DOI 10.1111/j.1365-2125.1977.tb00786.x; JONES BR, 1980, J AM GERIATR SOC, V28, P10, DOI 10.1111/j.1532-5415.1980.tb00116.x; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KIRKING DM, 1985, J CLIN HOSP PHARM, V10, P101; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, AM J MED, V87, P153; LIPPINCOTT JB, 1990, DRUG INTERACTION FAC; LOELIGER EA, 1964, THROMB DIATH HAEMOST, V10, P267; MACLENNAN WJ, 1977, GERONTOLOGY, V23, P360, DOI 10.1159/000212209; MANSON A, 1991, AM J PUBLIC HEALTH, V81, P1195, DOI 10.2105/AJPH.81.9.1195; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; OMALLEY K, 1977, BRIT J CLIN PHARMACO, V4, P309, DOI 10.1111/j.1365-2125.1977.tb00718.x; OREILLY RA, 1980, NEW ENGL J MED, V303, P160; PETITTI DB, 1989, J CLIN EPIDEMIOL, V42, P759, DOI 10.1016/0895-4356(89)90073-5; ROUTLEDGE PA, 1979, EUR J CLIN PHARMACOL, V15, P319, DOI 10.1007/BF00558434; Sackett DL, 1979, COMPLIANCE HLTH CARE; SHEPHERD AMM, 1977, BRIT J CLIN PHARMACO, V4, P315, DOI 10.1111/j.1365-2125.1977.tb00719.x; SHEPHERD AMM, 1978, POSTGRAD MED J, V54, P784, DOI 10.1136/pgmj.54.638.784; TOOHEY M, 1953, BRIT MED J, V1, P650, DOI 10.1136/bmj.1.4811.650; 1987, SADSTAT GUIDE PERSON	35	199	203	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					901	904		10.7326/0003-4819-116-11-901	http://dx.doi.org/10.7326/0003-4819-116-11-901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580446				2022-12-28	WOS:A1992HW13700004
J	VEGETO, E; ALLAN, GF; SCHRADER, WT; TSAI, MJ; MCDONNELL, DP; OMALLEY, BW				VEGETO, E; ALLAN, GF; SCHRADER, WT; TSAI, MJ; MCDONNELL, DP; OMALLEY, BW			THE MECHANISM OF RU486 ANTAGONISM IS DEPENDENT ON THE CONFORMATION OF THE CARBOXY-TERMINAL TAIL OF THE HUMAN PROGESTERONE-RECEPTOR	CELL			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION FUNCTIONS; CELL-FREE TRANSCRIPTION; HUMAN ESTROGEN-RECEPTOR; STEROID BINDING DOMAIN; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; RESPONSIVE ELEMENT; HORMONE RECEPTORS	The human progesterone receptor form B (hPR-B) was expressed in Saccharomyces cerevisiae together with a specific reporter plasmid. To understand the mechanism underlying antagonist ligand activity, libraries of hormone binding domain (HBD)-mutated hPR-B molecules were prepared. A mutant receptor was identified that had lost the ability to bind either progesterone or R5020; it could still bind RU486 and, surprisingly, fully activated transcription in the presence of this "antagonist" and other antiprogestins. When this receptor mutant was assayed in mammalian cells, RU486 again demonstrated agonistic activity. Sequence analysis indicated that the mutant phenotype was due to truncation of the carboxy (C)-terminal 42 aa. We conclude that amino acids in the extreme C-terminal region are required for the receptor to bind progesterone, while antagonists bind to a site located more N-terminal of the HBD. Our results suggest that the extreme C-terminal region of the receptor contains an inhibitory function that silences receptor transactivation in the absence of agonist and in the presence of antagonist.			VEGETO, E (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BAGCHI MK, 1992, IN PRESS P NATL ACAD; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAO CC, 1991, CANCER RES, V51, P3938; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LERNER CG, 1990, J BIOL CHEM, V265, P20085; MAK P, 1989, J BIOL CHEM, V264, P21613; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; Miller J. H, 1972, EXPT MOL GENETICS; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHNEIDER MR, 1990, J STEROID BIOCHEM, V37, P783, DOI 10.1016/0960-0760(90)90420-P; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0	68	352	371	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					703	713		10.1016/0092-8674(92)90234-4	http://dx.doi.org/10.1016/0092-8674(92)90234-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586949				2022-12-28	WOS:A1992HV08900015
J	PRITCHETT, ELC				PRITCHETT, ELC			DRUG-THERAPY - MANAGEMENT OF ATRIAL-FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PARKINSON-WHITE SYNDROME; INTRAVENOUS PROCAINAMIDE INFUSION; DIRECT-CURRENT CONVERSION; DOUBLE-BLIND CROSSOVER; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; ATRIOVENTRICULAR JUNCTION; VENTRICULAR-FIBRILLATION; HEART-RATE; FOLLOW-UP		DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,DURHAM,NC 27710	Duke University	PRITCHETT, ELC (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CLIN PHARMACOL,DURHAM,NC 27710, USA.				NCRR NIH HHS [MO1 RR30] Funding Source: Medline; NHLBI NIH HHS [R01 HL40392] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040392] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; ANDERSON S, 1986, AM HEART J, V111, P42; ATWOOD JE, 1988, CHEST, V93, P20, DOI 10.1378/chest.93.1.20; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; Boissel J P, 1981, Eur Heart J, V2, P49; BORGEAT A, 1986, AM J CARDIOL, V58, P496, DOI 10.1016/0002-9149(86)90022-6; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; BYRNEQUINN E, 1970, BRIT HEART J, V32, P370; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1556; CHEVALIER H, 1979, AM HEART J, V98, P361, DOI 10.1016/0002-8703(79)90049-8; CHIMIENTI M, 1987, EUR HEART J, V8, P282, DOI 10.1093/oxfordjournals.eurheartj.a062271; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CONNOLLY SJ, 1989, AM J CARDIOL, V63, P817, DOI 10.1016/0002-9149(89)90049-0; COPLEN SE, 1991, CIRCULATION, V83, P714; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COX JL, 1991, J THORAC CARDIOV SUR, V101, P584; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; CRIJNS HJ, 1988, AM J CARDIOL, V62, P1303, DOI 10.1016/0002-9149(88)90282-2; DALZELL GWN, 1990, Q J MED, V76, P903; DAVID D, 1979, AM J CARDIOL, V44, P1378, DOI 10.1016/0002-9149(79)90456-9; DIBIANCO R, 1984, AM HEART J, V108, P1121, DOI 10.1016/0002-8703(84)90592-1; DIMARCO JP, 1991, J AM COLL CARDIOL, V17, P976; DITTRICH HC, 1989, AM J CARDIOL, V63, P193, DOI 10.1016/0002-9149(89)90284-1; DUNN M, 1989, CHEST S118S, V95, pS18; ECHT DS, 1991, NEW ENGL J MED, V1, P324; ELLENBOGEN KA, 1991, J AM COLL CARDIOL, V18, P891, DOI 10.1016/0735-1097(91)90743-S; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FALK RH, 1989, ANN INTERN MED, V111, P107, DOI 10.7326/0003-4819-111-2-107; FELD GK, 1990, AM J CARDIOL, V66, P378, DOI 10.1016/0002-9149(90)90856-V; FENSTER PE, 1983, AM HEART J, V106, P501, DOI 10.1016/0002-8703(83)90692-0; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; Gold H, 1939, J PHARMACOL EXP THER, V67, P224; GULAMHUSEIN S, 1983, AM HEART J, V106, P145, DOI 10.1016/0002-8703(83)90452-0; HALPERN SW, 1980, BRIT HEART J, V44, P589; HARTEL G, 1970, BRIT HEART J, V32, P57; HENRY WL, 1976, CIRCULATION, V53, P273, DOI 10.1161/01.CIR.53.2.273; HILLESTAD L, 1971, BRIT HEART J, V33, P518; HWANG MH, 1984, ARCH INTERN MED, V144, P491, DOI 10.1001/archinte.144.3.491; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACOB AS, 1985, ANN EMERG MED, V14, P159, DOI 10.1016/S0196-0644(85)81080-5; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KAPPENBERGER LJ, 1985, CLIN CARDIOL, V8, P321, DOI 10.1002/clc.4960080603; KARLSON BW, 1988, EUR HEART J, V9, P284, DOI 10.1093/oxfordjournals.eurheartj.a062498; KAY GN, 1988, AM J CARDIOL, V62, P741, DOI 10.1016/0002-9149(88)91214-3; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KLEIN GJ, 1980, CIRCULATION, V261, P8; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LANG R, 1983, AM HEART J, V105, P820, DOI 10.1016/0002-8703(83)90246-6; LANGBERG JJ, 1991, AM J CARDIOL, V67, P142, DOI 10.1016/0002-9149(91)90436-O; LANGBERG JJ, 1989, CIRCULATION, V80, P1527, DOI 10.1161/01.CIR.80.6.1527; LEITCH JW, 1991, J AM COLL CARDIOL, V17, P970; Lewis T, 1922, HEART-J STUD CIRC, V9, P207; LIPKIN DP, 1988, BRIT HEART J, V59, P572; LLOYD EA, 1984, S AFR MED J, V65, P367; LUNDSTROM T, 1988, ACTA MED SCAND, V223, P53; MCGOVERN B, 1986, ANN INTERN MED, V104, P791, DOI 10.7326/0003-4819-104-6-791; MILLER HS, 1964, JAMA-J AM MED ASSOC, V189, P549; MORRIS JJ, 1966, ANN INTERN MED, V65, P216, DOI 10.7326/0003-4819-65-2-216; MORRIS JJ, 1965, CIRCULATION, V31, P670, DOI 10.1161/01.CIR.31.5.670; MUNGALL DR, 1980, ANN INTERN MED, V93, P689, DOI 10.7326/0003-4819-93-5-689; NEUSS H, 1983, EUR HEART J, V4, P347, DOI 10.1093/oxfordjournals.eurheartj.a061472; OLSSON SB, 1980, ACTA MED SCAND, V207, P5; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1987, STROKE, V18, P1098, DOI 10.1161/01.STR.18.6.1098; PRATT CM, 1990, AM J CARDIOL, V65, P103, DOI 10.1016/0002-9149(90)90034-X; PRITCHETT ELC, 1991, AM J CARDIOL, V67, P976, DOI 10.1016/0002-9149(91)90170-P; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; PRITCHETT ELC, 1991, J AM COLL CARDIOL, V17, P297, DOI 10.1016/S0735-1097(10)80090-7; RAWLES JM, 1990, BRIT HEART J, V63, P225; RESNEKOV L, 1971, BRIT HEART J, V33, P339; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; ROSENQVIST M, 1990, J AM COLL CARDIOL, V16, P1467, DOI 10.1016/0735-1097(90)90394-5; ROTH A, 1986, CIRCULATION, V73, P316, DOI 10.1161/01.CIR.73.2.316; SALERNO DM, 1989, AM J CARDIOL, V63, P1046, DOI 10.1016/0002-9149(89)90076-3; SCHEINMAN MM, 1989, NEW ENGL J MED, V320, P460, DOI 10.1056/NEJM198902163200710; SELLERS TD, 1977, CIRCULATION, V55, P15, DOI 10.1161/01.CIR.55.1.15; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHAPIRO W, 1968, CIRCULATION, V38, P1074, DOI 10.1161/01.CIR.38.6.1074; SODERMARK T, 1975, BRIT HEART J, V37, P486; SOKOLOW M, 1950, CIRCULATION, V1, P576, DOI 10.1161/01.CIR.1.4.576; STEIN B, 1989, CIRCULATION, V80, P1501, DOI 10.1161/01.CIR.80.6.1501; SZEKELY P, 1970, BRIT HEART J, V32, P741; SZEKELY P, 1964, BMJ-BRIT MED J, V1, P1209, DOI 10.1136/bmj.1.5392.1209; VITOLO E, 1981, ACTA CARDIOL, V36, P431; WAXMAN HL, 1981, ANN INTERN MED, V94, P1, DOI 10.7326/0003-4819-94-1-1; WENCKEBACH KF, 1914, UNREGELMASSIGE HERZT, P124; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1990, STROKE, V21, P538; 1991, CIRCULATION, V84, P527; 1990, NEW ENGL J MED, V322, P863; 1990, NEW ENGL J MED, V323, P1505; 1992, ANN INTERN MED, V116, P1	94	224	225	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1264	1271						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560803				2022-12-28	WOS:A1992HR44700006
J	KLEBER, FX				KLEBER, FX			TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											KLEBER, FX (corresponding author), MUNICH SCHWABING HOSP, W-8000 MUNICH 40, GERMANY.		Stewart Coats, Andrew/E-4451-2012	Stewart Coats, Andrew/0000-0002-2771-4260				KLEBER FX, IN PRESS BR HEART J; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	2	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1220	1220						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1557099				2022-12-28	WOS:A1992HR00800011
J	THORNBERRY, NA; BULL, HG; CALAYCAY, JR; CHAPMAN, KT; HOWARD, AD; KOSTURA, MJ; MILLER, DK; MOLINEAUX, SM; WEIDNER, JR; AUNINS, J; ELLISTON, KO; AYALA, JM; CASANO, FJ; CHIN, J; DING, GJF; EGGER, LA; GAFFNEY, EP; LIMJUCO, G; PALYHA, OC; RAJU, SM; ROLANDO, AM; SALLEY, JP; YAMIN, TT; LEE, TD; SHIVELY, JE; MACCROSS, M; MUMFORD, RA; SCHMIDT, JA; TOCCI, MJ				THORNBERRY, NA; BULL, HG; CALAYCAY, JR; CHAPMAN, KT; HOWARD, AD; KOSTURA, MJ; MILLER, DK; MOLINEAUX, SM; WEIDNER, JR; AUNINS, J; ELLISTON, KO; AYALA, JM; CASANO, FJ; CHIN, J; DING, GJF; EGGER, LA; GAFFNEY, EP; LIMJUCO, G; PALYHA, OC; RAJU, SM; ROLANDO, AM; SALLEY, JP; YAMIN, TT; LEE, TD; SHIVELY, JE; MACCROSS, M; MUMFORD, RA; SCHMIDT, JA; TOCCI, MJ			A NOVEL HETERODIMERIC CYSTEINE PROTEASE IS REQUIRED FOR INTERLEUKIN-1-BETA PROCESSING IN MONOCYTES	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONIST; SEQUENCE-ANALYSIS; MONONUCLEAR-CELLS; PRECURSOR; ENZYME; IDENTIFICATION; PROTEINASES; ACTIVATION; 1-BETA	Interleukin-1-beta (IL-1-beta)-converting enzyme cleaves the IL-1-beta precursor to mature IL-1-beta, an important mediator of inflammation. The identification of the enzyme as a unique cysteine protease and the design of potent peptide aldehyde inhibitors are described. Purification and cloning of the complementary DNA indicates that IL-1-beta-converting enzyme is composed of two nonidentical subunits that are derived from a single proenzyme, possibly by autoproteolysis. Selective inhibition of the enzyme in human blood monocytes blocks production of mature IL-1-beta, indicating that it is a potential therapeutic target.	MERCK SHARP & DOHME LTD, DEPT MOLEC IMMUNOL, POB 2000, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM & MOLEC PATHOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT MED CHEM RES, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC PHARMACOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM PROC RES & DEV, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOL DATA, RAHWAY, NJ 07065 USA; CITY HOPE NATL MED CTR, BECKMAN RES INT, DUARTE, CA 91010 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; City of Hope; Beckman Research Institute of City of Hope				Elliston, Keith/0000-0002-9110-9233; Kostura, Matthew/0000-0001-7940-7492				BAZAN JF, 1989, FEBS LETT, V249, P5, DOI 10.1016/0014-5793(89)80003-1; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BULL HG, 1985, J BIOL CHEM, V260, P2963; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUNT DF, 1987, P NATL ACAD SCI USA, V84, P620, DOI 10.1073/pnas.84.3.620; ITOH N, 1987, J BIOL CHEM, V262, P3132; KOBASHI K, 1967, ARCH BIOCHEM BIOPHYS, V121, P178, DOI 10.1016/0003-9861(67)90022-7; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LONNEMANN G, 1989, EUR J IMMUNOL, V19, P1531, DOI 10.1002/eji.1830190903; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RICH DH, 1986, PROTEINASE INHIBITOR, P153; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SCHMIDT JA, 1990, PEPTIDE GROWTH FACTO, P473; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHERIDAN RP, IN PRESS PROTEINS; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0	40	2062	2171	2	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1992	356	6372					768	774		10.1038/356768a0	http://dx.doi.org/10.1038/356768a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574116				2022-12-28	WOS:A1992HR18600041
J	SINGH, RB; RASTOGI, SS; VERMA, R; LAXMI, B; SINGH, R; GHOSH, S; NIAZ, MA				SINGH, RB; RASTOGI, SS; VERMA, R; LAXMI, B; SINGH, R; GHOSH, S; NIAZ, MA			RANDOMIZED CONTROLLED TRIAL OF CARDIOPROTECTIVE DIET IN PATIENTS WITH RECENT ACUTE MYOCARDIAL-INFARCTION - RESULTS OF ONE-YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; ATHEROSCLEROSIS; LIPOPROTEINS; INTERVENTION; FIBER; RISK	Objective - To test whether a fat reduced diet rich in soluble dietary fibre, antioxidant vitamins, and minerals reduces complications and mortality after acute myocardial infarction. Design - Randomised, single blind, controlled trial. Setting - Primary and secondary care research centre for patients with myocardial infarction. Subjects - 505 patients with suspected acute myocardial infarction. Those with definite or possible acute myocardial infarction and unstable angina based on World Health Organisation criteria were assigned to diet A (n = 204) or diet B (n = 202) within 24-48 hours of infarction. Interventions - Both groups were advised to follow a fat reduced diet. Group A was also advised to eat more fruit, vegetables, nuts, and grain products. Main outcome measures - Mortality from cardiac disease and other causes. Serum lipid concentrations and compliance with diet. Results - Blood lipoprotein concentrations and body weight fell significantly in patients in group A compared with those in group B (cholesterol fell by 0.74 mmol/l in group A v 0.32 mmol/l in group B, 95% confidence interval of difference 0.14 to 0.70, and weight by 7.1 v 3.0 kg, 0.52 to 7.68). The incidence of cardiac events was significantly lower in group A than group B (50 v 82 patients, p < 0.001). Group A also had lower total mortality (21 v 38 died, p < 0.01) than group B. Conclusions - Comprehensive dietary changes in conjunction with weight loss immediately after acute myocardial infarction may modulate blood lipoproteins and significantly reduce complications and mortality after one year.	COLLABORATING CTR RES,MORADABAD,INDIA		SINGH, RB (corresponding author), MED HOSP & RES CTR,CIVIL LINES,MORADABAD 10,UTTAR PRADESH,INDIA.							ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; [Anonymous], 1976, MYOCARDIAL INFARCTIO; ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301; BAGATELL CJ, 1984, AM J CLIN NUTR, V39, P421, DOI 10.1093/ajcn/39.3.421; BOULLIN DJ, 1981, LANCET, V1, P776; BURR ML, 1989, LANCET, V2, P757; HORROBIN DF, 1987, INT J CARDIOL, V17, P241, DOI 10.1016/0167-5273(87)90073-8; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KURUP PA, 1989, 21ST P ANN M NUTR SO, P27; LAMM G, 1988, Cardiovascular Drugs and Therapy, V2, P133, DOI 10.1007/BF00054264; LEREN P, 1989, J AM COLL NUTR, V8, P407; MATHUR KS, 1968, BMJ-BRIT MED J, V1, P30, DOI 10.1136/bmj.1.5583.30; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MENON S, 1968, BRIT MED J, V3, P351; RAO BSN, 1989, NUTRIENT COMPOSITION; RIEMERSMA RA, 1991, LANCET, V357, P1; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; SAINANI GS, 1976, LANCET, V2, P575; SCHETTLER G, 1979, PREV MED, V8, P581, DOI 10.1016/0091-7435(79)90336-0; SHAKELLE RB, 1989, LANCET, V1, P1177; SHARMA RD, 1989, 21ST P ANN M NUTR SO, P52; SINGH R B, 1990, Journal of Nutritional Medicine, V1, P179, DOI 10.3109/13590849009003156; SINGH RB, 1992, AM J CARDIOL, V69, P879, DOI 10.1016/0002-9149(92)90786-X; SINGH RB, 1991, NUTRITION, V7, P119; SINGH RB, 1991, NUTRITION CORONARY H; VANHANDEL E, 1957, J LAB CLIN MED, V50, P152; WILSON DE, 1973, J LAB CLIN MED, V82, P413; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; 1968, LANCET, V2, P693; 1991, REVISED DIETARY GUID; 1984, JAMA-J AM MED ASSOC, V251, P351; IN PRESS NUTRITION P; 1965, LANCET, V2, P501	35	335	342	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1015	1019		10.1136/bmj.304.6833.1015	http://dx.doi.org/10.1136/bmj.304.6833.1015			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586782	Bronze, Green Published			2022-12-28	WOS:A1992HQ14200018
J	HEDNER, T; SAMUELSSON, O; LUNDE, H; LINDHOLM, L; ANDREN, L; WIHOLM, BE				HEDNER, T; SAMUELSSON, O; LUNDE, H; LINDHOLM, L; ANDREN, L; WIHOLM, BE			ANGIO-EDEMA IN RELATION TO TREATMENT WITH ANGIOTENSIN CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; SWEDEN	Objective-To evaluate and describe the clinical course of angio-oedema reactions induced by angiotensin converting enzyme inhibitors. Design and methods-All reports of angio-oedema reactions associated with angiotensin converting enzyme inhibitors submitted to Swedish Adverse Reactions Advisory Committee were reviewed and the clinical courses summarised. Numbers of cases judged to be induced by angiotensin converting enzyme inhibitors were related to their annual usage, estimated from total sales of defined daily doses, as well as to the estimated number of new patients. All cases of angio-oedema associated with angiotensin converting enzyme inhibitors reported to the World Health Organisation's international drug information system were also summarised. Results-36 of the 38 reported cases in Sweden between 1981 and 1990 were judged to be related to angiotensin converting enzyme inhibitors. During 1981 through 1990, altogether 1309 cases of angio-oedema associated with angiotensin converting enzyme inhibitors were registered with the international drug information system. The incidence of reported cases of angio-oedema increased largely in parallel with the increased sales (usage) of angiotensin converting enzyme inhibitors. Of the 36 Swedish patients, 77% experienced the reaction within the first three weeks after starting treatment. 10 patients needed hospitalisation, two of whom had life threatening laryngeal obstruction. With one exception all 36 patients were free of symptoms within one week after discontinuing the drug. Conclusions-Angio-oedema induced by angiotensin converting enzyme inhibitors is a rare but potentially life threatening reaction, which in most instances occurs shortly after the start of treatment. Any patient in whom the reaction is suspected should have the treatment interrupted and, if necessary, be admitted for observation.	GOTHENBURG UNIV,SAHLGRENS HOSP,NEPHROL,S-41345 GOTHENBURG,SWEDEN; SWEDISH MED PROD AGCY,UPPSALA,SWEDEN; UNIV LUND,HLTH SCI CTR,DALBY,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Medical Products Agency; Lund University	HEDNER, T (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT CLIN PHARMACOL,S-41345 GOTHENBURG,SWEDEN.							CHIN HL, 1990, ANN INTERN MED, V112, P312, DOI 10.7326/0003-4819-112-4-312_2; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; ERDOS EG, 1990, J CARDIOVASC PHARM, V15, pS20; FROHLICH ED, 1989, HYPERTENSION S1, V13, P125; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P573; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; OLSSON S, 1989, SEMIN DERMATOL, V8, P72; ORFAN N, 1990, JAMA-J AM MED ASSOC, V264, P1287, DOI 10.1001/jama.264.10.1287; Osler W, 1888, AM J MED SCI, V95, P362; Quincke H, 1882, MONATSH PRAKT DERMAT, V1, P129; RASTAM L, 1986, ACTA MED SCAND, V219, P243; RUCINSKA EJ, 1989, MED TOXICOL ADV DRUG, V4, P144, DOI 10.1007/BF03259909; RUSH JE, 1987, J CARDIOVASC PHAR S3, V9, P99; SAMUELSSON O, 1985, J HYPERTENS, V3, P167, DOI 10.1097/00004872-198504000-00010; SCHROR K, 1990, J CARDIOVASC PHARM, V15, pS60, DOI 10.1097/00005344-199015061-00012; SEARS M, 1991, ASTHMA ITS PATHOLOGY, V1; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SOTER NA, 1977, FED PROC, V36, P1736; WARNER NJ, 1988, DRUGS, V35, P89, DOI 10.2165/00003495-198800355-00016; WERNZE H, 1988, Z KARDIOL, V77, P61; WESSLING A, 1990, EUR J CLIN PHARMACOL, V38, P329, DOI 10.1007/BF00315570; WIHOLM BE, 1984, 1983 SKAND INT S DET, P152; WOOD SM, 1987, BRIT MED J, V294, P91, DOI 10.1136/bmj.294.6564.91; 1990, J HYPERTENS, V8, P985; 1985, BMJ, V291, P97; 1988, ARCH INTERN MED, V148, P1023; ADVERSE REACTION REG; 1990, LAKARTIDNINGEN, V87, P2255; 1989, J HYPERTENS, V7, P689	29	111	113	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					941	946		10.1136/bmj.304.6832.941	http://dx.doi.org/10.1136/bmj.304.6832.941			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581715	Bronze, Green Published			2022-12-28	WOS:A1992HP06400018
J	GUSSONI, E; PAVLATH, GK; LANCTOT, AM; SHARMA, KR; MILLER, RG; STEINMAN, L; BLAU, HM				GUSSONI, E; PAVLATH, GK; LANCTOT, AM; SHARMA, KR; MILLER, RG; STEINMAN, L; BLAU, HM			NORMAL DYSTROPHIN TRANSCRIPTS DETECTED IN DUCHENNE MUSCULAR-DYSTROPHY PATIENTS AFTER MYOBLAST TRANSPLANTATION	NATURE			English	Article							MOSAIC EXPRESSION; MUSCLE-FIBERS; GENE; CARRIERS; DELETION; PROTEIN; LOCUS; CDNA	GENE delivery by transplantation of normal myoblasts has been proposed as a treatment of the primary defect, lack of the muscle protein dystrophin, that causes Duchenne muscular dystrophy (DMD), a lethal human muscle degenerative disorder 1,2. To test this possibility, we transplanted normal myoblasts from a father or an unaffected sibling into the muscle of eight boys with DMD, and assessed their production of dystrophin. Three patients with deletions in the dystrophin gene expressed normal dystrophin transcripts in muscle biopsy specimens taken from the transplant site one month after myoblast injection. Using the polymerase chain reaction we established that the dystrophin in these biopsies derived from donor myoblast DNA. These results show that transplanted myoblasts persist and produce dystrophin in muscle fibres of DMD patients.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305; CALIF PACIFIC MED CTR,DIV NEUROMUSCULAR RES,SAN FRANCISCO,CA 94118	Stanford University; Stanford University; California Pacific Medical Center			Gussoni, Emanuela/AAL-6150-2021	Gussoni, Emanuela/0000-0002-9915-3677; Steinman, Lawrence/0000-0002-2437-2250				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ARAHATA K, 1989, NEW ENGL J MED, V320, P138, DOI 10.1056/NEJM198901193200302; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BEGGS AH, 1990, HUM GENET, V86, P45; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BONILLA E, 1988, AM J PATHOL, V133, P440; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHAMBERLAIN JS, 1990, PCR PROTOCOLS GUIDE; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER BJ, 1990, LAB INVEST, V62, P171; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; FORREST SM, 1987, NATURE, V329, P638, DOI 10.1038/329638a0; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUGHES S, 1992, CELL, V68, P1; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; KARPATI G, 1989, AM J PATHOL, V135, P27; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAW PK, 1990, LANCET, V336, P114, DOI 10.1016/0140-6736(90)91628-N; MAN NT, 1990, FEBS LETT, V262, P237, DOI 10.1016/0014-5793(90)80199-S; PANZARA MA, IN PRESS BIOTECHNIQU; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; WATKINS SC, 1989, MUSCLE NERVE, V12, P861, DOI 10.1002/mus.880121013; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096	31	352	377	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					435	438		10.1038/356435a0	http://dx.doi.org/10.1038/356435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557125				2022-12-28	WOS:A1992HL83000064
J	HANNAY, D; USHERWOOD, T; PLATTS, M				HANNAY, D; USHERWOOD, T; PLATTS, M			WORKLOAD OF GENERAL-PRACTITIONERS BEFORE AND AFTER THE NEW CONTRACT	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess changes in general practitioners' workload associated with the new contract introduced in April 1990. Design - Weekly workload diary completed during four weeks in February-March 1990 and during the same period in 1991. Setting - Sheffield, United Kingdom. Subjects - All 300 general practitioners on Sheffield Family Health Services Authority list as principals in 1990 and 1991. Main outcome measures - Mean number of hours worked per week, number of patients seen each week, and mean time spent per patient. Results - 181 (60%) general practitioners responded in 1990 and 163 (54%) in 1991. Of these, 18 (10%) were not working in 1990 and 14 (7%) in 1991. General medical service work increased during a "normal working week" from a mean of 38.6 hours a week in 1990 to 40.6 hours in 1991, and non-general medical service work decreased from 5.4 hours a week to 4.5 hours. Hours spent on call were similar before and after the contract. For the 99 general practitioners who responded in both years, time spent on general medical service duties increased significantly (40.4 h in 1990 v 42.6 h in 1991; p = 0.033), mainly due to more time being spent in clinics. Significantly more patients were being seen in clinics (9 v 14; p = 0.001); the average time spent per patient remained at about 8 1/2 minutes during surgeries and 16 minutes for a home visit, and rose from 13 to 14 minutes for patients seen in clinics. The time spent on practice administration fell but not significantly. Conclusion - Since the new contract there has been a significant increase in general medical services work, mainly due to more patients being seen in clinics, with no reduction in the time spent per patient.			HANNAY, D (corresponding author), UNIV SHEFFIELD,DEPT GEN PRACTICE,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BUTLER JR, 1988, TOO MANY PATIENTS ST; CROMBIE DL, 1987, REPORT PRACTICE ACTI; RIDSDALE L, 1990, BRIT MED J, V301, P455, DOI 10.1136/bmj.301.6750.455; THOMAS K, 1989, J ROY COLL GEN PRACT, V39, P509; WILKIN D, 1988, ANATOMY URBAN GENERA; 1989, GENERAL PRACTICE NAT; 1991, GENERAL MED PRACTITI; 1989, WORKING PATIENTS; 1987, GENERAL MED PRACTITI	9	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					615	618		10.1136/bmj.304.6827.615	http://dx.doi.org/10.1136/bmj.304.6827.615			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559092	Green Published, Bronze			2022-12-28	WOS:A1992HH73300025
J	ZEITLYN, S; RAHMAN, AKSM; NIELSEN, BH; GOMES, M; KOFOED, PEL; MAHALANABIS, D				ZEITLYN, S; RAHMAN, AKSM; NIELSEN, BH; GOMES, M; KOFOED, PEL; MAHALANABIS, D			COMPLIANCE WITH DIPHTHERIA, TETANUS, AND PERTUSSIS IMMUNIZATION IN BANGLADESH - FACTORS IDENTIFYING HIGH-RISK GROUPS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To evaluate factors associated with non-compliance with having second vaccination against diphtheria, tetanus, and pertussis in a treatment centre in Dhaka to determine which children were most at risk of not completing immunisation. Design - Cohort study of infants given first dose of the vaccine and followed up six weeks later to ascertain compliance with having second dose. Factors associated with non-compliance were evaluated. Setting - Dhaka treatment centre of the International Centre for Diarrhoeal Disease Research, Bangladesh. Subjects - 136 unimmunised children aged 6 weeks to 23 months who lived within reach of the treatment centre. At time of the six week follow up 16 of the children could not be traced and seven had died. Interventions - All children received their first dose of the vaccine. In each case health education workers had informed the mother about the value of immunisation, and she was given clear instructions to bring the child back after four weeks for the second dose. Main outcome measure - Rate of non-compliance with advice to return child for second vaccination. Results - 46 of 113 children (41%) received the second dose of the vaccine. Factors most closely associated with mothers' failure to comply with the second dose were lack of education and low income. Children whose mothers knew most about immunisation at first interview were more likely to have their second dose. Conclusions - Preventive health care services such as immunisation are appropriately offered in treatment centres, but compliance among children varies with socioeconomic status and mother's education. Further research should be aimed at ways to make health education more effective among uneducated parents.	INT CTR DIARRHOEL DIS RES,CHILD HLTH PROGRAMME,POB 128,DHAKA 1000,BANGLADESH; INT CTR DIARRHOEL DIS RES BANGLADESH,DIV CLIN SCI,DHAKA 1000,BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)								BAIRAGI R, 1980, B WORLD HEALTH ORGAN, V58, P767; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GUPTA AD, 1988, COMMUNICATING IMMUNI; SCHULER SR, 1985, STUD FAMILY PLANN, V16, P260, DOI 10.2307/1966999; 1991, STATE WORLDS CHILDRE, P102; 1989, EXPANDED PROGRAMME I	7	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					606	609		10.1136/bmj.304.6827.606	http://dx.doi.org/10.1136/bmj.304.6827.606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559089	Green Published, Bronze			2022-12-28	WOS:A1992HH73300022
J	COLE, AT; BRUNDELL, S; HUDSON, N; HAWTHORNE, AB; MAHIDA, YR; HAWKEY, CJ				COLE, AT; BRUNDELL, S; HUDSON, N; HAWTHORNE, AB; MAHIDA, YR; HAWKEY, CJ			RANITIDINE, ASPIRIN, FOOD, AND THE STOMACH	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								DANESHMEND TK, 1990, GUT, V31, P514, DOI 10.1136/gut.31.5.514; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; HAWKEY CJ, 1991, CLIN SCI, V81, P565, DOI 10.1042/cs0810565; SATOH H, 1982, GASTROENTEROLOGY, V83, P210; STEPHENS FO, 1968, DIGESTION, V1, P267, DOI 10.1159/000196864	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					544	545		10.1136/bmj.304.6826.544-a	http://dx.doi.org/10.1136/bmj.304.6826.544-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559058	Green Published, Bronze			2022-12-28	WOS:A1992HG59900021
J	THUMMEL, CS				THUMMEL, CS			MECHANISMS OF TRANSCRIPTIONAL TIMING IN DROSOPHILA	SCIENCE			English	Editorial Material							IMMEDIATE-EARLY GENES; ECDYSONE-INDUCIBLE GENE; C-FOS; GROWTH-FACTOR; EARLY PUFF; ENCODES 2; 3T3 CELLS; MELANOGASTER; EXPRESSION; PRODUCTS				THUMMEL, CS (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112, USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; ASHBURNER M, 1972, CHROMOSOMA, V38, P255, DOI 10.1007/BF00290925; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BECKER HJ, 1959, CHROMOSOMA, V10, P654, DOI 10.1007/BF00396591; BURMEISTER M, 1988, Genomics, V2, P189, DOI 10.1016/0888-7543(88)90002-X; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CASJENS S, 1985, J VIROL, V53, P185, DOI 10.1128/JVI.53.1.185-191.1985; CHEN CN, 1987, NATURE, V329, P721, DOI 10.1038/329721a0; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DAVIS RL, 1986, MOL CELL BIOL, V6, P1464, DOI 10.1128/MCB.6.5.1464; DIBELLO PR, 1991, GENETICS, V129, P385; DRAGUNOW M, 1989, NEUROSCI BIOBEHAV R, V13, P301, DOI 10.1016/S0149-7634(89)80066-1; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUBB D, 1986, DEV GENET, V7, P119, DOI 10.1002/dvg.1020070302; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; JONES CW, 1991, GENETICS, V127, P535; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; PAO CC, 1973, J VIROL, V11, P1024, DOI 10.1128/JVI.11.6.1024-1026.1973; RAY PN, 1975, NATURE, V253, P647, DOI 10.1038/253647a0; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; TOOZE J, 1980, DNA TUMOR VIRUSES 2; WATSON JD, 1970, MOL BIOL GENE, P528	35	37	37	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					39	40		10.1126/science.1553530	http://dx.doi.org/10.1126/science.1553530			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553530				2022-12-28	WOS:A1992GX79100031
J	LAI, ECS; MOK, FPT; TAN, ESY; LO, CM; FAN, ST; YOU, KT; WONG, J				LAI, ECS; MOK, FPT; TAN, ESY; LO, CM; FAN, ST; YOU, KT; WONG, J			ENDOSCOPIC BILIARY DRAINAGE FOR SEVERE ACUTE CHOLANGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE SUPPURATIVE CHOLANGITIS; RISK; SPHINCTEROTOMY; SURGERY; STONES	Background. Emergency surgery for patients with severe acute cholangitis due to choledocholithiasis is associated with substantial morbidity and mortality. Because recent results suggested that emergency endoscopic drainage could improve the outcome of such patients, we undertook a prospective study to determine the role of this procedure as initial treatment. Methods. During a 43-month period, 82 patients with severe acute cholangitis due to choledocholithiasis were randomly assigned to undergo surgical decompression of the biliary tract (41 patients) or endoscopic biliary drainage (41 patients), followed by definitive treatment. Hospital mortality was analyzed with respect to the use of endoscopic biliary drainage and other clinical and laboratory findings. Prognostic determinants were studied by linear discriminant analysis. Results. Complications related to biliary tract decompression and subsequent definitive treatment developed in 14 patients treated with endoscopic biliary drainage and 27 treated with surgery (34 vs. 66 percent, P>0.05). The time required for normalization of temperature and stabilization of blood pressure was similar in the two groups, but more patients in the surgery group required ventilatory support. The hospital mortality rate was significantly lower for the patients who underwent endoscopy (4 deaths) than for those treated surgically (13 deaths) (10 vs. 32 percent, P<0.03). The presence of concomitant medical problems, a low platelet count, a high serum urea nitrogen concentration, and a low serum albumin concentration before biliary decompression were the other independent determinants of mortality in both groups. Conclusions. Endoscopic biliary drainage is a safe and effective measure for the initial control of severe acute cholangitis due to choledocholithiasis and to reduce the mortality associated with the condition.			LAI, ECS (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG.		Fan, Sheung Tat/C-4138-2009					ARMITAGE P, 1971, STATISTICAL METHODS, P184; BLAMEY SL, 1983, BRIT J SURG, V70, P535, DOI 10.1002/bjs.1800700910; BOEY JH, 1980, ANN SURG, V191, P264, DOI 10.1097/00000658-198003000-00002; DELMOTTE JS, 1982, GASTROENTEROLOGY, V82, P1042; GIGOT JF, 1989, ANN SURG, V209, P435, DOI 10.1097/00000658-198904000-00008; GOGEL HK, 1987, GASTROINTEST ENDOSC, V33, P210, DOI 10.1016/S0016-5107(87)71560-0; Ikeda S, 1981, World J Surg, V5, P587; KIIL J, 1989, SURGERY, V105, P51; KINOSHITA H, 1984, WORLD J SURG, V8, P963, DOI 10.1007/BF01656040; LAI ECS, 1990, SURGERY, V107, P268; LAI ECS, 1990, ANN SURG, V211, P55, DOI 10.1097/00000658-199001000-00009; LEESE T, 1986, BRIT J SURG, V73, P988, DOI 10.1002/bjs.1800731214; LEUNG JWC, 1989, LANCET, V1, P1307; OCONNOR MJ, 1982, ARCH SURG-CHICAGO, V117, P437; PESSA ME, 1987, ANN SURG, V205, P389, DOI 10.1097/00000658-198704000-00008; WELCH JP, 1976, AM J SURG, V131, P527, DOI 10.1016/0002-9610(76)90003-9	16	385	406	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1582	1586		10.1056/NEJM199206113262401	http://dx.doi.org/10.1056/NEJM199206113262401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584258	Green Submitted			2022-12-28	WOS:A1992HX63300002
J	ZIEGLER, TR; YOUNG, LS; BENFELL, K; SCHELTINGA, M; HORTOS, K; BYE, R; MORROW, FD; JACOBS, DO; SMITH, RJ; ANTIN, JH; WILMORE, DW				ZIEGLER, TR; YOUNG, LS; BENFELL, K; SCHELTINGA, M; HORTOS, K; BYE, R; MORROW, FD; JACOBS, DO; SMITH, RJ; ANTIN, JH; WILMORE, DW			CLINICAL AND METABOLIC EFFICACY OF GLUTAMINE-SUPPLEMENTED PARENTERAL-NUTRITION AFTER BONE-MARROW TRANSPLANTATION - A RANDOMIZED, DOUBLE-BLIND, CONTROLLED-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; GLUTAMINE; PARENTERAL NUTRITION; COST CONTROL	RAT SKELETAL-MUSCLE; NITROGEN-BALANCE; LIQUID-CHROMATOGRAPHY; INTESTINAL-MUCOSA; PROTEIN-SYNTHESIS; IMMUNE-SYSTEM; RECIPIENTS; COMPLICATIONS; SURGERY; HYPERALIMENTATION	Objective: To determine whether glutamine-supplemented parenteral nutrition improves nitrogen retention and reduces hospital morbidity compared with standard parenteral nutrition after bone marrow transplantation. Design: Double-blind, randomized, controlled clinical trial. Setting: University teaching hospital. Patients: Forty-five adults receiving allogeneic bone marrow transplants for hematologic malignancies. Intervention: Parenteral nutrition was initiated the day after bone marrow transplantation (day 1). The experimental solution was supplemented with L-glutamine (0.57 g/kg body weight per day) and provided estimated requirements for energy and protein. The control solution was a standard, glutamine-free, isonitrogenous, isocaloric formula. Measurements: Nitrogen balance was determined between days 4 and 11 in the initial 23 patients. The incidence of clinical infection and microbial colonization, time until bone marrow engraftment, indices of clinical care, and other data related to hospital morbidity were recorded for all patients. Results: The glutamine-supplemented patients (n = 24) were clinically similar to the controls (n = 21) at entrY. Nutrient intake was similar in both groups; however, nitrogen balance was improved in the glutamine-supplemented patients relative to the controls (- 1.4 +/- 0.5 g/d compared with - 4.2 +/- 1.2; P = 0.002). Fewer experimental patients developed clinical infection (three compared with nine in the control group; P = 0.041), and the incidence of microbial colonization was also significantly reduced. Hospital stay was shortened in patients receiving glutamine supplementation (29 +/-1 d compared with 36 +/- 2 d; P = 0.017). Conclusion: Patients receiving glutamine-supplemented parenteral nutrition after bone marrow transplantation had improved nitrogen balance, a diminished incidence of clinical infection, lower rates of microbial colonization, and shortened hospital stay compared with patients receiving standard parenteral nutrition. These effects occurred despite no differences between groups in the incidence of fever, antibiotic requirements, or time to neutrophil engraftment.	BRIGHAM & WOMENS HOSP, DEPT SURG, 75 FRANCIS ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV DIABET & METAB, BOSTON, MA 02115 USA; JOSLIN DIABET CTR, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, SURG METAB & NUTR LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL & ONCOL, BOSTON, MA 02115 USA; FREE UNIV AMSTERDAM, DEPT SURG, 1081 HV AMSTERDAM, NETHERLANDS; MT CLEMENS GEN HOSP, DEPT MED, MT CLEMENS, MI 48062 USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Vrije Universiteit Amsterdam; Tufts University; United States Department of Agriculture (USDA)					NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM036428] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39542] Funding Source: Medline; NIGMS NIH HHS [5P50 GM36428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTIN JH, 1991, BLOOD, V78, P2139; ARDAWI MSM, 1988, METABOLISM, V37, P99, DOI 10.1016/0026-0495(88)90036-4; BURKE DJ, 1989, ARCH SURG-CHICAGO, V124, P1396; CHENEY CL, 1987, J AM COLL NUTR, V6, P223; CHENEY CL, 1987, CANCER, V59, P1515, DOI 10.1002/1097-0142(19870415)59:8<1515::AID-CNCR2820590821>3.0.CO;2-D; COHEN ML, 1983, J INFECT DIS, V147, P789, DOI 10.1093/infdis/147.5.789; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; FOX AD, 1988, JPEN-PARENTER ENTER, V12, P325, DOI 10.1177/0148607188012004325; FOX AD, 1987, JPEN J PARENTER EN S, V12, pS8; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; HAMMARQVIST F, 1989, ANN SURG, V209, P455, DOI 10.1097/00000658-198904000-00011; HONG RW, 1990, SURG FORUM, V16, P9; JEPSON MM, 1988, AM J PHYSIOL, V255, pE166, DOI 10.1152/ajpendo.1988.255.2.E166; KAFKEWITZ D, 1983, AM J CLIN NUTR, V37, P1025; KLIMBERG VS, 1990, CANCER-AM CANCER SOC, V66, P62, DOI 10.1002/1097-0142(19900701)66:1<62::AID-CNCR2820660113>3.0.CO;2-E; LENSSEN P, 1987, JPEN-PARENTER ENTER, V11, P112, DOI 10.1177/0148607187011002112; MACLENNAN PA, 1988, FEBS LETT, V237, P133, DOI 10.1016/0014-5793(88)80186-8; MCDONALD GB, 1986, GASTROENTEROLOGY, V90, P460, DOI 10.1016/0016-5085(86)90949-2; MEYERS JD, 1990, SEMIN ONCOL, V17, P10; MEYERS JD, 1991, PRINCIPLES PRACTICE, P2291; MONDZAC A, 1965, J LAB CLIN MED, V66, P526; MULDER POM, 1989, CANCER-AM CANCER SOC, V64, P2045, DOI 10.1002/1097-0142(19891115)64:10&lt;2045::AID-CNCR2820641013&gt;3.0.CO;2-H; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEWSHOLME EA, 1988, NUTRITION, V4, P261; ODWYER ST, 1987, CLIN RES, V35, pA369; ODWYER ST, 1989, JPEN-PARENTER ENTER, V13, P579, DOI 10.1177/0148607189013006579; PARRYBILLINGS M, 1990, LANCET, V336, P523, DOI 10.1016/0140-6736(90)92083-T; PETERSEN FB, 1986, JPEN-PARENTER ENTER, V10, P58, DOI 10.1177/014860718601000158; PIRSCH JD, 1986, ANN INTERN MED, V104, P619, DOI 10.7326/0003-4819-104-5-619; RABINOWE SN, 1990, BLOOD S, V76, pA167; REED MD, 1983, CANCER, V51, P1563, DOI 10.1002/1097-0142(19830501)51:9<1563::AID-CNCR2820510902>3.0.CO;2-Q; SCHMIDT GM, 1980, EXP HEMATOL, V8, P506; SCRIMSHAW NS, 1959, AM J MED SCI, V237, P367; SHELDON GF, 1978, ARCH SURG-CHICAGO, V113, P504; SJOLIN J, 1989, AM J CLIN NUTR, V49, P62; SMITH RJ, 1985, J LIQ CHROMATOGR, V8, P1783, DOI 10.1080/01483918508074095; STEHLE P, 1989, LANCET, V1, P231; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; SZELUGA DJ, 1987, CANCER RES, V47, P3309; SZELUGA DJ, 1985, JPEN-PARENTER ENTER, V9, P139, DOI 10.1177/0148607185009002139; THOMAS ED, 1984, ANNU REV MED, V35, P1; WALSER M, 1991, AM J CLIN NUTR, V53, P1337, DOI 10.1093/ajcn/53.6.1337; WASSNER SJ, 1980, ANAL BIOCHEM, V104, P284, DOI 10.1016/0003-2697(80)90076-7; WEISDORF S, 1984, J PEDIATR GASTR NUTR, V3, P95, DOI 10.1097/00005176-198401000-00020; WEISDORF SA, 1987, TRANSPLANTATION, V43, P833, DOI 10.1097/00007890-198743060-00012; WELBOURNE TC, 1987, AM J PHYSIOL, V253, pF1069, DOI 10.1152/ajprenal.1987.253.6.F1069; WHITE LJ, 1989, ANN INTERN MED, V110, P734; WILMORE DW, 1983, NUTRITIONAL SUPPORT, P33; WILMORE DW, 1980, METABOLIC MANAGEMENT; WINDMUELLER HG, 1982, ADV ENZYMOL RAMB, V53, P201; ZIEGLER TR, 1990, JPEN-PARENTER ENTER, V14, pS137, DOI 10.1177/0148607190014004201	52	555	568	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					821	828		10.7326/0003-4819-116-10-821	http://dx.doi.org/10.7326/0003-4819-116-10-821			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567096				2022-12-28	WOS:A1992HT80200006
J	GILLMAN, MW; OLIVERIA, SA; MOORE, LL; ELLISON, RC				GILLMAN, MW; OLIVERIA, SA; MOORE, LL; ELLISON, RC			INVERSE ASSOCIATION OF DIETARY CALCIUM WITH SYSTOLIC BLOOD-PRESSURE IN YOUNG-CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTENSION; CHILDHOOD	Objective.-To investigate the association of dietary calcium with blood pressure in young children. Design.-Cohort. Setting.-General community. Subjects.-Eighty-nine boys and girls, aged 3 to 6 years, from The Framingham Children's Study. Measurements.-During the first year of the study, we derived nutrient data from multiple food diaries (a mean of 9.6 days of recording for each subject). At the beginning of the second year of the study, we obtained anthropometric data and up to five blood pressure readings (mean, 4.5) on each child at a single sitting. Results.-The range of subjects' average daily calcium intake was 4.9 to 19.6 mmol per 4200 kJ, with a mean of 12.8 mmol per 4200 kJ. Subjects' average systolic blood pressure ranged from 73 to 129 mm Hg, with a mean of 95.9 mm Hg; for diastolic blood pressure, the range was 37 to 78 mm Hg, mean 54.6 mm Hg. Multiple linear regression analysis, adjusted for the effects of sex, height, body mass index, and heart rate, showed that for each increment of 2.5 mmol of dietary calcium per 4200 kJ per day, systolic blood pressure was 2.27 mm Hg lower (95% confidence interval, 0.63 to 3.91 mm Hg; P = .008). We found no such association for diastolic blood pressure. Conclusion.-Dietary calcium is inversely related to systolic blood pressure in young children.			GILLMAN, MW (corresponding author), BOSTON UNIV,SCH MED,EVANS SECT PREVENT MED & EPIDEMIOL,B-612,88 E NEWTON ST,BOSTON,MA 02118, USA.			Moore, Lynn/0000-0002-1028-919X; Ellison, Robert Curtis/0000-0002-0582-7467	NHLBI NIH HHS [HL 35653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT BS, 1987, CIRCULATION, V76, P360; [Anonymous], 1987, PEDIATRICS, V79, P1; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; DAHL LK, 1970, P SOC EXP BIOL MED, V133, P1405, DOI 10.3181/00379727-133-34700; DEURENBERG P, 1990, BRIT J NUTR, V63, P293, DOI 10.1079/BJN19900116; ELLISON RC, 1984, AM J EPIDEMIOL, V120, P542, DOI 10.1093/oxfordjournals.aje.a113915; GILLMAN M, 1991, AM J EPIDEMIOL, V134, P730; GILLMAN MW, 1991, PEDIATRICS, V87, P708; JENNER DA, 1988, AM J CLIN NUTR, V47, P1052, DOI 10.1093/ajcn/47.6.1052; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; LAUER RM, 1989, PEDIATRICS, V84, P633; LEE D, 1957, AM J CLIN NUTR, V5, P166, DOI 10.1093/ajcn/5.2.166; LIEBMAN M, 1986, HYPERTENSION, V8, P843, DOI 10.1161/01.HYP.8.10.843; MARMOR JK, 1991, J CLIN EPIDEMIOL, V44, P531, DOI 10.1016/0895-4356(91)90216-V; MCCARRON DA, 1989, KIDNEY INT, V35, P717, DOI 10.1038/ki.1989.44; MCCARRON DA, 1991, AM J CLIN NUTR, V54, pS215, DOI 10.1093/ajcn/54.1.215S; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; MOORE LL, 1991, J PEDIATR-US, V118, P215, DOI 10.1016/S0022-3476(05)80485-8; NICKLAS TA, 1990, FOOD SOURCES NUTRIEN; ROSNER B, 1987, AM J EPIDEMIOL, V126, P1115, DOI 10.1093/oxfordjournals.aje.a114750; ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811; SOWERS JR, 1989, J LAB CLIN MED, V114, P338; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WITSCHI J, 1981, J AM DIET ASSOC, V78, P609; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; 1991, NIH912732 US DEP HLT	27	53	54	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2340	2343		10.1001/jama.267.17.2340	http://dx.doi.org/10.1001/jama.267.17.2340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564773				2022-12-28	WOS:A1992HR01500026
J	GUMBINER, BM				GUMBINER, BM			EPITHELIAL MORPHOGENESIS	CELL			English	Review							CELL; GASTRULATION; INDUCTION; EMBRYOS				GUMBINER, BM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.							Bard J. B. L., 1990, MORPHOGENESIS CELLUL; Bernfield M, 1984, ROLE EXTRACELLULAR M, P542; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CONDIC ML, 1991, DEVELOPMENT, V111, P23; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; HIRAI Y, 1992, CELL, V69; KELLER R, 1987, ZOOL SCI, V4, P763; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P719; Small JV, 1989, CURR OPIN CELL BIOL, V1, P75, DOI 10.1016/S0955-0674(89)80040-7; SMITH JC, 1990, DEVELOPMENT, V108, P229; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; WINKEL GK, 1990, DEV BIOL, V138, P1, DOI 10.1016/0012-1606(90)90171-E; WYLIE C, 1990, NATURE, V347, P337, DOI 10.1038/347337a0	21	194	202	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					385	387		10.1016/0092-8674(92)90440-N	http://dx.doi.org/10.1016/0092-8674(92)90440-N			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581959				2022-12-28	WOS:A1992HT07800001
J	DOHERTY, P; MOOLENAAR, CECK; ASHTON, SV; MICHALIDES, RJAM; WALSH, FS				DOHERTY, P; MOOLENAAR, CECK; ASHTON, SV; MICHALIDES, RJAM; WALSH, FS			THE VASE EXON DOWN-REGULATES THE NEURITE GROWTH-PROMOTING ACTIVITY OF NCAM-140	NATURE			English	Article							CELL-ADHESION MOLECULE; N-CAM; HOMOPHILIC BINDING; NERVOUS-SYSTEM; MUSCLE; OUTGROWTH; MECHANISM; BRAIN	AXONAL growth, guidance and synapse formation are controlled by receptors on neuronal growth cones that can recognize positive and inhibitory cues in the local microenvironment 1-3 . Four well characterized receptor systems are known that recognize the growth-promoting activities associated with the extracellular matrix and the membranes of cells such as astrocytes, muscle cells and Schwann cells; these are the integrins 4 and the homophilically binding cell adhesion molecules neural-cell adhesion molecule (NCAM), N-cadherin and L1 (refs 5-12). Alternative splicing generates 20-30 isoforms of NCAM and these can also be differentially glycosylated 13. There are two sites where alternative splicing changes the extracellular structure of membrane-bound NCAM and one of these (the MSD1 region) does not obviously affect function 6. Here we report that the variable alternatively spliced exon (VASE) in immunoglobulin domain 4 downregulates the neurite outgrowth-promoting activity of NCAM. The high level of VASE expression in the adult central as compared with peripheral nervous system 21 could contribute to the poor regenerative capacity of the former.	NETHERLANDS CANC INST,DEPT TUMOR BIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	DOHERTY, P (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		Doherty, Patrick/A-8752-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; CHUONG CM, 1984, J NEUROSCI, V4, P2354; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; Doherty P, 1989, CURR OPIN CELL BIOL, V1, P1102, DOI 10.1016/S0955-0674(89)80057-2; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MOOLENAAR CE, IN PRESS INT J CANCE; PATEL K, 1991, BRIT J CANCER, V63, P20; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; PREDIGER EA, 1988, P NATL ACAD SCI USA, V85, P9616, DOI 10.1073/pnas.85.24.9616; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271	30	144	146	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					791	793		10.1038/356791a0	http://dx.doi.org/10.1038/356791a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574117				2022-12-28	WOS:A1992HR18600049
J	KONIG, R; HUANG, LY; GERMAIN, RN				KONIG, R; HUANG, LY; GERMAIN, RN			MHC CLASS-II INTERACTION WITH CD4 MEDIATED BY A REGION ANALOGOUS TO THE MHC CLASS-I BINDING-SITE FOR CD8	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL HYBRIDOMA; DIRECTED MUTAGENESIS; SURFACE EXPRESSION; LYMPHOCYTES-T; MOLECULES; ANTIGENS; GENE; RECOGNITION; L3T4	INTERACTIONs between major histocompatibility complex (MHC) molecules and the CD4 or CD8 coreceptors have a major role in intrathymic T-cell selection 1. On mature T cells, each of these two glycoproteins is associated with a class-specific bias in MHC molecule recognition by the T-cell receptor. CD4+ T cells respond to antigen in association with MHC class II molecules and CD8+ T cells respond to antigen in association with MHC class I molecules. Physical interaction between the CD4/MHC class II molecules and CD8/MHC class I molecules has been demonstrated by cell adhesion assay 2-5, and a binding site for CD8 on class I has been identified 6,7. Here we demonstrate that a region of the MHC class II beta-chain beta-2-domain, structurally analogous to the CD8-binding loop in the MHC class I alpha-3 domain, is critical for function with both mouse and human CD4.			KONIG, R (corresponding author), NIAID, IMMUNOL LAB, LYMPHOCYTE BIOL SECT, BETHESDA, MD 20892 USA.		Konig, Rolf/B-3128-2008; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DALBADIEMCFARLAND G, 1982, P NATL ACAD SCI-BIOL, V79, P6409, DOI 10.1073/pnas.79.21.6409; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDING H, 1985, NATURE, V317, P425, DOI 10.1038/317425a0; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LOMBARDI G, 1991, J IMMUNOL, V147, P2034; MARGULIES DH, 1983, J IMMUNOL, V130, P463; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RONCHESE F, 1987, J IMMUNOL, V139, P629; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; TRAVERS P, 1984, NATURE, V310, P235, DOI 10.1038/310235a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	37	322	326	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1992	356	6372					796	798		10.1038/356796a0	http://dx.doi.org/10.1038/356796a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574118				2022-12-28	WOS:A1992HR18600051
J	EMANUEL, EJ; EMANUEL, LL				EMANUEL, EJ; EMANUEL, LL			4 MODELS OF THE PHYSICIAN-PATIENT RELATIONSHIP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATERNALISM		HARVARD UNIV,JOHN F KENNEDY SCH GOVT,PROGRAM ETH & PROFESS,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DIV MED ETH,BOSTON,MA 02115; AMER COLL PHYSICIANS,PHILADELPHIA,PA	Harvard University; Harvard University; Harvard Medical School; American College of Physicians	EMANUEL, EJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.							[Anonymous], 1986, HIST THEORY INFORM C; APPELBAUM PS, 1987, INFORMED CONSENT LEG, pCH2; BALLANTINE HT, 1979, NEW ENGL J MED, V301, P634, DOI 10.1056/NEJM197909203011204; BRANDT AM, 1978, HASTINGS CENT REP, V8, P21, DOI 10.2307/3561468; BROCK DW, 1990, NEW ENGL J MED, V322, P1595, DOI 10.1056/NEJM199005313222209; BROCK DW, 1991, KENNEDY INST ETHIC J, V1, P28; BURKE G, 1980, PRIMARY CARE, V7, P615; DWORKIN G, 1988, THEORY PRACTICE AUTO, pCH1; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; Frankfurt, 1971, J PHILOS, DOI [10.2307/2024717, DOI 10.2307/2024717]; FRIED C, 1976, YALE LAW J, V85, P1060, DOI 10.2307/795584; GOROVITZ S, 1982, DOCTORS DILEMMAS MOR, pCH6; INGELFINGER FJ, 1973, NEW ENGL J MED, V288, P791, DOI 10.1056/NEJM197304122881514; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; JONES JH, 1981, BAD BLOOD; Katz J., 1984, SILENT WORLD DOCTOR; KRUGMAN S, 1970, J AMER MED ASSOC, V212, P1019, DOI 10.1001/jama.212.6.1019; MacIntyre A., 2007, AFTER VIRTUE, V3rd; MACKLIN R, 1987, MORTAL CHOICES; MARZUK PM, 1985, NEW ENGL J MED, V313, P1474, DOI 10.1056/NEJM198512053132310; Plato Edith, 1961, BOLLINGEN SERIES, V71; Sandel M., 1982, LIBERALISM LIMITS JU; SIEGLER M, 1985, ARCH INTERN MED, V145, P713, DOI 10.1001/archinte.145.4.713; Stone A. A., 1976, MENTAL HLTH LAW SYST; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; TANNOCK IF, 1990, NEW ENGL J MED, V323, P989, DOI 10.1056/NEJM199010043231410; TAYLOR C, 1985, HUMAN AGENCY LANGUAG, P15; TSSAHA Panel, 1973, FINAL REPORT TUSKEGE; VEATCH RM, 1908, THEORY MED ETHICS; VEATCH RM, 1975, HASTINGS CENT REP, V2, P3; WALSH DC, 1992, JAMA-J AM MED ASSOC, V267, P663, DOI 10.1001/jama.267.5.663; Weber M., 1947, THEORY SOCIAL EC ORG; 1982, MAEKING HLTH CARE DE	33	1322	1349	1	96	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2221	2226		10.1001/jama.267.16.2221	http://dx.doi.org/10.1001/jama.267.16.2221			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556799				2022-12-28	WOS:A1992HN84100033
J	MCCORMICK, MC; BROOKSGUNN, J; WORKMANDANIELS, K; TURNER, J; PECKHAM, GJ				MCCORMICK, MC; BROOKSGUNN, J; WORKMANDANIELS, K; TURNER, J; PECKHAM, GJ			THE HEALTH AND DEVELOPMENTAL STATUS OF VERY-LOW-BIRTH-WEIGHT CHILDREN AT SCHOOL AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL DEMONSTRATION PROGRAM; PATENT DUCTUS-ARTERIOSUS; PERINATAL SERVICES; PREMATURE-INFANTS; BEHAVIOR PROBLEMS; 1000 GRAMS; FOLLOW-UP; REGIONALIZATION; INDOMETHACIN; MULTICENTER	Objective. - To assess the effect of improved survival of increasingly premature infants by examining the outcomes at school age of a large group of children born at different birth weights. Design. - Inception cohort. Setting/Participants. - Participants were selected from two previously studied multisite cohorts: very low-birth-weight (less-than-or-equal-to 1500 g) children referred to participating intensive care units and heavier birth-weight children drawn from a stratified random sample of births in geographically defined regions. Follow-up at 8 to 10 years of age was by a combination of telephone interview and home/clinic visits for 65.1% (1868) of those eligible. Main Outcome Measures. - The presence or absence of 17 specific conditions, limitations in activities of daily living due to health, mental health (affective health, behavior problems), and, for a subset, 10 scores. Results. - Decreasing birth weight was associated with an increased morbidity for all measures except affective health; those with birth weights of 1500 g or less were more likely to experience multiple health problems. Maternal educational attainment did not influence the association of birth weight with morbidity except for IQ among children whose birth weight was above 1000 g, for which socioeconomic disadvantage worsened the status of all children irrespective of birth weight. Conclusions. - Children born at lower birth weights experience increased morbidity at early school age. These results reinforce the importance of postdischarge, early intervention programs to reduce the risk of these later health problems.	HARVARD UNIV,SCH MED,DEPT PEDIAT,JOINT PROGRAM NEONATOL,BOSTON,MA 02115; COLUMBIA UNIV,NEW YORK,NY 10027; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV NEONATOL,PHILADELPHIA,PA	Harvard University; Harvard Medical School; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	MCCORMICK, MC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			McCormmick, Marie/0000-0002-3938-1707	NICHD NIH HHS [N01-HD-5-2928] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD052928] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; AYLWARD GP, 1985, J DEV BEHAV PEDIATR, V6, P3; BLAYNEY M, 1991, J PEDIATR-US, V118, P201, DOI 10.1016/S0022-3476(05)80483-4; BUEHLER JW, 1987, PUBLIC HEALTH REP, V102, P151; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; DARLINGTON RB, 1980, SCIENCE, V208, P202, DOI 10.1126/science.208.4440.202; DEAN JA, 1988, EPI INFO VERSION 3; DEGRAW C, 1988, J PEDIATR-US, V113, P971, DOI 10.1016/S0022-3476(88)80565-1; EISEN M, 1984, RAND R2313HEW; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; GERSONY WM, 1983, J PEDIATR-US, V102, P895, DOI 10.1016/S0022-3476(83)80022-5; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; GOUDY WJ, 1985, J GERONTOL, V40, P358, DOI 10.1093/geronj/40.3.358; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; HOY EA, 1988, INT J BEHAV DEV, V11, P37, DOI 10.1177/016502548801100104; HUNT JV, 1988, PEDIATRICS, V82, P596; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; KLOCKARS AJ, 1986, QUANTITATIVE APPLICA, V61; LASKY RE, 1987, AM J DIS CHILD, V141, P100, DOI 10.1001/archpedi.1987.04460010100037; McCormick M C, 1991, Paediatr Perinat Epidemiol, V5, P410, DOI 10.1111/j.1365-3016.1991.tb00727.x; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCCORMICK MC, 1985, JAMA-J AM MED ASSOC, V253, P799; MCCORMICK MC, 1990, J PEDIATR-US, V117, P687, DOI 10.1016/S0022-3476(05)83322-0; MUTCH LMM, 1989, ARCH DIS CHILD, V64, P1394, DOI 10.1136/adc.64.10_Spec_No.1394; NORTHWAY WH, 1990, NEW ENGL J MED, V323, P1793, DOI 10.1056/NEJM199012273232603; OVERPECK MD, 1989, PUBLIC HEALTH REP, V104, P58; PECKHAM GJ, 1984, J PEDIATR-US, V105, P285, DOI 10.1016/S0022-3476(84)80134-1; PETERSON JL, 1986, J MARRIAGE FAM, V48, P295, DOI 10.2307/352397; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; SAIGAL S, 1990, J PEDIATR-US, V116, P409, DOI 10.1016/S0022-3476(05)82835-5; SAIGAL S, 1989, J PEDIATR-US, V114, P839, DOI 10.1016/S0022-3476(89)80150-7; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SHAPIRO S, 1980, AM J OBSTET GYNECOL, V136, P363, DOI 10.1016/0002-9378(80)90863-7; SHONKOFF JP, 1987, PEDIATRICS, V80, P650; TEPLIN SW, 1991, J PEDIATR-US, V118, P768, DOI 10.1016/S0022-3476(05)80045-9; Wechsler DW., 1999, INTELLIGENCE SCALE C; WEGMAN ME, 1989, PEDIATRICS, V84, P943; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1987, HLTH TECHNOLOGY CASE, V38; 1991, J PEDIATR, V118, P761; 1988, SAS STAT USERS GUIDE; 1982, VITAL HLTH STATIS 10, V141	44	240	241	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2204	2208		10.1001/jama.267.16.2204	http://dx.doi.org/10.1001/jama.267.16.2204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HN841	1556798				2022-12-28	WOS:A1992HN84100030
J	HAMBLETON, P; COHEN, HE; PALMER, BJ; MELLING, J				HAMBLETON, P; COHEN, HE; PALMER, BJ; MELLING, J			ANTITOXINS AND BOTULINUM TOXIN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									PORTON DEV LTD,MED & REGULATORY ADM,MAIDENHEAD SL6 4UB,BERKS,ENGLAND		HAMBLETON, P (corresponding author), PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND.							ELSTON JS, 1988, EYE, V2, P12, DOI 10.1038/eye.1988.4; ELSTON JS, 1990, J PHYSIOLOGY PARIS, V84, P285; GARLAND PE, 1987, OPHTHALMOLOGY, V94, P288; STELL R, 1988, BRIT MED J, V297, P616, DOI 10.1136/bmj.297.6648.616; [No title captured]	5	43	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					959	960		10.1136/bmj.304.6832.959-a	http://dx.doi.org/10.1136/bmj.304.6832.959-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581719	Green Published, Bronze			2022-12-28	WOS:A1992HP06400023
J	JAY, PY; ELSON, EL				JAY, PY; ELSON, EL			SURFACE PARTICLE-TRANSPORT MECHANISM INDEPENDENT OF MYOSIN-II IN DICTYOSTELIUM	NATURE			English	Article							HEAVY-CHAIN; ACTIN; CELLS; DISCOIDEUM; FLOW; LAMELLIPODIA; GENERATION; RECEPTORS; AMEBAE	CELLULAR locomotion Could be driven by the rearward transport of membrane-bound particles observed on motile fibroblasts 1, keratinocytes 2 and neuronal growth cones 3. A force propelling free surface particles backwards could move the cell forwards if the particles were anchored to a rigid substratum. During capping, myosin II ('double-headed' myosin) draws crosslinked membrane proteins to the rear of a cell. The mhcA- mutant of the amoebal stage of the slime mould Dictyostelium discoideum, in which the myosin II gene has been deleted 4, cannot cap surface particles but can crawl along the substratum 5,6. Thus, the mechanism driving capping is not essential for locomotion. We show here that the null mutant is capable of a different type of active rearward transport, independent of myosin II and distinct from capping. The transported particles on mhcA- cells follow parallel paths. In the wild-type Ax2 strain, myosin II causes particles to converge towards a focal point and significantly increases the velocity of transport behind the leading edge of the cell.			JAY, PY (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110, USA.							BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; CARBONI JM, 1985, J CELL BIOL, V100, P1884, DOI 10.1083/jcb.100.6.1884; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; HELLIO R, 1985, J CELL SCI, V79, P327; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MOLDAY R, 1976, J CELL BIOL, V71, P314, DOI 10.1083/jcb.71.1.314; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1991, REV PHYSL, V53, P653; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	18	52	52	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					438	440		10.1038/356438a0	http://dx.doi.org/10.1038/356438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557126				2022-12-28	WOS:A1992HL83000065
J	NIENHUIS, H; GOLDACRE, M; SEAGROATT, V; GILL, L; VESSEY, M				NIENHUIS, H; GOLDACRE, M; SEAGROATT, V; GILL, L; VESSEY, M			INCIDENCE OF DISEASE AFTER VASECTOMY - A RECORD LINKAGE RETROSPECTIVE COHORT STUDY	BRITISH MEDICAL JOURNAL			English	Article							TESTICULAR CANCER; PROSTATE-CANCER; RISK; ATHEROSCLEROSIS; HEALTH; TESTIS	Objective - To determine whether vasectomy is associated with an increased risk of several diseases, and in particular testicular cancer, after operation. Design - Retrospective cohort study using linked medical record abstracts. Setting - Six health districts in Oxford region. Subjects - 13246 men aged 25-49 years who had undergone vasectomy between 1970 and 1986, and 22 196 comparison subjects who had been admitted during the same period for one of three specified elective operations, appendicitis, or injuries. Main outcome measures - Hospital admission and death after vasectomy or comparison event. Results - The mean durations of follow up were 6.6 years for men with a vasectomy and 7.5 years for men with a comparison condition. The relative risk of cancer of the testis in the vasectomy cohort (4 cases) compared with that in the other cohorts (17 cases) was 0.46 (95% confidence interval 0.1 to 1.4), that of cancer of the prostate (1 v 5 cases) 0.44 (0.1 to 4-0), and that of myocardial infarction (97 v 226 cases) 1.00 (0.8 to 1.3). There was no evidence of an increase associated with vasectomy in the incidence of a range of other diseases. Conclusion - Vasectomy was not associated with an increased risk of testicular cancer or the other diseases studied. With respect to prostatic cancer, while we found no cause for concern, longer periods of observation on large numbers of men are required.	UNIV OXFORD,CLIN EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND	University of Oxford; Radcliffe Infirmary; University of Oxford								Acheson E.D., 1967, MED RECORD LINKAGE; ALEXANDER NJ, 1978, SCIENCE, V201, P538, DOI 10.1126/science.96532; CALE ARJ, 1990, BRIT MED J, V300, P370, DOI 10.1136/bmj.300.6721.370; CHI IC, 1990, INT J EPIDEMIOL, V19, P32, DOI 10.1093/ije/19.1.32; CLARKSON TB, 1980, J CLIN INVEST, V65, P15, DOI 10.1172/JCI109645; GILL LE, 1987, TXB MED RECORD LINKA, P39; GOLDACRE M, 1979, VASECTOMY IMMUNOLOGI, P567; GOLDACRE MJ, 1983, NEW ENGL J MED, V308, P805, DOI 10.1056/NEJM198304073081403; GOLDACRE MJ, 1985, RECENT ADV COMMUNITY, P242; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; KRONMAL RA, 1988, LANCET, V1, P22; LEPOW IH, 1979, VASECTOMY IMMUNOLOGI; LINNET L, 1983, UROLOGY, V22, P101, DOI 10.1016/0090-4295(83)90487-9; MASSEY FJ, 1984, JAMA-J AM MED ASSOC, V252, P1023, DOI 10.1001/jama.252.8.1023; MCDONALD SW, 1990, BRIT MED J, V301, P618, DOI 10.1136/bmj.301.6753.618; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; MUIR C, 1987, CANCER INCIDENCE 5 C, V5, P660; PERRIN EB, 1984, AM J PUBLIC HEALTH, V74, P128, DOI 10.2105/AJPH.74.2.128; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SELLAR C, 1990, J EPIDEMIOL COMMUN H, V44, P313, DOI 10.1136/jech.44.4.313; SIDNEY S, 1987, J UROLOGY, V138, P795, DOI 10.1016/S0022-5347(17)43377-5; STRADER CH, 1988, AM J EPIDEMIOL, V128, P56, DOI 10.1093/oxfordjournals.aje.a114958; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; TANG GH, 1988, INT J EPIDEMIOL, V17, P608; THORNHILL JA, 1988, EUR UROL, V14, P429; WALKER AM, 1981, JAMA-J AM MED ASSOC, V245, P2315, DOI 10.1001/jama.245.22.2315	28	61	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					743	746		10.1136/bmj.304.6829.743	http://dx.doi.org/10.1136/bmj.304.6829.743			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571679	Green Published, Bronze			2022-12-28	WOS:A1992HK80000019
J	COCKBURN, J; RUTH, D; SILAGY, C; DOBBIN, M; REID, Y; SCOLLO, M; NACCARELLA, L				COCKBURN, J; RUTH, D; SILAGY, C; DOBBIN, M; REID, Y; SCOLLO, M; NACCARELLA, L			RANDOMIZED TRIAL OF 3 APPROACHES FOR MARKETING SMOKING CESSATION PROGRAMS TO AUSTRALIAN GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article							INTERVENTION; HELP	Objective - To compare three approaches for marketing a quit smoking intervention kit to general practitioners. Design - Randomised trial of (a) personal delivery and presentation by an educational facilitator with a follow up visit six weeks later; (b) delivery to the receptionist by a friendly volunteer courier with a follow up phone call six weeks later, or (c) postal delivery with a follow up letter six weeks later. Setting - Melbourne, Australia. Subjects - 264 randomly selected general practitioners. Data collection - A research assistant visited each doctor four months after delivery and measured use of components of the kit. A questionnaire measuring perceptions of aspects of the kit and its delivery was completed by doctors. Costs of each approach were calculated. Results - Doctors receiving the educational facilitator approach were significantly more likely than those receiving the other two approaches to have seen the kit, to rate the method of delivery as engendering motivation to try the kit, to have used one of the "intensive intervention" components from the kit, to report that they found the kit less complicated, and to report greater knowledge of how to use the kit. There were no significant differences in use of "minimal intervention" components of the kit, ratings of overall acceptability of delivery, perceptions of cultural and structural barriers to using the kit, and ratings of the overall acceptability of the kit. The cost of the educational facilitator approach ($A142/doctor) was 24 times that of the mailed approach. The volunteer courier approach ($A14) was twice the cost of the mailed approach. Conclusion - Educational facilitators and volunteer couriers do not seem to be cost effective strategies for distributing smoking interventions.	VICTORIAN SMOKING & HLTH PROGRAM,MELBOURNE,AUSTRALIA; MONASH UNIV,DEPT COMMUNITY MED,CLAYTON,VIC 3168,AUSTRALIA; MONASH UNIV,DEPT SOCIAL & PREVENT MED,CLAYTON,VIC 3168,AUSTRALIA	Monash University; Monash University	COCKBURN, J (corresponding author), ANTI CANC COUNCIL VICTORIA,CTR BEHAV RES CANC,CARLTON,VIC 3053,AUSTRALIA.							AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BORLAND R, 1991, QUIT EVALUATION STUD, V5; COPEMAN RC, 1989, MED J AUSTRALIA, V151, P83, DOI 10.5694/j.1326-5377.1989.tb101167.x; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DICKINSON JA, 1989, MED J AUSTRALIA, V150, P420, DOI 10.5694/j.1326-5377.1989.tb136560.x; FOWLER G, 1989, LANCET, V1, P1253; GLYNN T J, 1989, Health Education Research, V4, P479, DOI 10.1093/her/4.4.479; GREENWOOD J, 1989, HLTH ACTION INT NEWS, V48, P1; HELMSTADTER GC, 1984, PRINCIPLES PSYCHOL M; MAGUIRE P, 1978, PSYCHOL MED, V8, P695, DOI 10.1017/S0033291700018894; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; RICHMOND RL, 1986, BMJ-BRIT MED J, V292, P803, DOI 10.1136/bmj.292.6523.803; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SILAGY C, 1989, MED J AUSTRALIA, V151, P486, DOI 10.5694/j.1326-5377.1989.tb101275.x; SLAMA K, 1988, THESIS U NEWCASTLE N; WILSON DH, 1990, MED J AUSTRALIA, V152, P518, DOI 10.5694/j.1326-5377.1990.tb125351.x; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; 1989, US PREVENTION TASK F, P289; 1984, AUSTR HLTH SURVEY 19	19	60	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					691	694		10.1136/bmj.304.6828.691	http://dx.doi.org/10.1136/bmj.304.6828.691			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK761	1571645	Green Published, Bronze			2022-12-28	WOS:A1992HK76100028
J	ENDE, J; DAVIDOFF, F				ENDE, J; DAVIDOFF, F			WHAT IS A CURRICULUM	ANNALS OF INTERNAL MEDICINE			English	Article								Dissatisfaction with the current internal medicine residency experience has led to proposals for various new curricula. Unfortunately, the more basic question of "What is a curriculum?" or more accurately, "What curriculum model is most appropriate for clinical training?" has remained largely unexamined. The dominant curriculum model, although valuable, may not be adequate for the task. In its place we propose an experiential model that is more congruent with the realities of graduate medical education.	AMER COLL PHYSICIANS, INDEPENDENCE MALL W, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	American College of Physicians; University of Pennsylvania								ATKINS E, 1991, J CURRICULUM SUPERVI, V6, P312; BARKER LR, 1990, J GEN INTERN MED, V5, pS3, DOI 10.1007/BF02600433; BORDAGE G, 1991, ACAD MED, V66, pS70, DOI 10.1097/00001888-199109000-00045; Brookfield S. D., 1990, UNDERSTANDING FACILI; Daloz L.S., 1986, EFFECTIVE TEACHING M; DAVIDOFF F, 1989, ANN INTERN MED, V110, P757, DOI 10.7326/0003-4819-110-10-757; DAVIDOFF F, 1990, 2ND P HRSA PRIM CAR, P233; Eisner E. W., 1974, CONFLICTING CONCEPTI, P1; EISNER EW, 1985, ED IMAGINATION DESIG, P115; Elstein AS, 1978, MED PROBLEM SOLVING; Jarvis P., 1987, ADULT LEARNING SOCIA; KASSIRER JP, 1992, NEW ENGL J MED, V326, P60, DOI 10.1056/NEJM199201023260112; Kolb D., 1984, EXPT LEARNING; LUDMERER KM, 1985, LEARNING HEAL DEV AM, P16; McNeil J. D., 1985, CURRICULUM COMPREHEN; Perkins D., 1989, EDUC RESEARCHER, V18, P16, DOI [DOI 10.3102/0013189X018001016, 10.3102/0013189X018001016]; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; Schon Donald A., 1988, ED REFLECTIVE PRACTI; 1991, CAREERS INTERNAL MED, V7, P10	19	22	22	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1055	1057		10.7326/0003-4819-116-12-1055	http://dx.doi.org/10.7326/0003-4819-116-12-1055			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586115				2022-12-28	WOS:A1992HY79400005
J	GOLD, W; VELLEND, H; BRUNTON, J				GOLD, W; VELLEND, H; BRUNTON, J			THE AIR CRESCENT SIGN CAUSED BY STAPHYLOCOCCUS-AUREUS LUNG INFECTION IN A NEUTROPENIC PATIENT WITH LEUKEMIA	ANNALS OF INTERNAL MEDICINE			English	Note						LEUKEMIA, LYMPHOCYTIC, ACUTE; NEUTROPENIA; AIR CRESCENT SIGN; STAPHYLOCOCCUS-AUREUS; LUNG DISEASES	ASPERGILLOSIS	The radiographic air crescent sign has been associated with both infectious and noninfectious clinical conditions. Pulmonary aspergilloma is the most frequent cause of this radiographic sign. In the neutropenic host, angioinvasive fungal infection, usually with Aspergillus species, is the most common cause of this radiologic abnormality. We report the case of a patient with acute lymphoblastic leukemia who developed the air crescent sign as a result of lung infection with Staphylococcus aureus.	TORONTO HOSP, DEPT MICROBIOL & INFECT DIS,DIV GEN, 200 ELIZABETH ST,NUW 13-124, TORONTO M5G 2C4, ONTARIO, CANADA; MT SINAI HOSP, TORONTO M5G 1X5, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto								Albelda SM., 1988, PULMONARY DIS DISORD, P1639; BARD R, 1975, RESPIRATION, V32, P247; CURTIS AM, 1979, RADIOLOGY, V133, P17, DOI 10.1148/133.1.17; FUNADA H, 1984, CANCER, V53, P2721, DOI 10.1002/1097-0142(19840615)53:12&lt;2721::AID-CNCR2820531228&gt;3.0.CO;2-Y; GEFTER WB, 1985, RADIOLOGY, V157, P605, DOI 10.1148/radiology.157.3.4059547; GOLD W, 1992, ANN INTERN MED, V116, P910, DOI 10.7326/0003-4819-116-11-910; PRZYJEMSKI C, 1980, CANCER, V46, P1701, DOI 10.1002/1097-0142(19801001)46:7&lt;1701::AID-CNCR2820460733&gt;3.0.CO;2-4; SLEVIN ML, 1982, THORAX, V37, P554, DOI 10.1136/thx.37.7.554	8	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					910	911		10.7326/0003-4819-116-11-910	http://dx.doi.org/10.7326/0003-4819-116-11-910			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580448				2022-12-28	WOS:A1992HW13700006
J	DIFFLEY, JFX; COCKER, JH				DIFFLEY, JFX; COCKER, JH			PROTEIN DNA INTERACTIONS AT A YEAST REPLICATION ORIGIN	NATURE			English	Article							NUCLEASE-SENSITIVE REGIONS; SACCHAROMYCES-CEREVISIAE; CHROMATIN; ARS1; PURIFICATION; INITIATION; SEQUENCES; SILENCER	AN understanding of the protein-DNA interactions in vivo at origins of DNA replication in eukaryotes is essential to delineate the mechanism of initiation of DNA synthesis and its control in the cell cycle 1,2. In the yeast Saccharomyces cerevisiae, a family of sequences known as autonomously replicating sequences (ARSs) function as origins of bidirectional DNA replication on plasmids and, in several instances, also in their normal chromosomal location 3. Here we use nucleotide resolution genomic footprinting to investigate the association of proteins with ARS1. Nuclease protection patterns indicate that at least two different cellular factors interact with functional elements in ARS1. The first seems to be ARS-binding factor 1. The second seems to be a novel protein that generates extensive protection over the essential ARS consensus sequence and phased DNaseI-sensitive sites across a functionally important flanking sequence. Hypersensitivity of this region to cleavage by copper phenanthroline indicates that it is under torsional strain, analogous to that produced at transcriptional start sites by assembly of an initiation complex. The protection in situ is similar to that generated by the origin recognition complex (ORC) protein.			DIFFLEY, JFX (corresponding author), IMPERIAL CANC RES FUND, BLANCHE LANE, POTTERS BAR EN6 3LD, HERTS, ENGLAND.			Diffley, John/0000-0001-5184-7680				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CAMPBELL JL, IN PRESS MOL BIOL YE; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIFFLEY JFX, 1990, TRENDS GENET, V6, P426; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HUIBREGTSE JM, 1991, METHOD ENZYMOL, V194, P550; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Sambrook J, 1989, MOL CLONING LABORATO; SAWODOGO M, 1985, R G CELL, V43, P165; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1986, J MOL BIOL, V190, P177, DOI 10.1016/0022-2836(86)90291-3; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; van Holde KE., 1989, SPRINGER SERIES MOL; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; [No title captured]	33	321	324	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					169	172		10.1038/357169a0	http://dx.doi.org/10.1038/357169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579168				2022-12-28	WOS:A1992HU12200062
J	KRISHNA, S; BENAROCH, P; PILLAI, S				KRISHNA, S; BENAROCH, P; PILLAI, S			TETRAMERIC CELL-SURFACE MHC CLASS-I MOLECULES	NATURE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN; COMPLEX; MOUSE	PURIFIED major histocompatibility complex (MHC) class I molecules have been studied at high resolution by X-ray crystallography 1; the structure is a complex of a single heavy chain, a beta-2-microglobulin light chain and a tightly bound peptide moiety. We show here that complete MHC class I molecules are post-translationally assembled into tetramers (made up of four heavy chains and four beta-2-microglobulin units) and that this tetrameric species is expressed on the cell surface. The multivalent tetrameric structure of class I molecules can be reconciled with models of T-cell activation that invoke antigen-receptor crosslinking, as opposed to models that depend on an allosteric change.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KRISHNA, S (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET GRP,MOLEC IMMUNOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129, USA.			Benaroch, Philippe/0000-0002-2655-0129				BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRAUN J, 1983, J IMMUNOL, V130, P2113; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1981, J IMMUNOL, V127, P1691; MICHAELSON J, 1983, IMMUNOGENETICS, V17, P219, DOI 10.1007/BF00364409; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; OZATO K, 1980, J IMMUNOL, V125, P2473; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125	15	33	34	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					164	167		10.1038/357164a0	http://dx.doi.org/10.1038/357164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579167				2022-12-28	WOS:A1992HU12200060
J	MURAKAMI, M; TSUBATA, T; OKAMOTO, M; SHIMIZU, A; KUMAGAI, S; IMURA, H; HONJO, T				MURAKAMI, M; TSUBATA, T; OKAMOTO, M; SHIMIZU, A; KUMAGAI, S; IMURA, H; HONJO, T			ANTIGEN-INDUCED APOPTOTIC DEATH OF LY-1 B-CELLS RESPONSIBLE FOR AUTOIMMUNE-DISEASE IN TRANSGENIC MICE	NATURE			English	Article							ANTIBODY-SECRETING CELLS; LYMPHOCYTES-B; RHEUMATOID-FACTOR; SOMATIC MUTATION; CLONAL DELETION; DNA; MOUSE; AUTOANTIBODIES; ENUMERATION; LINEAGE	STUDIES on transgenic mice expressing immunoglobulins against self-antigens 1-6 have shown that self-tolerance is maintained by active elimination (clonal deletion) 1-3,7, functional inactivation (clonal anergy) 4,5,8 of self-reactive B cells, or a combination of both 6. We have established and characterized a transgenic mouse line expressing an anti-erythrocyte autoantibody 6. In contrast to other autoantibody transgenic lies, about 50% of the animals of this transgenic line suffer from autoimmune disease, indicating a loss of self-tolerance. Here we show that peritoneal Ly-1 B cells (also known as B-1 cells 9) are responsible for this autoimmune disease in our transgenic mice. A few self-reactive Ly-1 B cells that have somehow escaped the deletion mechanism expand in the peritoneum because of the absence of self-antigen. These Ly-1 B cells are eliminated in vivo by apoptosis once exposed to self-antigen. On the basis of these results we propose a novel autoantibody production mechanism whereby self-reactive B cells sequestered in compartments free of self-antigens may survive, proliferate and be activated for generation of pathogenic autoantibodies in autoimmune diseases.	KYOTO UNIV, FAC MED, DEPT INTERNAL MED 2, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, CTR MOLEC BIOL & GENET, SAKYO KU, KYOTO 606, JAPAN	Kyoto University; Kyoto University	MURAKAMI, M (corresponding author), KYOTO UNIV, FAC MED, DEPT MED CHEM, SAKYO KU, KYOTO 606, JAPAN.		Tsubata, Takeshi/AAI-7489-2021; Honjo, Tasuku/N-4470-2016	Tsubata, Takeshi/0000-0003-0760-1258; 				BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; CASALI P, 1989, J IMMUNOL, V143, P3476; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GIUSTI AM, 1987, P NATL ACAD SCI USA, V84, P2926, DOI 10.1073/pnas.84.9.2926; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P30; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1987, SCIENCE, V236, P81, DOI 10.1126/science.3105057; HARDY RR, 1986, IMMUNOL REV, V93, P53, DOI 10.1111/j.1600-065X.1986.tb01502.x; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313, DOI 10.1002/eji.1830161021; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; MARCOS MAR, 1989, EUR J IMMUNOL, V19, P2031, DOI 10.1002/eji.1830191110; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P2013, DOI 10.1073/pnas.79.6.2013; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SMITH HR, 1983, ANNU REV IMMUNOL, V1, P175, DOI 10.1146/annurev.iy.01.040183.001135; WILLIAMS JR, 1974, NATURE, V252, P754, DOI 10.1038/252754a0	32	270	270	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1992	357	6373					77	80		10.1038/357077a0	http://dx.doi.org/10.1038/357077a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1574128				2022-12-28	WOS:A1992HT22900062
J	FARROW, DC; HUNT, WC; SAMET, JM				FARROW, DC; HUNT, WC; SAMET, JM			GEOGRAPHIC-VARIATION IN THE TREATMENT OF LOCALIZED BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPARING TOTAL MASTECTOMY; SMALL-AREA VARIATIONS; HEALTH-CARE SERVICES; CAROTID ENDARTERECTOMY; OUTCOMES MOVEMENT; NEW-MEXICO; NEW-HAVEN; AGE; RADIOTHERAPY; PATTERNS	Background. Breast-conserving surgery followed by radiation therapy is as effective as modified radical mastectomy in treating women with localized breast cancer, as demonstrated by clinical trials reported during the 1980s. The extent to which breast-conserving surgery has been adopted in various regions of the United States is not known. Methods. We assessed variations in the use of breast-conserving surgery from 1983 to 1986 in 18,399 non-Hispanic white, 324 Hispanic, and 1174 black women with breast cancer in nine areas of the United States, using data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Results. The proportion of white women with localized breast cancer who underwent breast-conserving surgery ranged from 9.2 percent (Iowa) to 32.1 percent (Seattle) in 1983-1984 and from 19.6 percent (Iowa) to 41.5 percent (Seattle) in 1985-1986. Between 1983 and 1986, the use of breast-conserving surgery increased in each area, but the relative rankings of the areas changed little. The frequency of the use of breast-conserving surgery in black and Hispanic women was comparable to that in white women. The proportion of women who received radiation therapy after breast-conserving surgery also varied geographically and increased from 1983 to 1986 in all areas. Older women in all areas and black women in Atlanta and Detroit were less likely than other women to receive radiotherapy after breast-conserving surgery. Conclusions. There is marked variation in the United States in the use of breast-conserving surgery for localized breast cancer. The variation is not explained by demographic factors, although race and age affect the use of radiotherapy after breast-conserving surgery.	UNIV NEW MEXICO,MED CTR,CTR CANC,NEW MEXICO TUMOR REGISTRY,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,DEPT FAMILY & COMMUNITY MED,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico; University of New Mexico					AHRQ HHS [HS 06879] Funding Source: Medline; NCI NIH HHS [N01-CN-05228] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006879] Funding Source: NIH RePORTER; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005228] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAQUET CR, 1986, DHHS NIH862785 PUBL; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; DAWSON JH, 1987, JAMA-J AM MED ASSOC, V258, P2570, DOI 10.1001/jama.258.18.2570; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; KLEINMAN JC, 1983, MED CARE, V21, P1232, DOI 10.1097/00005650-198312000-00010; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; LEAPE LL, 1989, NEW ENGL J MED, V321, P653, DOI 10.1056/NEJM198909073211006; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; MOR V, 1985, J AM GERIATR SOC, V33, P585, DOI 10.1111/j.1532-5415.1985.tb06313.x; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RIES LAG, 1990, DDHS NIH902789 PUBL; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SAMET JM, 1987, J NATL CANCER I, V79, P457; SHAMBAUGH EM, 1977, DHEW NIH771448 PUBL; STEINFELD AD, 1989, J AM GERIATR SOC, V37, P335, DOI 10.1111/j.1532-5415.1989.tb05501.x; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; 1985, SAS USERS GUIDE STAT; 1988, NIH882789 PUBL	35	423	424	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1097	1101		10.1056/NEJM199204233261701	http://dx.doi.org/10.1056/NEJM199204233261701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552910				2022-12-28	WOS:A1992HP80000001
J	BODANSKY, HJ; STAINES, A; STEPHENSON, C; HAIGH, D; CARTWRIGHT, R				BODANSKY, HJ; STAINES, A; STEPHENSON, C; HAIGH, D; CARTWRIGHT, R			EVIDENCE FOR AN ENVIRONMENTAL-EFFECT IN THE ETIOLOGY OF INSULIN-DEPENDENT DIABETES IN A TRANSMIGRATORY POPULATION	BRITISH MEDICAL JOURNAL			English	Article							ASIAN CHILDREN; PREVALENCE; MELLITUS	Objective - To examine whether children of families moving from an area of low incidence of childhood diabetes to one which is higher show a corresponding rise in disease incidence. Design - Disease incidence study over 12 years. Setting - Bradford District Metropolitan Council area. Subjects - All subjects aged 0-16 years resident within the study area. Main outcome measures - The incidences of childhood diabetes in Asian and non-Asian families. Results - The incidence of diabetes in Asian children increased from 3.1/100000 per year in 1978-81 to 11.7/100000 per year in 1988-90 (chi-2 for trend = 4.95, df = 1, p = 0.026) whereas that for other children remained constant at 10.5/100000 per year. Over the entire study period rates were lower in Asian females (4.9/100000 per year) than in Asian males (8.8/100000 per year) whereas the reverse was true for other children (males 9.2/100000 per year; females 12.0/100000 per year) (test for common odds ratio: chi-2 = 3.81, df = 1, p = 0.052). Conclusions - Offspring of this transmigratory population had a rising incidence of childhood diabetes which was approaching that of the indigenous population. The data provide strong evidence for an environmental effect in the aetiology of insulin dependent diabetes.	UNIV LEEDS,LEUKAEMIA RES FUND,CTR CLIN EPIDEMIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; ST LUKES HOSP,DEPT PAEDIAT,BRADFORD,ENGLAND	University of Leeds	BODANSKY, HJ (corresponding author), GEN INFIRM,PROFESSORIAL MED UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Staines, Anthony/AFQ-7565-2022	Staines, Anthony/0000-0001-9161-1357				BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BODANSKY HJ, 1987, ARCH DIS CHILD, V62, P227, DOI 10.1136/adc.62.3.227; BURDEN AC, 1990, INT J DIABETES DEV C, V10, P8; GAMBLE DR, 1988, CLIN DIABETES; HELGASON T, 1981, LANCET, V2, P716; MARMOT G, 1989, ETHNIC FACTORS HLTH, P12; Menon PSN., 1990, INT J DIABETES DEV C, V10, P11; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; Payne R. W., 1987, GENSTAT 5 REFERENCE; REIJONEN H, 1990, DIABETOLOGIA, V33, P357, DOI 10.1007/BF00404640; SAMANTA A, 1987, DIABETIC MED, V4, P65, DOI 10.1111/j.1464-5491.1987.tb00832.x; SAMANTA A, 1990, LANCET, V335, P1341, DOI 10.1016/0140-6736(90)91219-Z; SIMMONS D, 1990, DIABETIC MED, V7, P238, DOI 10.1111/j.1464-5491.1990.tb01377.x; TONIOLO A, 1988, CLIN DIABETES; WALKER A, 1980, DIABETES, V29, P1036, DOI 10.2337/diabetes.29.12.1036; 1987, BMJ, V295, P479	17	140	144	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1020	1022		10.1136/bmj.304.6833.1020	http://dx.doi.org/10.1136/bmj.304.6833.1020			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586783	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200019
J	DARBY, SC; OLSEN, JH; DOLL, R; THAKRAR, B; BROWN, PD; STORM, HH; BARLOW, L; LANGMARK, F; TEPPO, L; TULINIUS, H				DARBY, SC; OLSEN, JH; DOLL, R; THAKRAR, B; BROWN, PD; STORM, HH; BARLOW, L; LANGMARK, F; TEPPO, L; TULINIUS, H			TRENDS IN CHILDHOOD LEUKEMIA IN THE NORDIC COUNTRIES IN RELATION TO FALLOUT FROM ATMOSPHERIC NUCLEAR-WEAPONS TESTING	BRITISH MEDICAL JOURNAL			English	Article							YOUNG-PEOPLE; MORTALITY; LEUKEMIA; CANCER	Objective - To obtain further information about the risks of childhood leukaemia after exposure to ionising radiation at low doses and low dose rates before or after birth or to the father's testes shortly before conception. Design - Observational study of trends in incidence of childhood leukaemia in relation to estimated radiation exposures due to fallout from atmospheric nuclear weapons testing during the 1950s and 1960s. Setting - Nordic countries. Subjects - Children aged under 15 years. Main outcome measures - Incidence rates of leukaemia by age at diagnosis, sex, country, and calendar year of diagnosis or year of birth; exposure category; relation between leukaemia and exposure for children aged 0-14 and 0-4 separately. Results - During the high fallout period the average estimated dose equivalent to the fetal red bone marrow was around 140-mu-Sv and the average annual testicular dose 140-mu-Sv. There was little evidence of increased incidence of leukaemia among children born in these years. Doses to the red bone marrow of a child after birth were higher, and during the high exposure period children would have been subjected to an additional dose equivalent of around 1500-mu-Sv, similar to doses received by children in several parts of central and eastern Europe owing to the Chernobyl accident and about 50% greater than the annual dose equivalent to the red bone marrow of a child from natural radiation. Leukaemia incidence and red marrow dose was not related overall, but rates of leukaemia in the high exposure period were slightly higher than in the surrounding medium exposure period (relative risk for ages 0-14: 1.07, 95% confidence interval 1.00 to 1.14; for ages 0-4: 1.11, 1.00 to 1.24). Conclusions - Current predicted risks of childhood leukaemia after exposure to radiation are not greatly underestimated for low dose rate exposures.	CANC REGISTRY NORWAY,INST EPIDEMIOL CANC RES,OSLO 3,NORWAY; DANISH CANC REGISTRY,DANISH CANC SOC,DK-2100 COPENHAGEN 0,DENMARK; NATL BOARD HLTH & WELF,SWEDISH CANC REGISTRY,S-10630 STOCKHOLM,SWEDEN; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,SF-00170 HELSINKI,FINLAND; ICELAND CANC REGISTRY,IS-125 REYKJAVIK,ICELAND	University of Oslo; Danish Cancer Society; National Board of Health & Welfare; Finnish Cancer Registry	DARBY, SC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.			Olsen, Jorgen Helge/0000-0001-9633-5662; Storm, Hans/0000-0001-7223-8198				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; DIONIAN J, 1987, NRPBR202; ETHERINGTON G, 1990, ENV CONTAMINATION FO, V2, P327; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HARVEY EB, 1985, NEW ENGL J MED, V312, P541, DOI 10.1056/NEJM198502283120903; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; MORREY M, 1988, EUR11523EN COMM EUR; Muirhead CR., 1989, J RADIOL PROTECT, V9, P209; PAYNE CD, 1986, GLIM SYSTEM RELEASE; PIFER JW, 1963, J NATL CANCER I, V31, P1333; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; STEVENS W, 1990, JAMA-J AM MED ASSOC, V264, P585, DOI 10.1001/jama.264.5.585; 1987, NRPBGS8 NAT RAD PROT; 1987, NRBPGS7 NAT RAD PROT; 1962 UN SCI COMM EFF; 1972 UN SCI COMM EFF; 1964 UN SCI COMM EFF; 1966 UN SCI COMM EFF; 1969 UN SCI COMM EFF; 1990, EUR12551EN COMM EUR	25	43	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1005	1009		10.1136/bmj.304.6833.1005	http://dx.doi.org/10.1136/bmj.304.6833.1005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586779	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200015
J	KLAR, A; BALDASSARE, M; JESSELL, TM				KLAR, A; BALDASSARE, M; JESSELL, TM			F-SPONDIN - A GENE EXPRESSED AT HIGH-LEVELS IN THE FLOOR PLATE ENCODES A SECRETED PROTEIN THAT PROMOTES NEURAL CELL-ADHESION AND NEURITE EXTENSION	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN MALARIA PARASITE; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX; SPINAL NEURONS; THROMBOSPONDIN; GLYCOPROTEIN; OUTGROWTH; PROPERDIN; SEQUENCES	The floor plate is a cell group implicated in the control of neural cell pattern and axonal growth in the developing vertebrate nervous system. To identify molecules that might mediate the functions of the floor plate, we have used subtractive hybridization techniques to isolate floor plate-enriched cDNA clones. One such clone encodes a novel secreted protein, F-spondin, which is expressed at high levels in the floor plate. The C-terminal half of the protein contains six repeats identified previously in thrombospondin and other proteins implicated in cell adhesion. F-spondin is expressed in the floor plate at the time that axons first extend and at lower levels in the peripheral nerve. Recombinant F-spondin promotes the attachment of spinal cord and sensory neuron cells and the out-growth of neurites in vitro. F-spondin may contribute to the growth and guidance of axons in both the spinal cord and the PNS.			KLAR, A (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		Klar, Avihu/AHC-4770-2022					ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1990, BLOOD S1, V76, pA445; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; CULOTTI J G, 1991, Journal of Cell Biology, V115, p122A; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1985, J NEUROSCI, V5, P3278; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GOUNDIS D, 1988, NATURE, V335, P62; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Hedgecock E.M., 1990, Seminars in the Neurosciences, V2, P159; HEDGECOCK EM, 1990, NEURON, V2, P61; HESSION C, 1991, J BIOL CHEM, V266, P6682; HOLLEY JA, 1987, DEV BIOL, V123, P375, DOI 10.1016/0012-1606(87)90396-4; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KARAGOGEOS D, 1991, DEVELOPMENT, V112, P61; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUWADA JY, 1990, J COMP NEUROL, V302, P617, DOI 10.1002/cne.903020316; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MCKANNA JA, 1989, SCIENCE, V243, P1477, DOI 10.1126/science.2928781; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; OSTERHOUT DJ, 1992, IN PRESS DEV BIOL; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; PERKINS SJ, 1989, BIOCHEMISTRY-US, V28, P7176, DOI 10.1021/bi00444a007; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; PLACZEK M, 1991, IN PRESS DEVELOPMENT; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH K A, 1991, Journal of Cell Biology, V115, p441A; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Romijn HJ, 1982, DEV BRAIN RES, V2, P583; Sambrook J., 1989, MOL CLONING; SANES JR, 1990, COLD SH Q B, V55, P419; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHNER M, 1990, MORPHOREGULATORY MOL, P443; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SMITH KF, 1991, BIOCHEMISTRY-US, V30, P8000, DOI 10.1021/bi00246a018; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; SUN X, 1989, J BIOL CHEM, V264, P2885; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TUTTLE R, 1989, DEV NEUROSCI-BASEL, V11, P289, DOI 10.1159/000111907; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; Weber A., 1938, Bio-Morphosis Basel, V1, P30; WEHRLE B, 1990, DEVELOPMENT, V110, P401; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; YAGINUMA H, 1991, J COMP NEUROL, V304, P78, DOI 10.1002/cne.903040107; YAGINUMA H, 1991, J NEUROSCI, V11, P2598; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	85	319	341	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					95	110		10.1016/0092-8674(92)90121-R	http://dx.doi.org/10.1016/0092-8674(92)90121-R			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555244				2022-12-28	WOS:A1992HM44500009
J	RICHARDS, P				RICHARDS, P			EDUCATIONAL IMPROVEMENT OF THE PREREGISTRATION PERIOD OF GENERAL CLINICAL-TRAINING	BRITISH MEDICAL JOURNAL			English	Article											RICHARDS, P (corresponding author), ST MARYS HOSP,IMPERIAL COLL,SCH MED,LONDON W2 1PG,ENGLAND.							DELAMOTHE T, 1991, BRIT MED J, V302, P1482, DOI 10.1136/bmj.302.6791.1482; DOWLING S, 1991, DOCTORS MAKING EXPER; DYER C, 1991, BRIT MED J, V303, P1218, DOI 10.1136/bmj.303.6812.1218; FORD J, 1991, BRIT MED J, V302, P118; HARRIS CM, 1985, BMJ, V29, P1811; SPINDLER S, IN PRESS DOCTORS BE	6	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					625	627		10.1136/bmj.304.6827.625	http://dx.doi.org/10.1136/bmj.304.6827.625			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH733	1559093	Green Published, Bronze			2022-12-28	WOS:A1992HH73300027
J	BRYAN, CS				BRYAN, CS			OSLER, LYMAN, AND PAGE - A TALE OF 3 TEXTS	ANNALS OF INTERNAL MEDICINE			English	Article						OSLER, WILLIAM; LYMAN, HENRY; PAGE, RICHARD; HISTORY OF MEDICINE; TEXTBOOKS, MEDICAL		In 1892, new textbooks of medicine with similar titles were published by three prominent physicians: William Osler of Baltimore, Henry Munson Lyman of Chicago, and Richard Channing Moore Page of New York City. Osler wrote in the encyclopedic tradition of earlier 19th century authors. Lyman and Page wrote shorter books in the belief that students were better served by brevity. Osler's text overshadowed the others not only because of its authoritativeness and charm but also because Osler captured the emerging definition of internal medicine as a broad, dynamic, and investigative specialty.			BRYAN, CS (corresponding author), UNIV S CAROLINA, SCH MED, DEPT MED, 2 RICHLAND MED PK, SUITE 502, COLUMBIA, SC 29203 USA.							Berkow Robert., 1992, MERCK MANUAL DIAGNOS, V16th; CECIL RL, 1927, TXB MED AM; COLE PC, 1899, MEMORIAM RCM PAGE, P7; CUSHING H, 1925, LIFE W OSLER, V2, P339; DUNAGAN WC, 1989, MANUAL MED THERAPEUT; FLINT A, 1886, TREATISE PRINCIPLES; FYE B, 1988, GRAND ROUNDS 100 YEA, P78; GOLDEN RL, 1992, ANN INTERN MED, V116, P255, DOI 10.7326/0003-4819-116-3-255; GOLDEN RL, 1988, W OSLER ANNOTATED BI, P128; Harrison TR, 1950, PRINCIPLES INTERNAL; Harvey A., 1978, INTERURBAN CLIN CLUB; HARVEY AM, 1981, SCI BEDSIDE CLIN RES, P21; KELLY HA, 1928, DICT AM MED BIOGRAPH, P767; LEROY EC, 1989, CAN B MED HIST, V36, P57; LUDMERER KM, 1985, LEARNING HEAL DEV AM, P135; LYMAN HM, 1892, TXB PRINCIPLES PRACT; LYMAN HM, 1893, JAMA-J AM MED ASSOC, V20, P132; Osler W, 1901, J AMER MED ASSOC, V36, P1673; OSLER W, 1892, REMARKS SPECIALISM, P2; Osler W, 1892, PRINCIPLES PRACTICE; OSLER W, 1908, ALABAMA STUDENT OTHE, P1; OSLER W, 1928, AEQUANIMITAS OTHER A, P139; PAGE RC, 1889, HDB PHYSICAL DIAGNOS; PAGE RC, 1892, TXB PRACTICE MED; Pepper W, 1885, SYSTEM PRACTICAL MED; Starr P., 1982, SOCIAL TRANSFORMATIO, P116; STEVENS R, 1986, ANN INTERN MED, V105, P592, DOI 10.7326/0003-4819-105-4-592; STEVENS R, 1988, GRAND ROUNDS 100 YEA, P339; WATSON T, 1872, LECTURES PRINCIPLES; 1905, COUNSELS IDEALS WRIT, P151; 1904, BIOGRAPHIES PHYSICIA, P32; 1892, MED NEWS, V60, P422	32	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				1021	1024		10.7326/0003-4819-116-12-1021	http://dx.doi.org/10.7326/0003-4819-116-12-1021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586092				2022-12-28	WOS:A1992HY79300013
J	FALLON, HJ				FALLON, HJ			SIMPLE MODIFICATIONS OF THE CURRENT CURRICULUM TO ENHANCE EDUCATIONAL-EXPERIENCE	ANNALS OF INTERNAL MEDICINE			English	Article								Changes in medical practice and in the financing of hospital care have resulted in a narrowing spectrum of adult medical illness among hospitalized patients. Residency training based primarily in the hospital underemphasizes many diseases and disorders that are treated exclusively at ambulatory sites. Curriculum modifications should allow for increased training time for residents in the ambulatory care setting. Reducing clinical inpatient service demands on residents and alleviating the attendant stress will allow more time for such educational experiences. The Medical College of Virginia has had recent experience with three modifications to the curriculum, which are intended to accomplish these ends: a specialized unit for inpatient services, which is not staffed by interns; a reorganization of the daily inpatient care schedule; and a modified "night float" team.			FALLON, HJ (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT INTERNAL MED, BOX 500 MCV STN, RICHMOND, VA 23298 USA.							WARTMAN SA, 1990, J GEN INTERN MED, V5, pS59, DOI 10.1007/BF02600439	1	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1103	1105		10.7326/0003-4819-116-12-1103	http://dx.doi.org/10.7326/0003-4819-116-12-1103			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586127				2022-12-28	WOS:A1992HY79400017
J	LEVEY, GS				LEVEY, GS			CHANGING THE CURRICULUM FOR INTERNAL-MEDICINE RESIDENCY TRAINING	ANNALS OF INTERNAL MEDICINE			English	Article								The academic leadership of internal medicine is considering fundamental changes in the curriculum for internal medicine residency training. The impetus to change the curriculum is derived from various socioeconomic changes during the past 10 years. These changes have resulted in a drastically shortened length of stay of patients in hospitals, an emphasis on outpatient care by reimbursement agencies, and a sharp decline in the numbers of U.S. medical graduates selecting careers in internal medicine. Curriculum change will mandate that we define the roles of general internists and subspecialists in the delivery of primary care and that we re-define how we train these two groups of internists. We must focus attention on the issue of service compared with education and must confront the issue of how best to train foreign medical graduates. Any curriculum change will also have to accommodate residents selecting careers in research in order to ensure an adequate supply of physician-scientists. Before implementing any change in curriculum, we must put into place a rigorous, prospective evaluation system. We must be able to accurately assess both positive and negative outcomes of these changes and make necessary midcourse corrections. The impetus for curriculum change in internal medicine will, it is hoped, ultimately benefit the public, the trainees, and the practice of internal medicine.			LEVEY, GS (corresponding author), MERCK & CO INC, MERCK HUMAN HLTH DIV, POB 2000, R33-73, RAHWAY, NJ 07065 USA.							ANDERSEN RM, 1989, ANN INTERN MED, V110, P922, DOI 10.7326/0003-4819-110-11-922; BABBOTT D, 1991, ANN INTERN MED, V114, P16, DOI 10.7326/0003-4819-114-1-16; EARLEY LE, 1987, SUM AM BOARD INT MED; GOLDSTEIN JL, 1986, J CLIN INVEST, V78, P848, DOI 10.1172/JCI112652; GREENFIELD S, IN PRESS JAMA; MCCARTY DJ, 1987, NEW ENGL J MED, V317, P567, DOI 10.1056/NEJM198708273170909; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; 1988, ANN INTERN MED, V108, P139; 1981, DHHS HRA8165181657G	9	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	2				1046	1050		10.7326/0003-4819-116-12-1046	http://dx.doi.org/10.7326/0003-4819-116-12-1046			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY794	1586113				2022-12-28	WOS:A1992HY79400003
J	HERSKOVIC, A; MARTZ, K; ALSARRAF, M; LEICHMAN, L; BRINDLE, J; VAITKEVICIUS, V; COOPER, J; BYHARDT, R; DAVIS, L; EMAMI, B				HERSKOVIC, A; MARTZ, K; ALSARRAF, M; LEICHMAN, L; BRINDLE, J; VAITKEVICIUS, V; COOPER, J; BYHARDT, R; DAVIS, L; EMAMI, B			COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; SOUTHWEST ONCOLOGY GROUP; PREOPERATIVE CHEMOTHERAPY; RADIATION-THERAPY; CLINICAL-TRIALS; EXPERIENCE; SURGERY	Background. The efficacy of conventional treatment with surgery and radiation for cancer of the esophagus is limited. The median survival is less than 10 months, and less than 10 percent of patients survive for 5 years. Recent studies have suggested that combined chemotherapy and radiation therapy may result in improved survival. Methods. This phase III prospective, randomized, and stratified trial was undertaken to evaluate the efficacy of four courses of combined fluorouracil (1000 mg per square meter of body-surface area daily for four days) and cisplatin (75 mg per square meter on the first day) plus 5000 cGy of radiation therapy, as compared with 6400 cGy of radiation therapy alone, in patients with squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus. The trial was stopped after the accumulated results in 121 patients demonstrated a significant advantage for survival in the patients who received chemotherapy and radiation therapy. Results. The median survival was 8.9 months in the radiation-treated patients, as compared with 12.5 months in the patients treated with chemotherapy and radiation therapy. In the former group, the survival rates at 12 and 24 months were 33 percent and 10 percent, respectively, whereas they were 50 percent and 38 percent in the patients receiving combined therapy (P<0.001). Seven patients in the radiotherapy group and 25 in the combined-therapy group were alive at the time of the analysis. The patients who received combined treatment had fewer local (P<0.02) and fewer distant (P<0.01) recurrences. Severe and life-threatening side effects occurred in 44 percent and 20 percent, respectively, of the patients who received combined therapy, as compared with 25 percent and 3 percent of those treated with radiation alone. Conclusions. Concurrent therapy with cisplatin and fluorouracil and radiation is superior to radiation therapy alone in patients with localized carcinoma of the esophagus, as measured by control of local tumors, distant metastases, and survival, but at the cost of increased side effects.	RADIAT THERAPY ONCOL GRP HEADQUARTERS, PHILADELPHIA, PA USA; WAYNE STATE UNIV, SCH MED, DETROIT, MI 48201 USA; WAYNE STATE UNIV, DEPT MED, DIV HEMATOL & MED ONCOL, DETROIT, MI 48202 USA; UNIV SO CALIF, DEPT MED, LOS ANGELES, CA 90089 USA; HARPER GRACE HOSP, DETROIT, MI 48201 USA; UNIV N DAKOTA, DEPT RADIAT ONCOL, GRAND FORKS, ND 58201 USA; NYU, SCH MED, DEPT RADIAT ONCOL, NEW YORK, NY 10003 USA; WASHINGTON UNIV, SCH MED, DEPT RADIAT ONCOL, ST LOUIS, MO 63110 USA	Radiation Therapy Oncology Group (RTOG); Wayne State University; Henry Ford Health System; Henry Ford Hospital; Wayne State University; University of Southern California; University of North Dakota Grand Forks; New York University; Washington University (WUSTL)	HERSKOVIC, A (corresponding author), OAKWOOD HOSP, DEPT RADIAT ONCOL, 18101 OAKWOOD BLVD, DEARBORN, MI 48123 USA.				NATIONAL CANCER INSTITUTE [U10CA032102, U10CA021661, U10CA032115] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32115, CA32102, CA21661] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BYFIELD JE, 1990, CANC CHEMOTHERAPY IN, P521; CEDERQVIST C, 1978, ACTA CHIR SCAND, V144, P233; COIA LR, 1991, INT J RADIAT ONCOL, V20, P29, DOI 10.1016/0360-3016(91)90134-P; COX DR, 1972, J R STAT SOC B, V34, P187; EARLAM R, 1980, BRIT J SURG, V67, P457, DOI 10.1002/bjs.1800670702; EARLAM R, 1980, BRIT J SURG, V67, P381, DOI 10.1002/bjs.1800670602; FORASTIERE AA, 1990, J CLIN ONCOL, V8, P119, DOI 10.1200/JCO.1990.8.1.119; FRANKLIN R, 1983, CANCER, V51, P1062, DOI 10.1002/1097-0142(19830315)51:6<1062::AID-CNCR2820510615>3.0.CO;2-2; GREEN SJ, 1987, J CLIN ONCOL, V5, P1477, DOI 10.1200/JCO.1987.5.9.1477; HERSKOVIC A, 1988, INT J RADIAT ONCOL, V15, P655, DOI 10.1016/0360-3016(88)90308-2; HILGENBERG AD, 1988, ANN THORAC SURG, V45, P357, DOI 10.1016/S0003-4975(98)90004-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEN DP, 1982, CANCER, V49, P1174, DOI 10.1002/1097-0142(19820315)49:6<1174::AID-CNCR2820490618>3.0.CO;2-W; LEICHMAN L, 1984, SEMIN ONCOL, V11, P178; LOKICH JJ, 1987, CANCER, V60, P275, DOI 10.1002/1097-0142(19870801)60:3<275::AID-CNCR2820600302>3.0.CO;2-R; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER JI, 1985, ANN THORAC SURG, V40, P289, DOI 10.1016/S0003-4975(10)60044-6; NIGRO ND, 1983, CANCER, V51, P1826, DOI 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POPLIN E, 1987, J CLIN ONCOL, V5, P622, DOI 10.1200/JCO.1987.5.4.622; POPP MB, 1986, ARCH SURG-CHICAGO, V121, P1330, DOI 10.1001/archsurg.121.11.1330; ROSENBERG JC, 1989, CANCER PRINCIPLES PR, V1, P725; SEYDEL HG, 1988, INT J RADIAT ONCOL, V14, P33, DOI 10.1016/0360-3016(88)90047-8; SISCHY B, 1990, P AN M AM SOC CLIN, V9, P105; YIN WB, 1990, 1989 P BRACH M REM A, P52; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	26	1618	1683	4	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1593	1598		10.1056/NEJM199206113262403	http://dx.doi.org/10.1056/NEJM199206113262403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584260				2022-12-28	WOS:A1992HX63300004
J	GREEN, S				GREEN, S			ANTINEOPLASTONS - AN UNPROVED CANCER-THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DNA; PEPTIDES				GREEN, S (corresponding author), ZOL CONSULTANTS INC,NEW YORK,NY, USA.				NATIONAL CANCER INSTITUTE [R44CA041953] Funding Source: NIH RePORTER; NCI NIH HHS [R44 CA 41953] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHRAF AQ, 1986, DRUG EXP CLIN RES, V12, P37; BRUZYNSKI SR, 1985, Patent No. 4558057; BURZYNSK.SR, 1974, FED PROC, V33, P547; BURZYNSK.SR, 1973, FED PROC, V32, P766; BURZYNSKI S, 1969, CLIN CHIM ACTA, V25, P231, DOI 10.1016/0009-8981(69)90259-9; BURZYNSKI S, 1985, RECENT ADV CHEMOTHER, P586; BURZYNSKI SR, 1986, DRUG EXP CLIN RES, V12, P11; BURZYNSKI SR, 1974, PHYSIOL CHEM PHYS M, V6, P457; BURZYNSKI SR, 1976, PHYSIOL CHEM PHYS M, V8, P13; BURZYNSKI SR, 1977, PHYSIOL CHEM PHYS M, V9, P485; BURZYNSKI SR, 1976, PHYSIOL CHEM PHYS M, V8, P276; BURZYNSKI SR, 1974, ANTINEOPLASTIC PEPTI; CHRISTIE GA, 1962, LANCET, V2, P249; DIPAOLO JA, 1963, JAMA-J AM MED ASSOC, V183, P139; ERIGUCHI N, 1988, Journal of Japan Society for Cancer Therapy, V23, P1560; HENDRY LB, 1987, DRUG EXP CLIN RES, V13, P77; JAMES MO, 1972, PROC R SOC SER B-BIO, V182, P25, DOI 10.1098/rspb.1972.0064; LEESON P, 1988, 8TH INT S FUT TRENDS; LEHNER AF, 1986, DRUG EXP CLIN RES, V12, P57; LETROMBETTA, 1990, COMMUNICATION    JUL, P447; LETROMBETTA, 1990, COMMUNICATION; LICHTENSTEIN N, 1977, ISRAEL J MED SCI, V13, P316; LOO YH, 1979, J NEUROCHEM, V32, P1699, DOI 10.1111/j.1471-4159.1979.tb02282.x; MOLDAVE K, 1957, J BIOL CHEM, V229, P463; MULDOON TG, 1987, DRUG EXP CLIN RES, V13, P83; PEPPER C, 1984, 98435 PUBL; RUTZ D, 1990, TAKYPEOPLE CANCER TA; Sherwin CP, 1919, J BIOL CHEM, V40, P259; TSUDA H, 1991, KURUME MED J, V37, P97; UNGAR G, 1973, FED PROC, V32, P367; UNGAR G, 1972, Federation Proceedings, V31, P398; WEN GY, 1980, ANN NEUROL, V7, P557, DOI 10.1002/ana.410070609; WESTPHAL O, 1975, INT ARCH ALLER A IMM, V49, P1, DOI 10.1159/000231374; XU W, 1988, SHANDONG MED U B; 1985, GUIDELINE STERILE DR; 1989, MERCK INDEX, P703; 1991, BIOCH ORGANIC COMPOU, P779; 1990, BURZYNSKI CLIN; 1981, MICROBIOLOGICAL EVAL, V4	39	11	11	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2924	2928		10.1001/jama.267.21.2924	http://dx.doi.org/10.1001/jama.267.21.2924			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583762				2022-12-28	WOS:A1992HW13300030
J	WECHSLER, H; ISAAC, N				WECHSLER, H; ISAAC, N			BINGE DRINKERS AT MASSACHUSETTS COLLEGES - PREVALENCE, DRINKING STYLE, TIME TRENDS, AND ASSOCIATED PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CONSUMPTION	Objective. --To compare drinking patterns among college freshmen with those found among students at similar schools 12 years ago, and to describe in detail the differences between "binge" drinkers and "nonbinge" drinkers. Design. --Mailed survey. Setting. --Fourteen 4-year colleges in Massachusetts. Participants. --A total of 1669 first-year college students. Main Outcome Measures. --The survey instrument contains a variety of self-report measures of drinking behaviors, attitudes, and consequences. "Binge" drinking is defined as the consumption of five or more drinks on one or more occasions in the past 2 weeks. Main Results. --The proportion of "frequent-heavy" drinkers remained constant between the 1977 and 1989 surveys (30% vs 31% of men; 13% vs 14% of women), but today's students get intoxicated more often and are more motivated to drink to get drunk. The proportion of students who said "to get drunk" was a "somewhat" or "very important" reason for drinking was two to three times as high in 1989 as in 1977. Among students surveyed in 1989, binge drinkers drank greater quantities, with greater regularity, and experienced more intoxication and alcohol-associated problems than did nonbinge drinkers. Close to half of the binge drinkers (46.5% of men, 48.3% of women) were drunk twice or more in the past month, compared with 5% or fewer of the nonbinge drinkers. Conclusions. --The stability over time of the prevalence of frequent heavy drinking among college students indicates an apparent failure of both social and institutional policies to alter this behavior. Binge drinkers in particular appear to be a population whose drinking patterns and attitudes place them and those around them at increased risk for adverse consequences.	HARVARD UNIV,SCH PUBL HLTH,CTR INJURY CONTROL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	WECHSLER, H (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							ENGS RC, 1988, PUBLIC HEALTH REP, V103, P667; JOHNSTON LD, 1991, DRUG USE AM HIGH SCH, V2; MEILMAN PW, 1990, J STUD ALCOHOL, V51, P389, DOI 10.15288/jsa.1990.51.389; OHARE TM, 1990, J STUD ALCOHOL, V51, P536, DOI 10.15288/jsa.1990.51.536; REINISCH OJ, 1991, N3189CHF RAND CORP P; ROOM R, 1971, DRINKING DRUG PRACTI, V3, P15; Straus R, 1953, DRINKING IN COLLEGE; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; WECHSLER H, 1991, ALCOHOL COLLEGE FRES; 1990, ALCOHOL HLTH; 1990, CAMPUS LIFE SEARCH C	11	213	213	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2929	2931						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW133	1583763				2022-12-28	WOS:A1992HW13300031
J	RICH, GM; ULICK, S; COOK, S; WANG, JZ; LIFTON, RP; DLUHY, RG				RICH, GM; ULICK, S; COOK, S; WANG, JZ; LIFTON, RP; DLUHY, RG			GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM IN A LARGE KINDRED - CLINICAL SPECTRUM AND DIAGNOSIS USING A CHARACTERISTIC BIOCHEMICAL PHENOTYPE	ANNALS OF INTERNAL MEDICINE			English	Article						ALDOSTERONISM; GLUCOCORTICOIDS; HYPERTENSION; HYDROCORTISONE; HYPOKALEMIA	SUPPRESSIBLE HYPER-ALDOSTERONISM; ANGIOTENSIN-II; RADIOIMMUNOASSAY; PLASMA; URINE; ZONE	Objective: To define the clinical spectrum of glucocorticoid-remediable aldosteronism (GRA) in a large kindred. Design: Screening all at-risk relatives of a proband for GRA using a specific biochemical phenotype and collecting of medical histories of kindred members from five generations. Setting: Outpatient General Clinical Research Centers and patients' homes. Measurements: Screening was done while patients were on a self-selected diet and included blood pressure determinations; serum potassium and plasma renin activity and aldosterone measurements; and 24-hour urinary tetrahydroaldosterone, 18-oxotetrahydrocortisol, and 18-hydroxycortisol measurements. Results: Diagnosis of GRA was established on the basis of a previously described specific biochemical abnormality, overproduction of the cortisol C-18 oxidation products (18-oxotetrahydrocortisol and 18-hydroxycortisol) in urine and their ratio relative to tetrahydroaldosterone. Glucocorticoid-remediable aldosteronism was diagnosed in 11 additional patients spanning three generations; this group included the youngest patient (3 months old) ever diagnosed with GRA. Complete penetrance of the biochemical abnormality is likely, with 11 of 18 at-risk patients displaying the phenotype. All patients with GRA had elevated blood pressure. Affected adult patients had been diagnosed as hypertensive before reaching 21 years of age (n = 7 mean, 16.1 +/- 3.4 years). All affected patients were normokalemic (4.3 +/- 0.3 mmol/L). Conclusion: Hypertension is a characteristic feature of GRA. Elevated blood pressure in this kindred developed at an early age and often was severe. Because a normal potassium level does not exclude the diagnosis of GRA, the disorder may be underdiagnosed. The value of a specific cortisol C-18 oxidation phenotype in the diagnosis of GRA has been confirmed.	BRIGHAM & WOMENS HOSP, DIV ENDOCRINOL HYPERTENS, 221 LONGWOOD AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA; VET AFFAIRS HOSP, BRONX, NY USA; UNIV UTAH, SCH MED, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; NEW YORK HOSP, NEW YORK, NY 10021 USA; UNIV UTAH, SCH MED, DEPT HUMAN GENET, SALT LAKE CITY, UT 84132 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Cornell University; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; NewYork-Presbyterian Hospital; Utah System of Higher Education; University of Utah					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323, R01HL045321] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1-RR-02635] Funding Source: Medline; NHLBI NIH HHS [HL-18323, R01-HL45321] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, PEDIATRICS, V79, P1; CHU MD, 1982, J BIOL CHEM, V257, P2218; EMANUEL RL, 1973, J LAB CLIN MED, V81, P632; FALLO F, 1985, CLIN ENDOCRINOL, V22, P777, DOI 10.1111/j.1365-2265.1985.tb00168.x; FALLO F, 1990, COMPREHENSIE ENDOCRI, P87; GANGULY A, 1981, J CLIN ENDOCR METAB, V53, P1040, DOI 10.1210/jcem-53-5-1040; GIEBINK GS, 1973, J CLIN ENDOCR METAB, V36, P715, DOI 10.1210/jcem-36-4-715; GILL JR, 1981, J CLIN ENDOCR METAB, V53, P331, DOI 10.1210/jcem-53-2-331; GOMEZSANCHEZ CE, 1988, J CLIN ENDOCR METAB, V67, P444, DOI 10.1210/jcem-67-3-444; GRIM CE, 1980, PEDIATRICS, V65, P597; LEE SM, 1982, ACTA ENDOCRINOL-COP, V99, P251, DOI 10.1530/acta.0.0990251; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MAYES D, 1970, J CLIN ENDOCR METAB, V30, P682, DOI 10.1210/jcem-30-5-682; NEW MI, 1980, LANCET, V1, P550; NEW MI, 1967, J CLIN ENDOCR METAB, V27, P300, DOI 10.1210/jcem-27-2-300; NEW MI, 1986, SERONO S, V10; NICHOLS AL, 1977, RADIOIMMUNOASSAY MAN; OBERFIELD SE, 1981, J CLIN ENDOCR METAB, V53, P158, DOI 10.1210/jcem-53-1-158; RUDER HJ, 1972, J CLIN ENDOCR METAB, V35, P219, DOI 10.1210/jcem-35-2-219; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; ULICK S, 1991, J STEROID BIOCHEM, V38, P59, DOI 10.1016/0960-0760(91)90401-P; ULICK S, 1990, J CLIN ENDOCR METAB, V71, P1151, DOI 10.1210/jcem-71-5-1151; ULICK S, 1991, ENDOCRIN METAB CLIN, V20, P269, DOI 10.1016/S0889-8529(18)30268-8; ULICK S, 1983, J BIOL CHEM, V258, P5498; ULICK S, 1982, CLIN EXP HYPERTENS A, V4, P1771, DOI 10.3109/10641968209061640; ULICK S, 1989, SERONO S, V57, P313; ZACHARIAH PK, 1991, JAMA-J AM MED ASSOC, V265, P1414, DOI 10.1001/jama.265.11.1414	27	143	144	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					813	820		10.7326/0003-4819-116-10-813	http://dx.doi.org/10.7326/0003-4819-116-10-813			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567095				2022-12-28	WOS:A1992HT80200005
J	SCHULTZ, MC; REEDER, RH; HAHN, S				SCHULTZ, MC; REEDER, RH; HAHN, S			VARIANTS OF THE TATA-BINDING PROTEIN CAN DISTINGUISH SUBSETS OF RNA POLYMERASE-I, POLYMERASE-II, AND POLYMERASE-III PROMOTERS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; GENES	Transcription extracts prepared from yeast that are deficient in the TATA-binding protein (TBP or TFIID) are also impaired in specific promoter recognition by all three nuclear RNA polymerases (pol I, II, and III). Specific initiation can be rescued by the addition of purified recombinant TBP, demonstrating that pol I, II, and III all require this factor, A mutation of TBP has been identified that will function with pol I but not with pol II or III. Conversely, another mutation, which inactivates TATA element binding in vitro, will function with pol I and III promoters but is inactive for a pol II promoter. Thus, it is possible to identify TBP variants that will only function on different subsets of all nuclear promoters.			SCHULTZ, MC (corresponding author), HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BELL GI, 1977, J BIOL CHEM, V252, P8118; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; CHOE SY, 1992, NUCLEIC ACIDS RES, V20, P279, DOI 10.1093/nar/20.2.279; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GEIDUSCHEK P, 1992, IN PRESS TRANSCRIPTI; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REEDER RH, 1992, IN PRESS TRANSCRIPTI; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; ZAWEL L, 1992, IN PRESS PROGR NUCLE; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	30	198	199	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					697	702		10.1016/0092-8674(92)90233-3	http://dx.doi.org/10.1016/0092-8674(92)90233-3			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586948				2022-12-28	WOS:A1992HV08900014
J	REINHOLDHUREK, B; SHUB, DA				REINHOLDHUREK, B; SHUB, DA			SELF-SPLICING INTRONS IN TRANSFER-RNA GENES OF WIDELY DIVERGENT BACTERIA	NATURE			English	Article							GROUP-I INTRONS; INTERVENING SEQUENCE; TETRAHYMENA; ANTICODON; EVOLUTION; EXCISION; INVITRO	THE organization of eukaryotic genes into exons separated by introns has been considered as a primordial arrangement 1,2 but because it does not exist in eubacterial genomes it may be that introns are relatively recent acquisitions 3 . A self-splicing group I intron has been found in cyanobacteria at the same position of the same gene (that encoding leucyl transfer RNA, UAA anticodon) as a similar group I intron of chloroplasts 4,5, which indicates that this intron predates the invasion of eukaryotic cells by cyanobacterial endosymbionts. But it is not clear from this isolated example whether introns are more generally present in different genes or in more diverse branches of the eubacteria. Many mitochondria have intron-rich genomes and were probably derived from the alpha subgroup of the purple bacteria 6 (or Proteobacteria 7), so ancient introns might also have been retained in these bacteria. We describe here the discovery of two small (237 and 205 nucleotides) self-splicing group I introns in members of two proteobacterial subgroups, Agrobacterium tumefaciens (alpha) and Azoarcus sp. (beta). The introns are inserted in genes for tRNA(Arg) and tRNA(Ile), respectively, after the third anticodon nucleotide. Their occurrence in different genes of phylogenetically diverse bacteria indicates that group I introns have a widespread distribution among eubacteria.	SUNY ALBANY, DEPT BIOL SCI, 1400 WASHINGTON AVE, ALBANY, NY 12222 USA; SUNY ALBANY, CTR MOLEC GENET, ALBANY, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany								ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CHOFFAT Y, 1988, MOL CELL BIOL, V8, P3332, DOI 10.1128/MCB.8.8.3332; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOTT JM, 1986, CELL, V47, P81, DOI 10.1016/0092-8674(86)90368-5; JOHNSON PF, 1983, NATURE, V302, P681, DOI 10.1038/302681a0; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; LEE CP, 1991, J BIOL CHEM, V266, P18012; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8121, DOI 10.1073/pnas.88.18.8121; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; VANTOL H, 1988, NUCLEIC ACIDS RES, V16, P1951, DOI 10.1093/nar/16.5.1951; WINANS SC, 1988, J BACTERIOL, V170, P4047, DOI 10.1128/jb.170.9.4047-4054.1988; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; Young J. P. W., 1992, BIOL NITROGEN FIXATI, V1544, P43	25	161	203	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					173	176		10.1038/357173a0	http://dx.doi.org/10.1038/357173a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579169				2022-12-28	WOS:A1992HU12200063
J	BLENDON, RJ; EDWARDS, JN; HYAMS, AL				BLENDON, RJ; EDWARDS, JN; HYAMS, AL			MAKING THE CRITICAL CHOICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							ASHBY J, 1988, ACHIEVEMENT ACCESS A; AUKERMAN GF, 1991, JAMA-J AM MED ASSOC, V265, P2856; BLENDON RJ, 1991, JAMA-J AM MED ASSOC, V265, P2563, DOI 10.1001/jama.265.19.2563; BRONOW RS, 1991, JAMA-J AM MED ASSOC, V265, P2511, DOI 10.1001/jama.265.19.2511; BUSH G, 1992, PRESIDENTS COMPREHEN; BUTLER SM, 1991, JAMA-J AM MED ASSOC, V265, P2541, DOI 10.1001/jama.265.19.2541; CLINTON B, 1992, B CLINTONS HLTH CARE; DAVIS K, 1991, JAMA-J AM MED ASSOC, V265, P2525, DOI 10.1001/jama.265.19.2525; ENTHOVEN AC, 1991, JAMA-J AM MED ASSOC, V265, P2532, DOI 10.1001/jama.265.19.2532; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; FEIN R, 1991, JAMA-J AM MED ASSOC, V265, P2555; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2549, DOI 10.1001/jama.265.19.2549; HOLAHAN J, 1991, JAMA-J AM MED ASSOC, V265, P2537, DOI 10.1001/jama.265.19.2537; KERREY B, 1991, JAMA-J AM MED ASSOC, V265, P552; NUTTER DO, 1991, JAMA-J AM MED ASSOC, V265, P2516, DOI 10.1001/jama.265.19.2516; ROCKEFELLER JD, 1991, JAMA-J AM MED ASSOC, V265, P2507, DOI 10.1001/jama.265.19.2507; ROYBAL ER, 1991, JAMA-J AM MED ASSOC, V265, P2545, DOI 10.1001/jama.265.19.2545; Schieber G J, 1990, Health Care Financ Rev, V11, P159; SCHIEBER GJ, 1989, HEALTH AFFAIR, V8, P169, DOI 10.1377/hlthaff.8.3.169; SCHRAMM CJ, 1991, JAMA-J AM MED ASSOC, V265, P3296, DOI 10.1001/jama.265.24.3296; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; TODD JS, 1991, JAMA-J AM MED ASSOC, V265, P2503; TSONGAS P, 1992, TSONGAS HLTH ALL AM; 1992, GALLUP ORG POLL  JAN; 1990, CALL ACTIONS FINAL R, P66; 1991, 0160360323 UN HLTH I; 1992, NY TIMES        0108; 1991, NY TIMES         AUG; 1988, 100EE CONGR RES SERV; 1991, JAMA-J AM MED ASSOC, V265, P2529; 1992, AHAS NATIONAL HLTH R; 1991, HLTH CARE REFORM PRO; 1991, EXCELLENT HLTH CARE	33	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2509	2520		10.1001/jama.267.18.2509	http://dx.doi.org/10.1001/jama.267.18.2509			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1573729				2022-12-28	WOS:A1992HT06800032
J	VALLEN, EA; SCHERSON, TY; ROBERTS, T; VANZEE, K; ROSE, MD				VALLEN, EA; SCHERSON, TY; ROBERTS, T; VANZEE, K; ROSE, MD			ASYMMETRIC MITOTIC SEGREGATION OF THE YEAST SPINDLE POLE BODY	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CA-2+-BINDING PROTEIN; CELL-CYCLE; GENE; DUPLICATION; TUBULIN; FUSIONS; CLONING; MUTANT; ACTIN	The yeast KAR1 gene is required for spindle pole body (SPB) duplication and nuclear fusion. We determine here that KAR1-beta-galactosidase hybrid proteins localize to the outer face of the SPB. Remarkably, after SPB duplication, the hybrid protein was found associated with only one of the two SPBs, usually the one that enters the bud. Using an ndc1 mutant, which forms a defective SPB at the nonpermissive temperature, we found that the hybrid was exclusively associated with the "new" SPB. Two regions of KAR1 contribute to its localization; an internal 70 residue region was necessary and sufficient to localize hybrids to the SPB, and the hydrophobic carboxyl terminus localized proteins to the nuclear envelope. The localization domains correspond to two functional domains required for SPB duplication. We suggest that KAR1 is anchored to the nuclear envelope and interacts with at least one other SPB component during the cell cycle.			VALLEN, EA (corresponding author), LEWIS THOMAS LAB, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.			Rose, Mark/0000-0003-1112-4765	NIGMS NIH HHS [GM37739, R01 GM037739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; BYERS B, 1981, MOL GENETICS YEAST, P119; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FINK GR, 1976, INT CELL BIOL 1976 1, P414; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SALISBURY JL, 1988, J CELL BIOL, V107, P635, DOI 10.1083/jcb.107.2.635; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; THOMAS JH, 1986, CELL, V44, P65, DOI 10.1016/0092-8674(86)90485-X; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; WINEY M, 1992, CENTROSOME, P201; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	36	89	90	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					505	515		10.1016/0092-8674(92)90451-H	http://dx.doi.org/10.1016/0092-8674(92)90451-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581964				2022-12-28	WOS:A1992HT07800012
J	STRATHDEE, CA; GAVISH, H; SHANNON, WR; BUCHWALD, M				STRATHDEE, CA; GAVISH, H; SHANNON, WR; BUCHWALD, M			CLONING OF CDNAS FOR FANCONIS ANEMIA BY FUNCTIONAL COMPLEMENTATION	NATURE			English	Article							EPSTEIN-BARR-VIRUS; HUMAN-CELLS; MAMMALIAN-CELLS; ANEMIA; REPLICATION; SEQUENCES; MEMBRANE; PROTEINS; REPAIR; VECTOR	Fanconi's anaemia is a rare autosomal recessive disorder characterized by progressive pancytopaenia and a cellular hypersensitivity to DNA crosslinking agents. Four genetic complementation groups have been identified so far, and here we use a functional complementation method to clone complementary DNAs that correct the defect of group C cells. The cDNAs encode alternatively processed transcripts of a new gene, designated FACC, which is mutated in group C patients. The predicted FACC polypeptide does not contain any motifs common to other proteins and so represents a new gene involved in the cellular response to DNA damage.	HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ALTHOFF MZ, 1953, KINDERHEIL, V72, P267; ANDERSON WF, 1991, HUM GENE THER, V2, P193, DOI 10.1089/hum.1991.2.3-193; AUERBACH AD, 1989, BLOOD, V73, P391; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; BRADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BUCHWALD M, 1989, FANCONI ANEMIA CLIN, P226; COLBEREGARAPIN F, 1986, GENE, V50, P279, DOI 10.1016/0378-1119(86)90332-X; DUCKWORTHRYSIECKI G, 1985, SOMAT CELL MOLEC GEN, V11, P35, DOI 10.1007/BF01534732; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; FUJIWARA Y, 1977, J MOL BIOL, V113, P635, DOI 10.1016/0022-2836(77)90227-3; GLUCKMAN E, 1984, SEMIN HEMATOL, V21, P20; GLUCKMAN E, 1989, FANCONI ANEMIA CLIN, P60; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; JOENJE H, 1989, FANCONI ANEMIA CLIN, P174; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P131; LEEDER JS, 1989, ANAL BIOCHEM, V177, P364, DOI 10.1016/0003-2697(89)90067-5; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI MS, 1973, CANCER RES, V33, P1829; SCHROEDER TM, 1976, HUM GENET, V32, P257, DOI 10.1007/BF00295817; SCHROEDER TM, 1964, HUMANGENETIK, V1, P194, DOI 10.1007/BF00389636; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRATHDEE CA, IN PRESS NATURE GENE; Szybalski W., 1967, ANTIBIOTICS, V1, P211; THOMPSON LH, 1991, MUTAT RES, V247, P213, DOI 10.1016/0027-5107(91)90017-I; VANDUUREN BL, 1969, ANN NY ACAD SCI, V163, P633, DOI 10.1111/j.1749-6632.1969.tb24883.x; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; [No title captured]	35	529	539	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					763	767		10.1038/356763a0	http://dx.doi.org/10.1038/356763a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574115				2022-12-28	WOS:A1992HR18600040
J	WINKENS, RAG; POP, P; GROL, RPTM; KESTER, ADM; KNOTTNERUS, JA				WINKENS, RAG; POP, P; GROL, RPTM; KESTER, ADM; KNOTTNERUS, JA			EFFECT OF FEEDBACK ON TEST ORDERING BEHAVIOR OF GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article							COST-CONTAINMENT; CONTROLLED TRIAL; STRATEGIES; MODIFY; PHYSICIANS; PATTERNS	Objective - To assess the effects of feedback on the test ordering behaviour of general practitioners. Design - Comparison of requests at two diagnostic centres, and internal comparison between tests which were discussed in feedback and tests which were not. Setting - A diagnostic centre in Maastricht giving feedback and another elsewhere in the Netherlands (laboratory A) not giving feedback. Subjects - All 85 general practitioners in the region of Maastricht, and all general practitioners in the region of laboratory A. Main outcome measures - Numbers of tests requested by general practitioners. Results - Requests at the Maastricht diagnostic centre decreased soon after the onset of feedback whereas there was a persistent increase in requests at laboratory A. Tests that were discussed showed the strongest decrease (maximum 40%), though tests that were not discussed decreased as well (maximum 27%). Conclusions - Feedback on diagnostic requests may exert a strong influence on request behaviour. Four years after the onset of feedback the effects were still noticeable.	UNIV LIMBURG,DEPT GEN PRACTICE,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT MED INFORMAT & STAT,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Maastricht University; Hasselt University	WINKENS, RAG (corresponding author), DIAGNOST CTR MAASTRICHT,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Knottnerus, Andre/F-4866-2013; Grol, Richard/C-8523-2013; Knottnerus, Johannes A/A-3829-2009					BAREFORD D, 1990, BRIT MED J, V301, P1305, DOI 10.1136/bmj.301.6764.1305; BERWICK DM, 1986, JAMA-J AM MED ASSOC, V255, P1450, DOI 10.1001/jama.255.11.1450; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; EISENBERG JM, 1977, J MED EDUC, V52, P578; ENDE J, 1983, JAMA-J AM MED ASSOC, V250, P770; Fleiss JL, 1981, STAT METHODS RATES P; FOWKES FGR, 1986, LANCET, V1, P367; FRASER CG, 1987, ANN CLIN BIOCHEM, V24, P223, DOI 10.1177/000456328702400301; GROSSMAN RM, 1983, MED CARE, V21, P783, DOI 10.1097/00005650-198308000-00003; HORDER J, 1986, J R COLL GEN PRACT, V36, P518; MARTON KI, 1985, ARCH INTERN MED, V145, P816, DOI 10.1001/archinte.145.5.816; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; POP P, 1989, J ROY COLL GEN PRACT, V39, P507; RHYNE RL, 1989, J FAM PRACTICE, V8, P1003; Sprij B, 1989, Ned Tijdschr Geneeskd, V133, P1115; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; ZAAT JOM, 1991, HUISARTS WETENSCHAP, V34, P72	19	61	61	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1093	1096		10.1136/bmj.304.6834.1093	http://dx.doi.org/10.1136/bmj.304.6834.1093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586825	Green Published, Bronze			2022-12-28	WOS:A1992HR13600021
J	ZIEGLER, EJ; SMITH, CR				ZIEGLER, EJ; SMITH, CR			ANTIENDOTOXIN MONOCLONAL-ANTIBODIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									CENTOCOR INC,MALVERN,PA 19355	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	ZIEGLER, EJ (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.							SCHULMAN KA, 1991, JAMA-J AM MED ASSOC, V266, P3466, DOI 10.1001/jama.266.24.3466; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1991, 1991 OP M VACC REL B, V1, P39	4	22	22	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1165	1165						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552929				2022-12-28	WOS:A1992HP80000029
J	GEWIRTZ, JD				GEWIRTZ, JD			A MEMORY OF BLOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2173	2173						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556784				2022-12-28	WOS:A1992HN84100009
J	DANG, CV				DANG, CV			MYELODYSPLASTIC SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											DANG, CV (corresponding author), JOHNS HOPKINS UNIV,SCH MED,1012 ROSS BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.		Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522				APPELBAUM FR, 1990, ANN INTERN MED, V112, P590, DOI 10.7326/0003-4819-112-8-590; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; CASTRO M, 1991, J RHEUMATOL, V18, P721; CHESON BD, 1990, ANN INTERN MED, V112, P932, DOI 10.7326/0003-4819-112-12-932; GEDDES AD, 1990, BRIT J HAEMATOL, V76, P194, DOI 10.1111/j.1365-2141.1990.tb07871.x; GREENBERG PL, 1991, BLOOD REV, V5, P42, DOI 10.1016/0268-960X(91)90007-Y; JACOBS A, 1989, BLOOD REV, V3, P105, DOI 10.1016/0268-960X(89)90005-2; LIST AF, 1990, J CLIN ONCOL, V8, P1424, DOI 10.1200/JCO.1990.8.8.1424; MUFTI GJ, 1985, BRIT J HAEMATOL, V59, P425, DOI 10.1111/j.1365-2141.1985.tb07329.x; NOEL P, 1991, MAYO CLIN PROC, V66, P485, DOI 10.1016/S0025-6196(12)62389-1; STEIN RS, 1991, BLOOD, V78, P1658; YUNIS JJ, 1986, BLOOD, V67, P1721	12	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2077	2080		10.1001/jama.267.15.2077	http://dx.doi.org/10.1001/jama.267.15.2077			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552643				2022-12-28	WOS:A1992HM65000035
J	BEGUN, DJ; AQUADRO, CF				BEGUN, DJ; AQUADRO, CF			LEVELS OF NATURALLY-OCCURRING DNA POLYMORPHISM CORRELATE WITH RECOMBINATION RATES IN DROSOPHILA-MELANOGASTER	NATURE			English	Article							RESTRICTION-MAP VARIATION; DROSOPHILA-MELANOGASTER; MOLECULAR EVOLUTION; REGION; LOCUS; 87A	Two genomic regions with unusually low recombination rates in Drosophila melanogaster have normal levels of divergence but greatly reduced nucleotide diversity 1,2, apparently resulting from the fixation of advantageous mutations and the associated hitch-hiking effect 3,4 . Here we show that for 20 gene regions from across the genome, the amount of nucleotide diversity in natural populations of D. melanogaster is positively correlated with the regional rate of recombination. This cannot be explained by variation in mutation rates and/or functional constraint, because we observe no correlation between recombination rates and DNA sequence divergence between D. melanogaster and its sibling species, D. simulans. We suggest that the correlation may result from genetic hitch-hiking associated with the fixation of advantageous mutants. Hitch-hiking thus seems to occur over a large fraction of the Drosophila genome and may constitute a major constraint on levels of genetic variation in nature.			BEGUN, DJ (corresponding author), CORNELL UNIV, GENET & DEV SECT, BIOTECHNOL BLDG, ITHACA, NY 14853 USA.				NIGMS NIH HHS [R01 GM036431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADE M, 1989, MOL BIOL EVOL, V6, P123; AQUADRO CF, 1988, GENETICS, V119, P875; AQUADRO CF, 1986, GENETICS, V114, P1165; ASHBURNER M, 1991, DROSOPHILA GENETIC M, V69; BEGUN DJ, 1991, GENETICS, V129, P1147; BERRY AJ, 1991, GENETICS, V129, P1111; BIRKY CW, 1988, P NATL ACAD SCI USA, V85, P6414, DOI 10.1073/pnas.85.17.6414; BROWN AJL, 1983, P NATL ACAD SCI-BIOL, V80, P5350, DOI 10.1073/pnas.80.17.5350; BROWN AJL, 1981, NATURE, V290, P677, DOI 10.1038/290677a0; EANES WF, 1989, MOL BIOL EVOL, V6, P384; GAME AY, 1990, GENETICS, V126, P1021; Hochman B., 1976, GENET BIOL DROSOPHIL, V1b, P903; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; KAPLAN NL, 1989, GENETICS, V123, P887; Kimura M., 1983, NEUTRAL THEORY MOL E; LANGE BW, 1990, GENETICS, V126, P921; LANGLEY CH, 1982, P NATL ACAD SCI-BIOL, V79, P5631, DOI 10.1073/pnas.79.18.5631; LANGLEY CH, 1988, GENETICS, V119, P619; LANGLEY CH, POPULATION BIOL GENE, P75; Lindsley D. L., 1967, GENETIC VARIATIONS D; LINDSLEY DL, 1977, PHILOS T R SOC B, V277, P295, DOI 10.1098/rstb.1977.0019; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MERRIAM J, 1991, SCIENCE, V254, P221, DOI 10.1126/science.1925579; MIYASHITA N, 1988, GENETICS, V120, P199; Nei M., 1987, MOL EVOLUTIONARY GEN; SCHAEFFER SW, 1988, MOL BIOL EVOL, V5, P30; SOUSA V, 1988, CHROMOSOME MAPS DROS; TAJIMA F, 1990, GENETICS, V125, P447; TAKANO TS, 1991, GENETICS, V129, P753	30	750	758	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 9	1992	356	6369					519	520		10.1038/356519a0	http://dx.doi.org/10.1038/356519a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560824				2022-12-28	WOS:A1992HN23100057
J	MERBS, SL; NATHANS, J				MERBS, SL; NATHANS, J			ABSORPTION-SPECTRA OF HUMAN CONE PIGMENTS	NATURE			English	Article							HUMAN COLOR-VISION; MOLECULAR-GENETICS; BOVINE RHODOPSIN; POLYMORPHISM; SENSITIVITY	HUMAN colour vision is mediated by three light-sensitive pigments, each found in a different cone-cell type 1. The absorption spectra of the human cone pigments have been sought for over a century 2 using techniques such as psychophysical colour matching 3, reflection densitometry 4, electroretinography 5, single-cell action spectra 6 and, most directly, microspectrophotometry 7,8. We report here a direct determination of the human cone pigment photobleaching difference absorption spectra after the production of each cone pigment apoprotein in tissue culture cells transfected with the corresponding complementary DNA clones 9,10. The mean values for the wavelength of maximal absorption are 426 nm for the blue pigment, 530 nm for the green pigment, and 552 nm and 557 nm for two polymorphic variants of the red pigment.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	MERBS, SL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Nathans, Jeremy/0000-0001-8106-5460				ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, NJ PHYSL, V266, P647; Boynton R. M., 1979, HUMAN COLOR VISION; BROWN PK, 1964, SCIENCE, V144, P45, DOI 10.1126/science.144.3614.45; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Maniatis T, 1989, DECONTAMINATION DILU; Maxwell J.C., 1860, PHIL T R SOC LOND, V150, P57, DOI DOI 10.1098/RSTL.1860.0005; NATHANS J, 1989, VISION RES, V29, P907, DOI 10.1016/0042-6989(89)90105-3; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; RUSHTON WAH, 1972, HDB SENSORY PHYSL, V7, P364; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0	22	243	246	0	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					433	435		10.1038/356433a0	http://dx.doi.org/10.1038/356433a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557124				2022-12-28	WOS:A1992HL83000063
J	ERIKSSON, AE; BAASE, WA; ZHANG, XJ; HEINZ, DW; BLABER, M; BALDWIN, EP; MATTHEWS, BW				ERIKSSON, AE; BAASE, WA; ZHANG, XJ; HEINZ, DW; BLABER, M; BALDWIN, EP; MATTHEWS, BW			RESPONSE OF A PROTEIN-STRUCTURE TO CAVITY-CREATING MUTATIONS AND ITS RELATION TO THE HYDROPHOBIC EFFECT	SCIENCE			English	Article							ACID SIDE-CHAINS; T4 LYSOZYME; PHAGE-T4 LYSOZYME; THERMAL-STABILITY; DISULFIDE BONDS; AMINO-ACIDS; ALPHA-HELIX; STABILIZATION; THERMOSTABILITY; RESOLUTION	Six "cavity-creating" mutants, LeU46 --> Ala (L46A), L99A, L118A, L121A, L133A, and Phe153 --> Ala (F153A), were constructed within the hydrophobic core of phage T4 lysozyme. The substitutions decreased the stability of the protein at pH 3.0 by different amounts, ranging from 2.7 kilocalories per mole (kcal mol-1) for L46A and L121A to 5.0 kcal mol-1 for L99A. The double mutant L99A/F153A was also constructed and decreased in stability by 8.3 kcal mol-1. The x-ray structures of all of the variants were determined at high resolution. In every case, removal of the wild-type side chain allowed some of the surrounding atoms to move toward the vacated space but a cavity always remained, which ranged in volume from 24 cubic angstroms (angstrom 3) for LA6A to 150 angstrom 3 for L99A. No solvent molecules were observed in any of these cavities. The destabilization of the mutant Leu --> Ala proteins relative to wild type can be approximated by a constant term (approximately 2.0 kcal mol-1) plus a term that increases in proportion to the size of the cavity. The constant term is approximately equal to the transfer free energy of leucine relative to alanine as determined from partitioning between aqueous and organic solvents. The energy term that increases with the size of the cavity can be expressed either in terms of the cavity volume (24 to 33 cal mol-1 angstrom -3) or in terms of the cavity surface area (20 cal mol-1 angstrom -2). The results suggest how to reconcile a number of conflicting reports concerning the strength of the hydrophobic effect in proteins.	UNIV OREGON, HOWARD HUGHES MED INST, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; University of Oregon			Blaber, Michael/N-1083-2019; Blaber, Michael/E-7478-2011; Blaber, Michael/ABA-5031-2021	Blaber, Michael/0000-0002-6856-1643; Baldwin, Enoch/0000-0002-1472-0944	NIGMS NIH HHS [GM21967, GM13709, GM12989] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021967, F32GM012989, F32GM013709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; ALBER T, 1987, METHOD ENZYMOL, V154, P511; ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BRANDTS JF, 1967, J AM CHEM SOC, V89, P4826, DOI 10.1021/ja00995a002; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAMODARAN S, 1986, J BIOL CHEM, V261, P7220; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; DEYOUNG LR, 1990, J PHYS CHEM-US, V94, P801, DOI 10.1021/j100365a054; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; ERIKSSON A, UNPUB; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; Fersht AR., 1977, ENZYME STRUCTURE MEC; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1989, J BIOL CHEM, V264, P16059; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MCREE DE, 1990, J BIOL CHEM, V265, P14234; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; SCHMID MF, 1981, ACTA CRYSTALLOGR A, V37, P701, DOI 10.1107/S0567739481001587; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; Sharp KA, 1991, CURR OPIN STRUC BIOL, V1, P171, DOI 10.1016/0959-440X(91)90057-Z; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; TANFORD C, 1980, HYDROPHOBIC EFFECT; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEAST RC, 1977, HDB CHEM PHYSICS, P57; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401	38	899	913	0	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 10	1992	255	5041					178	183		10.1126/science.1553543	http://dx.doi.org/10.1126/science.1553543			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553543	Green Submitted			2022-12-28	WOS:A1992GY70400030
J	DROSSMAN, DA; THOMPSON, WG				DROSSMAN, DA; THOMPSON, WG			THE IRRITABLE-BOWEL-SYNDROME - REVIEW AND A GRADUATED MULTICOMPONENT TREATMENT APPROACH	ANNALS OF INTERNAL MEDICINE			English	Review						COLONIC DISEASES, FUNCTIONAL; STRESS, PSYCHOLOGICAL; SEVERITY OF ILLNESS INDEX; IRRITABLE BOWEL SYNDROME; DIET THERAPY	COLONIC MYOELECTRICAL ACTIVITY; FUNCTIONAL GASTROINTESTINAL DISORDERS; APPARENTLY HEALTHY PEOPLE; PSYCHIATRIC-ILLNESS; DIVERTICULAR-DISEASE; ALTERNATIVE MEDICINE; PSYCHOSOCIAL FACTORS; PEPPERMINT OIL; PEPTIC-ULCER; LIFE EVENTS	The irritable bowel syndrome is a common chronic disorder having a broad clinical spectrum of severity. Although only a small proportion of those afflicted seek medical help for their symptoms, a subset have severe and intractable symptoms. A positive diagnosis should be established from the history and physical examination; endoscopic and radiologic investigations should be minimized. We suggest that the physician also assess the severity of the illness based on its symptomatic and functional features and the patient's behavioral response. Classifying the disorder in this manner permits a graduated treatment approach that emphasizes education, reassurance, and dietary adjustment for mild symptoms. Moderate symptom severity requires, in addition, identification and modification of factors exacerbating symptoms, psychotherapeutic and behavioral techniques and, if a certain symptom type predominates, pharmacologic agents directed toward the presumed gastrointestinal motor dysfunction. For severe symptoms, physician-based behavior modification and psychopharmacologic agents are helpful. When the disorder is intractable, referral may be needed, for example, to a pain treatment center. In all cases, the skillful physician must ensure continued psychosocial support to enhance coping and continued focus on the palliative aspects of care rather than on cure.	UNIV OTTAWA, OTTAWA CIV HOSP, OTTAWA K1Y 4E9, ONTARIO, CANADA	University of Ottawa; Ottawa Hospital Research Institute	DROSSMAN, DA (corresponding author), UNIV N CAROLINA, DIV DIGEST DIS, 420 BURNETT WOMACK, CB 7080, CHAPEL HILL, NC 27599 USA.							ALMY TP, 1949, GASTROENTEROLOGY, V12, P425, DOI 10.1016/S0016-5085(49)80125-9; ARONOFF GM, 1986, J CONSULT CLIN PSYCH, V54, P769; BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; BLANCHARD EB, 1987, BIOFEEDBACK SELF-REG, V12, P63, DOI 10.1007/BF01000079; BOMMELAER G, 1986, GASTROEN CLIN BIOL, V10, P7; BUENO L, 1988, BAILLIERE CLIN GASTR, V2, P123, DOI 10.1016/0950-3528(88)90024-3; BUENO L, 1980, GUT, V21, P480, DOI 10.1136/gut.21.6.480; BURNS DG, 1986, S AFR MED J, V70, P91; BYTZER P, 1989, GUT, V30, P1379, DOI 10.1136/gut.30.10.1379; CALLIES AL, 1987, ARCH GEN PSYCHIAT, V44, P157; CANN PA, 1984, DIGEST DIS SCI, V29, P239, DOI 10.1007/BF01296258; CHAUDHARY NA, 1962, Q J MED, V31, P307; CONNELL AM, 1962, GUT, V3, P342, DOI 10.1136/gut.3.4.342; CRAIG TKJ, 1984, J PSYCHOSOM RES, V28, P411, DOI 10.1016/0022-3999(84)90073-4; CUMMING W, 1849, LOND MED GAZETTE NS, V9, P969; DANIVAT D, 1988, BRIT MED J, V296, P1710, DOI 10.1136/bmj.296.6638.1710; DEW MJ, 1984, BRIT J CLIN PRACT, V38, P394; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1982, GASTROENTEROLOGY, V83, P529; DROSSMAN DA, 1991, TXB GASTROENTEROLOGY, P546; DROSSMAN DA, 1989, GASTROINTESTINAL DIS, P3; DROSSMAN DA, 1991, GASTROENTEROLOGY INT, V4, P77; EBERHARD G, 1988, NEUROPSYCHOBIOLOGY, V19, P25, DOI 10.1159/000118429; FERGUSON A, 1977, LANCET, V2, P613; FIELDING JF, 1977, IRISH J MED SCI, V146, P162, DOI 10.1007/BF03030953; FORD MJ, 1987, GUT, V28, P160, DOI 10.1136/gut.28.2.160; GREENBAUM DS, 1987, DIGEST DIS SCI, V32, P257, DOI 10.1007/BF01297051; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HAMEROFF SR, 1984, J CLIN PSYCHIAT, V45, P47; HARVEY RF, 1989, LANCET, V1, P424; HARVEY RF, 1983, LANCET, V1, P632; HARVEY RF, 1973, LANCET, V1, P1; HARVEY RF, 1987, LANCET, V1, P963; HEATON KW, 1985, IRRITABLE BOWEL SYND, P203; HEEFNER JD, 1978, PSYCHOSOMATICS, V19, P540; HISLOP IG, 1979, MED J AUSTRALIA, V1, P372, DOI 10.5694/j.1326-5377.1979.tb126963.x; HOLMES KM, 1982, BRIT MED J, V285, P1533, DOI 10.1136/bmj.285.6354.1533; HYAMS JS, 1983, GASTROENTEROLOGY, V84, P30; HYLAND JMP, 1980, DIGESTION, V20, P293, DOI 10.1159/000198450; KAMES LD, 1990, PAIN, V41, P41, DOI 10.1016/0304-3959(90)91107-T; KELLOW JE, 1988, GUT, V29, P1236, DOI 10.1136/gut.29.9.1236; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KENDALL GPN, 1990, GUT, V31, P1062, DOI 10.1136/gut.31.9.1062; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KLEIN KB, 1990, SEMIN GASTRO DIS, V1, P43; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; KUMAR D, 1985, LANCET, V2, P973; LOWMAN BC, 1987, J CLIN GASTROENTEROL, V9, P324, DOI 10.1097/00004836-198706000-00017; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MCINTOSH D, 1992, IN PRESS AM J GASTRO; MCMICHAE.HB, 1965, LANCET, V1, P717; MELZACK R, 1986, PSYCHOL PAIN, P1; Mendis B L, 1982, Ceylon Med J, V27, P171; MITCHELL CM, 1987, GASTROENTEROLOGY, V92, P1282, DOI 10.1016/S0016-5085(87)91099-7; MULLERLISSNER SA, 1987, GUT, V28, P1033, DOI 10.1136/gut.28.8.1033; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; NARDUCCI F, 1985, AM J GASTROENTEROL, V80, P317; NASH P, 1986, BRIT J CLIN PRACT, V40, P292; PALMER RL, 1974, POSTGRAD MED J, V50, P416, DOI 10.1136/pgmj.50.585.416; PILOWSKY I, 1990, PAIN, V40, P3, DOI 10.1016/0304-3959(90)91045-K; PIMPARKAR B D, 1970, Journal of the Indian Medical Association, V54, P95; PRIOR A, 1990, GUT, V31, P896, DOI 10.1136/gut.31.8.896; Read N. J., 1987, International Conference IACHEI 87: `How to Internationalise Technology Transfer'; READ NW, 1980, GASTROENTEROLOGY, V78, P264; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SCHAFFSTEIN W, 1990, CURR THER RES CLIN E, V47, P136; SCHWARZ SP, 1990, BEHAV RES THER, V28, P331, DOI 10.1016/0005-7967(90)90085-W; SCIARRETTA G, 1987, GUT, V28, P970, DOI 10.1136/gut.28.8.970; SEGAL I, 1984, S AFR MED J, V65, P72; SHIMBERG EF, 1988, RELIEF IBS; SMART HL, 1986, GUT, V27, P826, DOI 10.1136/gut.27.7.826; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; SNAPE WJ, 1976, GASTROENTEROLOGY, V70, P326; STRAUSS MB, 1968, FAMILIAR MED QUOTATI, P394; SULLIVAN MA, 1978, NEW ENGL J MED, V298, P878, DOI 10.1056/NEJM197804202981604; SULLIVAN SN, 1983, J CLIN GASTROENTEROL, V5, P499, DOI 10.1097/00004836-198312000-00006; SUN WM, 1990, GUT, V31, P1056, DOI 10.1136/gut.31.9.1056; SVEDLUND J, 1983, LANCET, V2, P589; SVENDSEN JH, 1985, SCAND J GASTROENTERO, V20, P415, DOI 10.3109/00365528509089673; SVENSSON TH, 1987, PSYCHOPHARMACOLOGY, V92, P1, DOI 10.1007/BF00215471; SWARBRICK ET, 1980, LANCET, V2, P443; TALLEY NJ, 1989, ANN INTERN MED, V111, P671, DOI 10.7326/0003-4819-111-8-671; THAYSEN EH, 1976, GUT, V17, P965, DOI 10.1136/gut.17.12.965; THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089; THOMPSON WG, 1986, AM J GASTROENTEROL, V81, P95; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; THOMPSON WG, 1982, DIGEST DIS SCI, V27, P605, DOI 10.1007/BF01297216; THOMPSON WG, 1986, CAN MED ASSOC J, V134, P111; THOMPSON WG, 1992, IN PRESS GASTROENTER; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; THOMPSON WG, 1989, GUT REACTIONS; THOMPSON WG, 1990, CURRENT TOPICS GASTR, P236; THOMPSON WG, 1989, GUT REACTIONS, P181; TURA B, 1990, BRAIN RES, V518, P19, DOI 10.1016/0006-8993(90)90948-B; URBAIN JLC, 1988, DIGEST DIS SCI, V33, P779, DOI 10.1007/BF01550963; VANOUTRYVE M, 1991, J CLIN GASTROENTEROL, V13, P49; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; WALKER EA, 1990, AM J PSYCHIAT, V147, P1656; WALKER EA, 1990, AM J PSYCHIAT, V147, P565; WALLER SL, 1969, LANCET, V2, P753; WANGEL AG, 1965, GASTROENTEROLOGY, V48, P69; WARD NG, 1979, PAIN, V7, P331, DOI 10.1016/0304-3959(79)90089-7; WELCH GW, 1985, BRIT MED J, V291, P1382, DOI 10.1136/bmj.291.6506.1382; WELGAN P, 1988, GASTROENTEROLOGY, V94, P1150, DOI 10.1016/0016-5085(88)90006-6; Wen B Z, 1988, Zhonghua Liu Xing Bing Xue Za Zhi, V9, P345; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHITEHEAD WE, 1981, MED CLIN N AM, V65, P1397, DOI 10.1016/S0025-7125(16)31478-X; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P336, DOI 10.1016/0016-5085(90)90822-I; WHITEHEAD WE, 1982, DIGEST DIS SCI, V27, P202, DOI 10.1007/BF01296915; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; WISE TN, 1982, PSYCHOSOMATICS, V23, P465; YOUNG SJ, 1976, GASTROENTEROLOGY, V70, P162; ZWETCHKENBAUM JF, 1988, AM J GASTROENTEROL, V83, P901	116	232	245	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				1009	1016		10.7326/0003-4819-116-12-1009	http://dx.doi.org/10.7326/0003-4819-116-12-1009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586090				2022-12-28	WOS:A1992HY79300011
J	GILMAN, S				GILMAN, S			ADVANCES IN NEUROLOGY .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITRON EMISSION TOMOGRAPHY; IDIOPATHIC PARKINSONS-DISEASE; CEREBRAL BLOOD-FLOW; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; ENVIRONMENTAL TOXINS; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; MOTOR FLUCTUATIONS; XE-133 INHALATION; ADRENAL-MEDULLA				GILMAN, S (corresponding author), UNIV MICHIGAN, MED CTR, DEPT NEUROL, 1500 E MED CTR DR, 1914 TAUBMAN CTR, ANN ARBOR, MI 48109 USA.							ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALBIN RL, 1992, NEUROSCIENCE, V46, P35, DOI 10.1016/0306-4522(92)90006-N; Barbeau A., 1986, HDB CLIN NEUROLOGY, P87; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BIRKMAYER W, 1983, ACTA NEUROL SCAND, V68, P103, DOI 10.1111/j.1600-0404.1983.tb01522.x; BJORKLUND A, 1987, TRENDS NEUROSCI, V10, P509, DOI 10.1016/0166-2236(87)90131-7; BOHN MC, 1987, SCIENCE, V237, P913, DOI 10.1126/science.2887034; BRADLEY WG, 1984, RADIOLOGY, V152, P695, DOI 10.1148/radiology.152.3.6463251; BROOKS DJ, 1991, J CEREB BLOOD FLOW M, V11, pS229; BURNS RS, 1985, NEW ENGL J MED, V312, P1418, DOI 10.1056/NEJM198505303122203; CARR DH, 1984, J COMPUT ASSIST TOMO, V8, P385, DOI 10.1097/00004728-198406000-00003; DAMATO RJ, 1986, SCIENCE, V231, P987, DOI 10.1126/science.3080808; DEVOLDER AG, 1989, ANN NEUROL, V26, P239, DOI 10.1002/ana.410260210; DUARA R, 1992, CLIN BRAIN IMAGING P, P294; FARDE L, 1988, PSYCHOPHARMACOLOGY, V94, P471, DOI 10.1007/BF00212840; FERRARI MD, 1991, J NEUROL, V238, pS53, DOI 10.1007/BF01642907; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; FERRARI MD, 1989, NEUROLOGY, V39, P1239, DOI 10.1212/WNL.39.9.1239; FISCHER HW, 1986, RADIOLOGY, V159, P561, DOI 10.1148/radiology.159.2.3961193; FOSTER NL, 1988, ANN NEUROL, V24, P399, DOI 10.1002/ana.410240308; FREED CR, 1988, NEW ENGL J MED, V319, P370; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GIBBY WA, 1992, CLIN BRAIN IMAGING P, P3; GILMAN S, 1988, ANN NEUROL, V23, P223, DOI 10.1002/ana.410230303; GILMAN S, 1991, J CEREB BLOOD FLOW M, V11, pS230; GOADSBY PJ, 1991, ANN NEUROL, V29, P91, DOI 10.1002/ana.410290116; GOETZ CG, 1987, NEUROLOGY, V37, P875, DOI 10.1212/WNL.37.5.875; GOETZ CG, 1991, NEUROLOGY, V41, P1719, DOI 10.1212/WNL.41.11.1719; GRAHAM WC, 1990, LIFE SCI, V47, pPL91, DOI 10.1016/0024-3205(90)90376-3; HANSEN JT, 1988, EXP NEUROL, V102, P65, DOI 10.1016/0014-4886(88)90079-9; HENRY TR, 1991, J CEREB BLOOD FLOW M, V11, pS412; HOLTHOFF VA, 1991, J CEREB BLOOD FLOW M, V11, pS810; HUMPHREY PPA, 1989, CEPHALALGIA, V9, P23; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; INOUE Y, 1985, J COMPUT ASSIST TOMO, V9, P129, DOI 10.1097/00004728-198501000-00024; JANKOVIC J, 1988, PARKINSONS DISEASE M, P95; JAVITCH JA, 1984, EUR J PHARMACOL, V106, P455, DOI 10.1016/0014-2999(84)90740-4; JUNCK L, 1989, ANN NEUROL, V26, P752, DOI 10.1002/ana.410260611; KLOCKGETHER T, 1991, ANN NEUROL, V30, P717, DOI 10.1002/ana.410300513; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81; KUHL DE, 1982, ANN NEUROL, V12, P425, DOI 10.1002/ana.410120504; KURLAN R, 1986, ANN NEUROL, V20, P262, DOI 10.1002/ana.410200213; LANCE JW, 1989, CEPHALALGIA, V9, P7; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LASSEN NA, 1992, CLIN BRAIN IMAGING P, P108; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEE BI, 1988, ARCH NEUROL-CHICAGO, V45, P397, DOI 10.1001/archneur.1988.00520280043014; LEENDERS K L, 1987, Neurology, V37, P113; LEENDERS KL, 1990, ARCH NEUROL-CHICAGO, V47, P1290, DOI 10.1001/archneur.1990.00530120034007; LEENDERS KL, 1986, J NEUROL NEUROSUR PS, V49, P853, DOI 10.1136/jnnp.49.8.853; LEENDERS KL, 1991, J CEREB BLOOD FLOW M, V11, pS818; LINDVALL O, 1989, ARCH NEUROL-CHICAGO, V46, P615, DOI 10.1001/archneur.1989.00520420033021; LINET MS, 1989, JAMA-J AM MED ASSOC, V261, P2211, DOI 10.1001/jama.261.15.2211; LUFKIN RB, 1992, CLIN BRAIN IMAGING P, P39; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; MANNISTO PT, 1989, TRENDS PHARMACOL SCI, V10, P54, DOI 10.1016/0165-6147(89)90075-8; MASARYK TJ, 1989, RADIOLOGY, V171, P793, DOI 10.1148/radiology.171.3.2717754; MASARYK TJ, 1989, RADIOLOGY, V171, P801, DOI 10.1148/radiology.171.3.2717755; MAZZIOTTA JC, 1987, NEW ENGL J MED, V316, P357, DOI 10.1056/NEJM198702123160701; Mazziotta JC, 1992, CLIN BRAIN IMAGING P, P244; MAZZIOTTA JC, 1992, CLIN BRAIN IMAGING P, P458; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MERIKANGAS KR, 1991, CEPHALALGIA, V11, P108, DOI 10.1177/0333102491011S1158; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; MORRIS JC, 1989, ARCH NEUROL-CHICAGO, V46, P651, DOI 10.1001/archneur.1989.00520420071025; MOSELEY ME, 1989, J COMPUT ASSIST TOMO, V13, P167, DOI 10.1097/00004728-198901000-00044; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MOSKOWITZ MA, 1991, J NEUROL, V238, pS18, DOI 10.1007/BF01642901; MYLECHARANE EJ, 1991, J NEUROL, V238, pS45, DOI 10.1007/BF01642906; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NUTT JG, 1984, NEW ENGL J MED, V310, P483, DOI 10.1056/NEJM198402233100802; NUTT JG, 1990, NEUROLOGY, V40, P340; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLSEN TS, 1987, ARCH NEUROL-CHICAGO, V44, P156, DOI 10.1001/archneur.1987.00520140028013; OTTO D, 1990, J NEUROSCI, V10, P1912; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Pearce J., 1975, MODERN TOPICS MIGRAI, P107; PHELPS ME, 1992, CLIN BRAIN IMAGING P, P71; PINCUS JH, 1988, NEUROLOGY, V38, P481, DOI 10.1212/WNL.38.3.481; QUINN N, 1989, J NEUROL NEUROSUR PS, P78; Raskin N, 1988, HEADACHE; RASKIN NH, 1987, HEADACHE, V27, P416, DOI 10.1111/j.1526-4610.1987.hed2708416.x; RASKIN NH, 1991, NEW ENGL J MED, V325, P353, DOI 10.1056/NEJM199108013250509; SAGE JI, 1988, ANN NEUROL, V24, P87, DOI 10.1002/ana.410240116; SAXENA PR, 1989, TRENDS PHARMACOL SCI, V10, P200, DOI 10.1016/0165-6147(89)90238-1; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; SNYDER SH, 1991, NATURE, V350, P195, DOI 10.1038/350195a0; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TANNER CM, 1989, TRENDS NEUROSCI, V12, P49, DOI 10.1016/0166-2236(89)90135-5; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; THEODORE WH, 1992, CLIN BRAIN IMAGING P, P136; TYLER JL, 1992, CLIN BRAIN IMAGING P, P166; TYRRELL PJ, 1990, ARCH NEUROL-CHICAGO, V47, P1318, DOI 10.1001/archneur.1990.00530120062011; VORSTRUP S, 1986, ACTA NEUROL SCAND, V74, P439, DOI 10.1111/j.1600-0404.1986.tb07869.x; WATERS WE, 1986, HEADACHE SERIES CLIN; WELCH K, 1984, CEPHALALGIA, V4, P227, DOI 10.1046/j.1468-2982.1984.0404227.x; WELCH KMA, 1990, ARCH NEUROL-CHICAGO, V47, P458, DOI 10.1001/archneur.1990.00530040114027; WELCH KMA, 1989, NEW ADV HEADACHE RES, P143	102	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1608	1616		10.1056/NEJM199206113262405	http://dx.doi.org/10.1056/NEJM199206113262405			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584262				2022-12-28	WOS:A1992HX63300006
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			RISKY BUSINESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GUIDE		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,BOSTON,MA 02111, USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION, P29; CHAMBERS HF, 1984, ENDOCARDITIS, P183; COHEN C, 1991, JAMA-J AM MED ASSOC, V265, P1299, DOI 10.1001/jama.265.10.1299; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; HUBBELL G, 1981, AM HEART J, V102, P85, DOI 10.1016/0002-8703(81)90418-X; MOSS AH, 1991, JAMA-J AM MED ASSOC, V265, P1295, DOI 10.1001/jama.265.10.1295; ROBERTS R, 1990, Emergency Medicine Clinics of North America, V8, P665; SCHWARTZ WB, 1989, NY TIMES        1016, pA21; SHAW GB, 1908, NORD SUD, V127, P197; SHAW GB, 1908, NORD SUD, V127, P5; SHAW GB, 1908, NORD SUD, V127, P408; WEARS RL, 1991, ANN EMERG MED, V20, P749, DOI 10.1016/S0196-0644(05)80836-4	13	5	6	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1546	1549		10.1056/NEJM199206043262307	http://dx.doi.org/10.1056/NEJM199206043262307			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579138				2022-12-28	WOS:A1992HW97200007
J	SESSO, R; SANTOS, AP; NISHIDA, SK; KLAG, MJ; CARVALHAES, JT; AJZEN, H; RAMOS, OL; PEREIRA, AB				SESSO, R; SANTOS, AP; NISHIDA, SK; KLAG, MJ; CARVALHAES, JT; AJZEN, H; RAMOS, OL; PEREIRA, AB			PREDICTION OF STEROID RESPONSIVENESS IN THE IDIOPATHIC NEPHROTIC SYNDROME USING URINARY RETINOL-BINDING PROTEIN AND BETA-2-MICROGLOBULIN	ANNALS OF INTERNAL MEDICINE			English	Article						RETINOL-BINDING PROTEINS; BETA 2 MICROGLOBULIN; NEPHROTIC SYNDROME; NEPHROSIS, LIPOID	RENAL-FUNCTION	Objectives: To determine the prevalence of early proximal tubular dysfunction, measured by urinary excretion of retinol-binding protein (RBP) and beta-2-microglobulin (B2M), in patients with the idiopathic nephrotic syndrome and to investigate the value of these tests in predicting steroid responsiveness. Design: Before-after trial with 8-week treatment period. Setting: Tertiary referral center. Patients: Sequential sample of 37 patients with the idiopathic nephrotic syndrome caused by minimal change disease, focal segmental glomerulosclerosis, or mesangial proliferative glomerulonephritis. Intervention: All patients were treated with prednisone as one dose of 1 to 1.5 mg/kg body weight per day for 8 weeks. Measurements: Urinary RBP was measured by an immunoenzymometric assay and B2M, by an enzyme-linked immunosorbent assay. Remission of the nephrotic syndrome after steroid treatment was the main outcome variable. Results: Elevated levels of urinary RBP and B2M before treatment were detected in 65% and 75% of the patients, respectively. Median urinary RBP and B2M, before treatment, were significantly higher in the steroid-unresponsive group than in the responsive group (P < 0.01). In the steroid-responsive group, urinary RBP and B2M levels decreased significantly after remission (P < 0.01). In the steroid-unresponsive group, the likelihood ratios for urinary RBP greater than 4000-mu-g/g creatinine and for B2M greater than 3000-mu-g/g creatinine were 3.8 and 3.0, respectively. The probability was 100% that values of RBP of less than 1300-mu-g/g creatinine and B2M of less than 130-mu-g/g creatinine were from steroid-responsive patients. Multivariate analysis confirmed that higher urinary levels of RBP and B2M were associated with a lower likelihood of steroid responsiveness, independent of age and histologic diagnosis. Conclusions: Proximal tubular dysfunction is frequent in patients with the idiopathic nephrotic syndrome. Pretreatment urinary RBP and B2M levels may be helpful in identifying nephrotic patients who are more likely to be responsive to steroids.	ESCOLA PAULISTA MED SCH, DIV NEPHROL, BR-04023 SAO PAULO, BRAZIL; ESCOLA PAULISTA MED SCH, DEPT PEDIAT, BR-04023 SAO PAULO, BRAZIL	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	SESSO, R (corresponding author), JOHNS HOPKINS MED INST, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, 600 N WOLFE ST, CARNEGIE 292, BALTIMORE, MD 21205 USA.		Sesso, Ricardo C C/B-4767-2013	Tavares, Alze/0000-0003-0783-0106; Sesso, Ricardo/0000-0002-1062-0073				BERNARD AM, 1987, CLIN CHEM, V33, P775; BOHLE A, 1990, PATHOL RES PRACT, V186, P135, DOI 10.1016/S0344-0338(11)81021-6; BOUISSOU F, 1980, CLIN NEPHROL, V14, P135; CAMERON JS, 1990, AM J NEPHROL, V10, P81; EDDY AA, 1989, AM J PATHOL, V135, P719; ERDREICH LS, 1981, AM J EPIDEMIOL, V114, P649, DOI 10.1093/oxfordjournals.aje.a113236; FERRUA B, 1980, J IMMUNOL METHODS, V36, P149, DOI 10.1016/0022-1759(80)90039-3; MCVICAR M, 1980, J PEDIATR-US, V97, P918, DOI 10.1016/S0022-3476(80)80420-3; PEREIRA A B, 1991, Clinical Chemistry, V37, P1062; PORTMAN RJ, 1986, KIDNEY INT, V30, P91, DOI 10.1038/ki.1986.156; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SCHARDIJN GHC, 1987, KIDNEY INT, V32, P635, DOI 10.1038/ki.1987.255; SHIOJI R, 1974, CLIN NEPHROL, V2, P76; STICKLER GB, 1960, PEDIATRICS, V26, P75; TEGLAERS WH, 1955, HELV PAEDIATR ACTA, V10, P269	15	30	30	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					905	909		10.7326/0003-4819-116-11-905	http://dx.doi.org/10.7326/0003-4819-116-11-905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580447				2022-12-28	WOS:A1992HW13700005
J	HELLMANN, DB				HELLMANN, DB			SPONDYLOARTHROPATHY WITH HIDRADENITIS SUPPURATIVA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							DISEASES				HELLMANN, DB (corresponding author), JOHNS HOPKINS UNIV, SCH MED, 1830 E MONUMENT ST, ROOM 9030, BALTIMORE, MD 21205 USA.							ARNETT FC, 1987, B RHEUM DIS, V37, P1; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; ELLIS BI, 1987, RADIOLOGY, V162, P541, DOI 10.1148/radiology.162.2.2948214; KNITZER RH, 1991, SEMIN ARTHRITIS RHEU, V20, P247, DOI 10.1016/0049-0172(91)90020-Z; ROSNER IA, 1982, ANN INTERN MED, V97, P520, DOI 10.7326/0003-4819-97-4-520; SCHWARTZ BD, 1990, ARTHRITIS RHEUM, V33, P457, DOI 10.1002/art.1780330401; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117	8	8	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2363	2365		10.1001/jama.267.17.2363	http://dx.doi.org/10.1001/jama.267.17.2363			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564778				2022-12-28	WOS:A1992HR01500031
J	MAYFORD, M; BARZILAI, A; KELLER, F; SCHACHER, S; KANDEL, ER				MAYFORD, M; BARZILAI, A; KELLER, F; SCHACHER, S; KANDEL, ER			MODULATION OF AN NCAM-RELATED ADHESION MOLECULE WITH LONG-TERM SYNAPTIC PLASTICITY IN APLYSIA	SCIENCE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; SENSORY NEURONS; HETEROSYNAPTIC FACILITATION; STRUCTURAL-CHANGES; PROTEIN-SYNTHESIS; SENSITIZATION; DOMAINS; MEMBER; STIMULATION	A form of learning in the marine mollusk Aplysia, long-term sensitization of the gill- and siphon-withdrawal reflex, results in the formation of new synaptic connections between the presynaptic siphon sensory neurons and their target cells. These structural changes can be mimicked, when the cells are maintained in culture, by application of serotonin, an endogenous facilitating neurotransmitter in Aplysia. A group of cell surface proteins, designated Aplysia cell adhesion molecules (apCAM's) was down-regulated in the sensory neurons in response to serotonin. The deduced amino acid sequence obtained from complementary DNA clones indicated that the apCAM's are a family of proteins that seem to arise from a single gene. The apCAM's are members of the immunoglobulin class of cell adhesion molecules and resemble two neural cell adhesion molecules, NCAM and fasciclin II. In addition to regulating newly synthesized apCAM, serotonin also altered the amount of preexisting apCAM on the cell surface of the presynaptic sensory neurons. By contrast, the apCAM on the surface of the postsynaptic motor neuron was not modulated by serotonin. This rapid, transmitter-mediated down-regulation of a cell adhesion molecule in the sensory neurons may be one of the early molecular changes in long-term synaptic facilitation.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	MAYFORD, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168 ST, NEW YORK, NY 10032 USA.			Mayford, Mark/0000-0002-9001-5024; Keller, Flavio/0000-0002-6449-6960				BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P9356, DOI 10.1073/pnas.85.23.9356; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; CHANG FLF, 1984, BRAIN RES, V309, P35, DOI 10.1016/0006-8993(84)91008-4; CHANGE FL, 1984, BRAIN RES, V309, P476; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HUFFNER WB, 1991, CURR OPIN NEUROBIOL, V1, P388; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KELLER F, 1990, J CELL BIOL, V111, P2637, DOI 10.1083/jcb.111.6.2637; KELLER F, UNPUB; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LEMMON V, 1992, J NEUROSCI, V12, P818; MEYFORD M, UNPUB; MONTAROLO P G, 1991, Society for Neuroscience Abstracts, V17, P1591; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; RAYPORT SG, 1986, J NEUROSCI, V6, P759; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHACHER S, 1990, COLD SPRING HARB SYM, V55, P187; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	46	362	366	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					638	644		10.1126/science.1585176	http://dx.doi.org/10.1126/science.1585176			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585176				2022-12-28	WOS:A1992HR18500025
J	GOLDBERG, DJ; MACKINNON, H; SMITH, R; PATEL, NB; SCRIMGEOUR, JB; INGLIS, JM; PEUTHERER, JF; URQUHART, GE; EMSLIE, JAN; COVELL, RG; REID, D				GOLDBERG, DJ; MACKINNON, H; SMITH, R; PATEL, NB; SCRIMGEOUR, JB; INGLIS, JM; PEUTHERER, JF; URQUHART, GE; EMSLIE, JAN; COVELL, RG; REID, D			PREVALENCE OF HIV AMONG CHILDBEARING WOMEN AND WOMEN HAVING TERMINATION OF PREGNANCY - MULTIDISCIPLINARY STEERING GROUP-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION	Objective - To determine the prevalence of HIV among pregnant women, in particular those whose behaviour or that of their partners put them at "low risk" of infection. Design - Voluntary named or anonymous HIV testing of pregnant women during 21 months (November 1988 to July 1990). Subjects and setting - All women who planned to continue their pregnancy and attended clinics serving the antenatal populations of Edinburgh and Dundee. All women admitted for termination of pregnancy to gynaecology wards serving the pregnant populations of Dundee and outlying rural areas. Main outcome measures-Period prevalence of HIV antibody positivity. Results - 91% of antenatal clinic attenders and 97% of women having termination of pregnancy agreed to HIV testing on a named or anonymous basis. HIV period prevalences for antenatal clinic attenders and women having termination of pregnancy tested in Dundee were 0.13% and 0.85% respectively, and for antenatal clinic attenders tested in Edinburgh 0.26%. For those at "low risk" rates for antenatal clinic attenders and women having termination of pregnancy in Dundee were 0.11% and 0.13%, and for antenatal clinic attenders in Edinburgh 0.02%. In Dundee HIV prevalence among women having a termination of pregnancy (0.85%) was significantly greater than that among antenatal clinic attenders (0.13%). Conclusions - HIV infection is undoubtedly occurring among women at "low risk," and it is clear that a policy of selective testing of those at only "high risk" is inadequate for pregnant women living in areas of high prevalence such as Edinburgh and Dundee. Moreover, when studying pregnant populations in such areas there is the need to include those having a termination of pregnancy.	RUCHILL HOSP, COMMUN DIS SCOTLAND UNIT, GLASGOW G20 9NB, SCOTLAND; EASTERN GEN HOSP, DEPT OBSTET, EDINBURGH, SCOTLAND; NINEWELLS HOSP, DEPT REPROD MED, DUNDEE, SCOTLAND; CITY HOSP EDINBURGH, REG VIRUS LAB, EDINBURGH EH10 5SB, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; NINEWELLS HOSP, DEPT MED MICROBIOL, DUNDEE, SCOTLAND	University of Dundee; University of Edinburgh; University of Dundee								ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BIRD AG, 1988, LANCET, V1, P713; EMANUELLI F, 1991, 7 P INT C AIDS, V2, P364; GILL ON, 1989, BRIT MED J, V299, P1295, DOI 10.1136/bmj.299.6711.1295; HADLINGTON S, 1988, NATURE, V333, P486, DOI 10.1038/333486a0; HEATH RB, 1988, LANCET, V1, P1394; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; MEADOWS J, 1991, 7 P INT C AIDS, V1, P380; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; SAAH AJ, 1991, TANSCRIPT, V19, P7; SMITH R, 1990, BRIT MED J, V301, P518, DOI 10.1136/bmj.301.6751.518; TAPPIN DM, 1991, LANCET, V337, P1565; Urquhart G. E. D., 1987, Communicable Diseases in Scotland, V21, P5; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, LANCET, V335, P575; 1991, COMMUNICABLE DISEA S, V25, pA208; 1991, COMMUNICABLE DISEASE, V1, pR69	18	42	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1992	304	6834					1082	1085		10.1136/bmj.304.6834.1082	http://dx.doi.org/10.1136/bmj.304.6834.1082			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586820	Green Published, Bronze			2022-12-28	WOS:A1992HR13600015
J	LAW, NW; TRAPNELL, JE				LAW, NW; TRAPNELL, JE			DOES A TRUSS BENEFIT A PATIENT WITH INGUINAL-HERNIA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOURNEMOUTH HOSP,GEN SURG,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND									CONDON RE, 1971, SURG CLIN N AM, V51, P1325; GOLDMAN M, 1991, BRIT MED J, V302, P238, DOI 10.1136/bmj.302.6770.238-d; Ljungdahl I, 1973, ACTA CHIR SCAND    S, V439, P7	3	12	12	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1092	1092		10.1136/bmj.304.6834.1092	http://dx.doi.org/10.1136/bmj.304.6834.1092			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586824	Green Published, Bronze			2022-12-28	WOS:A1992HR13600019
J	HARTWIG, JH; THELEN, M; ROSEN, A; JANMEY, PA; NAIRN, AC; ADEREM, A				HARTWIG, JH; THELEN, M; ROSEN, A; JANMEY, PA; NAIRN, AC; ADEREM, A			MARCKS IS AN ACTIN FILAMENT CROSS-LINKING PROTEIN REGULATED BY PROTEIN-KINASE-C AND CALCIUM CALMODULIN	NATURE			English	Article							PROMINENT CELLULAR SUBSTRATE; MOLECULAR-CLONING; PHORBOL ESTERS; 87-KDA PROTEIN; GROWTH-FACTORS; PHOSPHORYLATION; BRAIN; MYRISTOYLATION; PURIFICATION; EXPRESSION	AGONISTS that stimulate protein kinase C (PKC) induce profound changes in cell morphology correlating with the reorganization of submembranous actin 1,2, but no direct connection between PKC and actin assembly has been identified 3. The myristoylated, alanine-rich C kinase substrate (MARCKS) binds calmodulin 4,5 and is a predominant, specific substrate of PKC which is phosphorylated during macrophage and neutrophil activation 6-8, growth factor-dependent mitogenesis 9,10 and neurosecretion 11,12; it is redistributed from plasma membrane to cytoplasm when phosphorylated 13-15 and is involved in leukocyte motility 14,15. Here we report that MARCKS is a filamentous (F) actin crosslinking protein, with activity that is inhibited by PKC-mediated phosphorylation and by binding to calcium-calmodulin. MARCKS may be a regulated crossbridge between actin and the plasma membrane, and modulation of the actin crosslinking activity of the MARCKS protein by calmodulin and phosphorylation represents a potential convergence of the calcium-calmodulin and PKC signal transduction pathways in the regulation of the actin cytoskeleton.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021; BRIGHAM & WOMENS HOSP,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Rockefeller University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Nairn, Angus/0000-0002-7075-0195				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; CORWIN HL, 1983, DEV BIOL, V99, P61, DOI 10.1016/0012-1606(83)90254-3; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P641, DOI 10.1083/jcb.86.2.641; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHETERLINE P, 1986, J MUSCLE RES CELL M, V7, P405, DOI 10.1007/BF01753583; SNYDERMAN R, 1987, REV INFECT DIS, V9, P562; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YIN HL, 1980, J BIOL CHEM, V255, P9494	31	664	673	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					618	622		10.1038/356618a0	http://dx.doi.org/10.1038/356618a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560845				2022-12-28	WOS:A1992HP03100054
J	BAIN, JD; SWITZER, C; CHAMBERLIN, AR; BENNER, SA				BAIN, JD; SWITZER, C; CHAMBERLIN, AR; BENNER, SA			RIBOSOME-MEDIATED INCORPORATION OF A NONSTANDARD AMINO-ACID INTO A PEPTIDE THROUGH EXPANSION OF THE GENETIC-CODE	NATURE			English	Article							SITE-SPECIFIC INCORPORATION; ENZYMATIC INCORPORATION; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; BASE PAIR; RNA; DNA; ANALOG; STOP	ONE serious limitation facing protein engineers is the availability of only 20 'proteinogenic' amino acids encoded by natural messenger RNA. The lack of structural diversity among these amino acids restricts the mechanistic and structural issues that can be addressed by site-directed mutagenesis. Here we describe a new technology for incorporating non-standard amino acids into polypeptides by ribosome-based translation. In this technology, the genetic code is expanded through the creation of a 65th codon-anticodon pair from unnatural nucleoside bases having non-standard hydrogen-bonding patterns 1,2. This new codon-anticodon pair efficiently supports translation in vitro to yield peptides containing a non-standard amino acid. The versatility of the ribosome as a synthetic tool offers new possibilities for protein engineering, and compares favourably with another recently described approach in which the genetic code is simply rearranged to recruit stop codons to play a coding role 3-9.	UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521; SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND	University of California System; University of California Riverside; Swiss Federal Institutes of Technology Domain; ETH Zurich	BAIN, JD (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BAIN JD, 1991, TETRAHEDRON, V14, P2389; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FLUCK MM, 1977, MOL GEN GENET, V151, P137, DOI 10.1007/BF00338688; HECHT SM, 1978, J BIOL CHEM, V253, P4517; JUKES TH, 1991, NATURE, V352, P575, DOI 10.1038/352575a0; KAST P, 1991, THESIS ETH ZURICH; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LYTTLE MH, 1991, J ORG CHEM, V56, P4608, DOI 10.1021/jo00015a010; MANTSCH HH, 1975, BIOCHEMISTRY-US, V14, P5593, DOI 10.1021/bi00697a009; MCBRIDE LJ, 1986, J AM CHEM SOC, V108, P2040, DOI 10.1021/ja00268a052; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; ROBERTS JW, 1975, J BIOL CHEM, V250, P5530; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROESSER JR, 1986, BIOCHEMISTRY-US, V25, P6361, DOI 10.1021/bi00369a003; SEPIOL J, 1976, Z NATURFORSCH C, V31, P361; SMRT J, 1970, J BIOL CHEM, V245, P2753; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; VALLE RPC, 1988, FEBS LETT, V235, P1, DOI 10.1016/0014-5793(88)81225-0	27	260	290	2	69	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					537	539		10.1038/356537a0	http://dx.doi.org/10.1038/356537a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560827				2022-12-28	WOS:A1992HN23100064
J	REYNOLDS, BA; WEISS, S				REYNOLDS, BA; WEISS, S			GENERATION OF NEURONS AND ASTROCYTES FROM ISOLATED CELLS OF THE ADULT MAMMALIAN CENTRAL-NERVOUS-SYSTEM	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; RAT-BRAIN; PROLIFERATION; DIFFERENTIATION; LOCALIZATION; INVITRO	Neurogenesis in the mammalian central nervous system is believed to end in the period just after birth; in the mouse striatum no new neurons are produced after the first few days after birth. In this study, cells isolated from the striatum of the adult mouse brain were induced to proliferate in vitro by epidermal growth factor. The proliferating cells initially expressed nestin, an intermediate filament found in neuroepithelial stem cells, and subsequently developed the morphology and antigenic properties of neurons and astrocytes. Newly generated cells with neuronal morphology were immunoreactive for gamma-aminobutyric acid and substance P, two neurotransmitters of the adult striatum in vivo. Thus, cells of the adult mouse striatum have the capacity to divide and differentiate into neurons and astrocytes.	UNIV CALGARY,FAC MED,DEPT PATHOL,NEUROSCI RES GRP,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA; UNIV CALGARY,FAC MED,DEPT PHARMACOL & THERAPEUT,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary; University of Calgary								ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; BAYER SA, 1985, ANN NY ACAD SCI, V457, P163, DOI 10.1111/j.1749-6632.1985.tb20804.x; BIRECREE E, 1991, DEV BRAIN RES, V60, P145, DOI 10.1016/0165-3806(91)90043-I; CATTANEO E, 1991, TRENDS NEUROSCI, V14, P338, DOI 10.1016/0166-2236(91)90158-Q; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FREDERIKSEN K, 1988, J NEUROSCI, V8, P144; GENSBURGER C, 1987, FEBS LETT, V217, P1, DOI 10.1016/0014-5793(87)81230-9; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; JACOBSON M, 1991, DEV NEUROBIOL, P41; KAY AR, 1986, J NEUROSCI METH, V16, P227, DOI 10.1016/0165-0270(86)90040-3; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; REYNOLDS BR, UNPUB; SIMPSON DL, 1982, J NEUROSCI RES, V8, P453, DOI 10.1002/jnr.490080233; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238; WERNER MH, 1988, J HISTOCHEM CYTOCHEM, V36, P81, DOI 10.1177/36.1.3275713; WILLIAMS JS, 1991, NEUROSCIENCE, V43, P437, DOI 10.1016/0306-4522(91)90306-9; [No title captured]	23	4118	4710	12	361	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1707	1710		10.1126/science.1553558	http://dx.doi.org/10.1126/science.1553558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553558				2022-12-28	WOS:A1992HK81200039
J	EVANS, JWH; SINGER, M; CHAPPLE, CR; MACARTNEY, N; WALKER, JM; MILROY, EJG				EVANS, JWH; SINGER, M; CHAPPLE, CR; MACARTNEY, N; WALKER, JM; MILROY, EJG			HEMODYNAMIC EVIDENCE FOR CARDIAC STRESS DURING TRANSURETHRAL PROSTATECTOMY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare haemodynamic performance during transurethral prostatectomy and non-endoscopic control procedures similar in duration and surgical trauma. Design - Controlled comparative study. Setting - London teaching hospital. Patients - 33 men aged 50-85 years in American Society of Anesthesiologists risk groups 1 and 11 undergoing transurethral prostatectomy (20), herniorrhaphy (eight), or testicular exploration (five). Main outcome measures - Percentage change from baseline in mean arterial pressure, heart rate, Doppler indices of stroke volume and cardiac output, and index of systemic vascular resistance, and change from baseline in core temperature. Results - In the control group mean arterial pressure fell to 11% (95% confidence interval - 17% to - 5%) below baseline at two minutes into surgery and remained below baseline; there were no other overall changes in haemodynamic variables and the core temperature was stable. During transurethral prostatectomy mean arterial pressure increased by 16% (5% to 27%) at the two minute recording and remained raised throughout. Bradycardia reached -7% (-14% to 1%) by the end of the procedure. Doppler indices of stroke volume fell progressively to 15% (-24% to -6%) below baseline at the end of the procedure, and the index of cardiac output fell to 21% (-32% to -10%) below baseline by the end of the procedure. The index of systemic vascular resistance was increased by 28% (17% to 38%) at two minutes, and by 46-8% (28% to 66%) at the end of the procedure. Core temperature fell by a mean of 0.8 (-1.0 to -0.6)-degrees-C. Significant differences existed between the two groups in summary measures of mean arterial pressure (p < 0.05), Doppler indices of stroke volume (p < 0.005) and cardiac output (p < 0.005), index of systemic vascular resistance (p < 0.0005), and core temperature (p < 0.0001). Conclusions - Important haemodynamic disturbances were identified during routine apparently uneventful transurethral prostatectomy but not during control procedures. These responses may be related to the rapid central cooling observed during transurethral prostatectomy and require further study.	MIDDLESEX HOSP, DEPT MED, LONDON W1N 8AA, ENGLAND; MIDDLESEX HOSP, DEPT ANAESTHESIA, LONDON W1N 8AA, ENGLAND; MIDDLESEX HOSP, DEPT CARDIOL, LONDON W1N 8AA, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London	EVANS, JWH (corresponding author), MIDDLESEX HOSP, DEPT UROL, LONDON W1N 8AA, ENGLAND.			Walker, John Malcolm/0000-0002-8559-7218; Chapple, Christopher/0000-0002-2960-9931				ALLEN PIM, 1987, BRIT J SURG, V74, P987, DOI 10.1002/bjs.1800741109; ALLEN TD, 1973, J UROLOGY, V110, P433, DOI 10.1016/S0022-5347(17)60242-8; ARMITAGE P, 1971, STATISTICAL METHODS, P185; BLANDY JP, 1971, BRIT MED J, V1, P31, DOI 10.1136/bmj.1.5739.31; BRAUNWALD E, 1971, AM J CARDIOL, V27, P416, DOI 10.1016/0002-9149(71)90439-5; CARLI F, 1989, BAILLIERE CLIN ANAES, V3, P405, DOI 10.1016/S0950-3501(89)80009-1; CARPENTER AA, 1984, UROLOGY, V23, P122, DOI 10.1016/0090-4295(84)90003-7; CHAPPLE CR, 1990, BRIT J UROL, V66, P58, DOI 10.1111/j.1464-410X.1990.tb14866.x; CHISHOLM GD, 1989, BRIT MED J, V299, P215, DOI 10.1136/bmj.299.6693.215; COPPINGER SWV, 1989, LANCET, V2, P859, DOI 10.1016/S0140-6736(89)93016-X; CORK RC, 1983, ANESTH ANALG, V62, P211; DEANGELIS J, 1982, CRIT CARE MED, V10, P38, DOI 10.1097/00003246-198201000-00010; EVANS JWH, 1991, BRIT J UROL, V67, P376, DOI 10.1111/j.1464-410X.1991.tb15165.x; FLECHNER SM, 1982, J UROLOGY, V127, P257, DOI 10.1016/S0022-5347(17)53732-5; GHANEM AN, 1990, BRIT J UROL, V66, P71, DOI 10.1111/j.1464-410X.1990.tb14868.x; HEATHCOTE PS, 1986, BRIT J UROL, V58, P669, DOI 10.1111/j.1464-410X.1986.tb05909.x; HOLTGREWE HL, 1962, J UROLOGY, V87, P450, DOI 10.1016/S0022-5347(17)64980-2; IMRIE MM, 1990, BRIT J ANAESTH, V64, P346, DOI 10.1093/bja/64.3.346; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; KULATILAKE AE, 1981, BRIT J UROL, V53, P261, DOI 10.1111/j.1464-410X.1981.tb06101.x; KUNIN SA, 1969, J UROLOGY, V102, P469, DOI 10.1016/S0022-5347(17)62175-X; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MEBUST WK, 1970, J UROLOGY, V103, P632, DOI 10.1016/S0022-5347(17)62017-2; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; MELCHIOR J, 1974, J UROLOGY, V112, P634, DOI 10.1016/S0022-5347(17)59817-1; MERIN RG, 1980, ANESTHESIOLOGY, V53, P439, DOI 10.1097/00000542-198012000-00001; NEAL DE, 1990, BRIT J UROL, V66, P449, DOI 10.1111/j.1464-410X.1990.tb14986.x; PERKINS JB, 1969, J UROLOGY, V101, P93, DOI 10.1016/S0022-5347(17)62281-X; RABKE HB, 1962, J UROLOGY, V87, P447, DOI 10.1016/S0022-5347(17)64979-6; RAWSTRON RE, 1981, ANAESTH INTENS CARE, V9, P43, DOI 10.1177/0310057X8100900107; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROOS NP, 1987, J UROLOGY, V137, P1184, DOI 10.1016/S0022-5347(17)44442-9; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; SACH R, 1977, BRIT J SURG, V64, P210, DOI 10.1002/bjs.1800640318; SCHULTESASSE U, 1982, BRIT J ANAESTH, V54, P1053, DOI 10.1093/bja/54.10.1053; SINGER M, 1989, CRIT CARE MED, V17, P447, DOI 10.1097/00003246-198905000-00014; SINGER M, 1990, CONTINUOUS HAEMODYNA; TINGWALD GR, 1982, SURG GYNECOL OBSTET, V154, P704; VERRILLI RA, 1962, J UROLOGY, V87, P184, DOI 10.1016/S0022-5347(17)64935-8; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WILLIAMS G, 1989, BRIT MED J, V298, P1429, DOI 10.1136/bmj.298.6685.1429; [No title captured]; 1985, HOSPITAL INPATIENT E; 1989, LANCET, V1, P1361	44	32	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1992	304	6828					666	671		10.1136/bmj.304.6828.666	http://dx.doi.org/10.1136/bmj.304.6828.666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571637	Bronze, Green Published			2022-12-28	WOS:A1992HK76100018
J	CALVERLEY, DC; JONES, GW; KELTON, JG				CALVERLEY, DC; JONES, GW; KELTON, JG			SPLENIC RADIATION FOR CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA	ANNALS OF INTERNAL MEDICINE			English	Article						SPLEEN; RADIOTHERAPY; THROMBOCYTOPENIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PREDNISONE	CHRONIC LYMPHOCYTIC-LEUKEMIA; PURPURA; SPLENECTOMY; IRRADIATION	Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.	MCMASTER UNIV, MED CTR, DEPT MED, ROOM 2N34, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON L8N 3Z5, ONTARIO, CANADA; HAMILTON REG CANC CTR, DEPT RADIAT ONCOL, HAMILTON L8V 1C3, ONTARIO, CANADA; CANADIAN RED CROSS, BLOOD TRANSFUS SERV, HAMILTON, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								AKWARI OE, 1987, ANN SURG, V206, P529, DOI 10.1097/00000658-198710000-00014; BRENNAN MF, 1975, AM J SURG, V129, P490, DOI 10.1016/0002-9610(75)90197-X; BYHARDT RW, 1975, CANCER, V35, P1621, DOI 10.1002/1097-0142(197506)35:6<1621::AID-CNCR2820350622>3.0.CO;2-U; COLA B, 1986, INT SURG, V71, P195; COMAS FV, 1968, AMER J ROENTGENOL RA, V104, P668, DOI 10.2214/ajr.104.3.668; COON WW, 1987, SURG GYNECOL OBSTET, V164, P225; DAILEY MO, 1980, NEW ENGL J MED, V302, P215, DOI 10.1056/NEJM198001243020406; GUINEY MJ, 1989, INT J RADIAT ONCOL, V16, P225, DOI 10.1016/0360-3016(89)90035-7; JACOBS P, 1986, Q J MED, V58, P153; PIZZUTO J, 1984, BLOOD, V64, P1179; RUSSO D, 1987, HAEMATOLOGICA, V72, P445; SCHWARTZ SI, 1980, SURGERY, V88, P497; STRATTON JR, 1989, J NUCL MED, V30, P629; TERSTAPPEN LWMM, 1988, EUR J HAEMATOL, V41, P496; WARKENTIN TE, 1990, DRUGS, V40, P531, DOI 10.2165/00003495-199040040-00004; WILLIAMS WJ, 1990, HEMATOLOGY, P1381	16	32	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				977	981		10.7326/0003-4819-116-12-977	http://dx.doi.org/10.7326/0003-4819-116-12-977			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586107				2022-12-28	WOS:A1992HY79300004
J	TILL, M; LEE, N; SOPER, WD; MURPHY, RL				TILL, M; LEE, N; SOPER, WD; MURPHY, RL			TYPHLITIS IN PATIENTS WITH HIV-1 INFECTION	ANNALS OF INTERNAL MEDICINE			English	Note						TYPHLITIS; HUMAN IMMUNODEFICIENCY VIRUS; NEUTROPENIA; ABDOMINAL PAIN; ACQUIRED IMMUNODEFICIENCY SYNDROME	NEUTROPENIC ENTEROCOLITIS; MANAGEMENT; ADULTS; AIDS	Typhlitis, or inflammation of the cecum, causes significant morbidity and mortality in neutropenic patients. Most cases occur in patients with hematologic malignancies who have received antineoplastic chemotherapy. These patients often require surgical intervention. We have recently observed several patients infected with the human immunodeficiency virus type 1 (HIV-1) who have developed a clinical syndrome compatible with typhlitis. During a 15-month period, six patients experienced eight episodes of typhlitis. Only one patient, however, had severe neutropenia (absolute neutrophil count, < 500 cells/mm3), which has been considered a hallmark of this disease. These patients presented with fever, right lower quadrant abdominal pain, and localized peritoneal signs. Of the five patients who had computed tomographic examination of the abdomen, four showed mural thickening of the cecum. All patients responded well to conservative management consisting of broad-spectrum intravenous antibiotics and bowel rest. Physicians should be aware that this syndrome occurs in HIV-1 infected patients despite the possible absence of neutropenia and should consider the diagnosis when these patients present with fever and right lower quadrant pain.	NORTHWESTERN UNIV, SCH MED, INFECT DIS SECT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT SURG, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University	TILL, M (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, 303 E SUPER ST 8E, CHICAGO, IL 60611 USA.			Murphy, Robert/0000-0003-3936-2052				ALT B, 1985, AM J SURG, V149, P405, DOI 10.1016/S0002-9610(85)80119-7; CUTRONA AE, 1991, REV INFECT DIS, V13, P828; ELLIS M, 1988, J INFECT DIS, V158, P1268, DOI 10.1093/infdis/158.6.1268; KOEA JB, 1989, BRIT J SURG, V76, P821, DOI 10.1002/bjs.1800760821; KUNKEL JM, 1986, DIS COLON RECTUM, V29, P196, DOI 10.1007/BF02555024; MOWER WJ, 1986, ARCH SURG-CHICAGO, V121, P571; MURPHY PM, 1988, J INFECT DIS, V158, P627, DOI 10.1093/infdis/158.3.627; NEWBOLD KM, 1989, DIGEST DIS, V7, P281; RODGERS VD, 1991, SEMIN GASTROINTEST D, V2, P17; SHAKED A, 1983, DIS COLON RECTUM, V26, P351, DOI 10.1007/BF02561717	10	31	31	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				998	1000		10.7326/0003-4819-116-12-998	http://dx.doi.org/10.7326/0003-4819-116-12-998			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586111				2022-12-28	WOS:A1992HY79300009
J	GAVRAS, H				GAVRAS, H			ORAL MILRINONE IN SEVERE CHRONIC HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											GAVRAS, H (corresponding author), BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA.							[Anonymous], 1990, Lancet, V336, P1; CURFMAN GD, 1991, NEW ENGL J MED, V325, P1509, DOI 10.1056/NEJM199111213252111; GAVRAS H, 1978, CIRCULATION, V58, P770, DOI 10.1161/01.CIR.58.5.770; PACKER M, 1986, NEW ENGL J MED, V315, P847, DOI 10.1056/NEJM198610023151402; POULEUR H, 1991, AM J CARDIOL, V68, P71, DOI 10.1016/0002-9149(91)90713-U; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	8	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1566	1566						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579143				2022-12-28	WOS:A1992HW97200013
J	BELKIN, BM; NEELON, FA				BELKIN, BM; NEELON, FA			THE ART OF OBSERVATION - OSLER,WILLIAM AND THE METHOD OF ZADIG	ANNALS OF INTERNAL MEDICINE			English	Article						HISTORY OF MEDICINE; OSLER, WILLIAM; ZADIG; EDUCATION, MEDICAL; MEDICAL HISTORY TAKING	BEDSIDE	William Osler's greatest innovation as a teacher, said Rufus Cole, was his use of "the method of Zadig." Zadig, the hero of Voltaire's 1747 novelette of the same name, used careful and practiced observation of seemingly inconspicuous details to propose astounding (and correct) causal sequences that, he argued, were the logical antecedents to facts at hand. His mode of reasoning, called "retrospective prophecy" by Huxley, is the cornerstone of branches of science that use inference to reconstruct and explain the unobserved past. Archaeologists, astronomers, art connoisseurs, and physicians are, sometimes unwittingly, devotees of Zadig's method. A prime example was the Edinburgh surgeon Joseph Bell who served as medical mentor to Arthur Conan Doyle and became the model for Sherlock-Holmes (whose "elementary" deductions parallel Zadig's). Osler's enduring legacy rests, at least in part, on his embodiment of the fundamental elements of Zadig's method: lack of pretense. thoughtful and informed observation, attention to subtle detail, and unbiased assessment. Present-day students of medicine will find that familiarity with and application of the method of Zadig can provide a framework on which to base and by which to embellish their daily work.	DUKE UNIV, MED CTR, BOX 3021, DURHAM, NC 27710 USA	Duke University								BATHWAYT R, 1892, TALK C DOYLE, V2, P50; BELL J, 1892, ADVENTURES S HOLMES, V3, P79; Block Haskell M., 1956, CANDIDE OTHER WRITIN; COLE R, 1949, ARCH INTERN MED, V84, P54, DOI 10.1001/archinte.1949.00230010064013; EDDY DM, 1982, NEW ENGL J MED, V306, P1263, DOI 10.1056/NEJM198205273062104; FITZGERALD FT, 1982, WESTERN J MED, V137, P169; FOUCAULT M, 1975, BIRTH CLINIC; Futcher T B, 1935, Can Med Assoc J, V32, P357; Huxley TH, 1888, SCI CULTURE OTHER ES; LINFORS EW, 1980, NEW ENGL J MED, V303, P1230, DOI 10.1056/NEJM198011203032110; Mackenzie J, 1914, BRIT MED J, V1914, P17, DOI 10.1136/bmj.1.2766.17; Maxted G H, 1991, N C Med J, V52, P307; NOVAK M, 1976, MAN MED, V1, P95; Osler W, 1914, Br Med J, V1, P10; Osler W, 1901, J AMER MED ASSOC, V36, P1673; Osler W., 1903, MED NEWS NEW YORK, V82, P49; REMER TG, 1985, SERENDIPITY 3 PRINCE; SHEPHERED M, 1985, S HOLMES CASE FREUD; SLADEN FJ, 1949, N C MED J, V10, P607; Thayer WS, 1919, B JOHNS HOPKINS HOSP, V30, P198; THAYER WS, 1931, OSLER OTHER PAPERS; WOLLHEIM R, 1974, ART MIND	22	20	22	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					863	866		10.7326/0003-4819-116-10-863	http://dx.doi.org/10.7326/0003-4819-116-10-863			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567100				2022-12-28	WOS:A1992HT80200013
J	CHEN, JW; LEE, J; JAYARAM, M				CHEN, JW; LEE, J; JAYARAM, M			DNA CLEAVAGE IN TRANS BY THE ACTIVE-SITE TYROSINE DURING FLP RECOMBINATION - SWITCHING PROTEIN PARTNERS BEFORE EXCHANGING STRANDS	CELL			English	Article							CEREVISIAE 2-MU-M PLASMID; CIRCLE PLASMID; MECHANISM; MUTANTS; TARGET; IDENTIFICATION; RECOGNITION; RESOLVASE; SUBSTRATE; BENDS	Each recombination event mediated by the Flp recombinase is the sum of four strand breakage and reunion reactions executed in two steps of two-strand exchanges. The reaction requires four Flp monomers. The key catalytic residue in Flp is Tyr-343. Arg-191, His-305, and Arg-308 appear to facilitate the cleavage and exchange steps of recombination. These four residues constitute the invariant tetrad of the Int family site-specific recombinases. Complementation tests between "step-arrest" mutants of Flp suggest that each Flp protomer harbors a "fractional active site." Hybrid "half site-recombinase" complexes reveal that efficient catalysis occurs when the Arg-His-Arg triad is present on one Flp monomer and the active site Tyr on a second monomer. Strand cleavage by an Flp monomer occurs virtually exclusively on the half site to which its partner protein is bound (cleavage in trans), and almost never on the half site to which it is bound (cleavage in cis). Trans-cleavage by Flp can provide a means for functionally exchanging Flp monomers between two DNA partners. Such a mechanism would be germane to recombination, since cleavage and rejoining in cis can only restore the parental substrate configuration and cannot yield recombinants.			CHEN, JW (corresponding author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.		Lee, Jehee/AAS-3229-2021	Lee, Jehee/0000-0001-9144-3648				AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ANDREWS BJ, 1986, MOL CELL BIOL, V6, P2482, DOI 10.1128/MCB.6.7.2482; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1991, J MOL BIOL, V218, P107, DOI 10.1016/0022-2836(91)90877-9; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; EVANS BR, 1990, J BIOL CHEM, V265, P18504; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; Maniatis T., 1982, MOL CLONING; PAN H, 1991, J BIOL CHEM, V266, P11347; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1986, MOL CELL BIOL, V6, P4329, DOI 10.1128/MCB.6.12.4329; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIAN XH, 1992, IN PRESS J BIOL CHEM; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SERRE MC, 1992, IN PRESS J MOL BIOL; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	24	152	156	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					647	658		10.1016/0092-8674(92)90228-5	http://dx.doi.org/10.1016/0092-8674(92)90228-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586945				2022-12-28	WOS:A1992HV08900009
J	LANDEFELD, CS; ANDERSON, PA				LANDEFELD, CS; ANDERSON, PA			GUIDELINE-BASED CONSULTATION TO PREVENT ANTICOAGULANT-RELATED BLEEDING - A RANDOMIZED, CONTROLLED TRIAL IN A TEACHING HOSPITAL	ANNALS OF INTERNAL MEDICINE			English	Article						ANTICOAGULANTS; HEMORRHAGE; ANTIINFLAMMATORY AGENTS, NONSTEROIDAL; PRACTICE GUIDELINES	NATIVE PROTHROMBIN ANTIGEN; CONTROLLED CLINICAL-TRIAL; PROXIMAL-VEIN THROMBOSIS; HEPARIN-THERAPY; HEMORRHAGIC COMPLICATIONS; WARFARIN THERAPY; ACUTE-CARE; IMPEDANCE PLETHYSMOGRAPHY; ANTITHROMBOTIC THERAPY; DIFFERENT INTENSITIES	Objective: To test the efficacy of consultation designed to prevent anticoagulant-related bleeding. Design: Randomized, controlled trial. Setting: A large teaching hospital. Patients: A total of 101 patients at increased (> 15%) risk for major, in-hospital bleeding while starting long-term anticoagulant therapy who were identified using a validated prediction rule. Interventions: Fifty-five patients received usual care under the direction of the attending physician who had initiated anticoagulant therapy. Forty-six patients received guideline-based consultation in addition to usual care. Guideline-based consultation included individualized review of the risks and benefits of anticoagulant therapy and, on the basis of current practice guidelines, recommendations for daily management. Measurements: The main outcome was in-hospital bleeding, which was classified using a reliable, explicit index. Results: Major or minor bleeding occurred in 17 of 55 patients (31%) receiving usual care alone, compared with 6 of 46 patients (13%) receiving consultation in addition to usual care (P = 0.03). The protective efficacy of consultation was 58% (95% Cl, 3% to 82%). Consultation was associated with similar reductions in the frequencies of major bleeding (from 13% to 4%) and minor bleeding (from 18% to 9%). Consultative recommendations had an 84% compliance rate and directly affected anticoagulant management: In the consult group, nonsteroidal anti-inflammatory agents were stopped in six patients (13%), and therapeutic ranges were achieved more often for activated partial thromboplastin times (52% compared with 45% in the usual care group, P = 0.08) and for prothrombin times (47% compared with 27% in the usual care group, P < 0.001). Nearly all housestaff and attending physicians (91%) for patients receiving consultation also reported that consultation improved housestaff learning. The consult group had a somewhat lower rate of thromboembolism in the 90 days after discharge (5% compared with 17%, P = 0.06). Death rates and mean lengths of stay were similar in the two groups. Conclusion: Guideline-based consultation was associated with reduction in the frequency of anticoagulant-related bleeding in patients at increased risk for major in-hospital bleeding.	CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA; DEPT VET AFFAIRS MED CTR, CLEVELAND, OH 44106 USA	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	LANDEFELD, CS (corresponding author), UNIV HOSP CLEVELAND, 2074 ABINGTON RD, CLEVELAND, OH 44106 USA.				NIA NIH HHS [AGO4391] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG004391] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN CM, 1986, JAMA-J AM MED ASSOC, V255, P2617, DOI 10.1001/jama.255.19.2617; ALLEN EV, 1947, ANN INTERN MED, V27, P371, DOI 10.7326/0003-4819-27-3-371; [Anonymous], 1986, CHEST, V89, p1S; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; CHARLSON ME, 1983, AM J MED, V75, P121, DOI 10.1016/0002-9343(83)91175-0; COON WW, 1974, ARCH INTERN MED, V133, P386, DOI 10.1001/archinte.133.3.386; DAVIS FB, 1977, ARCH INTERN MED, V137, P197, DOI 10.1001/archinte.137.2.197; DOBLE N, 1987, J ROY SOC MED, V80, P627, DOI 10.1177/014107688708001009; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; EPSTEIN PE, 1990, ANN INTERN MED, V113, P646, DOI 10.7326/0003-4819-113-9-646; FORFAR JC, 1979, BRIT HEART J, V42, P128; FORFAR JC, 1982, AM HEART J, V103, P445, DOI 10.1016/0002-8703(82)90292-7; FRETWELL MD, 1990, J AM GERIATR SOC, V38, P1073, DOI 10.1111/j.1532-5415.1990.tb01368.x; FURIE B, 1984, BLOOD, V64, P445; FURIE B, 1990, BLOOD, V75, P344; GALLUS A, 1986, LANCET, V2, P1293; GLAZIER RL, 1976, JAMA-J AM MED ASSOC, V236, P1365, DOI 10.1001/jama.236.12.1365; GOLDMAN L, 1983, ARCH INTERN MED, V143, P1753, DOI 10.1001/archinte.143.9.1753; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HOGAN DB, 1990, AGE AGEING, V19, P107, DOI 10.1093/ageing/19.2.107; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KELTON JG, 1980, SEMIN HEMATOL, V17, P259; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOCHWESE.J, 1971, NEW ENGL J MED, V285, P547, DOI 10.1056/NEJM197109022851005; LANDEFELD CS, 1990, AM J MED, V89, P569, DOI 10.1016/0002-9343(90)90174-C; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, AM J MED, V87, P153; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LEVINE MN, 1989, CHEST, V95, pS26, DOI 10.1378/chest.95.2.26S; MANT MJ, 1977, LANCET, V1, P1133; MCINNES GT, 1987, J ROY COLL PHYS LOND, V21, P42; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; Murray GDW, 1938, ANN SURG, V108, P163, DOI 10.1097/00000658-193808000-00002; OREILLY RA, 1970, PHARMACOL REV, V22, P35; OVESEN L, 1988, EUR J CLIN PHARMACOL, V34, P521, DOI 10.1007/BF01046714; PETERSEN P, 1989, LANCET, V1, P175; PEYMAN MA, 1958, ACTA MED SCANDI S339, V162, P1; PUPA LE, 1986, AM J MED, V81, P508, DOI 10.1016/0002-9343(86)90307-4; ROBEN NJ, 1990, MED ROUNDS, V3, P63; SALZMAN EW, 1975, NEW ENGL J MED, V292, P1046, DOI 10.1056/NEJM197505152922002; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SAYA FG, 1985, AM J HOSP PHARM, V42, P1965, DOI 10.1093/ajhp/42.9.1965; SHERMAN DG, 1989, CHEST, V95, pS140; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SVEC JM, 1985, THER DRUG MONIT, V7, P174, DOI 10.1097/00007691-198506000-00006; WALKER AM, 1980, JAMA-J AM MED ASSOC, V244, P1209, DOI 10.1001/jama.244.11.1209; WATSON AJM, 1984, BRIT MED J, V288, P557, DOI 10.1136/bmj.288.6416.557; WESER JK, 1971, NEW ENGL J MED, V285, P487; WESSLER S, 1984, NEW ENGL J MED, V311, P645; WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730; WILSON JR, 1979, AM HEART J, V97, P155, DOI 10.1016/0002-8703(79)90349-1; ZWEIFLER AJ, 1962, NEW ENGL J MED, V267, P283, DOI 10.1056/NEJM196208092670604; 1990, NEW ENGL J MED, V322, P863	60	56	60	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					829	837		10.7326/0003-4819-116-10-829	http://dx.doi.org/10.7326/0003-4819-116-10-829			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567097				2022-12-28	WOS:A1992HT80200007
J	PAPPAS, PG; POTTAGE, JC; POWDERLY, WG; FRASER, VJ; STRATTON, CW; MCKENZIE, S; TAPPER, ML; CHMEL, H; BONEBRAKE, FC; BLUM, R; SHAFER, RW; KING, C; DISMUKES, WE				PAPPAS, PG; POTTAGE, JC; POWDERLY, WG; FRASER, VJ; STRATTON, CW; MCKENZIE, S; TAPPER, ML; CHMEL, H; BONEBRAKE, FC; BLUM, R; SHAFER, RW; KING, C; DISMUKES, WE			BLASTOMYCOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						BLASTOMYCOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM INFECTIONS; AMPHOTERICIN-B; KETOCONAZOLE; HUMAN IMMUNODEFICIENCY VIRUS	DERMATITIDIS; KETOCONAZOLE; ITRACONAZOLE; INFECTIONS; PULMONARY	Objective: To describe the clinical, demographic, radiographic, diagnostic, and therapeutic aspects of blastomycosis in patients with the acquired immunodeficiency syndrome (AIDS). Design: A retrospective survey. Setting: Ten university medical centers and community hospitals, six in geographic areas endemic for Blastomyces dermatitidis, and four outside the endemic area. Patients: We identified 15 patients with blastomycosis and positive serologic test results for human immunodeficiency virus (HIV). Measurements: A diagnosis of blastomycosis was based on a positive culture (14 patients) or typical histopathologic features (one patient) for B. dermatitidis in clinical specimens. Results: Twelve of 15 patients had a previous or concomitant AIDS-defining illness at the time of diagnosis of blastomycosis, and only one patient had a CD4 lymphocyte count of greater than 200 cells/mm3. Two patterns of disease emerged: localized pulmonary involvement (seven patients), and disseminated or extrapulmonary blastomycosis (eight patients). Central nervous system involvement was common (40%). Six patients died within 21 days of presentation with blastomycosis, including four patients with disseminated and two with fulminant pulmonary disease. Among the nine patients who survived longer than 1 month, all received amphotericin B as initial antifungal therapy, and most received subsequent therapy with ketoconazole. Only two of these nine patients died with evidence of progressive blastomycosis. Conclusions: Blastomycosis is a late and frequently fatal infectious complication in a few patients with AIDS. In these patients, overwhelming disseminated disease including involvement of the central nervous system is common, and it is associated with a high early mortality. Initial therapy with amphotericin B is appropriate in patients with AIDS and presumptive blastomycosis.			PAPPAS, PG (corresponding author), UNIV ALABAMA, DIV INFECT DIS, 229 TINSLEY HARRISON TOWER, UNIV STN, BIRMINGHAM, AL 35294 USA.			Powderly, William/0000-0001-7808-3086; Fraser, Victoria/0000-0001-6251-0733	NIAID NIH HHS [N01-AI-15082] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARATHOON EG, 1989, MYCOSES, V32, P109, DOI 10.1111/j.1439-0507.1989.tb02300.x; BRADSHER RW, 1984, AM REV RESPIR DIS, V129, P430; BRADSHER RW, 1985, ANN INTERN MED, V103, P872, DOI 10.7326/0003-4819-103-6-872; BROWN LR, 1991, MAYO CLIN PROC, V66, P29, DOI 10.1016/S0025-6196(12)61172-0; CHERNISS EI, 1956, ANN INTERN MED, V44, P105, DOI 10.7326/0003-4819-44-1-105; CHIU J, 1988, 4 INT C AIDS STOCKH; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DISMUKES WE, 1985, ANN INTERN MED, V103, P861, DOI 10.7326/0003-4819-103-6-861; DUTTERA J, 1969, SOUTHERN MED J, V62, P295; EHNI W, 1989, AM J MED, V86, P831, DOI 10.1016/0002-9343(89)90483-X; ENG RHK, 1986, AM J MED, V81, P19, DOI 10.1016/0002-9343(86)90176-2; ESPINELINGROFF A, 1984, ANTIMICROB AGENTS CH, V26, P5, DOI 10.1128/AAC.26.1.5; EVANS ME, 1982, AM REV RESPIR DIS, V126, P1099; FRASER VJ, 1991, J INFECT DIS, V163, P1378, DOI 10.1093/infdis/163.6.1378; GRIFFITH JE, 1979, CHEST, V75, P630, DOI 10.1378/chest.75.5.630; HERD AM, 1990, CAN MED ASSOC J, V143, P1329; KITCHEN LW, 1989, J INFECT DIS, V160, P911, DOI 10.1093/infdis/160.5.911; KLEIN BS, 1986, NEW ENGL J MED, V314, P529, DOI 10.1056/NEJM198602273140901; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P471, DOI 10.7326/0003-4819-109-6-471; LASKEY W, 1978, ANN INTERN MED, V88, P50, DOI 10.7326/0003-4819-88-1-50; ONAL E, 1976, AM REV RESPIR DIS, V113, P83; PETERSON PK, 1982, MEDICINE, V61, P360, DOI 10.1097/00005792-198211000-00002; RECHT LD, 1982, AM REV RESPIR DIS, V125, P359; ROOS KL, 1987, MEDICINE, V66, P224, DOI 10.1097/00005792-198705000-00006; SAROSI GA, 1979, AM REV RESPIR DIS, V120, P911; STEVENS DA, 1990, REV INFECT DIS, V12, pS304; Turner S, 1986, Semin Respir Infect, V1, P22; WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001; WITORSCH P, 1968, MEDICINE, V47, P169, DOI 10.1097/00005792-196805000-00001; 1987, MMWR S, V36, P1	31	158	159	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					847	853		10.7326/0003-4819-116-10-847	http://dx.doi.org/10.7326/0003-4819-116-10-847			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567099				2022-12-28	WOS:A1992HT80200011
J	MOLINA, TJ; KISHIHARA, K; SIDEROVSKI, DP; VANEWIJK, W; NARENDRAN, A; TIMMS, E; WAKEHAM, A; PAIGE, CJ; HARTMANN, KU; VEILLETTE, A; DAVIDSON, D; MAK, TW				MOLINA, TJ; KISHIHARA, K; SIDEROVSKI, DP; VANEWIJK, W; NARENDRAN, A; TIMMS, E; WAKEHAM, A; PAIGE, CJ; HARTMANN, KU; VEILLETTE, A; DAVIDSON, D; MAK, TW			PROFOUND BLOCK IN THYMOCYTE DEVELOPMENT IN MICE LACKING P56(LCK)	NATURE			English	Article							TYROSINE-PROTEIN-KINASE; T-CELL DEVELOPMENT; SIGNAL TRANSDUCTION; CD4; RECEPTOR; TRANSCRIPTS; EXPRESSION; ACTIVATION; P56LCK; GENE	THE protein Lck (p56lck) has a relative molecular mass of 56,000 and belongs to the Src family of tyrosine kinases 1-3. It is expressed exclusively in lymphoid cells, predominantly in thymocytes and peripheral T cells 4-5. Lck associates specifically with the cytoplasmic domains of both CD4 and CD8 T-cell surface glycoproteins 6,7 and interacts with the beta-chain of the interleukin-2 receptor 8, which implicates Lck activity in signal transduction during thymocyte ontogeny 9-13 and activation of mature T cells 14-19. Here we generate an lck null mutation by homologous recombination in embryonic stem cells to evaluate the role of p56lck in T-cell development and activation. Lck-deficient mice show a pronounced thymic atrophy, with a dramatic reduction in the double-positive (CD4+CD8+) thymocyte population. Mature, single-positive thymocytes are not detectable in these mice and there are only very few peripheral T cells. These results illustrate the crucial role of this T-cell-specific tyrosine kinase in the thymocyte development.	UNIV TORONTO, ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ONTARIO, CANADA; ERASMUS UNIV, DEPT CELL BIOL & IMMUNOL 2, 3000 DR ROTTERDAM, NETHERLANDS; UNIV MARBURG, INST EXPTL IMMUNOL, W-3550 MARBURG, GERMANY; MCGILL UNIV, CTR CANC, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Erasmus University Rotterdam; Philipps University Marburg; McGill University			Siderovski, David Peter/AAA-9603-2019; Molina, Thierry/ABA-5214-2020	Siderovski, David Peter/0000-0002-0688-8210; Molina, Thierry/0000-0002-3929-9754				ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FERRICK DA, 1989, IMMUNOL TODAY, V10, P403, DOI 10.1016/0167-5699(89)90035-2; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; PAIGE CJ, 1982, J IMMUNOL METHODS, V52, P51, DOI 10.1016/0022-1759(82)90349-0; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0	29	945	982	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					161	164		10.1038/357161a0	http://dx.doi.org/10.1038/357161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579166				2022-12-28	WOS:A1992HU12200059
J	BARRACLOUGH, J; PINDER, P; CRUDDAS, M; OSMOND, C; TAYLOR, I; PERRY, M				BARRACLOUGH, J; PINDER, P; CRUDDAS, M; OSMOND, C; TAYLOR, I; PERRY, M			LIFE EVENTS AND BREAST-CANCER PROGNOSIS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether psychosocial stress, in the form of adverse life events and social difficulties, depressive illness, or lack of confiding relationships, shortens the postoperative disease free interval in breast cancer patients. Design - Prospective follow up of a cohort of newly diagnosed breast cancer patients for 42 months after primary surgical treatment, using a life events and social difficulties schedule (LEDS) and assessment of depressive symptomatology (DSM-III). Setting - Patients recruited from breast clinics in Southampton and Portsmouth were interviewed in their homes. Patients - 204 women (83% of 246 consecutive cases) treated either by mastectomy or wide excision followed by radiotherapy interviewed four, 24, and 42 months after operation. Main outcome measures - Hazard ratios for relapse of breast cancer in relation to various measures of psychosocial stress. Relapse was defined as local recurrence or distant metastasis, or both, with histological or radiological confirmation and timed from the month when clinical symptoms began. Results - After adjustment for age and axillary lymph node involvement, the hazard ratio associated with severe life events or social difficulties (excluding "own health" ones), or both, during the year before breast cancer surgery was 0.43 (95% confidence interval 0.20 to 0.93); for those during the follow up period it was 0.88 (0.48 to 1.64). For prolonged major depression before surgery and during the follow up period, hazard ratios were 1.26 (0.49 to 3.26) and 0.85 (0.41 to 1.79) respectively. For absence of a full confidant the figures were 0.93 (0.42 to 2.09) and 0.86 (0.38 to 1.93). Conclusion - These results give no support to the theory that psychosocial stress contributes to relapse of breast cancer.	UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PSYCHIAT,SOUTHAMPTON SO9 4PE,ENGLAND; SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,SURG UNIT,SOUTHAMPTON SO9 4PE,ENGLAND; QUEEN ALEXANDRA HOSP,PORTSMOUTH PO6 3LY,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital				Osmond, Clive/0000-0002-9054-4655				Brown G., 1978, SOCIAL ORIGINS DEPRE; COX DR, 1984, ANAL SURVIVAL DATA, P112; DEAN C, 1989, J PSYCHOSOM RES, V33, P561, DOI 10.1016/0022-3999(89)90063-9; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; HOLLAND JC, 1989, HDB PSYCHOONCOLOGY, P705; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; 1980, DIAGNOSTIC STATISTIC	7	96	96	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1078	1081		10.1136/bmj.304.6834.1078	http://dx.doi.org/10.1136/bmj.304.6834.1078			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586819	Green Published, Bronze			2022-12-28	WOS:A1992HR13600014
J	HEDGES, SB; BOGART, JP; MAXSON, LR				HEDGES, SB; BOGART, JP; MAXSON, LR			ANCESTRY OF UNISEXUAL SALAMANDERS	NATURE			English	Article							JEFFERSONIANUM COMPLEX; AMBYSTOMA; ORIGIN; SEQUENCES	IN eastern North America there are populations of all-female salamanders that incorporate the nuclear genomes of two or three of four sympatric bisexual species. The hybrids can be diploid, triploid, tetraploid or pentaploid, and 18 different combinations have been reported. All hybrids require sperm from a sympatric male of one of the bisexual species to reproduce, but the sperm may or may not be incorporated in the egg. Some of the hybrids are believed to represent separate, clonal species, but little is known of the origin of this hybrid complex. Vertebrate mitochondrial DNA is inherited maternally, allowing identification of the female parent that gave rise to hybrid lineages. A portion of the cytochrome b gene was sequenced from diploid and triploid hybrids that represent combinations of all four species. Nearly all hybrids had a similar mitochondrial genome sequence, independent of nuclear genome composition and ploidy, and the sequence was distinct from that of any of the four bisexual species. The hybrids maintain a mitochondrial lineage that has evolved independently of their nuclear genome and represent the most ancient known unisexual vertebrate lineage.	UNIV GUELPH,DEPT ZOOL,GUELPH N1G 2W1,ONTARIO,CANADA	University of Guelph	HEDGES, SB (corresponding author), PENN STATE UNIV,DEPT BIOL,INST MOLEC EVOLUT GENET,UNIV PK,PA 16802, USA.							ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AVISE JC, 1991, EVOLUTION, V45, P1530, DOI 10.1111/j.1558-5646.1991.tb02657.x; BOGART JP, 1986, CAN J GENET CYTOL, V28, P605, DOI 10.1139/g86-089; BOGART JP, 1989, SCIENCE, V246, P1032, DOI 10.1126/science.2587986; BOGART JP, 1980, POLYPLOIDY BIOL RELE, P341, DOI DOI 10.1007/978-1-4613-3069-1_; BOGART JP, 1989, NY STATE MUS B, V466, P209; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HEDGES SB, 1991, MOL BIOL EVOL, V8, P767; HIGHTON R, 1976, EVOLUTION, V30, P33, DOI 10.1111/j.1558-5646.1976.tb00879.x; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; JUKES T H, 1969, P21; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KRAUS F, 1990, P NATL ACAD SCI USA, V87, P2235, DOI 10.1073/pnas.87.6.2235; KRAUS F, 1985, OCCAS PAP MUS ZOOL U, V709, P1; Kraus Fred, 1989, New York State Museum Bulletin, V466, P218; LOWCOCK LA, 1989, CAN J ZOOL, V67, P350, DOI 10.1139/z89-052; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SESSIONS SK, 1982, CHROMOSOMA, V84, P599, DOI 10.1007/BF00286329; STUDIER JA, 1988, MOL BIOL EVOL, V5, P729; TAYLOR AS, 1990, GENOME, V33, P837, DOI 10.1139/g90-126; UZZELL TM, 1967, EVOLUTION, V21, P345, DOI 10.1111/j.1558-5646.1967.tb00163.x; Vrijenhoek Robert C., 1989, New York State Museum Bulletin, V466, P19	25	109	114	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					708	710		10.1038/356708a0	http://dx.doi.org/10.1038/356708a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570014				2022-12-28	WOS:A1992HQ14600059
J	DEUTSCH, JC; NEFDT, RJC				DEUTSCH, JC; NEFDT, RJC			OLFACTORY CUES INFLUENCE FEMALE CHOICE IN 2 LEK-BREEDING ANTELOPES	NATURE			English	Article							MALE MATING SUCCESS; MATE CHOICE; FALLOW DEER; LEKKING; BEHAVIOR	PRONOUNCED differences in mating success between males holding territories clustered on traditional mating grounds (leks) are commonly cited as evidence of female choice for male phenotypes 1-6, but female ungulates appear to prefer particular territories 6-12 even when no other individuals are on the lek 11,12. Female choice of territories may be influenced by spatial features 7-10,12, but observations suggest that females may also be attracted to successful territories by olfactory cues in the soil 13. Here we report that transferring the topsoil between successful and unsuccessful territories on leks of two reduncine antelope species caused the numbers of females and matings on the unsuccessful territories to increase tenfold. Females were probably attracted to the soil by smells that had accumulated from heavy use by other females. Because of this attraction, stochastic process may play an important part in generating the variance in mating success between territory holders on leks.			DEUTSCH, JC (corresponding author), DEPT ZOOL,LARGE ANIM RES GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							Alexander R.D., 1975, P35; APOLLONIO M, 1990, ANIM BEHAV, V39, P205, DOI 10.1016/S0003-3472(05)80864-4; BALMFORD A, 1991, TRENDS ECOL EVOL, V6, P87, DOI 10.1016/0169-5347(91)90181-V; BALMFORD A, 1990, THESIS CAMBRIDGE U; Bradbury J.W., 1985, P301; Bradbury J.W., 1983, P109; Buechner H. K., 1965, Zeitschrift fuer Tierpsychologie, V22, P209; BUECHNER HK, 1961, SCIENCE, V133, P698, DOI 10.1126/science.133.3454.698; CLUTTONBROCK TH, 1988, BEHAV ECOL SOCIOBIOL, V23, P281, DOI 10.1007/BF00300575; CLUTTONBROCK TH, 1989, NATURE, V340, P463, DOI 10.1038/340463a0; DEUTSCH JC, IN PRESS BEHAV ECOL; FLOODY O R, 1975, Zeitschrift fuer Tierpsychologie, V37, P192; FRYXELL JM, 1987, ETHOLOGY, V75, P211; Gibson RM, 1991, BEHAV ECOL, V2, P165, DOI 10.1093/beheco/2.2.165; GOSLING LM, 1987, ANIM BEHAV, V35, P620, DOI 10.1016/S0003-3472(87)80298-1; GOSLING LM, 1990, ANIM BEHAV, V40, P272, DOI 10.1016/S0003-3472(05)80922-4; HINDLE JE, 1990, J REPROD FERTIL, V90, P571; HOGANWARBURG AJ, 1966, ARDEA, V54, P111; HOGLUND J, 1990, ANIM BEHAV, V40, P23, DOI 10.1016/S0003-3472(05)80662-1; HOGLUND J, 1990, BEHAVIOUR, V114, P221, DOI 10.1163/156853990X00130; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LASLEY BL, 1985, ADV VET SCI COMP MED, V30, P209; LEUTHOLD W, 1966, BEHAVIOUR, V27, P215, DOI 10.1163/156853966X00164; MCDONALD DB, 1989, ANIM BEHAV, V37, P1007, DOI 10.1016/0003-3472(89)90145-0; MODHA KL, 1973, THESIS MAKERERE U KA; SCHUSTER RH, 1976, SCIENCE, V192, P1240, DOI 10.1126/science.192.4245.1240; WADE MJ, 1990, P NATL ACAD SCI USA, V87, P5749, DOI 10.1073/pnas.87.15.5749	27	48	48	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					596	598		10.1038/356596a0	http://dx.doi.org/10.1038/356596a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560842				2022-12-28	WOS:A1992HP03100046
J	MITTLER, JE; LENSKI, RE				MITTLER, JE; LENSKI, RE			EXPERIMENTAL-EVIDENCE FOR AN ALTERNATIVE TO DIRECTED MUTATION IN THE BGL OPERON	NATURE			English	Article							ESCHERICHIA-COLI; MUTANTS; INSERTION; SELECTION; POPULATIONS; HYPOTHESIS; EVOLUTION; SEQUENCE; ORIGIN	THE directed mutation hypothesis 1-6 suggests that some mutations occur more often when selectively advantageous than when neutral or disadvantageous, challenging the principle that the selective value of a mutation does not affect the rate of its occurrence 7-11. Mutations in the bgl operon of Escherichia coli have been reported to be a case of directed mutation 2. E. coli K12 strain chi-342LD cannot grow on salicin but derivatives with two mutations in the bgl operon, an excision of IS150 (formally called IS103; ref. 12) from bglF and a point mutation or insertion in bglR 13-15, grow rapidly on this sugar. When chi-342LD is grown on a medium containing salicin, bglF excision mutants accumulate to a frequency of > 1%, even though these mutants are reportedly 2 unable to grow on salicin, and Sal+ double mutants subsequently attain a high frequency. Comparable accumulations of excision mutants and Sal+ double mutants are not observed in the absence of salicin. As salicin is not mutagenic, it has been suggested that excision mutations in bglF might serve only to create the potential for a secondary selectively advantageous mutation 2. We show here, however, that these double mutants can be accounted for by spontaneous mutation to intermediate genotypes in non-growing populations, coupled with slow growth of some of these intermediates on salicin, which enables their populations to reach a size where secondary mutations allowing rapid growth on salicin become common.	MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824	Michigan State University	MITTLER, JE (corresponding author), UNIV CALIF IRVINE,DEPT ECOL & EVOLUT BIOL,IRVINE,CA 92717, USA.			Lenski, Richard/0000-0002-1064-8375				BENSON SA, 1991, GENETICS, V129, P647; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHARLESWORTH D, 1988, NATURE, V336, P525, DOI 10.1038/336525a0; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1991, P NATL ACAD SCI USA, V88, P5882, DOI 10.1073/pnas.88.13.5882; HALL BG, 1989, GENOME, V31, P265, DOI 10.1139/g89-044; HALL BG, 1990, GENETICS, V126, P5; HALL BG, 1989, GENETICS, V121, P423; LEDERBERG J, 1989, GENETICS, V121, P395; LENSKI RE, 1989, TRENDS ECOL EVOL, V4, P148, DOI 10.1016/0169-5347(89)90218-8; LENSKI RE, 1989, P NATL ACAD SCI USA, V86, P2775, DOI 10.1073/pnas.86.8.2775; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; PARTRIDGE L, 1988, NATURE, V336, P22, DOI 10.1038/336022a0; REYNOLDS AE, 1981, NATURE, V293, P625, DOI 10.1038/293625a0; REYNOLDS AE, 1985, UCLA S MOL CELL BIOL, V20, P265; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; STAHL FW, 1990, NATURE, V346, P791, DOI 10.1038/346791a0; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEWART FM, 1990, GENETICS, V124, P175; SYMONDS N, 1989, NATURE, V337, P119, DOI 10.1038/337119a0	21	41	41	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					446	448		10.1038/356446a0	http://dx.doi.org/10.1038/356446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557128				2022-12-28	WOS:A1992HL83000068
J	MARTIN, GA; YATANI, A; CLARK, R; CONROY, L; POLAKIS, P; BROWN, AM; MCCORMICK, F				MARTIN, GA; YATANI, A; CLARK, R; CONROY, L; POLAKIS, P; BROWN, AM; MCCORMICK, F			GAP DOMAINS RESPONSIBLE FOR RAS P21-DEPENDENT INHIBITION OF MUSCARINIC ATRIAL K+ CHANNEL CURRENTS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; GENE-PRODUCT; SRC; RECEPTORS; P21; PHOSPHORYLATION; SIMILARITY; BINDING; CLAMP	The interaction between the low molecular weight G protein ras p21 and a guanosine triphosphatase activating protein (GA-P) uncouples a heterotrimeric G protein (G(k)) from muscarinic receptors. Through the use of isolated atrial cell membranes and genetically engineered GAP deletion mutants, the src homology regions (SH2-SH3) at the amino terminus of GAP have been identified as the domains responsible for this effect. Deletion of the domain required to stimulate the guanosine triphosphatase activity of ras p21 relieves the requirement for ras p21 in this system. A model is presented that suggests that ras p21 induces a conformational change in GAP, which allows the SH2-SH3 regions of GAP to function.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine	MARTIN, GA (corresponding author), CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.				NCI NIH HHS [CA51992-01] Funding Source: Medline; NHLBI NIH HHS [HL36930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BROWN AM, 1984, NATURE, V311, P570, DOI 10.1038/311570a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FORCE T, 1991, J BIOL CHEM, V266, P6650; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OKABE K, 1989, Biophysical Journal, V55, p586A; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RAPP UR, 1991, ONCOGENE, V6, P495; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252; YATANI A, 1991, J BIOL CHEM, V266, P22222; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	37	143	222	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					192	194		10.1126/science.1553544	http://dx.doi.org/10.1126/science.1553544			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553544				2022-12-28	WOS:A1992GY70400034
J	PERLMAN, JM; MOYA, F				PERLMAN, JM; MOYA, F			SYNTHETIC SURFACTANTS IN INFANTS WITH RESPIRATORY-DISTRESS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											PERLMAN, JM (corresponding author), UNIV TEXAS,SW MED CTR,DALLAS,TX 75235, USA.							LIECHTY EA, 1991, PEDIATRICS, V88, P19; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; SHANNON DC, 1982, NEW ENGL J MED, V306, P959, DOI 10.1056/NEJM198204223061604	3	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1703	1704						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588992				2022-12-28	WOS:A1992HY62800023
J	CENTERWALL, BS				CENTERWALL, BS			TELEVISION AND VIOLENCE - THE SCALE OF THE PROBLEM AND WHERE TO GO FROM HERE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEWBORN-INFANTS; IMITATION; EXPOSURE; GESTURES; BEHAVIOR; VIEWER		UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								ANDISON FS, 1977, PUBLIC OPIN QUART, V41, P314, DOI 10.1086/268390; BAKER RK, 1969, VIOLENCE MEDIA STAFF; Centerwall B. S., 1989, PUBLIC COMMUNICATION, V2, P1; CENTERWALL BS, 1990, SOC PSYCH PSYCH EPID, V25, P149, DOI 10.1007/BF00782744; CENTERWALL BS, 1989, AM J EPIDEMIOL, V129, P643, DOI 10.1093/oxfordjournals.aje.a115180; CLARK KR, 1989, SEATTLE TIMES   0810, pF12; Dietz W H, 1991, Curr Probl Pediatr, V21, P8, DOI 10.1016/0045-9380(91)90034-I; DUBOW S, 1991, TEMPLE LAW REV, V64, P609; FLAVELL JH, 1986, AM PSYCHOL, V41, P418, DOI 10.1037/0003-066X.41.4.418; GERBNER G, 1989, VIOLENCE PROFILE END; HARRIS L, 1977, HARRIS SURVEY   0804; Hearold S., 1986, PUBLIC COMMUNICATION, P65; HELLER MS, 1976, STUDIES VIOLENCE TEL; HENNIGAN KM, 1982, J PERS SOC PSYCHOL, V42, P461, DOI 10.1037/0022-3514.42.3.461; HUESMANN LR, 1986, J SOC ISSUES, V42, P125, DOI 10.1111/j.1540-4560.1986.tb00246.x; JOHNSON JM, 1990, CRIMINAL VICTIMIZATI; Joy L. A., 1986, IMPACT TELEVISION NA, P303; KRUTTSCHNITT C, 1986, CRIMINOLOGY, V24, P235, DOI 10.1111/j.1745-9125.1986.tb01495.x; MELTZOFF AN, 1988, DEV PSYCHOL, V24, P470, DOI 10.1037/0012-1649.24.4.470; MELTZOFF AN, 1988, CHILD DEV, V59, P1221, DOI 10.2307/1130485; MELTZOFF AN, 1983, CHILD DEV, V54, P702, DOI 10.2307/1130058; MELTZOFF AN, 1989, DEV PSYCHOL, V25, P954, DOI 10.1037/0012-1649.25.6.954; MELTZOFF AN, 1992, ENCY LEARNING MEMORY; Milavsky JR, 1982, TELEVISION AGGRESSIO; PEARL D, 1982, TELEVISION BEHAVIOR; ROTHENBERG MB, 1975, JAMA-J AM MED ASSOC, V234, P1043, DOI 10.1001/jama.234.10.1043; SIGNORIELLI N, 1982, TELEVISION BEHAVIOR, P158; WOOD W, 1991, PSYCHOL BULL, V109, P371, DOI 10.1037/0033-2909.109.3.371; ZYLKE JW, 1988, JAMA-J AM MED ASSOC, V260, P1831, DOI 10.1001/jama.260.13.1831; 1990, PEDIATRICS, V85, P1119; 1989, AM PUBLIC OPINION DA; 1989, DEATHS WHITES COLOUR; 1987, SURGEON GENERALS NW, P93; 1969, ESTABLISH JUSTICE IN, P187; 1991, STATISTICAL ABSTRACT; 1990, NIELSEN REPORT TELEV; 1990, VITAL STATISTICS US; 1976, 1976 P HOUS DEL JUN, P280; 1972, TELEVISION GROWING I; 1989, WORLD HLTH STATISTIC	40	91	92	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3059	3063						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588720				2022-12-28	WOS:A1992HW97000027
J	FELDMAN, AM; BAUGHMAN, KL; STROBECK, JE				FELDMAN, AM; BAUGHMAN, KL; STROBECK, JE			ORAL MILRINONE IN SEVERE CHRONIC HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							MULTICENTER TRIAL; OPC-8212		VALLEY HOSP, RIDGEWOOD, NJ 07451 USA		FELDMAN, AM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA.							FELDMAN AM, 1991, AM J CARDIOL, V68, P1203, DOI 10.1016/0002-9149(91)90194-P; GOLDBERG AD, 1990, CIRCULATION, V82, P673; GRUPP G, 1986, J CARDIOVASC PHARM, V8, P428, DOI 10.1097/00005344-198603000-00029; LAMBERTZ H, 1984, CIRCULATION, V69, P298, DOI 10.1161/01.CIR.69.2.298; LATHROP DA, 1989, EUR J PHARMACOL, V164, P487, DOI 10.1016/0014-2999(89)90256-2; RAPUNDALO ST, 1988, N-S ARCH PHARMACOL, V338, P692, DOI 10.1007/BF00165636; URETSKY BF, 1990, CIRCULATION, V82, P774, DOI 10.1161/01.CIR.82.3.774	7	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1565	1566						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579142				2022-12-28	WOS:A1992HW97200012
J	ROPP, L; VISINTAINER, P; UMAN, J; TRELOAR, D				ROPP, L; VISINTAINER, P; UMAN, J; TRELOAR, D			DEATH IN THE CITY - AN AMERICAN CHILDHOOD TRAGEDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HOMICIDE; MORTALITY; PATTERNS; CHILDREN	Objective. --To look at trends in mortality and homicide rates in a specific metropolitan area, comparing the urban and suburban mortality trends. Design. --Descriptive study of mortality rates. Linear regression determined whether changes in mortality rates over time represented significant trends. Setting. --Industrial metropolitan area in the United States, population, 2 337 891. Participants. --Pediatric deaths (1 to 18 years of age) in a 9-year period. Population characteristics: 36% black, 64% white, 50% each urban and suburban. Main Outcome Measures. --Pediatric mortality rates for 1980 through 1988, grouped by urban vs suburban, age, gender, and race. Rates calculated using national census figures and plotted over time. Results. --There was a 50% increase in all-cause mortality in the urban pediatric population as compared with no change or a slight decline in the suburban and national populations. The increase was found in the black urban population. Homicide showed the largest increase (252%). Firearm-related homicides accounted for the majority of homicide deaths. Conclusions. --(1) There were significant differences in mortality between the urban and suburban pediatric populations. (2) The increase in homicides, specifically firearm homicides, in the urban population accounted for the increase in overall mortality rates. (3) The increase in homicide rates was significant only for the 10- to 14-year-old males and the 15- to 18-year-old male and female portions of the black urban population. (4) Firearm homicides have become epidemic in the black urban population we studied.	HENRY FORD HOSP,DIV BIOSTAT & RES EPIDEMIOL,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	ROPP, L (corresponding author), HENRY FORD HOSP,DEPT EMERGENCY,DIV PEDIAT EMERGENCY MED,2799 W GRAND BLVD,DETROIT,MI 48202, USA.			Visintainer, Paul/0000-0002-2491-1242				BAKER SP, 1985, AM J PUBLIC HEALTH, V75, P587, DOI 10.2105/AJPH.75.6.587; BEAVER BL, 1990, J PEDIATR SURG, V25, P97, DOI 10.1016/S0022-3468(05)80171-X; CENTERWALL BS, 1991, AM J EPIDEMIOL, V134, P1245, DOI 10.1093/oxfordjournals.aje.a116027; CHRISTOFFEL K, 1990, 1990 P MED SCI WRIT; CHRISTOFFEL KK, 1983, AM J FOREN MED PATH, V4, P129, DOI 10.1097/00000433-198306000-00006; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; COPELAND AR, 1991, SOUTHERN MED J, V84, P175, DOI 10.1097/00007611-199102000-00006; FINGERHUT LA, 1989, AM J PUBLIC HEALTH, V79, P899, DOI 10.2105/AJPH.79.7.899; FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V263, P3292, DOI 10.1001/jama.263.24.3292; FINGERHUT LA, 1989, VITAL HLTH STAT, V3, P1; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; GITTELSOHN A, 1982, PHS821363 NAT CTR HL, P1; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HEDEBOE J, 1985, AM J PUBLIC HEALTH, V75, P651, DOI 10.2105/AJPH.75.6.651; JASON J, 1983, AM J DIS CHILD, V137, P578, DOI 10.1001/archpedi.1983.02140320054012; LEE R, 1971, AM J EPIDEMIOL, V134, P511; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; PAULSON JA, 1986, PEDIATRICS, V78, P1013; ROCKETT IRH, 1989, AM J PUBLIC HEALTH, V79, P1396, DOI 10.2105/AJPH.79.10.1396; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; Sullivan L, 1991, JAMA, V265, P2778, DOI 10.1001/jama.265.21.2778; Wood N P Jr, 1988, MMWR CDC Surveill Summ, V37, P47; 1990, HLTH PEOPLE 2000 NAT; 1980, PHS801260 US DEP HLT; 1992, AAP NEWS, V8, P22; 1990, ACEP NEWS, V9, P4; 1986, STATE METROPOLITAN A	28	27	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2905	2910		10.1001/jama.267.21.2905	http://dx.doi.org/10.1001/jama.267.21.2905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW133	1583759				2022-12-28	WOS:A1992HW13300027
J	MALKIN, D; JOLLY, KW; BARBIER, N; LOOK, AT; FRIEND, SH; GEBHARDT, MC; ANDERSEN, TI; BORRESEN, AL; LI, FP; GARBER, J; STRONG, LC				MALKIN, D; JOLLY, KW; BARBIER, N; LOOK, AT; FRIEND, SH; GEBHARDT, MC; ANDERSEN, TI; BORRESEN, AL; LI, FP; GARBER, J; STRONG, LC			GERMLINE MUTATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CHILDREN AND YOUNG-ADULTS WITH 2ND MALIGNANT NEOPLASMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER FAMILY SYNDROME; RETINOBLASTOMA GENE; ANTIGEN; EXPRESSION; CHILDHOOD; PROTEIN; SARCOMA; 17P13; RISK	Background. Acquired mutations in the p53 tumor-suppressor gene have been detected in several human cancers, including colon, breast, and lung cancer. Inherited mutations (transmitted through the germline) of this gene can underlie the Li-Fraumeni syndrome, a rare familial association of breast cancer in young women, childhood sarcomas, and other malignant neoplasms. We investigated the possibility that p53 mutations in the germline are associated with second primary cancers that arise in children and young adults who would not be considered as belonging to Li-Fraumeni families. Methods. Genomic DNA was extracted from the blood leukocytes of 59 children and young adults with a second primary cancer. The polymerase chain reaction, in combination with denaturant-gel electrophoresis and sequencing, was used to identify p53 gene mutations. Results. Mutations of p53 that changed the predicted amino acid sequence were identified in leukocyte DNA from 4 of the 59 patients (6.8 percent). In three cases, the mutations were identical to ones previously found in the p53 gene. The fourth mutation was the first germline mutation to be identified in exon 9, at codon 325. Analysis of leukocyte DNA from close relatives of three of the patients indicated that the mutations were inherited, but cancer had developed in only one parent at the start of the study. Conclusions. These findings identify an important subgroup of young patients with cancer who carry germline mutations in the p53 tumor-suppressor gene but whose family histories are not indicative of the Li-Fraumeni syndrome. The early detection of such mutations would be useful not only in treating these patients, but also in identifying family members who may be at high risk for the development of tumors.	MASSACHUSETTS GEN HOSP, CTR CANC, DIV MOLEC GENET, BLDG 149, 13TH ST, BOSTON, MA 02129 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT EXPTL PEDIAT & GENET, HOUSTON, TX 77025 USA; HARVARD UNIV, SCH MED,DANA FARBER CANC INST,INST CANC RES, DEPT GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; MASSACHUSETTS GEN HOSP, DEPT ORTHOPED SURG, BOSTON, MA 02114 USA; CHILDRENS HOSP MED CTR, DEPT ORTHOPED SURG, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DIV HEMATOL & ONCOL, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL & ONCOL, MEMPHIS, TN 38101 USA	Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; St Jude Children's Research Hospital			Malkin, David/AAW-8715-2021		NATIONAL CANCER INSTITUTE [P01CA023099, P01CA020180, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, CA-23099, CA-20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BURKE E, 1991, CANCER-AM CANCER SOC, V67, P1467, DOI 10.1002/1097-0142(19910301)67:5<1467::AID-CNCR2820670535>3.0.CO;2-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P448, DOI 10.1038/bjc.1989.92; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOVIG E, 1991, MUTAT RES, V262, P63, DOI 10.1016/0165-7992(91)90108-G; HOVIG E, 1991, MUTAT RES, V263, P61; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MEADOWS AT, 1991, HOSP PRACT, V26, P99; MEADOWS AT, 1991, HOSP PRACT, V26, P105; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TOGUCHIDA J, 1991, AM J HUM GENET, V49, P458; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WILLIAMS WR, 1985, FAM CANCER, P151; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOUNG JL, 1977, NATL CANCER I MONOGR, V57, P70	39	343	351	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1309	1315		10.1056/NEJM199205143262002	http://dx.doi.org/10.1056/NEJM199205143262002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1565144				2022-12-28	WOS:A1992HT80300002
J	KRULL, IS; MAZZEO, JR				KRULL, IS; MAZZEO, JR			CAPILLARY ELECTROPHORESIS - THE PROMISE AND THE PRACTICE	NATURE			English	Article							MICELLAR ELECTROKINETIC CHROMATOGRAPHY; OPTIMIZATION		NORTHEASTERN UNIV,BARNETT INST,BOSTON,MA 02115	Northeastern University	KRULL, IS (corresponding author), NORTHEASTERN UNIV,DEPT CHEM,341 MUGAR BLDG,360 HUNTINGTON AVE,BOSTON,MA 02115, USA.							[Anonymous], 1990, SCHWEIZ MONATSH, V70, P652; COMPTON BJ, 1991, J CHROMATOGR, V559, P357, DOI 10.1016/0021-9673(91)80085-U; DETERDING LJ, 1991, J CHROMATOGR, V554, P329, DOI 10.1016/S0021-9673(01)88460-0; FOLEY JP, 1990, ANAL CHEM, V62, P1302, DOI 10.1021/ac00212a019; GHOWSI K, 1990, ANAL CHEM, V62, P2714, DOI 10.1021/ac00223a013; GROSSMAN PD, 1991, J CHROMATOGR, V559, P257, DOI 10.1016/0021-9673(91)80076-S; GUTTMAN A, 1990, ANAL CHEM, V62, P137, DOI 10.1021/ac00201a010; HIGASHIJIMA T, 1992, ANAL CHEM, V64, P711, DOI 10.1021/ac00031a004; HJERTEN S, 1987, J CHROMATOGR, V387, P127, DOI 10.1016/S0021-9673(01)94519-4; HORVATH C, 1990, AM CHEM SOC S SERIES, V434; HUANG MX, 1992, J MICROCOLUMN SEP, V4, P135, DOI 10.1002/mcs.1220040205; JANDIK P, 1991, LC GC-MAG SEP SCI, V9, P634; JORGENSON JW, 1987, AM CHEM SOC S SERIES, V335; LOOKABAUGH M, 1991, J CHROMATOGR, V549, P357, DOI 10.1016/S0021-9673(00)91446-8; MAZZEO JR, 1991, ANAL CHEM, V63, P2852, DOI 10.1021/ac00024a009; MAZZEO JR, 1991, BIOTECHNIQUES, V10, P638; MAZZEO JR, 1992, J MICROCOLUMN SEP, V4, P29, DOI 10.1002/mcs.1220040107; NISHI H, 1990, J CHROMATOGR, V515, P245, DOI 10.1016/S0021-9673(01)89319-5; NOVOTNY MV, 1992, MAR PITTSB C NEW ORL; STREGE M, 1991, ANAL CHEM, V63, P1233, DOI 10.1021/ac00013a010; STREGEHUIS DS, 1992, J CHROMATOGR, V591, P341; SUTER MJF, 1991, J CHROMATOGR, V553, P101, DOI 10.1016/S0021-9673(01)88478-8; TSUJI K, 1991, J CHROMATOGR, V550, P823, DOI 10.1016/S0021-9673(01)88585-X; WAINRIGHT A, 1990, J MICROCOLUMN SEP, V2, P166; WANG TS, 1992, J CHROMATOGR, V594, P325, DOI 10.1016/0021-9673(92)80346-V; WHEAT TE, 1991, J LIQ CHROMATOGR, V14, P987, DOI 10.1080/01483919108049299; ZARE RN, 1992, MAR PITTSB C NEW ORL; WATERS APPLICATION B	28	33	34	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					92	94		10.1038/357092a0	http://dx.doi.org/10.1038/357092a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1574129				2022-12-28	WOS:A1992HT22900067
J	COLOMBO, MF; RAU, DC; PARSEGIAN, VA				COLOMBO, MF; RAU, DC; PARSEGIAN, VA			PROTEIN SOLVATION IN ALLOSTERIC REGULATION - A WATER EFFECT ON HEMOGLOBIN	SCIENCE			English	Article							HYDRATION FORCES; VOLUME CHANGES; ENERGETICS; BINDING; CHANNEL; SOLVENT; LINKAGE	The oxygen affinity of hemoglobin varies linearly with the chemical potential of water in the bathing medium, as seen from the osmotic effect of several neutral solutes, namely sucrose, stachyose, and two polyethyleneglycols (molecular weights of 150 and 400). The data, analyzed either by Wyman linkage equations or by Gibbs-Duhem relations, show that approximately 60 extra water molecules bind to hemoglobin during the transition from the fully deoxygenated tense (T) state to the fully oxygenated relaxed (R) state. This number, independent of the nature of the solute, agrees with the difference in water-accessible surface areas previously computed for the two conformations. The work of solvation in allosteric regulation can no longer go unrecognized.	NIDDKD,DIV COMP RES & TECHNOL,PHYS SCI LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	COLOMBO, MF (corresponding author), NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892, USA.		Colombo, Marcio F/K-5229-2013	Colombo, Marcio F/0000-0003-3035-3926				ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ANUSIEM ACI, 1976, ARCH BIOCHEM BIOPHYS, V175, P138, DOI 10.1016/0003-9861(76)90492-6; ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6536, DOI 10.1021/bi00268a033; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BLANK M, 1980, COLLOID SURFACE, V1, P139, DOI 10.1016/0166-6622(80)80001-1; BRANCACCIO A, COMMUNICATION; CHOTHIA C, 1976, P NATL ACAD SCI USA, V73, P3793, DOI 10.1073/pnas.73.11.3793; COLOMBO MF, 1990, BIOPHYS CHEM, V36, P33, DOI 10.1016/0301-4622(90)85004-P; COLOMBO MG, UNPUB; CORDONE L, 1983, BIOPOLYMERS, V22, P1677, DOI 10.1002/bip.360220706; DICERA E, 1990, BIOPHYS CHEM, V37, P147, DOI 10.1016/0301-4622(90)88015-K; HAIRE RN, 1983, BIOCHEMISTRY-US, V22, P327, DOI 10.1021/bi00271a015; HOPFIELD JJ, 1973, J MOL BIOL, V77, P207, DOI 10.1016/0022-2836(73)90332-X; JANIN J, 1985, BIOPOLYMERS, V24, P509, DOI 10.1002/bip.360240307; KORNBLATT JA, 1990, BIOCHEMISTRY-US, V29, P9370, DOI 10.1021/bi00492a010; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; PERUTZ M, 1990, MECHANISM COOPERATIV; PODGORNIK R, 1989, MACROMOLECULES, V22, P1780, DOI 10.1021/ma00194a048; PROUTY MS, 1985, J MOL BIOL, V184, P517, DOI 10.1016/0022-2836(85)90298-0; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; RAU DC, 1990, SCIENCE, V249, P1278, DOI 10.1126/science.2144663; Riggs A., 1981, Methods in Enzymology, V76, P5; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J, 1990, BINDING LINKAGE FUNC; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIMMERBERG J, 1990, BIOPHYS J, V57, P1049, DOI 10.1016/S0006-3495(90)82623-0	28	336	341	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					655	659		10.1126/science.1585178	http://dx.doi.org/10.1126/science.1585178			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585178				2022-12-28	WOS:A1992HR18500029
J	GRAHAM, DY; LEW, GM; KLEIN, PD; EVANS, DG; EVANS, DJ; SAEED, ZA; MALATY, HM				GRAHAM, DY; LEW, GM; KLEIN, PD; EVANS, DG; EVANS, DJ; SAEED, ZA; MALATY, HM			EFFECT OF TREATMENT OF HELICOBACTER-PYLORI INFECTION ON THE LONG-TERM RECURRENCE OF GASTRIC OR DUODENAL-ULCER - A RANDOMIZED, CONTROLLED-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HELICOBACTER-PYLORI; DUODENAL ULCER; RANITIDINE; STOMACH ULCER	CAMPYLOBACTER-PYLORI; MAINTENANCE THERAPY; ERADICATION; RELAPSE; CURE	. Objective: To determine the effect of treating Helicobacter pylori infection on the recurrence of gastric and duodenal ulcer disease. . Design: Follow-up of up to 2 years in patients with healed ulcers who had participated in randomized, controlled trials. . Setting: A Veterans Affairs hospital. . Participants: A total of 109 patients infected with H. Pylori who had a recently healed duodenal (83 patients) or gastric ulcer (26 patients) as confirmed by endoscopy. . Intervention: Patients received ranitidine, 300 mg, or ranitidine plus triple therapy. Triple therapy consisted of tetracycline, 2 g; metronidazole, 750 mg; and bismuth subsalicylate, 5 or 8 tablets (151 mg bismuth per tablet) and was administered for the first 2 weeks of treatment; ranitidine therapy was continued until the ulcer had healed or 16 weeks had elapsed. After ulcer healing, no maintenance antiulcer therapy was given. . Measurements: Endoscopy to assess ulcer recurrence was done at 3-month intervals or when a patient developed symptoms, for a maximum of 2 years. . Results: The probability of recurrence for patients who received triple therapy plus ranitidine was significantly lower than that for patients who received ranitidine alone: for patients with duodenal ulcer, 12% (95% Cl, 1% to 24%) com pared with 95% (Cl, 84% to 1 00%); for patients with gastric ulcer, 13% (Cl, 4% to 31%) compared with 74% (44% to 100%). Fifty percent of patients who received ranitidine alone for healing of duodenal or gastric ulcer had a relapse within 12 weeks of healing. Ulcer recurrence in the triple therapy group was related to the failure to eradicate H. pylori and to the use of nonsteroidal anti-inflammatory drugs. . Conclusions: Eradication of H. pylori infection markedly changes the natural history of peptic ulcer in patients with duodenal or gastric ulcer. Most peptic ulcers associated with H. pylori infection are curable.	USDA, AGR RES CTR, CHILDRENS NUTR RES CTR, HOUSTON, TX USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA	United States Department of Agriculture (USDA); Baylor College of Medicine	GRAHAM, DY (corresponding author), VET AFFAIRS MED CTR, 111D, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Graham, David/AAL-2165-2021		NIDDK NIH HHS [DK 39919] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039919] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COGHLAN JG, 1987, LANCET, V2, P1109; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; GRAHAM DY, 1987, LANCET, V1, P1174; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P493, DOI 10.1016/0016-5085(92)90095-G; GRAHAM DY, 1990, AM J GASTROENTEROL, V85, P1552; KLEIN PD, 1989, CAMPYLOBACTER PYLORI, P94; LAMBERT JR, 1987, GASTROENTEROLOGY, V92, P1489; MARSHALL BJ, 1988, LANCET, V2, P1437; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SONTAG SJ, 1988, AM J GASTROENTEROL, V83, P607; VANDEVENTER GM, 1989, NEW ENGL J MED, V320, P1113, DOI 10.1056/NEJM198904273201704	14	980	998	2	43	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					705	708		10.7326/0003-4819-116-9-705	http://dx.doi.org/10.7326/0003-4819-116-9-705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558340				2022-12-28	WOS:A1992HQ62300001
J	SPACH, DH; PANTHER, LA; THORNING, DR; DUNN, JE; PLORDE, JJ; MILLER, RA				SPACH, DH; PANTHER, LA; THORNING, DR; DUNN, JE; PLORDE, JJ; MILLER, RA			INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS	ANNALS OF INTERNAL MEDICINE			English	Note						ANGIOMATOSIS; BACILLARY; HUMAN IMMUNODEFICIENCY; VIRUS; ERYTHROMYCIN; BRAIN DISEASE	EPITHELIOID ANGIOMATOSIS; DISEASE	Bacillary angiomatosis, a recently described illness that occurs predominantly in patients infected with human immunodeficiency virus (HIV), has a wide spectrum of manifestations. Intracerebral lesions, however, have not yet been reported. We describe a 49-year-old HIV-positive man with cutaneous and intracerebral bacillary angiomatosis. The patient initially presented with an intracranial mass lesion and, after an extensive evaluation that included two brain biopsies, the cause remained unknown. We subsequently diagnosed cutaneous bacillary angiomatosis, which led to a retrospective diagnosis of intracerebral bacillary angiomatosis. The skin and brain lesions had typical features of bacillary angiomatosis; histologic vasoproliferative inflammatory responses and clumps of pleomorphic bacilli observed with Warthin-Starry staining. In addition, both lesions improved dramatically with erythromycin therapy. This case expands the spectrum of bacillary angiomatosis and identifies a new case of treatable brain lesions in HIV-inspected patients.	UNIV WASHINGTON, MED CTR, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SPACH, DH (corresponding author), DEPT VET AFFAIRS MED CTR, DIV INFECT DIS, 1660 S COLUMBIAN WAY, 111 ID, SEATTLE, WA 98108 USA.			Dunn, Jeffrey/0000-0002-1721-6081				BERGER TG, 1989, ARCH DERMATOL, V125, P1543, DOI 10.1001/archderm.125.11.1543; BIRTLES RJ, 1991, NEW ENGL J MED, V325, P1447; COCKERELL CJ, 1990, J AM ACAD DERMATOL, V22, P501, DOI 10.1016/0190-9622(90)70071-O; LEBOIT PE, 1990, ARCH DERMATOL, V126, P808, DOI 10.1001/archderm.126.6.808; MILAM MW, 1990, AM J MED, V88, P180, DOI 10.1016/0002-9343(90)90471-O; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SPACH DH, 1992, INT J DERMATOL, V31, P19, DOI 10.1111/j.1365-4362.1992.tb03512.x	8	53	56	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					740	742		10.7326/0003-4819-116-9-740	http://dx.doi.org/10.7326/0003-4819-116-9-740			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558347				2022-12-28	WOS:A1992HQ62300008
J	SCHIER, AF; GEHRING, WJ				SCHIER, AF; GEHRING, WJ			DIRECT HOMEODOMAIN DNA INTERACTION IN THE AUTOREGULATION OF THE FUSHI-TARAZU GENE	NATURE			English	Article							DROSOPHILA; PROTEINS; SPECIFICITY; BINDING; TRANSCRIPTION; ACTIVATION; REPRESSION; ELEMENTS; COMPLEX; SITE	A MAJOR problem in the elucidation of the molecular mechanisms governing development is the distinction between direct and indirect regulatory interactions among developmental control genes 1-5. In vivo studies have indicated that the Drosophila segmentation gene fushi tarazu (ftz) directly or indirectly autoregulates its expression 6. Here we describe a generally applicable experimental approach which establishes a direct in vivo interaction of the homeodomain protein ftz with the ftz cis-autoregulatory control region. In vitro studies have shown that the DNA-binding specificity of the ftz homeodomain can be changed by a single amino-acid substitution in the recognition helix (Gln 50 --> Lys) 7. Whereas wild-type ftz homeodomain binds preferentially to a CCATTA motif, the mutant homeodomain (ftzQ50K) recognizes a GGATTA motif. We now find that the in vivo activity of an ftz autoregulatory enhancer element is reduced by mutations of putative ftz-binding sites to GGATTA. This down-regulatory effect is specifically suppressed in vivo by the DNA-binding specificity mutant ftzQ50K. These results establish a direct positive autoregulatory feedback mechanism in the regulation of this homeobox gene.			SCHIER, AF (corresponding author), UNIV BASEL,BIOZENTRUM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Schier, Alexander Franz/0000-0001-7645-5325				AFFOLTER M, 1990, CURR OPINION CELL BI, V2, P1485; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; EBRIGHT RH, 1991, METHOD ENZYMOL, V208, P620; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARRISON SD, 1988, NUCLEIC ACIDS RES, V16, P11403, DOI 10.1093/nar/16.24.11403; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MAIER D, 1990, EMBO J, V9, P3957, DOI 10.1002/j.1460-2075.1990.tb07616.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRIS NR, 1979, CELL, V16, P437; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1992, EMBO J, V11, P382; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; TREISMAN J, 1989, CELL, V59, P553	30	144	144	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					804	807		10.1038/356804a0	http://dx.doi.org/10.1038/356804a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574120				2022-12-28	WOS:A1992HR18600054
J	BENJAMIN, CM; CHEW, GC; SILMAN, AJ				BENJAMIN, CM; CHEW, GC; SILMAN, AJ			JOINT AND LIMB SYMPTOMS IN CHILDREN AFTER IMMUNIZATION WITH MEASLES, MUMPS, AND RUBELLA VACCINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VIRUS VACCINE	Objective - To assess whether the combined measles, mumps, and rubella vaccine increases the incidence of joint and limb symptoms in young children. Design - Comparison of six week recalled incidence of symptoms in two groups of children: children who had been immunised at the start of the six weeks, and children eligible for immunisation but who had not received it. Setting - South Manchester Health Authority. Subjects - 2658 children immunised during July 1989-February 1990 and 2359 not yet immunised. Questionnaires were returned for 1846 immunised children and 1075 not immunised. Main outcome measure - Recalled rate of joint and limb episodes determined by postal questionnaire and later by clinical follow up. Results - Compared with non-immunised children the immunised group had an increased incidence of new episodes (relative risk 1.6 (95% confidence interval (1.2 to 2.1)) and first ever episodes, though this was not significant (1.7 (0.3 to 3.5)). The risk of first episodes was increased in girls (3.5 (1.1 to 12.2)) but not in boys (1.0 (0.4 to 2.6)). Similarly, an increased risk was seen in children aged under 5 (12.0 (1.6 to 92.3)) but not in older children (0.7 (0.3 to 1.5)). Most episodes were mild and self limiting, but three immunised children required hospital referral. Conclusion - Measles, mumps, and rubella vaccine is associated with an increased risk of episodes of joint and limb symptoms, especially in girls and children under 5. The risk of frank arthritis is substantially less than after wild rubella infection.	UNIV MANCHESTER, ARTHRIT & RHEUMATISM COUNCIL, EPIDEMIOL RES UNIT, STOPFORD BLDG, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								[Anonymous], 1969, AM J DIS CHILD, V118, P1; BALFOUR HH, 1976, AM J DIS CHILD, V130, P1089, DOI 10.1001/archpedi.1976.02120110051006; FRY J, 1962, BMJ-BRIT MED J, P833, DOI 10.1136/bmj.2.5308.833; HILDEBRANDT HM, 1966, NEW ENGL J MED, V274, P1428, DOI 10.1056/NEJM196606232742507; LASS R, 1961, BMJ-BRIT MED J, V2, P1613, DOI 10.1136/bmj.2.5267.1613; LOUDON ISL, 1953, BRIT MED J, V1, P1388, DOI 10.1136/bmj.1.4824.1388; MILLER C, 1989, PRACTITIONER, V233, P69; PELTOLA H, 1986, LANCET, V1, P939; PREBLUD SR, 1985, JAMA-J AM MED ASSOC, V254, P253, DOI 10.1001/jama.254.2.253; SPRUANCE SL, 1971, AM J DIS CHILD, V122, P105, DOI 10.1001/archpedi.1971.02110020039002; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; 1990, IMMUNISATION INFECTI	12	48	48	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1992	304	6834					1075	1078		10.1136/bmj.304.6834.1075	http://dx.doi.org/10.1136/bmj.304.6834.1075			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586818	Bronze, Green Published			2022-12-28	WOS:A1992HR13600013
J	ROPPER, AH				ROPPER, AH			CURRENT CONCEPTS - THE GUILLAIN-BARRE-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE IDIOPATHIC NEUROPATHY; ELECTRODIAGNOSTIC ABNORMALITIES; PROGNOSTIC FACTORS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; PATIENT; SERUM		TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University	ROPPER, AH (corresponding author), ST ELIZABETH HOSP,DIV NEUROL,NEUROL SERV,736 CAMBRIDGE ST,BOSTON,MA 02135, USA.							ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; ASBURY AK, 1969, MEDICINE, V48, P173, DOI 10.1097/00005792-196905000-00001; BAIER S, 1985, WOMAN BED NUMBER 10; BOREL CO, 1991, CHEST, V99, P444, DOI 10.1378/chest.99.2.444; BOWES D, 1984, CAN MED ASSOC J, V131, P1343; DEHAENE I, 1986, NEUROLOGY, V36, P851, DOI 10.1212/WNL.36.6.851; FEASBY TE, 1986, BRAIN, V109, P1115, DOI 10.1093/brain/109.6.1115; FEASBY TE, 1982, NEUROLOGY, V32, P1159; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; Guillain G, 1938, J BELGE NEUROL PSY, V38, P323; Guillain G., 1916, B MEM SOC MED HOP P, V40, P1462; HARRISON BM, 1984, ANN NEUROL, V15, P163, DOI 10.1002/ana.410150209; HARTUNG HP, 1990, NEUROLOGY, V40, P215, DOI 10.1212/WNL.40.2.215; HAYMAKER W, 1949, MEDICINE, V28, P59, DOI 10.1097/00005792-194902010-00003; HENSCHEL EO, 1977, ANESTHESIOLOGY, V47, P228, DOI 10.1097/00000542-197708000-00013; HONAVAR M, 1991, BRAIN, V114, P1245, DOI 10.1093/brain/114.3.1245; HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2; HUGHES RAC, 1991, LANCET, V338, P1142, DOI 10.1016/0140-6736(91)91995-7; KOSKI CL, 1988, ANN NEUROL, V24, P122; KURLAND LT, 1985, ARCH NEUROL-CHICAGO, V42, P1089, DOI 10.1001/archneur.1985.04060100075026; LANDRY JBO, 1859, GAZ HEBD MED CHIR, V6, P472; LOFFEL NB, 1977, J NEUROL SCI, V33, P71, DOI 10.1016/0022-510X(77)90183-6; MACFARLAND HR, 1966, ARCH NEUROL-CHICAGO, V14, P196; MCKHANN GM, 1988, ANN NEUROL, V23, P347, DOI 10.1002/ana.410230406; OSTERMAN PO, 1984, LANCET, V2, P1296; PRINEAS JW, 1981, ANN NEUROL, V9, P6, DOI 10.1002/ana.410090704; RAPHAEL JC, 1986, REV NEUROL, V142, P613; RICE D, 1977, BRIT MED J, V1, P1330, DOI 10.1136/bmj.1.6072.1330; ROPPER AH, 1986, ARCH NEUROL-CHICAGO, V43, P1150, DOI 10.1001/archneur.1986.00520110044012; ROPPER AH, 1990, ARCH NEUROL-CHICAGO, V47, P881, DOI 10.1001/archneur.1990.00530080065012; ROPPER AH, 1991, GUILLAINBARRE SYNDRO; ROPPER AH, 1988, NEUROLOGICAL NEUROSU, P253; SAIDA T, 1979, SCIENCE, V204, P1103, DOI 10.1126/science.451555; SHEARN MA, 1986, SOUTHERN MED J, V79, P800, DOI 10.1097/00007611-198607000-00004; SUMNER AJ, 1981, ANN NEUROL, V9, P28, DOI 10.1002/ana.410090706; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Vogel Speed, 1986, NO LAUGHING MATTER; WAKSMAN BH, 1955, J EXP MED, V102, P213, DOI 10.1084/jem.102.2.213; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P619, DOI 10.1136/jnnp.51.5.619; WINER JB, 1985, LANCET, V1, P1202; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P605, DOI 10.1136/jnnp.51.5.605; YOUNG RR, 1975, BRAIN, V98, P613, DOI 10.1093/brain/98.4.613; YUKI N, 1990, NEUROLOGY, V40, P1900, DOI 10.1212/WNL.40.12.1900; 1987, ANN NEUROL, V22, P753; 1984, NEUROLOGY, V35, P1096	46	531	543	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1130	1136						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552914				2022-12-28	WOS:A1992HP80000006
J	BUNCH, C				BUNCH, C			DEVELOPING A HOSPITAL INFORMATION STRATEGY - A CLINICIAN VIEW	BRITISH MEDICAL JOURNAL			English	Article											BUNCH, C (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,RESOURCE MANAGEMENT PROGRAMME,OXFORD OX3 9DU,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1033	1036		10.1136/bmj.304.6833.1033	http://dx.doi.org/10.1136/bmj.304.6833.1033			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586789	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200025
J	HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM				HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM			EPIPODOPHYLLOTOXINS, ALKYLATING-AGENTS, AND RADIATION AND RISK OF SECONDARY LEUKEMIA AFTER CHILDHOOD-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NON-HODGKINS LYMPHOMA; LOW-DOSE RADIATION; T-CELL LEUKEMIA; MYELODYSPLASTIC SYNDROME; 2ND MALIGNANCIES; OVARIAN-CANCER; NEURO-BLASTOMA; CHEMOTHERAPY	Objective-To investigate the incidence and aetiology of secondary leukaemia after childhood cancer in Britain. Design-Cohort study and a case-control study. Setting-Britain and population based National Register of Childhood Tumours. Subjects-Cohort of 16 422 one year survivors of childhood cancer diagnosed in Britain between 1962 and 1983, among whom 22 secondary leukaemias were observed. A case-control study of 26 secondary leukaemias observed among survivors of childhood cancer diagnosed in Britain between 1940 and 1983; % controls were selected matched for sex, type of first cancer, age at first cancer, and interval to diagnosis of secondary leukaemia. Main outcome measures-Dose of radiation averaged over patients' active bone marrow and total accumulated dose of epipodophyllotoxins, alkylating agents, vinca alkaloids, antimetabolites, and antibiotics (mg/m2) given for the original cancer. Results-Cumulative risk of secondary leukaemia within the cohort did not exceed 0.5% over the initial five years beyond one year survival, except that after non-Hodgkin's lymphomas 1.4% of patients developed secondary leukaemia. Corresponding figure for patients treated for non-Hodgkin's lymphomas in the early 1980s was 4%. The relative risk of secondary leukaemia increased significantly with exposure to epipodophyllotoxins and dose of radiation averaged over patients' active bone marrow. Ten patients developed leukaemia after having an epipodophyllotoxin-teniposide in nine cases, etoposide in one. Chromosomal translocations involving 11q23 were observed relating to two secondary leukaemias from a total of six for which there were successful cytogenetic studies after administration of an epipodophyllotoxin. Conclusions-Epipodophyllotoxins acting alone or together with alkylating agents or radiation seem to be involved in secondary leukaemia after childhood cancer.	ROYAL MANCHESTER CHILDRENS HOSP,PAEDIAT PATHOL,MANCHESTER M27 1HA,LANCS,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND; HOSP SICK CHILDREN,HAEMATOL & ONCOL,LONDON WC1N 3JH,ENGLAND; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025	Royal Manchester Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Texas System; UTMD Anderson Cancer Center	HAWKINS, MM (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.							BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BOICE JD, 1987, J NATL CANCER I, V79, P1295; Boice Jr J., 1984, RAD CARCINOGENESIS E; BOIVIN JF, 1986, AM J EPIDEMIOL, V123, P993, DOI 10.1093/oxfordjournals.aje.a114351; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CURTIS RE, 1984, J NATL CANCER I, V72, P531; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; DERBYSHIRE PJ, 1986, CLIN LAB HAEMATOL, V8, P71; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P792, DOI 10.1038/bjc.1989.165; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; GREENE MH, 1986, ANN INTERN MED, V105, P360, DOI 10.7326/0003-4819-105-3-360; HAAS JF, 1987, BRIT J CANCER, V55, P213, DOI 10.1038/bjc.1987.40; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KREISSMAN SG, 1990, P AN M AM SOC CLIN, V9, P219; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LONG BH, 1985, CANCER RES, V45, P3106; MOTT MG, 1984, BRIT J CANCER, V50, P463, DOI 10.1038/bjc.1984.202; MOTT MG, 1984, BRIT J CANCER, V50, P457, DOI 10.1038/bjc.1984.201; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRIETO F, 1990, CANCER GENET CYTOGEN, V45, P1, DOI 10.1016/0165-4608(90)90061-E; PUI CH, 1990, LANCET, V336, P1130, DOI 10.1016/0140-6736(90)92607-J; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; ROSS W, 1984, CANCER RES, V44, P5857; SECKERWALKER LM, 1985, MED PEDIATR ONCOL, V13, P48, DOI 10.1002/mpo.2950130112; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; THIRD MIC, 1988, CANCER GENET CYTOGEN, V32, P1; TRAVIS LB, 1991, CANCER-AM CANCER SOC, V67, P2002, DOI 10.1002/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WEH HJ, 1986, J CLIN ONCOL, V4, P1518, DOI 10.1200/JCO.1986.4.10.1518; WHANGPENG J, 1988, BLOOD, V71, P403; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; 1980, ORNL NUREGCRE1159 RE; 1990, EGRET REFERENCE MANU	46	186	188	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					951	958		10.1136/bmj.304.6832.951	http://dx.doi.org/10.1136/bmj.304.6832.951			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581717	Green Published, Bronze			2022-12-28	WOS:A1992HP06400021
J	KABACK, DB; GUACCI, V; BARBER, D; MAHON, JW				KABACK, DB; GUACCI, V; BARBER, D; MAHON, JW			CHROMOSOME SIZE-DEPENDENT CONTROL OF MEIOTIC RECOMBINATION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENETIC-MAP; MOLECULAR-CLONING; I DNA; YEAST; SEQUENCES	Smaller chromosomes have higher rates of meiotic reciprocal recombination (centimorgans per kilobase pair) than larger chromosomes. This report demonstrates that decreasing the size of Saccharomyces cerevisiae chromosomal DNA molecules increases rates of meiotic recombination and increasing chromosome size decreases recombination rates. These results indicate that chromosome size directly affects meiotic reciprocal recombination.			KABACK, DB (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103, USA.		Kaback, David/G-9973-2016	Kaback, David/0000-0002-5420-3335				BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COLEMAN KG, 1986, MOL CELL BIOL, V6, P4516, DOI 10.1128/MCB.6.12.4516; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; FASULLO MT, 1987, P NATL ACAD SCI USA, V84, P6215, DOI 10.1073/pnas.84.17.6215; GUACCI V, 1991, GENETICS, V127, P475; KABACK DB, 1984, GENETICS, V108, P67; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KABACK DB, UNPUB; KING JD, COMMUNICATION; LAMBIE EJ, 1986, GENETICS, V109, P303; LINK AJ, 1991, GENETICS, V127, P681; MAHON J, UNPUB; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MORTIMER RK, 1980, MICROBIOL REV, V44, P519, DOI 10.1128/MMBR.44.4.519-571.1980; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NICOLAS A, 1989, NATURE, V338, P85; PERKINS DD, 1974, GENETICS, V77, P459; PERKINS DD, 1949, GENETICS, V34, P607; PETES TD, 1977, P NATL ACAD SCI USA, V74, P5091, DOI 10.1073/pnas.74.11.5091; STEENSMA HY, 1989, CURR GENET, V16, P131; SUROSKY RT, 1988, GENETICS, V119, P273; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; WHYTE W, 1990, GENE, V95, P65, DOI 10.1016/0378-1119(90)90414-M	26	132	135	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					228	232		10.1126/science.1566070	http://dx.doi.org/10.1126/science.1566070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566070				2022-12-28	WOS:A1992HM89600031
J	VOSS, S				VOSS, S			HOW MUCH DO DOCTORS KNOW ABOUT THE NOTIFICATION OF INFECTIOUS-DISEASES	BRITISH MEDICAL JOURNAL			English	Article											VOSS, S (corresponding author), ODSTOCK HOSP,DEPT PUBL HLTH & EPIDEMIOL,SALISBURY SP2 8BJ,WILTS,ENGLAND.							CARTWRIGHT KAV, 1986, LANCET, V2, P558; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; HARVEY IM, 1989, HLTH TRENDS, V21, P73; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; 1989, REV LAW INFECTIOUS D	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					755	755		10.1136/bmj.304.6829.755	http://dx.doi.org/10.1136/bmj.304.6829.755			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571682	Green Published, Bronze			2022-12-28	WOS:A1992HK80000022
J	CHAMBERLAIN, JS; CHAMBERLAIN, JR; FENWICK, RG; WARD, PA; CASKEY, CT; DIMNIK, LS; BECHHANSEN, NT; HOAR, DI; TANTRAVAHI, U; RICHARDS, S; COVONE, AE; ROMEO, G; ABBS, S; BENTLEY, DR; BOBROW, M; RYSIECKI, G; RAY, PN; BOILEAU, C; JUNIEN, C; BOEHM, C; VENNE, VL; FUJIMURA, FK; SPIGA, I; FERRARI, M; TEDESCHI, S; BAKKER, E; KNEPPERS, ALJ; VANOMMEN, GJB; JAIN, K; SPECTOR, E; CRANDALL, B; KIURU, A; SAVONTAUS, ML; CASKEY, CT; CHAMBERLAIN, JS; CHAMBERLAIN, JR; RYSIECKI, G				CHAMBERLAIN, JS; CHAMBERLAIN, JR; FENWICK, RG; WARD, PA; CASKEY, CT; DIMNIK, LS; BECHHANSEN, NT; HOAR, DI; TANTRAVAHI, U; RICHARDS, S; COVONE, AE; ROMEO, G; ABBS, S; BENTLEY, DR; BOBROW, M; RYSIECKI, G; RAY, PN; BOILEAU, C; JUNIEN, C; BOEHM, C; VENNE, VL; FUJIMURA, FK; SPIGA, I; FERRARI, M; TEDESCHI, S; BAKKER, E; KNEPPERS, ALJ; VANOMMEN, GJB; JAIN, K; SPECTOR, E; CRANDALL, B; KIURU, A; SAVONTAUS, ML; CASKEY, CT; CHAMBERLAIN, JS; CHAMBERLAIN, JR; RYSIECKI, G			DIAGNOSIS OF DUCHENNE AND BECKER MUSCULAR-DYSTROPHIES BY POLYMERASE CHAIN-REACTION - A MULTICENTER STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-DIAGNOSIS; CDNA ANALYSIS; DMD GENE; DELETIONS; LOCUS	Objective. - To assess the efficiency, reliability, and ease of use of DNA diagnosis for Duchenne and Becker muscular dystrophies (DMD/BMD) using the polymerase chain reaction (PCR). Design. - DNA from the patients was screened for deletion mutations using multiplex PCR, and the results were compared with those obtained by Southern blot analysis. The PCR multiplex reaction detects nine specific "hot-spot" exons in the dystrophin gene while the Southern analysis detects 66 specific dystrophin gene restriction fragments. The multiplex reaction requires 50-fold less DNA than Southern analysis and thus is considerably more sensitive. Setting. - Fourteen university-affiliated and private genetic disease diagnostic laboratories. Patients. - Male patients with clinical signs of DMD/BMD. Cases were selected for analysis randomly, without knowledge of whether a deletion was present within the dystrophin gene. Main Outcome Measures. - The percentage of cases that were detectable by multiplex PCR in comparison with Southern analysis, the frequency, extent, and location of the detected deletion mutations. In some cases, duplication mutations were monitored. Results. - The accuracy of a single PCR multiplex amplification (nine exons) was compared with Southern analysis with 10 cDNA probes that cover the full length of the gene. The multiplex PCR analytic method detected 82% of those deletions detected by Southern analysis methods. In one of 745 analyses, the multiplex method suggested a single exon deletion, which was not confirmed by Southern analysis, representing a false-positive rate of 0.013%. Conclusions. - Multiplex PCR represents a sensitive and accurate method for deletion detection of 46% of all cases of DMD/BMD. The method requires 1 day for analysis, is easy to perform, and does not use radioactive tracers. As such, multiplex PCR represents an efficient and rapid method for prenatal or postnatal diagnosis of DMD/BMD.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; ALBERTA CHILDRENS PROV GEN HOSP,MOLEC DIAGNOST LAB,CALGARY T2T 5C7,ALBERTA,CANADA; COLUMBIA UNIV,DEPT OBSTET & GYNECOL,NEW YORK,NY 10027; GENESCREEN,DALLAS,TX; IST GIANNINA GASLINI,MOLEC GENET LAB,I-16148 GENOA,ITALY; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOLEC GENET,LONDON,ENGLAND; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; INSERM,DEPT GENET & FETAL PATHOL,F-75005 PARIS,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; NICHOLS INST,SAN JUAN CAPISTRANO,CA; SAN RAFFAELE HOSP,IST RICOVERO & CURA CARATTERE SCI,CLIN CHEM LAB,MILAN,ITALY; IST CLIN PERFEZIONAMENTO,CLIN RES LAB,MILAN,ITALY; SYLVIUS LABS,DEPT HUMAN GENET,LEIDEN,NETHERLANDS; UNIV CALIF LOS ANGELES,MED CTR,LOS ANGELES,CA 90024; UNIV TURKU,DEPT MED GENET,SF-20500 TURKU 50,FINLAND; HOWARD HUGHES MED INST,HOUSTON,TX	Baylor College of Medicine; Alberta Childrens Hospital; University of Calgary; Columbia University; University of Genoa; IRCCS Istituto Giannina Gaslini; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Institut National de la Sante et de la Recherche Medicale (Inserm); Johns Hopkins University; Nichols Institute; IRCCS Ca Granda Ospedale Maggiore Policlinico; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Turku; Howard Hughes Medical Institute			Covone, Angela/AAA-7859-2020; Bakker, Egbert/D-3525-2009; boileau, catherine/M-4482-2017	Covone, Angela/0000-0002-7669-5270; Bakker, Egbert/0000-0002-2843-7357; boileau, catherine/0000-0002-0371-7539				ABBS S, 1991, J MED GENET, V28, P304, DOI 10.1136/jmg.28.5.304; BAKKER E, 1989, J INHERIT METAB DIS, V12, P174, DOI 10.1007/BF01799293; BAUMBACH LL, 1989, NEUROLOGY, V39, P465, DOI 10.1212/WNL.39.4.465; BEGGS AH, 1990, HUM GENET, V86, P45; BEGGS AH, 1990, NUCLEIC ACIDS RES, V18, P1931, DOI 10.1093/nar/18.7.1931; BULMAN DE, 1991, AM J HUM GENET, V48, P295; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHAMBERLAIN JS, 1991, METHOD MOL BIOL, V9, P299; Chamberlain JS, 1990, CURRENT NEUROLOGY, V10, P65; CHAMBERLAIN JS, 1989, PCR PROTOCOLS GUIDE, P272; CLEMENS PR, 1991, AM J HUM GENET, V49, P951; DARRAS BT, 1988, AM J MED GENET, V29, P713, DOI 10.1002/ajmg.1320290341; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; EMERY AEH, 1987, OXFORD MONOGRAPHY ME, V15; FENWICK RG, 1990, AM J HUM GENET, V47, pA216; FUJIMURA FK, 1990, NEW ENGL J MED, V322, P61; HOFFMAN EP, 1989, NEUROLOGY, V39, P1011, DOI 10.1212/WNL.39.8.1011; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HU XY, 1990, AM J HUM GENET, V46, P682; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MOSER H, 1984, CURRENT CLIN PRACTIC, V20, P41; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OUDET C, 1990, HUM GENET, V84, P283; ROBERTS RG, 1989, NUCLEIC ACIDS RES, V17, P5961, DOI 10.1093/nar/17.15.5961; ROBERTS RG, 1991, AM J HUM GENET, V49, P298; WARD PA, 1989, AM J HUM GENET, V44, P270; WITKOWSKI J, 1990, J CHILD NEUROL, V4, P251	30	42	45	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2609	2615						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573747				2022-12-28	WOS:A1992HT82300026
J	LIGHT, DW				LIGHT, DW			THE PRACTICE AND ETHICS OF RISK-RATED HEALTH-INSURANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STATE; CARE	Health insurance in the United States is driven by competitive risk rating and is promoted as the best way to give policyholders optimal value for their money and to be fair to those with lower risks. In practice, however, competitive risk rating costs more than noncompetitive, universal systems of health insurance, and it erodes the basic function of insurance to spread infrequent large losses over a wide base. This article describes not only how risk rating covers least those with the greatest medical bills, but also how it has spawned a labyrinth of complex manipulations by insurance companies to charge more or pay less than actuarially fair risk rating would justify. The final section shows that even if risk rating were done fairly, it contradicts moral fairness. Many of the leading proposals for national health insurance do not address these practical and ethical issues. The medical profession and policymakers need to discuss them and take a stand on them.	UNIV MED & DENT NEW JERSEY,DEPT PSYCHIAT,DIV SOCIAL & BEHAV MED,CAMDEN,NJ; UNIV OXFORD BALLIOL COLL,OXFORD OX1 3BJ,ENGLAND	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Oxford								Beebe J, 1985, Health Care Financ Rev, V6, P27; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; CLIFFORD HA, 1987, HARVARD LAW REV, V99, P727; COTTON P, 1991, JAMA-J AM MED ASSOC, V265, P2451; DANIELS N, 1990, MILBANK Q, V68, P497, DOI 10.2307/3350192; DANIELS N, 1985, HLTH CARE; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; FREUDENHEIM M, 1992, NY TIMES        0329, V1, P24; GEER CT, 1991, FORBES          1209, P168; GRUMET GW, 1989, NEW ENGL J MED, V321, P607, DOI 10.1056/NEJM198908313210909; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HARVEY LK, 1990, AM MED ASS SURVEY PU; HEIDORN R, 1992, PHILADELPHIA IN 0329, pB1; HEIDORN R, 1992, PHILADELPHIA IN 0329, pB3; HUNT M, 1986, NY TIMES MAGAZI 0119, P55; Hunt Morton, 1986, N Y Times Mag; KOLATA G, 1992, NY TIMES        0304, pA15; Kolata G., 1992, NY TIMES, pAl; KRONICK R, 1991, INQUIRY-J HEALTH CAR, V28, P318; LIGHT DW, 1992, BERGEN REC      0313, P1; LUBITZ J, 1987, INQUIRY-J HEALTH CAR, V24, P362; MCCALL N, 1987, J HEALTH POLIT POLIC, V12, P53, DOI 10.1215/03616878-12-1-53; MCLEOD D, 1991, AARP B, V32, P4; MCQUEEN M, 1991, WALL STREET J   0628, pA14; MEIER B, 1992, NY TIMES        0104, P1; MEIER B, 1992, NY TIMES        0104, P46; NADEL MY, 1990, GAOTHRD9033 US ACCOU; NEIL RAW, 1991, BMJ, V302, P891; Nelkin D., 1989, DANGEROUS DIAGNOSTIC; Nozick Robert, 1974, ANARCHY STATE UTOPIA; PEAR R, 1991, NY TIMES        1105, pA17; PEAR R, 1991, NY TIMES        1118, pA1; PEAR R, 1991, NY TIMES        1204, pA20; Rawls J., 1971, THEORY JUSTICE; ROTHSTEIN MA, 1989, MED SCREENING WORKER; SAYWELL RM, 1989, J HEALTH POLIT POLIC, V14, P287, DOI 10.1215/03616878-14-2-287; SCHRAMM CJ, 1988, AIDS PATIENT CAR FEB, P4; SHIKLES JL, 1990, GAOTHRD9035 US GEN A; SHORT PF, 1990, NATIONAL MED EXPENDI; STONE DA, 1989, SOC RES, V56, P591; STONE DA, 1990, AM PROSPECT, P62; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; WALDHOLZ M, 1986, WALL STREET J   0218, P1; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WRIGHT R, 1990, NEW REPUBLIC    0709, P26; 1988, 85568 C RES SERV PUB; 1988, AIDS HLTH INSURANCE; 1988, PROMOTING HLTH INSUR; 1991, US IND OUTLOOK 1991; 1990, COMMUNITY RATE SCHED; 1983, SECURING ACCESS HLTH, P4; 1978, US DHEW052070047429; 1990, INDEMNITY PLANS COST; 1991, GAOHRD9190 US GEN AC; 1990, HRD9068 US GEN ACC O; 1986, GAOHRD878 US GEN ACC	56	99	99	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2503	2508		10.1001/jama.267.18.2503	http://dx.doi.org/10.1001/jama.267.18.2503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573728				2022-12-28	WOS:A1992HT06800031
J	CASKEY, CT; PIZZUTI, A; FU, YH; FENWICK, RG; NELSON, DL				CASKEY, CT; PIZZUTI, A; FU, YH; FENWICK, RG; NELSON, DL			TRIPLET REPEAT MUTATIONS IN HUMAN-DISEASE	SCIENCE			English	Article							MYOTONIC MUSCULAR-DYSTROPHY; PROTEIN KINASE; X SYNDROME; AMPLIFICATION	Triplet repeats are the sites of mutation in three human heritable disorders, spinal and bulbar muscular atrophy (SBMA), fragile X syndrome, and myotonic dystrophy (DM). These repeats are GC-rich and highly polymorphic in the normal population. Fragile X syndrome and DM are examples of diseases in which premutation alleles cause little or no disease in the individual, but give rise to significantly amplified repeats in affected progeny. This newly identified mechanism of mutation has, so far, been identified in two of the most common heritable disorders, fragile X syndrome and DM, and one rare disease, SBMA.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	CASKEY, CT (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030, USA.			PIZZUTI, Antonio/0000-0003-3245-1925	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029256] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000210] Funding Source: NIH RePORTER; NHGRI NIH HHS [P30-HG00210] Funding Source: Medline; NICHD NIH HHS [1R01HD29256, P30HD24064] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; Ballabio A, 1991, CURR OPIN GENET DEV, V1, P25, DOI 10.1016/0959-437X(91)80036-L; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; BYERS PH, 1989, METABOLIC BASIS INHE, P2805; CASKEY CT, 1991, CONT OB GYN, V36, P27; CHAMBERLAIN JS, IN PRESS J AM MED AS; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FRANKE C, 1990, J PHYSIOL-LONDON, V425, P391, DOI 10.1113/jphysiol.1990.sp018110; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GRIFFIN JE, 1980, NEW ENGL J MED, V302, P198, DOI 10.1056/NEJM198001243020404; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HARDING AE, 1982, J NEUROL NEUROSUR PS, V45, P1012, DOI 10.1136/jnnp.45.11.1012; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1972, LANCET, V2, P53; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; KORNELUK RG, 1989, GENOMICS, V5, P596, DOI 10.1016/0888-7543(89)90028-1; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LUBS HA, 1969, AM J HUM GENET, V21, P231; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; MCPHAUL MJ, 1991, FASEB J, V5, P2910, DOI 10.1096/fasebj.5.14.1752359; Myotonic Dystrophy Foundation, 2017, VOIC PAT REP MYOT DY; NUSSBAUM RL, 1989, METABOLIC BASIS INHE, P327; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ODELBERG SJ, COMMUNICATION; PERGOLIZZI RG, 1992, LANCET, V339, P271, DOI 10.1016/0140-6736(92)91334-5; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; ROSES AD, 1973, P NATL ACAD SCI USA, V70, P1855, DOI 10.1073/pnas.70.6.1855; ROSES AD, 1974, NATURE, V250, P245, DOI 10.1038/250245a0; SAR M, 1977, SCIENCE, V197, P77, DOI 10.1126/science.867053; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1985, HUM GENET, V69, P3289; STARK GR, 1990, GENE REARRANGEMENT F, P99; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; SUTHERLAND GR, 1985, FRAGILE SITES HUMAN, P53; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; TSILFIDIS C, 1991, AM J HUM GENET, V49, P961; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; WELLS RD, 1988, J BIOL CHEM, V263, P1095; YEUNG CY, 1983, J BIOL CHEM, V258, P5179; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]	56	403	430	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					784	789		10.1126/science.1589758	http://dx.doi.org/10.1126/science.1589758			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589758				2022-12-28	WOS:A1992HT23500030
J	LAGAAY, AM; VANDERMEIJ, JC; HIJMANS, W				LAGAAY, AM; VANDERMEIJ, JC; HIJMANS, W			VALIDATION OF MEDICAL HISTORY TAKING AS PART OF A POPULATION BASED SURVEY IN SUBJECTS AGED 85 AND OVER	BRITISH MEDICAL JOURNAL			English	Article									LEIDEN UNIV HOSP,DEPT PATHOL,GERONTOL SECT,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	LAGAAY, AM (corresponding author), LEIDEN UNIV HOSP,DEPT INTERNAL MED,BLDG 1,C1R-41,POB 9600,2300 RC LEIDEN,NETHERLANDS.				NIA NIH HHS [R01 AG06354] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006354] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DAVIS PB, 1989, J AM GERIATR SOC, V37, P249, DOI 10.1111/j.1532-5415.1989.tb06815.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; KELSEY JL, 1989, AM J EPIDEMIOL, V130, P857, DOI 10.1093/oxfordjournals.aje.a115418; OCONNOR DW, 1988, BMJ-BRIT MED J, V297, P1107, DOI 10.1136/bmj.297.6656.1107; RODGERS WL, 1987, J GERONTOL, V42, P387, DOI 10.1093/geronj/42.4.387	5	44	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1091	1092		10.1136/bmj.304.6834.1091	http://dx.doi.org/10.1136/bmj.304.6834.1091			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586823	Green Published			2022-12-28	WOS:A1992HR13600018
J	BASU, TN; GUTMANN, DH; FLETCHER, JA; GLOVER, TW; COLLINS, FS; DOWNWARD, J				BASU, TN; GUTMANN, DH; FLETCHER, JA; GLOVER, TW; COLLINS, FS; DOWNWARD, J			ABERRANT REGULATION OF RAS PROTEINS IN MALIGNANT-TUMOR CELLS FROM TYPE-1 NEUROFIBROMATOSIS PATIENTS	NATURE			English	Article							GENE; MUTATIONS; GAP; TRANSFORMATION; DELETIONS; SEQUENCE; RECEPTOR; ENCODES; LOCUS	DEFECTS in the NF1 gene have been implicated in the inherited disorder neurofibromatosis type 1, which is characterized by several developmental abnormalities including an increased frequency of benign and malignant tumours of neural crest origin (neurofibromas and neurofibrosarcomas respectively) 1. The NF1 gene encodes a ubiquitous protein homologous to p120GAP, the GTPase-activating protein (GAP) for the products of the ras protooncogenes 2-6. When expressed in non-mammalian systems, the region of the NF1 gene homologous to p120GAP produces a protein with GAP-like activity 7-9. Here we present evidence that the ras proteins in malignant tumour cell lines from patients with type 1 neurofibromatosis are in a constitutively activated state, as judged by the guanine nucleotide bound to them, and are necessary for cellular proliferation. These cells contain p21ras and p120GAP that are both functionally wild type, but barely any functional NF1 protein. Our results show that the NF1 protein is normally essential for correct negative regulation of ras proteins in the cell, even in the presence of normal p120GAP, and they support the hypothesis that NF1 is a tumour-suppressor gene whose product acts upstream of ras.	IMPERIAL CANC RES FUND,SIGNAL TRANSDUCT LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; UNIV MICHIGAN,SCH MED,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	Cancer Research UK; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Downward, Julian/A-3251-2012	Gutmann, David/0000-0002-3127-5045; Downward, Julian/0000-0002-2331-4729				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CANTRELL DA, 1988, IMMUNOLOGY, V65, P343; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	22	569	582	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					713	715		10.1038/356713a0	http://dx.doi.org/10.1038/356713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570015	Green Published			2022-12-28	WOS:A1992HQ14600061
J	FREYTAG, SO; GEDDES, TJ				FREYTAG, SO; GEDDES, TJ			RECIPROCAL REGULATION OF ADIPOGENESIS BY MYC AND C/EBP-ALPHA	SCIENCE			English	Article							ENHANCER BINDING-PROTEIN; TUMOR SUPPRESSOR GENES; C-MYC; CELL-DIFFERENTIATION; DNA-BINDING; EXPRESSION; SENESCENCE	3T3-L1 adipoblasts that express large amounts of c-Myc cannot terminally differentiate, raising the possibility that Myc inhibits the expression of genes that promote adipogenesis. The CCAAT/enhancer binding protein (C/EBP-alpha) is induced during 3T3-L1 adipogenesis when cells commit to the differentiation pathway. Transfection of 3T3-L1 adipoblasts with the gene that encodes C/EBP-alpha caused overt expression of the adipocyte morphology. Expression of Myc prohibited the normal induction of C/EBP-alpha and prevented adipogenesis. Enforced expression of C/EBP-alpha overcame the Myc-induced block to differentiation. These results provide a molecular basis for the regulation of adipogenesis and implicate Myc and C/EBP-alpha as pivotal controlling elements.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	FREYTAG, SO (corresponding author), HENRY FORD HOSP,MOLEC BIOL RES PROGRAM,DETROIT,MI 48202, USA.				NATIONAL CANCER INSTITUTE [R01CA051748] Funding Source: NIH RePORTER; NCI NIH HHS [CA51748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEAN M, 1986, J BIOL CHEM, V261, P9161; DHAR R, 1980, P NATL ACAD SCI USA, V77, P3938; FREYTAG S, UNPUB; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	34	282	286	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					379	382		10.1126/science.256.5055.379	http://dx.doi.org/10.1126/science.256.5055.379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566086				2022-12-28	WOS:A1992HP03200037
J	HARDY, JA; HIGGINS, GA				HARDY, JA; HIGGINS, GA			ALZHEIMERS-DISEASE - THE AMYLOID CASCADE HYPOTHESIS	SCIENCE			English	Editorial Material							HEREDITARY CEREBRAL-HEMORRHAGE; DOWNS-SYNDROME; MESSENGER-RNA; NEUROFIBRILLARY TANGLES; PROTEIN-PRECURSOR; BRAIN; LOCALIZATION; CDNA; GENE; TAU		UNIV S FLORIDA, DEPT PSYCHIAT, TAMPA, FL 33612 USA; NIA, BIOL CHEM LAB, BALTIMORE, MD 21224 USA	State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	HARDY, JA (corresponding author), ST MARYS HOSP, SCH MED, DEPT BIOCHEM, LONDON W2 1PG, ENGLAND.		Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423; Higgins, Gerry/0000-0002-0434-1465				ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GANDY S, 1991, Journal of Cell Biology, V115, p122A; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GREENBERG B D, 1991, Society for Neuroscience Abstracts, V17, P913; HAASS C, 1991, J NEUROSCI, V11, P3783; HARDY J, 1991, LANCET, V337, P1342; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1991, FASEB J, V5, P278, DOI 10.1096/fasebj.5.3.2001787; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MANN DMA, 1989, J NEUROL SCI, V89, P169, DOI 10.1016/0022-510X(89)90019-1; MANN DMA, 1989, NEUROPATH APPL NEURO, V15, P317, DOI 10.1111/j.1365-2990.1989.tb01232.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MATTSON MP, 1992, J NEUROSCI, V376; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; NEVE RL, 1990, PROG BRAIN RES, V86, P257; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1988, LANCET, V2, P1456; ROHER A, 1988, PROC R SOC SER B-BIO, V232, P367, DOI 10.1098/rspb.1988.0001; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA S S, 1991, Journal of Cell Biology, V115, p61A; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1990, BIOCHEM BIOPH RES CO, V166, P1192; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; VANDUIJN CM, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91611-W; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIRAK DO, 1991, J BIOL CHEM, V266, P21331; WISNIEWSKI HM, 1990, AM J MED GENET, P287, DOI 10.1002/ajmg.1320370757; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z	64	4682	4907	25	783	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					184	185		10.1126/science.1566067	http://dx.doi.org/10.1126/science.1566067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566067				2022-12-28	WOS:A1992HM89600019
J	EVAN, GI; WYLLIE, AH; GILBERT, CS; LITTLEWOOD, TD; LAND, H; BROOKS, M; WATERS, CM; PENN, LZ; HANCOCK, DC				EVAN, GI; WYLLIE, AH; GILBERT, CS; LITTLEWOOD, TD; LAND, H; BROOKS, M; WATERS, CM; PENN, LZ; HANCOCK, DC			INDUCTION OF APOPTOSIS IN FIBROBLASTS BY C-MYC PROTEIN	CELL			English	Article							PROGRAMMED CELL-DEATH; RAT VENTRAL PROSTATE; DNA-BINDING; GROWTH; DIFFERENTIATION; TRANSFORMATION; TRANSCRIPTION; EXPRESSION; EVENTS; G1	Although Rat-1 fibroblasts expressing c-myc constitutively are unable to arrest growth in low serum, their numbers do not increase in culture because of substantial cell death. We show this cell death to be dependent upon expression of c-myc protein and to occur by apoptosis. Regions of the c-myc protein required for induction of apoptosis overlap with regions necessary for cotransformation, autoregulation, and inhibition of differentiation, suggesting that the apoptotic function of c-myc protein is related to its other functions. Moreover, cells with higher levels of c-myc protein are more prone to cell death upon serum deprivation. Finally, we demonstrate that deregulated c-myc expression induces apoptosis in cells growth arrested by a variety of means and at various points in the cell cycle.	UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh	EVAN, GI (corresponding author), IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Penn, Linda/0000-0001-8133-5459				ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; COTTER TG, 1990, ANTICANCER RES, V10, P1153; DEAN M, 1986, J BIOL CHEM, V261, P9161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FIELD JK, 1990, ANTICANCER RES, V10, P1; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KYPRIANOU N, 1991, CANCER RES, V51, P162; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ormerod M.G., 1990, FLOW CYTOMETRY PRACT, P69; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATERS CM, 1991, ONCOGENE, V6, P797; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1987, ARCH TOXICOL, P3; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	42	2964	3042	2	95	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					119	128		10.1016/0092-8674(92)90123-T	http://dx.doi.org/10.1016/0092-8674(92)90123-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555236				2022-12-28	WOS:A1992HM44500011
J	DUHAMEL, JR; COLBY, CL; GOLDBERG, ME				DUHAMEL, JR; COLBY, CL; GOLDBERG, ME			THE UPDATING OF THE REPRESENTATION OF VISUAL SPACE IN PARIETAL CORTEX BY INTENDED EYE-MOVEMENTS	SCIENCE			English	Article							MECHANISMS; PRIMATE; MACAQUE; MEMORY	Every eye movement produces a shift in the visual image on the retina. The receptive field, or retinal response area, of an individual visual neuron moves with the eves so that after an eye movement it covers a new portion of visual space. For some parietal neurons, the location of the receptive field is shown to shift transiently before an eve movement. In addition, nearly all parietal neurons respond when an eye movement brings the site of a previously flashed stimulus into the receptive field. Parietal cortex both anticipates the retinal consequences of eye movements and updates the retinal coordinates of remembered stimuli to generate a continuously accurate representation of visual space.	NEI,SENSORIMOTOR RES LAB,BLDG 10,ROOM 10C 101,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			Duhamel, Jean-René/M-4723-2017	Duhamel, Jean-René/0000-0003-0210-1027				ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; [Anonymous], 1962, TREATISE PHYSL OPTIC; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; DROULEZ J, 1990, MOTOR CONTROL CONCEP, P137; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1990, COLD SPRING HARB SYM, V55, P729; GOLDBERG ME, 1990, J NEUROPHYSIOL, V64, P489, DOI 10.1152/jn.1990.64.2.489; GOLDENBERG DH, 1983, J FUTURES MARKETS, V3, P225, DOI 10.1002/fut.3990030210; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P745, DOI 10.1152/jn.1976.39.4.745; WURTZ RH, 1969, J NEUROPHYSIOL, V32, P727, DOI 10.1152/jn.1969.32.5.727; YIN TCT, 1977, SCIENCE, V197, P1381, DOI 10.1126/science.408924	13	1322	1326	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1992	255	5040					90	92						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX791	1553535				2022-12-28	WOS:A1992GX79100045
J	SODERSTROM, CA; DISCHINGER, PC; SMITH, GS; MCDUFF, DR; HEBEL, JR; GORELICK, DA				SODERSTROM, CA; DISCHINGER, PC; SMITH, GS; MCDUFF, DR; HEBEL, JR; GORELICK, DA			PSYCHOACTIVE SUBSTANCE DEPENDENCE AMONG TRAUMA CENTER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL; RECOGNITION; PREVALENCE; ABUSE; SEVERITY	Introduction.-The practice of assessing only trauma patients with elevated blood alcohol concentrations (BACs) or positive drug screens for psychoactive substance use disorders (PSUDs) was evaluated. Methods.-Twenty-four BAC-negative (BAC-) (BAC, 0) and 21 BAC-positive (BAC+) (BAC, greater-than-or-equal-to 22 mmol/L or 100 mg/dL; mean, 41 mmol/L; range, 24.3 to 79 mmol/L) adult trauma patients were evaluated for alcoholism and other PSUDs using the Structured Clinical Interview (SCI) from the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R). Approximately half were vehicular crash victims and 78% were men. Results.-A total of 64 PSUDs were diagnosed in 31 (68.9%) of the 45 patients; all but one was for dependence (vs abuse). Of the BAC+ patients, 14 (66.7%) met DSM-III-R criteria for alcohol dependence, 11 (78.6%) of whom also had other PSUDs not related to alcohol. Two other BAC+ patients had nonalcohol PSUDs. Of the BAC- patients, 11 (45.8%) had alcohol dependence, six (54.5%) of whom also had nonalcohol PSUDs. Another four BAC- patients had nonalcohol PSUDs. Overall, 76.2% of the BAC+ patients and 62.5% of the BAC- patients had a diagnosis of psychoactive substance dependence. Conclusion.-All patients admitted to trauma centers should be assessed for alcoholism and other PSUDs.	CHARLES MATHIAS NATL STUDY CTR TRAUMA & EMERGENCY, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY PREVENT, BALTIMORE, MD 21218 USA; UNIV MARYLAND, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, BALTIMORE, MD 21201 USA; NIDA, BETHESDA, MD USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	SODERSTROM, CA (corresponding author), MARYLAND INST EMERGENCY MED SERV SYST, R ADAMS COWLEY SHOCK TRAUMA CTR, DEPT SURG, 22 S GREENE ST, BALTIMORE, MD 21201 USA.		Gorelick, David/ABF-4941-2021	Smith, Gordon/0000-0002-2911-3071	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA007700] Funding Source: NIH RePORTER; NIAAA NIH HHS [R29AA07700] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CLARK DE, 1985, ANN EMERG MED, V14, P274, DOI 10.1016/S0196-0644(85)80456-X; CLEARY PD, 1988, AM J MED, V85, P466; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; HOFFMANN N G, 1989, Advances in Alcohol and Substance Abuse, V8, P119; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; Ramzy A I, 1988, Md Med J, V37, P517; REDMOND AD, 1987, ALCOHOL ALCOHOLISM, V22, P341; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; SILVERMAN JJ, 1985, J TRAUMA, V25, P544, DOI 10.1097/00005373-198506000-00014; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SOLOMON J, 1980, J STUD ALCOHOL, V41, P583, DOI 10.15288/jsa.1980.41.583; Spitzer R. L., 1987, STRUCTURED CLIN INTE; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; YERSIN B, 1989, ARCH INTERN MED, V149, P2071, DOI 10.1001/archinte.149.9.2071; 1990, US DHHS901656 PUBL; 1987, DIAGNOSTIC STATISTIC; 1989, INJURY PREVENTION M; 1991, ALCOHOL ALERT, P1; [No title captured]; 1990, MMWR, V39, P173; 1986, JAMA-J AM MED ASSOC, V255, P522; 1991, HS807693 US DEP TRAN; 1988, MMWR, V37, P753; 1991, ALCOHOL ALERT, V12, P1; 1990, RESOURCES OPTIMAL CA; 1987, MMWR, V36, P437	38	103	105	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2756	2759		10.1001/jama.267.20.2756	http://dx.doi.org/10.1001/jama.267.20.2756			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578594				2022-12-28	WOS:A1992HV26500022
J	STPETER, RF; NEWACHECK, PW; HALFON, N				STPETER, RF; NEWACHECK, PW; HALFON, N			ACCESS TO CARE FOR POOR CHILDREN - SEPARATE AND UNEQUAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-INCOME CHILDREN; MEDICAL-CARE; UNITED-STATES; HEALTH-CARE; SERVICES; IMPACT	Objective.-To determine how coverage by Medicaid affects the use of preventive care, as well as the location and continuity of care for poor children. Design.-Analysis of the 1988 National Health Interview Survey on Child Health Setting.-Nationally representative sample of the US noninstitutionalized, civilian population. Participants.-A total of 17710 children under 18 years of age selected in a stratified cluster sampling of US households. Intervention.-None. Main Outcome Measures.-The percentage of children with a usual source of routine care; the timeliness of visits for routine care; the usual source where routine care is received; and the continuity between sources of care. Results.-Poor children with Medicaid coverage were more likely than those without Medicaid to have a usual source of routine care (91% vs 78%, P < .001) and to receive routine care within an appropriate time interval (84% vs 69%, P < .001). However, poor children with Medicaid were less likely than children living above the poverty line to receive routine care in physicians' offices (56% vs 82%, P < .001) and more likely to lack continuity between usual sources of routine and sick care (18% vs 6%, P < .001). Children receiving routine care at community clinics compared with children receiving care at physicians' offices were more likely to receive sick care at a different location than where they receive routine care (40% vs 4%, P < .001) and also more likely to identify an emergency department as their usual source of sick care (9% vs 2%, P < .001). Conclusions.-While Medicaid does improve access to care for poor children, it does not ensure them access to the same locations and continuity of care as that available to other children. Recent changes in the Medicaid program may address some of these inequities, but others are likely to remain.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	STPETER, RF (corresponding author), UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,521 PARNASSUS AVE,C-126,SAN FRANCISCO,CA 94143, USA.							ADAMS PF, 1989, VITAL HLTH STAT 10, V173, P1; BLOOM B, 1985, VITAL HLTH STAT 0, V151, P1; BLOOM B, 1990, VITAL HLTH STATISTIC, V188; BUTLER JA, 1985, PEDIATRICS, V76, P495; DUTTON DB, 1981, DHHS PHS7955071 US D, P4; EGBUONU L, 1982, PEDIATRICS, V69, P550; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GORDIS L, 1973, NEW ENGL J MED, V289, P331, DOI 10.1056/NEJM197308162890701; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HILL IT, 1988, HLTH AFF, V7, P83; HINDS MD, 1991, NEW YORK TIMES  1114, pA20; HOCHHEISER LI, 1971, NEW ENGL J MED, V285, P148, DOI 10.1056/NEJM197107152850305; KASPER JD, 1987, MED CARE, V25, P386, DOI 10.1097/00005650-198705000-00003; KLEIN M, 1973, PEDIATRICS, V51, P833; KLEINMAN JC, 1981, MED CARE, V19, P1011, DOI 10.1097/00005650-198110000-00004; MCMANUS M, 1991, PEDIATRICS, V87, P909; NEWACHECK PW, 1988, AM J PUBLIC HEALTH, V78, P927, DOI 10.2105/AJPH.78.8.927; NEWACHECK PW, 1988, PEDIATRICS, V82, P462; OKADA LM, 1980, PUBLIC HEALTH REP, V95, P520; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; ROSENBAUM S, 1986, MILBANK Q, V64, P442, DOI 10.2307/3350028; Starfield B, 1982, J Public Health Policy, V3, P244, DOI 10.2307/3342443; Starfield B, 1985, EFFECTIVENESS MED CA; WAN TTH, 1978, J HEALTH SOC BEHAV, V19, P312, DOI 10.2307/2136563; WOOD DL, 1990, PEDIATRICS, V86, P666; YUDKOWSKY BK, 1990, PEDIATRICS, V85, P567; YUDKOWSKY BK, 1990, HLTH CARE FIN REV S, P89; 1991, ACCESS COMMUNITY HLT, P9; [No title captured]; 1985, REDUCING POVERTY CHI; 1989, CURRENT POPULATI P60, V166; 1991, GAOHRD9131FS US GEN; 1988, GUIDELINES HLTH SUPE, V2; 1990, L101508 PUBL; 1991, 1991 PHYS PAYM REV C, P304	35	154	154	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2760	2764		10.1001/jama.267.20.2760	http://dx.doi.org/10.1001/jama.267.20.2760			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV265	1578595				2022-12-28	WOS:A1992HV26500023
J	DELAMOTHE, T				DELAMOTHE, T			THE NEW NHS - 1ST YEARS EXPERIENCE - EAST-BIRMINGHAM - THE BEAST WAS FED	BRITISH MEDICAL JOURNAL			English	Article																		DELAMOTHE T, 1991, BRIT MED J, V303, P842, DOI 10.1136/bmj.303.6806.842; DELAMOTHE T, 1991, BRIT MED J, V302, P714, DOI 10.1136/bmj.302.6778.714	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1109	1111		10.1136/bmj.304.6834.1109	http://dx.doi.org/10.1136/bmj.304.6834.1109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586827	Bronze, Green Published			2022-12-28	WOS:A1992HR13600026
J	DEOM, CM; LAPIDOT, M; BEACHY, RN				DEOM, CM; LAPIDOT, M; BEACHY, RN			PLANT-VIRUS MOVEMENT PROTEINS	CELL			English	Review							TOBACCO MOSAIC-VIRUS; 30-KD PROTEIN; PLASMODESMATA; REPLICATION; PRODUCT		SCRIPPS RES INST, DIV PLANT BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	DEOM, CM (corresponding author), UNIV GEORGIA, DEPT PLANT PATHOL, ATHENS, GA 30602 USA.			Deom, C. Michael/0000-0002-7008-9720; Lapidot, Moshe/0000-0002-1227-4434				Atabekov J G, 1990, Adv Virus Res, V38, P201, DOI 10.1016/S0065-3527(08)60863-5; ATKINS D, 1991, J GEN VIROL, V72, P2831, DOI 10.1099/0022-1317-72-11-2831; ATKINS D, 1991, J GEN VIROL, V72, P209, DOI 10.1099/0022-1317-72-1-209; BERNA A, 1991, VIROLOGY, V182, P682, DOI 10.1016/0042-6822(91)90609-F; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1991, BIOESSAYS, V13, P373, DOI 10.1002/bies.950130802; DAWSON WO, 1988, PHYTOPATHOLOGY, V78, P783, DOI 10.1094/Phyto-78-783; DEOM CM, 1987, SCIENCE, V237, P389, DOI 10.1126/science.237.4813.389; DEOM CM, 1991, VIROLOGY, V180, P251, DOI 10.1016/0042-6822(91)90029-B; DEOM CM, 1990, P NATL ACAD SCI USA, V87, P3284, DOI 10.1073/pnas.87.9.3284; Gibbs A, 1976, INTERCELLULAR COMMUN, P149; HIBINO H, 1977, Annals of the Phytopathological Society of Japan, V43, P255, DOI 10.3186/jjphytopath.43.255; HOLT CA, 1991, VIROLOGY, V181, P109, DOI 10.1016/0042-6822(91)90475-Q; Hull R., 1991, Seminars in Virology, V2, P89; LINSTEAD PJ, 1988, J GEN VIROL, V69, P1809, DOI 10.1099/0022-1317-69-8-1809; LUCAS WJ, 1990, PARALLELS CELL CELL, P261; MAULE AJ, 1991, CRIT REV PLANT SCI, V9, P457, DOI 10.1080/07352689109382301; MESHI T, 1987, EMBO J, V6, P2557, DOI 10.1002/j.1460-2075.1987.tb02544.x; MESHI T, 1989, PLANT CELL, V1, P515, DOI 10.1105/tpc.1.5.515; ROBARDS AW, 1990, ANNU REV PLANT PHYS, V41, P369, DOI 10.1146/annurev.pp.41.060190.002101; TERRY BR, 1987, PLANTA, V171, P145, DOI 10.1007/BF00391090; TOMENIUS K, 1987, VIROLOGY, V160, P363, DOI 10.1016/0042-6822(87)90007-9; VANLENT J, 1991, J GEN VIROL, V72, P2615, DOI 10.1099/0022-1317-72-11-2615; WELLINK J, 1989, J GEN VIROL, V70, P2279, DOI 10.1099/0022-1317-70-9-2279; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377; WOLF S, 1991, PLANT CELL, V3, P593, DOI 10.1105/tpc.3.6.593	26	210	216	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					221	224		10.1016/0092-8674(92)90403-Y	http://dx.doi.org/10.1016/0092-8674(92)90403-Y			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568243				2022-12-28	WOS:A1992HQ18300002
J	KINTNER, C				KINTNER, C			REGULATION OF EMBRYONIC-CELL ADHESION BY THE CADHERIN CYTOPLASMIC DOMAIN	CELL			English	Article							XENOPUS EMBRYOS; MOLECULE UVOMORULIN; N-CAM; EXPRESSION; PROTEIN; CDNAS; JUNCTIONS; ECTODERM; REGION	Differential adhesion between embryonic cells has been proposed to be mediated by a family of closely related glycoproteins called the cadherins. The cadherins mediate adhesion in part through an interaction between the cadherin cytoplasmic domain and intracellular proteins, called the catenins. To determine whether these interactions could regulate cadherin function in embryos, a form of N-cadherin was generated that lacks an extracellular domain. Expression of this mutant in Xenopus embryos causes a dramatic inhibition of cell adhesion. Analysis of the mutant phenotype shows that at least two regions of the N-cadherin cytoplasmic domain can inhibit adhesion and that the mutant cadherin can inhibit catenin binding to E-cadherin. These results suggest that cadherin-mediated adhesion can be regulated by cytoplasmic interactions and that this regulation may contribute to morphogenesis when emerging tissues coexpress several cadherin types.			KINTNER, C (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, POB 85800, SAN DIEGO, CA 92186 USA.							ANGRES B, 1991, DEVELOPMENT, V111, P829; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; CHOI YS, 1989, J CELL BIOL, V108, P2449, DOI 10.1083/jcb.108.6.2449; CHOI YS, 1990, J CELL BIOL, V110, P1575, DOI 10.1083/jcb.110.5.1575; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GINSBERG D, 1991, DEVELOPMENT, V111, P315; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KELLER RE, 1980, J EMBRYOL EXP MORPH, V60, P201; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KINTNER C, 1988, NEURON, V1, P545, DOI 10.1016/0896-6273(88)90104-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOCH PJ, 1991, DIFFERENTIATION, V47, P29, DOI 10.1111/j.1432-0436.1991.tb00218.x; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEVI G, 1991, DEVELOPMENT, V111, P159; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NILLES LA, 1991, J CELL SCI, V99, P809; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; Sambrook J, 1989, MOL CLONING LABORATO; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796	42	370	386	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					225	236		10.1016/0092-8674(92)90404-Z	http://dx.doi.org/10.1016/0092-8674(92)90404-Z			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568244				2022-12-28	WOS:A1992HQ18300003
J	MATHERS, N; USHERWOOD, T				MATHERS, N; USHERWOOD, T			THE GATEKEEPER AND THE WIZARD REVISITED	BRITISH MEDICAL JOURNAL			English	Article											MATHERS, N (corresponding author), UNIV SHEFFIELD,DEPT GEN PRACTICE,SHEFFIELD S10 2RX,ENGLAND.							BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Cox D.R., 1961, QUEUES; DUDLEY HAF, 1985, QUEUING THEORY WAITI; MATHERS N, 1989, BRIT MED J, V298, P172, DOI 10.1136/bmj.298.6667.172; USHERWOOD TP, 1987, FAM PRACT, V4, P149, DOI 10.1093/fampra/4.2.149	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					969	971		10.1136/bmj.304.6832.969	http://dx.doi.org/10.1136/bmj.304.6832.969			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581723	Green Published, Bronze			2022-12-28	WOS:A1992HP06400028
J	PULLMAN, WE; BODMER, WF				PULLMAN, WE; BODMER, WF			CLONING AND CHARACTERIZATION OF A GENE THAT REGULATES CELL-ADHESION	NATURE			English	Article							DIFFERENTIATION; INTEGRINS; SURFACE; CANCER; FAMILY	MOLECULES of the cadherin and integrin families involved in cell-cell and cell-matrix adhesion have been implicated in epithelial differentiation, carcinogenesis and metastasis 1-6. Having observed that a colon cancer cell line bound avidly to collagen type I, inducing integrin-triggered glandular differentiation 7, We investigated the regulation of integrin function in these cells. We modified a mammalian expression cloning system 8 that used monoclonal antibody selection to clone cell surface molecules. Using attachment to collagen type I to select for adhesive phenotype, we isolated a complementary DNA clone that increases cell adhesion to components of the extracellular matrix. The corresponding gene (cell adhesion regulator, CAR) is located on the long arm of chromosome 16 (16q) and encodes a protein of 142 amino acids, which has an N-terminal myristoylation motif and a consensus tyrosine-kinase phosphorylation site at the C terminus. Removal of this tyrosine residue abolishes enhancement of cell-matrix adhesion. This gene may encode an adhesion signal transduction molecule that functions in the suppression of tumour invasion.			PULLMAN, WE (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Bodmer, Walter/0000-0001-6244-9792				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BICKNELL DC, 1991, GENOMICS, V10, P186, DOI 10.1016/0888-7543(91)90499-5; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HUSCHTSCHA LI, 1989, IN VITRO CELL DEV B, V25, P105, DOI 10.1007/BF02624419; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIGNATELLI M, 1990, J PATHOL, V162, P95, DOI 10.1002/path.1711620202; PIGNATELLI M, 1988, P NATL ACAD SCI USA, V85, P5561, DOI 10.1073/pnas.85.15.5561; RESH MD, 1990, ONCOGENE, V5, P1437; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAMBROOK J, 1991, MOL CLONING LABORATO, V3, P215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, CANCER RES, V50, P7184; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STERNBERG MJE, 1991, COMPUT APPL BIOSCI, V7, P257; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAPLEY P, 1989, ONCOGENE, V4, P325; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	25	93	95	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					529	532		10.1038/356529a0	http://dx.doi.org/10.1038/356529a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560826				2022-12-28	WOS:A1992HN23100061
J	KELLEHER, DJ; KREIBICH, G; GILMORE, R				KELLEHER, DJ; KREIBICH, G; GILMORE, R			OLIGOSACCHARYLTRANSFERASE ACTIVITY IS ASSOCIATED WITH A PROTEIN COMPLEX COMPOSED OF RIBOPHORIN-I AND RIBOPHORIN-II AND A 48KD PROTEIN	CELL			English	Article							ROUGH MICROSOMAL-MEMBRANES; ENDOPLASMIC-RETICULUM; N-GLYCOSYLATION; SUBSTRATE RECOGNITION; RIBOSOME BINDING; YEAST GENE; DOLICHOL; TRANSLOCATION; TRANSFERASE; SEQUENCE	Oligosaccharyltransferase catalyzes the N-linked glycosylation of asparagine residues on nascent polypeptides in the lumen of the rough endoplasmic reticulum (RER). A protein complex composed of 66, 63, and 48 kd subunits copurified with oligosaccharyltransferase from canine pancreas. The 66 and 63 kd subunits were shown by protein immunoblotting to be identical to ribophorin I and II, two previously identified RER glycoproteins that colocalize with membrane-bound ribosomes. The transmembrane segment of ribophorin I was found to be homologous to a recently proposed dolichol recognition consensus sequence. Based on a revision of the consensus sequence, we propose a model for the interaction of dolichol with the glycosyltransferases that catalyze the assembly and transfer of lipid-linked oligosaccharides.	NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016	New York University	KELLEHER, DJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768, R01GM021971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21971, GM 43768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; AUBERT JP, 1982, BIOPHYS RES COMMUN, V144, P1550; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CHALIFOUR RJ, 1988, J BIOL CHEM, V263, P15673; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAS RC, 1980, P NATL ACAD SCI-BIOL, V77, P3811, DOI 10.1073/pnas.77.7.3811; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GLABE CG, 1980, J BIOL CHEM, V255, P9236; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KIRKEGAARD LH, 1973, BIOCHEMISTRY-US, V12, P3627, DOI 10.1021/bi00743a009; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LIU T, 1979, J BIOL CHEM, V254, P4554; MARCANTONIO EE, 1982, EUR J BIOCHEM, V124, P217, DOI 10.1111/j.1432-1033.1982.tb05928.x; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MURGOLO NJ, 1989, BIOCHEMISTRY-US, V28, P253, DOI 10.1021/bi00427a035; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; Stewart JM, 1984, SOLID PHASE PEPTIDE; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931; ZHU XY, 1990, J BIOL CHEM, V265, P14250	43	238	245	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					55	65		10.1016/0092-8674(92)90118-V	http://dx.doi.org/10.1016/0092-8674(92)90118-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555242				2022-12-28	WOS:A1992HM44500006
J	LENO, GH; DOWNES, CS; LASKEY, RA				LENO, GH; DOWNES, CS; LASKEY, RA			THE NUCLEAR-MEMBRANE PREVENTS REPLICATION OF HUMAN G2 NUCLEI BUT NOT G1 NUCLEI IN XENOPUS EGG EXTRACT	CELL			English	Article							PERMEABILIZED CHROMAFFIN CELLS; SYNCHRONIZED HELA-CELLS; STREPTOLYSIN-O; DNA-REPLICATION; TETANUS TOXIN; CATECHOLAMINE SECRETION; PURIFIED DNA; INITIATION; ENVELOPE; RELEASE	We have used synchronized HeLa cells to investigate the role of the nuclear membrane in preventing rereplication in a single cell cycle. Nuclei were prepared with intact nuclear membranes using streptolysin-O or digitonin and assayed for replication in Xenopus egg extracts. Intact G1 nuclei replicate semiconservatively, but intact G2 nuclei do not replicate in egg extract. However, permeabilizing the nuclear membranes of G2 nuclei by treatment with NP-40 allows them all to replicate in egg extract under cell cycle control, suggesting that integrity of the nuclear membrane is required to distinguish G2 from G1 human nuclei and to prevent rereplication within a single cell cycle. The results are discussed in terms of the previously proposed licensing factor model.	UNIV CAMBRIDGE, CRC MAMMALIAN DNA REPAIR GRP, CAMBRIDGE CB2 3EJ, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	University of Cambridge; University of Cambridge	LENO, GH (corresponding author), UNIV CAMBRIDGE, WELLCOME CRC INST CANC & DEV BIOL, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BROWN DB, 1985, EXP CELL RES, V156, P251, DOI 10.1016/0014-4827(85)90279-4; DEROEPER A, 1977, NATURE, V265, P469, DOI 10.1038/265469a0; DOWNES CS, 1982, NUCLEIC ACIDS RES, V10, P5357, DOI 10.1093/nar/10.17.5357; DOWNES CS, 1979, BIOPHYS J, V25, P129, DOI 10.1016/S0006-3495(79)85282-0; DOWNES CS, 1987, ANAL BIOCHEM, V165, P56, DOI 10.1016/0003-2697(87)90200-4; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUGO F, 1986, INFECT IMMUN, V54, P641, DOI 10.1128/IAI.54.3.641-645.1986; JOST E, 1981, J CELL SCI, V47, P25; LAZAROVICI P, 1989, FEBS LETT, V253, P121, DOI 10.1016/0014-5793(89)80943-3; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; PAINE PL, 1975, J CELL BIOL, V66, P652, DOI 10.1083/jcb.66.3.652; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; PRIGENT D, 1976, BIOCHIM BIOPHYS ACTA, V443, P288, DOI 10.1016/0005-2736(76)90511-3; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; WILSON SP, 1983, J BIOL CHEM, V258, P4994; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944	33	125	128	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					151	158		10.1016/0092-8674(92)90126-W	http://dx.doi.org/10.1016/0092-8674(92)90126-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555238				2022-12-28	WOS:A1992HM44500014
J	KRAULIS, PJ; RAINE, ARC; GADHAVI, PL; LAUE, ED				KRAULIS, PJ; RAINE, ARC; GADHAVI, PL; LAUE, ED			STRUCTURE OF THE DNA-BINDING DOMAIN OF ZINC GAL4	NATURE			English	Article							REGULATORY PROTEIN; YEAST; ACTIVATOR; PROGRAM; FINGER	THE yeast transcriptional activator GAL4 binds co-operatively to four related 17-base-pair sequences within an upstream activating sequence (UAS(G)) to activate transcription of the GAL1 and GAL10 genes 1. It belongs to a class of gene regulatory proteins which all contain a highly conserved cysteine-rich region within their DNA-binding domains 2,3. This region binds zinc 4-7 and it has been proposed that the cysteine residues coordinate the zinc, creating a structure analogous to one of the 'zinc fingers' of the transcription factor TFIIIA (ref. 8). Using H-1-Cd-113 two-dimensional nuclear magnetic resonance spectra of the cadmium form of the domain, we previously showed that the protein contains a Cd2Cys6 cluster where cysteines 11 and 28 act as bridging ligands 9. A similar study of a fragment of GAL4 has recently been published 10. We report here the solution structure of the DNA binding domain of GAL4; two helix-turn-strand motifs pack around a Zn2Cys6 cluster in a novel pseudo-symmetrical arrangement. The results show that the GAL4 zinc-binding domain differs significantly from both the TFIIIA-type zinc finger 11 and the steroid hormone receptor DNA-binding domains 12.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CTR MOLEC RECOGNIT, TENNIS COURT RD, CAMBRIDGE CB2 1QW, ENGLAND	University of Cambridge				Laue, Ernest/0000-0002-7476-4148; Kraulis, Per/0000-0003-0560-974X				BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; GADHAVI PL, 1990, FEBS LETT, V276, P49, DOI 10.1016/0014-5793(90)80504-C; GADHAVI PL, 1991, FEBS LETT, V281, P223, DOI 10.1016/0014-5793(91)80398-M; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIESINGER C, 1985, J AM CHEM SOC, V107, P6394, DOI 10.1021/ja00308a042; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HYBERTS SG, 1989, J MAGN RESON, V81, P418, DOI 10.1016/0022-2364(89)90076-0; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NILGES M, 1990, X PLOR MANUAL V21; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; POVEY JF, 1990, FEBS LETT, V266, P142, DOI 10.1016/0014-5793(90)81525-S; POVEY JF, 1990, THESIS U CAMBRIDGE; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4	26	119	123	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					448	450		10.1038/356448a0	http://dx.doi.org/10.1038/356448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557129				2022-12-28	WOS:A1992HL83000069
J	DONEHOWER, LA; HARVEY, M; SLAGLE, BL; MCARTHUR, MJ; MONTGOMERY, CA; BUTEL, JS; BRADLEY, A				DONEHOWER, LA; HARVEY, M; SLAGLE, BL; MCARTHUR, MJ; MONTGOMERY, CA; BUTEL, JS; BRADLEY, A			MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS	NATURE			English	Article							CELL-CYCLE CONTROL; WILD-TYPE P53; MONOCLONAL-ANTIBODY; T-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; PROTO-ONCOGENE; MOUSE; GENE; EXPRESSION	Mutations in the p53 tumour-suppressor gene are the most frequently observed genetic lesions in human cancers. To investigate the role of the p53 gene in mammalian development and tumorigenesis, a null mutation was introduced into the gene by homologous recombination in murine embryonic stem cells. Mice homozygous for the null allele appear normal but are prone to the spontaneous development of a variety of neoplasms by 6 months of age. These observations indicate that a normal p53 gene is dispensable for embryonic development, that its absence predisposes the animal to neoplastic disease, and that an oncogenic mutant form of p53 is not obligatory for the genesis of many types of tumours.	BAYLOR COLL MED, CTR COMPARAT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	DONEHOWER, LA (corresponding author), BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA.			Bradley, Allan/0000-0002-2349-8839; Butel, Janet/0000-0002-6876-3245				ALISON RH, 1987, VET PATHOL, V24, P226, DOI 10.1177/030098588702400305; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DAVID YB, 1988, ONCOGENE, V3, P179; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JARVIS DL, 1984, VIROLOGY, V134, P168, DOI 10.1016/0042-6822(84)90282-4; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1990, NATURE, V64, P313; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAITA K, 1988, TOXICOL PATHOL, V16, P340, DOI 10.1177/019262338801600305; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOWAT M, 1985, NATURE, V61, P2777; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SLAGLE BL, 1984, CANCER RES, V44, P2155; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUSSI T, 1990, ONCOGENE, V5, P945; SQUIRE RA, 1978, PATHOLOGY LABORATORY, P1054; SRIVASTAVA S, 1990, NATURE, V348, P757; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STUTMAN O, 1974, FED PROC, V33, P2028; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YANDELL D W, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P459; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	4046	4170	4	197	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					215	221		10.1038/356215a0	http://dx.doi.org/10.1038/356215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552940				2022-12-28	WOS:A1992HJ94400048
J	WANNAMETHEE, G; SHAPER, AG				WANNAMETHEE, G; SHAPER, AG			PHYSICAL-ACTIVITY AND STROKE IN BRITISH MIDDLE-AGED MEN	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; HEART-DISEASE; QUESTIONNAIRE; HEALTH; DEATH	Objectives - To assess the relation between physical activity and stroke and to determine the overall benefit of physical activity for all major cardiovascular events. Design - Prospective study of a cohort of men followed up for 9-5 years. Setting - General practices in 24 towns in England, Wales, and Scotland (British regional heart study). Subjects - 7735 men aged 40-59 at screening, selected at random from one general practice in each of 24 towns. Main outcome measures - Fatal and non-fatal strokes and heart attacks. Results - 128 major strokes (fatal and non-fatal) occurred. Physical activity was inversely associated with risk of stroke independent of coronary risk factors, heavy drinking, and pre-existing ischaemic heart disease or stroke (relative risk 1.0 for inactivity, 0.6 moderate activity, and 0.3 vigorous activity; test for trend p = 0.008). The association remained after excluding men reporting regular sporting (vigorous) activity. However, vigorous physical activity was associated with a marginally significant increased risk of heart attack compared with moderate or moderately vigorous activity in men with no pre-existing ischaemic heart disease or stroke (relative risk 1.6; 95% confidence interval 0.96 to 2.8). In men with symptomatic ischaemic heart disease or stroke those doing moderately vigorous or vigorous activity had a risk of heart attack slightly higher than that in inactive men (relative risk = 1.6; 0.8 to 3.3). Conclusions - Moderate physical activity significantly reduces the risk of stroke and heart attacks in men both with and without pre-existing ischaemic heart disease. More vigorous activity did not confer any further protection. Moderate activity, such as frequent walking and recreational activity or weekly sporting activity, should be encouraged without restriction.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977				BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; HERMAN B, 1982, STROKE, V13, P334, DOI 10.1161/01.STR.13.3.334; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; PAFFENBA.RS, 1967, LANCET, V1, P753, DOI 10.1016/S0140-6736(67)91367-0; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SLATTERY ML, 1989, CIRCULATION, V79, P3104; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	15	179	182	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					597	601		10.1136/bmj.304.6827.597	http://dx.doi.org/10.1136/bmj.304.6827.597			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH733	1559088	Bronze, Green Published			2022-12-28	WOS:A1992HH73300020
J	MORRIS, JK; COOK, DG; SHAPER, AG				MORRIS, JK; COOK, DG; SHAPER, AG			NONEMPLOYMENT AND CHANGES IN SMOKING, DRINKING, AND BODY-WEIGHT	BRITISH MEDICAL JOURNAL			English	Article							AGED BRITISH MEN; CARDIOVASCULAR RISK-FACTORS; ALCOHOL-CONSUMPTION; SOCIAL-CLASS; UNEMPLOYMENT; HEALTH; MORTALITY; BEHAVIOR; BRITAIN	Objective - To assess the effect of unemployment and early retirement on cigarette smoking, alcohol consumption, and body weight in middle aged British men. Design - Prospective cohort study (British regional heart study.) Setting - One general practice in 24 towns in Britain. Subjects - 6057 men aged 40-59 who had been continuously employed for five years before the initial screening. Five years after screening 4412 men had been continuously employed and 1645 had experienced some unemployment or retired. Main outcome measures - Numbers of cigarettes smoked and units of alcohol consumed per week and body mass index (kg/m2). Results - At initial screening significantly higher percentages of men who subsequently experienced non-employment smoked or had high alcohol consumption than of men who remained continuously employed: 43.0% versus 37.0% continuously employed for cigarette smoking (95% confidence interval for difference 3.2% to 9.0%) and 12.1% versus 9.0% for heavy drinking (1.3% to 5.1%). There was no evidence that men increased their smoking or drinking on becoming non-employed. Men non-employed through illness were significantly more likely to reduce their smoking and drinking than men who remained continuously employed. Men who experienced non-employment were significantly more likely to gain over 10% in weight than men who remained continuously employed: 7.5% versus 5.0% continuously employed (0.9% to 4.0%). Conclusions - Loss of employment was not associated with increased smoking or drinking but was associated with an increased likelihood of gaining weight. The long term effects of the higher levels of smoking and alcohol consumption before nonemployment should be taken into account when comparing mortality and morbidity in groups of unemployed and employed people.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Morris, Joan/0000-0002-7164-612X; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1970, CLASSIFICATION OCCUP; BRAY GA, 1978, INT J OBESITY, V2, P99; COOK DG, 1982, LANCET, V1, P1290; CRAWFORD A, 1987, BRIT J ADDICT, V82, P1007; CUMMINS RO, 1981, BRIT MED J, V283, P1497, DOI 10.1136/bmj.283.6305.1497; HAMMARSTROM A, 1988, SOC SCI MED, V26, P1025, DOI 10.1016/0277-9536(88)90220-1; HEADY P, 1989, LIVING STANDARDS UNE; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; IVERSEN L, 1986, SOC SCI MED, V22, P107, DOI 10.1016/0277-9536(86)90314-X; KASL SV, 1972, INT J EPIDEMIOL, V1, P111, DOI 10.1093/ije/1.2.111; KENDELL RE, 1983, BRIT MED J, V287, P809, DOI 10.1136/bmj.287.6395.809; KESSLER RC, 1987, J HEALTH SOC BEHAV, V28, P51, DOI 10.2307/2137140; Kirby H D, 1986, Health Visit, V59, P312; LEE AJ, 1990, BRIT J ADDICT, V85, P1165; MATTIASSON I, 1990, BRIT MED J, V301, P461, DOI 10.1136/bmj.301.6750.461; MOSER KA, 1984, LANCET, V2, P1324; NARENDRANTHAN W, 1985, J R STAT SOC A STAT, V148, P254, DOI 10.2307/2981970; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMART RG, 1979, J OCCUP ENVIRON MED, V21, P731, DOI 10.1097/00043764-197911000-00005; WALDRON I, 1989, AM J PREV MED, V3, P142; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WARR P, 1983, J APPL SOC PSYCHOL, V13, P206, DOI 10.1111/j.1559-1816.1983.tb01735.x; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; 1985, SAS USERS GUIDE STAT; 1984, GENERAL HOUSEHOLD SU; 1986, GENERAL HOUSEHOLD SU; 1980, GENERAL HOUSEHOLD SU; 1986, SUGI SUPPLEMENTAL LI; 1988, GENERAL HOUSEHOLD SU; 1990, GENERAL HOUSEHOLD SU	33	101	101	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					536	541		10.1136/bmj.304.6826.536	http://dx.doi.org/10.1136/bmj.304.6826.536			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG599	1559056	Green Published, Bronze			2022-12-28	WOS:A1992HG59900018
J	MIDDLEKAUFF, HR; WIENER, I; SAXON, LA; STEVENSON, WG				MIDDLEKAUFF, HR; WIENER, I; SAXON, LA; STEVENSON, WG			LOW-DOSE AMIODARONE FOR ATRIAL-FIBRILLATION - TIME FOR A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						AMIODARONE; ATRIAL FIBRILLATION; ANTI-ARRHYTHMIA AGENTS; HEART FAILURE, CONGESTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG	SINUS RHYTHM; VENTRICULAR-TACHYCARDIA; ANTIARRHYTHMIC DRUGS; FLECAINIDE ACETATE; QUINIDINE THERAPY; DOUBLE-BLIND; EFFICACY; MAINTENANCE; SAFETY; PLACEBO	Because atrial fibrillation is associated with substantial morbidity, restoration of sinus rhythm is desirable. Long-term maintenance of sinus rhythm often requires chronic antiarrhythmic therapy. Class I antiarrhythmic drugs such as quinidine or propafenone maintain sinus rhythm in approximately 50% of patients at 1 year and have risks for proarrhythmia and noncardiac toxicity. Studies of low-dose amiodarone for atrial fibrillation have reported sinus rhythm maintenance in 53% to 79% of patients during a mean follow-up of 27 months. Amiodarone has a lower incidence of proarrhythmia and heart failure exacerbation compared with class I drugs. Most noncardiac side effects are dose related, and low-dose amiodarone (< 300 mg/d) is well tolerated. The time has come for a large-scale prospective evaluation of low-dose amiodarone treatment early in the course of atrial fibrillation.			MIDDLEKAUFF, HR (corresponding author), UNIV CALIF LOS ANGELES, SCH MED,DEPT MED,DIV CARDIOL,47-123 CHS, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA.							ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; ANTMAN EM, 1990, J AM COLL CARDIOL, V15, P698, DOI 10.1016/0735-1097(90)90649-A; BERNS E, 1987, AM J CARDIOL, V59, P1337, DOI 10.1016/0002-9149(87)90915-5; BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; Boissel J P, 1981, Eur Heart J, V2, P49; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; BYRNEQUINN E, 1970, BRIT HEART J, V32, P370; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; DUSMAN RE, 1990, CIRCULATION, V82, P51, DOI 10.1161/01.CIR.82.1.51; FALK RH, 1989, ANN INTERN MED, V111, P107, DOI 10.7326/0003-4819-111-2-107; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HAMMILL SC, 1988, AM J CARDIOL, V61, P473, DOI 10.1016/0002-9149(88)90312-8; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HARTEL G, 1970, BRIT HEART J, V32, P57; HILLESTAD L, 1971, BRIT HEART J, V33, P518; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; JOSEPHSON ME, 1989, ANN INTERN MED, V111, P101, DOI 10.7326/0003-4819-111-2-101; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOWEY PR, 1988, CHEST, V93, P54, DOI 10.1378/chest.93.1.54; LLOYD EA, 1984, S AFR MED J, V65, P367; MARTIN A, 1986, BRIT J CLIN PRACT, V40, P52; MASON JW, 1987, NEW ENGL J MED, V316, P455; MATTIONI TA, 1989, ANN INTERN MED, V111, P574, DOI 10.7326/0003-4819-111-7-574; MIDDLEKAUFF H R, 1991, Journal of the American College of Cardiology, V17, p92A; MITCHELL LB, 1989, CIRCULATION, V80, P34, DOI 10.1161/01.CIR.80.1.34; NACCARELLI GV, 1985, PHARMACOTHERAPY, V5, P298; NGUYEN PT, 1986, CIRCULATION, V74, P340, DOI 10.1161/01.CIR.74.2.340; PETERSEN P, 1989, LANCET, V1, P175; PORTERFIELD JG, 1989, AM J CARDIOL, V63, P114, DOI 10.1016/0002-9149(89)91091-6; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; RINKENBERGER RL, 1988, AM J CARDIOL, V62, pD44; SODERMARK T, 1975, BRIT HEART J, V37, P486; SOYKA LF, 1988, AM J CARDIOL, V62, pL63, DOI 10.1016/0002-9149(88)90019-7; STANTON MS, 1989, J AM COLL CARDIOL, V14, P209, DOI 10.1016/0735-1097(89)90074-0; VANGELDER IC, 1989, AM J CARDIOL, V64, P1317, DOI 10.1016/0002-9149(89)90574-2; VITOLO E, 1981, ACTA CARDIOL, V36, P431; 1990, NEW ENGL J MED, V322, P863	43	48	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				1017	1020		10.7326/0003-4819-116-12-1017	http://dx.doi.org/10.7326/0003-4819-116-12-1017			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586091				2022-12-28	WOS:A1992HY79300012
J	FINGERHUT, LA; INGRAM, DD; FELDMAN, JJ				FINGERHUT, LA; INGRAM, DD; FELDMAN, JJ			FIREARM AND NONFIREARM HOMICIDE AMONG PERSONS 15 THROUGH 19 YEARS OF AGE - DIFFERENCES BY LEVEL OF URBANIZATION, UNITED-STATES, 1979 THROUGH 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To examine trends (1979 through 1989) and current status in firearm and nonfirearm homicide rates by level of urbanization among persons 15 through 19 years of age. Design. - The Compressed Mortality File, a county-level mortality and population database maintained by the National Center for Health Statistics, Centers for Disease Control, Hyattsville, Md, and the 1980 Human Resource Profile County Codes are used to analyze age-, sex-, and race-specific firearm and nonfirearm homicide rates by urbanization level. Setting. - United States, 1979 through 1989. Subjects. - Black and white males and females 15 through 19 years of age whose underlying cause of death was either firearm homicide (E965.0 through E965.4 or E970) or nonfirearm homicide (E960 through E964, E965.5 through E969, or E971 through E978) in the ICD-9 (International Statistical Classification of Diseases, Injuries, and Causes of Death, Ninth Revision). Main Outcome Measures. - Urbanization level-specific firearm and nonfirearm homicide rates. Results. - The 1989 firearm homicide rate in metropolitan counties was nearly five times the rate in nonmetropolitan counties (13.7 vs 2.9 deaths per 100000 population). Firearm homicide rates were highest in core metropolitan counties, 27.7 per 100000 population; rates were higher for black males than for any other race-sex group in each of five county urbanization strata for 1979 through 1989. Nonfirearm homicide rates are considerably lower, with smaller urban differentials; the rate in metropolitan counties was 1.4 times the rate in nonmetropolitan counties (2.6 vs 1.8 per 100 000 population). From 1979 through 1984, firearm homicide rates declined in each of the county strata. From 1984 through 1987, firearm homicide rates increased, and from 1987 through 1989 they increased rapidly, from 23% to 35% per year in the four metropolitan strata. From 1979 through 1989, nonfirearm homicide rates declined or remained stable. Conclusions. - Large urbanization differentials in firearm homicide and smaller differentials in nonfirearm homicide are identified. Firearm homicide rates are highest and increasing the fastest among black teenage males in the core, fringe, and medium metropolitan strata.			FINGERHUT, LA (corresponding author), CTR DIS CONTROL,NATL CTR HLTH STAT,OFF ANAL & EPIDEMIOL,ROOM 1080,6525 BELCREST RD,HYATTSVILLE,MD 20782, USA.							FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V263, P3292, DOI 10.1001/jama.263.24.3292; FINGERHUT LA, 1989, ADV DATA VITAL HLTH, P1; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; 1990, USER DOCUMENTATION O; [No title captured]; 1989, WORLD HLTH STATISTIC	6	126	126	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3048	3053		10.1001/jama.267.22.3048	http://dx.doi.org/10.1001/jama.267.22.3048			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588719				2022-12-28	WOS:A1992HW97000025
J	STITHAM, S				STITHAM, S			INNOCENCE ABROAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											STITHAM, S (corresponding author), ALASKA NATIVE MED CTR,ANCHORAGE,AK, USA.							RATHMAN R, 1991, SRI LANKA HUMAN RIGH; Ross R, 1988, SRI LANKA COUNTRY ST; WEAVER MA, 1988, NEW YORKER      0321, P39; WEST J, 1991, ASIAWEEK        0308, P13; 1981, EC SOCIAL SURVEY ASI, P40	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3082	3083						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW970	1588725				2022-12-28	WOS:A1992HW97000033
J	LARSEN, GL				LARSEN, GL			CURRENT CONCEPTS - ASTHMA IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ALLERGEN-INDUCED INCREASE; BRONCHIAL RESPONSIVENESS; AIRWAY RESPONSIVENESS; CHILDHOOD ASTHMA; DERMATOPHAGOIDES-PTERONYSSINUS; BECLOMETHASONE DIPROPIONATE; INHALED CORTICOSTEROIDS; SODIUM CROMOGLYCATE; CONTROL SYMPTOMS; CONTROLLED TRIAL		UNIV COLORADO,SCH MED,PEDIAT PULM MED SECT,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	LARSEN, GL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAROGALVEZ R, 1987, ANN ALLERGY, V59, P298; AVITAL A, 1991, AM REV RESPIR DIS, V144, P36, DOI 10.1164/ajrccm/144.1.36; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BHAGAT RG, 1985, AM REV RESPIR DIS, V131, P902; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRUNETTE MG, 1988, PEDIATRICS, V81, P624; BUIST AS, 1988, CHEST, V93, P449, DOI 10.1378/chest.93.3.449; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1989, J ALLERGY CLIN IMMUN, V83, P913, DOI 10.1016/0091-6749(89)90105-X; CRESCIOLI S, 1991, ANN ALLERGY, V66, P245; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EIGEN H, 1987, J ALLERGY CLIN IMMUN, V80, P612, DOI 10.1016/0091-6749(87)90016-9; ELLULMICALLEF R, 1975, LANCET, V2, P1269; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HENDELES L, 1992, J PEDIATR-US, V120, P177, DOI 10.1016/S0022-3476(05)80423-8; HOAG JE, 1991, ANN ALLERGY, V66, P53; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P747, DOI 10.1016/0091-6749(87)90206-5; MCCONNOCHIE KM, 1986, AM J DIS CHILD, V140, P806, DOI 10.1001/archpedi.1986.02140220088039; MCCONNOCHIE KM, 1989, PEDIATR PULM, V6, P138, DOI 10.1002/ppul.1950060303; MOHIUDDIN AA, 1990, AM REV RESPIR DIS, V142, P1153, DOI 10.1164/ajrccm/142.5.1153; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1985, ANN ALLERGY, V54, P541; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; NELSON HS, 1991, AM REV RESPIR DIS, V144, P249, DOI 10.1164/ajrccm/144.2.249; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; REED CE, 1991, NEW ENGL J MED, V325, P425, DOI 10.1056/NEJM199108083250610; REED CE, 1987, J ALLERGY CLIN IMMUN, V80, P442; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; STORR J, 1987, LANCET, V1, P879; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; TEPPER RS, 1987, J APPL PHYSIOL, V62, P1155, DOI 10.1152/jappl.1987.62.3.1155; UCHIDA DA, 1990, SEMIN RESPIR MED, V11, P211, DOI 10.1055/s-2007-1006205; VANBEVER HP, 1988, ALLERGY, V43, P378, DOI 10.1111/j.1398-9995.1988.tb00432.x; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WELLIVER RC, 1986, AM J DIS CHILD, V140, P34, DOI 10.1001/archpedi.1986.02140150036029; WILSON MC, 1987, SEMIN RESPIR MED, V8, P279, DOI 10.1055/s-2007-1012666; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1992, ARCH DIS CHILD, V67, P240; 1990, MMWR, V39, P493	68	67	68	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1540	1545						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579137				2022-12-28	WOS:A1992HW97200006
J	HERTZMAN, PA; MADDOUX, GL; STERNBERG, EM; HEYES, MP; MEFFORD, IN; KEPHART, GM; GLEICH, GJ				HERTZMAN, PA; MADDOUX, GL; STERNBERG, EM; HEYES, MP; MEFFORD, IN; KEPHART, GM; GLEICH, GJ			REPEATED CORONARY-ARTERY SPASM IN A YOUNG WOMAN WITH THE EOSINOPHILIA-MYALGIA-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MAJOR BASIC-PROTEIN; CLINICAL CHARACTERISTICS; MYOCARDIAL-INFARCTION; GRANULE PROTEINS; LOCALIZATION; TRYPTOPHAN; INGESTION; ANGINA; TISSUES; DEATH	We report a case of repeated coronary artery spasm with myocardial injury in a 37-year-old woman with the eosinophilia-myalgia syndrome. This patient did not have a medical history of cardiac-related illness or risk factors for coronary artery disease. The presence of eosinophil granule major basic protein in otherwise normal-appearing myocardial tissue, along with normal plasma levels of tryptophan metabolites, suggests that the mechanism of vasospasm in this patient might involve toxic eosinophil proteins or focal myocardial lesions, but not the production of excess tryptophan metabolites.	NEW MEXICO HEART CLIN, ALBUQUERQUE, NM USA; ALCOHOL DRUG ABUSE & MENTAL HLTH ADM, BETHESDA, MD USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic	HERTZMAN, PA (corresponding author), LOS ALAMOS MED CTR, LOS ALAMOS, NM 87544 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, R01AI031155, R01AI015231] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31155, AI 15231] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1990, J IMMUNOL, V144, P3961; DEMELLO DE, 1990, NEW ENGL J MED, V323, P1542, DOI 10.1056/NEJM199011293232207; FILLEY WV, 1982, LANCET, V2, P11; GIULIANI E, 1991, CARDIOLOGY FUNDAMENT, P1309; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HERTZMAN PA, 1991, J RHEUMATOL, V18, P867; HIRAKAWA Y, 1989, AM J MED, V87, P472; JAMES TN, 1991, ANN INTERN MED, V18, P1367; KALSNER S, 1984, SCIENCE, V223, P1435, DOI 10.1126/science.6701530; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KIMURA T, 1989, CIRCULATION, V79, P1118, DOI 10.1161/01.CIR.79.5.1118; MADDOX DE, 1984, J EXP MED, V160, P29, DOI 10.1084/jem.160.1.29; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; NAKAMURA M, 1987, CIRCULATION, V75, P1110, DOI 10.1161/01.CIR.75.6.1110; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; ROHRBACH MS, 1990, J EXP MED, V172, P1271, DOI 10.1084/jem.172.4.1271; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TAI PC, 1982, BIOCHEM J, V204, P75, DOI 10.1042/bj2040075; TAI PC, 1987, LANCET, V1, P643; WATERS DD, 1982, AM J CARDIOL, V49, P658, DOI 10.1016/0002-9149(82)91943-9	22	18	19	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2932	2934		10.1001/jama.267.21.2932	http://dx.doi.org/10.1001/jama.267.21.2932			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583764				2022-12-28	WOS:A1992HW13300032
J	OBRIEN, TR; GEORGE, JR; HOLMBERG, SD				OBRIEN, TR; GEORGE, JR; HOLMBERG, SD			HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 INFECTION IN THE UNITED-STATES - EPIDEMIOLOGY, DIAGNOSIS, AND PUBLIC-HEALTH IMPLICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-2 INFECTION; WEST-AFRICA; BLOOD-DONORS; AIDS; TRANSMISSION; IMMUNOASSAY; FRANCE				OBRIEN, TR (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,MAILSTOP E45,ATLANTA,GA 30333, USA.							ADAMS CW, 1990, 6TH INT C AIDS SAN F; AYANIAN J, 1989, 5TH INT C AIDS MONTR; AYANIAN JZ, 1989, NEW ENGL J MED, V320, P1422, DOI 10.1056/NEJM198905253202119; AYRES L, 1990, AIDS, V4, P131, DOI 10.1097/00002030-199002000-00006; BENITOGARCIA A, 1990, 6TH INT C AIDS SAN F; BRUCKER G, 1987, LANCET, V1, P223; BRUNVEZINET F, 1987, LANCET, V1, P128; BUSCH MP, 1990, TRANSFUSION, V30, P184, DOI 10.1046/j.1537-2995.1990.30290162908.x; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; COUROUCE AM, 1989, TRANSFUSION, V29, P368, DOI 10.1046/j.1537-2995.1989.29489242808.x; DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DELMISTRO A, 1992, J ACQ IMMUN DEF SYND, V5, P19; DUFOORT G, 1988, LANCET, V2, P510; ESBER EC, 1988 US FOOD DRUG AD; GEORGE JR, 1990, AIDS, V4, P321, DOI 10.1097/00002030-199004000-00006; GEORGE JR, 1991, TESTING AIDS OTHER R; GNANN JW, 1987, SCIENCE, V237, P1346, DOI 10.1126/science.2888192; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HA B, 1991, Transfusion (Bethesda), V31, p49S; HO DD, 1990, AIDS, V4, P1301, DOI 10.1097/00002030-199012000-00028; HOFF R, 1989, 4TH CONS C TEST HUM; HORSBURGH CR, 1988, TRANSFUSION, V28, P192, DOI 10.1046/j.1537-2995.1988.28288179031.x; JACKSON J B, 1988, Clinical Microbiology Reviews, V1, P124; KANKI PJ, 1987, SCIENCE, V236, P827, DOI 10.1126/science.3033826; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; MARLINK R, 1991, 7 INT C AIDS FLOR; MARTIN R, 1990, 6TH INT C AIDS SAN F; MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008; MULDER PGH, 1983, AM J EPIDEMIOL, V117, P377, DOI 10.1093/oxfordjournals.aje.a113553; MYERS RA, 1992, J ACQ IMMUN DEF SYND, V5, P417; NEUMANN PW, 1989, CAN MED ASSOC J, V140, P125; OBRIEN TR, 1991, AIDS, V5, P85, DOI 10.1097/00002030-199101000-00012; ONORATO I, 1991, 7 INT C AIDS FLOR; PARKMAN PD, 1990, USE GENETIC SYSTEMS; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PETRUCCI J M, 1991, Transfusion (Bethesda), V31, p5S; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; POPOVSKY M A, 1991, Transfusion (Bethesda), V31, p49S; POPOVSKY MA, 1990, NEW ENGL J MED, V322, P1887; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; POULSON AG, 1992, J ACQ IMMUN DEF SYND, P525; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RUEF C, 1989, AM J MED, V86, P709, DOI 10.1016/0002-9343(89)90451-8; SCHOCHETMAN G, 1988, 4TH INT C AIDS STOCK, P93; SCHUMACHER RT, 1990, 6TH INT C AIDS SAN F; SIMON F, 1989, 5 INT C AIDS MONTR; VERONESI R, 1987, LANCET, V2, P402; WERNER A, 1987, LANCET, V1, P868; 1989, MMWR, V38, P579; 1988, MMWR, V37, P33; 1989, MMWR, V38, P572; 1990, WHO WKLY EPIDEM REC, V65, P281; 1990, MMWR, V39, P829	55	54	54	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2775	2779						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578597				2022-12-28	WOS:A1992HV26500026
J	FELDMAN, GJ; PARKER, HW				FELDMAN, GJ; PARKER, HW			VISCERAL LARVA MIGRANS ASSOCIATED WITH THE HYPEREOSINOPHILIC SYNDROME AND THE ONSET OF SEVERE ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Note						ASTHMA; LARVA MIGRANS, VISCERAL; TOXOCARIASIS; RESPIRATORY INSUFFICIENCY; PULMONARY EOSINOPHILIA		This report describes a patient who presented with new-onset asthma resulting in respiratory failure, hypereosinophilia, and extreme elevation of IgE titers due to visceral larva migrans syndrome. Diagnosis was confirmed serologically by enzyme-linked immunosorbent assay. Although rare reports have described the occurrence of toxocariasis in adults, the diagnosis was presumptive and severe respiratory involvement with status asthmaticus has not been reported.			FELDMAN, GJ (corresponding author), DARTMOUTH HITCHCOCK MED CTR, 1 MED CTR DR, LEBANON, NH 03756 USA.							AREAN VM, 1971, TOXOCARIASIS PATHOLO, P808; BEAVER PC, 1952, PEDIATRICS, V9, P7; CHURG J, 1951, AM J PATHOL, V27, P277; FAULKNER LC, 1975, J AM VET MED ASSOC, V166, P477; GLICKMAN L, 1978, AM J TROP MED HYG, V27, P492, DOI 10.4269/ajtmh.1978.27.492; GLICKMAN LT, 1987, AM J EPIDEMIOL, V125, P1019, DOI 10.1093/oxfordjournals.aje.a114618; KAMEYA S, 1986, J CLIN GASTROENTEROL, V8, P438, DOI 10.1097/00004836-198608000-00011; MOK CH, 1968, CLIN PEDIATR, V7, P565, DOI 10.1177/000992286800700912; RIVERA R. S., 1950, BOL ASOC MED PUERTO RICO, V42, P197; SCHANTZ PM, 1978, NEW ENGL J MED, V298, P436, DOI 10.1056/NEJM197802232980806; SNYDER CH, 1961, PEDIATRICS, V28, P85	11	46	47	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					838	840		10.7326/0003-4819-116-10-838	http://dx.doi.org/10.7326/0003-4819-116-10-838			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567098				2022-12-28	WOS:A1992HT80200008
J	NEWBERGER, EH; BARKAN, SE; LIEBERMAN, ES; MCCORMICK, MC; YLLO, K; GARY, LT; SCHECHTER, S				NEWBERGER, EH; BARKAN, SE; LIEBERMAN, ES; MCCORMICK, MC; YLLO, K; GARY, LT; SCHECHTER, S			ABUSE OF PREGNANT-WOMEN AND ADVERSE BIRTH OUTCOME - CURRENT KNOWLEDGE AND IMPLICATIONS FOR PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRENATAL-CARE; MATERNAL WORK; MARIJUANA USE; FETAL GROWTH; COCAINE USE; WEIGHT; ALCOHOL; SMOKING; STRESS; PREVALENCE		HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OBSTET & GYNECOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,BOSTON,MA 02115; WHEATON COLL,DEPT SOCIOL,NORTON,MA 02766	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	NEWBERGER, EH (corresponding author), CHILDRENS HOSP MED CTR,DEPT MED,300 LONGWOOD AVE,BOSTON,MA 02115, USA.			McCormmick, Marie/0000-0002-3938-1707	NIMH NIH HHS [MH18265-08] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABEL EL, 1980, HUM BIOL, V52, P593; AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; BOYCE WT, 1985, SOC SCI MED, V11, P1279; Brown G., 1978, SOCIAL ORIGINS DEPRE; BULLOCK L, 1989, AM J NURS, P1153; BUTLER NR, 1972, BMJ-BRIT MED J, V2, P127, DOI 10.1136/bmj.2.5806.127; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; DONALDSON PJ, 1984, MED CARE, V22, P177, DOI 10.1097/00005650-198402000-00009; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; ELSTER AB, 1984, AM J OBSTET GYNECOL, V149, P845, DOI 10.1016/0002-9378(84)90602-1; Fisher ER., 1988, BATTERED WOMEN SURVI; Gary L. T., 1991, FEMINIST SOCIAL WORK, P19; GELLES RJ, 1975, FAM COORD, V24, P81, DOI 10.2307/583055; GELLES RJ, 1988, J MARRIAGE FAMIL AUG, P841; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; HATCH EE, 1986, AM J EPIDEMIOL, V124, P986, DOI 10.1093/oxfordjournals.aje.a114488; HAWKINS DF, 1987, VIOLENCE BLACK FAMIL; HELTON A, 1986, PROTOCOL CARE BATTER; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HELTON AS, 1987, BIRTH-ISS PERINAT C, V14, P142, DOI 10.1111/j.1523-536X.1987.tb01476.x; HILLARD PJA, 1985, OBSTET GYNECOL, V66, P185; Homer C J, 1990, Paediatr Perinat Epidemiol, V4, P161, DOI 10.1111/j.1365-3016.1990.tb00634.x; HOMER CJ, 1990, AM J PUBLIC HEALTH, V80, P173, DOI 10.2105/AJPH.80.2.173; ISTVAN J, 1986, PSYCHOL BULL, V100, P331, DOI 10.1037/0033-2909.100.3.331; KLINE J, 1980, LANCET, V2, P176, DOI 10.1016/S0140-6736(80)90062-8; LINN S, 1983, AM J PUBLIC HEALTH, V73, P1161, DOI 10.2105/AJPH.73.10.1161; LITTLE RE, 1977, AM J PUBLIC HEALTH, V67, P1154, DOI 10.2105/AJPH.67.12.1154; MAMMELLE N, 1984, AM J EPIDEMIOL, V119, P309; MCANARNEY ER, 1990, AM J DIS CHILD, V144, P789, DOI 10.1001/archpedi.1990.02150310057027; MCKIBBEN L, 1989, PEDIATRICS, V84, P531; MILLS JL, 1984, JAMA-J AM MED ASSOC, V252, P1875, DOI 10.1001/jama.252.14.1875; NORBECK JS, 1983, J HEALTH SOC BEHAV, V24, P30, DOI 10.2307/2136301; OUELLETTE EM, 1977, NEW ENGL J MED, V297, P528, DOI 10.1056/NEJM197709082971003; PEARLMAN MD, 1990, NEW ENGL J MED, V323, P1609; PICONE TA, 1989, AM J CLIN NUTR, V6, P1205; RUSSELL DEH, 1982, RAPE MARRIAGE, P57; Sammons L N, 1981, MCN Am J Matern Child Nurs, V6, P246; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; SIMPSON WJ, 1957, AM J OBSTET GYNECOL, V73, P808, DOI 10.1016/0002-9378(57)90391-5; SORENSON SB, 1987, AM J EPIDEMIOL, V126, P1154, DOI 10.1093/oxfordjournals.aje.a114753; STEIN Z, 1983, AM J PUBLIC HEALTH, V73, P1154, DOI 10.2105/AJPH.73.10.1154; TEITELMAN AM, 1990, AM J EPIDEMIOL, V131, P104, DOI 10.1093/oxfordjournals.aje.a115463; Walker L., 1984, BATTERED WOMAN SYNDR; ZUCKERMAN B, 1989, AM J OBSTET GYNECOL, V160, P1107, DOI 10.1016/0002-9378(89)90170-1; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; ZUCKERMAN BS, 1986, PEDIATRICS, V77, P459; 1979, US DHEW PHS7955071 P, P24; 1985, PREVENTING LOW BIRTH, P72	50	140	144	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2370	2372		10.1001/jama.267.17.2370	http://dx.doi.org/10.1001/jama.267.17.2370			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HR015	1564780				2022-12-28	WOS:A1992HR01500033
J	HENGARTNER, MO; ELLIS, RE; HORVITZ, HR				HENGARTNER, MO; ELLIS, RE; HORVITZ, HR			CAENORHABDITIS-ELEGANS GENE CED-9 PROTECTS CELLS FROM PROGRAMMED CELL-DEATH	NATURE			English	Article							C-ELEGANS; MOTOR NEURONS; X-CHROMOSOME; NEMATODE; SURVIVAL; MUTANTS; ACTIVATION; LINEAGES	The gene ced-9 of the nematode Caenorhabditis elegans acts to protect cells from programmed cell death. A mutation that abnormally activates ced-9 prevents the cell deaths that occur during normal C. elegans development. Conversely, mutations that inactivate ced-9 cause cells that normally live to undergo programmed cell death; these mutations result in embryonic lethality, indicating that ced-9 function is essential for development. The ced-9 gene functions by negatively regulating the activities of other genes that are required for the process of programmed cell death.			HENGARTNER, MO (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,ROOM 56-629,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BRENNER S, 1974, GENETICS, V77, P71; CASSADA R, 1981, DEV BIOL, V84, P193, DOI 10.1016/0012-1606(81)90383-3; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; COHEN JJ, 1984, J IMMUNOL, V132, P38; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS HM, 1991, GENETICS, V129, P79; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, REV CELL BIOL, V7, P663; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GREENWALD IS, 1980, GENETICS, V96, P147; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MENEELY PM, 1979, GENETICS, V92, P99; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; ROSENBLUTH RE, 1981, GENETICS, V99, P415; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1983, GENETICS, V104, P619; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE JG, 1986, PHILOS T R SOC LON B, V311, P1; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	40	708	747	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					494	499		10.1038/356494a0	http://dx.doi.org/10.1038/356494a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560823				2022-12-28	WOS:A1992HN23100048
J	OESTERHELD, M; SALA, OE; MCNAUGHTON, SJ				OESTERHELD, M; SALA, OE; MCNAUGHTON, SJ			EFFECT OF ANIMAL HUSBANDRY ON HERBIVORE-CARRYING CAPACITY AT A REGIONAL SCALE	NATURE			English	Article							COMMUNITY STRUCTURE; ECOSYSTEM; RAINFALL; BIOMASS	ALL significant properties of the herbivore trophic level, including biomass, consumption and productivity, are significantly correlated with primary productivity across a broad range of terrestrial ecosystems 1,2. Here we show that livestock biomass in South American agricultural ecosystems across a 25-fold gradient of primary productivity exhibited a relationship with a slope essentially identical to unmanaged ecosystems, but with a substantially greater y-intercept. Therefore the biomass of herbivores supported per unit of primary productivity is about an order of magnitude greater in agricultural than in natural ecosystems, for a given level of primary production. We also present evidence of an increase in livestock body size with primary productivity, a pattern previously characterized in natural ecosystems 3. To our knowledge this is the first quantitative documentation at a regional scale of the impact of animal husbandry practices, such as herding, stock selection and veterinary care, on the biomass and size-structure of livestock herds compared with native herbivores.	SYRACUSE UNIV,BIOL RES LABS,SYRACUSE,NY 13244	Syracuse University	OESTERHELD, M (corresponding author), UNIV BUENOS AIRES,FAC AGRON,DEPT ECOL,AV SAN MARTIN 4453,RA-1417 BUENOS AIRES,ARGENTINA.			Sala, Osvaldo/0000-0003-0142-9450; Oesterheld, Martin/0000-0001-8462-0087				COE MJ, 1976, OECOLOGIA, V22, P341, DOI 10.1007/BF00345312; COUGHENOUR MB, 1985, SCIENCE, V230, P619, DOI 10.1126/science.230.4726.619; Darwin C, 1872, ORIGIN SPECIES; EAST R, 1984, AFR J ECOL, V22, P245, DOI 10.1111/j.1365-2028.1984.tb00700.x; ERRINGTON PL, 1956, SCIENCE, V124, P304, DOI 10.1126/science.124.3216.304; GOLLEY FB, 1961, ECOLOGY, V42, P581, DOI 10.2307/1932247; Lauenroth W. K., 1979, Perspectives in grassland ecology., P3; MCNAUGHTON SJ, 1983, ECOL MONOGR, V53, P291, DOI 10.2307/1942533; MCNAUGHTON SJ, 1984, AM NAT, V124, P863, DOI 10.1086/284321; MCNAUGHTON SJ, 1989, NATURE, V341, P142, DOI 10.1038/341142a0; MCNAUGHTON SJ, 1991, COMPARATIVE ANALYSES OF ECOSYSTEMS, P120; MCNAUGHTON SJ, IN PRESS BIOL RELATI; MILCHUNAS DG, 1988, AM NAT, V132, P87, DOI 10.1086/284839; MOEN J, 1991, NATURE, V353, P510, DOI 10.1038/353510a0; SALA OE, 1986, VEGETATIO, V67, P27; SCARNECCHIA DL, 1990, J RANGE MANAGE, V43, P553, DOI 10.2307/4002363; Sharkey M. J., 1970, Mammalia, V34, P564, DOI 10.1515/mamm.1970.34.4.564; WESTOBY M, 1985, AM NAT, V126, P870, DOI 10.1086/284460; 1987, PRODUCTION YB 1986; 1980, CENSO GENERAL AGROPE; 1974, EMPADRONAMIENTO NACI	21	157	168	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					234	236		10.1038/356234a0	http://dx.doi.org/10.1038/356234a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552941				2022-12-28	WOS:A1992HJ94400055
J	ACHIRON, R; GLASER, J; GELERNTER, I; HEGESH, J; YAGEL, S				ACHIRON, R; GLASER, J; GELERNTER, I; HEGESH, J; YAGEL, S			EXTENDED FETAL ECHOCARDIOGRAPHIC EXAMINATION FOR DETECTING CARDIAC-MALFORMATIONS IN LOW-RISK PREGNANCIES	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL HEART-DISEASE; PRENATAL-DIAGNOSIS	Objective - To improve the rate of prenatal detection of cardiac malformations in a low risk population. Design - Comparison of extended fetal echocardiography with the standard four chamber view in detecting abnormalities. Extended echocardiography comprised the four chamber view and visualisation of the left ventricular outflow tract, the right ventricular outflow tract, and the main pulmonary artery and its branches. In cases with abnormal results complete echocardiographic studies were performed by a paediatric cardiologist using M mode, Doppler, and colour flow mapping techniques. Setting - Obstetric ultrasonographic unit at Shaare-Zedek Medical Centre, Jerusalem. Subjects - 5400 fetuses in low risk pregnancies between 18 and 24 weeks' gestation (mean 21 weeks); 53 were lost to follow up. Main outcome measures - Detection of abnormality before and after birth. Results - During the study 23 infants (0.4%) were born with cardiac abnormalities, 21 of whom had major structural and functional heart disease. 18 fetuses had heart disease diagnosed prenatally, 11 by the four chamber view alone (sensitivity 48%) and a further seven by extended echocardiography (sensitivity 78%). Five fetal cardiac defects were missed prenatally (false negative rate 22%). These included coarctation of aorta, persistent truncus arteriosus, tetralogy of Fallot, ventricular septal defect, and pulmonic stenosis. Only one false positive diagnosis (coarctation of aorta) was made (specificity 99.9%, false positive rate 0.1%). The abnormality was correctly identified in 17 out of 18 cases. Conclusions - The extended fetal heart examination detected 86% (18/21) of major abnormalities in a low risk population. The examination should be incorporated into routine prenatal ultrasonographic investigations.	MT SCOPUS HOSP,DEPT OBSTET & GYNAECOL,DIAGNOST ULTRASOUND UNIT,JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,PAEDIAT CARDIOL UNIT,IL-91000 JERUSALEM,ISRAEL; TEL AVIV UNIV,SCH MATH SCI,STAT LAB,IL-69978 TEL AVIV,ISRAEL; CHAIM SHEBA MED CTR,DEPT OBSTET & GYNAECOL,PAEDIAT CARDIOL UNIT,IL-52621 TEL HASHOMER,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Tel Aviv University; Chaim Sheba Medical Center	ACHIRON, R (corresponding author), CHAIM SHEBA MED CTR,DEPT OBSTET & GYNAECOL,DIAGNOST ULTRASOUND UNIT,IL-52621 TEL HASHOMER,ISRAEL.							ALLAN LD, 1984, BRIT HEART J, V52, P542; ALLAN LD, 1986, BRIT MED J, V292, P1717, DOI 10.1136/bmj.292.6537.1717; ALLAN LD, 1980, BRIT HEART J, V44, P445; [Anonymous], 1980, Pediatrics, V65, P375; BENACERRAF BR, 1987, RADIOLOGY, V165, P847, DOI 10.1148/radiology.165.3.3685364; BROWNLEE KA, 1984, STATISTICAL THEORY M, P154; COPEL JA, 1987, AM J OBSTET GYNECOL, V157, P648, DOI 10.1016/S0002-9378(87)80022-4; DEVORE GR, 1988, ULTRASOUND Q, V6, P299; GEMBRUCH U, 1989, PRENATAL DIAG, V9, P535, DOI 10.1002/pd.1970090802; HOFFMAN JIE, 1978, AM J CARDIOL, V42, P641, DOI 10.1016/0002-9149(78)90635-5; KEITH JD, 1978, HEART DISEASE INFANC, P9; KLEINMAN CS, 1980, PEDIATRICS, V65, P1059; LIAN ZH, 1986, AM J HUM GENET, V39, P648; SCOTT DJ, 1984, BRIT HEART J, V52, P248; 1985, VITAL STATISTICS US, V2, P5	15	209	224	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					671	674		10.1136/bmj.304.6828.671	http://dx.doi.org/10.1136/bmj.304.6828.671			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1571638	Green Published, Bronze			2022-12-28	WOS:A1992HK76100019
J	BERKEL, H; BIRDSELL, DC; JENKINS, H				BERKEL, H; BIRDSELL, DC; JENKINS, H			BREAST AUGMENTATION - A RISK FACTOR FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARCINOGENICITY; 2,4-TOLUENEDIAMINE; RATS	Background. A relation between breast augmentation and the subsequent risk of breast cancer has been postulated. Since an estimated 2 million women in the United States alone have received breast implants, even a small increase in the risk of breast cancer could have considerable public health consequences. Methods. We performed a population-based nonconcurrent cohort-linkage study. All women in Alberta, Canada, who underwent cosmetic breast augmentation from 1973 through 1986 were included in the implant cohort (n = 11,676). This cohort was compared with the cohort of all women in Alberta in whom a first primary breast cancer was diagnosed (n = 13,557). The expected number of breast-cancer cases in the implant cohort was estimated by applying age-specific and calendar year-specific incidence rates of breast cancer (obtained from the Alberta Cancer Registry) to the implant cohort, Standardized incidence ratios were calculated by dividing the observed by the expected number of breast-cancer cases in the implant cohort. Results. Forty-one patients with implants were subsequently found to have breast cancer. The expected number was 86.2. The standardized incidence ratio was thus 47.6 percent, significantly lower than expected (P<0.01). The average length of follow-up in the implant cohort was 10.2 years, and the average length of time from breast augmentation to the diagnosis of breast cancer was 7.5 years. Conclusions. Women who undergo breast augmentation with silicone implants have a lower risk of breast cancer than the general population. This finding suggests that these women are drawn from a population already at low risk and that the implants do not substantially increase the risk.	UNIV CALGARY, FOOTHILLS HOSP,SCH MED,DEPT SURG, DIV PLAST & RECONSTRUCT SURG, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary	BERKEL, H (corresponding author), ALBERTA CANC BOARD, DIV EPIDEMIOL & PREVENT ONCOL, 9707 110 ST, 6TH FL, EDMONTON T5K 2L9, ALBERTA, CANADA.							BAILAR JC, 1964, BIOMETRICS, V20, P639; BENAVENT WJ, 1973, PLAST RECONSTR SURG, V51, P588, DOI 10.1097/00006534-197305000-00026; BERKEL J, 1990, INCIDENCE SURVIVAL D; BINGHAM HG, 1988, ANN PLAS SURG, V20, P236, DOI 10.1097/00000637-198803000-00007; BLAKESLEE S, 1991, GLAMOUR          AUG; BOWERS DG, 1969, PLAST RECONSTR SURG, V44, P541, DOI 10.1097/00006534-196912000-00003; BOYES DC, 1991, CAN MED ASSOC J, V145, P1125; CARDY RH, 1979, J NATL CANCER I, V62, P1107; CHAN SC, 1991, CLIN CHEM, V37, P756; CHOLNOKY TD, 1970, PLAST RECONSTR SURG, V45, P573, DOI 10.1097/00006534-197006000-00007; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; GILES AL, 1976, J TOXICOL ENV HEALTH, V1, P433, DOI 10.1080/15287397609529342; HARRIS HI, 1961, PLAST RECONSTR SURG, V28, P81, DOI 10.1097/00006534-196107000-00007; HIROHATA T, 1977, BRIT MED J, V2, P641, DOI 10.1136/bmj.2.6087.641-c; HOOPES JE, 1967, PLAST RECONSTR SURG, V39, P263, DOI 10.1097/00006534-196703000-00005; HSIEH CC, 1991, EUR J CANCER, V27, P131, DOI 10.1016/0277-5379(91)90469-T; ITO N, 1969, CANCER RES, V29, P1137; KOCH M, 1985, CHRONIC DIS CAN, V5, P74; LILIENFELD AM, 1976, F EIDEMIOLOGY; ROHLFING C, 1991, LONGEVITY        JUL; SNYDERMAN R K, 1960, Plast Reconstr Surg Transplant Bull, V25, P253, DOI 10.1097/00006534-196003000-00006; SONTAG JM, 1981, JNCI-J NATL CANCER I, V66, P591; UMEDA M, 1955, Gan, V46, P597; VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312; WYNDER EL, 1969, CANCER, V24, P1235, DOI 10.1002/1097-0142(196912)24:6<1235::AID-CNCR2820240629>3.0.CO;2-G	25	163	165	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1649	1653		10.1056/NEJM199206183262501	http://dx.doi.org/10.1056/NEJM199206183262501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588977	Bronze			2022-12-28	WOS:A1992HY62800001
J	FEUTREN, G; MIHATSCH, MJ				FEUTREN, G; MIHATSCH, MJ			RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROTOXICITY; TRANSPLANTS; CREATININE; CHILDREN; THERAPY; RATS	Background. Cyclosporine is an immunosuppressive drug that is used to treat patients with autoimmune disease as well a's patients who have received allografts. The drug can cause renal damage, but the incidence of and risk factors for nephropathy in patients treated with cyclosporine for autoimmune or inflammatory diseases are not known. Methods. We analyzed data from renal biopsies performed in 192 patients (129 adults and 63 children) who had been treated with cyclosporine for insulin-dependent diabetes mellitus of recent onset, uveitis, psoriasis, Sjogren's syndrome, or polychondritis. The mean (+/-SD) initial dose of cyclosporine was 8.2+/-2.8 mg per kilogram of body weight per day, and the duration of treatment was 4 to 39 months (median, 13). Results. Forty-one patients (37 adults and 4 children) had cyclosporine-induced nephropathy, defined as at least moderate focal interstitial fibrosis with tubular atrophy, arteriolar alterations, or both. As compared with patients in whom nephropathy did not develop, these patients received a larger initial dose of cyclosporine (9.3+/-2.8 vs. 8.0+/-2.8 mg per kilogram per day), had a larger maximal increase in the serum creatinine concentration above base-line values (101+/-77 percent vs. 50+/-33 percent), and were older (31+/-13 vs. 23+/-12 years). These three variables were shown by multivariate logistic-regression analysis to be significant risk factors. The duration of the elevation in the serum creatinine concentration and the occurrence of elevated blood pressure were not additional risk factors. Conclusions. Nephropathy is an important potential effect of cyclosporine therapy. The risk of its development in patients with autoimmune diseases who are treated with cyclosporine can be minimized by allowing a dose no higher than 5 mg per kilogram per day and avoiding increases in serum creatinine of more than 30 percent above the patient's base-line value.	UNIV BASEL,INST PATHOL,CH-4051 BASEL,SWITZERLAND	University of Basel	FEUTREN, G (corresponding author), SANDOZ PHARMA LTD,DEPT CLIN RES IMMUNOL,CH-4002 BASEL,SWITZERLAND.							[Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; ANTIGNAC C, 1989, KIDNEY INT, V35, P1336, DOI 10.1038/ki.1989.132; ASSAN R, 1990, DIABETES, V39, P768, DOI 10.2337/diabetes.39.7.768; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; BOUGNERES PF, 1988, NEW ENGL J MED, V318, P663, DOI 10.1056/NEJM198803173181103; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093, DOI 10.1097/00007890-199006000-00013; Donatsch P, 1981, J Immunoassay, V2, P19, DOI 10.1080/01971528108062989; EKNOYAN G, 1988, DISEASES KIDNEY, P2191; FEUTREN G, 1988, TRANSPLANT P, V20, P356; FEUTREN G, 1991, LANCET, V38, P1017; GILBERT SC, 1989, J AM ACAD DERMATOL, V21, P470, DOI 10.1016/S0190-9622(89)70209-7; HOYER PF, 1984, CLIN NEPHROL, V22, P68; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; MIESCHER PA, 1987, KLIN WOCHENSCHR, V65, P727, DOI 10.1007/BF01736809; MIHATSCH MJ, 1986, PROG ALLERGY, V38, P447; MIHATSCH MJ, 1983, TRANSPLANT P, V15, P2821; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; MOSS NG, 1985, P NATL ACAD SCI USA, V82, P8222, DOI 10.1073/pnas.82.23.8222; MYERS BD, 1988, TRANSPLANTATION, V46, P694, DOI 10.1097/00007890-198811000-00014; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; PALESTINE AG, 1986, NEW ENGL J MED, V314, P1293, DOI 10.1056/NEJM198605153142005; SVENSON K, 1986, ARCH INTERN MED, V146, P2007, DOI 10.1001/archinte.146.10.2007; THOMSON SC, 1989, J CLIN INVEST, V83, P960, DOI 10.1172/JCI113982; TOMLANOVICH S, 1986, AM J KIDNEY DIS, V8, P332, DOI 10.1016/S0272-6386(86)80107-X; 1988, SAS USERS GUIDE STAT; 1990, BR J DERMATOL S36, V122, P95	26	417	426	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1654	1660		10.1056/NEJM199206183262502	http://dx.doi.org/10.1056/NEJM199206183262502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588978	Bronze			2022-12-28	WOS:A1992HY62800002
J	WILKES, MS; DOBLIN, BH; SHAPIRO, MF				WILKES, MS; DOBLIN, BH; SHAPIRO, MF			PHARMACEUTICAL ADVERTISEMENTS IN LEADING MEDICAL JOURNALS - EXPERTS ASSESSMENTS	ANNALS OF INTERNAL MEDICINE			English	Article						ADVERTISING; DRUG INFORMATION SERVICES; DRUG INDUSTRY; UNITED-STATES-FOOD-AND-DRUG-ADMINISTRATION	DRUG COMPANIES; PHYSICIANS; INFORMATION; DOCTORS; GIFTS	Objective: To assess both the accuracy of scientific data presented in print pharmaceutical advertisements and the compliance of these advertisements with current Food and Drug Administration (FDA) standards. Design: Cross-sectional survey. Measurements: Each full-page pharmaceutical advertisement (n = 109) appearing in 10 leading medical journals, along with all available references cited in the advertisement (82% of the references cited were available) were sent to three reviewers: two physicians in the relevant clinical area who were experienced in peer review and one academic clinical pharmacist. Reviewers, 95% of whom responded, were asked to evaluate the advertisements using criteria based on FDA guidelines, to judge the educational value and overall quality of the advertisements, and to make a recommendation regarding publication. Results: In 30% of cases, two or more reviewers disagreed with the advertisers' claim that the drug was the "drug of choice." Reviewers felt that information on efficacy was balanced with that on side effects and contraindications in 49% of advertisements but was not balanced in 40%. Reviewers agreed with advertisements' claims that the drug was safe in 86% of the cases but judged that headlines in 32% of the advertisements containing headlines misled the reader about efficacy. In 44% of cases, reviewers felt that the advertisement would lead to improper prescribing if a physician had no other information about the drug other than that contained in the advertisement. Fifty-seven percent of advertisements were judged by two or more reviewers to have little or no educational value. Overall, reviewers would not have recommended publication of 28% of the advertisements and would have required major revisions in 34% before publication. Conclusion: In the opinion of the reviewers, many advertisements contained deficiencies in areas in which the FDA has established explicit standards of quality. New strategies are needed to ensure that advertisements comply with standards intended to promote proper use of the products and to protect the consumer.			WILKES, MS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90024 USA.				PHS HHS [R01-90-1088] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD SR, 1991, LANCET, V338, P1384; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; CHRISTENSEN DB, 1979, SOC SCI MED-MED SOC, V13, P313, DOI 10.1016/0160-7979(79)90066-3; FASSOLD RW, 1968, CAN MED ASSOC J, V98, P701; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1369, DOI 10.1001/jama.263.10.1369; GORSKI TN, 1990, JAMA-J AM MED ASSOC, V263, P2177, DOI 10.1001/jama.1990.03440160039016; JACOBY J, 1975, J MARKETING, V39, P65, DOI 10.2307/1250601; LINN LS, 1972, SOC SCI MED, V6, P199, DOI 10.1016/0037-7856(72)90025-X; LIPTON HL, 1988, DRUGS ELDERLY CLIN S; LOCK S, 1986, DIFFICULT BALANCE, P24; MILLSTEIN LG, 1983, AM PHARM, V23, P54, DOI 10.1016/S0160-3450(16)32075-X; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; MOSER RH, 1977, ANN INTERN MED, V87, P114, DOI 10.7326/0003-4819-87-1-114; RELMAN AS, 1979, NEW ENGL J MED, V301, P999, DOI 10.1056/NEJM197911013011811; SCHIFF G, 1990, JAMA-J AM MED ASSOC, V263, P658, DOI 10.1001/jama.1990.03440050052019; ZELLMER WA, 1987, AM J HOSP PHARM, V44, P1651, DOI 10.1093/ajhp/44.7.1651; ZUCKERMAN H, 1971, MINERVA, V9, P66, DOI 10.1007/BF01553188; 1991, OEI01900000000482 DE; 1989, HLTH CARE COMMUNICAT	20	206	212	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					912	919		10.7326/0003-4819-116-11-912	http://dx.doi.org/10.7326/0003-4819-116-11-912			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580449				2022-12-28	WOS:A1992HW13700007
J	WATKINS, DI; MCADAM, SN; LIU, XM; STRANG, CR; MILFORD, EL; LEVINE, CG; GARBER, TL; DOGON, AL; LORD, CI; GHIM, SH; TROUP, GM; HUGHES, AL; LETVIN, NL				WATKINS, DI; MCADAM, SN; LIU, XM; STRANG, CR; MILFORD, EL; LEVINE, CG; GARBER, TL; DOGON, AL; LORD, CI; GHIM, SH; TROUP, GM; HUGHES, AL; LETVIN, NL			NEW RECOMBINANT HLA-B ALLELES IN A TRIBE OF SOUTH-AMERICAN AMERINDIANS INDICATE RAPID EVOLUTION OF MHC CLASS-I LOCI	NATURE			English	Article							POLYMERASE CHAIN-REACTION; MECHANISMS; MOLECULES; AMPLIFICATION; POLYMORPHISM; SEQUENCES; ANTIGENS; CLONING; GENES	EVIDENCE suggests that the New World was colonized only 11,000-40,000 years ago by Palaeo-Indians 1. The descendants of these Palaeo-Indians therefore provide a unique opportunity to study the effects of selection on major histocompatibility complex class I genes over a short period. Here we analyse the class I alleles of the Waorani of South America and the Zuni of North America. Four of the Waorani HLA-B alleles were new functional variants which could be accounted for by intralocus recombination. In contrast, all of the Zuni HLA-A and -B molecules were present in caucasians and orientals. This suggests that the new Waorani HLA-B variants arose in South America. The description of four new HLA-B alleles in the Waorani and another five new HLA-B alleles from two other tribes of South American Amerindians 2 indicates that the HLA-B locus can evolve rapidly in isolated populations. These studies underline the importance of gathering genetic data on endangered native human populations 3.	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; TEXAS A&M UNIV SYST,COLL VET MED,COLLEGE STN,TX 77843; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; PENN STATE UNIV,DEPT BIOL,MUELLER LAB 208,UNIV PK,PA 16802	Harvard University; Brigham & Women's Hospital; Texas A&M University System; Texas A&M University College Station; University of New Mexico; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	WATKINS, DI (corresponding author), HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,1 PINE HILL DR,SOUTHBOROUGH,MA 01772, USA.							BELICH MP, 1992, NATURE, V357, P326, DOI 10.1038/357326a0; BLACK FL, 1990, ORIGENS ADAPTACOES D; CASTANO AR, 1992, IMMUNOGENETICS, V35, P344; CASTANO AR, 1991, IMMUNOGENETICS, V34, P281, DOI 10.1007/BF00211991; CIANETTI L, 1989, IMMUNOGENETICS, V29, P80, DOI 10.1007/BF00395855; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; GUSSOW D, 1987, IMMUNOGENETICS, V25, P313, DOI 10.1007/BF00404424; HAYASHI H, 1989, J IMMUNOL, V142, P306; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KATO K, 1989, J IMMUNOL, V143, P3371; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LARRICK JW, 1985, AM J PHYS ANTHROPOL, V66, P445, DOI 10.1002/ajpa.1330660412; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LITTLE AM, 1992, IMMUNOGENETICS, V35, P41; MARSHALL E, 1990, SCIENCE, V249, P738, DOI 10.1126/science.249.4970.738; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MULLER CA, 1989, IMMUNOGENETICS, V30, P200, DOI 10.1007/BF02421207; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; OOBA T, 1989, IMMUNOGENETICS, V30, P76, DOI 10.1007/BF02421534; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARHAM P, 1989, J IMMUNOL, V142, P3937; PARHAM P, 1979, J IMMUNOL, V123, P342; POHLA H, 1989, IMMUNOGENETICS, V29, P297, DOI 10.1007/BF00352839; ROBERTS L, 1991, SCIENCE, V252, P1614, DOI 10.1126/science.2047869; Salzano FM, 1988, S AM INDIANS CASE ST; SCHURR TG, 1990, AM J HUM GENET, V46, P613; SEEMANN GHA, 1986, EMBO J, V5, P547, DOI 10.1002/j.1460-2075.1986.tb04245.x; TORRONI A, 1992, GENETICS, V130, P153; TRUP GM, 1973, HISTOCOMPATIBILITY T, P339; WATKINS DI, 1991, IMMUNOGENETICS, V33, P79; WATKINS DI, 1988, EUR J IMMUNOL, V18, P1425, DOI 10.1002/eji.1830180919; WAYS JP, 1987, IMMUNOGENETICS, V25, P323, DOI 10.1007/BF00404425; WOODBURY RB, 1979, HDB N AM INDIANS SW, V9, P467; WRIGHT S., 1938, Science (Washington), V87, P430; YANG SY, 1989, HISTOCOMPATIBILITY T, P309	37	249	254	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					329	333		10.1038/357329a0	http://dx.doi.org/10.1038/357329a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589035				2022-12-28	WOS:A1992HW13200048
J	BAGASRA, O; HAUPTMAN, SP; LISCHNER, HW; SACHS, M; POMERANTZ, RJ				BAGASRA, O; HAUPTMAN, SP; LISCHNER, HW; SACHS, M; POMERANTZ, RJ			DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRUS IN MONONUCLEAR-CELLS BY INSITU POLYMERASE CHAIN-REACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN GLIAL-CELLS; PERIPHERAL-BLOOD; HTLV-III; T-CELL; INFECTED INDIVIDUALS; HIV INFECTION; SYNDROME AIDS; DNA; EXPRESSION; HYBRIDIZATION	Background. Studies of human immunodeficiency virus type 1 (HIV-1) infection have attempted to quantitate the viral load and correlate it with the degree of immune deficiency. In one study, only about 1 in 10,000 peripheral-blood mononuclear cells (PBMC) expressed HIV-1, but in other studies, at least 1 in 100 CD4-positive cells was infected and harbored the HIV-1 provirus. Methods. We developed a new, highly sensitive in situ polymerase-chain-reaction (PCR) method that amplifies selected genetic regions within intact single cells. We used this technique to determine the proportion of PBMC carrying HIV-1 provirus in infected patients in different stages of disease. Results. None of the PBMC from 11 HIV-1-seronegative patients were found to be positive for HIV-1 provirus by the in situ PCR method. In 56 patients infected with HIV-1, the percentage of PBMC with HIV-1 ranged from 0.1 percent to 13.5 percent. The mean percentage of infected mononuclear cells was greater in 13 patients with persistent generalized adenopathy (mean, 6.6 percent) and 19 with the acquired immunodeficiency syndrome (Stages IV-A to IV-C) (4.6 percent) than in 19 patients with asymptomatic HIV-1 infection (0.9 percent) (P < 0.001). However, in five patients with Kaposi's sarcoma (Stage IV-D), an average of only 1.6 percent of mononuclear cells were infected Conclusions. In HIV-1 infection, the proportion of PBMC that are infected appears to be at least 10 times higher than previously described. It is likely that most infected cells contain HIV-1 provirus in a latent or defective form that was not detected in some earlier studies.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; ST CHRISTOPHERS HOSP CHILDREN,DEPT PEDIAT,PHILADELPHIA,PA 19133; TEMPLE UNIV,PHILADELPHIA,PA 19122	Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	BAGASRA, O (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,1025 WALNUT ST,SUITE 813,PHILADELPHIA,PA 19107, USA.				NIAID NIH HHS [AI-00930] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000930] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BORKOWSKY W, 1987, LANCET, V1, P1168; BRINCHMANN JE, 1991, J VIROL, V65, P2019, DOI 10.1128/JVI.65.4.2019-2023.1991; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLEWLEY JP, 1989, J VIROL METHODS, V25, P179, DOI 10.1016/0166-0934(89)90031-1; CLOUSE KA, 1989, J IMMUNOL, V142, P431; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEFRANCHIS R, 1988, NUCLEIC ACIDS RES, V16, P10355, DOI 10.1093/nar/16.21.10355; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; DICKOVER RE, 1990, J CLIN MICROBIOL, V28, P2130, DOI 10.1128/JCM.28.9.2130-2133.1990; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENESCA J, 1990, J INFECT DIS, V162, P1025, DOI 10.1093/infdis/162.5.1025; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HO DD, 1987, NEW ENGL J MED, V317, P278; HORSBURGH RC, 1990, J INFECT DIS, V152, P542; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; IKEUCHI K, 1990, J VIROL, V64, P4226, DOI 10.1128/JVI.64.9.4226-4231.1990; JACKSON JB, 1988, JAMA-J AM MED ASSOC, V260, P2236; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; KELLER GH, 1989, ANAL BIOCHEM, V177, P27, DOI 10.1016/0003-2697(89)90007-9; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; KWOK S, 1989, PCR PROTOCOLS GUIDE, P142; LEWIS DE, 1990, J INFECT DIS, V162, P1373, DOI 10.1093/infdis/162.6.1373; LIFSON AR, 1990, J INFECT DIS, V161, P436, DOI 10.1093/infdis/161.3.436; LOCHE M, 1988, LANCET, V2, P418; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MONTAGNIER L, 1984, SCIENCE, V225, P63, DOI 10.1126/science.6328661; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POZNANSKY MC, 1991, J ACQ IMMUN DEF SYND, V4, P368; PYUN KH, 1987, NEW ENGL J MED, V317, P611, DOI 10.1056/NEJM198709033171006; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SALAHUDDIN SZ, 1985, P NATL ACAD SCI USA, V82, P5530, DOI 10.1073/pnas.82.16.5530; SALAHUDDIN SZ, 1986, BLOOD, V68, P281; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TSUBOTA H, 1989, J IMMUNOL, V143, P858; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; [No title captured]	56	276	293	2	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1385	1391		10.1056/NEJM199205213262103	http://dx.doi.org/10.1056/NEJM199205213262103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1569974				2022-12-28	WOS:A1992HU89000003
J	GOLDSTEIN, B				GOLDSTEIN, B			INDUCTION OF GUT IN CAENORHABDITIS-ELEGANS EMBRYOS	NATURE			English	Article								Two types of developmental events can cause an embryonic cell to adopt a fate different from that of its neighbours: during a cell division particular contents may be segregated to only one daughter cell and cells may experience different external cues, commonly in the form of inductive cell interactions. Work on development in the nematode Caenorhabditis elegans suggests that most cell fates are specified without a need for cell interactions. In particular, the gut cell lineage of C. elegans has been used as a primary example of specification by differential segregation of determinants 1. Here I re-examine the role of induction in gut specification by isolating early blastomeres. In C. elegans, the gut derives from all the progeny of a single blastomere (E) of the eight-cell stage 2. When a gut precursor cell (EMS) is isolated during the first half of the four-cell stage, gut does not differentiate. Gut differentiation is rescued by recombining EMS with its posterior neighbour (P2), but not by recombining EMS with one or both of the other two cells of the four-cell stage. These results demonstrate that P2 induces EMS to form gut in C. elegans.			GOLDSTEIN, B (corresponding author), UNIV TEXAS,DEPT ZOOL,CTR DEV BIOL,AUSTIN,TX 78712, USA.			Goldstein, Bob/0000-0001-6961-675X				Chitwood, 1974, INTRO NEMATOLOGY; Davidson E. H., 1986, GENE ACTIVITY EARLY; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; LAUFER JS, 1981, SCIENCE, V211, P402, DOI 10.1126/science.7194506; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MAINE EM, 1990, BIOESSAYS, V12, P265, DOI 10.1002/bies.950120604; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0	12	184	184	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					255	257		10.1038/357255a0	http://dx.doi.org/10.1038/357255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589023				2022-12-28	WOS:A1992HV19500059
J	MOLLER, AP				MOLLER, AP			FEMALE SWALLOW PREFERENCE FOR SYMMETRICAL MALE SEXUAL ORNAMENTS	NATURE			English	Article							FLUCTUATING ASYMMETRY; TAIL LENGTH; CHOICE	MANY secondary sexual characters are supposed to have evolved as a response to female choice of the most extravagantly ornamented males 1, a hypothesis supported by studies demonstrating female preferences for the most ornamented males 2-5. Comparative studies of elaborate feather ornaments in birds have shown that (1) ornaments have larger degrees of fluctuating asymmetry 6 (small, random deviations from bilateral symmetry caused by an inability of individuals to cope with environmental and genetic stress during development of a character 7) than other morphological traits, and (2) the degree of fluctuating asymmetry is often negatively related to the size of the ornament 6. The negative relationship between ornament asymmetry and size suggests that ornament size reliably reflects male quality because the largest secondary sex traits demonstrate the least degree of fluctuating asymmetry. I manipulated tail length and tail asymmetry independently in male swallows (Hirundo rustica) to determine whether ornament size or asymmetry were used as cues in mate choice. Male swallows with elongated, symmetric tails mated earlier, and enjoyed larger annual reproductive success than did males with shortened tails and increased asymmetry. Females therefore prefer large as well as symmetric ornaments, which suggests that females in their mate choice use ornament asymmetry and size as reliable indicators of male quality.	UNIV UPPSALA,DEPT ZOOL,S-75122 UPPSALA,SWEDEN	Uppsala University			Moller, Anders/O-6665-2016	Moller, Anders/0000-0003-3739-4675				ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Darwin C., 1871, P475; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LUDWIG W, 1932, RECHTS LINK PROBLEM; MOLLER AP, 1990, ANIM BEHAV, V39, P458, DOI 10.1016/S0003-3472(05)80409-9; MOLLER AP, 1988, NATURE, V332, P640, DOI 10.1038/332640a0; MOLLER AP, 1991, P ROY SOC B-BIOL SCI, V245, P1, DOI 10.1098/rspb.1991.0080; MOLLER AP, 1991, P ROY SOC B-BIOL SCI, V243, P59, DOI 10.1098/rspb.1991.0010; MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; PARSONS PA, 1990, BIOL REV, V65, P131, DOI 10.1111/j.1469-185X.1990.tb01186.x; PETRIE M, 1991, ANIM BEHAV, V41, P323, DOI 10.1016/S0003-3472(05)80484-1; SMITH HG, 1990, BEHAV ECOL SOCIOBIOL, V28, P195; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	15	397	400	0	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					238	240		10.1038/357238a0	http://dx.doi.org/10.1038/357238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589021				2022-12-28	WOS:A1992HV19500053
J	BELL, SP; STILLMAN, B				BELL, SP; STILLMAN, B			ATP-DEPENDENT RECOGNITION OF EUKARYOTIC ORIGINS OF DNA-REPLICATION BY A MULTIPROTEIN COMPLEX	NATURE			English	Article							ESCHERICHIA-COLI CHROMOSOME; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEINS; T-ANTIGEN; YEAST; INVITRO; PURIFICATION; INITIATION; SEQUENCE; PLASMIDS	A multiprotein complex that specifically recognizes cellular origins of DNA replication has been identified and purified from the yeast Saccharomyces cerevisiae. We observe a strong correlation between origin function and origin recognition by this activity. Interestingly, specific DNA binding by the origin recognition complex is dependent upon the addition of ATP. We propose that the origin recognition complex acts as the initiator protein for S. cerevisiae origins of DNA replication.			BELL, SP (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Bell, Stephen/0000-0002-2876-610X; Stillman, Bruce/0000-0002-9453-4091				BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JAZWINSKI SM, 1982, P NATL ACAD SCI-BIOL, V79, P3428, DOI 10.1073/pnas.79.11.3428; JAZWINSKI SM, 1984, J BIOL CHEM, V259, P6852; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KORNBERG A, 1992, DNA REPLICATION, P1; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PALZKILL TG, 1988, CELL, V37, P299; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	46	1021	1039	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					128	134		10.1038/357128a0	http://dx.doi.org/10.1038/357128a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579162				2022-12-28	WOS:A1992HU12200048
J	TOGUCHIDA, J; YAMAGUCHI, T; DAYTON, SH; BEAUCHAMP, RL; HERRERA, GE; ISHIZAKI, K; YAMAMURO, T; MEYERS, PA; LITTLE, JB; SASAKI, MS; WEICHSELBAUM, RR; YANDELL, DW				TOGUCHIDA, J; YAMAGUCHI, T; DAYTON, SH; BEAUCHAMP, RL; HERRERA, GE; ISHIZAKI, K; YAMAMURO, T; MEYERS, PA; LITTLE, JB; SASAKI, MS; WEICHSELBAUM, RR; YANDELL, DW			PREVALENCE AND SPECTRUM OF GERMLINE MUTATIONS OF THE P53 GENE AMONG PATIENTS WITH SARCOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENZYMATIC AMPLIFICATION; CANCER; DNA; RETINOBLASTOMA; PROTEIN; TRANSFORMATION; POLYMORPHISMS; EVOLUTION; SEQUENCE; ONCOGENE	Background. Recent studies have identified germline mutations of the p53 tumor-suppressor gene in families with the Li-Fraumeni syndrome, a rare inherited disorder characterized by a high risk of sarcomas of bone and soft tissue, breast cancer, and other tumors. in this report, we address the possibility that some sporadic sarcomas may be associated with new germline mutations of the p53 gene, which would not be manifested as familial cancer unless the patient survived to reproduce. Methods. We studied DNA from peripheral leukocytes of 196 patients with sarcoma and from 200 controls. Of the 196 patients with sarcoma, 15 were selected because they had had multiple primary cancers or had a family history of cancer. The entire coding sequence and splice junctions of the p53 gene were analyzed for mutations. Results. Eight germline mutations were found, three in patients with no known family history of cancer and five in patients with an unusual personal or family history of cancer. Four mutations caused amino acid substitutions, and four caused stop codons. These mutations were not present in any of the 200 controls. Conclusions. New germline mutations of the p53 gene are rare among patients with "sporadic" sarcoma but may be common in patients with sarcoma whose background includes either multiple primary cancers or a family history of cancer. Diverse mutations of this gene were associated with an increased likelihood of cancer; hence, the entire gene should be considered a target for heritable mutation. It appears that the group of patients with cancer who carry germline mutations of the p53 gene is more diverse than is suggested by the clinical definition of the Li-Fraumeni syndrome. The identification of carriers could be of substantial clinical importance.	MASSACHUSETTS EYE & EAR HOSP,HOWE LAB,243 CHARLES ST,BOSTON,MA 02114; KYOTO UNIV,CTR RADIAT BIOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,KYOTO 606,JAPAN; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV CHICAGO,MED CTR,CHICAGO,IL 60637	Kyoto University; Kyoto University; Memorial Sloan Kettering Cancer Center; Harvard University; Harvard T.H. Chan School of Public Health; University of Chicago; University of Chicago Medical Center								ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; CRIST WM, 1990, J CLIN ONCOL, V8, P443, DOI 10.1200/JCO.1990.8.3.443; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GOORIN AM, 1985, NEW ENGL J MED, V313, P1637, DOI 10.1056/NEJM198512263132605; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGUCHIARIGA SMM, 1988, ONCOGENE, V3, P509; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIM JH, 1991, J NATL CANCER I, V83, P38; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKEBE H, 1988, GANN MONOGRAPH CANCE, V35; TAMBOLI A, 1990, ARCH OPHTHALMOL-CHIC, V108, P128, DOI 10.1001/archopht.1990.01070030134045; TAMURA G, 1991, CANCER RES, V51, P3056; VOGEL F, 1979, HUM GENET, V52, P1; YANDELL DW, 1989, AM J HUM GENET, V45, P547	35	300	306	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1301	1308		10.1056/NEJM199205143262001	http://dx.doi.org/10.1056/NEJM199205143262001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1565143				2022-12-28	WOS:A1992HT80300001
J	THIBAULT, GE				THIBAULT, GE			THE LANDLADY CONFIRMS THE DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANION GAP				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKY,BOSTON,MA 02132, USA.							EICHENHOLZ A, 1963, METABOLISM, V12, P164; Elstein AS, 1978, MED PROBLEM SOLVING; EMMETT M, 1977, MEDICINE, V56, P38, DOI 10.1097/00005792-197756010-00002; GABOW PA, 1985, KIDNEY INT, V27, P472, DOI 10.1038/ki.1985.34; GABOW PA, 1980, NEW ENGL J MED, V303, P854, DOI 10.1056/NEJM198010093031505; GABOW PA, 1978, ARCH INTERN MED, V138, P1481, DOI 10.1001/archinte.138.10.1481; HILL JB, 1973, NEW ENGL J MED, V288, P1110, DOI 10.1056/NEJM197305242882107; KASSIRER JP, 1978, ANN INTERN MED, V89, P245, DOI 10.7326/0003-4819-89-2-245; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; SIEGLER M, 1975, NEW ENGL J MED, V293, P853, DOI 10.1056/NEJM197510232931705	10	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1272	1275		10.1056/NEJM199205073261907	http://dx.doi.org/10.1056/NEJM199205073261907			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560804				2022-12-28	WOS:A1992HR44700007
J	KIM, JJ; FANSELOW, MS				KIM, JJ; FANSELOW, MS			MODALITY-SPECIFIC RETROGRADE-AMNESIA OF FEAR	SCIENCE			English	Article							LESIONS; RATS; HIPPOCAMPAL; MEMORY; MECHANISMS	Emotional responses such as fear are rapidly acquired through classical conditioning. This report examines the neural substrate underlying memory of acquired fear. Rats were classically conditioned to fear both tone and context through the use of aversive foot shocks. Lesions were made in the hippocampus either 1, 7, 14, or 28 days after training. Contextual fear was abolished in the rats that received lesions 1 day after fear conditioning. However, rats for which the interval between learning and hippocampal lesions was longer retained significant contextual fear memory. In the same animals, lesions did not affect fear response to the tone at any time. These results indicate that fear memory is not a single process and that the hippocampus may have a time-limited role in associative fear memories evoked by polymodal (contextual) but not unimodal (tone) sensory stimuli.			KIM, JJ (corresponding author), UNIV CALIF LOS ANGELES, DEPT PSYCHOL, LOS ANGELES, CA 90024 USA.			Kim, Jeansok/0000-0001-7964-106X				BANDLER R, 1991, PROGR BRAIN RES, V87, P269; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; FANSELOW MS, 1991, NATO ADV SCI I A-LIF, V213, P151; FANSELOW MS, 1986, LEARN MOTIV, V17, P16, DOI 10.1016/0023-9690(86)90018-4; HITCHCOCK JM, 1986, BEHAV NEUROSCI, V110, P11; IWATA J, 1986, BRAIN RES, V368, P161, DOI 10.1016/0006-8993(86)91055-3; KAPP BS, 1979, PHYSIOL BEHAV, V23, P1109, DOI 10.1016/0031-9384(79)90304-4; Milner B, 1972, Clin Neurosurg, V19, P421; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PENFIELD W, 1958, ARCH NEURO PSYCHIATR, V79, P475, DOI 10.1001/archneurpsyc.1958.02340050003001; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHMALTZ LW, 1972, J COMP PHYSIOL PSYCH, V79, P328, DOI 10.1037/h0032531; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SOLOMON PR, 1977, J COMP PHYSIOL PSYCH, V91, P407, DOI 10.1037/h0077330; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; SQUIRE LR, 1990, NEURAL MODELS PLASTI, P208; THOMPSON RF, 1990, PHILOS T ROY SOC B, V329, P161, DOI 10.1098/rstb.1990.0161; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; WINOCUR G, 1987, BEHAV NEUROSCI, V101, P617, DOI 10.1037/0735-7044.101.5.617; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	23	1906	1925	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					675	677		10.1126/science.1585183	http://dx.doi.org/10.1126/science.1585183			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585183				2022-12-28	WOS:A1992HR18500036
J	LEDERLE, FA; PARENTI, CM; BERSKOW, LC; ELLINGSON, KJ				LEDERLE, FA; PARENTI, CM; BERSKOW, LC; ELLINGSON, KJ			THE IDLE INTRAVENOUS CATHETER	ANNALS OF INTERNAL MEDICINE			English	Article						CATHETERIZATION; IATROGENIC DISEASE; CROSS INFECTION; BACTEREMIA; PHLEBITIS	COMPLICATIONS; PREVENTION; INFECTION; THERAPY; DEVICES; GAUZE	. Objective: To assess the prevalence of idle peripheral intravenous (IV) catheters (those without any therapeutic use) on regular-care medical wards. . Design: Observation, interviews, and chart review. . Setting: A university-affiliated VA medical center. . Patients: All 959 inpatients on 4 regular-care medical wards during a 6-week period, including 484 IV catheter episodes and 2983 patient-days of IV catheter use. . Main Outcome Measure: Idle IV catheter use. . Results: Thirty-five percent of all IV catheter episodes (95% Cl, 32% to 38%) had 2 or more consecutive idle days. In only 6 of these (1%) could a specific reason for the catheter be determined. Seventeen percent of all patients on regular-care medical wards (Cl, 15% to 19%) had an idle IV catheter for 2 or more consecutive days. Twenty percent of all patient-days of IV catheter use were idle (Cl, 19% to 21%). . Conclusions: Our data suggest that IV are frequently used unnecessarily. Future efforts to reduce IV catheter complication rates should focus on reducing unnecessary use as well as on improving techniques to reduce infection rates when use is appropriate.			LEDERLE, FA (corresponding author), MINNEAPOLIS DEPT VET AFFAIRS MED CTR, DEPT MED 111-0, 1 VET DR, MINNEAPOLIS, MN 55417 USA.							COLLIGNON PJ, 1984, MED J AUSTRALIA, V141, P345, DOI 10.5694/j.1326-5377.1984.tb132802.x; GOLDMANN DA, 1973, ANN INTERN MED, V79, P848, DOI 10.7326/0003-4819-79-6-848; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; LITTENBERG B, 1987, J GEN INTERN MED, V2, P411, DOI 10.1007/BF02596369; MAKI DG, 1991, ANN INTERN MED, V114, P845, DOI 10.7326/0003-4819-114-10-845; MAKI DG, 1981, AM J MED, V70, P739, DOI 10.1016/0002-9343(81)90605-7; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P2396, DOI 10.1001/jama.258.17.2396; RICH EC, 1985, AM J MED, V79, P577, DOI 10.1016/0002-9343(85)90054-3; SIMMONS BP, 1982, INFECT CONT HOSP EP, V3, P61, DOI 10.1017/S0195941700057131; TAGER IB, 1983, AM J EPIDEMIOL, V118, P839; TOMFORD JW, 1984, ARCH INTERN MED, V144, P1191, DOI 10.1001/archinte.144.6.1191; TULLY JL, 1981, AM J MED, V70, P702, DOI 10.1016/0002-9343(81)90600-8; TURNIDGE J, 1984, MED J AUSTRALIA, V141, P37, DOI 10.5694/j.1326-5377.1984.tb132666.x	13	71	72	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					737	738		10.7326/0003-4819-116-9-737	http://dx.doi.org/10.7326/0003-4819-116-9-737			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558345				2022-12-28	WOS:A1992HQ62300006
J	CAMMAROTA, G; SCHEIRLE, A; TAKACS, B; DORAN, DM; KNORR, R; BANNWARTH, W; GUARDIOLA, J; SINIGAGLIA, F				CAMMAROTA, G; SCHEIRLE, A; TAKACS, B; DORAN, DM; KNORR, R; BANNWARTH, W; GUARDIOLA, J; SINIGAGLIA, F			IDENTIFICATION OF A CD4 BINDING-SITE ON THE BETA-2-DOMAIN OF HLA-DR MOLECULES	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CELL-SURFACE-ANTIGENS; CLASS-I MOLECULES; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; MHC CLASS; COMPLEX; RECEPTOR; RECOGNITION; ACTIVATION	THE CD4 and CD8 molecules are transmembrane glycoproteins expressed by functionally distinct subsets of mature T cells. CD4+ and CD8+ T cells recognize antigens on major histocompatibility complex (MHC) class II-bearing and class I-bearing target cells respectively 1-3. The ability of monoclonal antibodies against CD4 and CD8 to block antigen recognition by T cells, as well as cell-cell adhesion assays 4-7, indicate that CD4 and CD8 bind to non-polymorphic determinants of class II or class I MHC. Here we demonstrate that soluble recombinant HLA-DR4 molecules from insect cells and HLA-DR-derived peptides bind to immobilized recombinant soluble CD4. CD4 binds recombinant soluble DR4 heterodimers, as well as the soluble DR4-beta-chain alone. Furthermore, two out of twelve DR4-beta-peptides could interact specifically with CD4. These findings show that CD4 interacts with a region of MHC class II molecules analogous to a previously identified loop in class I MHC proteins that binds CD8 (refs 8,9).	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Roche Holding; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Cammarota, Giovanni/AAD-1732-2022	Cammarota, Giovanni/0000-0002-3626-6148				AUTIERO M, 1991, VIROLOGY, V185, P820, DOI 10.1016/0042-6822(91)90553-N; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DEGLIANTONI G, 1985, J EXP MED, V161, P1152, DOI 10.1084/jem.161.5.1152; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GORGA JC, 1987, J BIOL CHEM, V262, P16087; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOSCICKI RA, 1983, J IMMUNOL, V131, P743; NOLLI ML, 1986, THROMB HAEMOSTASIS, V56, P214; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SINIGAGLIA F, 1992, METHOD ENZYMOL, V203, P370; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	25	272	281	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					799	801		10.1038/356799a0	http://dx.doi.org/10.1038/356799a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574119				2022-12-28	WOS:A1992HR18600052
J	WALDRON, T				WALDRON, T			IS DUPLICATE PUBLISHING ON THE INCREASE	BRITISH MEDICAL JOURNAL			English	Article							PUBLICATION; REDUNDANT				WALDRON, T (corresponding author), BRITISH JOURNAL IND MED,LONDON WC1H 9JR,ENGLAND.							ANGELL M, 1989, NEW ENGL J MED, V320, P1212, DOI 10.1056/NEJM198905043201812; LOCK S, 1984, BRIT MED J, V288, P661, DOI 10.1136/bmj.288.6418.661; LOCK S, 1989, BRIT MED J, V298, P1203; 1989, EUROPEAN SCI EDITING, P9	4	38	38	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1029	1029		10.1136/bmj.304.6833.1029	http://dx.doi.org/10.1136/bmj.304.6833.1029			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586787	Green Published, Bronze			2022-12-28	WOS:A1992HQ14200023
J	PIL, PM; LIPPARD, SJ				PIL, PM; LIPPARD, SJ			SPECIFIC BINDING OF CHROMOSOMAL PROTEIN-HMG1 TO DNA DAMAGED BY THE ANTICANCER DRUG CISPLATIN	SCIENCE			English	Article							PLATINUM COMPLEXES; CIS-DIAMMINEDICHLOROPLATINUM(II); TRANS-DIAMMINEDICHLOROPLATINUM(II); ADDUCTS; REPLICATION; CELLS	The mechanism of action of the anticancer compound cis-diamminedichloroplatinum(II) (cisplatin) involves covalent binding to DNA. In an effort to understand the tumor-specific cytotoxicity of such DNA damage, the interactions of these lesions with cellular proteins have been studied. One such protein has been identified as the high-mobility group protein HMG1. Recombinant rat HMG1 binds specifically (dissociation constant 3.7 +/- 2.0 x 10(-7) molar) to DNA containing cisplatin d(GpG) or d(ApG) intrastrand cross-links, which unwind and bend DNA in a specific manner, but not to DNA modified by therapeutically inactive platinum analogs. These results suggest how HMG1 might bind to altered DNA structures and may be helpful in designing new antitumor drugs.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PA, 1991, CANCER COMMUN, V3, P1; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BIANCHI ME, 1991, GENE, V104, P271, DOI 10.1016/0378-1119(91)90261-9; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CHAO CCK, 1991, BIOCHEM J, V277, P875, DOI 10.1042/bj2770875; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CICCARELLI RB, 1985, BIOCHEMISTRY-US, V24, P7533, DOI 10.1021/bi00347a005; Cleare, 1973, BIOINORG CHEM, V2, P187, DOI DOI 10.1016/S0006-3061(00)80249-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KECK MV, IN PRESS J AM CHEM S; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P9, DOI [DOI 10.1007/978-3-642-84150-7-2, DOI 10.1007/978-3-642-84150-7]; MAREKOV LN, 1984, BIOCHIM BIOPHYS ACTA, V789, P63, DOI 10.1016/0167-4838(84)90061-X; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; SCOVELL WM, 1989, J MACROMOL SCI CHEM, VA26, P455, DOI 10.1080/00222338908051987; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TREIBER DK, UNPUB; VISSE R, 1991, J BIOL CHEM, V266, P7609; 1991, CANCER FACTS FIGURES	29	530	540	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					234	237		10.1126/science.1566071	http://dx.doi.org/10.1126/science.1566071			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566071				2022-12-28	WOS:A1992HM89600033
J	ALTSCHUH, D; VIX, O; REES, B; THIERRY, JC				ALTSCHUH, D; VIX, O; REES, B; THIERRY, JC			A CONFORMATION OF CYCLOSPORINE-A IN AQUEOUS ENVIRONMENT REVEALED BY THE X-RAY STRUCTURE OF A CYCLOSPORINE-FAB COMPLEX	SCIENCE			English	Article							MOLECULAR REPLACEMENT METHOD; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; CRYSTALLOGRAPHIC REFINEMENT; MONOCLONAL-ANTIBODIES; MULTIDOMAIN PROTEINS; CYCLOPHILIN; FRAGMENT	The conformation of the immunosuppressive drug cyclosporin A (CsA) in a complex with a Fab molecule has been established by crystallographic analysis to 2.65 angstrom resolution. This conformation of CsA is similar to that recently observed in the complex with the rotamase cyclophilin, its binding protein in vivo, and totally different from its conformation in an isolated form as determined from x-ray and nuclear magnetic resonance analysis. Because the surfaces of CsA interacting with cyclophilin or with the Fab are not identical, these results suggest that the conformation of CsA observed in the bound form preexists in aqueous solution and is not produced by interaction with the proteins.	CNRS,INST BIOL MOLEC & CELLULAIRE,CRISTALLOG LAB,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	ALTSCHUH, D (corresponding author), CNRS,INST BIOL MOLEC & CELLULAIRE,IMMUNOCHIM LAB,15 RUE DESCARTES,F-67084 STRASBOURG,FRANCE.		Altschuh, Danièle/P-8658-2016					ALTSCHUH D, 1989, J MOL BIOL, V209, P177, DOI 10.1016/0022-2836(89)90181-2; BOREL JF, 1976, IMMUNOLOGY, V31, P631; BRUNGER AT, 1990, XPLOR MANUAL VERSION; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CYGLER M, 1988, ACTA CRYSTALLOGR A, V44, P300, DOI 10.1107/S0108767387012236; CYGLER M, 1988, ACTA CRYSTALLOGR A, V44, P38, DOI 10.1107/S0108767387008365; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FUJINAGA M, 1989, J APPL CRYSTALLOGR, V22, P1, DOI 10.1107/S0021889888009550; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JONES A, 1982, FRODO GRAPHICS FITTI, P303; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KESSLER H, 1985, HELV CHIM ACTA, V68, P661, DOI 10.1002/hlca.19850680318; LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; PETCHER TJ, 1976, HELV CHIM ACTA, V59, P1480, DOI 10.1002/hlca.19760590509; PRECHEUR B, 1991, EUR J BIOCHEM, V201, P67; QUESNIAUX VFJ, 1987, MOL IMMUNOL, V24, P1159, DOI 10.1016/0161-5890(87)90162-3; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHMITTER D, 1990, MOL IMMUNOL, V27, P1029, DOI 10.1016/0161-5890(90)90126-K; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STEIN R L, 1991, Current Biology, V1, P234, DOI 10.1016/0960-9822(91)90067-7; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082	35	101	102	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					92	94		10.1126/science.1566062	http://dx.doi.org/10.1126/science.1566062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566062				2022-12-28	WOS:A1992HL82200033
J	RAFF, MC				RAFF, MC			SOCIAL CONTROLS ON CELL-SURVIVAL AND CELL-DEATH	NATURE			English	Review							NERVE GROWTH-FACTOR; MITOCHONDRIAL-MEMBRANE PROTEIN; FACTOR DEPRIVATION; LIVER HYPERPLASIA; PROGRAMMED DEATH; RAT-LIVER; C-KIT; APOPTOSIS; DELETION; BCL-2	Programmed cell death occurs in most animal tissues at some stage of their development, but the molecular mechanism by which it is executed is unknown. For some mammalian cells, programmed death seems to occur by default unless suppressed by signals from other cells. Such dependence on specific survival signals provides a simple way to eliminate misplaced cells, for regulating cell numbers and, perhaps, for selecting the fittest cells. But how general is this dependence on survival signals?			RAFF, MC (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOL, MEDAWAR BLDG, GOWER ST, LONDON WC1E 6BT, ENGLAND.							AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; ALBERS B, 1989, MOL BIOL CELL, P748; [Anonymous], [No title captured]; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARRES B, IN PRESS CELL; BASERGA R, 1985, BIOL CELL REPRODUCTI; BENEDETTI A, 1988, J HEPATOL, V7, P319, DOI 10.1016/S0168-8278(88)80004-7; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BIGGERS J. D., 1971, Methods in mammalian embryology, P86; BOWEN ID, 1981, DEATH BIOL PATHOLOGY; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; BURSCH W, 1985, VIRCHOWS ARCH B, V50, P153; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Byskov A.G., 1982, P1; CAMPENOT RB, 1982, DEV BIOL, V93, P13, DOI 10.1016/0012-1606(82)90233-0; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COLUMBANO A, 1985, LAB INVEST, V52, P670; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; HAM RG, 1981, TISSUE GROWTH FACTOR, P13; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HAMMAR SP, 1971, J CELL SCI, V8, P229; HENGARTNER MO, IN PRESS NATURE; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOST A, 1970, PHILOS T ROY SOC B, V259, P119, DOI 10.1098/rstb.1970.0052; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KERR JFR, 1974, J CELL SCI, V14, P571; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KORSCHING S, 1983, P NATL ACAD SCI-BIOL, V80, P3513, DOI 10.1073/pnas.80.11.3513; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRYPIANOU N, 1988, ENDOCRINOLOGY, V122, P552; LEDDACOLUMBANO GM, 1989, AM J PATHOL, V135, P657; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; Lockshin R. A, 1981, CELL DEATH BIOL PATH, P79; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MONPETIT ML, 1986, PROSTATE, V8, P25; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OATES PS, 1986, AM J PHYSIOL, V250, pG9, DOI 10.1152/ajpgi.1986.250.1.G9; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SEARLE J, 1982, PATHOL ANNU, V17, P229; SILVERS WK, 1979, COAT COLORS MICE MOD, P242; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SVRZIC D, 1990, BIOCHEM BIOPH RES CO, V172, P54, DOI 10.1016/S0006-291X(05)80172-X; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TATA JR, 1971, SOC EXP BIOL S, V25, P161; TOMEI LD, 1991, APOPTOSIS MOL BASIS; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHAN T, 1990, J CELL BIOL, V111, P257, DOI 10.1083/jcb.111.1.257; UMANSKY SR, 1982, J THEOR BIOL, V97, P591, DOI 10.1016/0022-5193(82)90360-5; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WADEWITZ AG, 1988, FEBS LETT, V241, P19, DOI 10.1016/0014-5793(88)81022-6; WATANABEFUKUNAG.R, IN PRESS NATURE; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILLIAMS JR, 1974, NATURE, V252, P754, DOI 10.1038/252754a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1973, J PATHOL, V111, P85, DOI 10.1002/path.1711110203; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; [No title captured]	82	2492	2596	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					397	400		10.1038/356397a0	http://dx.doi.org/10.1038/356397a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557121				2022-12-28	WOS:A1992HL83000052
J	BODE, J; KOHWI, Y; DICKINSON, L; JOH, T; KLEHR, D; MIELKE, C; KOHWISHIGEMATSU, T				BODE, J; KOHWI, Y; DICKINSON, L; JOH, T; KLEHR, D; MIELKE, C; KOHWISHIGEMATSU, T			BIOLOGICAL SIGNIFICANCE OF UNWINDING CAPABILITY OF NUCLEAR MATRIX ASSOCIATING DNAS	SCIENCE			English	Article							SCAFFOLD-ATTACHED REGIONS; CHROMOSOMAL LOOP ANCHORAGE; DROSOPHILA-MELANOGASTER; TOPOISOMERASE-II; SUPERCOILED DNA; SITES; GENE; TRANSCRIPTION; CHROMATIN; CELLS	Matrix attachment regions (MARs) are thought to separate chromatin into topologically constrained loop domains. A MAR located 5' of the human beta-interferon gene becomes stably base-unpaired under superhelical strain, as do the MARs flanking the immunoglobulin heavy chain gene enhancer; in both cases a nucleation site exists for DNA unwinding. Concatemerized oligonucleotides containing the unwinding nucleation site exhibited a strong affinity for the nuclear scaffold and augmented SV40 promoter activity in stable transformants. Mutated concatemerized oligonucleotides resisted unwinding, showed weak affinity for the nuclear scaffold, and did not enhance promoter activity. These results suggest that the DNA feature capable of relieving superhelical strain is important for MAR functions.	GESELL BIOTECHNOL FORSCH GMBH,MASCHERODER WEG 1,W-3300 BRAUNSCHWEIG,GERMANY; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Gesellschaft fur Biotechnologische Forschung mbH; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA039681, R01CA051377] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA39681, R0I CA51377] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; CLARK P, 1991, EMBO J, V10, P387; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KAY V, UNPUB; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOCHETKOV N K, 1971, Tetrahedron Letters, V22, P1993; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, UNPUB; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MIZUTANI M, 1991, P NATL ACAD SCI USA, V88, P718, DOI 10.1073/pnas.88.3.718; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PROBST H, 1985, EUR J BIOCHEM, V146, P167, DOI 10.1111/j.1432-1033.1985.tb08634.x; SINDEN RR, 1987, J CHEM EDUC, V64, P294, DOI 10.1021/ed064p294; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	42	395	415	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					195	197		10.1126/science.1553545	http://dx.doi.org/10.1126/science.1553545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1553545				2022-12-28	WOS:A1992GY70400035
